RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA)

ABSTRACT

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against CTNNB1 gene expression.

SEQUENCE LISTING

The sequence listing submitted via EFS, in compliance with 37 CFR§1.52(e)(5), is incorporated herein by reference. The sequence listingtext file submitted via EFS contains the file “SequenceListingSIRONC2”,created on Jul. 25, 2011 which is 2,173,912 bytes in size.

BACKGROUND OF THE INVENTION

Beta catenin (also known as cadherin-associated protein and β-catenin),is a member of the catenin family of cytosolic proteins. β-catenin isencoded by the CTNNB1 gene.

β-catenin is a pivotal player in the Wnt/Wg signaling pathway, mediatorsof several developmental processes. In the absence of Wnt, glycogensynthase kinase 3 (GSK-3β), a serine/threonine protein kinaseconstitutively phosphorylates the β-catenin protein. When Wnt is presentand binds to any of the family members of the frizzled receptors (Fz),an intracellular signaling protein known as dishevelled (Dsh) isrecruited to the membrane and phosphorylated. GSK-3β is inhibited by theactivation of Dsh. As a result, β-catenin levels increase in the cytosoland are translocated into the nucleus to perform a variety of functions.β-catenin acts together with the transcription factors TCF and LEF toactivate specific target genes involved in different processes.

β-catenin undergoes phosphorylation upon growth factor stimulationresulting in reduced cell adhesion, thereby functioning as a componentof adherin junctions which are multiprotein complexes that mediate celladhesion, cell-cell communication and cytoskeletal anchoring. (Willertet al., 1998, Curr. Opin. Genet. Dev. 8:95-102).

Thompson et al. suggest that β-catenin plays an important role invarious aspects of liver biology including liver development (bothembryonic and postnatal), liver regeneration following partialhepatectomy, hepatocyte growth factor (HGF)-induced hepatomegaly, liverzonation, and pathogenesis of liver cancer. (Thompson M D., 2007,Hepatology May; 45(5):1298-305).

Wang et al. (2008) have shown that β-catenin can function as anoncogene. (Wang et al., 2008, Cancer Epidemiol. Biomarkers Prev. 17(8):2101-8). In patients with basal cell carcinoma an increased level inβ-catenin is present and leads to the increase in proliferation ofrelated tumors. Mutations in the β-catenin gene are a cause ofcolorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB),hepatoblastoma, and ovarian cancer.

The role of β-catenin in the development of colorectal cancer has beenshown to be regulated by the expression product of the APC (adenomatouspolyposis of the colon) gene, a tumor suppressor. (Korinek et al.,Science, 1997, 275:1784-1787; Morin et al., Science, 1997,275:1787-1790). The APC protein normally binds β-catenin in conjunctionwith TCF/LEF forming a transcription factor complex. Morin et al. (Morinet al., Science, 1997, 275:1787-1790) report that APC proteindown-regulates the transcriptional activation mediated by β-catenin andTcf-4 in colon cancer. Their results indicate that the regulation ofβ-catenin is critical to APC's tumor suppressive effect and that thisregulation can be circumvented by mutations in either APC or β-catenin.

Mutations in the β-catenin gene are either truncations that lead todeletion of part of the N-terminus of β-catenin, or point mutations thataffect the serine and threonine residues that are targeted by GSK3α/β orCKIα. These mutant β-catenin proteins are refractory to phosphorylationand thus escape proteasomal degradations. Consequently, β-cateninaccumulates within affected cells. Stabilized and nuclear-localizedβ-catenin is a hallmark of nearly all cases of colon cancer. (Clevers,H., 2006, Cell 127:469-480). Morin et al. demonstrated that mutations ofβ-catenin that altered phosphorylation sites rendered the cellsinsensitive to APC-mediated down-regulation of β-catenin and that thisdisrupted mechanism was critical to colorectal tumorigenesis. (Morin etal., 1997, Science 275:1787-1790).

Other studies also report on the detection of mutations in β-catenin invarious cancer cell lines (see e.g., Chan et al., 1999, Nature Genet.21:410-413; Blaker et al., 1999, Genes Chromosomes Cancer 25:399-402;Sagae et al., 1999, Jpn. J. Cancer Res. 90:510-515; Wang et al., 2008,Cancer Epidemiol. Biomarkers Prev. 17(8):2101-8). Additionally,abnormally high amounts of β-catenin have also been found in melanomacell lines (see e.g., Rubinfeld et al., 1997, Science, 275:1790-1792).

Likewise other cancers, such as hepatocellular carcinoma (HCC), havealso been associated with the Wnt/beta-catenin pathway. HCC is a complexand heterogeneous disease accounting for more than 660,000 new cases peryear worldwide. Multiple reports have shown that Wnt signalingcomponents are activated in human HCC patients. Activated Wnt signalingand nuclear beta-catenin correlate with recurrence of disease and poorprognosis (Takigawa et al. 2008, Curr Drug Targets November;9(11):1013-24). Elevated nuclear beta-catenin staining has beendocumented in 17-66% of HCC patients (Zulehner et al. 2010, Am J Pathol.January; 176(1):472-81; Yu et al. 2009, J Hepatol. May; 50(5):948-57).Merck's internal dataset on ˜300 HCC patient tumors generated incollaboration with the Hong Kong University indicates Wnt signalingcomponents are activated in 50% of HCC patients. External data haveshown activating beta-catenin mutations in 13-40% of HCC patients, whileinactivating Axin 1 or 2 mutations were present in ˜10% of HCC patients(Lee et al. 2006, Frontiers in Bioscience May 1:11:1901-1915).

Preclinical studies provide evidence that activation of theWnt/beta-catenin pathway is important in the generation and maintenanceof HCC. Liver-targeted disruption of APC in mice activates beta-cateninsignaling and leads to the formation of HCC (Colnot et al. 2004, ProcNatl Acad Sci USA. December 7; 101(49):17216-21). Althoughoverexpression of a beta-catenin mutant lacking the GSK-3betaphosphorylation sites alone is not sufficient for hepatocarcinogenesis(Harada et al. 2002, Cancer Res. April 1; 62(7):1971-7.), overexpressionof tumorigenic mutant beta-catenin has been shown to make micesusceptible to HCC induced by DEN (diethylnitrosamine), a knowncarcinogen (Nejak-Bowen et al. 2010, Hepatology 2010 May; 51(5):1603-13.Interestingly, 95% of HCC tumors initiated by overexpression of thehuman Met receptor in mice (Tre-Met transgenic mouse model) harborbeta-catenin activating mutations (Tward et al. 2007, Proc Natl Acad SciUSA. September 11; 104(37):14771-6). This finding reflects the humandisease and suggests that the Wnt pathway cooperates with Met signalingduring hepatocarcinogenesis. High rates of beta-catenin activatingmutations are also found in other transgenic mouse models for HCC (16%beta-catenin mutations in FGF19, 55% in c-Myc and 41% in H-Rastransgenic mice) (Nicholes et al. 2002, Am J Pathol. June;160(6):2295-307 de la Coste et al. 1998, Proc Natl Acad Sci USA. July21; 95(15):8847-51).

Preclinical studies have also shown that beta-catenin is a valid targetfor HCC. Beta-catenin siRNAs inhibit proliferation and viability ofhuman HCC cell lines (Zeng et al. 2007). Similarly, treatment of humanHCC cell lines with an anti-Wnt-1 antibody or TCF4/beta-cateninantagonists induce apoptosis, reduction of c-Myc, cyclin D1 and survivinexpression as well as suppress tumor growth in vivo (Wei et al. 2009,Mol Cancer September 24; 8:76; Wei et al. 2010, Int J Cancer. May 15;126(10):2426-36.2010).

Hepatocellular carcinoma (HCC) is a common and aggressive cancer forwhich effective therapies are lacking The Wnt/beta-catenin pathway isactivated in a high proportion of HCC cases (˜50%), frequently owing tomutations in beta-catenin (i.e. CTNNB1) or in the beta-catenindestruction complex (e.g. Axin1). Moreover, the Wnt pathway as a targethas proven to be challenging and is currently undruggable by smallmolecule inhibitors, making beta-catenin an attractive target for anRNAi-based therapeutic approach (Llovet et al. 2008, Hepatology October:48: 1312-1327).

Alteration of gene expression, specifically CTNNB1 gene expression,through RNA interference (hereinafter “RNAi”) is one approach formeeting this need. RNAi is induced by short single-stranded RNA(“siRNA”) or double-stranded RNA (“dsRNA”) molecules. The short dsRNAmolecules, called “short interfering nucleic acids (“siNA”)” or “shortinterfering RNA” or “siRNA” or “RNAi inhibitors” silence the expressionof messenger RNAs (“mRNAs”) that share sequence homology to the siNA.This can occur via cleavage of the mRNA mediated by an endonucleasecomplex containing a siNA, commonly referred to as an RNA-inducedsilencing complex (RISC). Cleavage of the target RNA typically takesplace in the middle of the region complementary to the guide sequence ofthe siNA duplex (Elbashir et al., 2001, Genes Dev., 15:188). Inaddition, RNA interference can also involve small RNA (e.g., micro-RNAor miRNA) mediated gene silencing, presumably through cellularmechanisms that either inhibit translation or that regulate chromatinstructure and thereby prevent transcription of target gene sequences(see for example Allshire, 2002, Science, 297:1818-1819; Volpe et al.,2002, Science, 297:1833-1837; Jenuwein, 2002, Science, 297:2215-2218;and Hall et al., 2002, Science, 297:2232-2237). Despite significantadvances in the field of RNAi, there remains a need for agents that caninhibit CTNNB1 gene expression and that can treat disease associatedwith CTNNB1 expression such as cancer.

SUMMARY OF THE INVENTION

The invention provides a solution to the problem of treating diseasesthat respond to the modulation of the CTNNB1 gene expression using novelshort interfering nucleic acid (siNA) molecules to modulate CTNNB1expression.

The present invention provides compounds, compositions, and methodsuseful for modulating the expression of CTNNB1 genes, specifically thoseCTNNB1 genes associated with cancer and for treating such conditions byRNA interference (RNAi) using small nucleic acid molecules.

In particular, the instant invention features small nucleic acidmolecules, i.e., short interfering nucleic acid (siNA) moleculesincluding, but not limited to, short interfering RNA (siRNA),double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA(shRNA) and circular RNA molecules and methods used to modulate theexpression of CTNNB1 genes and/or other genes involved in pathways ofCTNNB1 gene expression and/or activity.

In one aspect, the invention provides double-stranded short interferingnucleic acid (siNA) molecules that inhibit the expression of a CTNNB1gene in a cell or mammal, wherein the double-stranded siNAs comprise asense and an antisense stand. The antisense strand comprises a sequencethat is complementary to at least a part of an RNA associated with theexpression of the CTNNB1 gene. The sense strand comprises a sequencethat is complementary to the antisense strand. In various embodiments,at least one strand comprises at least a 15 nucleotide sequence selectedfrom the group of sequences consisting of SEQ ID NOS:1-6374. In certainembodiments, the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementarity to a target sequence setforth in Table 1a. In other and/or in the same embodiments, theantisense strand comprises at least a 15, 16, 17, 18, or 19 nucleotidesequence of one of the antisense sequences set forth in Table 1b. Insome embodiments, the sense strand comprises at least a 15, 16, 17, 18,or 19 nucleotide sequence of a sense strand sequence as set forth inTable 1b.

In certain embodiments of this aspect of the invention, double-strandedshort interfering nucleic acid (siNA) molecules are provided wherein theantisense stand comprises a modified sequence as set forth in Table 1cthat has sequence complementarity to a target sequence of the invention.In some embodiments, the sense strand also comprises a modified sequenceas set forth in Table 1c.

In certain embodiments, the present invention provides a double-strandedshort interfering nucleic acid (siNA) molecule that modulates theexpression of CTNNB1, wherein the siNA comprises a sense strand and anantisense strand; each strand is independently 15 to 30 nucleotides inlength; and the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementary to any of:

5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 5) 5′-ACGACUAGUUCAGUUGCUU-3′;(SEQ ID NO: 194) 5′-GGAUGAUCCUAGCUAUCGU-3′; (SEQ ID NO: 196) or5′-CCAGGAUGAUCCUAGCUAU-3′. (SEQ ID NO: 151)

In some embodiments of the invention, the antisense strand of a siNAmolecule comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

5′-UUUCGAAUCAAUCCAACAG-3′; (SEQ ID NO: 4918) 5′-AAGCAACUGAACUAGUCGU-3′;(SEQ ID NO: 5107) 5′-ACGAUAGCUAGGAUCAUCC-3′; (SEQ ID NO: 5109) or5′-AUAGCUAGGAUCAUCCUGG-3′; (SEQ ID NO: 5064)

In some embodiments, the sense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 5) 5′-ACGACUAGUUCAGUUGCUU-3′;(SEQ ID NO: 194) 5′-GGAUGAUCCUAGCUAUCGU-3′; (SEQ ID NO: 196) or5′-CCAGGAUGAUCCUAGCUAU-3′. (SEQ ID NO: 151)

In some embodiments, a siNA molecule of the invention comprises any of:

5′-CUGUUGGAUUGAUUCGAAA-3′ (SEQ ID NO: 5) and 5′-UUUCGAAUCAAUCCAACAG-3′;(SEQ ID NO: 4918) or 5′-ACGACUAGUUCAGUUGCUU-3′ (SEQ ID NO: 194) and5′-AAGCAACUGAACUAGUCGU-3′; (SEQ ID NO: 5107) or5′-GGAUGAUCCUAGCUAUCGU-3′ (SEQ ID NO: 196) and5′-ACGAUAGCUAGGAUCAUCC-3′; (SEQ ID NO: 5109) or5′-CCAGGAUGAUCCUAGCUAU-3′ (SEQ ID NO: 151) and5′-AUAGCUAGGAUCAUCCUGG-3′. (SEQ ID NO: 5064)

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6372 and 6374.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6370 and 6369.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 2021 and 2068.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 6372 and 6373.

In some embodiments, a siNA molecule of the invention comprises SEQ IDNOS: 2147 and 6368

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA) of        the invention;    -   (b) a cationic lipid compound having any of compound numbers        1-46 or any combination thereof;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA) of        the invention;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 6372 and 6374;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 6370 and 6369;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 2021 and 2068;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 6372 and 6373;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, the invention features a composition comprising:

-   -   (a) a double-stranded short interfering nucleic acid (siNA)        having SEQ ID NOS: 2147 and 6368;    -   (b) (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;    -   (c) cholesterol;    -   (d) DSPC; and    -   (e) PEG-DMG.

In some embodiments, a composition of the invention comprises anyCationic Lipid having any of compound numbers 1-46 in the followingmolar ratios:

Cationic Lipid/Cholesterol/PEG-DMG 56.6/38/5.4;

Cationic Lipid/Cholesterol/PEG-DMG 60/38/2;

Cationic Lipid/Cholesterol/PEG-DMG 67.3/29/3.7;

Cationic Lipid/Cholesterol/PEG-DMG 49.3/47/3.7;

Cationic Lipid/Cholesterol/PEG-DMG 50.3/44.3/5.4;

Cationic Lipid/Cholesterol/PEG-C-DMA/DSPC 40/48/2/10;

Cationic Lipid/Cholesterol/PEG-DMG/DSPC 40/48/2/10; and

Cationic Lipid/Cholesterol/PEG-DMG/DSPC 58/30/2/10.

In some embodiments, a composition of the invention comprises(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, cholesterol,DSPC, and PEG-DMG, having a molar ratio of 50:30:10:2 respectively.

In some embodiments, a composition of the invention further comprises acryo-protectant. In some embodiments, the cryoprotectant is Sucrose,Trehalose, Raffinose, Stachyose, Verbascose, Mannitol, Glucose, Lactose,Maltose, Maltotriose-heptaose, Dextran, Hydroxyethyl Starch, Insulin,Sorbitol, Glycerol, Arginine, Histidine, Lysine, Proline,Dimethylsulfoxide or any combination thereof. In some embodiments, thecryoprotectant is Sucrose. In some embodiments, the cryoprotectant isTrehalose. In some embodiments, the cryoprotectant is a combination ofSucrose and Trehalose.

In some embodiments of the invention, all of the nucleotides of siNAs ofthe invention are unmodified. In other embodiments, one or more (e.g.,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) of the nucleotide positionsindependently in either one or both strands of an siNA molecule aremodified. Modifications include nucleic acid sugar modifications, basemodifications, backbone (internucleotide linkage) modifications,non-nucleotide modifications, and/or any combination thereof. In certaininstances, purine and pyrimidine nucleotides are differentiallymodified. For example, purine and pyrimidine nucleotides can bedifferentially modified at the 2′-sugar position (i.e., at least onepurine has a different modification from at least one pyrimidine in thesame or different strand at the 2′-sugar position). In certain instancesthe purines are unmodified in one or both strands, while the pyrimidinesin one or both strands are modified. In certain other instances, thepyrimidines are unmodified in one or both strands, while the purines inone or both strands are modified. In some instances, at least onemodified nucleotide is a 2′-deoxy-2′-fluoro nucleotide, a 2′-deoxynucleotide, or a 2′-O-alkyl nucleotide. In some instances, at least 5 ormore of the pyrimidine nucleotides in one or both stands are either all2′-deoxy-2′-fluoro or all 2′-O-methylpyrimidine nucleotides. In someinstances, at least 5 or more of the purine nucleotides in one or bothstands are either all 2′-deoxy-2′-fluoro or all 2′-O-methyl purinenucleotides. In certain instances, wherein the siNA molecules compriseone or more modifications as described herein, the nucleotides atpositions 1, 2, and 3 at the 5′ end of the guide (antisense) strand areunmodified.

In certain embodiments, the siNA molecules of the invention have 3′overhangs of one, two, three, or four nucleotide(s) on one or both ofthe strands. In other embodiments, the siNA molecules lack overhangs(i.e., have blunt ends). Preferably, the siNA molecule has 3′ overhangsof two nucleotides on both the sense and antisense strands. Theoverhangs can be modified or unmodified. Examples of modifiednucleotides in the overhangs include, but are not limited to, 2′-O-alkylnucleotides, 2′-deoxy-2′-fluoro nucleotides, locked nucleic acid (LNA)nucleotides, or 2′-deoxy nucleotides. The overhang nucleotides in theantisense strand can comprise nucleotides that are complementary tonucleotides in the CTNNB1 target sequence. Likewise, the overhangs inthe sense stand can comprise nucleotides that are in the CTNNB1 targetsequence. In certain instances, the siNA molecules of the invention havetwo 3′ overhang nucleotides on the antisense stand that are 2′-O-alkyl(e.g., 2′-O-methyl) nucleotides and two 3′ overhang nucleotides on thesense stand that are 2′-deoxy nucleotides. In other instances, the siNAmolecules of the invention have two 3′ overhang nucleotides that are2′-O-alkyl (e.g., 2′-O-methyl) nucleotides on both the antisense standand on the sense stand. In certain embodiments, the 2′-O-alkylnucleotides are 2′-O-methyl uridine nucleotides. In certain instances,the overhangs also comprise one or more phosphorothioate linkagesbetween nucleotides of the overhang.

In some embodiments, the siNA molecules of the invention have caps (alsoreferred to herein as “terminal caps.” The cap can be present at the5′-terminus (5′-cap) or at the 3′-terminus (3′-cap) or can be present onboth termini, such as at the 5′ and 3′ termini of the sense strand ofthe siNA.

In some embodiments, the siNA molecules of the invention arephosphorylated at the 5′ end of the antisense strand. The phosphategroup can be a phosphate, a diphosphate or a triphosphate.

The siNA molecules of the invention when double stranded can besymmetric or asymmetric. Each strand of these double stranded siNAsindependently can range in nucleotide length between 3 and 30nucleotides. Generally, each strand of the siNA molecules of theinvention is about 15 to 30 (i.e., about 19, 20, 21, 22, 23 or 24)nucleotides in length.

The siNA molecules of the invention, which are double stranded or have aduplex structure, independently comprise about 3 to about 30 (e.g.,about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) base pairs. Generally, theduplex structure of siNAs of the invention is between 15 and 30, moregenerally between 18 and 25, yet more generally between 19 and 24, andmost generally between 19 and 21 base pairs in length.

In certain embodiments, double-stranded short interfering nucleic acid(siNA) molecules are provided, wherein the molecule has a sense strandand an antisense strand and comprises formula (A):

B—N_(X3)—(N)_(X2)B-3′

B(N)_(X1)—N_(X4)—[N]_(X5)-5′  (A)

-   -   wherein, the upper strand is the sense strand and the lower        strand is the antisense strand of the double-stranded nucleic        acid molecule; wherein the antisense strand comprises at least a        15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 4918,        SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064, and the        sense strand comprises a sequence having complementarity to the        antisense strand;    -   each N is independently a nucleotide which is unmodified or        chemically modified or a non-nucleotide;    -   each B is a terminal cap that is present or absent;    -   (N) represents overhanging nucleotides, each of which is        independently unmodified or chemically modified;    -   [N] represents nucleotides that are ribonucleotides;    -   X1 and X2 are independently integers from 0 to 4;    -   X3 is an integer from 15 to 30;    -   X4 is an integer from 9 to 30; and    -   X5 is an integer from 0 to 6, provided that the sum of X4 and X5        is 15-30.

In one embodiment, the invention features a double-stranded shortinterfering nucleic acid (siNA) of formula (A); wherein

-   -   (a) one or more pyrimidine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (b) one or more purine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (c) one or more pyrimidine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof; and    -   (d) one or more purine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides,

The present invention further provides compositions comprising thedouble-stranded nucleic acid molecules described herein with optionallya pharmaceutically acceptable carrier or diluent.

The administration of the composition can be carried out by knownmethods, wherein the nucleic acid is introduced into a desired targetcell in vitro or in vivo.

Commonly used techniques for introduction of the nucleic acid moleculesof the invention into cells, tissues, and organisms include the use ofvarious carrier systems, reagents and vectors. Non-limiting examples ofsuch carrier systems suitable for use in the present invention includeconjugates, nucleic-acid-lipid particles, lipid nanoparticles (LNP),liposomes, lipoplexes, micelles, virosomes, virus like particles (VLP),nucleic acid complexes, and mixtures thereof.

The compositions of the invention can be in the form of an aerosol,dispersion, solution (e.g., an injectable solution), a cream, ointment,tablet, powder, suspension or the like. These compositions may beadministered in any suitable way, e.g. orally, sublingually, buccally,parenterally, nasally, or topically. In some embodiments, thecompositions are aerosolized and delivered via inhalation.

The molecules and compositions of the present invention have utilityover a broad range of therapeutic applications. Accordingly anotheraspect of this invention relates to the use of the compounds andcompositions of the invention in treating a subject. The invention thusprovides a method for treating a subject, such as a human, sufferingfrom a condition which is mediated by the action, or by the loss ofaction, of CTNNB1, wherein the method comprises administering to thesubject an effective amount of a double-stranded short interferingnucleic acid (siNA) molecule of the invention. In certain embodiments,the condition is cancer.

These and other aspects of the invention will be apparent upon referenceto the following detailed description and attached figures. Moreover, itis contemplated that any method or composition described herein can beimplemented with respect to any other method or composition describedherein and that different embodiments may be combined.

Additionally, patents, patent applications, and other documents arecited throughout the specification to describe and more specifically setforth various aspects of this invention. Each of these references citedherein is hereby incorporated by reference in its entirety, includingthe drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a non-limiting proposed mechanistic representation oftarget RNA degradation involved in RNAi. Double-stranded RNA (dsRNA),which is generated by RNA-dependent RNA polymerase (RdRP) from foreignsingle-stranded RNA, for example viral, transposon, or other exogenousRNA, activates the DICER enzyme that in turn generates siNA duplexes.Alternately, synthetic or expressed siNA can be introduced directly intoa cell by appropriate means. An active siNA complex forms thatrecognizes a target RNA, resulting in degradation of the target RNA bythe RISC endonuclease complex or in the synthesis of additional RNA byRNA-dependent RNA polymerase (RdRP), which can activate DICER and resultin additional siNA molecules, thereby amplifying the RNAi response.

FIG. 2 shows non-limiting examples of chemically modified siNAconstructs of the present invention using a generalized structure of arepresentative siNA duplex. The specific modifications shown in thefigure can be utilized alone or in combination with other modificationsof the figure, in addition to other modifications and features describedherein with reference to any siNA molecule of the invention. In thefigure, N stands for any nucleotide or optionally a non-nucleotide asdescribed here. The upper strand, having B—N_(X3)—(N)_(X2)—B-3′ is thesense (or passenger) strand of the siNA, whereas the lower strand,having B(N)_(X1)—N_(X4)—[N]_(X5)-5′ is the antisense (or guide) strandof the siNA. Nucleotides (or optional non-nucleotides) of internalportions of the sense strand are designated N_(X3) and nucleotides (oroptional non-nucleotides) of internal portions of the antisense strandare designated N_(X4). Nucleotides (or optional non-nucleotides) of theinternal portions are generally base paired between the two strands, butcan optionally lack base pairing (e.g. have mismatches or gaps) in someembodiments. Nucleotides (or optional non-nucleotides) of overhangregions are designated by parenthesis (N). Nucleotides of the5′-terminal portion of the antisense strand are designated [N]. Terminalcaps are optionally present at the 5′ and/or 3′ end of the sense strandand further optionally present at the 3′-end of the antisense strand.Generally, each strand can independently range from about 15 to about 30nucleotides in length, but can vary depending on the presence of anyoverhang nucleotides. In certain embodiments, X1 and X2 areindependently integers from 0 to 4; X3 is an integer from 15 to 30; X4is an integer from 9 to 30; X5 is an integer from 0 to 6, provided thatthe sum of X4 and X5 is 15-30. Various modifications are shown for thenucleotides of the sense and antisense strands of the siNA constructs.The (N) overhang nucleotide positions can be chemically modified asdescribed herein (e.g., 2′-O-methyl, 2′-deoxy-2′-fluoro, 2′-deoxy, LNA,universal bases etc.) and can be either derived from a correspondingtarget nucleic acid sequence or not. The constructs shown in the figurecan also comprise phosphorothioate linkages as described herein. Forexample, phosphorothioate linkages can exist between any N, (N), and/or[N] positions. Such phosphorothioate incorporation can be utilizedbetween purine “R” and pyrimidine “Y” positions, or for stabilization ofpyrimidine linkages in general. Furthermore, although not depicted onthe Figure, the constructs shown in the figure can optionally include aribonucleotide at the 9th position from the 5′-end of the sense strandor the 11^(th) position based on the 5′-end of the guide strand bycounting 11 nucleotide positions in from the 5′-terminus of the guidestrand. Similarly, the antisense strand can include a ribonucleotide atthe 14^(th) position from the 5′-end, or alternately can be selected ordesigned so that a 2′-O-alkyl nucleotide (e.g., a 2′-O-methyl purine) isnot present at this position. Furthermore, although not shown in theFigure, the 5′-terminal position of the antisense strand can comprise aterminal phosphate group as described herein. The antisense strandgenerally comprises sequence complementary to any target nucleic acidsequence of the invention, such as those set forth in Table 1a herein.

FIG. 3 shows non-limiting examples of certain combinations ofmodifications applied to the representative siNA duplex described inFIG. 2. The table shown below the representative structure providesspecific combinations of (N)_(X1), (N)_(X2), N_(X3), N_(X4), and/or[N]_(X5) nucleotide (and optional non-nucleotide) positions. Forexample, combinations of 5 or more (e.g., 5, 6, 7, 8, 9, or 10 or more)N_(X3) and 5 or more (e.g., 5, 6, 7, 8, 9, or 10 or more) N_(X4)pyrimidine “Y” and purine “R” nucleotides are specified, each of whichcan independently have specific (N)_(X1), and/or (N)_(X2), substitutionsas shown in the figure, in addition to optional phosphorothioatesubstitutions. The 5′-terminal antisense strand [N] nucleotides aregenerally ribonucleotides, but can also be modified or unmodifieddepending on if they are purine “R” or pyrimidine “Y” nucleotides

FIG. 4A-C shows non-limiting examples of different siNA constructs ofthe invention. The criteria of the representative structures shown inFIGS. 2 and 3 can be applied to any of the structures shown in FIG.4A-C.

The examples shown in FIG. 4A (constructs 1, 2, and 3) have 19representative base pairs; however, different embodiments of theinvention include any number of base pairs described herein. Bracketedregions represent nucleotide overhangs, for example, comprising about 1,2, 3, or 4 nucleotides in length, preferably about 2 nucleotides.Constructs 1 and 2 can be used independently for RNAi activity.Construct 2 can comprise a polynucleotide or non-nucleotide linker,which can optionally be designed as a biodegradable linker. In oneembodiment, the loop structure shown in construct 2 can comprise abiodegradable linker that results in the formation of construct 1 invivo and/or in vitro. In another example, construct 3 can be used togenerate construct 2 under the same principle wherein a linker is usedto generate the active siNA construct 2 in vivo and/or in vitro, whichcan optionally utilize another biodegradable linker to generate theactive siNA construct 1 in vivo and/or in vitro. As such, the stabilityand/or activity of the siNA constructs can be modulated based on thedesign of the siNA construct for use in vivo or in vitro and/or invitro.

The examples shown in FIG. 4B represent different variations ofdouble-stranded nucleic acid molecule of the invention, such asmicroRNA, that can include overhangs, bulges, loops, and stem-loopsresulting from partial complementarity. Such motifs having bulges,loops, and stem-loops are generally characteristics of miRNA. Thebulges, loops, and stem-loops can result from any degree of partialcomplementarity, such as mismatches or bulges of about 1, 2, 3, 4, 5, 6,7, 8, 9, 10 or more nucleotides in one or both strands of thedouble-stranded nucleic acid molecule of the invention.

The example shown in FIG. 4C represents a model double-stranded nucleicacid molecule of the invention comprising a 19 base pair duplex of two21 nucleotide sequences having dinucleotide 3′-overhangs. The top strand(1) represents the sense strand (passenger strand), the middle strand(2) represents the antisense (guide strand), and the lower strand (3)represents a target polynucleotide sequence. The dinucleotide overhangs(NN) can comprise a sequence derived from the target polynucleotide. Forexample, the 3′-(NN) sequence in the guide strand can be complementaryto the 5′-[NN] sequence of the target polynucleotide. In addition, the5′-(NN) sequence of the passenger strand can comprise the same sequenceas the 5′-[NN] sequence of the target polynucleotide sequence. In otherembodiments, the overhangs (NN) are not derived from the targetpolynucleotide sequence, for example where the 3′-(NN) sequence in theguide strand are not complementary to the 5′-[NN] sequence of the targetpolynucleotide and the 5′-(NN) sequence of the passenger strand cancomprise different sequence from the 5′-[NN] sequence of the targetpolynucleotide sequence. In additional embodiments, any (NN) nucleotidesare chemically modified, e.g., as 2′-O-methyl, 2′-deoxy-2′-fluoro,and/or other modifications herein. Furthermore, the passenger strand cancomprise a ribonucleotide position N of the passenger strand. For therepresentative 19 base pair 21 mer duplex shown, position N can be 9nucleotides in from the 3′ end of the passenger strand. However, induplexes of differing length, the position N is determined based on the5′-end of the guide strand by counting 11 nucleotide positions in fromthe 5′-terminus of the guide strand and picking the corresponding basepaired nucleotide in the passenger strand. Cleavage by Ago2 takes placebetween positions 10 and 11 as indicated by the arrow. In additionalembodiments, there are two ribonucleotides, NN, at positions 10 and 11based on the 5′-end of the guide strand by counting 10 and 11 nucleotidepositions in from the 5′-terminus of the guide strand and picking thecorresponding base paired nucleotides in the passenger strand.

FIG. 5 shows non-limiting examples of different stabilizationchemistries (1-10) that can be used, for example, to stabilize the 5′and/or 3′-ends of siNA sequences of the invention, including (1)[3-3′]-inverted deoxyribose; (2) deoxyribonucleotide; (3)[5′-3′]-3′-deoxyribonucleotide; (4) [5′-3′]-ribonucleotide; (5)[5′-3′]-3′-O-methyl ribonucleotide; (6) 3′-glyceryl; (7)[3′-5′]-3′-deoxyribonucleotide; (8) [3′-3′]-deoxyribonucleotide; (9)[5′-2′]-deoxyribonucleotide; and (10) [5-3′]-dideoxyribonucleotide (whenX═O). In addition to modified and unmodified backbone chemistriesindicated in the figure, these chemistries can be combined withdifferent sugar and base nucleotide modifications as described herein.

FIG. 6 shows a non-limiting example of a strategy used to identifychemically modified siNA constructs of the invention that are nucleaseresistant while preserving the ability to mediate RNAi activity.Chemical modifications are introduced into the siNA construct based oneducated design parameters (e.g. introducing 2′-modifications, basemodifications, backbone modifications, terminal cap modifications etc).The modified construct is tested in an appropriate system (e.g., humanserum for nuclease resistance, shown, or an animal model for PK/deliveryparameters). In parallel, the siNA construct is tested for RNAiactivity, for example in a cell culture system such as a luciferasereporter assay and/or against endogenous mRNA). Lead siNA constructs arethen identified which possess a particular characteristic whilemaintaining RNAi activity, and can be further modified and assayed onceagain. This same approach can be used to identify siNA-conjugatemolecules with improved pharmacokinetic profiles, delivery, and RNAiactivity.

FIG. 7 shows non-limiting examples of phosphorylated siNA molecules ofthe invention, including linear and duplex constructs and asymmetricderivatives thereof.

FIG. 8 shows non-limiting examples of chemically modified terminalphosphate groups of the invention.

FIG. 9 shows a non-limiting example of a cholesterol linkedphosphoramidite that can be used to synthesize cholesterol conjugatedsiNA molecules of the invention. An example is shown with thecholesterol moiety linked to the 5′-end of the sense strand of an siNAmolecule.

FIG. 10 depicts an embodiment of 5′ and 3′ inverted abasic cap linked toa nucleic acid strand.

DETAILED DESCRIPTION OF THE INVENTION A. Terms and Definitions

The following terminology and definitions apply as used in the presentapplication.

The term “abasic” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to sugar moieties lackinga nucleobase or having a hydrogen atom (H) or other non-nucleobasechemical groups in place of a nucleobase at the 1′ position of the sugarmoiety, see for example Adamic et al., U.S. Pat. No. 5,998,203. In oneembodiment, an abasic moiety of the invention is a ribose, deoxyribose,or dideoxyribose sugar.

The term “acyclic nucleotide” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to anynucleotide having an acyclic ribose sugar, for example where any of theribose carbon/carbon or carbon/oxygen bonds are independently or incombination absent from the nucleotide.

The term “alkyl” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to a saturated orunsaturated hydrocarbons, including straight-chain, branched-chain,alkenyl, alkynyl groups and cyclic groups, but excludes aromatic groups.Notwithstanding the foregoing, alkyl also refers to non-aromaticheterocyclic groups. Preferably, the alkyl group has 1 to 12 carbons.More preferably, it is a lower alkyl of from 1 to 7 carbons, morepreferably 1 to 4 carbons. The alkyl group can be substituted orunsubstituted. When substituted, the substituted group(s) is preferably,hydroxyl, halogen, cyano, C1-C4 alkoxy, ═O, ═S, NO₂, SH, NH₂, or NR₁R₂,where R₁ and R₂ independently are H or C1-C4 alkyl.

The phrase “agents that interfere with cell cycle checkpoints” refers tocompounds that inhibit protein kinases that transduce cell cyclecheckpoint signals, thereby sensitizing the cancer cell to DNA damagingagents.

The phrase “agents that interfere with receptor tyrosine kinases (RTKs)”refers to compounds that inhibit RTKs and therefore inhibit mechanismsinvolved in oncogenesis and tumor progression.

The phrase “androgen receptor modulators” refers to compounds thatinterfere or inhibit the binding of androgens to the receptor,regardless of mechanism.

The phrase “angiogenesis inhibitors” refers to compounds that inhibitthe formation of new blood vessels, regardless of mechanism.

The term “aryl” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to an aromatic group thathas at least one ring having a conjugated pi electron system andincludes carbocyclic aryl, heterocyclic aryl and biaryl groups, all ofwhich can be optionally substituted. The preferred substituent(s) ofaryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, C1-C4alkoxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, NH₂, and NR₁R₂groups, where R₁ and R₂ independently are H or C1-C4 alkyl.

The term “alkylaryl” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to an alkylgroup (as described above) covalently joined to an aryl group (asdescribed above). Carbocyclic aryl groups are groups wherein the ringatoms on the aromatic ring are all carbon atoms. The carbon atoms areoptionally substituted. Heterocyclic aryl groups are groups having from1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainderof the ring atoms are carbon atoms. Suitable heteroatoms include oxygen,sulfur, and nitrogen, and examples of heterocyclic aryl groups havingsuch heteroatoms include furanyl, thienyl, pyridyl, pyrrolyl, N-loweralkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, alloptionally substituted. Preferably, the alkyl group is a C1-C4 alkylgroup.

The term “amide” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers to an —C(O)—NH—R, where Ris either alkyl, aryl, alkylaryl or hydrogen.

The phrase “antisense region” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to a nucleotide sequence ofan siNA molecule having complementarity to a target nucleic acidsequence. In addition, the antisense region of an siNA molecule canoptionally comprise a nucleic acid sequence having complementarity to asense region of the siNA molecule. In one embodiment, the antisenseregion of the siNA molecule is referred to as the antisense strand orguide strand.

The phrase “asymmetric hairpin” refers to a linear siNA moleculecomprising an antisense region, a loop portion that can comprisenucleotides or non-nucleotides, and a sense region that comprises fewernucleotides than the antisense region to the extent that the senseregion has enough complementary nucleotides to base pair with theantisense region and form a duplex with loop. For example, an asymmetrichairpin siNA molecule of the invention can comprise an antisense regionhaving length sufficient to mediate RNAi in a cell or in vitro system(e.g. about 15 to about 30, or about 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, or 30 nucleotides) and a loop region comprisingabout 4 to about 12 (e.g., about 4, 5, 6, 7, 8, 9, 10, 11, or 12)nucleotides, and a sense region having about 3 to about 25 (e.g., about3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,23, 24, or 25) nucleotides that are complementary to the antisenseregion. The asymmetric hairpin siNA molecule can also comprise a5′-terminal phosphate group that can be chemically modified. The loopportion of the asymmetric hairpin siNA molecule can comprisenucleotides, non-nucleotides, linker molecules, or conjugate moleculesas described herein.

The term “biodegradable” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to degradationin a biological system, for example, enzymatic degradation or chemicaldegradation.

The term “biodegradable linker” as used herein refers to its meaning asis generally accepted in the art. With reference to exemplary nucleicacid molecules of the invention, the term refers to a linker moleculethat is designed to connect one molecule to another molecule, and whichis susceptible to degradation in a biological system. The linker can bea nucleic acid or non-nucleic acid based linker. For example, abiodegradable linker can be used to attach a ligand or biologicallyactive molecule to an siNA molecule of the invention. Alternately, abiodegradable linker can be used to connect the sense and antisensestrands of an siNA molecule of the invention. The biodegradable linkeris designed such that its stability can be modulated for a particularpurpose, such as delivery to a particular tissue or cell type. Thestability of a nucleic acid-based biodegradable linker molecule can bemodulated by using various chemistries, for example combinations ofribonucleotides, deoxyribonucleotides, and chemically modifiednucleotides, such as 2′-O-methyl, 2′-fluoro, 2′-amino, 2′-β-amino,2′-C-allyl, 2′-O-allyl, and other 2′-modified or base modifiednucleotides. The biodegradable nucleic acid linker molecule can be adimer, trimer, tetramer or longer nucleic acid molecule, for example, anoligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, or 20 nucleotides in length, or can comprise a singlenucleotide with a phosphorus-based linkage, for example, aphosphoramidate or phosphodiester linkage. The biodegradable nucleicacid linker molecule can also comprise nucleic acid backbone, nucleicacid sugar, or nucleic acid base modifications.

The phrase “biologically active molecule” as used herein refers to itsmeaning as is generally accepted in the art. With reference to exemplarynucleic acid molecules of the invention, the term refers to compounds ormolecules that are capable of eliciting or modifying a biologicalresponse in a system and/or are capable of modulating thepharmacokinetics and/or pharmacodynamics of other biologically activemolecules. Examples of biologically active molecules, include siNAmolecules alone or in combination with other molecules including, butnot limited to therapeutically active molecules such as antibodies,cholesterol, hormones, antivirals, peptides, proteins,chemotherapeutics, small molecules, vitamins, co-factors, nucleosides,nucleotides, oligonucleotides, enzymatic nucleic acids, antisensenucleic acids, triplex forming oligonucleotides, polyamines, polyamides,polyethylene glycol, other polyethers, 2-5A chimeras, siNA, dsRNA,allozymes, aptamers, decoys and analogs thereof.

The phrase “biological system” as used herein refers to its meaning asis generally accepted in the art. The term generally refers to material,in a purified or unpurified form, from biological sources including, butnot limited to, human or animal, wherein the system comprises thecomponents required for RNAi activity. Thus, the phrase includes, forexample, a cell, tissue, subject, or organism, or extract thereof. Theterm also includes reconstituted material from a biological source.

The phrase “blunt end” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to termini of adouble-stranded siNA molecule having no overhanging nucleotides. Forexample, the two strands of a double-stranded siNA molecule having bluntends align with each other with matched base-pairs without overhangingnucleotides at the termini. A siNA duplex molecule of the invention cancomprise blunt ends at one or both termini of the duplex, such astermini located at the 5′-end of the antisense strand, the 5′-end of thesense strand, or both termini of the duplex.

The term “cap” also referred to herein as “terminal cap,” as used hereinrefers to its meaning as is generally accepted in the art. Withreference to exemplary nucleic acid molecules of the invention, the termrefers to a moiety, which can be a chemically modified nucleotide ornon-nucleotide that can be incorporated at one or more termini of one ormore nucleic acid molecules of the invention. These terminalmodifications protect the nucleic acid molecule from exonucleasedegradation, and can help in delivery and/or localization within a cell.The cap can be present at the 5′-terminus (5′-cap) or at the 3′-terminal(3′-cap) or can be present on both termini of any nucleic acid moleculeof the invention. A cap can be present at the 5′-end, 3-end and/or 5′and 3′-ends of the sense strand of a nucleic acid molecule of theinvention. Additionally, a cap can optionally be present at the 3′-endof the antisense strand of a nucleic acid molecule of the invention. Innon-limiting examples, the 5′-cap includes, but is not limited to, LNA;glyceryl; inverted deoxy abasic residue (moiety); 4′,5′-methylenenucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide;carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides;alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage;threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide;3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety;3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety;1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexylphosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; orbridging or non-bridging methylphosphonate moiety. Non-limiting examplesof the 3′-cap include, but are not limited to, LNA; glyceryl; inverteddeoxy abasic residue (moiety); 4′,5′-methylene nucleotide;1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide; carbocyclicnucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate;3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecylphosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide;L-nucleotide; alpha-nucleotide; modified base nucleotide;phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seconucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentylnucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasicmoiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediolphosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate;phosphorothioate and/or phosphorodithioate; bridging or non bridgingmethylphosphonate; and 5′-mercapto moieties (for more details seeBeaucage and Iyer, 1993, Tetrahedron 49, 1925; incorporated by referenceherein). FIG. 5 shows some non-limiting examples of various caps.

The term “cell” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary nucleic acid moleculesof the invention, the term is used in its usual biological sense, anddoes not refer to an entire multicellular organism, e.g., specificallydoes not refer to a human being. The cell can be present in an organism,e.g., birds, plants and mammals, such as humans, cows, sheep, apes,monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g.,bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cellcan be of somatic or germ line origin, totipotent or pluripotent,dividing or non-dividing. The cell can also be derived from or cancomprise a gamete or embryo, a stem cell, or a fully differentiatedcell.

The phrase “chemical modification” as used herein refers to its meaningas is generally accepted in the art. With reference to exemplary nucleicacid molecules of the invention, the term refers to any modification ofthe chemical structure of the nucleotides that differs from nucleotidesof native siRNA or RNA in general. The term “chemical modification”encompasses the addition, substitution, or modification of native siRNAor RNA at the sugar, base, or internucleotide linkage, as describedherein or as is otherwise known in the art. In certain embodiments, theterm “chemical modification” can refer to certain forms of RNA that arenaturally occurring in certain biological systems, for example2′-O-methyl modifications or inosine modifications.

The term “CTNNB1” refers to catenin (cadherin-associated protein), beta1 which is gene that encodes CTNNB1 proteins, CTNNB1 peptides, CTNNB1polypeptides, CTNNB1 regulatory polynucleotides (e.g., CTNNB1 miRNAs andsiNAs), mutant CTNNB1 genes, and splice variants of a CTNNB1 genes, aswell as other genes involved in CTNNB1 pathways of gene expressionand/or activity. Thus, each of the embodiments described herein withreference to the term “CTNNB1” are applicable to all of the protein,peptide, polypeptide, and/or polynucleotide molecules covered by theterm “CTNNB1”, as that term is defined herein. Comprehensively, suchgene targets are also referred to herein generally as “target” sequences(including the target sequences listed in Table 1a).

The term “complementarity” or “complementary” as used herein refers toits meaning as is generally accepted in the art. With reference toexemplary nucleic acid molecules of the invention, the terms generallyrefer to the formation or existence of hydrogen bond(s) between onenucleic acid sequence and another nucleic acid sequence by eithertraditional Watson-Crick or other non-traditional types of bonding asdescribed herein. In reference to the nucleic molecules of the presentinvention, the binding free energy for a nucleic acid molecule with itscomplementary sequence is sufficient to allow the relevant function ofthe nucleic acid to proceed, e.g., RNAi activity. Determination ofbinding free energies for nucleic acid molecules is well known in theart (see, e.g., Turner et al., 1987, CSH Symp. Quant. Biol. LII pp.123-133; Frier et al., 1986, Proc. Nat. Acad. Sci. USA 83:9373-9377;Turner et al., 1987, J. Am. Chem. Soc. 109:3783-3785). Perfectcomplementary means that all the contiguous residues of a nucleic acidsequence will hydrogen bond with the same number of contiguous residuesin a second nucleic acid sequence. Partial complementarity can includevarious mismatches or non-based paired nucleotides (e.g., 1, 2, 3, 4, 5,6, 7, 8, 9, 10 or more mismatches, non-nucleotide linkers, or non-basedpaired nucleotides) within the nucleic acid molecule, which can resultin bulges, loops, or overhangs that result between the sense strand orsense region and the antisense strand or antisense region of the nucleicacid molecule or between the antisense strand or antisense region of thenucleic acid molecule and a corresponding target nucleic acid molecule.Such partial complementarity can be represented by a % complementaritythat is determined by the number of non-base paired nucleotides, i.e.,about 50%, 60%, 70%, 80%, 90% etc. depending on the total number ofnucleotides involved. Such partial complementarity is permitted to theextent that the nucleic acid molecule (e.g., siNA) maintains itsfunction, for example the ability to mediate sequence specific RNAi.

The terms “composition” or “formulation” as used herein refer to theirgenerally accepted meaning in the art. These terms generally refer to acomposition or formulation, such as in a pharmaceutically acceptablecarrier or diluent, in a form suitable for administration, e.g.,systemic or local administration, into a cell or subject, including, forexample, a human. Suitable forms, in part, depend upon the use or theroute of entry, for example oral, transdermal, inhalation, or byinjection. Such forms should not prevent the composition or formulationfrom reaching a target cell (i.e., a cell to which the negativelycharged nucleic acid is desirable for delivery). For example,compositions injected into the blood stream should be soluble. Otherfactors are known in the art, and include considerations such astoxicity and forms that prevent the composition or formulation fromexerting its effect. As used herein, pharmaceutical formulations includeformulations for human and veterinary use. Non-limiting examples ofagents suitable for formulation with the nucleic acid molecules of theinstant invention include: Lipid Nanoparticles (see for example Sempleet al., 2010, Nat. Biotechnol., February; 28(2):172-6.); P-glycoproteininhibitors (such as Pluronic P85); biodegradable polymers, such as poly(DL-lactide-coglycolide) microspheres for sustained release delivery(Emerich, D F et al, 1999, Cell Transplant, 8, 47-58); and loadednanoparticles, such as those made of polybutylcyanoacrylate. Othernon-limiting examples of delivery strategies for the nucleic acidmolecules of the instant invention include material described in Boadoet al., 1998, J. Pharm. Sci., 87, 1308-1315; Tyler et al., 1999, FEBSLett., 421, 280-284; Pardridge et al., 1995, PNAS USA., 92, 5592-5596;Boado, 1995, Adv. Drug Delivery Rev., 15, 73-107; Aldrian-Herrada etal., 1998, Nucleic Acids Res., 26, 4910-4916; and Tyler et al., 1999,PNAS USA., 96, 7053-7058. A “pharmaceutically acceptable composition” or“pharmaceutically acceptable formulation” can refer to a composition orformulation that allows for the effective distribution of the nucleicacid molecules of the instant invention to the physical location mostsuitable for their desired activity.

The phrase “cytotoxic/cytostatic agents” refer to compounds that causecell death or inhibit cell proliferation primarily by interferingdirectly with the cell's functioning or inhibit or interfere with cellmytosis, including alkylating agents, tumor necrosis factors,intercalators, hypoxia activatable compounds, microtubuleinhibitors/microtubule-stabilizing agents, inhibitors of mitotickinesins, inhibitors of histone deacetylase, inhibitors of kinasesinvolved in mitotic progression, antimetabolites; biological responsemodifiers; hormonal/anti-hormonal therapeutic agents, hematopoieticgrowth factors, monoclonal antibody targeted therapeutic agents,topoisomerase inhibitors, proteasome inhibitors and ubiquitin ligaseinhibitors.

The phrase “estrogen receptor modulators” refers to compounds thatinterfere with or inhibit the binding of estrogen to the receptor,regardless of mechanism.

The term “gene” or “target gene” as used herein refers to their meaningas is generally accepted in the art. The terms generally refer a nucleicacid (e.g., DNA or RNA) sequence that comprises partial length or entirelength coding sequences necessary for the production of a polypeptide.The target gene can also include the UTR or non-coding region of thenucleic acid sequence. A gene or target gene can also encode afunctional RNA (fRNA) or non-coding RNA (ncRNA), such as small temporalRNA (stRNA), micro RNA (miRNA), small nuclear RNA (snRNA), shortinterfering RNA (siRNA), small nucleolar RNA (snRNA), ribosomal RNA(rRNA), transfer RNA (tRNA) and precursor RNAs thereof. Such non-codingRNAs can serve as target nucleic acid molecules for siNA mediated RNAinterference in modulating the activity of fRNA or ncRNA involved infunctional or regulatory cellular processes. Aberrant fRNA or ncRNAactivity leading to disease can therefore be modulated by siNA moleculesof the invention. siNA molecules targeting fRNA and ncRNA can also beused to manipulate or alter the genotype or phenotype of a subject,organism or cell, by intervening in cellular processes such as geneticimprinting, transcription, translation, or nucleic acid processing(e.g., transamination, methylation etc.). The target gene can be a genederived from a cell, an endogenous gene, a transgene, or exogenous genessuch as genes of a pathogen, for example a virus, which is present inthe cell after infection thereof. The cell containing the target genecan be derived from or contained in any organism, for example a plant,animal, protozoan, virus, bacterium, or fungus. Non-limiting examples ofplants include monocots, dicots, or gymnosperms. Non-limiting examplesof animals include vertebrates or invertebrates. Non-limiting examplesof fungi include molds or yeasts. For a review, see for example Snyderand Gerstein, 2003, Science, 300, 258-260.

The phrase “HMG-CoA reductase inhibitors” refers to inhibitors of3-hydroxy-3-methylglutaryl-CoA reductase. The term HMG-CoA reductaseinhibitor as used herein includes all pharmaceutically acceptablelactone and open-acid forms (i.e., where the lactone ring is opened toform the free acid) as well as salt and ester forms of compounds thathave HMG-CoA reductase inhibitory activity, and therefore the use ofsuch salts, esters, open-acid and lactone forms is included within thescope of this invention.

The phrase “homologous sequence” as used herein refers to its meaning asis generally accepted in the art. The term generally refers a nucleotidesequence that is shared by one or more polynucleotide sequences, such asgenes, gene transcripts and/or non-coding polynucleotides. For example,a homologous sequence can be a nucleotide sequence that is shared by twoor more genes encoding related but different proteins, such as differentmembers of a gene family, different protein epitopes, different proteinisoforms or completely divergent genes. A homologous sequence can be anucleotide sequence that is shared by two or more non-codingpolynucleotides, such as noncoding DNA or RNA, regulatory sequences,introns, and sites of transcriptional control or regulation. Homologoussequences can also include sequence regions shared by more than onepolynucleotide sequence. Homology does not need to be perfect identity(100%), as partially homologous sequences are also contemplated by andwithin the scope of the instant invention (e.g., at least 95%, 94%, 93%,92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80% etc.).Percent homology is the number of matching nucleotides between twosequences divided by the total length being compared, multiplied by 100.

The phrase “improved RNAi activity” refers to an increase in RNAiactivity measured in vitro and/or in vivo, where the RNAi activity is areflection of both the ability of the siNA to mediate RNAi and thestability of the siNAs of the invention. In this invention, the productof these activities can be increased in vitro and/or in vivo compared toan all RNA siNA or an siNA containing a plurality of ribonucleotides. Insome cases, the activity or stability of the siNA molecule can bedecreased (i.e., less than ten-fold), but the overall activity of thesiNA molecule is enhanced in vitro and/or in vivo.

The terms “inhibit,” “down-regulate,” or “reduce” as used herein refersto its meaning as is generally accepted in the art. With reference toexemplary nucleic acid molecules of the invention, the term generallyrefers the reduction in the expression of the gene, or level of RNAmolecules or equivalent RNA molecules encoding one or more proteins orprotein subunits, or activity of one or more proteins or proteinsubunits, below that observed in the absence of the nucleic acidmolecules (e.g., siNA) of the invention. Down-regulation can also beassociated with post-transcriptional silencing, such as, RNAi mediatedcleavage or by alteration in DNA methylation patterns or DNA chromatinstructure Inhibition, down-regulation or reduction with an siNA moleculecan be in reference to an inactive molecule, an attenuated molecule, ansiNA molecule with a scrambled sequence, or an siNA molecule withmismatches or alternatively, it can be in reference to the system in theabsence of the nucleic acid.

The phrase “inhibitors of cell proliferation and survival signalingpathway” refers to pharmaceutical agents that inhibit cell surfacereceptors and signal transduction cascades downstream of those surfacereceptors.

The term “integrin blockers” refers to compounds which selectivelyantagonize, inhibit or counteract binding of a physiological ligand tothe α _(ωβ) ₃ integrin, to compounds which selectively antagonize,inhibit or counteract binding of a physiological ligand to the α _(ωβ) ₅integrin, to compounds which antagonize, inhibit or counteract bindingof a physiological ligand to both the α _(ωβ) ₃ integrin and the α _(ωβ)₅ integrin, and to compounds which antagonize, inhibit or counteract theactivity of the particular integrin(s) expressed on capillaryendothelial cells. The term also refers to antagonists of the α _(ω)β_(0.6) α _(ω) β_(0.8) α₁β_(0.1) α₂β_(0.1) α₅β_(0.1) α₆β₁ and α₆β₄integrins. The term also refers to antagonists of any combination of α_(ωβ) ₃, α _(ωβ) ₅, α _(ω) β_(0.6) α _(ω) β_(0.8) α₁β_(0.1) α₂β_(0.1)α₅β_(0.1) α₆β₁ and α₆β₄ integrins.

The terms “intermittent” or “intermittently” as used herein refers toits meaning as is generally accepted in the art. The term generallyrefers to periodic stopping and starting at either regular or irregularintervals.

The terms “internucleoside linkage” or “internucleoside linker” or“internucleotide linkage” or “internucleotide linker” are used hereininterchangeably and refer to any linker or linkage between twonucleoside units, as is known in the art, including, for example, butnot limitation, phosphate, analogs of phosphate, phosphonate, guanidium,hydroxylamine, hydroxylhydrazinyl, amide, carbamate, alkyl, andsubstituted alkyl linkages. The internucleoside linkages constitute thebackbone of a nucleic acid molecule.

The terms “mammalian” or “mammal” as used herein refers to its meaningas is generally accepted in the art. The term generally refers to anywarm blooded vertebrate species, such as a human, mouse, rat, dog, cat,hamster, guinea pig, rabbit, livestock, and the like.

The phrase “metered dose inhaler” or MDI refers to a unit comprising acan, a secured cap covering the can and a formulation metering valvesituated in the cap. MDI systems includes a suitable channeling device.Suitable channeling devices comprise for example, a valve actuator and acylindrical or cone-like passage through which medicament can bedelivered from the filled canister via the metering valve to the nose ormouth of a patient such as a mouthpiece actuator.

The term “microRNA” or “miRNA” as used herein refers to its meaning asis generally accepted in the art. The term generally refers a smalldouble-stranded RNA that regulates the expression of target messengerRNAs either by mRNA cleavage, translational repression/inhibition orheterochromatic silencing (see for example Ambros, 2004, Nature, 431,350-355; Bartel, 2004, Cell, 116, 281-297; Cullen, 2004, VirusResearch., 102, 3-9; He et al., 2004, Nat. Rev. Genet., 5, 522-531; Yinget al., 2004, Gene, 342, 25-28; and Sethupathy et al., 2006, RNA,12:192-197).

The term “modulate” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary nucleic acid moleculesof the invention, the term refers to when the expression of a gene, orlevel of one or more RNA molecules (coding or non-coding), or activityof one or more RNA molecules or proteins or protein subunits, isup-regulated or down-regulated, such that expression, level, or activityis greater than or less than that observed in the absence of themolecule that effects modulation. For example, the term “modulate” insome embodiments can refer to inhibition and in other embodiments canrefer to potentiation or up-regulation, e.g., of gene expression.

The phrase “modified nucleotide” as used herein refers to its meaning asis generally accepted in the art. The term generally refers anucleotide, which contains a modification in the chemical structure ofthe base, sugar and/or phosphate of the unmodified (or natural)nucleotide as is generally known in the art. Non-limiting examples ofmodified nucleotides are described herein and in U.S. application Ser.No. 12/064,014.

The phrase “NSAIDs that are selective COX-2 inhibitors” for purposesherein, refers to NSAIDs, which possess a specificity for inhibitingCOX-2 over COX-1 of at least 100 fold as measured by the ratio of IC₅₀for COX-2 over IC₅₀ for COX-1 evaluated by cell or microsomal assays.

The phrase “non-base paired” refers to nucleotides that are not basepaired between the sense strand or sense region and the antisense strandor antisense region of an double-stranded siNA molecule; and can includefor example, but not limitation, mismatches, overhangs, single strandedloops, etc.

The term “non-nucleotide” refers to any group or compound which can beincorporated into a nucleic acid chain in the place of one or morenucleotide units, such as for example but not limitation abasic moietiesor alkyl chains. The group or compound is “abasic” in that it does notcontain a commonly recognized nucleotide base, such as adenosine,guanine, cytosine, uracil or thymine and therefore lacks a nucleobase atthe 1′-position.

The term “nucleotide” is used as is generally recognized in the art.Nucleotides generally comprise a nucleobase, a sugar, and aninternucleoside linkage, e.g., a phosphate. The base can be a naturalbases (standard), modified bases, or a base analog, as are well known inthe art. Such bases are generally located at the 1′ position of anucleotide sugar moiety. Additionally, the nucleotides can be unmodifiedor modified at the sugar, internucleoside linkage, and/or base moiety,(also referred to interchangeably as nucleotide analogs, modifiednucleotides, non-natural nucleotides, non-standard nucleotides andothers; see, for example, U.S. application Ser. No. 12/064,014.

The term “overhang” as used herein refers to its meaning as is generallyaccepted in the art. With reference to exemplary double stranded nucleicacid molecules, the term generally refers to the terminal portion of anucleotide sequence that is not base paired between the two strands of adouble-stranded nucleic acid molecule (see for example, FIG. 4).Overhangs, when present, are typically at the 3′-end of one or bothstrands in a siNA duplex.

The term “parenteral” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers methods ortechniques of administering a molecule, drug, agent, or compound in amanner other than through the digestive tract, and includesepicutaneous, subcutaneous, intravascular (e.g., intravenous),intramuscular, or intrathecal injection or infusion techniques and thelike.

The phrase “pathway target” refers to any target involved in pathways ofgene expression or activity. For example, any given target can haverelated pathway targets that can include upstream, downstream, ormodifier genes in a biologic pathway. These pathway target genes canprovide additive or synergistic effects in the treatment of diseases,conditions, and traits herein.

The term “phosphorothioate” refers to an internucleotide phosphatelinkage comprising one or more sulfur atoms in place of an oxygen atom.Hence, the term phosphorothioate refers to both phosphorothioate andphosphorodithioate internucleotide linkages.

“Prenyl-protein transferase inhibitor” refers to a compound thatinhibits any one or any combination of the prenyl-protein transferaseenzymes, including farnesyl-protein transferase (FPTase),geranylgeranyl-protein transferase type I (GGPTase-I), andgeranylgeranyl-protein transferase type-II (GGPTase-II, also called RabGGPTase).

The phrase “retinoid receptor modulators” refers to compounds thatinterfere or inhibit the binding of retinoids to the receptor,regardless of mechanism.

The term “ribonucleotide” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to a nucleotidewith a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety.

The term “RNA” as used herein refers to its generally accepted meaningin the art. Generally, the term RNA refers to a molecule comprising atleast one ribofuranoside moiety. The term can include double-strandedRNA, single-stranded RNA, isolated RNA such as partially purified RNA,essentially pure RNA, synthetic RNA, recombinantly produced RNA, as wellas altered RNA that differs from naturally occurring RNA by theaddition, deletion, substitution and/or alteration of one or morenucleotides. Such alterations can include addition of non-nucleotidematerial, such as to the end(s) of the siNA or internally, for exampleat one or more nucleotides of the RNA. Nucleotides in the RNA moleculesof the instant invention can also comprise non-standard nucleotides,such as non-naturally occurring nucleotides or chemically synthesizednucleotides or deoxynucleotides. These altered RNAs can be referred toas analogs or analogs of naturally-occurring RNA.

The phrase “RNA interference” or term “RNAi” refer to the biologicalprocess of inhibiting or down regulating gene expression in a cell, asis generally known in the art, and which is mediated by shortinterfering nucleic acid molecules, see for example Zamore and Haley,2005, Science, 309, 1519-1524; Vaughn and Martienssen, 2005, Science,309, 1525-1526; Zamore et al., 2000, Cell, 101, 25-33; Bass, 2001,Nature, 411, 428-429; Elbashir et al., 2001, Nature, 411, 494-498; andKreutzer et al., International PCT Publication No. WO 00/44895;Zernicka-Goetz et al., International PCT Publication No. WO 01/36646;Fire, International PCT Publication No. WO 99/32619; Plaetinck et al.,International PCT Publication No. WO 00/01846; Mello and Fire,International PCT Publication No. WO 01/29058; Deschamps-Depaillette,International PCT Publication No. WO 99/07409; and Li et al.,International PCT Publication No. WO 00/44914; Allshire, 2002, Science,297, 1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein,2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297,2232-2237; Hutvagner and Zamore, 2002, Science, 297, 2056-60; McManus etal., 2002, RNA, 8, 842-850; Reinhart et al., 2002, Gene & Dev., 16,1616-1626; and Reinhart & Bartel, 2002, Science, 297, 1831).Additionally, the term RNAi is meant to be equivalent to other termsused to describe sequence specific RNA interference, such as posttranscriptional gene silencing, translational inhibition,transcriptional inhibition, or epigenetics. For example, siNA moleculesof the invention can be used to epigenetically silence genes at eitherthe post-transcriptional level or the pre-transcriptional level. In anon-limiting example, epigenetic modulation of gene expression by siNAmolecules of the invention can result from siNA mediated modification ofchromatin structure or methylation patterns to alter gene expression(see, for example, Verdel et al., 2004, Science, 303, 672-676;Pal-Bhadra et al., 2004, Science, 303, 669-672; Allshire, 2002, Science,297, 1818-1819; Volpe et al., 2002, Science, 297, 1833-1837; Jenuwein,2002, Science, 297, 2215-2218; and Hall et al., 2002, Science, 297,2232-2237). In another non-limiting example, modulation of geneexpression by siNA molecules of the invention can result from siNAmediated cleavage of RNA (either coding or non-coding RNA) via RISC, orvia translational inhibition, as is known in the art or modulation canresult from transcriptional inhibition (see for example Janowski et al.,2005, Nature Chemical Biology, 1, 216-222).

The phrase “RNAi inhibitor” refers to any molecule that can downregulate, reduce or inhibit RNA interference function or activity in acell or organism. An RNAi inhibitor can down regulate, reduce or inhibitRNAi (e.g., RNAi mediated cleavage of a target polynucleotide,translational inhibition, or transcriptional silencing) by interactionwith or interfering with the function of any component of the RNAipathway, including protein components such as RISC, or nucleic acidcomponents such as miRNAs or siRNAs. A RNAi inhibitor can be an siNAmolecule, an antisense molecule, an aptamer, or a small molecule thatinteracts with or interferes with the function of RISC, a miRNA, or ansiRNA or any other component of the RNAi pathway in a cell or organism.By inhibiting RNAi (e.g., RNAi mediated cleavage of a targetpolynucleotide, translational inhibition, or transcriptional silencing),a RNAi inhibitor of the invention can be used to modulate (e.g.,up-regulate or down regulate) the expression of a target gene.

The phrase “sense region” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to a nucleotide sequence ofan siNA molecule having complementarity to an antisense region of thesiNA molecule. In addition, the sense region of an siNA molecule cancomprise a nucleic acid sequence having homology or sequence identitywith a target nucleic acid sequence. In one embodiment, the sense regionof the siNA molecule is also referred to as the sense strand orpassenger strand.

The phrases “short interfering nucleic acid”, “siNA”, “short interferingRNA”, “siRNA”, “short interfering nucleic acid molecule”, “shortinterfering oligonucleotide molecule”, or “chemically modified shortinterfering nucleic acid molecule” refer to any nucleic acid moleculecapable of inhibiting or down regulating gene expression or viralreplication by mediating RNA interference (“RNAi”) or gene silencing ina sequence-specific manner. These terms can refer to both individualnucleic acid molecules, a plurality of such nucleic acid molecules, orpools of such nucleic acid molecules. The siNA can be a double-strandednucleic acid molecule comprising self-complementary sense and antisensestrands, wherein the antisense strand comprises a nucleotide sequencethat is complementary to a nucleotide sequence in a target nucleic acidmolecule or a portion thereof and the sense strand comprises anucleotide sequence corresponding to the target nucleic acid sequence ora portion thereof. The siNA can be a polynucleotide with a duplex,asymmetric duplex, hairpin or asymmetric hairpin secondary structure,having self-complementary sense and antisense regions, wherein theantisense region comprises a nucleotide sequence that is complementaryto a nucleotide sequence in a separate target nucleic acid molecule or aportion thereof and the sense region comprises a nucleotide sequencecorresponding to the target nucleic acid sequence or a portion thereof.The siNA can be a circular single-stranded polynucleotide having two ormore loop structures and a stem comprising self-complementary sense andantisense regions, wherein the antisense region comprises nucleotidesequence that is complementary to a nucleotide sequence in a targetnucleic acid molecule or a portion thereof and the sense regioncomprises a nucleotide sequence corresponding to the target nucleic acidsequence or a portion thereof, and wherein the circular polynucleotidecan be processed either in vivo or in vitro to generate an active siNAmolecule capable of mediating RNAi. The siNA can also comprise asingle-stranded polynucleotide having a nucleotide sequencecomplementary to nucleotide sequence in a target nucleic acid moleculeor a portion thereof (for example, where such siNA molecule does notrequire the presence within the siNA molecule of a nucleotide sequencecorresponding to the target nucleic acid sequence or a portion thereof),wherein the single-stranded polynucleotide can further comprise aterminal phosphate group, such as a 5′-phosphate (see for example,Martinez et al., 2002, Cell, 110, 563-574 and Schwarz et al., 2002,Molecular Cell, 10, 537-568), or 5′,3′-diphosphate.

The term “subject” as used herein refers to its meaning as is generallyaccepted in the art. The term generally refers an organism to which thenucleic acid molecules of the invention can be administered. A subjectcan be a mammal or mammalian cells, including a human or human cells.The term also refers to an organism, which is a donor or recipient ofexplanted cells or the cells themselves.

The phrase “systemic administration” as used herein refers to itsmeaning as is generally accepted in the art. The term generally refersin vivo systemic absorption or accumulation of drugs in the blood streamfollowed by distribution throughout the entire body.

The term “target” as it refers to CTNNB1 refers to any CTNNB1 targetprotein, peptide, or polypeptide, such as encoded by Genbank AccessionNos. shown in Table 5. The term also refers to nucleic acid sequences ortarget polynucleotide sequence encoding any target protein, peptide, orpolypeptide, such as proteins, peptides, or polypeptides encoded bysequences having Genbank Accession Nos. shown in Table 5. The target ofinterest can include target polynucleotide sequences, such as target DNAor target RNA. The term “target” is also meant to include othersequences, such as differing isoforms, mutant target genes, splicevariants of target polynucleotides, target polymorphisms, and non-coding(e.g., ncRNA, miRNA, stRNA, sRNA) or other regulatory polynucleotidesequences as described herein.

The phrase “target site” as used herein refers to its meaning as isgenerally accepted in the art. The term generally refers to a sequencewithin a target nucleic acid molecule, (e.g., RNA) that is “targeted”,e.g., for cleavage mediated by an siNA construct, which containssequences within its antisense region that are complementary to thetarget sequence.

The phrase “therapeutically effective amount” as used herein refers toits meaning as is generally accepted in the art. The term generallyrefers to the amount of the compound or composition that will elicit thebiological or medical response of a cell, tissue, system, animal orhuman that is be sought by the researcher, veterinarian, medical doctoror other clinician. For example, if a given clinical treatment isconsidered effective when there is at least a 25% reduction in ameasurable parameter associated with a disease or disorder, atherapeutically effective amount of a drug for the treatment of thatdisease or disorder is that amount necessary to effect at least a 25%reduction in that parameter.

The phrase “universal base” as used herein refers to its meaning as isgenerally accepted in the art. The term universal base generally refersto nucleotide base analogs that form base pairs with each of the naturalDNA/RNA bases with little or no discrimination between them.Non-limiting examples of universal bases include C-phenyl, C-naphthyland other aromatic derivatives, inosine, azole carboxamides, andnitroazole derivatives such as 3-nitropyrrole, 4-nitroindole,5-nitroindole, and 6-nitroindole as known in the art (see for example,Loakes, 2001, Nucleic Acids Research, 29, 2437-2447).

The term “up-regulate” as used herein refers to its meaning as isgenerally accepted in the art. With reference to exemplary nucleic acidmolecules of the invention, the term refers to an increase in theexpression of a gene, or level of RNA molecules or equivalent RNAmolecules encoding one or more proteins or protein subunits, or activityof one or more RNAs, proteins or protein subunits, above that observedin the absence of the nucleic acid molecules (e.g., siNA) of theinvention. In certain instances, up-regulation or promotion of geneexpression with an siNA molecule is above that level observed in thepresence of an inactive or attenuated molecule. In other instances,up-regulation or promotion of gene expression with siNA molecules isabove that level observed in the presence of, for example, an siNAmolecule with scrambled sequence or with mismatches. In still otherinstances, up-regulation or promotion of gene expression with a nucleicacid molecule of the instant invention is greater in the presence of thenucleic acid molecule than in its absence. In some instances,up-regulation or promotion of gene expression is associated withinhibition of RNA mediated gene silencing, such as RNAi mediatedcleavage or silencing of a coding or non-coding RNA target that downregulates, inhibits, or silences the expression of the gene of interestto be up-regulated. The down regulation of gene expression can, forexample, be induced by a coding RNA or its encoded protein, such asthrough negative feedback or antagonistic effects. The down regulationof gene expression can, for example, be induced by a non-coding RNAhaving regulatory control over a gene of interest, for example bysilencing expression of the gene via translational inhibition, chromatinstructure, methylation, RISC mediated RNA cleavage, or translationalinhibition. As such, inhibition or down regulation of targets that downregulate, suppress, or silence a gene of interest can be used toup-regulate expression of the gene of interest toward therapeutic use.

The term “vector” as used herein refers to its meaning as is generallyaccepted in the art. The term vector generally refers to any nucleicacid- and/or viral-based expression system or technique used to deliverone or more nucleic acid molecules.

B. siNA Molecules of the Invention

The present invention provides compositions and methods comprising siNAstargeted to CTNNB1 that can be used to treat diseases, e.g.,malignancies and/or cancers associated with CTNNB1 expression. Inparticular aspects and embodiments of the invention, the nucleic acidmolecules of the invention comprise at least a 15 nucleotide sequence ofthe sequences shown in Table 1a and Table 1b. The siNAs can be providedin several forms. For example, the siNA can be isolated as one or moresiNA compounds, or it may be in the form of a transcriptional cassettein a DNA plasmid. The siNA may also be chemically synthesized and caninclude modifications as shown, for example, but not limitation, inTable 1c and Table 6. Thus, in various embodiments, at least one strandor region of the nucleic acids of the invention comprises at least a 15nucleotide sequence selected from the group of sequences consisting ofSEQ ID NOS:1-6374. The siNAs can be administered alone orco-administered with other siNA molecules or with conventional agentsthat treat a CTNNB1 related disease or condition.

The siNA molecules of the invention can be used to mediate genesilencing, specifically CTNNB1, via interaction with RNA transcripts oralternately by interaction with particular gene sequences, wherein suchinteraction results in modulation of gene silencing either at thetranscriptional level or post-transcriptional level such as, forexample, but not limited to, RNAi or through cellular processes thatmodulate the chromatin structure or methylation patterns of the targetand prevent transcription of the target gene, with the nucleotidesequence of the target thereby mediating silencing. More specifically,the target is any of CTNNB1 RNA, DNA, or mRNA,

In one aspect, the invention provides short interfering nucleic acid(siNA) molecules for inhibiting the expression of the CTNNB1 gene in acell or mammal. The siNA can be single-stranded or double-stranded. Whendouble-stranded, the siNA comprising a sense and an antisense stand. Theantisense strand is complementary to at least a part of an mRNA formedin the expression of the CTNNB1 gene. The sense strand comprises aregion that is complementary to the antisense strand. In specificembodiments, the antisense strand comprises at least a 15 nucleotidesequence of an antisense sequence listed in Table 1b. Generally, thedouble-stranded siNA comprises at least a 15 nucleotide sequence of thesense strand in Table 1b and at least a 15 nucleotide sequence of theantisense strand in Table 1b. One or more of the nucleotides of thesiNAs of the invention are optionally modified. In further embodimentshaving modifications, some siNAs of the invention comprises at least onenucleotide sequence selected from the groups of sequences provide inTable 1c. In other embodiments, the siNA comprises at least twosequences selected from the group of sequences provided in Table 1c,wherein one of the at least two sequences is complementary to another ofthe at least two sequences and one of the at least two sequences iscomplementary to a sequence of a mRNA generated in the expression of theCTNNB1 gene. Examples of certain modified siNAs of the invention are inTable 1c.

The double stranded RNA molecules of the invention can comprise twodistinct and separate strands that can be symmetric or asymmetric andare complementary, i.e., two single-stranded RNA molecules, or cancomprise one single-stranded molecule in which two complementaryportions, e.g., a sense region and an antisense region, are base-paired,and are covalently linked by one or more single-stranded “hairpin” areas(i.e. loops) resulting in, for example, a single-stranded short-hairpinpolynucleotide or a circular single-stranded polynucleotide.

The linker can be polynucleotide linker or a non-nucleotide linker. Insome embodiments, the linker is a non-nucleotide linker. In someembodiments, a hairpin or circular siNA molecule of the inventioncontains one or more loop motifs, wherein at least one of the loopportions of the siNA molecule is biodegradable. For example, asingle-stranded hairpin siNA molecule of the invention is designed suchthat degradation of the loop portion of the siNA molecule in vivo cangenerate a double-stranded siNA molecule with 3′-terminal overhangs,such as 3′-terminal nucleotide overhangs comprising 1, 2, 3 or 4nucleotides. Or alternatively, a circular siNA molecule of the inventionis designed such that degradation of the loop portions of the siNAmolecule in vivo can generate a double-stranded siNA molecule with3′-terminal overhangs, such as 3′-terminal nucleotide overhangscomprising about 2 nucleotides.

In symmetric siNA molecules of the invention, each strand, the sense(passenger) strand and antisense (guide) strand, are independently about15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, or 30) nucleotides in length. Generally, each strand ofthe symmetric siNA molecules of the invention are about 19-24 (e.g.,about 19, 20, 21, 22, 23 or 24) nucleotides in length.

In asymmetric siNA molecules, the antisense region or strand of themolecule is about 15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20,21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides in length,wherein the sense region is about 3 to about 25 (e.g., about 3, 4, 5, 6,7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or25) nucleotides in length. Generally, each strand of the asymmetric siNAmolecules of the invention is about 19-24 (e.g., about 19, 20, 21, 22,23 or 24) nucleotides in length.

In yet other embodiments, siNA molecules of the invention comprisesingle stranded hairpin siNA molecules, wherein the siNA molecules areabout 25 to about 70 (e.g., about 25, 26, 27, 28, 29, 30, 31, 32, 33,34, 35, 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length.

In still other embodiments, siNA molecules of the invention comprisesingle-stranded circular siNA molecules, wherein the siNA molecules areabout 38 to about 70 (e.g., about 38, 40, 45, 50, 55, 60, 65, or 70)nucleotides in length.

In still other embodiments, siNA molecules of the invention comprisesingle-stranded non-circular siNA molecules, wherein the siNA moleculesare independently about 15 to about 30 (e.g., about 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotides in length.

In various symmetric embodiments, the siNA duplexes of the inventionindependently comprise about 15 to about 30 (e.g., about 15, 16, 17, 18,19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) base pairs.Generally, the duplex structure of siNAs of the invention is between 15and 30, more generally between 18 and 25, yet more generally between 19and 24, and most generally between 19 and 21 base pairs in length.

In yet other embodiments, where the duplex siNA molecules of theinvention are asymmetric, the siNA molecules comprise about 3 to 25(e.g., about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23, 24, or 25) base pairs. Generally, the duplexstructure of siNAs of the invention is between 15 and 25, more generallybetween 18 and 25, yet more generally between 19 and 24, and mostgenerally between 19 and 21 base pairs in length.

In still other embodiments, where the siNA molecules of the inventionare hairpin or circular structures, the siNA molecules comprise about 15to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, or 30) base pairs.

The sense strand and antisense strand, or the sense region and antisenseregion, of the siNA molecules of the invention can be complementary.Also, the antisense strand or antisense region can be complementary to anucleotide sequence or a portion thereof of the CTNNB1 target RNA. Thesense strand or sense region of the siNA can comprise a nucleotidesequence of a CTNNB1 gene or a portion thereof. In certain embodiments,the sense region or sense strand of an siNA molecule of the invention iscomplementary to that portion of the antisense region or antisensestrand of the siNA molecule that is complementary to a CTNNB1 targetpolynucleotide sequence, such as for example, but not limited to, thosesequences represented by GENBANK Accession Nos. shown in Table 5.

In some embodiments, siNA molecules of the invention have perfectcomplementarity between the sense strand or sense region and theantisense strand or antisense region of the siNA molecule. In other orthe same embodiments, the antisense strand of the siNA molecules of theinvention are perfectly complementary to a corresponding target nucleicacid molecule.

In yet other embodiments, siNA molecules of the invention have partialcomplementarity (i.e., less than 100% complementarity) between the sensestrand or sense region and the antisense strand or antisense region ofthe siNA molecule or between the antisense strand or antisense region ofthe siNA molecule and a corresponding target nucleic acid molecule.Thus, in some embodiments, the double-stranded nucleic acid molecules ofthe invention, have between about 15 to about 30 (e.g., about 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30) nucleotidesin one strand that are complementary to the nucleotides of the otherstrand. In other embodiments, the molecules have between about 15 toabout 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,27, 28, 29, or 30) nucleotides in the sense region that arecomplementary to the nucleotides of the antisense region. of thedouble-stranded nucleic acid molecule. In certain embodiments, thedouble-stranded nucleic acid molecules of the invention have betweenabout 15 to about 30 (e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23,24, 25, 26, 27, 28, 29, or 30) nucleotides in the antisense strand thatare complementary to a nucleotide sequence of its corresponding targetnucleic acid molecule.

In other embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions;provided, however, that the siNA molecule maintains its activity, forexample, to mediate RNAi. In a non-limiting example, the deletion,substitution, mismatch and/or addition can result in a loop or bulge, oralternately a wobble or other alternative (non Watson-Crick) base pair.Thus, in some embodiments, for example, the double-stranded nucleic acidmolecules of the invention, have 1 or more (e.g., 1, 2, 3, 4, 5, or 6)nucleotides, in one strand or region that are mismatches ornon-base-paired with the other strand or region. In other embodiments,the double-stranded nucleic acid molecules of the invention, have 1 ormore (e.g., 1, 2, 3, 4, 5, or 6) nucleotides in each strand or regionthat are mismatches or non-base-paired with the other strand or region.In a preferred embodiment, the siNA of the invention contains no morethan 3 mismatches. If the antisense strand of the siNA containsmismatches to a target sequence, it is preferable that the area ofmismatch not be located in the center of the region of complementarity.

In other embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions to asequence in Table 1b provided, however, that the siNA molecule maintainsits activity, for example, to mediate RNAi. In a non-limiting example,the deletion, substitution, mismatch and/or addition can result in aloop or bulge, or alternately a wobble or other alternative (nonWatson-Crick) base pair.

The invention also comprises double-stranded nucleic acid (siNA)molecules as otherwise described hereinabove in which the first strandand second strand are complementary to each other and wherein at leastone strand is hybridisable to the polynucleotide sequence of a sequencein Table 1b under conditions of high stringency, and wherein any of thenucleotides is unmodified or chemically modified.

Hybridization techniques are well known to the skilled artisan (see forinstance, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2ndEd., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.(1989)). Preferred stringent hybridization conditions include overnightincubation at 42° C. in a solution comprising: 50% formamide, 5×SSC (150mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6),5×Denhardt's solution, 10% dextran sulfate, and 20 microgram/mldenatured, sheared salmon sperm DNA; followed by washing the filters in0.1×SSC at about 65° C.

In one specific embodiment, the first strand has about 15, 16, 17, 18,19, 20 or 21 nucleotides that are complementary to the nucleotides ofthe other strand and at least one strand is hybridisable to apolynucleotide sequence in Table 1b. In a more preferred embodiment, thefirst strand has about 15, 16, 17, 18, 19, 20 or 21 nucleotides that arecomplementary to the nucleotides of the other strand and at least onestrand is hybridisable to SEQ ID NO: 1, SEQ ID NO: 1049, SEQ ID NO: 43,SEQ ID NO: 1091, SEQ ID NO: 51, SEQ ID NO: 1099, SEQ ID NO: 53, or SEQID NO:1101; under conditions of high stringency, and wherein any of thenucleotides is unmodified or chemically modified.

In certain embodiments, the siNA molecules of the invention compriseoverhangs of about 1 to about 4 (e.g., about 1, 2, 3 or 4) nucleotides.The nucleotides in the overhangs can be the same or differentnucleotides. In some embodiments, the overhangs occur at the 3′-end atone or both strands of the double-stranded nucleic acid molecule. Forexample, a double-stranded nucleic acid molecule of the invention cancomprise a nucleotide or non-nucleotide overhang at the 3′-end of theantisense strand/region, the 3′-end of the sense strand/region, or boththe antisense strand/region and the sense strand/region of thedouble-stranded nucleic acid molecule.

In some embodiments, the nucleotides comprising the overhang portion ofan siNA molecule of the invention comprise sequences based on the CTNNB1target polynucleotide sequence in which nucleotides comprising theoverhang portion of the antisense strand/region of an siNA molecule ofthe invention can be complementary to nucleotides in the CTNNB1 targetpolynucleotide sequence and/or nucleotides comprising the overhangportion of the sense strand/region of an siNA molecule of the inventioncan comprise the nucleotides in the CTNNB1 target polynucleotidesequence. Thus, in some embodiments, the overhang comprises a twonucleotide overhang that is complementary to a portion of the CTNNB1target polynucleotide sequence. In other embodiments, however, theoverhang comprises a two nucleotide overhang that is not complementaryto a portion of the CTNNB1 target polynucleotide sequence. In certainembodiments, the overhang comprises a 3′-UU overhang that is notcomplementary to a portion of the CTNNB1 target polynucleotide sequence.In other embodiments, the overhang comprises a UU overhang at the 3′ endof the antisense strand and a TT overhang at the 3′ end of the sensestrand. In other embodiments, the overhang comprises nucleotides asdescribed in the examples, Tables, and Figures herein.

In any of the embodiments of the siNA molecules described herein having3′-terminal nucleotide overhangs, the overhangs are optionallychemically modified at one or more nucleic acid sugar, base, or backbonepositions. Representative, but not limiting examples of modifiednucleotides in the overhang portion of a double-stranded nucleic acid(siNA) molecule of the invention include: 2′-O-alkyl (e.g.,2′-O-methyl), 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-deoxy-2′-fluoroarabino(FANA), 4′-thio, 2′-O-trifluoromethyl, 2′-O-ethyl-trifluoromethoxy,2′-O-difluoromethoxy-ethoxy, universal base, acyclic, or 5-C-methylnucleotides. In more preferred embodiments, the overhang nucleotides areeach independently, a 2′-O-alkyl nucleotide, a 2′-β-methyl nucleotide, a2′-dexoy-2-fluoro nucleotide, or a 2′-deoxy ribonucleotide. In someinstances the overhang nucleotides are linked by a one or morephosphorothioate linkages.

In yet other embodiments, siNA molecules of the invention compriseduplex nucleic acid molecules with blunt ends (i.e., without nucleotideoverhangs), where both ends are blunt, or alternatively, where one ofthe ends is blunt. In some embodiments, the siNA molecules of theinvention can comprises one blunt end, for example wherein the 5′-end ofthe antisense strand and the 3′-end of the sense strand do not have anyoverhanging nucleotides. In another example, the siNA molecule comprisesone blunt end, for example wherein the 3′-end of the antisense strandand the 5′-end of the sense strand do not have any overhangingnucleotides. In other embodiments, siNA molecules of the inventioncomprise two blunt ends, for example wherein the 3′-end of the antisensestrand and the 5′-end of the sense strand as well as the 5′-end of theantisense strand and 3′-end of the sense strand do not have anyoverhanging nucleotides.

In any of the embodiments or aspects of the siNA molecules of theinvention, the sense strand and/or the antisense strand can further havea cap, such as described herein or as known in the art, at the 3′-end,the 5′-end, or both of the 3′ and 5′-ends of the sense strand and/orantisense strand. Or as in the case of a hairpin siNA molecule, the capcan be at either one or both of the terminal nucleotides of thepolynucleotide. In some embodiments, the cap is at one of both of theends of the sense strand of a double-stranded siNA molecule. In otherembodiments, the cap is at the 3′-end of antisense (guide) strand. Inpreferred embodiments, the caps are at the 3′-end of the sense strandand the 5′-end of the sense strand.

Representative, but non-limiting examples of such terminal caps includean inverted abasic nucleotide, an inverted deoxy abasic nucleotide, aninverted nucleotide moiety, a group shown in FIG. 5, a glycerylmodification, an alkyl or cycloalkyl group, a heterocycle, or any othercap as is generally known in the art.

Any of the embodiments of the siNA molecules of the invention can have a5′ phosphate termini. In some embodiments, the siNA molecules lackterminal phosphates.

Any siNA molecule or construct of the invention can comprise one or morechemical modifications. Modifications can be used to improve in vitro orin vivo characteristics such as stability, activity, toxicity, immuneresponse (e.g., prevent stimulation of an interferon response, aninflammatory or pro-inflammatory cytokine response, or a Toll-likeReceptor (TlF) response), and/or bioavailability.

Applicants describe herein chemically modified siNA molecules withimproved RNAi activity and/or stability compared to correspondingunmodified siNA molecules. Various chemically modified siNA motifsdisclosed herein provide the capacity to maintain RNAi activity that issubstantially similar to unmodified or minimally modified active siRNA(see for example Elbashir et al., 2001, EMBO J., 20:6877-6888) while atthe same time providing nuclease resistance and pharmacokineticproperties suitable for use in therapeutic applications.

In various embodiments, the siNA molecules of the invention comprisemodifications wherein any (e.g., one or more or all) nucleotides presentin the sense and/or antisense strand are modified nucleotides (e.g.,wherein one nucleotide is modified, some nucleotides (i.e., plurality ormore than one) are modified, or all nucleotides are modifiednucleotides. In some embodiments, the siNA molecules of the inventionare partially modified (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50, 55, or 59 nucleotides are modified) with chemicalmodifications. In some embodiments, an siNA molecule of the inventioncomprises at least about 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30,32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60nucleotides that are modified nucleotides. In other embodiments, thesiNA molecules of the invention are completely modified (e.g., 100%modified) with chemical modifications, i.e., the siNA molecule does notcontain any ribonucleotides. In some of embodiments, one or more of thenucleotides in the sense strand of the siNA molecules of the inventionare modified. In the same or other embodiments, one or more of thenucleotides in the antisense strand of the siNA molecules of theinvention are modified.

The chemical modification within a single siNA molecule can be the sameor different. In some embodiments, at least one strand has at least onechemical modification. In other embodiments, each strand has at leastone chemical modifications, which can be the same or different, such as,sugar, base, or backbone (i.e., internucleotide linkage) modifications.In other embodiments, siNA molecules of the invention contain at least2, 3, 4, 5, or more different chemical modifications.

Non-limiting examples of chemical modifications that are suitable foruse in the present invention, are disclosed in U.S. patent applicationSer. Nos. 10/444,853; 10/981,966; 12/064,014 and in references citedtherein and include sugar, base, and phosphate, non-nucleotidemodifications, and/or any combination thereof.

In certain specific embodiments of the invention, at least one modifiednucleotide is a 2′-deoxy-2-fluoro nucleotide, a 2′-deoxy nucleotide, a2′-O-alkyl (e.g., 2′-O-methyl) nucleotide, or a locked nucleic acid(LNA) nucleotide as is generally recognized in the art.

In yet other embodiment of the invention, at least one nucleotide has aribo-like, Northern or A form helix configuration (see e.g., Saenger,Principles of Nucleic Acid Structure, Springer-Verlag ed., 1984).Non-limiting examples of nucleotides having a Northern configurationinclude locked nucleic acid (LNA) nucleotides (e.g., 2′-O,4′-C-methylene-(D-ribofuranosyl) nucleotides); 2′-methoxyethoxy (MOE)nucleotides; 2′-methyl-thio-ethyl nucleotides, 2′-deoxy-2′-fluoronucleotides; 2′-deoxy-2′-chloro nucleotides; 2′-azido nucleotides;2′-O-trifluoromethyl nucleotides; 2′-O-ethyl-trifluoromethoxynucleotides; 2′-O-difluoromethoxy-ethoxy nucleotides; 4′-thionucleotides and 2′-O-methyl nucleotides.

In various embodiments, a majority (e.g., greater than 50%) of thepyrimidine nucleotides present in the double-stranded siNA moleculecomprises a sugar modification. In some of the same and/or otherembodiments, a majority (e.g., greater than 50%) of the purinenucleotides present in the double-stranded siNA molecule comprises asugar modification.

In some embodiments, the pyrimidine nucleotides in the antisense strandare 2′-β-methyl or 2′-deoxy-2′-fluoro pyrimidine nucleotides and thepurine nucleotides present in the antisense strand are 2′-O-methylnucleotides or 2′-deoxy nucleotides. In other embodiments, thepyrimidine nucleotides in the sense strand are 2′-deoxy-2′-fluoropyrimidine nucleotides and the purine nucleotides present in the sensestrand are 2′-O-methyl or 2′-deoxy purine nucleotides.

In certain embodiments of the invention, all the pyrimidine nucleotidesin the complementary region on the sense strand are 2′-deoxy-2′-fluoropyrimidine nucleotides. In certain embodiments, all of the pyrimidinenucleotides in the complementary region of the antisense strand are2′-deoxy-2′-fluoro pyrimidine nucleotides. In certain embodiments, allthe purine nucleotides in the complementary region on the sense strandare 2′-deoxy purine nucleotides. In certain embodiments, all of thepurines in the complementary region on the antisense strand are2′-O-methyl purine nucleotides. In certain embodiments, all of thepyrimidine nucleotides in the complementary regions on the sense strandare 2′-deoxy-2′-fluoro pyrimidine nucleotides; all of the pyrimidinenucleotides in the complementary region of the antisense strand are2′-deoxy-2′-fluoro pyrimidine nucleotides; all the purine nucleotides inthe complementary region on the sense strand are 2′-deoxy purinenucleotides and all of the purines in the complementary region on theantisense strand are 2′-O-methyl purine nucleotides.

In some embodiments, at least 5 or more of the pyrimidine nucleotides inone or both stands are 2′-deoxy-2′-fluoro pyrimidine nucleotides. Insome embodiments, at least 5 or more of the pyrimidine nucleotides inone or both stands are 2′-O-methylpyrimidine nucleotides. In someembodiments, at least 5 or more of the purine nucleotides in one or bothstands are 2′-deoxy-2′-fluoro purine nucleotides In some embodiments, atleast 5 or more of the purine nucleotides in one or both stands are2′-O-methyl purine nucleotides.

In certain embodiments, the purines and pyrimidines are differentiallymodified at the 2′-sugar position (i.e., at least one purine has adifferent modification from at least one pyrimidine in the same ordifferent strand at the 2′-sugar position). For example, in someinstances, at least 5 or more of the pyrimidine nucleotides in one orboth stands are 2′-deoxy-2′-fluoro pyrimidine nucleotides and at least 5or more purine nucleotides in one or both strands are 2′-O-methyl purinenucleotides. In other instances at least 5 or more of the pyrimidinenucleotides in one or both stands are 2′-O-methylpyrimidine nucleotidesand at least 5 or more purine nucleotides in one or both strands are2′-deoxy-2′-fluoro purine nucleotides.

Further non-limiting examples of sense and antisense strands of suchsiNA molecules having various modifications and modifications patternsare shown in FIGS. 2 and 3.

Any of the above described modifications, or combinations thereof,including those in the references cited, can be applied to any of thesiNA molecules of the invention.

The modified siNA molecules of the invention can comprise modificationsat various locations within the siNA molecule. In some embodiments, thedouble-stranded siNA molecule of the invention comprises modifiednucleotides at internal base paired positions within the siNA duplex. Inother embodiments, a double-stranded siNA molecule of the inventioncomprises modified nucleotides at non-base paired or overhang regions ofthe siNA molecule. In yet other embodiments, a double-stranded siNAmolecule of the invention comprises modified nucleotides at terminalpositions of the siNA molecule. For example, such terminal regionsinclude the 3′-position and/or 5′-position of the sense and/or antisensestrand or region of the siNA molecule. Additionally, any of the modifiedsiNA molecules of the invention can have a modification in one or botholigonucleotide strands of the siNA duplex, for example in the sensestrand, the antisense strand, or both strands. Moreover, with regard tochemical modifications of the siNA molecules of the invention, eachstrand of the double-stranded siNA molecules of the invention can haveone or more chemical modifications, such that each strand comprises adifferent pattern of chemical modifications.

In certain embodiments each strand of a double-stranded siNA molecule ofthe invention comprises a different pattern of chemical modifications,such as any Stab modification chemistries described herein (see Table 9)or any combination thereof, i.e., different combinations of definedStabilzation chemistry (Stab) sense and antisense strands. Further,non-limiting examples of modification schemes that could give rise todifferent patterns of modifications are shown in Table 9. Thestabilization chemistries referred to in Table 9 as Stab, can becombined in any combination of sense/antisense chemistries, such as Stab7/8, Stab 7/11, Stab 8/8, Stab 18/8, Stab 18/11, Stab 12/13, Stab 7/13,Stab 18/13, Stab 7/19, Stab 8/19, Stab 18/19, Stab 7/20, Stab 8/20, Stab18/20, Stab 7/32, Stab 8/32, or Stab 18/32 or any other combination ofStabilization chemistries.

In any of the siNAs of the invention, one or more (for example 1, 2, 3,4 or 5) nucleotides at the 5′-end of the guide strand or guide region(also known as antisense strand or antisense region) of the siNAmolecule are ribonucleotides.

In certain embodiments, the present invention provides a double-strandedshort interfering nucleic acid (siNA) molecule that modulates theexpression of CTNNB1, wherein the siNA comprises a sense strand and anantisense strand; each strand is independently 15 to 30 nucleotides inlength; and the antisense strand comprises at least 15, 16, 17, 18, or19 nucleotides having sequence complementary to any of:

5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 5) 5′-ACGACUAGUUCAGUUGCUU-3′;(SEQ ID NO: 194) 5′-GGAUGAUCCUAGCUAUCGU-3′; (SEQ ID NO: 196) or5′-CCAGGAUGAUCCUAGCUAU-3′. (SEQ ID NO: 151)

In some embodiments, the antisense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

5′-UUUCGAAUCAAUCCAACAG-3′; (SEQ ID NO: 4918) 5′-AAGCAACUGAACUAGUCGU-3′;(SEQ ID NO: 5107) 5′-ACGAUAGCUAGGAUCAUCC-3′; (SEQ ID NO: 5109) or5′-AUAGCUAGGAUCAUCCUGG-3′. (SEQ ID NO: 5064)

In some embodiments, the sense strand of a siNA molecule of theinvention comprises at least a 15, 16, 17, 18, or 19 nucleotide sequenceof:

5′-CUGUUGGAUUGAUUCGAAA-3′; (SEQ ID NO: 5) 5′-ACGACUAGUUCAGUUGCUU-3′;(SEQ ID NO: 194) 5′-GGAUGAUCCUAGCUAUCGU-3′; (SEQ ID NO: 196) or5′-CCAGGAUGAUCCUAGCUAU-3′. (SEQ ID NO: 151)

In some embodiments, a siNA molecule of the invention comprises any of:

5′-CUGUUGGAUUGAUUCGAAA-3′ (SEQ ID NO: 5) and 5′-UUUCGAAUCAAUCCAACAG-3′;(SEQ ID NO: 4918) or 5′-ACGACUAGUUCAGUUGCUU-3′ (SEQ ID NO: 194) and5′-AAGCAACUGAACUAGUCGU-3′; (SEQ ID NO: 5107) or5′-GGAUGAUCCUAGCUAUCGU-3′ (SEQ ID NO: 196) and5′-ACGAUAGCUAGGAUCAUCC-3′; (SEQ ID NO: 5109) or5′-CCAGGAUGAUCCUAGCUAU-3′ (SEQ ID NO: 151) and5′-AUAGCUAGGAUCAUCCUGG-3′. (SEQ ID NO: 5064)

Any of the above described modifications, or combinations thereof,including those in the references cited, can be applied to any of theseembodiments.

In certain embodiments, the nucleotides of the at least a 15, 16, 17,18, or 19 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ IDNO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO:151, or SEQ ID NO: 5064 form a contiguous stretch of nucleotides.

In some embodiments, the siNA molecule can contain one or morenucleotide deletions, substitutions, mismatches and/or additions to theat least 15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 5, SEQID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO:5109, SEQ ID NO: 151, or SEQ ID NO: 5064; provided, however, that thesiNA molecule maintains its activity, for example, to mediate RNAi. In anon-limiting example, the deletion, substitution, mismatch and/oraddition can result in a loop or bulge, or alternately a wobble or otheralternative (non Watson-Crick) base pair.

In certain embodiments of the invention, double-stranded siNA moleculesare provided, wherein the molecule has a sense strand and an antisensestrand and comprises the following formula (A):

B—N_(X3)—(N)_(X2)B-3′

B(N)_(X1)—N_(X4)—[N]_(X5)-5′  (A)

-   -   wherein, the upper strand is the sense strand and the lower        strand is the antisense strand of the double-stranded nucleic        acid molecule; wherein the antisense strand comprises at least a        15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO: 4918,        SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064, and the        sense strand comprises a sequence having complementarity to the        antisense strand;    -   each N is independently a nucleotide which is unmodified or        chemically modified or a non-nucleotide;    -   each B is a terminal cap that is present or absent;    -   (N) represents overhanging nucleotides, each of which is        independently unmodified or chemically modified;

[N] represents nucleotides that are ribonucleotides;

-   -   X1 and X2 are independently integers from 0 to 4;    -   X3 is an integer from 15 to 30;    -   X4 is an integer from 9 to 30; and    -   X5 is an integer from 0 to 6, provided that the sum of X4 and X5        is 15-30.

In certain embodiments, the nucleotides of the at least a 15, 16, 17,18, or 19 nucleotide sequence of SEQ ID NO: 4918, SEQ ID NO: 5107, SEQID NO: 5109, or SEQ ID NO: 5064 form a contiguous stretch ofnucleotides.

In some embodiments, the siNA molecule of formula A can contain one ormore nucleotide deletions, substitutions, mismatches and/or additions tothe at least 15, 16, 17, 18, or 19 nucleotide sequence of SEQ ID NO:4918, SEQ ID NO: 5107, SEQ ID NO: 5109, or SEQ ID NO: 5064; provided,however, that the siNA molecule maintains its activity, for example, tomediate RNAi. In a non-limiting example, the deletion, substitution,mismatch and/or addition can result in a loop or bulge, or alternately awobble or other alternative (non Watson-Crick) base pair.

In one embodiment, the invention features a double-stranded shortinterfering nucleic acid (siNA) of formula (A); wherein

-   -   (a) one or more pyrimidine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (b) one or more purine nucleotides in N_(X4) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof;    -   (c) one or more pyrimidine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof; and    -   (d) one or more purine nucleotides in N_(X3) positions are        independently 2′-deoxy-2′-fluoro nucleotides, 2′-O-alkyl        nucleotides, 2′-deoxy nucleotides, ribonucleotides, or any        combination thereof.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-deoxy-2′-fluoro nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are 2′-O-alkyl nucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-deoxy-2′-fluoro nucleotides; and    -   (d) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X3) positions        are 2′-deoxy nucleotides.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-O-alkyl nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are ribonucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-O-alkyl nucleotides; and    -   (d) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X3) positions        are ribonucleotides.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A); wherein

-   -   (a) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X4)        positions are 2′-deoxy-2′-fluoro nucleotides;    -   (b) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X4) positions        are 2′-O-alkyl nucleotides;    -   (c) 1, 2, 3, 4, 5 or more pyrimidine nucleotides in N_(X3)        positions are 2′-O-alkyl nucleotides; and    -   (d) 1, 2, 3, 4, 5 or more purine nucleotides in N_(X3) positions        are 2′-deoxy-2′-fluoro nucleotides.

In certain embodiments, the invention features a double-stranded shortinterfering nucleic acid (siNA) molecule of formula (A) furthercomprising one or more phosphorothioate internucleotide linkages.

In some embodiments, siNA molecules having formula A comprise a terminalphosphate group at the 5′-end of the antisense strand or antisenseregion of the nucleic acid molecule.

In various embodiments, siNA molecules having formula A comprise X5=0,1, 2, or 3; each X1 and X2=1 or 2; X3=18, 19, 20, 21, 22, or 23, andX4=17, 18, 19, 20, 21, 22, or 23.

In certain embodiments, siNA molecules having formula A comprise X5=3.In other embodiments siNA molecules having formula A comprise X5=0.

In certain embodiments, siNA molecules having formula A comprise X1=2and X2=2.

In various embodiments, siNA molecules having formula A comprise X5=0,X1=2, and X2=2. In other embodiments, siNA molecules having formula Acomprise X5=3, X1=2, and X2=2.

In one specific embodiment, an siNA molecule having formula A comprisesX5=3; each X1 and X2=2; X3=19, and X4=16.

In another specific embodiment, an siNA molecule having formula Acomprises X5=0; each X1 and X2=2; X3=19, and X4=19.

In certain embodiments, siNA molecules having formula A comprise caps(B) at the 3′ and 5′ ends of the sense strand or sense region.

In certain embodiments, siNA molecules having formula A comprise caps(B) at the 3′-end of the antisense strand or antisense region.

In various embodiments, siNA molecules having formula A comprise caps(B) at the 3′ and 5′ ends of the sense strand or sense region and caps(B) at the 3′-end of the antisense strand or antisense region.

In yet other embodiments, siNA molecules having formula A comprise caps(B) only at the 5′-end of the sense (upper) strand of thedouble-stranded nucleic acid molecule.

In some embodiments, siNA molecules having formula A further compriseone or more phosphorothioate internucleotide linkages between thenucleotides. In certain embodiments, siNA molecules having formula Acomprise one or more phosphorothioate internucleotide linkages betweenthe first terminal (N) and the adjacent nucleotide on the 3′ end of thesense strand, antisense strand, or both sense strand and antisensestrands of the nucleic acid molecule. For example, a double-strandednucleic acid molecule can comprise X1 and/or X2=2 having overhangingnucleotide positions with a phosphorothioate internucleotide linkage,e.g., (NsN) where “s” indicates phosphorothioate.

In some embodiments, one or more of the nucleotides of siNA moleculeshaving formula A have a universal base.

In certain embodiments, siNA molecules having formula A have at position14 from the 5′-end of the antisense strand a ribonucleotide when thenucleotide at that position 14 is a purine. In other embodiments, siNAmolecules having formula A have at position 14 from the 5′-end of theantisense strand a ribonucleotide, a 2′-deoxy-2′-fluoro nucleotide or a2′-O-methyl nucleotide when the nucleotide at that position 14 is apyrimidine nucleotide.

In some embodiments, siNA molecules having formula A comprises (N)nucleotides in the antisense strand (lower strand) that arecomplementary to nucleotides in a CTNNB1 target polynucleotide sequence,which also has complementarity to the N and [N] nucleotides of theantisense (lower) strand.

In certain embodiments, one or more siNA molecules of the invention aremodified according to modification criteria as shown and described inU.S. Ser. No. 61/408,428 and U.S. Ser. No. 61/408,303, both of which areincorporated by reference herein.

Any of the above described modifications, or combinations thereof,discussed above as applicable to siNAs of the invention, including thosein the references cited, can be applied to any of the embodiments tosiNA molecules of the present invention.

C. Generation/Synthesis of siNA Molecules

The siNAs of the invention can be obtained using a number of techniquesknown to those of skill in the art. For example the siNA can bechemically synthesized or may be encoded by plasmid (e.g., transcribedas sequences that automatically fold into duplexes with hairpin loops.).siNA can also be generated by cleavage of longer dsRNA (e.g., dsRNAgreater than about 25 nucleotides in length) by the E coli RNase II orDicer. These enzymes process the dsRNA into biologically active siNA(see, e.g., Yang et al., PNAS USA 99:9942-9947 (2002); Calegari et al.PNAS USA 99:14236 (2002) Byron et al. Ambion Tech Notes; 10 (1):4-6(2009); Kawaski et al., Nucleic Acids Res., 31:981-987 (2003), Knightand Bass, Science, 293:2269-2271 (2001) and Roberston et al., J. Biol.Chem. 243:82 (1969).

1. Chemical Synthesis

Preferably, siNA of the invention are chemically synthesized.Oligonucleotides (e.g., certain modified oligonucleotides or portions ofoligonucleotides lacking ribonucleotides) are synthesized usingprotocols known in the art, for example as described in Caruthers etal., 1992, Methods in Enzymology 211, 3-19, Thompson et al.,International PCT Publication No. WO 99/54459, Wincott et al., 1995,Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997, Methods Mol.Bio., 74, 59, Brennan et al., 1998, Biotechnol Bioeng., 61, 33-45, andBrennan, U.S. Pat. No. 6,001,311. The synthesis of oligonucleotidesmakes use of common nucleic acid protecting and coupling groups, such asdimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. siNAmolecules without modifications are synthesized using procedures asdescribed in Usman et al., 1987, J. Am. Chem. Soc., 109, 7845; Scaringeet al., 1990, Nucleic Acids Res., 18, 5433. These syntheses makes use ofcommon nucleic acid protecting and coupling groups, such asdimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end thatcan be used for certain siNA molecules of the invention.

In certain embodiments, the siNA molecules of the invention aresynthesized, deprotected, and analyzed according to methods described inU.S. Pat. Nos. 6,995,259, 6,686,463, 6,673,918, 6,649,751, 6,989,442,and U.S. patent application Ser. No. 10/190,359.

In a non-limiting synthesis example, small scale syntheses are conductedon a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scaleprotocol with a 2.5 min coupling step for 2′-O-methylated nucleotidesand a 45 second coupling step for 2′-deoxy nucleotides or2′-deoxy-2′-fluoro nucleotides. Table 10 outlines the amounts and thecontact times of the reagents used in the synthesis cycle.

Alternatively, the siNA molecules of the present invention can besynthesized separately and joined together post-synthetically, forexample, by ligation (Moore et al., 1992, Science 256, 9923; Draper etal., International PCT Publication No. WO 93/23569; Shabarova et al.,1991, Nucleic Acids Research 19, 4247; Bellon et al., 1997, Nucleosides& Nucleotides, 16, 951; Bellon et al., 1997, Bioconjugate Chem. 8, 204),or by hybridization following synthesis and/or deprotection.

Various siNA molecules of the invention can also be synthesized usingthe teachings of Scaringe et al., U.S. Pat. Nos. 5,889,136; 6,008,400;and 6,111,086.

2. Vector Expression

Alternatively, siNA molecules of the invention that interact with anddown-regulate gene encoding target CTNNB1 molecules can be expressed anddelivered from transcription units (see for example Couture et al.,1996, TIG., 12, 510) inserted into DNA or RNA vectors. The recombinantvectors can be DNA plasmids or viral vectors. siNA expressing viralvectors can be constructed based on, but not limited to,adeno-associated virus, retrovirus, adenovirus, or alphavirus.

In some embodiments, pol III based constructs are used to expressnucleic acid molecules of the invention. Transcription of the siNAmolecule sequences can be driven from a promoter for eukaryotic RNApolymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III(pol III). (see for example, Thompson, U.S. Pat. Nos. 5,902,880 and6,146,886). (See also, Izant and Weintraub, 1985, Science, 229, 345;McGarry and Lindquist, 1986, Proc. Natl. Acad. Sci., USA 83, 399;Scanlon et al., 1991, Proc. Natl. Acad. Sci. USA, 88, 10591-5;Kashani-Sabet et al., 1992, Antisense Res. Dev., 2, 3-15; Dropulic etal., 1992, J. Virol., 66, 1432-41; Weerasinghe et al., 1991, J. Virol.,65, 5531-4; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89,10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Sarver etal., 1990 Science, 247, 1222-1225; Thompson et al., 1995, Nucleic AcidsRes., 23, 2259; Good et al., 1997, Gene Therapy, 4, 45. Transcripts frompol II or pol III promoters are expressed at high levels in all cells;the levels of a given pol II promoter in a given cell type depends onthe nature of the gene regulatory sequences (enhancers, silencers, etc.)present nearby. Prokaryotic RNA polymerase promoters are also used,providing that the prokaryotic RNA polymerase enzyme is expressed in theappropriate cells (Elroy-Stein and Moss, 1990, Proc. Natl. Acad. Sci.USA, 87, 6743-7; Gao and Huang 1993, Nucleic Acids Res., 21, 2867-72;Lieber et al., 1993, Methods Enzymol., 217, 47-66; Zhou et al., 1990,Mol. Cell. Biol., 10, 4529-37). Several investigators have demonstratedthat nucleic acid molecules expressed from such promoters can functionin mammalian cells (e.g. Kashani-Sabet et al., 1992, Antisense Res.Dev., 2, 3-15; Ojwang et al., 1992, Proc. Natl. Acad. Sci. USA, 89,10802-6; Chen et al., 1992, Nucleic Acids Res., 20, 4581-9; Yu et al.,1993, Proc. Natl. Acad. Sci. USA, 90, 6340-4; L'Huillier et al., 1992,EMBO J., 11, 4411-8; Lisziewicz et al., 1993, Proc. Natl. Acad. Sci.U.S. A, 90, 8000-4; Thompson et al., 1995, Nucleic Acids Res., 23, 2259;Sullenger & Cech, 1993, Science, 262, 1566). More specifically,transcription units such as the ones derived from genes encoding U6small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA areuseful in generating high concentrations of desired RNA molecules suchas siNA in cells (Thompson et al., supra; Couture and Stinchcomb, 1996,supra; Noonberg et al., 1994, Nucleic Acid Res., 22, 2830; Noonberg etal., U.S. Pat. No. 5,624,803; Good et al., 1997, Gene Ther., 4, 45;Beigelman et al., International PCT Publication No. WO 96/18736. Theabove siNA transcription units can be incorporated into a variety ofvectors for introduction into mammalian cells, including but notrestricted to, plasmid DNA vectors, viral DNA vectors (such asadenovirus or adeno-associated virus vectors), or viral RNA vectors(such as retroviral or alphavirus vectors) (for a review see Couture andStinchcomb, 1996, supra).

Vectors used to express the siNA molecules of the invention can encodeone or both strands of an siNA duplex, or a single self-complementarystrand that self hybridizes into an siNA duplex. The nucleic acidsequences encoding the siNA molecules of the instant invention can beoperably linked in a manner that allows expression of the siNA molecule(see for example Paul et al., 2002, Nature Biotechnology, 19, 505;Miyagishi and Taira, 2002, Nature Biotechnology, 19, 497; Lee et al.,2002, Nature Biotechnology, 19, 500; and Novina et al., 2002, NatureMedicine, advance online publication doi: 10.1038/nm725).

D. Carrier/Delivery Systems

The siNA molecules of the invention are added directly, or can becomplexed with cationic lipids, packaged within liposomes, or as arecombinant plasmid or viral vectors which express the siNA molecules,or otherwise delivered to target cells or tissues. Methods for thedelivery of nucleic acid molecules are described in Akhtar et al., 1992,Trends Cell Bio., 2, 139; Delivery Strategies for AntisenseOligonucleotide Therapeutics, ed. Akhtar, 1995, Maurer et al., 1999,Mol. Membr. Biol., 16, 129-140; Hofland and Huang, 1999, Handb. Exp.Pharmacol., 137, 165-192; and Lee et al., 2000, ACS Symp. Ser., 752,184-192. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al.,PCT WO 94/02595 further describe the general methods for delivery ofnucleic acid molecules. These protocols can be utilized for the deliveryof virtually any nucleic acid molecule. Nucleic acid molecules can beadministered to cells by a variety of methods known to those of skill inthe art, including, but not restricted to, encapsulation in liposomes,by iontophoresis, or by incorporation into other vehicles, such asbiodegradable polymers, hydrogels, cyclodextrins (see for example,Gonzalez et al., 1999, Bioconjugate Chem., 10, 1068-1074; Wang et al.,International PCT Publication Nos. WO 03/47518 and WO 03/46185),poly(lactic-co-glycolic)acid (PLGA) and PLCA microspheres (see forexample U.S. Pat. No. 6,447,796 and US Patent Application PublicationNo. US 2002130430), biodegradable nanocapsules, and bioadhesivemicrospheres, or by proteinaceous vectors (O'Hare and Normand,International PCT Publication No. WO 00/53722).

In one aspect, the present invention provides carrier systems containingthe siNA molecules described herein. In some embodiments, the carriersystem is a lipid-based carrier system, cationic lipid, or liposomenucleic acid complexes, a liposome, a micelle, a virosome, a lipidnanoparticle or a mixture thereof. In other embodiments, the carriersystem is a polymer-based carrier system such as a cationicpolymer-nucleic acid complex. In additional embodiments, the carriersystem is a cyclodextrin-based carrier system such as a cyclodextrinpolymer-nucleic acid complex. In further embodiments, the carrier systemis a protein-based carrier system such as a cationic peptide-nucleicacid complex. Preferably, the carrier system is a lipid nanoparticle(“LNP”) formulation.

In certain embodiments, the siNA molecules of the invention areformulated with a lipid nanoparticle composition such as is described inU.S. patent application Ser. Nos. 11/353,630, 11/586,102, 61/189,295,61/204,878, 61/235,476, 61/249,807, 61/298,022, 61/351,373, 61/347,640,61/345,754, 61/322,054, 12/640,342, and 12/617,079, and PCT ApplicationsNos. PCT/US10/020,013 and PCT/US09/053,336. In certain preferredembodiments, the siNA molecules of the invention are formulated with alipid nanoparticle composition comprising a cationiclipid/Cholesterol/PEG-C-DMA/DSPC in a 40/48/2/10 ratio or a cationiclipid/Cholesterol/PEG-DMG/DSPC in a 40/48/2/10 ratio. In more certainembodiments, the cationic lipid is DLinDMA (see Table 12), the PEG isPEG-DMG, and the N/P ratio of the formulation is 2.8. In more preferredembodiments, the cationic lipid is DLinDMA (see Tables 11 & 12).

In various embodiments, lipid nanoparticle formulations described inTable 11 are applied to any siNA molecule or combination of siNAmolecules herein. In some embodiments, the invention features acomposition comprising an siNA molecule of the invention formulated asany of formulation LNP-051; LNP-053; LNP-054; LNP-069; LNP-073; LNP-077;LNP-080; LNP-082; LNP-083; LNP-060; LNP-061; LNP-086; LNP-097; LNP-098;LNP-099; LNP-100; LNP-101; LNP-102; LNP-103; or LNP-104 (see Table 11).

In certain other embodiments, the invention features a compositioncomprising an siNA molecule of the invention formulated with any of thecationic lipid formulations described in U.S. Patent Application Nos.61/189,295, 61/204,878, 61/235,476, 61/249,807, and 61/298,022.

In other embodiments, the invention features conjugates and/or complexesof siNA molecules of the invention. Such conjugates and/or complexes canbe used to facilitate delivery of siNA molecules into a biologicalsystem, such as a cell. The conjugates and complexes provided by theinstant invention can impart therapeutic activity by transferringtherapeutic compounds across cellular membranes, altering thepharmacokinetics, and/or modulating the localization of nucleic acidmolecules of the invention. Non-limiting, examples of such conjugatesare described in U.S. Publication Nos. US2008/0152661 A1 and US2004/0162260 A1 (e.g., CDM-LBA, CDM-Pip-LBA, CDM-PEG, CDM-NAG, etc.) andU.S. patent application Ser. Nos. 10/427,160 10/201,394, 61/322,422, and61/315,223; and U.S. Pat. Nos. 6,528,631; 6,335,434; 6,235,886;6,153,737; 5,214,136; and 5,138,045.

In various embodiments, polyethylene glycol (PEG) can be covalentlyattached to siNA compounds of the present invention. The attached PEGcan be any molecular weight, preferably from about 100 to about 50,000daltons (Da).

In yet other embodiments, the invention features compositions orformulations comprising surface-modified liposomes containing poly(ethylene glycol) lipids (PEG-modified, or long-circulating liposomes orstealth liposomes) and siNA molecules of the invention, such as isdisclosed in for example, International PCT Publication No. WO 96/10391;Ansell et al., International PCT Publication No. WO 96/10390; Holland etal., International PCT Publication No. WO 96/10392.

In some embodiments, the siNA molecules of the invention can also beformulated or complexed with polyethyleneimine and derivatives thereof,such as polyethyleneimine-polyethyleneglycol-N-acetylgalactosamine(PEI-PEG-GAL) or polyethyleneimine-polyethyleneglycol-tri-N-acetylgalactosamine (PEI-PEG-triGAL)derivatives. In one embodiment, the nucleic acid molecules of theinvention are formulated as described in U.S. Patent ApplicationPublication No. 20030077829.

In other embodiments, siNA molecules of the invention are complexed withmembrane disruptive agents such as those described in U.S. PatentApplication Publication No. 20010007666. In still other embodiments, themembrane disruptive agent or agents and the siNA molecule are alsocomplexed with a cationic lipid or helper lipid molecule, such as thoselipids described in U.S. Pat. No. 6,235,310.

In certain embodiments, siNA molecules of the invention are complexedwith delivery systems as described in U.S. Patent ApplicationPublication Nos. 2003077829; 20050287551; 20050164220; 20050191627;20050118594; 20050153919; 20050085486; and 20030158133; andInternational PCT Publication Nos. WO 00/03683 and WO 02/087541.

In some embodiments, a liposomal formulation of the invention comprisesan siNA molecule of the invention (e.g., siNA) formulated or complexedwith compounds and compositions described in U.S. Pat. Nos. 6,858,224;6,534,484; 6,287,591; 6,835,395; 6,586,410; 6,858,225; 6,815,432;6,586,001; 6,120,798; 6,977,223; 6,998,115; 5,981,501; 5,976,567;5,705,385; and U.S. Patent Application Publication Nos. 2006/0019912;2006/0019258; 2006/0008909; 2005/0255153; 2005/0079212; 2005/0008689;2003/0077829, 2005/0064595, 2005/0175682, 2005/0118253; 2004/0071654;2005/0244504; 2005/0265961 and 2003/0077829.

Alternatively, recombinant plasmids and viral vectors, as discussedabove, which express siNAs of the invention can be used to deliver themolecules of the invention. Delivery of siNA molecule expressing vectorscan be systemic, such as by intravenous or intra-muscularadministration, by administration to target cells ex-planted from asubject followed by reintroduction into the subject, or by any othermeans that would allow for introduction into the desired target cell(for a review see Couture et al., 1996, TIG., 12, 510). Such recombinantplasmids can also be administered directly or in conjunction with asuitable delivery reagents, including, for example, the Minis TransitLT1 lipophilic reagent; lipofectin; lipofectamine; cellfectin;polycations (e.g., polylysine) or liposomes lipid-based carrier system,cationic lipid, or liposome nucleic acid complexes, a micelle, avirosome, a lipid nanoparticle.

E. Kits

The present invention also provides nucleic acids in kit form. The kitmay comprise a container. The kit typically contains a nucleic acid ofthe invention with instructions for its administration. In certaininstances, the nucleic acids may have a targeting moiety attached.Methods of attaching targeting moieties (e.g. antibodies, proteins) areknown to those of skill in the art. In certain instances, the nucleicacids are chemically modified. In other embodiments, the kit containsmore than one siNA molecule of the invention. The kits may comprise ansiNA molecule of the invention with a pharmaceutically acceptablecarrier or diluent. The kits may further comprise excipients.

F. Therapeutic Uses/Pharmaceutical Compositions

The present body of knowledge in CTNNB1 research indicates the need formethods to assay CTNNB1 activity and for compounds that can regulateCTNNB1 expression for research, diagnostic, and therapeutic use. Asdescribed infra, the nucleic acid molecules of the present invention canbe used in assays to diagnose disease state related of CTNNB1 levels. Inaddition, the nucleic acid molecules and pharmaceutical compositions canbe used to treat disease states related to CTNNB1 RNA levels.

1. Disease States Associated with CTNNB1

Particular disease states that can be associated with CTNNB1 expressionmodulation include various cancers including solid tumors. Non-limitingexamples of such cancers include: bilary tract cancer, bladder cancer,transitional cell carcinoma, urothelial carcinoma, osteosarcoma, braincancer, gliomas, astrocytomas, breast carcinoma, metaplastic carcinoma,cervical cancer, cervical squamous cell carcinoma, rectal cancer,colorectal carcinoma, colon cancer, hereditary nonpolyposis colorectalcancer, colorectal adenocarcinomas, gastrointestinal stromal tumors(GISTs), endometrial carcinoma, endometrial stromal sarcomas, esophagealcancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma,ocular melanoma, uveal melanoma, gallbladder carcinomas, gallbladderadenocarcinoma, renal cell carcinoma, clear cell renal cell carcinoma,transitional cell carcinoma, urothelial carcinomas, wilms tumor,leukemia, acute lymocytic leukemia (ALL), acute myeloid leukemia (AML),chronic lymphocytic (CLL), chronic myeloid (CML), chronic myelomonocytic(CMML), liver cancer, liver carcinoma, hepatoma, hepatocellularcarcinoma, cholangiocarcinoma, hepatoblastoma, Lung cancer, non-smallcell lung cancer (NSCLC), mesothelioma, B-cell lymphomas, non-Hodgkinlymphoma, diffuse large B-cell lymphoma, Mantle cell lymphoma, T-celllymphomas, non-Hodgkin lymphoma, precursor T-lymphoblasticlymphoma/leukemia, peripheral T-cell lymphomas, multiple myeloma,nasopharyngeal carcinoma (NPC), neuroblastoma, oropharyngeal cancer,oral cavity squamous cell carcinomas, osteosarcoma, ovarian carcinoma,pancreatic cancer, pancreatic ductal adenocarcinoma, pseudopapillaryneoplasms, acinar cell carcinomas, Prostate cancer, prostateadenocarcinoma, skin cancer, melanoma, malignant melanoma, cutaneousmelanoma, small intestine carcinomas, stomach cancer, gastric carcinoma,gastrointestinal stromal tumor (GIST), uterine cancer, and uterinesarcoma.

It is understood that the siNA molecules of the invention can degradethe target CTNNB1 mRNA (and thus inhibit the diseases stated above).Inhibition of a disease can be evaluated by directly measuring theprogress of the disease in a subject. It can also be inferred throughobserving a change or reversal in a condition associated with thedisease. Additionally, the siNA molecules of the invention can be usedas a prophylaxis. Thus, the use of the nucleic acid molecules andpharmaceutical compositions of the invention can be used to ameliorate,treat, prevent, and/or cure these diseases and others associated withregulation of CTNNB1 gene expression.

2. Pharmaceutical Compositions

The siNA molecules of the instant invention provide useful reagents andmethods for a variety of therapeutic, prophylactic, cosmetic,veterinary, diagnostic, target validation, genomic discovery, geneticengineering, and pharmacogenomic applications.

a. Formulations

Thus, the present invention, in one aspect, also provides forpharmaceutical compositions of the siNA molecules described, i.e.,compositions in a pharmaceutically acceptable carrier or diluent. Thesepharmaceutical compositions include salts, esters, or salts of suchesters, of the above compounds, e.g., acid addition salts, for example,salts of hydrochloric, hydrobromic, hydroiodic, acetic acid, and benzenesulfonic acid. Other salts include for example, sodium, potassium,manganese, ammonium, and calcium salts. These formulations orcompositions can comprise a pharmaceutically acceptable carrier ordiluent as is generally known in the art.

In one embodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 5. In another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 4918. In yet anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 194. In still another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5107. In anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 196. In another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5109. In anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising at least a 15 nucleotide sequenceof SEQ ID NO: 151. In yet another embodiment, the invention features apharmaceutical composition comprising an siNA molecule comprising atleast a 15 nucleotide sequence of SEQ ID NO: 5064. In still anotherembodiment, the invention features a pharmaceutical compositioncomprising an siNA molecule comprising formula (A).

The siNA molecules of the invention are preferably formulated aspharmaceutical compositions prior to administering to a subject,according to techniques known in the art. Pharmaceutical compositions ofthe present invention are characterized as being at least sterile andpyrogen-free. Methods for preparing pharmaceutical compositions of theinvention are within the skill in the art for example as described inRemington's Pharmaceutical Science, 17^(th) ed., Mack PublishingCompany, Easton, Pa. (1985).

In some embodiments, pharmaceutical compositions of the invention (e.g.siNA and/or LNP formulations thereof) further comprise conventionalpharmaceutical excipients and/or additives. Suitable pharmaceuticalexcipients include preservatives, flavoring agents, stabilizers,antioxidants, osmolality adjusting agents, buffers, and pH adjustingagents. Suitable additives include physiologically biocompatible buffers(e.g., trimethylamine hydrochloride), addition of chelants (such as, forexample, DTPA or DTPA-bisamide) or calcium chelate complexes (as forexample calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions ofcalcium or sodium salts (for example, calcium chloride, calciumascorbate, calcium gluconate or calcium lactate). In addition,antioxidants and suspending agents can be used.

Non-limiting examples of various types of formulations for localadministration include ointments, lotions, creams, gels, foams,preparations for delivery by transdermal patches, powders, sprays,aerosols, capsules or cartridges for use in an inhaler or insufflator ordrops (for example eye or nose drops), solutions/suspensions fornebulization, suppositories, pessaries, retention enemas and chewable orsuckable tablets or pellets (for example for the treatment of aphthousulcers) or liposome or microencapsulation preparations.

Ointments, creams and gels, can, for example, can be formulated with anaqueous or oily base with the addition of suitable thickening and/orgelling agent and/or solvents. Non limiting examples of such bases canthus, for example, include water and/or an oil such as liquid paraffinor a vegetable oil such as arachis oil or castor oil, or a solvent suchas polyethylene glycol. Various thickening agents and gelling agents canbe used depending on the nature of the base. Non-limiting examples ofsuch agents include soft paraffin, aluminum stearate, cetostearylalcohol, polyethylene glycols, woolfat, beeswax, carboxypolymethyleneand cellulose derivatives, and/or glyceryl monostearate and/or non-ionicemulsifying agents.

In one embodiment lotions can be formulated with an aqueous or oily baseand will in general also contain one or more emulsifying agents,stabilizing agents, dispersing agents, suspending agents or thickeningagents.

In one embodiment powders for external application can be formed withthe aid of any suitable powder base, for example, talc, lactose orstarch. Drops can be formulated with an aqueous or non-aqueous base alsocomprising one or more dispersing agents, solubilizing agents,suspending agents or preservatives.

Compositions intended for oral use can be prepared according to anymethod known to the art for the manufacture of pharmaceuticalcompositions and such compositions can contain one or more suchsweetening agents, flavoring agents, coloring agents or preservativeagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets contain the active ingredient in admixture withnon-toxic pharmaceutically acceptable excipients that are suitable forthe manufacture of tablets. These excipients can be, for example, inertdiluents; such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for examplestarch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets can be uncoated or they canbe coated by known techniques. In some cases such coatings can beprepared by known techniques to delay disintegration and absorption inthe gastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonosterate or glyceryl distearate can be employed.

Formulations for oral use can also be presented as hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules wherein the active ingredient is mixed with water or anoil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in a mixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example sodiumcarboxymethylcellulose, methylcellulose, hydropropyl-methylcellulose,sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia;dispersing or wetting agents can be a naturally-occurring phosphatide,for example, lecithin, or condensation products of an alkylene oxidewith fatty acids, for example polyoxyethylene stearate; or condensationproducts of ethylene oxide with long chain aliphatic alcohols, forexample heptadecaethyleneoxycetanol, or condensation products ofethylene oxide with partial esters derived from fatty acids and ahexitol such as polyoxyethylene sorbitol monooleate, or condensationproducts of ethylene oxide with partial esters derived from fatty acidsand hexitol anhydrides, for example polyethylene sorbitan monooleate.The aqueous suspensions can also contain one or more preservatives, forexample ethyl, or n-propyl p-hydroxybenzoate, one or more coloringagents, one or more flavoring agents, and one or more sweetening agents,such as sucrose or saccharin.

Oily suspensions can be formulated by suspending the active ingredientsin a vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions can contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents and flavoring agents can beadded to provide palatable oral preparations. These compositions can bepreserved by the addition of an anti-oxidant such as ascorbic acid

Pharmaceutical compositions of the invention can also be in the form ofoil-in-water emulsions. The oily phase can be a vegetable oil or amineral oil or mixtures of these. Suitable emulsifying agents can benaturally-occurring gums, for example gum acacia or gum tragacanth,naturally-occurring phosphatides, for example soy bean, lecithin, andesters or partial esters derived from fatty acids and hexitol,anhydrides, for example sorbitan monooleate, and condensation productsof the said partial esters with ethylene oxide, for examplepolyoxyethylene sorbitan monooleate. The emulsions can also containsweetening and flavoring agents.

Syrups and elixirs can be formulated with sweetening agents, for exampleglycerol, propylene glycol, sorbitol, glucose or sucrose. Suchformulations can also contain a demulcent, a preservative and flavoringand coloring agents. The pharmaceutical compositions can be in the formof a sterile injectable aqueous or oleaginous suspension. Thissuspension can be formulated according to the known art using thosesuitable dispersing or wetting agents and suspending agents that havebeen mentioned above. The sterile injectable preparation can also be asterile injectable solution or suspension in a non-toxic parentallyacceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that can beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium. For this purpose, any bland fixed oilcan be employed including synthetic mono- or diglycerides. In addition,fatty acids such as oleic acid find use in the preparation ofinjectables.

The nucleic acid molecules of the invention can also be administered inthe form of suppositories, e.g., for rectal administration of the drug.These compositions can be prepared by mixing the drug with a suitablenon-irritating excipient that is solid at ordinary temperatures butliquid at the rectal temperature and will therefore melt in the rectumto release the drug. Such materials include cocoa butter andpolyethylene glycols.

Nucleic acid molecules of the invention can be administered parenterallyin a sterile medium. The drug, depending on the vehicle andconcentration used, can either be suspended or dissolved in the vehicle.Advantageously, adjuvants such as local anesthetics, preservatives andbuffering agents can be dissolved in the vehicle.

In other embodiments, the siNA and LNP compositions and formulationsprovided herein for use in pulmonary delivery further comprise one ormore surfactants. Suitable surfactants or surfactant components forenhancing the uptake of the compositions of the invention includesynthetic and natural as well as full and truncated forms of surfactantprotein A, surfactant protein B, surfactant protein C, surfactantprotein D and surfactant Protein E, di-saturated phosphatidylcholine(other than dipalmitoyl), dipalmitoylphosphatidylcholine,phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol,phosphatidylethanolamine, phosphatidylserine; phosphatidic acid,ubiquinones, lysophosphatidylethanolamine, lysophosphatidylcholine,palmitoyl-lysophosphatidylcholine, dehydroepiandrosterone, dolichols,sulfatidic acid, glycerol-3-phosphate, dihydroxyacetone phosphate,glycerol, glycero-3-phosphocholine, dihydroxyacetone, palmitate,cytidine diphosphate (CDP) diacylglycerol, CDP choline, choline, cholinephosphate; as well as natural and artificial lamellar bodies which arethe natural carrier vehicles for the components of surfactant, omega-3fatty acids, polyenic acid, polyenoic acid, lecithin, palmitinic acid,non-ionic block copolymers of ethylene or propylene oxides,polyoxypropylene, monomeric and polymeric, polyoxyethylene, monomericand polymeric, poly (vinyl amine) with dextran and/or alkanoyl sidechains, Brij 35, Triton X-100 and synthetic surfactants ALEC, Exosurf,Survan and Atovaquone, among others. These surfactants can be usedeither as single or part of a multiple component surfactant in aformulation, or as covalently bound additions to the 5′ and/or 3′ endsof the nucleic acid component of a pharmaceutical composition herein.

b. Combinations

The siNAs and pharmaceutical formulations according to the invention canbe administered to a subject alone or used in combination with orinclude one or more other therapeutic agents, for example, anticanceragents. Thus, combinations of the presently disclosed compounds withother anti-cancer or chemotherapeutic agents are within the scope of theinvention. Examples of such agents can be found in Cancer Principles andPractice of Oncology by V. T. Devita and S. Hellman (editors), 6^(th)edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers. Aperson of ordinary skill in the art would be able to discern whichcombinations of agents would be useful based on the particularcharacteristics of the drugs and the cancer involved. Such anti-canceragents include, but are not limited to, the following: estrogen receptormodulators, androgen receptor modulators, retinoid receptor modulators,cytotoxic/cytostatic agents, antiproliferative agents, prenyl-proteintransferase inhibitors, HMG-CoA reductase inhibitors and otherangiogenesis inhibitors, inhibitors of cell proliferation and survivalsignaling, apoptosis inducing agents and agents that interfere with cellcycle checkpoints. The siNAs of the invention are also useful incombination with any therapeutic agent used in the treatment of HCC, forexample, but not limitation sorafenib. The instant compounds areparticularly useful when co-administered with radiation therapy.

In a further embodiment, therefore, the invention provides a combinationcomprising an siNA molecule of the invention, such as for example, butnot limitation, an siNA molecule comprising at least a 15 nucleotidesequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO:5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO: 151, or SEQ ID NO:5064; or formula (A) or a pharmaceutically acceptable salt, solvate orphysiologically functional derivative thereof together with one or moreanti-cancer or chemotherapeutic agents.

In certain embodiments, the instant siNA molecules of the invention areuseful in combination with known anti-cancer agents including thefollowing: estrogen receptor modulators, androgen receptor modulators,retinoid receptor modulators, cytotoxic agents, antiproliferativeagents, prenyl-protein transferase inhibitors, HMG-CoA reductaseinhibitors, HIV protease inhibitors, reverse transcriptase inhibitors,and other angiogenesis inhibitors.

Examples of estrogen receptor modulators that can be used in combinationwith the compounds of the invention include, but are not limited to,tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene,fulvestrant,447-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate,4,4′-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.

Examples of androgen receptor modulators that can be used in combinationwith the compounds of the invention include, but are not limited to,finasteride and other 5α-reductase inhibitors, nilutamide, flutamide,bicalutamide, liarozole, and abiraterone acetate.

Examples of such retinoid receptor modulators that can be used incombination with the compounds of the invention include, but are notlimited to, bexarotene, tretinoin, 13-cis-retinoic acid, 9-cis-retinoicacid, α-difluoromethylornithine, ILX23-7553, trans-N-(4′-hydroxyphenyl)retinamide, and N-4-carboxyphenyl retinamide.

Examples of cytotoxic agents that can be used in combination with thecompounds of the invention include, but are not limited to, sertenef,cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altretamine,prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin,oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfantosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa,lobaplatin, satraplatin, profiromycin, cisplatin, irofulven,dexifosfamide, cis-aminedichloro(2-methyl-pyridine)platinum,benzylguanine, glufosfamide, GPX100, (trans, trans,trans)-bis-mu-(hexane-1,6-diamine)-mu-[diamine-platinum(II)]bis[diamine(chloro)platinum(II)]tetrachloride, diarizidinylspermine, arsenic trioxide,1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine, zorubicin,idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin,pinafide, valrubicin, amrubicin, antineoplaston,3′-deamino-3′-morpholino-13-deoxo-10-hydroxycaminomycin, annamycin,galarubicin, elinafide, MEN10755, and4-demethoxy-3-deamino-3-aziridinyl-4-methylsulphonyl-daunorubicin (seeWO 00/50032).

An example of a hypoxia activatable compound that can be used incombination with the compounds of the invention is tirapazamine.

Examples of proteasome inhibitors that can be used in combination withthe compounds of the invention include, but are not limited to,lactacystin and bortezomib.

Examples of microtubule inhibitors/microtubule-stabilising agents thatcan be used in combination with the compounds of the invention include,but are not limited to, paclitaxel, vindesine sulfate,3′,4′-didehydro-4′-deoxy-8′-norvincaleukoblastine, docetaxol, rhizoxin,dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881,BMS184476, vinflunine, cryptophycin,2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide,anhydrovinblastine,N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide,TDX258, the epothilones (see for example U.S. Pat. Nos. 6,284,781 and6,288,237) and BMS188797.

Some examples of topoisomerase inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, are topotecan, hycaptamine, irinotecan, rubitecan,6-ethoxypropionyl-3′,4′-O-exo-benzylidene-chartreusin,9-methoxy-N,N-dimethyl-5-nitropyrazolo[3,4,5-kl] acridine-2-(6H)propanamine,1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3′,4′:b,7]-indolizino[1,2b] quinoline-10,13(9H,15H)dione, lurtotecan,7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100,BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane,2′-dimethylamino-2′-deoxy-etoposide, GL331,N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, (5a, 5 aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N-methylamino]ethyl]-5-[4-hydro0xy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexohydrofuro(3′,4′:6,7)naphtho(2,3-d)-1,3-dioxol-6-one,2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanthridinium,6,9-bis[(2-aminoethyl)amino]benzo[g]isoguinoline-5,10-dione,5-(3-aminopropylamino)-7,10-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5,1-de]acridin-6-one,N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide,N-(2-(dimethylamino)ethyl)acridine-4-carboxamide,6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one,and dimesna.

Examples of inhibitors of mitotic kinesins, and in particular the humanmitotic kinesin KSP, that can be used in combination with the compoundsof the invention include, but are not limited to, inhibitors describedin PCT Publications WO 01/30768, WO 01/98278, WO 03/050,064, WO03/050,122, WO 03/049,527, WO 03/049,679, WO 03/049,678, WO04/039774,WO03/079973, WO03/099211, WO03/105855, WO03/106417, WO04/037171,WO04/058148, WO04/058700, WO04/126699, WO05/018638, WO05/019206,WO05/019205, WO05/018547, WO05/017190, US2005/0176776. In an embodimentinhibitors of mitotic kinesins include, but are not limited toinhibitors of KSP, inhibitors of MKLP1, inhibitors of CENP-E, inhibitorsof MCAK, inhibitors of Kifl4, inhibitors of Mphosph1 and inhibitors ofRab6-KIFL.

Examples of “histone deacetylase inhibitors” that can be used incombination with the compounds of the invention include, but are notlimited to, TSA, oxamflatin, PXD101, MG98, valproic acid and scriptaid.Further reference to other histone deacetylase inhibitors may be foundin the following manuscript; Miller, T. A. et al. J. Med. Chem.46(24):5097-5116 (2003).

Inhibitors of kinases involved in mitotic progression that can be usedin combination with the compounds of the invention include, but are notlimited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases(PLK) (in particular inhibitors of PLK-1), inhibitors of bub-1 andinhibitors of bub-R1.

Antiproliferative agents that can be used in combination with thecompounds of the invention include, but are not limited to, antisenseRNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231,and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur,pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine,galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate,raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed,pemetrexed, nelzarabine, 2′-deoxy-2′-methylidenecytidine,2′-fluoromethylene-2′-deoxycytidine, N-[5-(2,3-dihydro-benzofuryl)sulfonyl]-N′-(3,4-dichlorophenyl)urea,N6-[4-deoxy-4-[N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-manno-heptopyranosyl]adenine,aplidine, ecteinascidin, troxacitabine,4-[2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b][1,4]thiazin-6-yl-(S)-ethyl]-2,5-thienoyl-L-glutamic acid,aminopterin, 5-fluorouracil, alanosine,11-acetyl-8-(carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)-tetradeca-2,4,6-trien-9-yl acetic acid ester, swainsonine,lometrexol, dexrazoxane, methioninase,2′-cyano-2′-deoxy-N4-palmitoyl-1-B-D-arabino furanosyl cytosine and3-aminopyridine-2-carboxaldehyde thiosemicarbazone.

Examples of monoclonal antibody targeted therapeutic agents that can beused in combination with the compounds of the invention include thosetherapeutic agents which have cytotoxic agents or radioisotopes attachedto a cancer cell specific or target cell specific monoclonal antibody,such as, for example, Bexxar.

Examples of HMG-CoA reductase inhibitors that may be used that can beused in combination with the compounds of the invention include, but arenot limited to, lovastatin (MEVACOR®; see U.S. Pat. Nos. 4,231,938,4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Pat. Nos.4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S.Pat. Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589),fluvastatin (LESCOL®; see U.S. Pat. Nos. 5,354,772, 4,911,165,4,929,437, 5,189,164, 5,118,853, 5,290,946 and 5,356,896) andatorvastatin (LIPITOR®; see U.S. Pat. Nos. 5,273,995, 4,681,893,5,489,691 and 5,342,952). The structural formulas of these andadditional HMG-CoA reductase inhibitors that may be used in the instantmethods are described at page 87 of M. Yalpani, “Cholesterol LoweringDrugs”, Chemistry & Industry, pp. 85-89 (5 Feb. 1996) and U.S. Pat. Nos.4,782,084 and 4,885,314.

Examples of prenyl-protein transferase inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, can be found in the following publications and patents: WO96/30343, WO 97/18813, WO 97/21701, WO 97/23478, WO 97/38665, WO98/28980, WO 98/29119, WO 95/32987, U.S. Pat. No. 5,420,245, U.S. Pat.No. 5,523,430, U.S. Pat. No. 5,532,359, U.S. Pat. No. 5,510,510, U.S.Pat. No. 5,589,485, U.S. Pat. No. 5,602,098, European Patent Publ. 0 618221, European Patent Publ. 0 675 112, European Patent Publ. 0 604 181,European Patent Publ. 0 696 593, WO 94/19357, WO 95/08542, WO 95/11917,WO 95/12612, WO 95/12572, WO 95/10514, U.S. Pat. No. 5,661,152, WO95/10515, WO 95/10516, WO 95/24612, WO 95/34535, WO 95/25086, WO96/05529, WO 96/06138, WO 96/06193, WO 96/16443, WO 96/21701, WO96/21456, WO 96/22278, WO 96/24611, WO 96/24612, WO 96/05168, WO96/05169, WO 96/00736, U.S. Pat. No. 5,571,792, WO 96/17861, WO96/33159, WO 96/34850, WO 96/34851, WO 96/30017, WO 96/30018, WO96/30362, WO 96/30363, WO 96/31111, WO 96/31477, WO 96/31478, WO96/31501, WO 97/00252, WO 97/03047, WO 97/03050, WO 97/04785, WO97/02920, WO 97/17070, WO 97/23478, WO 97/26246, WO 97/30053, WO97/44350, WO 98/02436, and U.S. Pat. No. 5,532,359. For an example ofthe role of a prenyl-protein transferase inhibitor on angiogenesis seeEuropean J. of Cancer, Vol. 35, No. 9, pp. 1394-1401 (1999).

Examples of angiogenesis inhibitors that can be used in combination withthe compounds of the invention include, but are not limited to, tyrosinekinase inhibitors, such as inhibitors of the tyrosine kinase receptorsFlt-1 (VEGFR1) and Flk-1/KDR (VEGFR2), inhibitors of epidermal-derived,fibroblast-derived, or platelet derived growth factors, MMP (matrixmetalloprotease) inhibitors, integrin blockers, interferon-α,interleukin-12, pentosan polysulfate, cyclooxygenase inhibitors,including nonsteroidal anti-inflammatories (NSAIDs) like aspirin andibuprofen as well as selective cyclooxy-genase-2 inhibitors likecelecoxib and rofecoxib (PNAS, Vol. 89, p. 7384 (1992); JNCI, Vol. 69,p. 475 (1982); Arch. Opthalmol., Vol. 108, p. 573 (1990); Anat. Rec.,Vol. 238, p. 68 (1994); FEBS Letters, Vol. 372, p. 83 (1995); Clin,Orthop. Vol. 313, p. 76 (1995); J. Mol. Endocrinol., Vol. 16, p. 107(1996); Jpn. J. Pharmacol., Vol. 75, p. 105 (1997); Cancer Res., Vol.57, p. 1625 (1997); Cell, Vol. 93, p. 705 (1998); Intl. J. Mol. Med.,Vol. 2, p. 715 (1998); J. Biol. Chem., Vol. 274, p. 9116 (1999)),steroidal anti-inflammatories (such as corticosteroids,mineralocorticoids, dexamethasone, prednisone, prednisolone, methylpred,betamethasone), carboxyamidotriazole, combretastatin A-4, squalamine,6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin,troponin-1, angiotensin II antagonists (see Fernandez et al., J. Lab.Clin. Med. 105:141-145 (1985)), and antibodies to VEGF (see, NatureBiotechnology, Vol. 17, pp. 963-968 (October 1999); Kim et al., Nature,362, 841-844 (1993); WO 00/44777; and WO 00/61186).

Other therapeutic agents that modulate or inhibit angiogenesis may alsobe used in combination with the compounds of the instant invention andinclude agents that modulate or inhibit the coagulation and fibrinolysissystems (see review in Clin. Chem. La. Med. 38:679-692 (2000)). Examplesof such agents that modulate or inhibit the coagulation and fibrinolysispathways that can be used in combination with the compounds of theinvention include, but are not limited to, heparin (see Thromb. Haemost.80:10-23 (1998)), low molecular weight heparins and carboxypeptidase Uinhibitors (also known as inhibitors of active thrombin activatablefibrinolysis inhibitor [TAFIa]) (see Thrombosis Res. 101:329-354(2001)). TAFIa inhibitors have been described in PCT Publication WO03/013,526 and U.S. Ser. No. 60/349,925 (filed Jan. 18, 2002).

Agents that interfere with cell cycle checkpoints that can be used incombination with the compounds of the invention include, but are notlimited to, inhibitors of ATR, ATM, the Chk1 and Chk2 kinases and cdkand cdc kinase inhibitors and are specifically exemplified by7-hydroxystaurosporin, flavopiridol, CYC202 (Cyclacel) and BMS-387032.

Agents that interfere with receptor tyrosine kinases (RTKs) that can beused in combination with the compounds of the invention include, but arenot limited to, inhibitors of c-Kit, Eph, PDGF, Flt3 and CTNNB1. Furtheragents include inhibitors of RTKs as described by Bume-Jensen andHunter, Nature, 411:355-365, 2001.

Inhibitors of cell proliferation and survival signaling pathway that canbe used in combination with the compounds of the invention include, butare not limited to, inhibitors of EGFR (for example gefitinib anderlotinib), inhibitors of ERB-2 (for example trastuzumab), inhibitors ofIGFR, inhibitors of cytokine receptors, inhibitors of CTNNB1, inhibitorsof PI3K (for example LY294002), serine/threonine kinases (including butnot limited to inhibitors of Akt such as described in WO 02/083064, WO02/083139, WO 02/083140, US 2004-0116432, WO 02/083138, US 2004-0102360,WO 03/086404, WO 03/086279, WO 03/086394, WO 03/084473, WO 03/086403, WO2004/041162, WO 2004/096131, WO 2004/096129, WO 2004/096135, WO2004/096130, WO 2005/100356, WO 2005/100344), inhibitors of Raf kinase(for example BAY-43-9006), inhibitors of MEK (for example CI-1040 andPD-098059) and inhibitors of mTOR (for example Wyeth CCI-779). Suchagents include small molecule inhibitor compounds and antibodyantagonists.

Apoptosis inducing agents that can be used in combination with thecompounds of the invention include, but are not limited to, activatorsof TNF receptor family members (including the TRAIL receptors).

NSAIDs that are selective COX-2 inhibitors that can be used incombination with the compounds of the invention include, but are notlimited to, those NSAIDs disclosed in U.S. Pat. No. 5,474,995, U.S. Pat.No. 5,861,419, U.S. Pat. No. 6,001,843, U.S. Pat. No. 6,020,343, U.S.Pat. No. 5,409,944, U.S. Pat. No. 5,436,265, U.S. Pat. No. 5,536,752,U.S. Pat. No. 5,550,142, U.S. Pat. No. 5,604,260, U.S. Pat. No.5,698,584, U.S. Pat. No. 5,710,140, WO 94/15932, U.S. Pat. No.5,344,991, U.S. Pat. No. 5,134,142, U.S. Pat. No. 5,380,738, U.S. Pat.No. 5,393,790, U.S. Pat. No. 5,466,823, U.S. Pat. No. 5,633,272, andU.S. Pat. No. 5,932,598, all of which are hereby incorporated byreference.

Inhibitors of COX-2 that are particularly useful in combination with thecompounds of the invention include:3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone; and5-chloro-3-(4-methylsulfonyl)-phenyl-2-(2-methyl-5-pyridinyl)pyridine;or a pharmaceutically acceptable salt thereof.

Compounds that have been described as specific inhibitors of COX-2 andare therefore useful in the present invention include, but are notlimited to: parecoxib, CELEBREX® and BEXTRA® or a pharmaceuticallyacceptable salt thereof.

Angiogenesis inhibitors that can be used in combination with thecompounds of the invention include, but are not limited to, endostatin,ukrain, ranpirnase, IM862,5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]oct-6-yl(chloroacetyl)carbamate, acetyldinanaline,5-amino-1-[[3,5-dichloro-4-(4-chlorobenzoyl)-phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide,CM101, squalamine, combretastatin, RPI4610, NX31838, sulfatedmannopentaose phosphate,7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolocarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino]-bis-(1,3-naphthalene disulfonate),and 3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone (SU5416).

Tyrosine kinase inhibitors that can be used in combination with thecompounds of the invention include, but are not limited to,N-(trifluoromethylphenyl)-5-methylisoxazol-4-carboxamide,3-[(2,4-dimethylpyrrol-5-yl)methylidenyl)indolin-2-one,17-(allylamino)-17-demethoxygeldanamycin,4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-[3-(4-morpholinyl)propoxyl]quinazoline,N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine,BIBX1382,2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-hydroxy-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one,SH268, genistein, imatinib (STI571), CEP2563,4-(3-chlorophenylamino)-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidinemethanesulfonate, 4-(3-bromo-4-hydroxyphenyl)amino-6,7-dimethoxyquinazoline,4-(4′-hydroxyphenyl)amino-6,7-dimethoxyquinazoline, SU6668, STI571A,N-4-chlorophenyl-4-(4-pyridylmethyl)-1-phthalazinamine, and EMD121974.

Combinations with compounds other than anti-cancer compounds are alsoencompassed in the instant compositions and methods. For example,combinations of the instantly claimed compounds with PPAR-γ (i.e.,PPAR-gamma) agonists and PPAR-δ (i.e., PPAR-delta) agonists are usefulin the treatment of certain malignancies. PPAR-γ and PPAR-δ are thenuclear peroxisome proliferator-activated receptors γ and δ. Theexpression of PPAR-γ on endothelial cells and its involvement inangiogenesis has been reported in the literature (see J. Cardiovasc.Pharmacol. 31:909-913 (1998); J. Biol. Chem. 274:9116-9121 (1999);Invest. Ophthalmol. Vis. Sci. 41:2309-2317 (2000)). More recently,PPAR-γ agonists have been shown to inhibit the angiogenic response toVEGF in vitro; both troglitazone and rosiglitazone maleate inhibit thedevelopment of retinal neovascularization in mice. (Arch. Ophthamol.119:709-717 (2001)). Examples of PPAR-γ agonists and PPARγ/α agoniststhat can be used in combination with the compounds of the inventioninclude, but are not limited to, thiazolidinediones (such as DRF2725,CS-011, troglitazone, rosiglitazone, and pioglitazone), fenofibrate,gemfibrozil, clofibrate, GW2570, SB219994, AR-H039242, JTT-501, MCC-555,GW2331, GW409544, NN2344, KRP297, NP0110, DRF4158, NN622, G1262570,PNU182716, DRF552926,2-[(5,7-dipropyl-3-trifluoromethyl-1,2-benzisoxazol-6-yl)oxy]-2-methylpropionicacid (disclosed in U.S. Ser. No. 09/782,856), and2(R)-7-(3-(2-chloro-4-(4-fluorophenoxy)phenoxy)propoxy)-2-ethylchromane-2-carboxylicacid (disclosed in U.S. Ser. No. 60/235,708 and 60/244,697).

Another embodiment of the instant invention is the use of the presentlydisclosed compounds in combination with gene therapy for the treatmentof cancer. For an overview of genetic strategies to treating cancer seeHall et al. (Am J Hum Genet. 61:785-789 (1997)) and Kufe et al. (CancerMedicine, 5th Ed, pp 876-889, B C Decker, Hamilton, 2000). Gene therapycan be used to deliver any tumor suppressing gene. Examples of suchgenes include, but are not limited to, p53, which can be delivered viarecombinant virus-mediated gene transfer (see U.S. Pat. No. 6,069,134,for example), a uPA/uPAR antagonist (“Adenovirus-Mediated Delivery of auPA/uPAR Antagonist Suppresses Angiogenesis-Dependent Tumor Growth andDissemination in Mice,” Gene Therapy, August 5(8):1105-13 (1998)), andinterferon gamma (J Immunol 164:217-222 (2000)).

The compounds of the instant invention may also be administered incombination with an inhibitor of inherent multidrug resistance (MDR), inparticular MDR associated with high levels of expression of transporterproteins. Such MDR inhibitors include inhibitors of p-glycoprotein(P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833(valspodar).

A compound of the present invention may be employed in conjunction withanti-emetic agents to treat nausea or emesis, including acute, delayed,late-phase, and anticipatory emesis, which may result from the use of acompound of the present invention, alone or with radiation therapy. Forthe prevention or treatment of emesis, a compound of the presentinvention may be used in conjunction with other anti-emetic agents,especially neurokinin-1 receptor antagonists, 5HT3 receptor antagonists,such as ondansetron, granisetron, tropisetron, and zatisetron, GABABreceptor agonists, such as baclofen, a corticosteroid such as Decadron(dexamethasone), Kenalog, Aristocort, Nasalide, Preferid, Benecorten orothers such as disclosed in U.S. Pat. Nos. 2,789,118, 2,990,401,3,048,581, 3,126,375, 3,929,768, 3,996,359, 3,928,326 and 3,749,712, anantidopaminergic, such as the phenothiazines (for exampleprochlorperazine, fluphenazine, thioridazine and mesoridazine),metoclopramide or dronabinol. In an embodiment, an anti-emesis agentselected from a neurokinin-1 receptor antagonist, a 5HT3 receptorantagonist and a corticosteroid is administered as an adjuvant for thetreatment or prevention of emesis that may result upon administration ofthe instant compounds.

Neurokinin-1 receptor antagonists of use in conjunction with thecompounds of the present invention are fully described, for example, inU.S. Pat. Nos. 5,162,339, 5,232,929, 5,242,930, 5,373,003, 5,387,595,5,459,270, 5,494,926, 5,496,833, 5,637,699, 5,719,147; European PatentPublication Nos. EP 0 360 390, 0 394 989, 0 428 434, 0 429 366, 0 430771, 0 436 334, 0 443 132, 0 482 539, 0 498 069, 0 499 313, 0 512 901, 0512 902, 0 514 273, 0 514 274, 0 514 275, 0 514 276, 0 515 681, 0 517589, 0 520 555, 0 522 808, 0 528 495, 0 532 456, 0 533 280, 0 536 817, 0545 478, 0 558 156, 0 577 394, 0 585 913, 0 590 152, 0 599 538, 0 610793, 0 634 402, 0 686 629, 0 693 489, 0 694 535, 0 699 655, 0 699 674, 0707 006, 0 708 101, 0 709 375, 0 709 376, 0 714 891, 0 723 959, 0 733632 and 0 776 893; PCT International Patent Publication Nos. WO90/05525, 90/05729, 91/09844, 91/18899, 92/01688, 92/06079, 92/12151,92/15585, 92/17449, 92/20661, 92/20676, 92/21677, 92/22569, 93/00330,93/00331, 93/01159, 93/01165, 93/01169, 93/01170, 93/06099, 93/09116,93/10073, 93/14084, 93/14113, 93/18023, 93/19064, 93/21155, 93/21181,93/23380, 93/24465, 94/00440, 94/01402, 94/02461, 94/02595, 94/03429,94/03445, 94/04494, 94/04496, 94/05625, 94/07843, 94/08997, 94/10165,94/10167, 94/10168, 94/10170, 94/11368, 94/13639, 94/13663, 94/14767,94/15903, 94/19320, 94/19323, 94/20500, 94/26735, 94/26740, 94/29309,95/02595, 95/04040, 95/04042, 95/06645, 95/07886, 95/07908, 95/08549,95/11880, 95/14017, 95/15311, 95/16679, 95/17382, 95/18124, 95/18129,95/19344, 95/20575, 95/21819, 95/22525, 95/23798, 95/26338, 95/28418,95/30674, 95/30687, 95/33744, 96/05181, 96/05193, 96/05203, 96/06094,96/07649, 96/10562, 96/16939, 96/18643, 96/20197, 96/21661, 96/29304,96/29317, 96/29326, 96/29328, 96/31214, 96/32385, 96/37489, 97/01553,97/01554, 97/03066, 97/08144, 97/14671, 97/17362, 97/18206, 97/19084,97/19942 and 97/21702; and in British Patent Publication Nos. 2 266 529,2 268 931, 2 269 170, 2 269 590, 2 271 774, 2 292 144, 2 293 168, 2 293169, and 2 302 689. The preparation of such compounds is fully describedin the aforementioned patents and publications, which are incorporatedherein by reference.

In an embodiment, the neurokinin-1 receptor antagonist for use inconjunction with the compounds of the present invention is selectedfrom:2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine,or a pharmaceutically acceptable salt thereof, which is described inU.S. Pat. No. 5,719,147.

A compound of the instant invention may also be useful for treating orpreventing cancer, including bone cancer, in combination withbisphosphonates (understood to include bisphosphonates, diphosphonates,bisphosphonic acids and diphosphonic acids). Examples of bisphosphonatesinclude but are not limited to: etidronate (Didronel), pamidronate(Aredia), alendronate (Fosamax), risedronate (Actonel), zoledronate(Zometa), ibandronate (Boniva), incadronate or cimadronate, clodronate,EB-1053, minodronate, neridronate, piridronate and tiludronate includingany and all pharmaceutically acceptable salts, derivatives, hydrates andmixtures thereof.

A compound of the instant invention may also be administered with anagent useful in the treatment of anemia. Such an anemia treatment agentis, for example, a continuous eythropoiesis receptor activator (such asepoetin alfa).

A compound of the instant invention may also be administered with anagent useful in the treatment of neutropenia. Such a neutropeniatreatment agent is, for example, a hematopoietic growth factor whichregulates the production and function of neutrophils such as a humangranulocyte colony stimulating factor, (G-CSF). Examples of a G-CSFinclude filgrastim and PEG-filgrastim.

A compound of the instant invention may also be administered with animmunologic-enhancing drug, such as levamisole, isoprinosine andZadaxin.

A compound of the instant invention may also be useful for treating orpreventing breast cancer in combination with aromatase inhibitors.Examples of aromatase inhibitors include but are not limited to:anastrozole, letrozole and exemestane.

A compound of the instant invention may also be useful for treating orpreventing cancer in combination with other siNA therapeutics.

The compounds of the instant invention may also be administered incombination with γ-secretase inhibitors and/or inhibitors of NOTCHsignaling. Such inhibitors include compounds described in WO 01/90084,WO 02/30912, WO 01/70677, WO 03/013506, WO 02/36555, WO 03/093252, WO03/093264, WO 03/093251, WO 03/093253, WO 2004/039800, WO 2004/039370,WO 2005/030731, WO 2005/014553, U.S. Ser. No. 10/957,251, WO2004/089911, WO 02/081435, WO 02/081433, WO 03/018543, WO 2004/031137,WO 2004/031139, WO 2004/031138, WO 2004/101538, WO 2004/101539 and WO02/47671 (including LY-450139).

A compound of the instant invention may also be useful for treating orpreventing cancer in combination with PARP inhibitors.

A compound of the instant invention may also be useful for treatingcancer in combination with the following therapeutic agents: abarelix(Plenaxis Depot®); aldesleukin (Prokine®); Aldesleukin (Proleukin®);Alemtuzumabb (Campath®); alitretinoin (Panretin); allopurinol(Zyloprim®); altretamine (Hexylen®); amifostine (Ethyol®); anastrozole(Arimidex®); arsenic trioxide (Trisenox®); asparaginase (Elspar®);azacitidine (Vidaza®); bendamustine hydrochloride (Treanda®);bevacuzimab (Avastin®); bexarotene capsules (Targretin®); bexarotene gel(Targretin®); bleomycin (Blenoxane®); bortezomib (Velcade®); brefeldinA; busulfan intravenous (Busulfex®); busulfan oral (Myleran®);calusterone (Methosarb®); capecitabine (Xeloda®); carboplatin(Paraplatin®); carmustine (BCNU®, BiCNU®); carmustine (Gliadel®);carmustine with Polifeprosan 20 Implant (Gliadel Wafer®); celecoxib(Celebrex®); cetuximab (Erbitux®); chlorambucil (Leukeran®); cisplatin(Platinol®); cladribine (Leustatin 2-CdA®); clofarabine (Clolar®);cyclophosphamide (Cytoxan®, Neosar®); cyclophosphamide (CytoxanInjection®); cyclophosphamide (Cytoxan Tablet®); cytarabine(Cytosar-U®); cytarabine liposomal (DepoCyt®); dacarbazine (DTIC-Dome®);dactinomycin, actinomycin D (Cosmegen®); dalteparin sodium injection(Fragmin®); Darbepoetin alfa (Aranesp®); dasatinib (Sprycel®);daunorubicin liposomal (DanuoXome®); daunorubicin, daunomycin(Daunorubicin®); daunorubicin, daunomycin (Cerubidine®); degarelix(Firmagon®); Denileukin diftitox (Ontak®); dexrazoxane (Zinecard®);dexrazoxane hydrochloride (Totect®); didemnin B; 17-DMAG; docetaxel(Taxotere®); doxorubicin (Adriamycin PFS®); doxorubicin (Adriamycin®,Rubex®); doxorubicin (Adriamycin PFS Injection®); doxorubicin liposomal(Doxil®); dromostanolone propionate (Dromostanolone®); dromostanolonepropionate (Masterone Injection®); eculizumab injection (Soliris®);Elliott's B Solution (Elliott's B Solution®); eltrombopag (Promacta®);epirubicin (Ellence®); Epoetin alfa (Epogen®); erlotinib (Tarceva®);estramustine (Emcyt®); ethinyl estradiol; etoposide phosphate(Etopophos®); etoposide, VP-16 (Vepesid®); everolimus tablets(Afinitor®); exemestane (Aromasin®); ferumoxytol (Feraheme Injection®);Filgrastim (Neupogen®); floxuridine (intraarterial) (FUDR®); fludarabine(Fludara®); fluorouracil, 5-FU (Adrucil®); fulvestrant (Faslodex®);gefitinib (Iressa®); geldanamycin; gemcitabine (Gemzar®); gemtuzumabozogamicin (Mylotarg®); goserelin acetate (Zoladex Implant®); goserelinacetate (Zoladex®); histrelin acetate (Histrelin Implant®); hydroxyurea(Hydrea®); Ibritumomab Tiuxetan (Zevalin®); idarubicin (Idamycin®);ifosfamide (IFEX®); imatinib mesylate (Gleevec®); interferon alfa 2a(Roferon A®); Interferon alfa-2b (Intron A®); iobenguane 1123 injection(AdreView®); irinotecan (Camptosar®); ixabepilone (Ixempra®); lapatinibtablets (Tykerb®); lenalidomide (Revlimid®); letrozole (Femara®);leucovorin (Wellcovorin®, Leucovorin®); Leuprolide Acetate (Eligard®);levamisole (Ergamisol®); lomustine, CCNU (CeeBU®); meclorethamine,nitrogen mustard (Mustargen®); megestrol acetate (Megace®); melphalan,L-PAM (Alkeran®); mercaptopurine, 6-MP (Purinethol®); mesna (Mesnex®);mesna (Mesnex Tabs®); methotrexate (Methotrexate®); methoxsalen(Uvadex®); 8-methoxypsoralen; mitomycin C (Mutamycin®); mitotane(Lysodren®); mitoxantrone (Novantrone®); mitramycin; nandrolonephenpropionate (Durabolin-50®); nelarabine (Arranon®); nilotinib(Tasigna®); Nofetumomab (Verluma®); ofatumumab (Arzerra®); Oprelvekin(Neumega®); oxaliplatin (Eloxatin®); paclitaxel (Paxene®); paclitaxel(Taxol®); paclitaxel protein-bound particles (Abraxane®); palifermin(Kepivance®); pamidronate (Aredia®); panitumumab (Vectibix®); pazopanibtablets (Votrienttm®); pegademase (Adagen (Pegademase Bovine)®);pegaspargase (Oncaspar®); Pegfilgrastim (Neulasta®); pemetrexed disodium(Alimta®); pentostatin (Nipent®); pipobroman (Vercyte®); plerixafor(Mozobil®); plicamycin, mithramycin (Mithracin®); porfimer sodium(Photofrin®); pralatrexate injection (Folotyn®); procarbazine(Matulane®); quinacrine (Atabrine®); rapamycin; Rasburicase (Elitek®);raloxifene hydrochloride (Evista®); Rituximab (Rituxan®); romidepsin(Istodax®); romiplostim (Nplate®); sargramostim (Leukine®); Sargramostim(Prokine®); sorafenib (Nexavar®); streptozocin (Zanosar®); sunitinibmaleate (Sutent®); talc (Sclerosol®); tamoxifen (Nolvadex®);temozolomide (Temodar®); temsirolimus (Torisel®); teniposide, VM-26(Vumon®); testolactone (Teslac®); thioguanine, 6-TG (Thioguanine®);thiopurine; thiotepa (Thioplex®); topotecan (Hycamtin®); toremifene(Fareston); Tositumomab (Bexxar®); Tositumomab/I-131 tositumomab(Bexxar®); trans-retinoic acid; Trastuzumab (Herceptin®); tretinoin,ATRA (Vesanoid®); triethylenemelamine; Uracil Mustard (Uracil MustardCapsules®); valrubicin (Valstar®); vinblastine (Velban®); vincristine(Oncovin®); vinorelbine (Navelbine®); vorinostat (Zolinza®); wortmannin;and zoledronate (Zometa®).

The invention also provides a combination comprising an siNA molecule ofthe invention comprising at least a 15 nucleotide sequence of SEQ ID NO:5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQID NO: 5109, SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A) and/or apharmaceutically acceptable salt, solvate or physiologically functionalderivative thereof together with another CTNNB1 inhibitor.

The combinations referred to above can conveniently be presented for usein the form of a pharmaceutical formulation and thus pharmaceuticalcompositions comprising a combination as defined above together with apharmaceutically acceptable diluent or carrier represent a furtheraspect of the invention.

The individual compounds of such combinations can be administered eithersequentially or simultaneously in separate or combined pharmaceuticalformulations. In one embodiment, the individual compounds will beadministered simultaneously in a combined pharmaceutical formulation.

Thus, the described molecules could be used in combination with one ormore known compounds, treatments, or procedures to prevent or treatdiseases, disorders, conditions, and traits described herein in asubject or organism as are known in the art, such as other CTNNB1inhibitors.

3. Therapeutic Applications

The present body of knowledge in CTNNB1 research indicates the need formethods that can regulate CTNNB1 expression for therapeutic use.

Thus, one aspect of the invention comprises a method of treating asubject including, but not limited to, a human suffering from acondition which is mediated by the action, or by loss of action, ofCTNNB1 gene expression, which method comprises administering to saidsubject an effective amount of a double-stranded siNA molecule of theinvention. In one embodiment of this aspect, the siNA moleculescomprises at least a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO:4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109,SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A). In anotherembodiment of this aspect, the condition is or is caused by cancer.Thus, in certain embodiments the molecules and compositions of theinstant invention are useful in a method for treating cancer. Cancerstreatable according to this aspect of the invention include bilary tractcancer, bladder cancer, transitional cell carcinoma, urothelialcarcinoma, osteosarcoma, brain cancer, gliomas, astrocytomas, breastcarcinoma, metaplastic carcinoma, cervical cancer, cervical squamouscell carcinoma, rectal cancer, colorectal carcinoma, colon cancer,hereditary nonpolyposis colorectal cancer, colorectal adenocarcinomas,gastrointestinal stromal tumors (GISTs), endometrial carcinoma,endometrial stromal sarcomas, esophageal cancer, esophageal squamouscell carcinoma, esophageal adenocarcinoma, ocular melanoma, uvealmelanoma, gallbladder carcinomas, gallbladder adenocarcinoma, renal cellcarcinoma, clear cell renal cell carcinoma, transitional cell carcinoma,urothelial carcinomas, wilms tumor, leukemia, acute lymocytic leukemia(ALL), acute myeloid leukemia (AML), chronic lymphocytic (CLL), chronicmyeloid (CML), chronic myelomonocytic (CMML), liver cancer, livercarcinoma, hepatoma, hepatocellular carcinoma, cholangiocarcinoma,hepatoblastoma, lung cancer, non-small cell lung cancer (NSCLC),mesothelioma, B-cell lymphomas, non-Hodgkin lymphoma, diffuse largeB-cell lymphoma, Mantle cell lymphoma, T-cell lymphomas, non-Hodgkinlymphoma, precursor T-lymphoblastic lymphoma/leukemia, peripheral T-celllymphomas, multiple myeloma, nasopharyngeal carcinoma (NPC),neuroblastoma, oropharyngeal cancer, oral cavity squamous cellcarcinomas, osteosarcoma, ovarian carcinoma, pancreatic cancer,pancreatic ductal adenocarcinoma, pseudopapillary neoplasms, acinar cellcarcinomas, prostate cancer, prostate adenocarcinoma, skin cancer,melanoma, malignant melanoma, cutaneous melanoma, small intestinecarcinomas, stomach cancer, gastric carcinoma, gastrointestinal stromaltumor (GIST), uterine cancer, uterine sarcoma

In one embodiment, the siNA molecules of the instant invention areuseful in a method for treating or preventing cancer selected from:brain cancer, breast carcinoma, cervical cancer, colorectal carcinoma,renal cell carcinoma, leukemia, hepatocellular carcinoma, lung cancer,B-cell lymphomas, multiple myeloma, ovarian carcinoma, pancreaticcancer, prostate cancer, melanoma, and gastric carcinoma. In certainembodiments, the compounds of the instant invention are useful fortreating breast carcinoma, colorectal carcinoma, hepatocellularcarcinoma, lung cancer; and prostate cancer. In a particular embodiment,the compounds of the instant invention are useful for treatinghepatocellular carcinoma.

In another embodiment, the siNA molecules of the instant invention areuseful in a method for the prevention or modulation of the metastases ofcancer cells and cancer. In particular, the siNA molecules of theinstant invention are useful in a method to prevent or modulate themetastases of brain cancer, breast carcinoma, cervical cancer,colorectal carcinoma, renal cell carcinoma, leukemia, hepatocellularcarcinoma, lung cancer, B-cell lymphomas, multiple myeloma, ovariancarcinoma, pancreatic cancer, prostate cancer, melanoma, and gastriccarcinoma.

In certain embodiments, the administration of the siNA molecule is vialocal administration or systemic administration. In other embodiments,the invention features contacting the subject or organism with an siNAmolecule of the invention via local administration to relevant tissuesor cells, such as lung cells and tissues, such as via pulmonarydelivery. In yet other embodiments, the invention features contactingthe subject or organism with an siNA molecule of the invention viasystemic administration (such as via intravenous or subcutaneousadministration of siNA) to relevant tissues or cells, such as canceroustissues or cells in a subject or organism.

siNA molecules of the invention are also used as reagents in ex vivoapplications. For example, siNA reagents are introduced into tissue orcells that are transplanted into a subject for therapeutic effect. Thecells and/or tissue can be derived from an organism or subject thatlater receives the explant, or can be derived from another organism orsubject prior to transplantation. The siNA molecules can be used tomodulate the expression of one or more genes in the cells or tissue,such that the cells or tissue obtain a desired phenotype or are able toperform a function when transplanted in vivo. In one embodiment, certainCTNNB1 target cells from a patient are extracted. These extracted cellsare contacted with CTNNB1 siNAs targeting a specific nucleotide sequencewithin the cells under conditions suitable for uptake of the siNAs bythese cells (e.g., using delivery reagents such as cationic lipids,liposomes and the like or using techniques such as electroporation tofacilitate the delivery of siNAs into cells). The cells are thenreintroduced back into the same patient or other patients.

For therapeutic applications, a pharmaceutically effective dose of thesiNA molecules or pharmaceutical compositions of the invention isadministered to the subject. A pharmaceutically effective dose is thatdose required to prevent, inhibit the occurrence, or treat (alleviate asymptom to some extent, preferably all of the symptoms) a disease state.One skilled in the art can readily determine a therapeutically effectivedose of the siNA of the invention to be administered to a given subject,by taking into account factors, such as the size and weight of thesubject, the extent of the disease progression or penetration, the age,health, and sex of the subject, the route of administration, and whetherthe administration is regional or systemic. Generally, an amount between0.1 μg/kg and 100 mg/kg body weight/day of active ingredients isadministered dependent upon potency of the negatively charged polymer.Optimal dosing schedules can be calculated from measurements of drugaccumulation in the body of the patient. The siNA molecules of theinvention can be administered in a single dose or in multiple doses.

siNA molecules of the instant invention can be administered oncemonthly, once weekly, once daily (QD), or divided into multiple monthly,weekly, or daily doses, such as, for example, but not limitation, twicedaily (BID), three times daily (TID), once every two weeks. Persons ofordinary skill in the art can easily estimate repetition rates fordosing based on measured residence times and concentrations of the drugin bodily fluids or tissues.

In addition, the administration can be continuous, i.e., every day, orintermittently. For example, intermittent administration of a compoundof the instant invention may be administration one to six days per weekor it may mean administration in cycles (e.g. daily administration fortwo to eight consecutive weeks, then a rest period with noadministration for up to one week) or it may mean administration onalternate days.

G. Administration

Compositions or formulations can be administered in a variety of ways.Non-limiting examples of administration methods of the invention includeoral, buccal, sublingual, parenteral (i.e., intraarticularly,intravenously, intraperitoneally, subcutaneously, or intramuscularly),local rectal administration or other local administration. In oneembodiment, the composition of the invention can be administered byinsufflation and inhalation. Administration can be accomplished viasingle or divided doses. In some embodiments, the pharmaceuticalcompositions are administered intravenously or intraperitoneally by abolus injection (see, e.g., U.S. Pat. No. 5,286,634). Lipid nucleic acidparticles can be administered by direct injection at the site of diseaseor by injection at a site distal from the site of disease (see, e.g.,Culver, HUMAN GENE THERAPY, MaryAnn Liebert, Inc., Publishers, New York.pp. 70-71 (1994)). In one embodiment, the siNA molecules of theinvention and formulations or compositions thereof are administered to acell, subject, or organism as is described herein and as is generallyknown in the art.

1. In Vivo Administration

In any of the methods of treatment of the invention, the siNA can beadministered to the subject systemically as described herein orotherwise known in the art, either alone as a monotherapy or incombination with additional therapies described herein or as are knownin the art. Systemic administration can include, for example, pulmonary(inhalation, nebulization etc.) intravenous, subcutaneous,intramuscular, catheterization, nasopharangeal, transdermal, ororal/gastrointestinal administration as is generally known in the art.

In any of the methods of treatment or prevention of the invention, thesiNA can be administered to the subject locally or to local tissues asdescribed herein or otherwise known in the art, either alone as amonotherapy or in combination with additional therapies as are known inthe art. Local administration can include, for example, inhalation,nebulization, catheterization, implantation, direct injection,dermal/transdermal application, patches, stenting, ear/eye drops, orportal vein administration to relevant tissues, or any other localadministration technique, method or procedure, as is generally known inthe art.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered to the liver as is generallyknown in the art (see for example Wen et al., 2004, World JGastroenterol., 10, 244-9; Murao et al., 2002, Pharm Res., 19, 1808-14;Liu et al., 2003, gene Ther., 10, 180-7; Hong et al., 2003, J PharmPharmacol., 54, 51-8; Herrmann et al., 2004, Arch Virol., 149, 1611-7;and Matsuno et al., 2003, gene Ther., 10, 1559-66).

In one embodiment, the invention features the use of methods to deliverthe siNA molecules of the instant invention to hematopoietic cells,including monocytes and lymphocytes. These methods are described indetail by Hartmann et al., 1998, J. Phamacol. Exp. Ther., 285(2),920-928; Kronenwett et al., 1998, Blood, 91(3), 852-862; Filion andPhillips, 1997, Biochim. Biophys. Acta., 1329(2), 345-356; Ma and Wei,1996, Leuk. Res., 20(11/12), 925-930; and Bongartz et al., 1994, NucleicAcids Research, 22(22), 4681-8.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered directly or topically (e.g.,locally) to the dermis or follicles as is generally known in the art(see for example Brand, 2001, Curr. Opin. Mol. Ther., 3, 244-8; Regnieret al., 1998, J. Drug Target, 5, 275-89; Kanikkannan, 2002, BioDrugs,16, 339-47; Wraight et al., 2001, Pharmacol. Ther., 90, 89-104; andPreat and Dujardin, 2001, STP PharmaSciences, 11, 57-68). In oneembodiment, the siNA molecules of the invention and formulations orcompositions thereof are administered directly or topically using ahydroalcoholic gel formulation comprising an alcohol (e.g., ethanol orisopropanol), water, and optionally including additional agents suchisopropyl myristate and carbomer 980. In other embodiments, the siNA areformulated to be administered topically to the nasal cavity. Topicalpreparations can be administered by one or more applications per day tothe affected area; over skin areas occlusive dressings canadvantageously be used. Continuous or prolonged delivery can be achievedby an adhesive reservoir system.

In one embodiment, an siNA molecule of the invention is administerediontophoretically, for example to a particular organ or compartment(e.g., the eye, back of the eye, heart, liver, kidney, bladder,prostate, tumor, CNS etc.). Non-limiting examples of iontophoreticdelivery are described in, for example, WO 03/043689 and WO 03/030989,which are incorporated by reference in their entireties herein.

In one embodiment, the siNA molecules of the invention and formulationsor compositions thereof are administered to the lung as is describedherein and as is generally known in the art. In another embodiment, thesiNA molecules of the invention and formulations or compositions thereofare administered to lung tissues and cells as is described in U.S.Patent Publication Nos. 2006/0062758; 2006/0014289; and 2004/0077540.

2. Aerosols and Delivery Devices

a. Aerosol Formulations

The compositions of the present invention, either alone or incombination with other suitable components, can be made into aerosolformulations (i.e., they can be “nebulized”) to be administered viainhalation (e.g., intranasally or intratracheally) (see, Brigham et al.,Am. J. Sci., 298:278 (1989)). Aerosol formulations can be placed intopressurized acceptable propellants, such as dichlorodifluoromethane,propane, nitrogen, and the like.

In one embodiment, the siNA molecules of the invention and formulationsthereof are administered via pulmonary delivery, such as by inhalationof an aerosol or spray dried formulation administered by an inhalationdevice or nebulizer, providing rapid local uptake of the nucleic acidmolecules into relevant pulmonary tissues. Solid particulatecompositions containing respirable dry particles of micronized nucleicacid compositions can be prepared by grinding dried or lyophilizednucleic acid compositions, and then passing the micronized compositionthrough, for example, a 400 mesh screen to break up or separate outlarge agglomerates. A solid particulate composition comprising the siNAcompositions of the invention can optionally contain a dispersant whichserves to facilitate the formation of an aerosol as well as othertherapeutic compounds. A suitable dispersant is lactose, which can beblended with the nucleic acid compound in any suitable ratio, such as a1 to 1 ratio by weight.

Spray compositions comprising siNA molecules or compositions of theinvention can, for example, be formulated as aqueous solutions orsuspensions or as aerosols delivered from pressurized packs, such as ametered dose inhaler, with the use of a suitable liquefied propellant.In one embodiment, aerosol compositions of the invention suitable forinhalation can be either a suspension or a solution and generallycontain an siNA molecule comprising at least a 15 nucleotide sequence ofSEQ ID NO: 5, SEQ ID NO: 4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ IDNO: 196, SEQ ID NO: 5109, SEQ ID NO: 151, or SEQ ID NO: 5064; or formula(A), and a suitable propellant such as a fluorocarbon orhydrogen-containing chlorofluorocarbon or mixtures thereof, particularlyhydrofluoroalkanes, especially 1,1,1,2-tetrafluoroethane,1,1,1,2,3,3,3-heptafluoro-n-propane or a mixture thereof. The aerosolcomposition can optionally contain additional formulation excipientswell known in the art such as surfactants. Non-limiting examples includeoleic acid, lecithin or an oligolactic acid or derivative such as thosedescribed in WO94/21229 and WO98/34596 and co-solvents for exampleethanol. In one embodiment a pharmaceutical aerosol formulation of theinvention comprising a compound of the invention and a fluorocarbon orhydrogen-containing chlorofluorocarbon or mixtures thereof aspropellant, optionally in combination with a surfactant and/or aco-solvent.

The aerosol formulations of the invention can be buffered by theaddition of suitable buffering agents.

Aerosol formulations can include optional additives includingpreservatives if the formulation is not prepared sterile. Non-limitingexamples include, methyl hydroxybenzoate, anti-oxidants, flavorings,volatile oils, buffering agents and emulsifiers and other formulationsurfactants. In one embodiment, fluorocarbon or perfluorocarbon carriersare used to reduce degradation and provide safer biocompatiblenon-liquid particulate suspension compositions of the invention (e.g.,siNA and/or LNP formulations thereof). In another embodiment, a devicecomprising a nebulizer delivers a composition of the invention (e.g.,siNA and/or LNP formulations thereof) comprising fluorochemicals thatare bacteriostatic thereby decreasing the potential for microbial growthin compatible devices.

Capsules and cartridges comprising the composition of the invention foruse in an inhaler or insufflator, of for example gelatine, can beformulated containing a powder mix for inhalation of a compound of theinvention and a suitable powder base such as lactose or starch. In oneembodiment, each capsule or cartridge contains an siNA moleculecomprising at least a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO:4918, SEQ ID NO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109,SEQ ID NO: 151, or SEQ ID NO: 5064; or formula (A), and one or moreexcipients. In another embodiment, the compound of the invention can bepresented without excipients such as lactose

The aerosol compositions of the present invention can be administeredinto the respiratory system as a formulation including particles ofrespirable size, e.g. particles of a size sufficiently small to passthrough the nose, mouth and larynx upon inhalation and through thebronchi and alveoli of the lungs. In general, respirable particles rangefrom about 0.5 to 10 microns in size. In one embodiment, the particulaterange can be from 1 to 5 microns. In another embodiment, the particulaterange can be from 2 to 3 microns. Particles of non-respirable size whichare included in the aerosol tend to deposit in the throat and beswallowed, and the quantity of non-respirable particles in the aerosolis thus minimized. For nasal administration, a particle size in therange of 10-500 um is preferred to ensure retention in the nasal cavity.

In some embodiments, an siNA composition of the invention isadministered topically to the nose for example, for the treatment ofrhinitis, via pressurized aerosol formulations, aqueous formulationsadministered to the nose by pressurized pump or by nebulization.Suitable formulations contain water as the diluent or carrier for thispurpose. In certain embodiments, the aqueous formulations foradministration of the composition of the invention to the lung or nosecan be provided with conventional excipients such as buffering agents,tonicity modifying agents and the like.

b. Devices

The siNA molecules of the invention can be formulated and delivered asparticles and/or aerosols as discussed above and dispensed from variousaerosolization devices known by those of skill in the art.

Aerosols of liquid or non-liquid particles comprising an siNA moleculeor formulation of the invention can be produced by any suitable means,such as with a device comprising a nebulizer (see for example U.S. Pat.No. 4,501,729) such as ultrasonic or air jet nebulizers.

Solid particle aerosols comprising an siNA molecule or formulation ofthe invention and surfactant can be produced with any solid particulateaerosol generator. One type of solid particle aerosol generator usedwith the siNA molecules of the invention is an insufflator. A secondtype of illustrative aerosol generator comprises a metered dose inhaler(“MDI”). MDIs containing siNA molecules or formulations taught hereincan be prepared by methods of the art (for example, see Byron, above andWO96/32099).

The siNA molecules can also be formulated as a fluid formulation fordelivery from a fluid dispenser, such as those described and illustratedin WO05/044354.

In certain embodiments of the invention, nebulizer devices are used inapplications for conscious, spontaneously breathing subjects, and forcontrolled ventilated subjects of all ages. The nebulizer devices can beused for targeted topical and systemic drug delivery to the lung. In oneembodiment, a device comprising a nebulizer is used to deliver an siNAmolecule or formulation of the invention locally to lung or pulmonarytissues. In another embodiment, a device comprising a nebulizer is usedto deliver a an siNA molecule or formulation of the inventionsystemically.

H. Other Applications/Uses of siNA Molecules of the Invention

The siNA molecules of the invention can also be used for diagnosticapplications, research applications, and/or manufacture of medicants.

In one aspect, the invention features a method for diagnosing a disease,trait, or condition in a subject comprising administering to the subjecta composition of the invention under conditions suitable for thediagnosis of the disease, trait, or condition in the subject.

In one embodiment, siNA molecules of the invention are used to downregulate or inhibit the expression of CTNNB1 proteins arising fromhaplotype polymorphisms that are associated with a trait, disease orcondition in a subject or organism. Analysis of CTNNB1 genes, or CTNNB1protein or RNA levels can be used to identify subjects with suchpolymorphisms or those subjects who are at risk of developing traits,conditions, or diseases described herein. These subjects are amenable totreatment, for example, treatment with siNA molecules of the inventionand any other composition useful in treating diseases related to targetgene expression. As such, analysis of CTNNB1 protein or RNA levels canbe used to determine treatment type and the course of therapy intreating a subject. Monitoring of CTNNB1 protein or RNA levels can beused to predict treatment outcome and to determine the efficacy ofcompounds and compositions that modulate the level and/or activity ofcertain CTNNB1 proteins associated with a trait, disorder, condition, ordisease.

In another embodiment, the invention comprises use of a double-strandednucleic acid according to the invention for use in the manufacture of amedicament. In an embodiment, the medicament is for use in treating acondition that is mediated by the action, or by loss of action, ofCTNNB1. In one embodiment, the medicament is for use for the treatmentof cancer. In an embodiment, the medicament is for use for the treatmentof brain cancer, breast carcinoma, cervical cancer, colorectalcarcinoma, renal cell carcinoma, leukemia, hepatocellular carcinoma,lung cancer, B-cell lymphomas, multiple myeloma, ovarian carcinoma,pancreatic cancer, prostate cancer, melanoma, and gastric carcinoma. Ina particular embodiment, the compounds of the instant invention areuseful for treating hepatocellular carcinoma.

In certain embodiments, siNAs wherein at least one strand comprises atleast a 15 nucleotide sequence of SEQ ID NO: 5, SEQ ID NO: 4918, SEQ IDNO: 194, SEQ ID NO: 5107, SEQ ID NO: 196, SEQ ID NO: 5109, SEQ ID NO:151, or SEQ ID NO: 5064; or formula (A), are for use in a method fortreating a cancer, such as, for example but not limitation, braincancer, breast carcinoma, cervical cancer, colorectal carcinoma, renalcell carcinoma, leukemia, hepatocellular carcinoma, lung cancer, B-celllymphomas, multiple myeloma, ovarian carcinoma, pancreatic cancer,prostate cancer, melanoma, and gastric carcinoma.

I. Examples

The invention will now be illustrated with the following non-limitingexamples. Those of skill in the art will readily recognize a variety ofnon-critical parameters which can be changed or modified to yieldessentially the same results.

Example 1 Design, Synthesis, and Identification of siNAs Active AgainstCTNNB1

CTNNB1 siNA Synthesis

A series of siNA molecules were designed, synthesized and evaluated forefficacy against CTNNB1 gene expression. Certain CTNNB1 sequences weredesigned and selected by methods set forth in U.S. Application No.60/182,604. Other sequences were designed and selected using aproprietary algorithm. The primary criteria for design of certain of theCTNNB1 sequences for human siNAs were (i) homology between two species(human and rhesus monkey) and (ii) high efficacy scores as determined bya proprietary algorithm. The effects of the siNAs on CTNNB1 RNA levels.The target sequences of the siNAs that were selected are set forth inTable 1a (target sequences). The sense and antisense strands of the siNAsequences corresponding to the target sequences in Table 1a are setforth in Table 1b. Various chemically modified siNAs that weresynthesized are set forth in Table 1c.

TABLE 1a CTNNB1 Target Sequences, noting human target sites. Target SiteSEQ ID Target Sequence (human) NO: 1 UCGAGCUCAGAGGGUACGA 535 1GAGGCUCUUGUGCGUACUG 1601 2 GCCCAGAAUGCAGUUCGCC 1709 3CGAGCUCAGAGGGUACGAG 536 4 CUGUUGGAUUGAUUCGAAA 1797 5 GUCUGCUAUUGUACGUACC853 6 AAUUCUUGGCUAUUACGAC 1143 7 GGAUGUUCACAACCGAAUU 2014 8ACAGUAUGCAAUGACUCGA 520 9 AGCUUCCAGACACGCUAUC 814 10 UGUCUGCUAUUGUACGUAC852 11 ACUGUUGGAUUGAUUCGAA 1796 12 CAGGAUACCCAGCGCCGUA 1901 13GACACGCUAUCAUGCGUUC 822 14 UACUGUUGGAUUGAUUCGA 1795 15UUCUUGGCUAUUACGACAG 1145 16 ACACGCUAUCAUGCGUUCU 823 17CAGACACGCUAUCAUGCGU 820 18 UGUUGGAUUGAUUCGAAAU 1798 19CAGAUCCAAGUCAACGUCU 1380 20 AGGCUCUUGUGCGUACUGU 1602 21GCGUACUGUCCUUCGGGCU 1612 22 ACUAAUGUCCAGCGUUUGG 626 23CACAUCCUAGCUCGGGAUG 2000 24 GUUGCUGAGAGGGCUCGAG 2665 25CAUCUGACCAGCCGACACC 1676 26 UGCGUACUGUCCUUCGGGC 1611 27ACAAGAUUACAAGAAACGG 2269 28 GUUGUAAACUUGAUUAACU 674 29UAAACUUGAUUAACUAUCA 678 30 AUAUAAUGAGGACCUAUAC 1245 31AAACUUGAUUAACUAUCAA 679 32 GAAAUAGUUGAAGGUUGUA 1970 33AUAAUGAGGACCUAUACUU 1247 34 UUAAAUUCUUGGCUAUUAC 1140 35UGUAAACUUGAUUAACUAU 676 36 GUAAACUUGAUUAACUAUC 677 37UUGUAAACUUGAUUAACUA 675 38 GCUUUAGUAAAUAUAAUGA 1235 39UGGCCACCACCCUGGUGCU 2488 40 CUUUAGUAAAUAUAAUGAG 1236 41UUUAGUAAAUAUAAUGAGG 1237 42 GUAAAUCGUCCUUUAGGUA 2555 43ACCUCACUUGCAAUAAUUA 1545 44 UACCAUUCCAUUGUUUGUG 2050 45UCCAAAGAGUAGCUGCAGG 2097 46 UAUCCAGUUGAUGGGCUGC 2510 47CAUGCAGAAUACAAAUGAU 871 48 CCAAAGAGUAGCUGCAGGG 2098 49CACCAUCCCACUGGCCUCU 1767 50 ACCAUGCAGAAUACAAAUG 869 51AAGACAUCACUGAGCCUGC 1641 52 AAUCAGCUGGCCUGGUUUG 2582 53AACCUCACUUGCAAUAAUU 1544 54 ACCUCAUGGAUGGGCUGCC 2550 55ACCAUUCCAUUGUUUGUGC 2051 56 CCAUGCAGAAUACAAAUGA 870 57CUUCGUCAUCUGACCAGCC 1670 58 CUGUGAACUUGCUCAGGAC 2122 59AGACAUCACUGAGCCUGCC 1642 60 GAGCCAAUGGCUUGGAAUG 2324 61ACUGAGCCUGCCAUCUGUG 1649 62 AUUGAAGCUGAGGGAGCCA 2159 63GUUAUGGUCCAUCAGCUUU 785 64 AAUGUGGUCACCUGUGCAG 1511 65AGCUGGCCUGGUUUGAUAC 2586 66 UGGCUGAACCAUCACAGAU 642 67CACCCACCAUCCCACUGGC 1763 68 CAAUGGCUUGGAAUGAGAC 2328 69UGGACCACAAGCAGAGUGC 1280 70 CCAUUCCAUUGUUUGUGCA 2052 71CAGGACCUCAUGGAUGGGC 2546 72 GUGAACUUGCUCAGGACAA 2124 73CCAGGACCUCAUGGAUGGG 2545 74 GGCUGAACCAUCACAGAUG 643 75GGUGCUGACUAUCCAGUUG 2501 76 AUGGCUUGGAAUGAGACUG 2330 77GGGAAGACAUCACUGAGCC 1638 78 UGGUGACAGGGAAGACAUC 1630 79UGCUCAUCCCACUAAUGUC 616 80 CUAUCCAGUUGAUGGGCUG 2509 81GGACCUCAUGGAUGGGCUG 2548 82 CCCACUGGCCUCUGAUAAA 1773 83UCCGAAUGUCUGAGGACAA 2247 84 UGGCUUGGAAUGAGACUGC 2331 85UUCAGAUGAUAUAAAUGUG 1498 86 CCACAAGAUUACAAGAAAC 2267 87CUCACUUGCAAUAAUUAUA 1547 88 CACUUGCAAUAAUUAUAAG 1549 89GUACCAUGCAGAAUACAAA 867 90 UCAACGUCUUGUUCAGAAC 1390 91AUCCCAUCUACACAGUUUG 593 92 UACUCAAGCUGAUUUGAUG 274 93ACCAGGUGGUGGUUAAUAA 759 94 GCUGCAACUAAACAGGAAG 1439 95UGGAUUGAUUCGAAAUCUU 1801 96 CAGAUGAUAUAAAUGUGGU 1500 97AUGGUGUCUGCUAUUGUAC 848 98 CACAAGAUUACAAGAAACG 2268 99CAAAUGAUGUAGAAACAGC 882 100 GCCACAAGAUUACAAGAAA 2266 101UACAAAUGAUGUAGAAACA 880 102 UCGAAAUCUUGCCCUUUGU 1810 103GAUUAACUAUCAAGAUGAU 685 104 CCAGUGGAUUCUGUGUUGU 1007 105AAAGGCUACUGUUGGAUUG 1789 106 ACAAGUAGCUGAUAUUGAU 499 107GAUGGAACAUGAGAUGGGU 2470 108 UCAAGAUGAUGCAGAACUU 694 109CAAGCUGAUUUGAUGGAGU 278 110 UGGACUCUCAGGAAUCUUU 1415 111UAAAUACCAUUCCAUUGUU 2046 112 AUUACAUCAAGAAGGAGCU 1057 113UCAGGAAUCUUUCAGAUGC 1422 114 UGAUUAACUAUCAAGAUGA 684 115ACUUCACUCUAGGAAUGAA 2197 116 AACAUGCAGUUGUAAACUU 666 117AAGCUGAUUUGAUGGAGUU 279 118 UCUGGGUUCAGAUGAUAUA 1492 119UUACUUCACUCUAGGAAUG 2195 120 AGGAAUCUUUCAGAUGCUG 1424 121GCUGAAACAUGCAGUUGUA 661 122 GUUGCUUGUUCGUGCACAU 1882 123GGAAGAAAUAGUUGAAGGU 1966 124 AGGACAAGCCACAAGAUUA 2259 125CAUGCGUUCUCCUCAGAUG 832 126 GAUGAUCCCAGCUACCGUU 2346 127AGCCUGCCAUCUGUGCUCU 1653 128 UGGAUAUCGCCAGGAUGAU 2389 129UCUUCGUCAUCUGACCAGC 1669 130 UGUGAACUUGCUCAGGACA 2123 131CCUGUGCAGCUGGAAUUCU 1521 132 UGAACUUGCUCAGGACAAG 2125 133UGCUGACUAUCCAGUUGAU 2503 134 GAUGAUAUAAAUGUGGUCA 1502 135GUGCUGACUAUCCAGUUGA 2502 136 UGACUAUCCAGUUGAUGGG 2506 137AACUUGCUCAGGACAAGGA 2127 138 CUGACUAUCCAGUUGAUGG 2505 139GCUCAUCCCACUAAUGUCC 617 140 GCUGACUAUCCAGUUGAUG 2504 141AUGAUAUAAAUGUGGUCAC 1503 142 CUCAUCCCACUAAUGUCCA 618 143GCUUUAUUCUCCCAUUGAA 2074 144 CUGGUGCUGACUAUCCAGU 2499 145AACUGUCUUUGGACUCUCA 1406 146 AGGGCAUGCAGAUCCCAUC 582 147GAUAUAAAUGUGGUCACCU 1505 148 UUCAGAUGCUGCAACUAAA 1432 149AAGAAAUAGUUGAAGGUUG 1968 150 CCAGGAUGAUCCUAGCUAU 2398 151UGGCCAUCUUUAAGUCUGG 954 152 AGCUGAUAUUGAUGGACAG 505 153UCGGGAUGUUCACAACCGA 2011 154 UGUAGAAGCUGGUGGAAUG 1339 155UAAAUAUAAUGAGGACCUA 1242 156 CUGAGACAUUAGAUGAGGG 567 157AGUAAAUAUAAUGAGGACC 1240 158 UGGAUACCUCCCAAGUCCU 438 159AGGAUGCCUUGGGUAUGGA 2445 160 AUUGUACGUACCAUGCAGA 860 161UUUGGACUCUCAGGAAUCU 1413 162 UUGGAUUGAUUCGAAAUCU 1800 163UCAGAGGACUAAAUACCAU 2037 164 CCAGGAUGCCUUGGGUAUG 2443 165AUGGAACAUGAGAUGGGUG 2471 166 GGCUACUGUUGGAUUGAUU 1792 167AGGACCUCAUGGAUGGGCU 2547 168 UCUGUGCUCUUCGUCAUCU 1662 169UGAUGGAGUUGGACAUGGC 288 170 AUGAGGGCAUGCAGAUCCC 579 171ACUAUCCAGUUGAUGGGCU 2508 172 UGAGGGCAUGCAGAUCCCA 580 173UUGGAUAUCGCCAGGAUGA 2388 174 GCCCAGGACCUCAUGGAUG 2543 175AACUUGCCACACGUGCAAU 708 176 CCCAAGUCCUGUAUGAGUG 447 177CACAGAUGCUGAAACAUGC 654 178 CUGGGACCUUGCAUAACCU 912 179AGUGGAUUCUGUGUUGUUU 1009 180 AAUGCAAGCUUUAGGACUU 1354 181AGAAAUAGUUGAAGGUUGU 1969 182 UCCGCAUGGAAGAAAUAGU 1959 183GCUAUGUUCCCUGAGACAU 557 184 UCUGAGUGGUAAAGGCAAU 403 185UGCAAGCUUUAGGACUUCA 1356 186 UGGACAGUAUGCAAUGACU 517 187UUAGUAAAUAUAAUGAGGA 1238 188 CUCAGAUGGUGUCUGCUAU 843 189AGAACAAGUAGCUGAUAUU 496 190 CUUGGAUAUCGCCAGGAUG 2387 191CAUCUGUGCUCUUCGUCAU 1660 192 CCCUGGUGCUGACUAUCCA 2497 193ACGACUAGUUCAGUUGCUU 1870 194 UCUUGGACUUGAUAUUGGU 2353 195GGAUGAUCCUAGCUAUCGU 2401 196 AAUACAAAUGAUGUAGAAA 878 197GAACCAUCACAGAUGCUGA 647 198 UUCACAUCCUAGCUCGGGA 1998 199UGCAGAUCCCAUCUACACA 588 200 GGACUAAAUACCAUUCCAU 2042 201CUGCUAUUGUACGUACCAU 855 202 CAGAGGACUAAAUACCAUU 2038 203GAUAAAGGCUACUGUUGGA 1786 204 AGAUGAUAUAAAUGUGGUC 1501 205AAAUCAUGCACCUUUGCGU 1834 206 ACGACAGACUGCCUUCAAA 1157 207UAGUAAAUAUAAUGAGGAC 1239 208 UAAUGAGGACCUAUACUUA 1248 209UGCUGAAACAUGCAGUUGU 660 210 AUUUGAUGGAGUUGGACAU 285 211CUGCCAAGUGGGUGGUAUA 1582 212 UGGACUACCAGUUGUGGUU 1735 213UUAAUAAGGCUGCAGUUAU 771 214 ACAUCAAGAAGGAGCUAAA 1060 215GGAUAUCGCCAGGAUGAUC 2390 216 CUGACAGAGUUACUUCACU 2186 217GUGACAGGGAAGACAUCAC 1632 218 UCAUCCCACUAAUGUCCAG 619 219CUGCCAUCUGUGCUCUUCG 1656 220 AUAUAAAUGUGGUCACCUG 1506 221CCACCCUGGUGCUGACUAU 2494 222 UGCUCUUCGUCAUCUGACC 1666 223ACAGGGAAGACAUCACUGA 1635 224 AGUUGGACAUGGCCAUGGA 294 225UUGGCUGAACCAUCACAGA 641 226 UAGAUGAGGGCAUGCAGAU 576 227AGAUGAGGGCAUGCAGAUC 577 228 AUCUGUGCUCUUCGUCAUC 1661 229GAACUUGCCACACGUGCAA 707 230 CCAUCUGUGCUCUUCGUCA 1659 231AUGGCAACCAAGAAAGCAA 1185 232 GAAACAUGCAGUUGUAAAC 664 233UGGUUAAGCUCUUACACCC 1749 234 AGCUUUAGUAAAUAUAAUG 1234 235CUAUCAAGAUGAUGCAGAA 691 236 AAGUCAACGUCUUGUUCAG 1387 237GAUCCAAGUCAACGUCUUG 1382 238 CUAUCAUGCGUUCUCCUCA 828 239AAUAUAAUGAGGACCUAUA 1244 240 GUGCUAUCUGUCUGCUCUA 1304 241GAAGCUUCCAGACACGCUA 812 242 UAAUUAUAAGAACAAGAUG 1558 243AUACAAAUGAUGUAGAAAC 879 244 CUGUCUGCUCUAGUAAUAA 1311 245UGCUAUUGUACGUACCAUG 856 246 UGCUGAAGGUGCUAUCUGU 1296 247UCUUUAAGUCUGGAGGCAU 960 248 AUACCAUUCCAUUGUUUGU 2049 249AGGCUACUGUUGGAUUGAU 1791 250 CAGUUAUGGUCCAUCAGCU 783 251ACAAGAUGAUGGUCUGCCA 1569 252 GACAUAUGCAGCUGCUGUU 2224 253CCAUCAUCGUGAGGGCUUA 934 254 GACAGAUCCAAGUCAACGU 1378 255GAGACAUUAGAUGAGGGCA 569 256 UUCGCCUUCACUAUGGACU 1722 257UGUUCAGCUUCUGGGUUCA 1483 258 AUCUUGGACUUGAUAUUGG 2352 259CGUGCAAUCCCUGAACUGA 719 260 AGGUGGUGGUUAAUAAGGC 762 261UCUACACAGUUUGAUGCUG 599 262 AGAUGGCCCAGAAUGCAGU 1704 263CAAGAUUACAAGAAACGGC 2270 264 CUGAAACAUGCAGUUGUAA 662 265CUCCUUCUCUGAGUGGUAA 396 266 AGCAAGCUCAUCAUACUGG 1199 267AUUAUAAGAACAAGAUGAU 1560 268 UCUGUCUGCUCUAGUAAUA 1310 269AAGCUUUAGUAAAUAUAAU 1233 270 GCCGGCUAUUGUAGAAGCU 1330 271UGUCUGCUCUAGUAAUAAG 1312 272 AAUAAUUAUAAGAACAAGA 1556 273UAUGGCCAGGAUGCCUUGG 2438 274 UGUCCCGCAAAUCAUGCAC 1826 275CUUGUUCAGAACUGUCUUU 1397 276 GCUGUGAUACGAUGCUUCA 3181 277GCGCCGUACGUCCAUGGGU 1912 278 AGAUGGUGUCUGCUAUUGU 846 279AGAACUGUCUUUGGACUCU 1404 280 CAUGCAGAUCCCAUCUACA 586 281CUCCUUGGGACUCUUGUUC 1469 282 GGUGCCACUACCACAGCUC 380 283AGCUGGUGGAAUGCAAGCU 1345 284 CCAUUCCACGACUAGUUCA 1863 285CAGCGUUUGGCUGAACCAU 635 286 AUCUUUAAGUCUGGAGGCA 959 287UGGCCAGGAUGCCUUGGGU 2440 288 GAAUACAAAUGAUGUAGAA 877 289UGGAUGGGCUGCCUCCAGG 2556 290 CGUACGUCCAUGGGUGGGA 1916 291GGUGUCUGCUAUUGUACGU 850 292 GGUGCUAUCUGUCUGCUCU 1303 293CCUUCACUAUGGACUACCA 1726 294 GACUCUUGUUCAGCUUCUG 1477 295AUCUACACAGUUUGAUGCU 598 296 GUUUGUGCAGCUGCUUUAU 2062 297CAAGAAACGGCUUUCAGUU 2278 298 GUUCAGUUGCUUGUUCGUG 1877 299UCAGAUGAUAUAAAUGUGG 1499 300 AAUGUUAAAUUCUUGGCUA 1136 301UGGGUUCAGAUGAUAUAAA 1494 302 AAUAGUUGAAGGUUGUACC 1972 303CAUGCAGUUGUAAACUUGA 668 304 AAUCUGAAUAAAGUGUAAC 2945 305CACCACCCUGGUGCUGACU 2492 306 GAGUUGGACAUGGCCAUGG 293 307AUACCCAGCGCCGUACGUC 1905 308 GAGGGCUUACUGGCCAUCU 944 309GAGGGCAUGCAGAUCCCAU 581 310 GAAGGGAUGGAAGGUCUCC 1454 311GUCUGAGGACAAGCCACAA 2254 312 UCAUGCACCUUUGCGUGAG 1837 313GGAAUCUUUCAGAUGCUGC 1425 314 UCACCUGACAGAUCCAAGU 1372 315CUGAAGGUGCUAUCUGUCU 1298 316 GUCAUCUGACCAGCCGACA 1674 317CAUUCCACGACUAGUUCAG 1864 318 UGAUCCUAGCUAUCGUUCU 2404 319GAGCCCUUCACAUCCUAGC 1992 320 GAUGAGGGCAUGCAGAUCC 578 321AUGGGUAGGGUAAAUCAGU 3091 322 GUGCAAUCCCUGAACUGAC 720 323AUUCCAUUGUUUGUGCAGC 2054 324 CAUUCUGGUGCCACUACCA 374 325UACCAUGCAGAAUACAAAU 868 326 AUGCAGUUCGCCUUCACUA 1716 327UUACUGGCCAUCUUUAAGU 950 328 GCUUCUGGGUUCAGAUGAU 1489 329CAGGAAGGGAUGGAAGGUC 1451 330 GCUUAUGGCAACCAAGAAA 1181 331UGACAGGGAAGACAUCACU 1633 332 AUCGCCAGGAUGAUCCUAG 2394 333AGUAAUAAGCCGGCUAUUG 1322 334 AAUGAUGUAGAAACAGCUC 884 335UCUGAGGACAAGCCACAAG 2255 336 GGUCUCCUUGGGACUCUUG 1466 337UGUUCAGAACUGUCUUUGG 1399 338 CUGGUGCCACUACCACAGC 378 339GUCCAUGGGUGGGACACAG 1921 340 GUGCGUUUAGCUGGUGGGC 1085 341ACGUACCAUGCAGAAUACA 865 342 GAUGUUCACAACCGAAUUG 2015 343AGAAAGCAAGCUCAUCAUA 1195 344 GUUCAGCUUCUGGGUUCAG 1484 345GCAGGGUGCCAUUCCACGA 1855 346 UAGAAGCUGGUGGAAUGCA 1341 347CAUGGAAGAAAUAGUUGAA 1963 348 UGAUAUUGGUGCCCAGGGA 2362 349GGCAUGCAGAUCCCAUCUA 584 350 CGUACUGUCCUUCGGGCUG 1613 351UUACGACAGACUGCCUUCA 1155 352 UAGUCACUGGCAGCAACAG 334 353GCCAUUACAACUCUCCACA 1031 354 GCCUUCACUAUGGACUACC 1725 355GUUCACAACCGAAUUGUUA 2018 356 GGGACCUUGCAUAACCUUU 914 357AAGCCACAAGAUUACAAGA 2264 358 GCAGCAACAGUCUUACCUG 343 359UAUUACAUCAAGAAGGAGC 1056 360 UAAUAAGGCUGCAGUUAUG 772 361GGUGGUGGUUAAUAAGGCU 763 362 UAAUGUCCAGCGUUUGGCU 628 363CUUCUCUGAGUGGUAAAGG 399 364 ACCAGCCGACACCAAGAAG 1682 365AUACCUCCCAAGUCCUGUA 441 366 UCACUAUGGACUACCAGUU 1729 367AGGAUACCCAGCGCCGUAC 1902 368 AGGGAAGACAUCACUGAGC 1637 369GAUAUCGCCAGGAUGAUCC 2391 370 AAGUAGCUGAUAUUGAUGG 501 371CAAGCUUUAGGACUUCACC 1358 372 CCCUUUGUCCCGCAAAUCA 1821 373UUAGAUGAGGGCAUGCAGA 575 374 CAAUGACUCGAGCUCAGAG 528 375GUGGAUAUGGCCAGGAUGC 2433 376 GUUCAGAUGAUAUAAAUGU 1497 377UCAGGACAAGGAAGCUGCA 2134 378 UUGAAGCUGAGGGAGCCAC 2160 379UGGAGUUGGACAUGGCCAU 291 380 AGAUGCUGAAACAUGCAGU 657 381UGAUGGUCUGCCAAGUGGG 1575 382 ACAUGCAGUUGUAAACUUG 667 383CAGAGUUACUUCACUCUAG 2190 384 GACUCGAGCUCAGAGGGUA 532 385CUGGCCAUCUUUAAGUCUG 953 386 UACGAUGCUUCAAGAGAAA 3188 387UGACCAGCUCUCUCUUCAG 2301 388 CUCUCUUCAGAACAGAGCC 2310 389GCUUUCAGUUGAGCUGACC 2287 390 GGGUGGGACACAGCAGCAA 1927 391UGCCACACGUGCAAUCCCU 712 392 UCUGUGAACUUGCUCAGGA 2121 393UGAGUAAUGGUGUAGAACA 2898 394 GUUGGAUUGAUUCGAAAUC 1799 395UACAACUCUCCACAACCUU 1036 396 CAAGUCCUGUAUGAGUGGG 449 397AGGAAGGGAUGGAAGGUCU 1452 398 AGCUCAUCAUACUGGCUAG 1203 399GCAAGCUUUAGGACUUCAC 1357 400 AUGUGGUCACCUGUGCAGC 1512 401ACUCAAGCUGAUUUGAUGG 275 402 GACAUGGCCAUGGAACCAG 299 403GUAAAUAUAAUGAGGACCU 1241 404 CGCAUGGAAGAAAUAGUUG 1961 405GAUGCUGCAACUAAACAGG 1436 406 UGAUGGAACAUGAGAUGGG 2469 407CCAGGUGGUGGUUAAUAAG 760 408 UGAGGACAAGCCACAAGAU 2257 409ACUGGCCAUCUUUAAGUCU 952 410 AACGGCUUUCAGUUGAGCU 2283 411CUACUGUUGGAUUGAUUCG 1794 412 GUUGUGGUUAAGCUCUUAC 1745 413AUACUGGCUAGUGGUGGAC 1211 414 GACCUCAUGGAUGGGCUGC 2549 415UAGCUCGGGAUGUUCACAA 2007 416 GAACAUGAGAUGGGUGGCC 2474 417CAGAAUGCAGUUCGCCUUC 1712 418 ACGUCCAUGGGUGGGACAC 1919 419UGGUUCACCAGUGGAUUCU 1000 420 AUAUCGCCAGGAUGAUCCU 2392 421AACAGGAAGGGAUGGAAGG 1449 422 GUUGAGCUGACCAGCUCUC 2294 423AAAUGUUAAAUUCUUGGCU 1135 424 GGCUAUUGUAGAAGCUGGU 1333 425CAGUUGUGGUUAAGCUCUU 1743 426 CUACACAGUUUGAUGCUGC 600 427UGGAGGCAUUCCUGCCCUG 970 428 GGACAGUUUACCAGUUGCC 3137 429UCCAUUCUGGUGCCACUAC 372 430 UACACCCACCAUCCCACUG 1761 431CUGAGCCUGCCAUCUGUGC 1650 432 GAGGCAUUCCUGCCCUGGU 972 433CUUGGCUAUUACGACAGAC 1147 434 CCCUGAGACAUUAGAUGAG 565 435AUGCAAUGACUCGAGCUCA 525 436 UAGAGGCUCUUGUGCGUAC 1599 437UUCACUCUAGGAAUGAAGG 2199 438 GACAAGCCACAAGAUUACA 2261 439CAGAACUUGCCACACGUGC 705 440 GACCUUGCAUAACCUUUCC 916 441CACUACCACAGCUCCUUCU 385 442 CUAUUUGGGAUAUGUAUGG 3076 443UCUUGUUCAGAACUGUCUU 1396 444 GAUGCCUUGGGUAUGGACC 2447 445UUGUAGAAGCUGGUGGAAU 1338 446 AGGUGUGGCGACAUAUGCA 2215 447GCAAUCCCUGAACUGACAA 722 448 UGCUCUAGUAAUAAGCCGG 1316 449CCGACACCAAGAAGCAGAG 1687 450 AGAUGAUGCAGAACUUGCC 697 451UUGAUGGGCUGCCAGAUCU 2517 452 AGCCGACACCAAGAAGCAG 1685 453UAUGGGUAGGGUAAAUCAG 3090 454 CUCAUCAUACUGGCUAGUG 1205 455UAUUACGACAGACUGCCUU 1153 456 CAAUCCCUGAACUGACAAA 723 457UCUCCUUGGGACUCUUGUU 1468 458 GAGAUGGGUGGCCACCACC 2480 459CAGGGUGCCAUUCCACGAC 1856 460 AGUUACUUCACUCUAGGAA 2193 461UUGGACUUGAUAUUGGUGC 2355 462 CCCUUCACAUCCUAGCUCG 1995 463AGACACGCUAUCAUGCGUU 821 464 AAUGCAGUUCGCCUUCACU 1715 465CUUAUGGCAACCAAGAAAG 1182 466 CUCCCAAGUCCUGUAUGAG 445 467CUUACACCCACCAUCCCAC 1759 468 UGGAAGGUCUCCUUGGGAC 1461 469AGCCCUUCACAUCCUAGCU 1993 470 GAUGGGCUGCCUCCAGGUG 2558 471AGCUUCUGGGUUCAGAUGA 1488 472 GAGCCUGCCAUCUGUGCUC 1652 473UUAAGUCUGGAGGCAUUCC 963 474 ACCUGUGCAGCUGGAAUUC 1520 475UCCCGCAAAUCAUGCACCU 1828 476 AAGGUGUGGCGACAUAUGC 2214 477AGCUAUUGAAGCUGAGGGA 2155 478 GUUAGUCACUGGCAGCAAC 332 479UUCAGUUGCUUGUUCGUGC 1878 480 GAUGAUGGUCUGCCAAGUG 1573 481CUAAACAGGAAGGGAUGGA 1446 482 CCACGACUAGUUCAGUUGC 1868 483ACUAGUUCAGUUGCUUGUU 1873 484 GUUCACCAGUGGAUUCUGU 1002 485GUGGUAAAGGCAAUCCUGA 408 486 UUGAUGGAGUUGGACAUGG 287 487ACUUGCUCAGGACAAGGAA 2128 488 CCAGUUGAUGGGCUGCCAG 2513 489GAAAGCAAGCUCAUCAUAC 1196 490 ACAUUAGAUGAGGGCAUGC 572 491UCCCACUAAUGUCCAGCGU 622 492 GGCAACCAAGAAAGCAAGC 1187 493AAAUAGUUGAAGGUUGUAC 1971 494 GGAUAUGUAUGGGUAGGGU 3083 495UAAUCUGAAUAAAGUGUAA 2944 496 UGCACAUCAGGAUACCCAG 1894 497GUAAUAAGCCGGCUAUUGU 1323 498 AAGCUCAUCAUACUGGCUA 1202 499ACGUGCAAUCCCUGAACUG 718 500 AGUUGUGGUUAAGCUCUUA 1744 501AGGACCAGGUGGUGGUUAA 756 502 GCUCUAGUAAUAAGCCGGC 1317 503GAUUUGAUGGAGUUGGACA 284 504 UGAUGUAGAAACAGCUCGU 886 505CUGGUGGAUAUGGCCAGGA 2430 506 CAUCAUACUGGCUAGUGGU 1207 507GAUCCCAUCUACACAGUUU 592 508 CACGCUAUCAUGCGUUCUC 824 509GACAGUAUGCAAUGACUCG 519 510 AAGUUGUUGUAACCUGCUG 3166 511GCUAUUACGACAGACUGCC 1151 512 GCCUCCAGGUGACAGCAAU 2566 513UCCUGUAUGAGUGGGAACA 453 514 AUGCAGAUCCCAUCUACAC 587 515UUUCCCAUCAUCGUGAGGG 930 516 CCAAGUGGGUGGUAUAGAG 1585 517GGACCUUGCAUAACCUUUC 915 518 UCCCAAGUCCUGUAUGAGU 446 519CACGACUAGUUCAGUUGCU 1869 520 CCGCAUGGAAGAAAUAGUU 1960 521GGCCCAGAAUGCAGUUCGC 1708 522 CCAUGGAACCAGACAGAAA 306 523GAAACGGCUUUCAGUUGAG 2281 524 GGGAUAUGUAUGGGUAGGG 3082 525UUGGGACUCUUGUUCAGCU 1473 526 UAUGUUCCCUGAGACAUUA 559 527GGACUCUCAGGAAUCUUUC 1416 528 AAGCUGCAGAAGCUAUUGA 2145 529GCCCUUCACAUCCUAGCUC 1994 530 AGAGAUGGCCCAGAAUGCA 1702 531GCAAUCCUGAGGAAGAGGA 417 532 CAGGAUGCCUUGGGUAUGG 2444 533CUGCUAUGUUCCCUGAGAC 555 534 UUCACAACCGAAUUGUUAU 2019 535AAAGCAAGCUCAUCAUACU 1197 536 AGGCAAUCCUGAGGAAGAG 415 537UGUUUGUGCAGCUGCUUUA 2061 538 GGAAUGCAAGCUUUAGGAC 1352 539CCGGCUAUUGUAGAAGCUG 1331 540 AAUAAGCCGGCUAUUGUAG 1325 541UCAGCUUCUGGGUUCAGAU 1486 542 CCUGUAUGAGUGGGAACAG 454 543CACUCAAGAACAAGUAGCU 490 544 CCUUCACAUCCUAGCUCGG 1996 545AUGCACCUUUGCGUGAGCA 1839 546 UGUUCGUGCACAUCAGGAU 1888 547UCAGUUGCUUGUUCGUGCA 1879 548 CCCGCAAAUCAUGCACCUU 1829 549GCUGAUUUGAUGGAGUUGG 281 550 AUAGAGGCUCUUGUGCGUA 1598 551CAGGACAAGGAAGCUGCAG 2135 552 AGCUCUUACACCCACCAUC 1755 553CAUCACAGAUGCUGAAACA 651 554 CUAUUGUAGAAGCUGGUGG 1335 555AUGCCCAGGACCUCAUGGA 2541 556 UGACUCGAGCUCAGAGGGU 531 557AGUUUGAUGCUGCUCAUCC 606 558 UCCUUCGGGCUGGUGACAG 1620 559AUGAAGGUGUGGCGACAUA 2211 560 AGUUGAGCUGACCAGCUCU 2293 561CUGUAUGAGUGGGAACAGG 455 562 CUCAGAGGGUACGAGCUGC 540 563GGCAAUCCUGAGGAAGAGG 416 564 CAUACUGGCUAGUGGUGGA 1210 565ACAAGCCACAAGAUUACAA 2262 566 GCUCUUGUGCGUACUGUCC 1604 567AUGUGGAUACCUCCCAAGU 435 568 UUGUUUGUGCAGCUGCUUU 2060 569ACAUAUGCAGCUGCUGUUU 2225 570 UCAGUCCUUCACUCAAGAA 481 571ACCUUGCAUAACCUUUCCC 917 572 GGCGACAUAUGCAGCUGCU 2221 573UGGUGUCUGCUAUUGUACG 849 574 GUUCCCUGAGACAUUAGAU 562 575AUAAAGGCUACUGUUGGAU 1787 576 GUGCCAUUCCACGACUAGU 1860 577UGGGUGGUAUAGAGGCUCU 1590 578 GGCCAUCUUUAAGUCUGGA 955 579UAUUGGUGCCCAGGGAGAA 2365 580 CUCGAGCUCAGAGGGUACG 534 581AGAACUUGCCACACGUGCA 706 582 UACCAGUUGUGGUUAAGCU 1740 583CGUUUGGCUGAACCAUCAC 638 584 GCUAUUGUAGAAGCUGGUG 1334 585GGAGGCAUUCCUGCCCUGG 971 586 ACCACCCUGGUGCUGACUA 2493 587AAUCUUGCCCUUUGUCCCG 1814 588 CGUUUAGCUGGUGGGCUGC 1088 589CAGUUGAGCUGACCAGCUC 2292 590 UGAUAUAAAUGUGGUCACC 1504 591CUGAGUGGUAAAGGCAAUC 404 592 AAGGUGCUAUCUGUCUGCU 1301 593UCCUAGCUCGGGAUGUUCA 2004 594 UCAAGCUGAUUUGAUGGAG 277 595CCAGCUCUCUCUUCAGAAC 2304 596 ACAUGGCCAUGGAACCAGA 300 597UACCCAGCGCCGUACGUCC 1906 598 AUAGUUGAAGGUUGUACCG 1973 599AGCUUUAGGACUUCACCUG 1360 600 ACAUCCAAAGAGUAGCUGC 2094 601UUGCAUAACCUUUCCCAUC 920 602 UGGCCCAGAAUGCAGUUCG 1707 603AUUCGAAAUCUUGCCCUUU 1808 604 AUAAGCCGGCUAUUGUAGA 1326 605CGACAGACUGCCUUCAAAU 1158 606 UGCAGUUAUGGUCCAUCAG 781 607GUUUGAUGCUGCUCAUCCC 607 608 CUAAUGUCCAGCGUUUGGC 627 609CAAGUAGCUGAUAUUGAUG 500 610 UCUGACAGAGUUACUUCAC 2185 611GGUGGUAUAGAGGCUCUUG 1592 612 GACCAGGUGGUGGUUAAUA 758 613CCUCAUGGAUGGGCUGCCU 2551 614 UGUCUUUGGACUCUCAGGA 1409 615GAACAAGUAGCUGAUAUUG 497 616 GUGCCACUACCACAGCUCC 381 617GCACCUUUGCGUGAGCAGG 1841 618 GACUUCACCUGACAGAUCC 1368 619AAAUACCAUUCCAUUGUUU 2047 620 CUCAAGAACAAGUAGCUGA 492 621UCCUCUGUGAACUUGCUCA 2118 622 UCUGGAGGCAUUCCUGCCC 968 623AAGUCUGGAGGCAUUCCUG 965 624 UUGAAGGUUGUACCGGAGC 1977 625ACAUCCUAGCUCGGGAUGU 2001 626 ACCAAGAAAGCAAGCUCAU 1191 627UUUGGCUGAACCAUCACAG 640 628 CACACGUGCAAUCCCUGAA 715 629GCUCAUCAUACUGGCUAGU 1204 630 GGGUAGGGUAAAUCAGUAA 3093 631UUCACCUGACAGAUCCAAG 1371 632 UGGUAAAGGCAAUCCUGAG 409 633GAUCCUAGCUAUCGUUCUU 2405 634 UUCGUCAUCUGACCAGCCG 1671 635AAUCUUUCAGAUGCUGCAA 1427 636 UGCAGUUCGCCUUCACUAU 1717 637AGGAUGAUCCUAGCUAUCG 2400 638 CAGCUCUCUCUUCAGAACA 2305 639GGUGGGACACAGCAGCAAU 1928 640 CAGGAUGAUCCUAGCUAUC 2399 641AGGAAGAGGAUGUGGAUAC 426 642 AUCUGUCUGCUCUAGUAAU 1309 643UAACCUUUCCCAUCAUCGU 925 644 CUGCUUUAUUCUCCCAUUG 2072 645AAUUGUAAUCUGAAUAAAG 2939 646 UCUUGUUCAGCUUCUGGGU 1480 647GUUCGUGCACAUCAGGAUA 1889 648 AUGAUGCAGAACUUGCCAC 699 649GCUGAUAUUGAUGGACAGU 506 650 GGUUAAGCUCUUACACCCA 1750 651GCCCUUUGUCCCGCAAAUC 1820 652 UCAGAGGGUACGAGCUGCU 541 653AAACAUGCAGUUGUAAACU 665 654 CUUGCCCUUUGUCCCGCAA 1817 655UUACAAGAAACGGCUUUCA 2275 656 CACUCUGGUGGAUAUGGCC 2426 657CAUCUUUAAGUCUGGAGGC 958 658 UGCCAUCUGUGCUCUUCGU 1657 659UCUUGGCUAUUACGACAGA 1146 660 AUUUGGGAUAUGUAUGGGU 3078 661CAGUGGAUUCUGUGUUGUU 1008 662 CCUUCGGGCUGGUGACAGG 1621 663GGACACAGCAGCAAUUUGU 1932 664 CCAGCGCCGUACGUCCAUG 1909 665AAGAAACGGCUUUCAGUUG 2279 666 AUUAGAUGAGGGCAUGCAG 574 667ACCAGCUCUCUCUUCAGAA 2303 668 AGUUAUGGUCCAUCAGCUU 784 669GACUAUCCAGUUGAUGGGC 2507 670 AUGCUUGGUUCACCAGUGG 995 671CUAGCUCGGGAUGUUCACA 2006 672 CUCUUACACCCACCAUCCC 1757 673CUUGCUCAGGACAAGGAAG 2129 674 AGAUUACAAGAAACGGCUU 2272 675ACCACAGCUCCUUCUCUGA 389 676 AGAUGCUGCAACUAAACAG 1435 677UUAAGCUCUUACACCCACC 1752 678 AAUAAGGCUGCAGUUAUGG 773 679UUGGGAUAUGUAUGGGUAG 3080 680 GUAACCUGCUGUGAUACGA 3174 681UGGUCUGCCAAGUGGGUGG 1578 682 CCUUCUCUGAGUGGUAAAG 398 683GAAGCUAUUGAAGCUGAGG 2153 684 AUGCAGAACUUGCCACACG 702 685GUAGCUGAUAUUGAUGGAC 503 686 CUCAAGCUGAUUUGAUGGA 276 687GCAUGGAAGAAAUAGUUGA 1962 688 CUGGUGGAAUGCAAGCUUU 1347 689CCCAGGACCUCAUGGAUGG 2544 690 UUUGGGAUAUGUAUGGGUA 3079 691CAAAGUUGUUGUAACCUGC 3164 692 CCGAAUUGUUAUCAGAGGA 2026 693UAAUUGUAAUCUGAAUAAA 2938 694 AUUGUAAUCUGAAUAAAGU 2940 695CGAAUUGUUAUCAGAGGAC 2027 696 CCAAGUCCUGUAUGAGUGG 448 697AAGCCGGCUAUUGUAGAAG 1328 698 AUCCUAGCUAUCGUUCUUU 2406 699AUAACCUUUCCCAUCAUCG 924 700 GCCAAGUGGGUGGUAUAGA 1584 701CGACUAGUUCAGUUGCUUG 1871 702 UUGGUUCACCAGUGGAUUC 999 703GUUCAGAACUGUCUUUGGA 1400 704 UGCUGUGAUACGAUGCUUC 3180 705UCCAGGUGACAGCAAUCAG 2569 706 UAUGGUCCAUCAGCUUUCU 787 707UGCCAUUCCACGACUAGUU 1861 708 AACCAAGAAAGCAAGCUCA 1190 709AUAAUUAUAAGAACAAGAU 1557 710 GUUAAGCUCUUACACCCAC 1751 711UUGAGUAAUGGUGUAGAAC 2897 712 GUGUGGCGACAUAUGCAGC 2217 713GACCAGCUCUCUCUUCAGA 2302 714 UUGUACCGGAGCCCUUCAC 1984 715AUGGCCAUGGAACCAGACA 302 716 UGGUGGAUAUGGCCAGGAU 2431 717CCUCUGACAGAGUUACUUC 2183 718 AUGAUCCUAGCUAUCGUUC 2403 719AUGGUCCAUCAGCUUUCUA 788 720 GGACUCUUGUUCAGCUUCU 1476 721GCUAUCAUGCGUUCUCCUC 827 722 GCUGACCAGCUCUCUCUUC 2299 723UCGUGCACAUCAGGAUACC 1891 724 UACUUCACUCUAGGAAUGA 2196 725UGAAACAUGCAGUUGUAAA 663 726 UAUGCCAUUACAACUCUCC 1028 727UGUUAUCAGAGGACUAAAU 2032 728 GAUGGAAGGUCUCCUUGGG 1459 729CAUCCAAAGAGUAGCUGCA 2095 730 GCCGACACCAAGAAGCAGA 1686 731CUUUGGACUCUCAGGAAUC 1412 732 GGAACAUGAGAUGGGUGGC 2473 733UGGCAGUGCGUUUAGCUGG 1080 734 GGAAGCUGCAGAAGCUAUU 2143 735CUCUAGGAAUGAAGGUGUG 2203 736 GUACGAGCUGCUAUGUUCC 548 737UCCACGACUAGUUCAGUUG 1867 738 CCUCAGAUGGUGUCUGCUA 842 739CUCUGUGAACUUGCUCAGG 2120 740 GCAGUUAUGGUCCAUCAGC 782 741UCUUACACCCACCAUCCCA 1758 742 CGCCAGGAUGAUCCUAGCU 2396 743CACCUGACAGAUCCAAGUC 1373 744 UCACCUGUGCAGCUGGAAU 1518 745GGAUGGGCUGCCUCCAGGU 2557 746 UACCGGAGCCCUUCACAUC 1987 747UGAGACAUUAGAUGAGGGC 568 748 CACUCUAGGAAUGAAGGUG 2201 749UUGAUGCUGCUCAUCCCAC 609 750 UUCUCUGAGUGGUAAAGGC 400 751UGUUAGUCACUGGCAGCAA 331 752 GAAGAAAUAGUUGAAGGUU 1967 753CUUCACUCUAGGAAUGAAG 2198 754 CUGGGUUCAGAUGAUAUAA 1493 755GGACAAGCCACAAGAUUAC 2260 756 ACCCUGGUGCUGACUAUCC 2496 757UUGAUAUUGGUGCCCAGGG 2361 758 ACCUCCCAAGUCCUGUAUG 443 759GUAUGCAAUGACUCGAGCU 523 760 CCAGUUGUGGUUAAGCUCU 1742 761AUGACUCGAGCUCAGAGGG 530 762 UUGUUGUAACCUGCUGUGA 3169 763CCAAGUCAACGUCUUGUUC 1385 764 AUCAGAGGACUAAAUACCA 2036 765UGUAUGGGUAGGGUAAAUC 3088 766 CGUGAGCAGGGUGCCAUUC 1850 767UGAUGGGCUGCCAGAUCUG 2518 768 CUUGUUCGUGCACAUCAGG 1886 769CCAUCACAGAUGCUGAAAC 650 770 ACAGUUUACCAGUUGCCUU 3139 771ACCGAAUUGUUAUCAGAGG 2025 772 GCAGUGCGUUUAGCUGGUG 1082 773AACAUGAGAUGGGUGGCCA 2475 774 CCUGACAGAUCCAAGUCAA 1375 775GGGAUGUUCACAACCGAAU 2013 776 GGAUUGAUUCGAAAUCUUG 1802 777GAAGCUGCAGAAGCUAUUG 2144 778 AAUGACUCGAGCUCAGAGG 529 779UUGUUCAGCUUCUGGGUUC 1482 780 CCUCACUUGCAAUAAUUAU 1546 781CAGAUGGUGUCUGCUAUUG 845 782 CUUCACUCAAGAACAAGUA 487 783AUCACAGAUGCUGAAACAU 652 784 AGUUCGCCUUCACUAUGGA 1720 785UACUGGCCAUCUUUAAGUC 951 786 CAAGCUUUAGUAAAUAUAA 1232 787AGCCACAAGAUUACAAGAA 2265 788 AAGCAGAGAUGGCCCAGAA 1698 789GAUGCAGAACUUGCCACAC 701 790 AUCUUUCAGAUGCUGCAAC 1428 791UGGGACACAGCAGCAAUUU 1930 792 ACAGAUCCAAGUCAACGUC 1379 793ACAGCAGCAAUUUGUGGAG 1936 794 UGCAACUAAACAGGAAGGG 1441 795GCUCAGGACAAGGAAGCUG 2132 796 GACUAAAUACCAUUCCAUU 2043 797UUUGAUGCUGCUCAUCCCA 608 798 UGGCAGCAACAGUCUUACC 341 799AAGAAAGCAAGCUCAUCAU 1194 800 UGAUCUUGGACUUGAUAUU 2350 801CUGAAUAAAGUGUAACAAU 2948 802 ACUAAAUACCAUUCCAUUG 2044 803AUCCCACUAAUGUCCAGCG 621 804 CCACUACCACAGCUCCUUC 384 805CAUCAGGAUACCCAGCGCC 1898 806 UCACAGAUGCUGAAACAUG 653 807UUUGCGUGAGCAGGGUGCC 1846 808 GCUGAUCUUGGACUUGAUA 2348 809GGCUAUUACGACAGACUGC 1150 810 GGACAUGGCCAUGGAACCA 298 811AACAAGAUGAUGGUCUGCC 1568 812 UUACAUCAAGAAGGAGCUA 1058 813AAUCAUGCACCUUUGCGUG 1835 814 GCAAAUCAUGCACCUUUGC 1832 815GAGUGGUAAAGGCAAUCCU 406 816 UCGCCUUCACUAUGGACUA 1723 817AUCCAUUCUGGUGCCACUA 371 818 AUCAGGAUACCCAGCGCCG 1899 819AGUAUGCAAUGACUCGAGC 522 820 CGGCUUUCAGUUGAGCUGA 2285 821GCUGCAGUUAUGGUCCAUC 779 822 AUUGAGUAAUGGUGUAGAA 2896 823GUAAUCUGAAUAAAGUGUA 2943 824 UUGAUGGACAGUAUGCAAU 513 825GAUAUGUAUGGGUAGGGUA 3084 826 GAACAAGAUGAUGGUCUGC 1567 827UUAUCAGAGGACUAAAUAC 2034 828 UUCACCAGUGGAUUCUGUG 1003 829AAGGUUGUACCGGAGCCCU 1980 830 GUAGAAGCUGGUGGAAUGC 1340 831AUGCUGCAACUAAACAGGA 1437 832 UCACUCUGGUGGAUAUGGC 2425 833CUGAUUUGAUGGAGUUGGA 282 834 UCAUCAUACUGGCUAGUGG 1206 835GCUUGUUCGUGCACAUCAG 1885 836 UCUGCUCUAGUAAUAAGCC 1314 837UAUCUGUCUGCUCUAGUAA 1308 838 GCAAGCUCAUCAUACUGGC 1200 839AGAGGGUACGAGCUGCUAU 543 840 UGUGCGUACUGUCCUUCGG 1609 841GGAAGGGAUGGAAGGUCUC 1453 842 AUGCGUUCUCCUCAGAUGG 833 843GACAGAGUUACUUCACUCU 2188 844 UUGGCUAUUACGACAGACU 1148 845GGACUACCAGUUGUGGUUA 1736 846 UUCAGAACUGUCUUUGGAC 1401 847AUCUGACCAGCCGACACCA 1677 848 ACACAGCAGCAAUUUGUGG 1934 849UACCACAGCUCCUUCUCUG 388 850 CGUCCAUGGGUGGGACACA 1920 851UGUGGUUAAGCUCUUACAC 1747 852 UUGUACGUACCAUGCAGAA 861 853GAUACCCAGCGCCGUACGU 1904 854 UCAUGCGUUCUCCUCAGAU 831 855GCACAUCAGGAUACCCAGC 1895 856 GAUUACAAGAAACGGCUUU 2273 857ACUACCAGUUGUGGUUAAG 1738 858 GUCUUGUUCAGAACUGUCU 1395 859UCAUCUGACCAGCCGACAC 1675 860 CUUUGCGUGAGCAGGGUGC 1845 861CUGUCUUUGGACUCUCAGG 1408 862 UACAUCAAGAAGGAGCUAA 1059 863AGAUCCAAGUCAACGUCUU 1381 864 CAAGUCAACGUCUUGUUCA 1386 865UCCUUGGGACUCUUGUUCA 1470 866 GGUGGAAUGCAAGCUUUAG 1349 867CUGCAACUAAACAGGAAGG 1440 868 UUAGGACUUCACCUGACAG 1364 869AGUAGCUGAUAUUGAUGGA 502 870 UAUAAUGAGGACCUAUACU 1246 871CCUGCUGUGAUACGAUGCU 3178 872 AUGGGUGGCCACCACCCUG 2483 873GACUCUCAGGAAUCUUUCA 1417 874 GUGCACAUCAGGAUACCCA 1893 875UUCCAGACACGCUAUCAUG 817 876 UUGCCACACGUGCAAUCCC 711 877UCAGAUGCUGCAACUAAAC 1433 878 CUUUAGGACUUCACCUGAC 1362 879CAUGCACCUUUGCGUGAGC 1838 880 ACAACUCUCCACAACCUUU 1037 881UGGGACUCUUGUUCAGCUU 1474 882 GCUUGGUUCACCAGUGGAU 997 883UUCCCAUCAUCGUGAGGGC 931 884 GUCUGCUCUAGUAAUAAGC 1313 885CAGCUUCUGGGUUCAGAUG 1487 886 CGUCAUCUGACCAGCCGAC 1673 887UGUUCCCUGAGACAUUAGA 561 888 GCAACCAAGAAAGCAAGCU 1188 889GGAGUUGGACAUGGCCAUG 292 890 GUCCGCAUGGAAGAAAUAG 1958 891CUGAUCUUGGACUUGAUAU 2349 892 AUGGAAGGUCUCCUUGGGA 1460 893GAUGGUCUGCCAAGUGGGU 1576 894 ACUAUCAAGAUGAUGCAGA 690 895ACAGAUGCUGAAACAUGCA 655 896 UUCAGUUGAGCUGACCAGC 2290 897AGAGGCUCUUGUGCGUACU 1600 898 GGUGGAUAUGGCCAGGAUG 2432 899CUUGCCACACGUGCAAUCC 710 900 GAAUGCAGUUCGCCUUCAC 1714 901CCUAGCUCGGGAUGUUCAC 2005 902 UUCACUAUGGACUACCAGU 1728 903GAUGGGUGGCCACCACCCU 2482 904 UGGUUAAUAAGGCUGCAGU 768 905AUCAAGAUGAUGCAGAACU 693 906 CUGCUGUGAUACGAUGCUU 3179 907AUGCCUUGGGUAUGGACCC 2448 908 UGUGAUACGAUGCUUCAAG 3183 909GAGUGCUGAAGGUGCUAUC 1293 910 GAGGGUACGAGCUGCUAUG 544 911UUAAUUGUAAUCUGAAUAA 2937 912 CACCAAGAAGCAGAGAUGG 1691 913GAAUGCAAGCUUUAGGACU 1353 914 ACCUUUGCGUGAGCAGGGU 1843 915AGGUGCUAUCUGUCUGCUC 1302 916 UUGCUCAGGACAAGGAAGC 2130 917GCUGAGGGAGCCACAGCUC 2165 918 CUACCACAGCUCCUUCUCU 387 919UGGAACAUGAGAUGGGUGG 2472 920 GCUAUUGUACGUACCAUGC 857 921UCUUGCCCUUUGUCCCGCA 1816 922 UUAUAAGAACAAGAUGAUG 1561 923GGAAGCUUCCAGACACGCU 811 924 UAAGCCGGCUAUUGUAGAA 1327 925GGACCAGGUGGUGGUUAAU 757 926 CUGAUAUUGAUGGACAGUA 507 927UGGGUAGGGUAAAUCAGUA 3092 928 ACUUGAUAUUGGUGCCCAG 2359 929UAAGCUCUUACACCCACCA 1753 930 CUACUCAAGCUGAUUUGAU 273 931GGUGCCAUUCCACGACUAG 1859 932 UUGGACAUGGCCAUGGAAC 296 933CUGCUCAUCCCACUAAUGU 615 934 CAUGGCCAUGGAACCAGAC 301 935UAUGGCAACCAAGAAAGCA 1184 936 ACCAGUGGAUUCUGUGUUG 1006 937ACAGAGUUACUUCACUCUA 2189 938 UAGGACUUCACCUGACAGA 1365 939GCCAGGAUGCCUUGGGUAU 2442 940 AAUGAGGACCUAUACUUAC 1249 941AUUCUUGGCUAUUACGACA 1144 942 CUUUAUUCUCCCAUUGAAA 2075 943UAGCUGAUAUUGAUGGACA 504 944 GAACUGUCUUUGGACUCUC 1405 945UUAGUCACUGGCAGCAACA 333 946 CCAUUACAACUCUCCACAA 1032 947GUGGUUAAGCUCUUACACC 1748 948 UGAUUUGAUGGAGUUGGAC 283 949GCAGAGAUGGCCCAGAAUG 1700 950 ACUAAACAGGAAGGGAUGG 1445 951ACAAAUGUUAAAUUCUUGG 1133 952 GCAAUGACUCGAGCUCAGA 527 953CUCGGGAUGUUCACAACCG 2010 954 GUGUCUGCUAUUGUACGUA 851 955UGUGGAUACCUCCCAAGUC 436 956 GGAUGCCUUGGGUAUGGAC 2446 957AAAUUCUUGGCUAUUACGA 1142 958 UACGAGCUGCUAUGUUCCC 549 959CAGUGCGUUUAGCUGGUGG 1083 960 CAAGAUGAUGCAGAACUUG 695 961AUGAUGUAGAAACAGCUCG 885 962 UGCAGCUGCUUUAUUCUCC 2067 963CCACAGCUCCUUCUCUGAG 390 964 CAGUUCGCCUUCACUAUGG 1719 965AAGCUUCCAGACACGCUAU 813 966 UUUCAGUUGAGCUGACCAG 2289 967UCUGGUGCCACUACCACAG 377 968 CGCUAUCAUGCGUUCUCCU 826 969GACAGGGAAGACAUCACUG 1634 970 AUCAUACUGGCUAGUGGUG 1208 971GCUGGUGACAGGGAAGACA 1628 972 AUCCUAGCUCGGGAUGUUC 2003 973GUCCUGUAUGAGUGGGAAC 452 974 UGGGAUAUGUAUGGGUAGG 3081 975CUUGGACUUGAUAUUGGUG 2354 976 CCUUUGUCCCGCAAAUCAU 1822 977UGAAGGUGCUAUCUGUCUG 1299 978 CCUUCACUCAAGAACAAGU 486 979GAAGGUCUCCUUGGGACUC 1463 980 AGAAACGGCUUUCAGUUGA 2280 981ACCCAGCGCCGUACGUCCA 1907 982 CAUAACCUUUCCCAUCAUC 923 983GAAGGUUGUACCGGAGCCC 1979 984 GUCCCGCAAAUCAUGCACC 1827 985CAAGCUCAUCAUACUGGCU 1201 986 CGCCGUACGUCCAUGGGUG 1913 987AGAGUUACUUCACUCUAGG 2191 988 GUUGGACAUGGCCAUGGAA 295 989UGGCUAUUACGACAGACUG 1149 990 ACUCGAGCUCAGAGGGUAC 533 991ACAGUUUGAUGCUGCUCAU 604 992 GGUGGUUAAUAAGGCUGCA 766 993CUUUGUCCCGCAAAUCAUG 1823 994 AAUACCAUUCCAUUGUUUG 2048 995CCACACGUGCAAUCCCUGA 714 996 AUGGCCAGGAUGCCUUGGG 2439 997GGAUACCCAGCGCCGUACG 1903 998 UCGCCAGGAUGAUCCUAGC 2395 999UGGUCCAUCAGCUUUCUAA 789 1000 AUAUGUAUGGGUAGGGUAA 3085 1001CCCAGAAUGCAGUUCGCCU 1710 1002 UAUUGUAGAAGCUGGUGGA 1336 1003GUAUGGGUAGGGUAAAUCA 3089 1004 GAUCUUGGACUUGAUAUUG 2351 1005ACACGUGCAAUCCCUGAAC 716 1006 AGCGCCGUACGUCCAUGGG 1911 1007UGUACCGGAGCCCUUCACA 1985 1008 GUUGAUGGGCUGCCAGAUC 2516 1009ACACCCACCAUCCCACUGG 1762 1010 UACGACAGACUGCCUUCAA 1156 1011UUGUUCGUGCACAUCAGGA 1887 1012 CAAAUCAUGCACCUUUGCG 1833 1013GUCUGGAGGCAUUCCUGCC 967 1014 CACUAUGGACUACCAGUUG 1730 1015UAUCAUGCGUUCUCCUCAG 829 1016 GUAGAAACAGCUCGUUGUA 890 1017CUCCUCUGACAGAGUUACU 2181 1018 UGCUCAGGACAAGGAAGCU 2131 1019CAAGUGGGUGGUAUAGAGG 1586 1020 UGGUGGUUAAUAAGGCUGC 765 1021ACUUCACCUGACAGAUCCA 1369 1022 CGCCUUCACUAUGGACUAC 1724 1023UGCGUUCUCCUCAGAUGGU 834 1024 GUUGUACCGGAGCCCUUCA 1983 1025CGACACCAAGAAGCAGAGA 1688 1026 UCACCAGUGGAUUCUGUGU 1004 1027GGUGACAGGGAAGACAUCA 1631 1028 UCUAGUAAUAAGCCGGCUA 1319 1029GUGGUUAAUAAGGCUGCAG 767 1030 UCCUCAGAUGGUGUCUGCU 841 1031AUGGACAGUAUGCAAUGAC 516 1032 UGCGUGAGCAGGGUGCCAU 1848 1033ACUCUAGGAAUGAAGGUGU 2202 1034 GACAUUAGAUGAGGGCAUG 571 1035CUGGUGACAGGGAAGACAU 1629 1036 UGAUUCGAAAUCUUGCCCU 1806 1037GCUCUUACACCCACCAUCC 1756 1038 GUCCUUCGGGCUGGUGACA 1619 1039GUGCGUACUGUCCUUCGGG 1610 1040 UGGUGCUGACUAUCCAGUU 2500 1041GCUAUUGAAGCUGAGGGAG 2156 1042 CAACCAAGAAAGCAAGCUC 1189 1043GUGCAGCUGCUUUAUUCUC 2066 1044 CUAUCUGUCUGCUCUAGUA 1307 1045AAACAGGAAGGGAUGGAAG 1448 1046 ACUGGCUAGUGGUGGACCC 1213 1047CCUCUGUGAACUUGCUCAG 2119 1048 UGUAGAAACAGCUCGUUGU 889 1049CUGACAGAUCCAAGUCAAC 1376 1050 GGAAGAGGAUGUGGAUACC 427 1051ACCAUCACAGAUGCUGAAA 649 1052 CCGUACGUCCAUGGGUGGG 1915 1053CAUUCCAUUGUUUGUGCAG 2053 1054 CUCCAGGUGACAGCAAUCA 2568 1055CUACCAGUUGUGGUUAAGC 1739 1056 UUGUGGUUAAGCUCUUACA 1746 1057UAGUAAUAAGCCGGCUAUU 1321 1058 CAGUCCUUCACUCAAGAAC 482 1059AGCUGAUUUGAUGGAGUUG 280 1060 AGGUCUCCUUGGGACUCUU 1465 1061ACUAUGGACUACCAGUUGU 1731 1062 CAGCAGCAAUUUGUGGAGG 1937 1063CGUGCACAUCAGGAUACCC 1892 1064 CGUUCUCCUCAGAUGGUGU 836 1065CAGUAUGCAAUGACUCGAG 521 1066 GGUAUAGAGGCUCUUGUGC 1595 1067AUCCAGUUGAUGGGCUGCC 2511 1068 UGCCAAGUGGGUGGUAUAG 1583 1069ACAUCAGGAUACCCAGCGC 1897 1070 GCCAUCUUUAAGUCUGGAG 956 1071AACCUUUCCCAUCAUCGUG 926 1072 CUAGUUCAGUUGCUUGUUC 1874 1073UUCACUCAAGAACAAGUAG 488 1074 AAGAAGCAGAGAUGGCCCA 1695 1075UCCUCUGACAGAGUUACUU 2182 1076 AAUUGUUAUCAGAGGACUA 2029 1077UCUCAGUCCUUCACUCAAG 479 1078 UCCAGACACGCUAUCAUGC 818 1079CACUAAUGUCCAGCGUUUG 625 1080 UUGUAACCUGCUGUGAUAC 3172 1081CUUCUGGGUUCAGAUGAUA 1490 1082 GCCGUACGUCCAUGGGUGG 1914 1083UAGUUGAAGGUUGUACCGG 1974 1084 GAGGACAAGCCACAAGAUU 2258 1085GGGAGCCACAGCUCCUCUG 2170 1086 CUUCACCUGACAGAUCCAA 1370 1087UCUUUCAGAUGCUGCAACU 1429 1088 UGUAACCUGCUGUGAUACG 3173 1089CCUCCCAAGUCCUGUAUGA 444 1090 GGCAGUGCGUUUAGCUGGU 1081 1091CUCUAGUAAUAAGCCGGCU 1318 1092 GCUGUUAGUCACUGGCAGC 329 1093GUCAACGUCUUGUUCAGAA 1389 1094 GAAGAGGAUGUGGAUACCU 428 1095UAACCUGCUGUGAUACGAU 3175 1096 GUUAUUUGGAACCUUGUUU 3117 1097UCACAACCGAAUUGUUAUC 2020 1098 CGGGCUGGUGACAGGGAAG 1625 1099ACAACCGAAUUGUUAUCAG 2022 1100 CCACUAAUGUCCAGCGUUU 624 1101CACUGAGCCUGCCAUCUGU 1648 1102 GGUCCAUCAGCUUUCUAAA 790 1103AUCCCAAAGUUGUUGUAAC 3160 1104 UGAGGACCUAUACUUACGA 1251 1105UGUCUGAGGACAAGCCACA 2253 1106 AGUUGAUGGGCUGCCAGAU 2515 1107UGACCAGCCGACACCAAGA 1680 1108 AGGGAGCCACAGCUCCUCU 2169 1109AAAGUUGUUGUAACCUGCU 3165 1110 CUGCAGUUAUGGUCCAUCA 780 1111UGAAGGUUGUACCGGAGCC 1978 1112 UUCCCUGAGACAUUAGAUG 563 1113CUUCGGGCUGGUGACAGGG 1622 1114 UUGAGCUGACCAGCUCUCU 2295 1115GAACUUGCUCAGGACAAGG 2126 1116 CCAGCCGACACCAAGAAGC 1683 1117AGGGUGCCAUUCCACGACU 1857 1118 UUGUGCAGCUGCUUUAUUC 2064 1119UCACUCAAGAACAAGUAGC 489 1120 GCUGGUGGAAUGCAAGCUU 1346 1121GCAACUAAACAGGAAGGGA 1442 1122 AGGUUGUACCGGAGCCCUU 1981 1123AGGCUGCAGUUAUGGUCCA 777 1124 GCAGAUCCCAUCUACACAG 589 1125CUAGGAAUGAAGGUGUGGC 2205 1126 AGCUCCUUCUCUGAGUGGU 394 1127UUACAACUCUCCACAACCU 1035 1128 GGUAAAGGCAAUCCUGAGG 410 1129GUUCGCCUUCACUAUGGAC 1721 1130 CAAAUGUUAAAUUCUUGGC 1134 1131CUGUGAUACGAUGCUUCAA 3182 1132 ACAAAUGAUGUAGAAACAG 881 1133GGUACGAGCUGCUAUGUUC 547 1134 GAAUUGUUAUCAGAGGACU 2028 1135CAACCGAAUUGUUAUCAGA 2023 1136 GUGAUACGAUGCUUCAAGA 3184 1137AAAGGCAAUCCUGAGGAAG 413 1138 CAGCUCCUCUGACAGAGUU 2178 1139AUGGUCUGCCAAGUGGGUG 1577 1140 GCUACUGUUGGAUUGAUUC 1793 1141UGCAAUGACUCGAGCUCAG 526 1142 GACUUGAUAUUGGUGCCCA 2358 1143CAGAACUGUCUUUGGACUC 1403 1144 UAGUUCAGUUGCUUGUUCG 1875 1145ACAGACUGCCUUCAAAUUU 1160 1146 GGGUGGUAUAGAGGCUCUU 1591 1147AUGGACUACCAGUUGUGGU 1734 1148 AUUGUUAUCAGAGGACUAA 2030 1149UAAGGCUGCAGUUAUGGUC 775 1150 AAAUCUUGCCCUUUGUCCC 1813 1151AGCAGCAAUUUGUGGAGGG 1938 1152 AGAGGACUAAAUACCAUUC 2039 1153GCUGAAGGUGCUAUCUGUC 1297 1154 UGUAUGAGUGGGAACAGGG 456 1155CAGAUCCCAUCUACACAGU 590 1156 GACACAGCAGCAAUUUGUG 1933 1157GGGCAUGCAGAUCCCAUCU 583 1158 CAUGCCCAGGACCUCAUGG 2540 1159GAAGCUGAGGGAGCCACAG 2162 1160 CUGUUAGUCACUGGCAGCA 330 1161CUUGUUCAGCUUCUGGGUU 1481 1162 AAGCUGGUGGAAUGCAAGC 1344 1163GAGGAUGUGGAUACCUCCC 431 1164 AUAAAUGUGGUCACCUGUG 1508 1165UACGUCCAUGGGUGGGACA 1918 1166 GAUGGAGUUGGACAUGGCC 289 1167UGUCCAGCGUUUGGCUGAA 631 1168 GAGCAGGGUGCCAUUCCAC 1853 1169AAAUAUAAUGAGGACCUAU 1243 1170 UACUGGCUAGUGGUGGACC 1212 1171UGCUUGGUUCACCAGUGGA 996 1172 CUGAGGACAAGCCACAAGA 2256 1173CUUGUGCGUACUGUCCUUC 1607 1174 UGUUAUUUGGAACCUUGUU 3116 1175UAGCUUAUGGCAACCAAGA 1179 1176 UGAUACGAUGCUUCAAGAG 3185 1177UGGUAUAGAGGCUCUUGUG 1594 1178 GAUGUAGAAACAGCUCGUU 887 1179CCUUUCCCAUCAUCGUGAG 928 1180 GCGUUCUCCUCAGAUGGUG 835 1181UCAGGAUACCCAGCGCCGU 1900 1182 ACGGCUUUCAGUUGAGCUG 2284 1183GUUGAAGGUUGUACCGGAG 1976 1184 UAUCGCCAGGAUGAUCCUA 2393 1185GUGCUGAAGGUGCUAUCUG 1295 1186 GUCUUUGGACUCUCAGGAA 1410 1187GGGAUGGAAGGUCUCCUUG 1457 1188 UGAGCUGACCAGCUCUCUC 2296 1189CUUUCCCAUCAUCGUGAGG 929 1190 AAGCUUUAGGACUUCACCU 1359 1191UGGAAUGCAAGCUUUAGGA 1351 1192 CUGGAGGCAUUCCUGCCCU 969 1193AGUUCAGUUGCUUGUUCGU 1876 1194 GAGCUGCUAUGUUCCCUGA 552 1195GGCCAGGAUGCCUUGGGUA 2441 1196 GAUGAUCCUAGCUAUCGUU 2402 1197GAUUGAUUCGAAAUCUUGC 1803 1198 CAGAGAUGGCCCAGAAUGC 1701 1199CAGCGCCGUACGUCCAUGG 1910 1200 AUGUAGAAACAGCUCGUUG 888 1201AGUGCUGAAGGUGCUAUCU 1294 1202 GACUACCAGUUGUGGUUAA 1737 1203ACAGGAAGGGAUGGAAGGU 1450 1204 CAGGUGGUGGUUAAUAAGG 761 1205AAGGCUGCAGUUAUGGUCC 776 1206 UAAAUGUGGUCACCUGUGC 1509 1207UAAAGGCUACUGUUGGAUU 1788 1208 GAUGGACAGUAUGCAAUGA 515 1209UUCUGGGUUCAGAUGAUAU 1491 1210 GUACUGUCCUUCGGGCUGG 1614 1211CUUGGUUCACCAGUGGAUU 998 1212 UAUUGAAGCUGAGGGAGCC 2158 1213GUUGUUGUAACCUGCUGUG 3168 1214 AGCAGGGUGCCAUUCCACG 1854 1215GUCCUCUGUGAACUUGCUC 2117 1216 UCUGACCAGCCGACACCAA 1678 1217GCCAUGGAACCAGACAGAA 305 1218 AAGCUAUUGAAGCUGAGGG 2154 1219GAUUCGAAAUCUUGCCCUU 1807 1220 AGUUGCUUGUUCGUGCACA 1881 1221AAGAACAAGAUGAUGGUCU 1565 1222 AGUGGUAAAGGCAAUCCUG 407 1223CAGAUGCUGCAACUAAACA 1434 1224 CCUGAGACAUUAGAUGAGG 566 1225UCCCAAAGUUGUUGUAACC 3161 1226 CUGACCAGCCGACACCAAG 1679 1227AUCCAAAGAGUAGCUGCAG 2096 1228 AUGUCCAGCGUUUGGCUGA 630 1229UCUUGUGCGUACUGUCCUU 1606 1230 AGGAUGUGGAUACCUCCCA 432 1231GGCUGCAGUUAUGGUCCAU 778 1232 UCACAUCCUAGCUCGGGAU 1999 1233ACCAAGAAGCAGAGAUGGC 1692 1234 GCCACCACCCUGGUGCUGA 2490 1235CCCACUAAUGUCCAGCGUU 623 1236 ACUGGCAGCAACAGUCUUA 339 1237AUCUGAAUAAAGUGUAACA 2946 1238 GCCUGCCAUCUGUGCUCUU 1654 1239CAUUACAACUCUCCACAAC 1033 1240 CUCCUCAGAUGGUGUCUGC 840 1241CAGUUGCUUGUUCGUGCAC 1880 1242 AUCCUGAGGAAGAGGAUGU 420 1243CACCAGUGGAUUCUGUGUU 1005 1244 CAAGAAAGCAAGCUCAUCA 1193 1245CUUGCAUAACCUUUCCCAU 919 1246 CUUCACUAUGGACUACCAG 1727 1247UUGCUUGUUCGUGCACAUC 1883 1248 UAUUGUACGUACCAUGCAG 859 1249GAAAUCUUGCCCUUUGUCC 1812 1250 CUCUUGUGCGUACUGUCCU 1605 1251CACAACCGAAUUGUUAUCA 2021 1252 GCUCCUCUGACAGAGUUAC 2180 1253AGCGUUUGGCUGAACCAUC 636 1254 AAACGGCUUUCAGUUGAGC 2282 1255UUUGUCCCGCAAAUCAUGC 1824 1256 UCUAGGAAUGAAGGUGUGG 2204 1257AAGUCCUGUAUGAGUGGGA 450 1258 GGUUCACCAGUGGAUUCUG 1001 1259GGUCUGCCAAGUGGGUGGU 1579 1260 AGCUCCUCUGACAGAGUUA 2179 1261UUCUGGUGCCACUACCACA 376 1262 UGCUAUGUUCCCUGAGACA 556 1263AUUGAUUCGAAAUCUUGCC 1804 1264 CUCAUGGAUGGGCUGCCUC 2552 1265GCUGCUUUAUUCUCCCAUU 2071 1266 AUCAUGCACCUUUGCGUGA 1836 1267GUCACUGGCAGCAACAGUC 336 1268 UGAGUGGGAACAGGGAUUU 460 1269AAUUAUAAGAACAAGAUGA 1559 1270 UGGACAGUUUACCAGUUGC 3136 1271AUGAGGACCUAUACUUACG 1250 1272 GGAAGGUCUCCUUGGGACU 1462 1273UGGAAGAAAUAGUUGAAGG 1965 1274 GGUGUUAUUUGGAACCUUG 3114 1275GUGCUCUUCGUCAUCUGAC 1665 1276 GGCCAUGGAACCAGACAGA 304 1277CGGCUGUUAGUCACUGGCA 327 1278 UUCCACGACUAGUUCAGUU 1866 1279AGCAGAGAUGGCCCAGAAU 1699 1280 GCCAGGAUGAUCCUAGCUA 2397 1281GCCAUCUGUGCUCUUCGUC 1658 1282 UAGAAACAGCUCGUUGUAC 891 1283AGAUGAUGGUCUGCCAAGU 1572 1284 ACCUUUCCCAUCAUCGUGA 927 1285AUGGAGUUGGACAUGGCCA 290 1286 CUGUGCUCUUCGUCAUCUG 1663 1287UAUAAGAACAAGAUGAUGG 1562 1288 UCUGAAUAAAGUGUAACAA 2947 1289CCAGAAUGCAGUUCGCCUU 1711 1290 AGAACAAGAUGAUGGUCUG 1566 1291AUCUUGCCCUUUGUCCCGC 1815 1292 GCGUUUAGCUGGUGGGCUG 1087 1293GGGUUCAGAUGAUAUAAAU 1495 1294 UUUAGGACUUCACCUGACA 1363 1295CACAGCUCCUUCUCUGAGU 391 1296 AACGUCUUGUUCAGAACUG 1392 1297CACAGCAGCAAUUUGUGGA 1935 1298 GACUAGUUCAGUUGCUUGU 1872 1299GACAGACUGCCUUCAAAUU 1159 1300 CUCUCUCUUCAGAACAGAG 2308 1301GUCCAGCGUUUGGCUGAAC 632 1302 UAAGAACAAGAUGAUGGUC 1564 1303UCCAAGUCAACGUCUUGUU 1384 1304 ACACCAAGAAGCAGAGAUG 1690 1305CUCAGGAAUCUUUCAGAUG 1421 1306 UAAAUUCUUGGCUAUUACG 1141 1307CUAUGGACUACCAGUUGUG 1732 1308 CCAGCGUUUGGCUGAACCA 634 1309UCCCAUCAUCGUGAGGGCU 932 1310 AGGACUUCACCUGACAGAU 1366 1311UUGUGCGUACUGUCCUUCG 1608 1312 CCAUGGGUGGGACACAGCA 1923 1313GGAUGGAAGGUCUCCUUGG 1458 1314 CCCAGCGCCGUACGUCCAU 1908 1315GCUCAGAGGGUACGAGCUG 539 1316 AUGUUCACAACCGAAUUGU 2016 1317UGCUUGUUCGUGCACAUCA 1884 1318 AUGUUCCCUGAGACAUUAG 560 1319GUAAAGGCAAUCCUGAGGA 411 1320 CACUGGCAGCAACAGUCUU 338 1321AUCAUGCGUUCUCCUCAGA 830 1322 UAUGUAUGGGUAGGGUAAA 3086 1323GUGUUAUUUGGAACCUUGU 3115 1324 ACAGCUCCUCUGACAGAGU 2177 1325UAUGGACUACCAGUUGUGG 1733 1326 AUUCUGGUGCCACUACCAC 375 1327UGCCUCCAGGUGACAGCAA 2565 1328 UACCUCCCAAGUCCUGUAU 442 1329CCAGACACGCUAUCAUGCG 819 1330 UGAUGCAGAACUUGCCACA 700 1331GUUUAGCUGGUGGGCUGCA 1089 1332 GUCUGCCAAGUGGGUGGUA 1580 1333GGUUGUACCGGAGCCCUUC 1982 1334 GUACCGGAGCCCUUCACAU 1986 1335CAAUCCUGAGGAAGAGGAU 418 1336 GCUAUCUGUCUGCUCUAGU 1306 1337UGACAGAUCCAAGUCAACG 1377 1338 CAUGAUGGAACAUGAGAUG 2467 1339UUGGACUCUCAGGAAUCUU 1414 1340 CUCUUCGUCAUCUGACCAG 1668 1341UUGCCCUUUGUCCCGCAAA 1818 1342 GAAGCAGAGAUGGCCCAGA 1697 1343CCUUGCAUAACCUUUCCCA 918 1344 CAGUUUGAUGCUGCUCAUC 605 1345ACCUGACAGAUCCAAGUCA 1374 1346 CUUUCAGAUGCUGCAACUA 1430 1347GAUACGAUGCUUCAAGAGA 3186 1348 AUGCAAGCUUUAGGACUUC 1355 1349GGAUGUGGAUACCUCCCAA 433 1350 AGAAUGCAGUUCGCCUUCA 1713 1351CGAAAUCUUGCCCUUUGUC 1811 1352 ACUCAAGAACAAGUAGCUG 491 1353GAAUGAAGGUGUGGCGACA 2209 1354 UGCACCUUUGCGUGAGCAG 1840 1355ACGAGCUGCUAUGUUCCCU 550 1356 AAGAGGAUGUGGAUACCUC 429 1357GAUAUGGCCAGGAUGCCUU 2436 1358 UAUAGAGGCUCUUGUGCGU 1597 1359GGUUCAGAUGAUAUAAAUG 1496 1360 AGGGAUGGAAGGUCUCCUU 1456 1361UAUCCCAAAGUUGUUGUAA 3159 1362 UCUCUCUUCAGAACAGAGC 2309 1363CUGACCAGCUCUCUCUUCA 2300 1364 ACCUGCUGUGAUACGAUGC 3177 1365AUGGCAGUGCGUUUAGCUG 1079 1366 AUCCAAGUCAACGUCUUGU 1383 1367GCUGCCUCCAGGUGACAGC 2563 1368 AGUGCGUUUAGCUGGUGGG 1084 1369AGCCGGCUAUUGUAGAAGC 1329 1370 CAUUAGAUGAGGGCAUGCA 573 1371GAAGGUGUGGCGACAUAUG 2213 1372 AAGUGGGUGGUAUAGAGGC 1587 1373CUGAGGGAGCCACAGCUCC 2166 1374 GCGUUUGGCUGAACCAUCA 637 1375UCCUUCUCUGAGUGGUAAA 397 1376 GCAGUUCGCCUUCACUAUG 1718 1377GGACUUGAUAUUGGUGCCC 2357 1378 GUUUGGCUGAACCAUCACA 639 1379GCAUGCAGAUCCCAUCUAC 585 1380 GAUGGGCUGCCAGAUCUGG 2519 1381GGACUUCACCUGACAGAUC 1367 1382 CAACGUCUUGUUCAGAACU 1391 1383GAUAUUGAUGGACAGUAUG 509 1384 UGGCCAUGGAACCAGACAG 303 1385CAAGAACAAGUAGCUGAUA 494 1386 GGCUGUUAGUCACUGGCAG 328 1387CAUUGUUUGUGCAGCUGCU 2058 1388 UAAACAGGAAGGGAUGGAA 1447 1389AUAAGAACAAGAUGAUGGU 1563 1390 GUGGAAUGCAAGCUUUAGG 1350 1391GGAAUGAAGGUGUGGCGAC 2208 1392 GACACCAAGAAGCAGAGAU 1689 1393ACUGUCUUUGGACUCUCAG 1407 1394 GGACAAGGAAGCUGCAGAA 2137 1395UCUGCUAUUGUACGUACCA 854 1396 AGCUGCUUUAUUCUCCCAU 2070 1397AGGGUACGAGCUGCUAUGU 545 1398 GAAGACAUCACUGAGCCUG 1640 1399CGGGAUGUUCACAACCGAA 2012 1400 CAGCCGACACCAAGAAGCA 1684 1401UGUUCACAACCGAAUUGUU 2017 1402 GCUCUCUCUUCAGAACAGA 2307 1403UCAGAUGGUGUCUGCUAUU 844 1404 UGAGUGGUAAAGGCAAUCC 405 1405UGGUGCCACUACCACAGCU 379 1406 UUGUCCCGCAAAUCAUGCA 1825 1407CACCCUGGUGCUGACUAUC 2495 1408 AAUGUCCAGCGUUUGGCUG 629 1409GGGCUGCCUCCAGGUGACA 2561 1410 GAGUUACUUCACUCUAGGA 2192 1411UUCGAAAUCUUGCCCUUUG 1809 1412 GUAUAGAGGCUCUUGUGCG 1596 1413AGCUGACCAGCUCUCUCUU 2298 1414 CUAUUGUACGUACCAUGCA 858 1415UAUGCAAUGACUCGAGCUC 524 1416 UGCCCAGGACCUCAUGGAU 2542 1417AACAAGUAGCUGAUAUUGA 498 1418 AAGGCAAUCCUGAGGAAGA 414 1419CAAGAUGAUGGUCUGCCAA 1570 1420 UGCCAUUACAACUCUCCAC 1030 1421AUGUAUGGGUAGGGUAAAU 3087 1422 UGUGCUCUUCGUCAUCUGA 1664 1423AAGGCUACUGUUGGAUUGA 1790 1424 UACUGUCCUUCGGGCUGGU 1615 1425AUAAGGCUGCAGUUAUGGU 774 1426 UCGUCAUCUGACCAGCCGA 1672 1427GUUGUAACCUGCUGUGAUA 3171 1428 AAGAUUACAAGAAACGGCU 2271 1429UUAUGGCAACCAAGAAAGC 1183 1430 UCCAGUUGAUGGGCUGCCA 2512 1431GGGACACAGCAGCAAUUUG 1931 1432 AUGAUGGAACAUGAGAUGG 2468 1433UAUUUGGGAUAUGUAUGGG 3077 1434 CAGCUGCUUUAUUCUCCCA 2069 1435GCUACUCAAGCUGAUUUGA 272 1436 UCCCUGAGACAUUAGAUGA 564 1437GUGGAUACCUCCCAAGUCC 437 1438 UAGGAAUGAAGGUGUGGCG 2206 1439UGACAGAGUUACUUCACUC 2187 1440 AGCGGCUGUUAGUCACUGG 325 1441AUGGUUCAGAAUUAAACUU 3222 1442 AACCGAAUUGUUAUCAGAG 2024 1443GGGUGCCAUUCCACGACUA 1858 1444 AUGAUGGUCUGCCAAGUGG 1574 1445CACAUCAGGAUACCCAGCG 1896 1446 AGGAAUGAAGGUGUGGCGA 2207 1447GAAGGUGCUAUCUGUCUGC 1300 1448 CCAAGAAAGCAAGCUCAUC 1192 1449CGAGCUGCUAUGUUCCCUG 551 1450 CCUGGUGCUGACUAUCCAG 2498 1451UGCUAUCUGUCUGCUCUAG 1305 1452 AUUGUAGAAGCUGGUGGAA 1337 1453

TABLE 1b Various c-CTNNB1 siNA sense and antisense sequencescorresponding to the identified target sequences in Table 1a. SEQ SEQTarget Site ID ID (human) NO: Sense Sequence Antisense Sequence NO: 5351 UCGAGCUCAGAGGGUACGA UCGUACCCUCUGAGCUCGA 4914 1601 2GAGGCUCUUGUGCGUACUG CAGUACGCACAAGAGCCUC 4915 1709 3 GCCCAGAAUGCAGUUCGCCGGCGAACUGCAUUCUGGGC 4916 536 4 CGAGCUCAGAGGGUACGAG CUCGUACCCUCUGAGCUCG4917 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAG 4918 853 6GUCUGCUAUUGUACGUACC GGUACGUACAAUAGCAGAC 4919 1143 7 AAUUCUUGGCUAUUACGACGUCGUAAUAGCCAAGAAUU 4920 2014 8 GGAUGUUCACAACCGAAUU AAUUCGGUUGUGAACAUCC4921 520 9 ACAGUAUGCAAUGACUCGA UCGAGUCAUUGCAUACUGU 4922 814 10AGCUUCCAGACACGCUAUC GAUAGCGUGUCUGGAAGCU 4923 852 11 UGUCUGCUAUUGUACGUACGUACGUACAAUAGCAGACA 4924 1796 12 ACUGUUGGAUUGAUUCGAA UUCGAAUCAAUCCAACAGU4925 1901 13 CAGGAUACCCAGCGCCGUA UACGGCGCUGGGUAUCCUG 4926 822 14GACACGCUAUCAUGCGUUC GAACGCAUGAUAGCGUGUC 4927 1795 15 UACUGUUGGAUUGAUUCGAUCGAAUCAAUCCAACAGUA 4928 1145 16 UUCUUGGCUAUUACGACAG CUGUCGUAAUAGCCAAGAA4929 823 17 ACACGCUAUCAUGCGUUCU AGAACGCAUGAUAGCGUGU 4930 820 18CAGACACGCUAUCAUGCGU ACGCAUGAUAGCGUGUCUG 4931 1798 19 UGUUGGAUUGAUUCGAAAUAUUUCGAAUCAAUCCAACA 4932 1380 20 CAGAUCCAAGUCAACGUCU AGACGUUGACUUGGAUCUG4933 1602 21 AGGCUCUUGUGCGUACUGU ACAGUACGCACAAGAGCCU 4934 1612 22GCGUACUGUCCUUCGGGCU AGCCCGAAGGACAGUACGC 4935 626 23 ACUAAUGUCCAGCGUUUGGCCAAACGCUGGACAUUAGU 4936 2000 24 CACAUCCUAGCUCGGGAUG CAUCCCGAGCUAGGAUGUG4937 2665 25 GUUGCUGAGAGGGCUCGAG CUCGAGCCCUCUCAGCAAC 4938 1676 26CAUCUGACCAGCCGACACC GGUGUCGGCUGGUCAGAUG 4939 1611 27 UGCGUACUGUCCUUCGGGCGCCCGAAGGACAGUACGCA 4940 2269 28 ACAAGAUUACAAGAAACGG CCGUUUCUUGUAAUCUUGU4941 674 29 GUUGUAAACUUGAUUAACU AGUUAAUCAAGUUUACAAC 4942 678 30UAAACUUGAUUAACUAUCA UGAUAGUUAAUCAAGUUUA 4943 1245 31 AUAUAAUGAGGACCUAUACGUAUAGGUCCUCAUUAUAU 4944 679 32 AAACUUGAUUAACUAUCAA UUGAUAGUUAAUCAAGUUU4945 1970 33 GAAAUAGUUGAAGGUUGUA UACAACCUUCAACUAUUUC 4946 1247 34AUAAUGAGGACCUAUACUU AAGUAUAGGUCCUCAUUAU 4947 1140 35 UUAAAUUCUUGGCUAUUACGUAAUAGCCAAGAAUUUAA 4948 676 36 UGUAAACUUGAUUAACUAU AUAGUUAAUCAAGUUUACA4949 677 37 GUAAACUUGAUUAACUAUC GAUAGUUAAUCAAGUUUAC 4950 675 38UUGUAAACUUGAUUAACUA UAGUUAAUCAAGUUUACAA 4951 1235 39 GCUUUAGUAAAUAUAAUGAUCAUUAUAUUUACUAAAGC 4952 2488 40 UGGCCACCACCCUGGUGCU AGCACCAGGGUGGUGGCCA4953 1236 41 CUUUAGUAAAUAUAAUGAG CUCAUUAUAUUUACUAAAG 4954 1237 42UUUAGUAAAUAUAAUGAGG CCUCAUUAUAUUUACUAAA 4955 2555 43 GUAAAUCGUCCUUUAGGUAUACCUAAAGGACGAUUUAC 4956 1545 44 ACCUCACUUGCAAUAAUUA UAAUUAUUGCAAGUGAGGU4957 2050 45 UACCAUUCCAUUGUUUGUG CACAAACAAUGGAAUGGUA 4958 2097 46UCCAAAGAGUAGCUGCAGG CCUGCAGCUACUCUUUGGA 4959 2510 47 UAUCCAGUUGAUGGGCUGCGCAGCCCAUCAACUGGAUA 4960 871 48 CAUGCAGAAUACAAAUGAU AUCAUUUGUAUUCUGCAUG4961 2098 49 CCAAAGAGUAGCUGCAGGG CCCUGCAGCUACUCUUUGG 4962 1767 50CACCAUCCCACUGGCCUCU AGAGGCCAGUGGGAUGGUG 4963 869 51 ACCAUGCAGAAUACAAAUGCAUUUGUAUUCUGCAUGGU 4964 1641 52 AAGACAUCACUGAGCCUGC GCAGGCUCAGUGAUGUCUU4965 2582 53 AAUCAGCUGGCCUGGUUUG CAAACCAGGCCAGCUGAUU 4966 1544 54AACCUCACUUGCAAUAAUU AAUUAUUGCAAGUGAGGUU 4967 2550 55 ACCUCAUGGAUGGGCUGCCGGCAGCCCAUCCAUGAGGU 4968 2051 56 ACCAUUCCAUUGUUUGUGC GCACAAACAAUGGAAUGGU4969 870 57 CCAUGCAGAAUACAAAUGA UCAUUUGUAUUCUGCAUGG 4970 1670 58CUUCGUCAUCUGACCAGCC GGCUGGUCAGAUGACGAAG 4971 2122 59 CUGUGAACUUGCUCAGGACGUCCUGAGCAAGUUCACAG 4972 1642 60 AGACAUCACUGAGCCUGCC GGCAGGCUCAGUGAUGUCU4973 2324 61 GAGCCAAUGGCUUGGAAUG CAUUCCAAGCCAUUGGCUC 4974 1649 62ACUGAGCCUGCCAUCUGUG CACAGAUGGCAGGCUCAGU 4975 2159 63 AUUGAAGCUGAGGGAGCCAUGGCUCCCUCAGCUUCAAU 4976 785 64 GUUAUGGUCCAUCAGCUUU AAAGCUGAUGGACCAUAAC4977 1511 65 AAUGUGGUCACCUGUGCAG CUGCACAGGUGACCACAUU 4978 2586 66AGCUGGCCUGGUUUGAUAC GUAUCAAACCAGGCCAGCU 4979 642 67 UGGCUGAACCAUCACAGAUAUCUGUGAUGGUUCAGCCA 4980 1763 68 CACCCACCAUCCCACUGGC GCCAGUGGGAUGGUGGGUG4981 2328 69 CAAUGGCUUGGAAUGAGAC GUCUCAUUCCAAGCCAUUG 4982 1280 70UGGACCACAAGCAGAGUGC GCACUCUGCUUGUGGUCCA 4983 2052 71 CCAUUCCAUUGUUUGUGCAUGCACAAACAAUGGAAUGG 4984 2546 72 CAGGACCUCAUGGAUGGGC GCCCAUCCAUGAGGUCCUG4985 2124 73 GUGAACUUGCUCAGGACAA UUGUCCUGAGCAAGUUCAC 4986 2545 74CCAGGACCUCAUGGAUGGG CCCAUCCAUGAGGUCCUGG 4987 643 75 GGCUGAACCAUCACAGAUGCAUCUGUGAUGGUUCAGCC 4988 2501 76 GGUGCUGACUAUCCAGUUG CAACUGGAUAGUCAGCACC4989 2330 77 AUGGCUUGGAAUGAGACUG CAGUCUCAUUCCAAGCCAU 4990 1638 78GGGAAGACAUCACUGAGCC GGCUCAGUGAUGUCUUCCC 4991 1630 79 UGGUGACAGGGAAGACAUCGAUGUCUUCCCUGUCACCA 4992 616 80 UGCUCAUCCCACUAAUGUC GACAUUAGUGGGAUGAGCA4993 2509 81 CUAUCCAGUUGAUGGGCUG CAGCCCAUCAACUGGAUAG 4994 2548 82GGACCUCAUGGAUGGGCUG CAGCCCAUCCAUGAGGUCC 4995 1773 83 CCCACUGGCCUCUGAUAAAUUUAUCAGAGGCCAGUGGG 4996 2247 84 UCCGAAUGUCUGAGGACAA UUGUCCUCAGACAUUCGGA4997 2331 85 UGGCUUGGAAUGAGACUGC GCAGUCUCAUUCCAAGCCA 4998 1498 86UUCAGAUGAUAUAAAUGUG CACAUUUAUAUCAUCUGAA 4999 2267 87 CCACAAGAUUACAAGAAACGUUUCUUGUAAUCUUGUGG 5000 1547 88 CUCACUUGCAAUAAUUAUA UAUAAUUAUUGCAAGUGAG5001 1549 89 CACUUGCAAUAAUUAUAAG CUUAUAAUUAUUGCAAGUG 5002 867 90GUACCAUGCAGAAUACAAA UUUGUAUUCUGCAUGGUAC 5003 1390 91 UCAACGUCUUGUUCAGAACGUUCUGAACAAGACGUUGA 5004 593 92 AUCCCAUCUACACAGUUUG CAAACUGUGUAGAUGGGAU5005 274 93 UACUCAAGCUGAUUUGAUG CAUCAAAUCAGCUUGAGUA 5006 759 94ACCAGGUGGUGGUUAAUAA UUAUUAACCACCACCUGGU 5007 1439 95 GCUGCAACUAAACAGGAAGCUUCCUGUUUAGUUGCAGC 5008 1801 96 UGGAUUGAUUCGAAAUCUU AAGAUUUCGAAUCAAUCCA5009 1500 97 CAGAUGAUAUAAAUGUGGU ACCACAUUUAUAUCAUCUG 5010 848 98AUGGUGUCUGCUAUUGUAC GUACAAUAGCAGACACCAU 5011 2268 99 CACAAGAUUACAAGAAACGCGUUUCUUGUAAUCUUGUG 5012 882 100 CAAAUGAUGUAGAAACAGC GCUGUUUCUACAUCAUUUG5013 2266 101 GCCACAAGAUUACAAGAAA UUUCUUGUAAUCUUGUGGC 5014 880 102UACAAAUGAUGUAGAAACA UGUUUCUACAUCAUUUGUA 5015 1810 103UCGAAAUCUUGCCCUUUGU ACAAAGGGCAAGAUUUCGA 5016 685 104 GAUUAACUAUCAAGAUGAUAUCAUCUUGAUAGUUAAUC 5017 1007 105 CCAGUGGAUUCUGUGUUGUACAACACAGAAUCCACUGG 5018 1789 106 AAAGGCUACUGUUGGAUUGCAAUCCAACAGUAGCCUUU 5019 499 107 ACAAGUAGCUGAUAUUGAU AUCAAUAUCAGCUACUUGU5020 2470 108 GAUGGAACAUGAGAUGGGU ACCCAUCUCAUGUUCCAUC 5021 694 109UCAAGAUGAUGCAGAACUU AAGUUCUGCAUCAUCUUGA 5022 278 110 CAAGCUGAUUUGAUGGAGUACUCCAUCAAAUCAGCUUG 5023 1415 111 UGGACUCUCAGGAAUCUUUAAAGAUUCCUGAGAGUCCA 5024 2046 112 UAAAUACCAUUCCAUUGUUAACAAUGGAAUGGUAUUUA 5025 1057 113 AUUACAUCAAGAAGGAGCUAGCUCCUUCUUGAUGUAAU 5026 1422 114 UCAGGAAUCUUUCAGAUGCGCAUCUGAAAGAUUCCUGA 5027 684 115 UGAUUAACUAUCAAGAUGA UCAUCUUGAUAGUUAAUCA5028 2197 116 ACUUCACUCUAGGAAUGAA UUCAUUCCUAGAGUGAAGU 5029 666 117AACAUGCAGUUGUAAACUU AAGUUUACAACUGCAUGUU 5030 279 118 AAGCUGAUUUGAUGGAGUUAACUCCAUCAAAUCAGCUU 5031 1492 119 UCUGGGUUCAGAUGAUAUAUAUAUCAUCUGAACCCAGA 5032 2195 120 UUACUUCACUCUAGGAAUGCAUUCCUAGAGUGAAGUAA 5033 1424 121 AGGAAUCUUUCAGAUGCUGCAGCAUCUGAAAGAUUCCU 5034 661 122 GCUGAAACAUGCAGUUGUA UACAACUGCAUGUUUCAGC5035 1882 123 GUUGCUUGUUCGUGCACAU AUGUGCACGAACAAGCAAC 5036 1966 124GGAAGAAAUAGUUGAAGGU ACCUUCAACUAUUUCUUCC 5037 2259 125AGGACAAGCCACAAGAUUA UAAUCUUGUGGCUUGUCCU 5038 832 126 CAUGCGUUCUCCUCAGAUGCAUCUGAGGAGAACGCAUG 5039 2346 127 GAUGAUCCCAGCUACCGUUAACGGUAGCUGGGAUCAUC 5040 1653 128 AGCCUGCCAUCUGUGCUCUAGAGCACAGAUGGCAGGCU 5041 2389 129 UGGAUAUCGCCAGGAUGAUAUCAUCCUGGCGAUAUCCA 5042 1669 130 UCUUCGUCAUCUGACCAGCGCUGGUCAGAUGACGAAGA 5043 2123 131 UGUGAACUUGCUCAGGACAUGUCCUGAGCAAGUUCACA 5044 1521 132 CCUGUGCAGCUGGAAUUCUAGAAUUCCAGCUGCACAGG 5045 2125 133 UGAACUUGCUCAGGACAAGCUUGUCCUGAGCAAGUUCA 5046 2503 134 UGCUGACUAUCCAGUUGAUAUCAACUGGAUAGUCAGCA 5047 1502 135 GAUGAUAUAAAUGUGGUCAUGACCACAUUUAUAUCAUC 5048 2502 136 GUGCUGACUAUCCAGUUGAUCAACUGGAUAGUCAGCAC 5049 2506 137 UGACUAUCCAGUUGAUGGGCCCAUCAACUGGAUAGUCA 5050 2127 138 AACUUGCUCAGGACAAGGAUCCUUGUCCUGAGCAAGUU 5051 2505 139 CUGACUAUCCAGUUGAUGGCCAUCAACUGGAUAGUCAG 5052 617 140 GCUCAUCCCACUAAUGUCC GGACAUUAGUGGGAUGAGC5053 2504 141 GCUGACUAUCCAGUUGAUG CAUCAACUGGAUAGUCAGC 5054 1503 142AUGAUAUAAAUGUGGUCAC GUGACCACAUUUAUAUCAU 5055 618 143 CUCAUCCCACUAAUGUCCAUGGACAUUAGUGGGAUGAG 5056 2074 144 GCUUUAUUCUCCCAUUGAAUUCAAUGGGAGAAUAAAGC 5057 2499 145 CUGGUGCUGACUAUCCAGUACUGGAUAGUCAGCACCAG 5058 1406 146 AACUGUCUUUGGACUCUCAUGAGAGUCCAAAGACAGUU 5059 582 147 AGGGCAUGCAGAUCCCAUC GAUGGGAUCUGCAUGCCCU5060 1505 148 GAUAUAAAUGUGGUCACCU AGGUGACCACAUUUAUAUC 5061 1432 149UUCAGAUGCUGCAACUAAA UUUAGUUGCAGCAUCUGAA 5062 1968 150AAGAAAUAGUUGAAGGUUG CAACCUUCAACUAUUUCUU 5063 2398 151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGG 5064 954 152 UGGCCAUCUUUAAGUCUGGCCAGACUUAAAGAUGGCCA 5065 505 153 AGCUGAUAUUGAUGGACAG CUGUCCAUCAAUAUCAGCU5066 2011 154 UCGGGAUGUUCACAACCGA UCGGUUGUGAACAUCCCGA 5067 1339 155UGUAGAAGCUGGUGGAAUG CAUUCCACCAGCUUCUACA 5068 1242 156UAAAUAUAAUGAGGACCUA UAGGUCCUCAUUAUAUUUA 5069 567 157 CUGAGACAUUAGAUGAGGGCCCUCAUCUAAUGUCUCAG 5070 1240 158 AGUAAAUAUAAUGAGGACCGGUCCUCAUUAUAUUUACU 5071 438 159 UGGAUACCUCCCAAGUCCU AGGACUUGGGAGGUAUCCA5072 2445 160 AGGAUGCCUUGGGUAUGGA UCCAUACCCAAGGCAUCCU 5073 860 161AUUGUACGUACCAUGCAGA UCUGCAUGGUACGUACAAU 5074 1413 162UUUGGACUCUCAGGAAUCU AGAUUCCUGAGAGUCCAAA 5075 1800 163UUGGAUUGAUUCGAAAUCU AGAUUUCGAAUCAAUCCAA 5076 2037 164UCAGAGGACUAAAUACCAU AUGGUAUUUAGUCCUCUGA 5077 2443 165CCAGGAUGCCUUGGGUAUG CAUACCCAAGGCAUCCUGG 5078 2471 166AUGGAACAUGAGAUGGGUG CACCCAUCUCAUGUUCCAU 5079 1792 167GGCUACUGUUGGAUUGAUU AAUCAAUCCAACAGUAGCC 5080 2547 168AGGACCUCAUGGAUGGGCU AGCCCAUCCAUGAGGUCCU 5081 1662 169UCUGUGCUCUUCGUCAUCU AGAUGACGAAGAGCACAGA 5082 288 170 UGAUGGAGUUGGACAUGGCGCCAUGUCCAACUCCAUCA 5083 579 171 AUGAGGGCAUGCAGAUCCC GGGAUCUGCAUGCCCUCAU5084 2508 172 ACUAUCCAGUUGAUGGGCU AGCCCAUCAACUGGAUAGU 5085 580 173UGAGGGCAUGCAGAUCCCA UGGGAUCUGCAUGCCCUCA 5086 2388 174UUGGAUAUCGCCAGGAUGA UCAUCCUGGCGAUAUCCAA 5087 2543 175GCCCAGGACCUCAUGGAUG CAUCCAUGAGGUCCUGGGC 5088 708 176 AACUUGCCACACGUGCAAUAUUGCACGUGUGGCAAGUU 5089 447 177 CCCAAGUCCUGUAUGAGUG CACUCAUACAGGACUUGGG5090 654 178 CACAGAUGCUGAAACAUGC GCAUGUUUCAGCAUCUGUG 5091 912 179CUGGGACCUUGCAUAACCU AGGUUAUGCAAGGUCCCAG 5092 1009 180AGUGGAUUCUGUGUUGUUU AAACAACACAGAAUCCACU 5093 1354 181AAUGCAAGCUUUAGGACUU AAGUCCUAAAGCUUGCAUU 5094 1969 182AGAAAUAGUUGAAGGUUGU ACAACCUUCAACUAUUUCU 5095 1959 183UCCGCAUGGAAGAAAUAGU ACUAUUUCUUCCAUGCGGA 5096 557 184 GCUAUGUUCCCUGAGACAUAUGUCUCAGGGAACAUAGC 5097 403 185 UCUGAGUGGUAAAGGCAAU AUUGCCUUUACCACUCAGA5098 1356 186 UGCAAGCUUUAGGACUUCA UGAAGUCCUAAAGCUUGCA 5099 517 187UGGACAGUAUGCAAUGACU AGUCAUUGCAUACUGUCCA 5100 1238 188UUAGUAAAUAUAAUGAGGA UCCUCAUUAUAUUUACUAA 5101 843 189 CUCAGAUGGUGUCUGCUAUAUAGCAGACACCAUCUGAG 5102 496 190 AGAACAAGUAGCUGAUAUU AAUAUCAGCUACUUGUUCU5103 2387 191 CUUGGAUAUCGCCAGGAUG CAUCCUGGCGAUAUCCAAG 5104 1660 192CAUCUGUGCUCUUCGUCAU AUGACGAAGAGCACAGAUG 5105 2497 193CCCUGGUGCUGACUAUCCA UGGAUAGUCAGCACCAGGG 5106 1870 194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGU 5107 2353 195UCUUGGACUUGAUAUUGGU ACCAAUAUCAAGUCCAAGA 5108 2401 196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCC 5109 878 197 AAUACAAAUGAUGUAGAAAUUUCUACAUCAUUUGUAUU 5110 647 198 GAACCAUCACAGAUGCUGA UCAGCAUCUGUGAUGGUUC5111 1998 199 UUCACAUCCUAGCUCGGGA UCCCGAGCUAGGAUGUGAA 5112 588 200UGCAGAUCCCAUCUACACA UGUGUAGAUGGGAUCUGCA 5113 2042 201GGACUAAAUACCAUUCCAU AUGGAAUGGUAUUUAGUCC 5114 855 202 CUGCUAUUGUACGUACCAUAUGGUACGUACAAUAGCAG 5115 2038 203 CAGAGGACUAAAUACCAUUAAUGGUAUUUAGUCCUCUG 5116 1786 204 GAUAAAGGCUACUGUUGGAUCCAACAGUAGCCUUUAUC 5117 1501 205 AGAUGAUAUAAAUGUGGUCGACCACAUUUAUAUCAUCU 5118 1834 206 AAAUCAUGCACCUUUGCGUACGCAAAGGUGCAUGAUUU 5119 1157 207 ACGACAGACUGCCUUCAAAUUUGAAGGCAGUCUGUCGU 5120 1239 208 UAGUAAAUAUAAUGAGGACGUCCUCAUUAUAUUUACUA 5121 1248 209 UAAUGAGGACCUAUACUUAUAAGUAUAGGUCCUCAUUA 5122 660 210 UGCUGAAACAUGCAGUUGU ACAACUGCAUGUUUCAGCA5123 285 211 AUUUGAUGGAGUUGGACAU AUGUCCAACUCCAUCAAAU 5124 1582 212CUGCCAAGUGGGUGGUAUA UAUACCACCCACUUGGCAG 5125 1735 213UGGACUACCAGUUGUGGUU AACCACAACUGGUAGUCCA 5126 771 214 UUAAUAAGGCUGCAGUUAUAUAACUGCAGCCUUAUUAA 5127 1060 215 ACAUCAAGAAGGAGCUAAAUUUAGCUCCUUCUUGAUGU 5128 2390 216 GGAUAUCGCCAGGAUGAUCGAUCAUCCUGGCGAUAUCC 5129 2186 217 CUGACAGAGUUACUUCACUAGUGAAGUAACUCUGUCAG 5130 1632 218 GUGACAGGGAAGACAUCACGUGAUGUCUUCCCUGUCAC 5131 619 219 UCAUCCCACUAAUGUCCAG CUGGACAUUAGUGGGAUGA5132 1656 220 CUGCCAUCUGUGCUCUUCG CGAAGAGCACAGAUGGCAG 5133 1506 221AUAUAAAUGUGGUCACCUG CAGGUGACCACAUUUAUAU 5134 2494 222CCACCCUGGUGCUGACUAU AUAGUCAGCACCAGGGUGG 5135 1666 223UGCUCUUCGUCAUCUGACC GGUCAGAUGACGAAGAGCA 5136 1635 224ACAGGGAAGACAUCACUGA UCAGUGAUGUCUUCCCUGU 5137 294 225 AGUUGGACAUGGCCAUGGAUCCAUGGCCAUGUCCAACU 5138 641 226 UUGGCUGAACCAUCACAGA UCUGUGAUGGUUCAGCCAA5139 576 227 UAGAUGAGGGCAUGCAGAU AUCUGCAUGCCCUCAUCUA 5140 577 228AGAUGAGGGCAUGCAGAUC GAUCUGCAUGCCCUCAUCU 5141 1661 229AUCUGUGCUCUUCGUCAUC GAUGACGAAGAGCACAGAU 5142 707 230 GAACUUGCCACACGUGCAAUUGCACGUGUGGCAAGUUC 5143 1659 231 CCAUCUGUGCUCUUCGUCAUGACGAAGAGCACAGAUGG 5144 1185 232 AUGGCAACCAAGAAAGCAAUUGCUUUCUUGGUUGCCAU 5145 664 233 GAAACAUGCAGUUGUAAAC GUUUACAACUGCAUGUUUC5146 1749 234 UGGUUAAGCUCUUACACCC GGGUGUAAGAGCUUAACCA 5147 1234 235AGCUUUAGUAAAUAUAAUG CAUUAUAUUUACUAAAGCU 5148 691 236 CUAUCAAGAUGAUGCAGAAUUCUGCAUCAUCUUGAUAG 5149 1387 237 AAGUCAACGUCUUGUUCAGCUGAACAAGACGUUGACUU 5150 1382 238 GAUCCAAGUCAACGUCUUGCAAGACGUUGACUUGGAUC 5151 828 239 CUAUCAUGCGUUCUCCUCA UGAGGAGAACGCAUGAUAG5152 1244 240 AAUAUAAUGAGGACCUAUA UAUAGGUCCUCAUUAUAUU 5153 1304 241GUGCUAUCUGUCUGCUCUA UAGAGCAGACAGAUAGCAC 5154 812 242 GAAGCUUCCAGACACGCUAUAGCGUGUCUGGAAGCUUC 5155 1558 243 UAAUUAUAAGAACAAGAUGCAUCUUGUUCUUAUAAUUA 5156 879 244 AUACAAAUGAUGUAGAAAC GUUUCUACAUCAUUUGUAU5157 1311 245 CUGUCUGCUCUAGUAAUAA UUAUUACUAGAGCAGACAG 5158 856 246UGCUAUUGUACGUACCAUG CAUGGUACGUACAAUAGCA 5159 1296 247UGCUGAAGGUGCUAUCUGU ACAGAUAGCACCUUCAGCA 5160 960 248 UCUUUAAGUCUGGAGGCAUAUGCCUCCAGACUUAAAGA 5161 2049 249 AUACCAUUCCAUUGUUUGUACAAACAAUGGAAUGGUAU 5162 1791 250 AGGCUACUGUUGGAUUGAUAUCAAUCCAACAGUAGCCU 5163 783 251 CAGUUAUGGUCCAUCAGCU AGCUGAUGGACCAUAACUG5164 1569 252 ACAAGAUGAUGGUCUGCCA UGGCAGACCAUCAUCUUGU 5165 2224 253GACAUAUGCAGCUGCUGUU AACAGCAGCUGCAUAUGUC 5166 934 254 CCAUCAUCGUGAGGGCUUAUAAGCCCUCACGAUGAUGG 5167 1378 255 GACAGAUCCAAGUCAACGUACGUUGACUUGGAUCUGUC 5168 569 256 GAGACAUUAGAUGAGGGCA UGCCCUCAUCUAAUGUCUC5169 1722 257 UUCGCCUUCACUAUGGACU AGUCCAUAGUGAAGGCGAA 5170 1483 258UGUUCAGCUUCUGGGUUCA UGAACCCAGAAGCUGAACA 5171 2352 259AUCUUGGACUUGAUAUUGG CCAAUAUCAAGUCCAAGAU 5172 719 260 CGUGCAAUCCCUGAACUGAUCAGUUCAGGGAUUGCACG 5173 762 261 AGGUGGUGGUUAAUAAGGC GCCUUAUUAACCACCACCU5174 599 262 UCUACACAGUUUGAUGCUG CAGCAUCAAACUGUGUAGA 5175 1704 263AGAUGGCCCAGAAUGCAGU ACUGCAUUCUGGGCCAUCU 5176 2270 264CAAGAUUACAAGAAACGGC GCCGUUUCUUGUAAUCUUG 5177 662 265 CUGAAACAUGCAGUUGUAAUUACAACUGCAUGUUUCAG 5178 396 266 CUCCUUCUCUGAGUGGUAA UUACCACUCAGAGAAGGAG5179 1199 267 AGCAAGCUCAUCAUACUGG CCAGUAUGAUGAGCUUGCU 5180 1560 268AUUAUAAGAACAAGAUGAU AUCAUCUUGUUCUUAUAAU 5181 1310 269UCUGUCUGCUCUAGUAAUA UAUUACUAGAGCAGACAGA 5182 1233 270AAGCUUUAGUAAAUAUAAU AUUAUAUUUACUAAAGCUU 5183 1330 271GCCGGCUAUUGUAGAAGCU AGCUUCUACAAUAGCCGGC 5184 1312 272UGUCUGCUCUAGUAAUAAG CUUAUUACUAGAGCAGACA 5185 1556 273AAUAAUUAUAAGAACAAGA UCUUGUUCUUAUAAUUAUU 5186 2438 274UAUGGCCAGGAUGCCUUGG CCAAGGCAUCCUGGCCAUA 5187 1826 275UGUCCCGCAAAUCAUGCAC GUGCAUGAUUUGCGGGACA 5188 1397 276CUUGUUCAGAACUGUCUUU AAAGACAGUUCUGAACAAG 5189 3181 277GCUGUGAUACGAUGCUUCA UGAAGCAUCGUAUCACAGC 5190 1912 278GCGCCGUACGUCCAUGGGU ACCCAUGGACGUACGGCGC 5191 846 279 AGAUGGUGUCUGCUAUUGUACAAUAGCAGACACCAUCU 5192 1404 280 AGAACUGUCUUUGGACUCUAGAGUCCAAAGACAGUUCU 5193 586 281 CAUGCAGAUCCCAUCUACA UGUAGAUGGGAUCUGCAUG5194 1469 282 CUCCUUGGGACUCUUGUUC GAACAAGAGUCCCAAGGAG 5195 380 283GGUGCCACUACCACAGCUC GAGCUGUGGUAGUGGCACC 5196 1345 284AGCUGGUGGAAUGCAAGCU AGCUUGCAUUCCACCAGCU 5197 1863 285CCAUUCCACGACUAGUUCA UGAACUAGUCGUGGAAUGG 5198 635 286 CAGCGUUUGGCUGAACCAUAUGGUUCAGCCAAACGCUG 5199 959 287 AUCUUUAAGUCUGGAGGCA UGCCUCCAGACUUAAAGAU5200 2440 288 UGGCCAGGAUGCCUUGGGU ACCCAAGGCAUCCUGGCCA 5201 877 289GAAUACAAAUGAUGUAGAA UUCUACAUCAUUUGUAUUC 5202 2556 290UGGAUGGGCUGCCUCCAGG CCUGGAGGCAGCCCAUCCA 5203 1916 291CGUACGUCCAUGGGUGGGA UCCCACCCAUGGACGUACG 5204 850 292 GGUGUCUGCUAUUGUACGUACGUACAAUAGCAGACACC 5205 1303 293 GGUGCUAUCUGUCUGCUCUAGAGCAGACAGAUAGCACC 5206 1726 294 CCUUCACUAUGGACUACCAUGGUAGUCCAUAGUGAAGG 5207 1477 295 GACUCUUGUUCAGCUUCUGCAGAAGCUGAACAAGAGUC 5208 598 296 AUCUACACAGUUUGAUGCU AGCAUCAAACUGUGUAGAU5209 2062 297 GUUUGUGCAGCUGCUUUAU AUAAAGCAGCUGCACAAAC 5210 2278 298CAAGAAACGGCUUUCAGUU AACUGAAAGCCGUUUCUUG 5211 1877 299GUUCAGUUGCUUGUUCGUG CACGAACAAGCAACUGAAC 5212 1499 300UCAGAUGAUAUAAAUGUGG CCACAUUUAUAUCAUCUGA 5213 1136 301AAUGUUAAAUUCUUGGCUA UAGCCAAGAAUUUAACAUU 5214 1494 302UGGGUUCAGAUGAUAUAAA UUUAUAUCAUCUGAACCCA 5215 1972 303AAUAGUUGAAGGUUGUACC GGUACAACCUUCAACUAUU 5216 668 304 CAUGCAGUUGUAAACUUGAUCAAGUUUACAACUGCAUG 5217 2945 305 AAUCUGAAUAAAGUGUAACGUUACACUUUAUUCAGAUU 5218 2492 306 CACCACCCUGGUGCUGACUAGUCAGCACCAGGGUGGUG 5219 293 307 GAGUUGGACAUGGCCAUGG CCAUGGCCAUGUCCAACUC5220 1905 308 AUACCCAGCGCCGUACGUC GACGUACGGCGCUGGGUAU 5221 944 309GAGGGCUUACUGGCCAUCU AGAUGGCCAGUAAGCCCUC 5222 581 310 GAGGGCAUGCAGAUCCCAUAUGGGAUCUGCAUGCCCUC 5223 1454 311 GAAGGGAUGGAAGGUCUCCGGAGACCUUCCAUCCCUUC 5224 2254 312 GUCUGAGGACAAGCCACAAUUGUGGCUUGUCCUCAGAC 5225 1837 313 UCAUGCACCUUUGCGUGAGCUCACGCAAAGGUGCAUGA 5226 1425 314 GGAAUCUUUCAGAUGCUGCGCAGCAUCUGAAAGAUUCC 5227 1372 315 UCACCUGACAGAUCCAAGUACUUGGAUCUGUCAGGUGA 5228 1298 316 CUGAAGGUGCUAUCUGUCUAGACAGAUAGCACCUUCAG 5229 1674 317 GUCAUCUGACCAGCCGACAUGUCGGCUGGUCAGAUGAC 5230 1864 318 CAUUCCACGACUAGUUCAGCUGAACUAGUCGUGGAAUG 5231 2404 319 UGAUCCUAGCUAUCGUUCUAGAACGAUAGCUAGGAUCA 5232 1992 320 GAGCCCUUCACAUCCUAGCGCUAGGAUGUGAAGGGCUC 5233 578 321 GAUGAGGGCAUGCAGAUCC GGAUCUGCAUGCCCUCAUC5234 3091 322 AUGGGUAGGGUAAAUCAGU ACUGAUUUACCCUACCCAU 5235 720 323GUGCAAUCCCUGAACUGAC GUCAGUUCAGGGAUUGCAC 5236 2054 324AUUCCAUUGUUUGUGCAGC GCUGCACAAACAAUGGAAU 5237 374 325 CAUUCUGGUGCCACUACCAUGGUAGUGGCACCAGAAUG 5238 868 326 UACCAUGCAGAAUACAAAU AUUUGUAUUCUGCAUGGUA5239 1716 327 AUGCAGUUCGCCUUCACUA UAGUGAAGGCGAACUGCAU 5240 950 328UUACUGGCCAUCUUUAAGU ACUUAAAGAUGGCCAGUAA 5241 1489 329GCUUCUGGGUUCAGAUGAU AUCAUCUGAACCCAGAAGC 5242 1451 330CAGGAAGGGAUGGAAGGUC GACCUUCCAUCCCUUCCUG 5243 1181 331GCUUAUGGCAACCAAGAAA UUUCUUGGUUGCCAUAAGC 5244 1633 332UGACAGGGAAGACAUCACU AGUGAUGUCUUCCCUGUCA 5245 2394 333AUCGCCAGGAUGAUCCUAG CUAGGAUCAUCCUGGCGAU 5246 1322 334AGUAAUAAGCCGGCUAUUG CAAUAGCCGGCUUAUUACU 5247 884 335 AAUGAUGUAGAAACAGCUCGAGCUGUUUCUACAUCAUU 5248 2255 336 UCUGAGGACAAGCCACAAGCUUGUGGCUUGUCCUCAGA 5249 1466 337 GGUCUCCUUGGGACUCUUGCAAGAGUCCCAAGGAGACC 5250 1399 338 UGUUCAGAACUGUCUUUGGCCAAAGACAGUUCUGAACA 5251 378 339 CUGGUGCCACUACCACAGC GCUGUGGUAGUGGCACCAG5252 1921 340 GUCCAUGGGUGGGACACAG CUGUGUCCCACCCAUGGAC 5253 1085 341GUGCGUUUAGCUGGUGGGC GCCCACCAGCUAAACGCAC 5254 865 342 ACGUACCAUGCAGAAUACAUGUAUUCUGCAUGGUACGU 5255 2015 343 GAUGUUCACAACCGAAUUGCAAUUCGGUUGUGAACAUC 5256 1195 344 AGAAAGCAAGCUCAUCAUAUAUGAUGAGCUUGCUUUCU 5257 1484 345 GUUCAGCUUCUGGGUUCAGCUGAACCCAGAAGCUGAAC 5258 1855 346 GCAGGGUGCCAUUCCACGAUCGUGGAAUGGCACCCUGC 5259 1341 347 UAGAAGCUGGUGGAAUGCAUGCAUUCCACCAGCUUCUA 5260 1963 348 CAUGGAAGAAAUAGUUGAAUUCAACUAUUUCUUCCAUG 5261 2362 349 UGAUAUUGGUGCCCAGGGAUCCCUGGGCACCAAUAUCA 5262 584 350 GGCAUGCAGAUCCCAUCUA UAGAUGGGAUCUGCAUGCC5263 1613 351 CGUACUGUCCUUCGGGCUG CAGCCCGAAGGACAGUACG 5264 1155 352UUACGACAGACUGCCUUCA UGAAGGCAGUCUGUCGUAA 5265 334 353 UAGUCACUGGCAGCAACAGCUGUUGCUGCCAGUGACUA 5266 1031 354 GCCAUUACAACUCUCCACAUGUGGAGAGUUGUAAUGGC 5267 1725 355 GCCUUCACUAUGGACUACCGGUAGUCCAUAGUGAAGGC 5268 2018 356 GUUCACAACCGAAUUGUUAUAACAAUUCGGUUGUGAAC 5269 914 357 GGGACCUUGCAUAACCUUU AAAGGUUAUGCAAGGUCCC5270 2264 358 AAGCCACAAGAUUACAAGA UCUUGUAAUCUUGUGGCUU 5271 343 359GCAGCAACAGUCUUACCUG CAGGUAAGACUGUUGCUGC 5272 1056 360UAUUACAUCAAGAAGGAGC GCUCCUUCUUGAUGUAAUA 5273 772 361 UAAUAAGGCUGCAGUUAUGCAUAACUGCAGCCUUAUUA 5274 763 362 GGUGGUGGUUAAUAAGGCU AGCCUUAUUAACCACCACC5275 628 363 UAAUGUCCAGCGUUUGGCU AGCCAAACGCUGGACAUUA 5276 399 364CUUCUCUGAGUGGUAAAGG CCUUUACCACUCAGAGAAG 5277 1682 365ACCAGCCGACACCAAGAAG CUUCUUGGUGUCGGCUGGU 5278 441 366 AUACCUCCCAAGUCCUGUAUACAGGACUUGGGAGGUAU 5279 1729 367 UCACUAUGGACUACCAGUUAACUGGUAGUCCAUAGUGA 5280 1902 368 AGGAUACCCAGCGCCGUACGUACGGCGCUGGGUAUCCU 5281 1637 369 AGGGAAGACAUCACUGAGCGCUCAGUGAUGUCUUCCCU 5282 2391 370 GAUAUCGCCAGGAUGAUCCGGAUCAUCCUGGCGAUAUC 5283 501 371 AAGUAGCUGAUAUUGAUGG CCAUCAAUAUCAGCUACUU5284 1358 372 CAAGCUUUAGGACUUCACC GGUGAAGUCCUAAAGCUUG 5285 1821 373CCCUUUGUCCCGCAAAUCA UGAUUUGCGGGACAAAGGG 5286 575 374 UUAGAUGAGGGCAUGCAGAUCUGCAUGCCCUCAUCUAA 5287 528 375 CAAUGACUCGAGCUCAGAG CUCUGAGCUCGAGUCAUUG5288 2433 376 GUGGAUAUGGCCAGGAUGC GCAUCCUGGCCAUAUCCAC 5289 1497 377GUUCAGAUGAUAUAAAUGU ACAUUUAUAUCAUCUGAAC 5290 2134 378UCAGGACAAGGAAGCUGCA UGCAGCUUCCUUGUCCUGA 5291 2160 379UUGAAGCUGAGGGAGCCAC GUGGCUCCCUCAGCUUCAA 5292 291 380 UGGAGUUGGACAUGGCCAUAUGGCCAUGUCCAACUCCA 5293 657 381 AGAUGCUGAAACAUGCAGU ACUGCAUGUUUCAGCAUCU5294 1575 382 UGAUGGUCUGCCAAGUGGG CCCACUUGGCAGACCAUCA 5295 667 383ACAUGCAGUUGUAAACUUG CAAGUUUACAACUGCAUGU 5296 2190 384CAGAGUUACUUCACUCUAG CUAGAGUGAAGUAACUCUG 5297 532 385 GACUCGAGCUCAGAGGGUAUACCCUCUGAGCUCGAGUC 5298 953 386 CUGGCCAUCUUUAAGUCUG CAGACUUAAAGAUGGCCAG5299 3188 387 UACGAUGCUUCAAGAGAAA UUUCUCUUGAAGCAUCGUA 5300 2301 388UGACCAGCUCUCUCUUCAG CUGAAGAGAGAGCUGGUCA 5301 2310 389CUCUCUUCAGAACAGAGCC GGCUCUGUUCUGAAGAGAG 5302 2287 390GCUUUCAGUUGAGCUGACC GGUCAGCUCAACUGAAAGC 5303 1927 391GGGUGGGACACAGCAGCAA UUGCUGCUGUGUCCCACCC 5304 712 392 UGCCACACGUGCAAUCCCUAGGGAUUGCACGUGUGGCA 5305 2121 393 UCUGUGAACUUGCUCAGGAUCCUGAGCAAGUUCACAGA 5306 2898 394 UGAGUAAUGGUGUAGAACAUGUUCUACACCAUUACUCA 5307 1799 395 GUUGGAUUGAUUCGAAAUCGAUUUCGAAUCAAUCCAAC 5308 1036 396 UACAACUCUCCACAACCUUAAGGUUGUGGAGAGUUGUA 5309 449 397 CAAGUCCUGUAUGAGUGGG CCCACUCAUACAGGACUUG5310 1452 398 AGGAAGGGAUGGAAGGUCU AGACCUUCCAUCCCUUCCU 5311 1203 399AGCUCAUCAUACUGGCUAG CUAGCCAGUAUGAUGAGCU 5312 1357 400GCAAGCUUUAGGACUUCAC GUGAAGUCCUAAAGCUUGC 5313 1512 401AUGUGGUCACCUGUGCAGC GCUGCACAGGUGACCACAU 5314 275 402 ACUCAAGCUGAUUUGAUGGCCAUCAAAUCAGCUUGAGU 5315 299 403 GACAUGGCCAUGGAACCAG CUGGUUCCAUGGCCAUGUC5316 1241 404 GUAAAUAUAAUGAGGACCU AGGUCCUCAUUAUAUUUAC 5317 1961 405CGCAUGGAAGAAAUAGUUG CAACUAUUUCUUCCAUGCG 5318 1436 406GAUGCUGCAACUAAACAGG CCUGUUUAGUUGCAGCAUC 5319 2469 407UGAUGGAACAUGAGAUGGG CCCAUCUCAUGUUCCAUCA 5320 760 408 CCAGGUGGUGGUUAAUAAGCUUAUUAACCACCACCUGG 5321 2257 409 UGAGGACAAGCCACAAGAUAUCUUGUGGCUUGUCCUCA 5322 952 410 ACUGGCCAUCUUUAAGUCU AGACUUAAAGAUGGCCAGU5323 2283 411 AACGGCUUUCAGUUGAGCU AGCUCAACUGAAAGCCGUU 5324 1794 412CUACUGUUGGAUUGAUUCG CGAAUCAAUCCAACAGUAG 5325 1745 413GUUGUGGUUAAGCUCUUAC GUAAGAGCUUAACCACAAC 5326 1211 414AUACUGGCUAGUGGUGGAC GUCCACCACUAGCCAGUAU 5327 2549 415GACCUCAUGGAUGGGCUGC GCAGCCCAUCCAUGAGGUC 5328 2007 416UAGCUCGGGAUGUUCACAA UUGUGAACAUCCCGAGCUA 5329 2474 417GAACAUGAGAUGGGUGGCC GGCCACCCAUCUCAUGUUC 5330 1712 418CAGAAUGCAGUUCGCCUUC GAAGGCGAACUGCAUUCUG 5331 1919 419ACGUCCAUGGGUGGGACAC GUGUCCCACCCAUGGACGU 5332 1000 420UGGUUCACCAGUGGAUUCU AGAAUCCACUGGUGAACCA 5333 2392 421AUAUCGCCAGGAUGAUCCU AGGAUCAUCCUGGCGAUAU 5334 1449 422AACAGGAAGGGAUGGAAGG CCUUCCAUCCCUUCCUGUU 5335 2294 423GUUGAGCUGACCAGCUCUC GAGAGCUGGUCAGCUCAAC 5336 1135 424AAAUGUUAAAUUCUUGGCU AGCCAAGAAUUUAACAUUU 5337 1333 425GGCUAUUGUAGAAGCUGGU ACCAGCUUCUACAAUAGCC 5338 1743 426CAGUUGUGGUUAAGCUCUU AAGAGCUUAACCACAACUG 5339 600 427 CUACACAGUUUGAUGCUGCGCAGCAUCAAACUGUGUAG 5340 970 428 UGGAGGCAUUCCUGCCCUG CAGGGCAGGAAUGCCUCCA5341 3137 429 GGACAGUUUACCAGUUGCC GGCAACUGGUAAACUGUCC 5342 372 430UCCAUUCUGGUGCCACUAC GUAGUGGCACCAGAAUGGA 5343 1761 431UACACCCACCAUCCCACUG CAGUGGGAUGGUGGGUGUA 5344 1650 432CUGAGCCUGCCAUCUGUGC GCACAGAUGGCAGGCUCAG 5345 972 433 GAGGCAUUCCUGCCCUGGUACCAGGGCAGGAAUGCCUC 5346 1147 434 CUUGGCUAUUACGACAGACGUCUGUCGUAAUAGCCAAG 5347 565 435 CCCUGAGACAUUAGAUGAG CUCAUCUAAUGUCUCAGGG5348 525 436 AUGCAAUGACUCGAGCUCA UGAGCUCGAGUCAUUGCAU 5349 1599 437UAGAGGCUCUUGUGCGUAC GUACGCACAAGAGCCUCUA 5350 2199 438UUCACUCUAGGAAUGAAGG CCUUCAUUCCUAGAGUGAA 5351 2261 439GACAAGCCACAAGAUUACA UGUAAUCUUGUGGCUUGUC 5352 705 440 CAGAACUUGCCACACGUGCGCACGUGUGGCAAGUUCUG 5353 916 441 GACCUUGCAUAACCUUUCC GGAAAGGUUAUGCAAGGUC5354 385 442 CACUACCACAGCUCCUUCU AGAAGGAGCUGUGGUAGUG 5355 3076 443CUAUUUGGGAUAUGUAUGG CCAUACAUAUCCCAAAUAG 5356 1396 444UCUUGUUCAGAACUGUCUU AAGACAGUUCUGAACAAGA 5357 2447 445GAUGCCUUGGGUAUGGACC GGUCCAUACCCAAGGCAUC 5358 1338 446UUGUAGAAGCUGGUGGAAU AUUCCACCAGCUUCUACAA 5359 2215 447AGGUGUGGCGACAUAUGCA UGCAUAUGUCGCCACACCU 5360 722 448 GCAAUCCCUGAACUGACAAUUGUCAGUUCAGGGAUUGC 5361 1316 449 UGCUCUAGUAAUAAGCCGGCCGGCUUAUUACUAGAGCA 5362 1687 450 CCGACACCAAGAAGCAGAGCUCUGCUUCUUGGUGUCGG 5363 697 451 AGAUGAUGCAGAACUUGCC GGCAAGUUCUGCAUCAUCU5364 2517 452 UUGAUGGGCUGCCAGAUCU AGAUCUGGCAGCCCAUCAA 5365 1685 453AGCCGACACCAAGAAGCAG CUGCUUCUUGGUGUCGGCU 5366 3090 454UAUGGGUAGGGUAAAUCAG CUGAUUUACCCUACCCAUA 5367 1205 455CUCAUCAUACUGGCUAGUG CACUAGCCAGUAUGAUGAG 5368 1153 456UAUUACGACAGACUGCCUU AAGGCAGUCUGUCGUAAUA 5369 723 457 CAAUCCCUGAACUGACAAAUUUGUCAGUUCAGGGAUUG 5370 1468 458 UCUCCUUGGGACUCUUGUUAACAAGAGUCCCAAGGAGA 5371 2480 459 GAGAUGGGUGGCCACCACCGGUGGUGGCCACCCAUCUC 5372 1856 460 CAGGGUGCCAUUCCACGACGUCGUGGAAUGGCACCCUG 5373 2193 461 AGUUACUUCACUCUAGGAAUUCCUAGAGUGAAGUAACU 5374 2355 462 UUGGACUUGAUAUUGGUGCGCACCAAUAUCAAGUCCAA 5375 1995 463 CCCUUCACAUCCUAGCUCGCGAGCUAGGAUGUGAAGGG 5376 821 464 AGACACGCUAUCAUGCGUU AACGCAUGAUAGCGUGUCU5377 1715 465 AAUGCAGUUCGCCUUCACU AGUGAAGGCGAACUGCAUU 5378 1182 466CUUAUGGCAACCAAGAAAG CUUUCUUGGUUGCCAUAAG 5379 445 467 CUCCCAAGUCCUGUAUGAGCUCAUACAGGACUUGGGAG 5380 1759 468 CUUACACCCACCAUCCCACGUGGGAUGGUGGGUGUAAG 5381 1461 469 UGGAAGGUCUCCUUGGGACGUCCCAAGGAGACCUUCCA 5382 1993 470 AGCCCUUCACAUCCUAGCUAGCUAGGAUGUGAAGGGCU 5383 2558 471 GAUGGGCUGCCUCCAGGUGCACCUGGAGGCAGCCCAUC 5384 1488 472 AGCUUCUGGGUUCAGAUGAUCAUCUGAACCCAGAAGCU 5385 1652 473 GAGCCUGCCAUCUGUGCUCGAGCACAGAUGGCAGGCUC 5386 963 474 UUAAGUCUGGAGGCAUUCC GGAAUGCCUCCAGACUUAA5387 1520 475 ACCUGUGCAGCUGGAAUUC GAAUUCCAGCUGCACAGGU 5388 1828 476UCCCGCAAAUCAUGCACCU AGGUGCAUGAUUUGCGGGA 5389 2214 477AAGGUGUGGCGACAUAUGC GCAUAUGUCGCCACACCUU 5390 2155 478AGCUAUUGAAGCUGAGGGA UCCCUCAGCUUCAAUAGCU 5391 332 479 GUUAGUCACUGGCAGCAACGUUGCUGCCAGUGACUAAC 5392 1878 480 UUCAGUUGCUUGUUCGUGCGCACGAACAAGCAACUGAA 5393 1573 481 GAUGAUGGUCUGCCAAGUGCACUUGGCAGACCAUCAUC 5394 1446 482 CUAAACAGGAAGGGAUGGAUCCAUCCCUUCCUGUUUAG 5395 1868 483 CCACGACUAGUUCAGUUGCGCAACUGAACUAGUCGUGG 5396 1873 484 ACUAGUUCAGUUGCUUGUUAACAAGCAACUGAACUAGU 5397 1002 485 GUUCACCAGUGGAUUCUGUACAGAAUCCACUGGUGAAC 5398 408 486 GUGGUAAAGGCAAUCCUGA UCAGGAUUGCCUUUACCAC5399 287 487 UUGAUGGAGUUGGACAUGG CCAUGUCCAACUCCAUCAA 5400 2128 488ACUUGCUCAGGACAAGGAA UUCCUUGUCCUGAGCAAGU 5401 2513 489CCAGUUGAUGGGCUGCCAG CUGGCAGCCCAUCAACUGG 5402 1196 490GAAAGCAAGCUCAUCAUAC GUAUGAUGAGCUUGCUUUC 5403 572 491 ACAUUAGAUGAGGGCAUGCGCAUGCCCUCAUCUAAUGU 5404 622 492 UCCCACUAAUGUCCAGCGU ACGCUGGACAUUAGUGGGA5405 1187 493 GGCAACCAAGAAAGCAAGC GCUUGCUUUCUUGGUUGCC 5406 1971 494AAAUAGUUGAAGGUUGUAC GUACAACCUUCAACUAUUU 5407 3083 495GGAUAUGUAUGGGUAGGGU ACCCUACCCAUACAUAUCC 5408 2944 496UAAUCUGAAUAAAGUGUAA UUACACUUUAUUCAGAUUA 5409 1894 497UGCACAUCAGGAUACCCAG CUGGGUAUCCUGAUGUGCA 5410 1323 498GUAAUAAGCCGGCUAUUGU ACAAUAGCCGGCUUAUUAC 5411 1202 499AAGCUCAUCAUACUGGCUA UAGCCAGUAUGAUGAGCUU 5412 718 500 ACGUGCAAUCCCUGAACUGCAGUUCAGGGAUUGCACGU 5413 1744 501 AGUUGUGGUUAAGCUCUUAUAAGAGCUUAACCACAACU 5414 756 502 AGGACCAGGUGGUGGUUAA UUAACCACCACCUGGUCCU5415 1317 503 GCUCUAGUAAUAAGCCGGC GCCGGCUUAUUACUAGAGC 5416 284 504GAUUUGAUGGAGUUGGACA UGUCCAACUCCAUCAAAUC 5417 886 505 UGAUGUAGAAACAGCUCGUACGAGCUGUUUCUACAUCA 5418 2430 506 CUGGUGGAUAUGGCCAGGAUCCUGGCCAUAUCCACCAG 5419 1207 507 CAUCAUACUGGCUAGUGGUACCACUAGCCAGUAUGAUG 5420 592 508 GAUCCCAUCUACACAGUUU AAACUGUGUAGAUGGGAUC5421 824 509 CACGCUAUCAUGCGUUCUC GAGAACGCAUGAUAGCGUG 5422 519 510GACAGUAUGCAAUGACUCG CGAGUCAUUGCAUACUGUC 5423 3166 511AAGUUGUUGUAACCUGCUG CAGCAGGUUACAACAACUU 5424 1151 512GCUAUUACGACAGACUGCC GGCAGUCUGUCGUAAUAGC 5425 2566 513GCCUCCAGGUGACAGCAAU AUUGCUGUCACCUGGAGGC 5426 453 514 UCCUGUAUGAGUGGGAACAUGUUCCCACUCAUACAGGA 5427 587 515 AUGCAGAUCCCAUCUACAC GUGUAGAUGGGAUCUGCAU5428 930 516 UUUCCCAUCAUCGUGAGGG CCCUCACGAUGAUGGGAAA 5429 1585 517CCAAGUGGGUGGUAUAGAG CUCUAUACCACCCACUUGG 5430 915 518 GGACCUUGCAUAACCUUUCGAAAGGUUAUGCAAGGUCC 5431 446 519 UCCCAAGUCCUGUAUGAGU ACUCAUACAGGACUUGGGA5432 1869 520 CACGACUAGUUCAGUUGCU AGCAACUGAACUAGUCGUG 5433 1960 521CCGCAUGGAAGAAAUAGUU AACUAUUUCUUCCAUGCGG 5434 1708 522GGCCCAGAAUGCAGUUCGC GCGAACUGCAUUCUGGGCC 5435 306 523 CCAUGGAACCAGACAGAAAUUUCUGUCUGGUUCCAUGG 5436 2281 524 GAAACGGCUUUCAGUUGAGCUCAACUGAAAGCCGUUUC 5437 3082 525 GGGAUAUGUAUGGGUAGGGCCCUACCCAUACAUAUCCC 5438 1473 526 UUGGGACUCUUGUUCAGCUAGCUGAACAAGAGUCCCAA 5439 559 527 UAUGUUCCCUGAGACAUUA UAAUGUCUCAGGGAACAUA5440 1416 528 GGACUCUCAGGAAUCUUUC GAAAGAUUCCUGAGAGUCC 5441 2145 529AAGCUGCAGAAGCUAUUGA UCAAUAGCUUCUGCAGCUU 5442 1994 530GCCCUUCACAUCCUAGCUC GAGCUAGGAUGUGAAGGGC 5443 1702 531AGAGAUGGCCCAGAAUGCA UGCAUUCUGGGCCAUCUCU 5444 417 532 GCAAUCCUGAGGAAGAGGAUCCUCUUCCUCAGGAUUGC 5445 2444 533 CAGGAUGCCUUGGGUAUGGCCAUACCCAAGGCAUCCUG 5446 555 534 CUGCUAUGUUCCCUGAGAC GUCUCAGGGAACAUAGCAG5447 2019 535 UUCACAACCGAAUUGUUAU AUAACAAUUCGGUUGUGAA 5448 1197 536AAAGCAAGCUCAUCAUACU AGUAUGAUGAGCUUGCUUU 5449 415 537 AGGCAAUCCUGAGGAAGAGCUCUUCCUCAGGAUUGCCU 5450 2061 538 UGUUUGUGCAGCUGCUUUAUAAAGCAGCUGCACAAACA 5451 1352 539 GGAAUGCAAGCUUUAGGACGUCCUAAAGCUUGCAUUCC 5452 1331 540 CCGGCUAUUGUAGAAGCUGCAGCUUCUACAAUAGCCGG 5453 1325 541 AAUAAGCCGGCUAUUGUAGCUACAAUAGCCGGCUUAUU 5454 1486 542 UCAGCUUCUGGGUUCAGAUAUCUGAACCCAGAAGCUGA 5455 454 543 CCUGUAUGAGUGGGAACAG CUGUUCCCACUCAUACAGG5456 490 544 CACUCAAGAACAAGUAGCU AGCUACUUGUUCUUGAGUG 5457 1996 545CCUUCACAUCCUAGCUCGG CCGAGCUAGGAUGUGAAGG 5458 1839 546AUGCACCUUUGCGUGAGCA UGCUCACGCAAAGGUGCAU 5459 1888 547UGUUCGUGCACAUCAGGAU AUCCUGAUGUGCACGAACA 5460 1879 548UCAGUUGCUUGUUCGUGCA UGCACGAACAAGCAACUGA 5461 1829 549CCCGCAAAUCAUGCACCUU AAGGUGCAUGAUUUGCGGG 5462 281 550 GCUGAUUUGAUGGAGUUGGCCAACUCCAUCAAAUCAGC 5463 1598 551 AUAGAGGCUCUUGUGCGUAUACGCACAAGAGCCUCUAU 5464 2135 552 CAGGACAAGGAAGCUGCAGCUGCAGCUUCCUUGUCCUG 5465 1755 553 AGCUCUUACACCCACCAUCGAUGGUGGGUGUAAGAGCU 5466 651 554 CAUCACAGAUGCUGAAACA UGUUUCAGCAUCUGUGAUG5467 1335 555 CUAUUGUAGAAGCUGGUGG CCACCAGCUUCUACAAUAG 5468 2541 556AUGCCCAGGACCUCAUGGA UCCAUGAGGUCCUGGGCAU 5469 531 557 UGACUCGAGCUCAGAGGGUACCCUCUGAGCUCGAGUCA 5470 606 558 AGUUUGAUGCUGCUCAUCC GGAUGAGCAGCAUCAAACU5471 1620 559 UCCUUCGGGCUGGUGACAG CUGUCACCAGCCCGAAGGA 5472 2211 560AUGAAGGUGUGGCGACAUA UAUGUCGCCACACCUUCAU 5473 2293 561AGUUGAGCUGACCAGCUCU AGAGCUGGUCAGCUCAACU 5474 455 562 CUGUAUGAGUGGGAACAGGCCUGUUCCCACUCAUACAG 5475 540 563 CUCAGAGGGUACGAGCUGC GCAGCUCGUACCCUCUGAG5476 416 564 GGCAAUCCUGAGGAAGAGG CCUCUUCCUCAGGAUUGCC 5477 1210 565CAUACUGGCUAGUGGUGGA UCCACCACUAGCCAGUAUG 5478 2262 566ACAAGCCACAAGAUUACAA UUGUAAUCUUGUGGCUUGU 5479 1604 567GCUCUUGUGCGUACUGUCC GGACAGUACGCACAAGAGC 5480 435 568 AUGUGGAUACCUCCCAAGUACUUGGGAGGUAUCCACAU 5481 2060 569 UUGUUUGUGCAGCUGCUUUAAAGCAGCUGCACAAACAA 5482 2225 570 ACAUAUGCAGCUGCUGUUUAAACAGCAGCUGCAUAUGU 5483 481 571 UCAGUCCUUCACUCAAGAA UUCUUGAGUGAAGGACUGA5484 917 572 ACCUUGCAUAACCUUUCCC GGGAAAGGUUAUGCAAGGU 5485 2221 573GGCGACAUAUGCAGCUGCU AGCAGCUGCAUAUGUCGCC 5486 849 574 UGGUGUCUGCUAUUGUACGCGUACAAUAGCAGACACCA 5487 562 575 GUUCCCUGAGACAUUAGAU AUCUAAUGUCUCAGGGAAC5488 1787 576 AUAAAGGCUACUGUUGGAU AUCCAACAGUAGCCUUUAU 5489 1860 577GUGCCAUUCCACGACUAGU ACUAGUCGUGGAAUGGCAC 5490 1590 578UGGGUGGUAUAGAGGCUCU AGAGCCUCUAUACCACCCA 5491 955 579 GGCCAUCUUUAAGUCUGGAUCCAGACUUAAAGAUGGCC 5492 2365 580 UAUUGGUGCCCAGGGAGAAUUCUCCCUGGGCACCAAUA 5493 534 581 CUCGAGCUCAGAGGGUACG CGUACCCUCUGAGCUCGAG5494 706 582 AGAACUUGCCACACGUGCA UGCACGUGUGGCAAGUUCU 5495 1740 583UACCAGUUGUGGUUAAGCU AGCUUAACCACAACUGGUA 5496 638 584 CGUUUGGCUGAACCAUCACGUGAUGGUUCAGCCAAACG 5497 1334 585 GCUAUUGUAGAAGCUGGUGCACCAGCUUCUACAAUAGC 5498 971 586 GGAGGCAUUCCUGCCCUGG CCAGGGCAGGAAUGCCUCC5499 2493 587 ACCACCCUGGUGCUGACUA UAGUCAGCACCAGGGUGGU 5500 1814 588AAUCUUGCCCUUUGUCCCG CGGGACAAAGGGCAAGAUU 5501 1088 589CGUUUAGCUGGUGGGCUGC GCAGCCCACCAGCUAAACG 5502 2292 590CAGUUGAGCUGACCAGCUC GAGCUGGUCAGCUCAACUG 5503 1504 591UGAUAUAAAUGUGGUCACC GGUGACCACAUUUAUAUCA 5504 404 592 CUGAGUGGUAAAGGCAAUCGAUUGCCUUUACCACUCAG 5505 1301 593 AAGGUGCUAUCUGUCUGCUAGCAGACAGAUAGCACCUU 5506 2004 594 UCCUAGCUCGGGAUGUUCAUGAACAUCCCGAGCUAGGA 5507 277 595 UCAAGCUGAUUUGAUGGAG CUCCAUCAAAUCAGCUUGA5508 2304 596 CCAGCUCUCUCUUCAGAAC GUUCUGAAGAGAGAGCUGG 5509 300 597ACAUGGCCAUGGAACCAGA UCUGGUUCCAUGGCCAUGU 5510 1906 598UACCCAGCGCCGUACGUCC GGACGUACGGCGCUGGGUA 5511 1973 599AUAGUUGAAGGUUGUACCG CGGUACAACCUUCAACUAU 5512 1360 600AGCUUUAGGACUUCACCUG CAGGUGAAGUCCUAAAGCU 5513 2094 601ACAUCCAAAGAGUAGCUGC GCAGCUACUCUUUGGAUGU 5514 920 602 UUGCAUAACCUUUCCCAUCGAUGGGAAAGGUUAUGCAA 5515 1707 603 UGGCCCAGAAUGCAGUUCGCGAACUGCAUUCUGGGCCA 5516 1808 604 AUUCGAAAUCUUGCCCUUUAAAGGGCAAGAUUUCGAAU 5517 1326 605 AUAAGCCGGCUAUUGUAGAUCUACAAUAGCCGGCUUAU 5518 1158 606 CGACAGACUGCCUUCAAAUAUUUGAAGGCAGUCUGUCG 5519 781 607 UGCAGUUAUGGUCCAUCAG CUGAUGGACCAUAACUGCA5520 607 608 GUUUGAUGCUGCUCAUCCC GGGAUGAGCAGCAUCAAAC 5521 627 609CUAAUGUCCAGCGUUUGGC GCCAAACGCUGGACAUUAG 5522 500 610 CAAGUAGCUGAUAUUGAUGCAUCAAUAUCAGCUACUUG 5523 2185 611 UCUGACAGAGUUACUUCACGUGAAGUAACUCUGUCAGA 5524 1592 612 GGUGGUAUAGAGGCUCUUGCAAGAGCCUCUAUACCACC 5525 758 613 GACCAGGUGGUGGUUAAUA UAUUAACCACCACCUGGUC5526 2551 614 CCUCAUGGAUGGGCUGCCU AGGCAGCCCAUCCAUGAGG 5527 1409 615UGUCUUUGGACUCUCAGGA UCCUGAGAGUCCAAAGACA 5528 497 616 GAACAAGUAGCUGAUAUUGCAAUAUCAGCUACUUGUUC 5529 381 617 GUGCCACUACCACAGCUCC GGAGCUGUGGUAGUGGCAC5530 1841 618 GCACCUUUGCGUGAGCAGG CCUGCUCACGCAAAGGUGC 5531 1368 619GACUUCACCUGACAGAUCC GGAUCUGUCAGGUGAAGUC 5532 2047 620AAAUACCAUUCCAUUGUUU AAACAAUGGAAUGGUAUUU 5533 492 621 CUCAAGAACAAGUAGCUGAUCAGCUACUUGUUCUUGAG 5534 2118 622 UCCUCUGUGAACUUGCUCAUGAGCAAGUUCACAGAGGA 5535 968 623 UCUGGAGGCAUUCCUGCCC GGGCAGGAAUGCCUCCAGA5536 965 624 AAGUCUGGAGGCAUUCCUG CAGGAAUGCCUCCAGACUU 5537 1977 625UUGAAGGUUGUACCGGAGC GCUCCGGUACAACCUUCAA 5538 2001 626ACAUCCUAGCUCGGGAUGU ACAUCCCGAGCUAGGAUGU 5539 1191 627ACCAAGAAAGCAAGCUCAU AUGAGCUUGCUUUCUUGGU 5540 640 628 UUUGGCUGAACCAUCACAGCUGUGAUGGUUCAGCCAAA 5541 715 629 CACACGUGCAAUCCCUGAA UUCAGGGAUUGCACGUGUG5542 1204 630 GCUCAUCAUACUGGCUAGU ACUAGCCAGUAUGAUGAGC 5543 3093 631GGGUAGGGUAAAUCAGUAA UUACUGAUUUACCCUACCC 5544 1371 632UUCACCUGACAGAUCCAAG CUUGGAUCUGUCAGGUGAA 5545 409 633 UGGUAAAGGCAAUCCUGAGCUCAGGAUUGCCUUUACCA 5546 2405 634 GAUCCUAGCUAUCGUUCUUAAGAACGAUAGCUAGGAUC 5547 1671 635 UUCGUCAUCUGACCAGCCGCGGCUGGUCAGAUGACGAA 5548 1427 636 AAUCUUUCAGAUGCUGCAAUUGCAGCAUCUGAAAGAUU 5549 1717 637 UGCAGUUCGCCUUCACUAUAUAGUGAAGGCGAACUGCA 5550 2400 638 AGGAUGAUCCUAGCUAUCGCGAUAGCUAGGAUCAUCCU 5551 2305 639 CAGCUCUCUCUUCAGAACAUGUUCUGAAGAGAGAGCUG 5552 1928 640 GGUGGGACACAGCAGCAAUAUUGCUGCUGUGUCCCACC 5553 2399 641 CAGGAUGAUCCUAGCUAUCGAUAGCUAGGAUCAUCCUG 5554 426 642 AGGAAGAGGAUGUGGAUAC GUAUCCACAUCCUCUUCCU5555 1309 643 AUCUGUCUGCUCUAGUAAU AUUACUAGAGCAGACAGAU 5556 925 644UAACCUUUCCCAUCAUCGU ACGAUGAUGGGAAAGGUUA 5557 2072 645CUGCUUUAUUCUCCCAUUG CAAUGGGAGAAUAAAGCAG 5558 2939 646AAUUGUAAUCUGAAUAAAG CUUUAUUCAGAUUACAAUU 5559 1480 647UCUUGUUCAGCUUCUGGGU ACCCAGAAGCUGAACAAGA 5560 1889 648GUUCGUGCACAUCAGGAUA UAUCCUGAUGUGCACGAAC 5561 699 649 AUGAUGCAGAACUUGCCACGUGGCAAGUUCUGCAUCAU 5562 506 650 GCUGAUAUUGAUGGACAGU ACUGUCCAUCAAUAUCAGC5563 1750 651 GGUUAAGCUCUUACACCCA UGGGUGUAAGAGCUUAACC 5564 1820 652GCCCUUUGUCCCGCAAAUC GAUUUGCGGGACAAAGGGC 5565 541 653 UCAGAGGGUACGAGCUGCUAGCAGCUCGUACCCUCUGA 5566 665 654 AAACAUGCAGUUGUAAACU AGUUUACAACUGCAUGUUU5567 1817 655 CUUGCCCUUUGUCCCGCAA UUGCGGGACAAAGGGCAAG 5568 2275 656UUACAAGAAACGGCUUUCA UGAAAGCCGUUUCUUGUAA 5569 2426 657CACUCUGGUGGAUAUGGCC GGCCAUAUCCACCAGAGUG 5570 958 658 CAUCUUUAAGUCUGGAGGCGCCUCCAGACUUAAAGAUG 5571 1657 659 UGCCAUCUGUGCUCUUCGUACGAAGAGCACAGAUGGCA 5572 1146 660 UCUUGGCUAUUACGACAGAUCUGUCGUAAUAGCCAAGA 5573 3078 661 AUUUGGGAUAUGUAUGGGUACCCAUACAUAUCCCAAAU 5574 1008 662 CAGUGGAUUCUGUGUUGUUAACAACACAGAAUCCACUG 5575 1621 663 CCUUCGGGCUGGUGACAGGCCUGUCACCAGCCCGAAGG 5576 1932 664 GGACACAGCAGCAAUUUGUACAAAUUGCUGCUGUGUCC 5577 1909 665 CCAGCGCCGUACGUCCAUGCAUGGACGUACGGCGCUGG 5578 2279 666 AAGAAACGGCUUUCAGUUGCAACUGAAAGCCGUUUCUU 5579 574 667 AUUAGAUGAGGGCAUGCAG CUGCAUGCCCUCAUCUAAU5580 2303 668 ACCAGCUCUCUCUUCAGAA UUCUGAAGAGAGAGCUGGU 5581 784 669AGUUAUGGUCCAUCAGCUU AAGCUGAUGGACCAUAACU 5582 2507 670GACUAUCCAGUUGAUGGGC GCCCAUCAACUGGAUAGUC 5583 995 671 AUGCUUGGUUCACCAGUGGCCACUGGUGAACCAAGCAU 5584 2006 672 CUAGCUCGGGAUGUUCACAUGUGAACAUCCCGAGCUAG 5585 1757 673 CUCUUACACCCACCAUCCCGGGAUGGUGGGUGUAAGAG 5586 2129 674 CUUGCUCAGGACAAGGAAGCUUCCUUGUCCUGAGCAAG 5587 2272 675 AGAUUACAAGAAACGGCUUAAGCCGUUUCUUGUAAUCU 5588 389 676 ACCACAGCUCCUUCUCUGA UCAGAGAAGGAGCUGUGGU5589 1435 677 AGAUGCUGCAACUAAACAG CUGUUUAGUUGCAGCAUCU 5590 1752 678UUAAGCUCUUACACCCACC GGUGGGUGUAAGAGCUUAA 5591 773 679 AAUAAGGCUGCAGUUAUGGCCAUAACUGCAGCCUUAUU 5592 3080 680 UUGGGAUAUGUAUGGGUAGCUACCCAUACAUAUCCCAA 5593 3174 681 GUAACCUGCUGUGAUACGAUCGUAUCACAGCAGGUUAC 5594 1578 682 UGGUCUGCCAAGUGGGUGGCCACCCACUUGGCAGACCA 5595 398 683 CCUUCUCUGAGUGGUAAAG CUUUACCACUCAGAGAAGG5596 2153 684 GAAGCUAUUGAAGCUGAGG CCUCAGCUUCAAUAGCUUC 5597 702 685AUGCAGAACUUGCCACACG CGUGUGGCAAGUUCUGCAU 5598 503 686 GUAGCUGAUAUUGAUGGACGUCCAUCAAUAUCAGCUAC 5599 276 687 CUCAAGCUGAUUUGAUGGA UCCAUCAAAUCAGCUUGAG5600 1962 688 GCAUGGAAGAAAUAGUUGA UCAACUAUUUCUUCCAUGC 5601 1347 689CUGGUGGAAUGCAAGCUUU AAAGCUUGCAUUCCACCAG 5602 2544 690CCCAGGACCUCAUGGAUGG CCAUCCAUGAGGUCCUGGG 5603 3079 691UUUGGGAUAUGUAUGGGUA UACCCAUACAUAUCCCAAA 5604 3164 692CAAAGUUGUUGUAACCUGC GCAGGUUACAACAACUUUG 5605 2026 693CCGAAUUGUUAUCAGAGGA UCCUCUGAUAACAAUUCGG 5606 2938 694UAAUUGUAAUCUGAAUAAA UUUAUUCAGAUUACAAUUA 5607 2940 695AUUGUAAUCUGAAUAAAGU ACUUUAUUCAGAUUACAAU 5608 2027 696CGAAUUGUUAUCAGAGGAC GUCCUCUGAUAACAAUUCG 5609 448 697 CCAAGUCCUGUAUGAGUGGCCACUCAUACAGGACUUGG 5610 1328 698 AAGCCGGCUAUUGUAGAAGCUUCUACAAUAGCCGGCUU 5611 2406 699 AUCCUAGCUAUCGUUCUUUAAAGAACGAUAGCUAGGAU 5612 924 700 AUAACCUUUCCCAUCAUCG CGAUGAUGGGAAAGGUUAU5613 1584 701 GCCAAGUGGGUGGUAUAGA UCUAUACCACCCACUUGGC 5614 1871 702CGACUAGUUCAGUUGCUUG CAAGCAACUGAACUAGUCG 5615 999 703 UUGGUUCACCAGUGGAUUCGAAUCCACUGGUGAACCAA 5616 1400 704 GUUCAGAACUGUCUUUGGAUCCAAAGACAGUUCUGAAC 5617 3180 705 UGCUGUGAUACGAUGCUUCGAAGCAUCGUAUCACAGCA 5618 2569 706 UCCAGGUGACAGCAAUCAGCUGAUUGCUGUCACCUGGA 5619 787 707 UAUGGUCCAUCAGCUUUCU AGAAAGCUGAUGGACCAUA5620 1861 708 UGCCAUUCCACGACUAGUU AACUAGUCGUGGAAUGGCA 5621 1190 709AACCAAGAAAGCAAGCUCA UGAGCUUGCUUUCUUGGUU 5622 1557 710AUAAUUAUAAGAACAAGAU AUCUUGUUCUUAUAAUUAU 5623 1751 711GUUAAGCUCUUACACCCAC GUGGGUGUAAGAGCUUAAC 5624 2897 712UUGAGUAAUGGUGUAGAAC GUUCUACACCAUUACUCAA 5625 2217 713GUGUGGCGACAUAUGCAGC GCUGCAUAUGUCGCCACAC 5626 2302 714GACCAGCUCUCUCUUCAGA UCUGAAGAGAGAGCUGGUC 5627 1984 715UUGUACCGGAGCCCUUCAC GUGAAGGGCUCCGGUACAA 5628 302 716 AUGGCCAUGGAACCAGACAUGUCUGGUUCCAUGGCCAU 5629 2431 717 UGGUGGAUAUGGCCAGGAUAUCCUGGCCAUAUCCACCA 5630 2183 718 CCUCUGACAGAGUUACUUCGAAGUAACUCUGUCAGAGG 5631 2403 719 AUGAUCCUAGCUAUCGUUCGAACGAUAGCUAGGAUCAU 5632 788 720 AUGGUCCAUCAGCUUUCUA UAGAAAGCUGAUGGACCAU5633 1476 721 GGACUCUUGUUCAGCUUCU AGAAGCUGAACAAGAGUCC 5634 827 722GCUAUCAUGCGUUCUCCUC GAGGAGAACGCAUGAUAGC 5635 2299 723GCUGACCAGCUCUCUCUUC GAAGAGAGAGCUGGUCAGC 5636 1891 724UCGUGCACAUCAGGAUACC GGUAUCCUGAUGUGCACGA 5637 2196 725UACUUCACUCUAGGAAUGA UCAUUCCUAGAGUGAAGUA 5638 663 726 UGAAACAUGCAGUUGUAAAUUUACAACUGCAUGUUUCA 5639 1028 727 UAUGCCAUUACAACUCUCCGGAGAGUUGUAAUGGCAUA 5640 2032 728 UGUUAUCAGAGGACUAAAUAUUUAGUCCUCUGAUAACA 5641 1459 729 GAUGGAAGGUCUCCUUGGGCCCAAGGAGACCUUCCAUC 5642 2095 730 CAUCCAAAGAGUAGCUGCAUGCAGCUACUCUUUGGAUG 5643 1686 731 GCCGACACCAAGAAGCAGAUCUGCUUCUUGGUGUCGGC 5644 1412 732 CUUUGGACUCUCAGGAAUCGAUUCCUGAGAGUCCAAAG 5645 2473 733 GGAACAUGAGAUGGGUGGCGCCACCCAUCUCAUGUUCC 5646 1080 734 UGGCAGUGCGUUUAGCUGGCCAGCUAAACGCACUGCCA 5647 2143 735 GGAAGCUGCAGAAGCUAUUAAUAGCUUCUGCAGCUUCC 5648 2203 736 CUCUAGGAAUGAAGGUGUGCACACCUUCAUUCCUAGAG 5649 548 737 GUACGAGCUGCUAUGUUCC GGAACAUAGCAGCUCGUAC5650 1867 738 UCCACGACUAGUUCAGUUG CAACUGAACUAGUCGUGGA 5651 842 739CCUCAGAUGGUGUCUGCUA UAGCAGACACCAUCUGAGG 5652 2120 740CUCUGUGAACUUGCUCAGG CCUGAGCAAGUUCACAGAG 5653 782 741 GCAGUUAUGGUCCAUCAGCGCUGAUGGACCAUAACUGC 5654 1758 742 UCUUACACCCACCAUCCCAUGGGAUGGUGGGUGUAAGA 5655 2396 743 CGCCAGGAUGAUCCUAGCUAGCUAGGAUCAUCCUGGCG 5656 1373 744 CACCUGACAGAUCCAAGUCGACUUGGAUCUGUCAGGUG 5657 1518 745 UCACCUGUGCAGCUGGAAUAUUCCAGCUGCACAGGUGA 5658 2557 746 GGAUGGGCUGCCUCCAGGUACCUGGAGGCAGCCCAUCC 5659 1987 747 UACCGGAGCCCUUCACAUCGAUGUGAAGGGCUCCGGUA 5660 568 748 UGAGACAUUAGAUGAGGGC GCCCUCAUCUAAUGUCUCA5661 2201 749 CACUCUAGGAAUGAAGGUG CACCUUCAUUCCUAGAGUG 5662 609 750UUGAUGCUGCUCAUCCCAC GUGGGAUGAGCAGCAUCAA 5663 400 751 UUCUCUGAGUGGUAAAGGCGCCUUUACCACUCAGAGAA 5664 331 752 UGUUAGUCACUGGCAGCAA UUGCUGCCAGUGACUAACA5665 1967 753 GAAGAAAUAGUUGAAGGUU AACCUUCAACUAUUUCUUC 5666 2198 754CUUCACUCUAGGAAUGAAG CUUCAUUCCUAGAGUGAAG 5667 1493 755CUGGGUUCAGAUGAUAUAA UUAUAUCAUCUGAACCCAG 5668 2260 756GGACAAGCCACAAGAUUAC GUAAUCUUGUGGCUUGUCC 5669 2496 757ACCCUGGUGCUGACUAUCC GGAUAGUCAGCACCAGGGU 5670 2361 758UUGAUAUUGGUGCCCAGGG CCCUGGGCACCAAUAUCAA 5671 443 759 ACCUCCCAAGUCCUGUAUGCAUACAGGACUUGGGAGGU 5672 523 760 GUAUGCAAUGACUCGAGCU AGCUCGAGUCAUUGCAUAC5673 1742 761 CCAGUUGUGGUUAAGCUCU AGAGCUUAACCACAACUGG 5674 530 762AUGACUCGAGCUCAGAGGG CCCUCUGAGCUCGAGUCAU 5675 3169 763UUGUUGUAACCUGCUGUGA UCACAGCAGGUUACAACAA 5676 1385 764CCAAGUCAACGUCUUGUUC GAACAAGACGUUGACUUGG 5677 2036 765AUCAGAGGACUAAAUACCA UGGUAUUUAGUCCUCUGAU 5678 3088 766UGUAUGGGUAGGGUAAAUC GAUUUACCCUACCCAUACA 5679 1850 767CGUGAGCAGGGUGCCAUUC GAAUGGCACCCUGCUCACG 5680 2518 768UGAUGGGCUGCCAGAUCUG CAGAUCUGGCAGCCCAUCA 5681 1886 769CUUGUUCGUGCACAUCAGG CCUGAUGUGCACGAACAAG 5682 650 770 CCAUCACAGAUGCUGAAACGUUUCAGCAUCUGUGAUGG 5683 3139 771 ACAGUUUACCAGUUGCCUUAAGGCAACUGGUAAACUGU 5684 2025 772 ACCGAAUUGUUAUCAGAGGCCUCUGAUAACAAUUCGGU 5685 1082 773 GCAGUGCGUUUAGCUGGUGCACCAGCUAAACGCACUGC 5686 2475 774 AACAUGAGAUGGGUGGCCAUGGCCACCCAUCUCAUGUU 5687 1375 775 CCUGACAGAUCCAAGUCAAUUGACUUGGAUCUGUCAGG 5688 2013 776 GGGAUGUUCACAACCGAAUAUUCGGUUGUGAACAUCCC 5689 1802 777 GGAUUGAUUCGAAAUCUUGCAAGAUUUCGAAUCAAUCC 5690 2144 778 GAAGCUGCAGAAGCUAUUGCAAUAGCUUCUGCAGCUUC 5691 529 779 AAUGACUCGAGCUCAGAGG CCUCUGAGCUCGAGUCAUU5692 1482 780 UUGUUCAGCUUCUGGGUUC GAACCCAGAAGCUGAACAA 5693 1546 781CCUCACUUGCAAUAAUUAU AUAAUUAUUGCAAGUGAGG 5694 845 782 CAGAUGGUGUCUGCUAUUGCAAUAGCAGACACCAUCUG 5695 487 783 CUUCACUCAAGAACAAGUA UACUUGUUCUUGAGUGAAG5696 652 784 AUCACAGAUGCUGAAACAU AUGUUUCAGCAUCUGUGAU 5697 1720 785AGUUCGCCUUCACUAUGGA UCCAUAGUGAAGGCGAACU 5698 951 786 UACUGGCCAUCUUUAAGUCGACUUAAAGAUGGCCAGUA 5699 1232 787 CAAGCUUUAGUAAAUAUAAUUAUAUUUACUAAAGCUUG 5700 2265 788 AGCCACAAGAUUACAAGAAUUCUUGUAAUCUUGUGGCU 5701 1698 789 AAGCAGAGAUGGCCCAGAAUUCUGGGCCAUCUCUGCUU 5702 701 790 GAUGCAGAACUUGCCACAC GUGUGGCAAGUUCUGCAUC5703 1428 791 AUCUUUCAGAUGCUGCAAC GUUGCAGCAUCUGAAAGAU 5704 1930 792UGGGACACAGCAGCAAUUU AAAUUGCUGCUGUGUCCCA 5705 1379 793ACAGAUCCAAGUCAACGUC GACGUUGACUUGGAUCUGU 5706 1936 794ACAGCAGCAAUUUGUGGAG CUCCACAAAUUGCUGCUGU 5707 1441 795UGCAACUAAACAGGAAGGG CCCUUCCUGUUUAGUUGCA 5708 2132 796GCUCAGGACAAGGAAGCUG CAGCUUCCUUGUCCUGAGC 5709 2043 797GACUAAAUACCAUUCCAUU AAUGGAAUGGUAUUUAGUC 5710 608 798 UUUGAUGCUGCUCAUCCCAUGGGAUGAGCAGCAUCAAA 5711 341 799 UGGCAGCAACAGUCUUACC GGUAAGACUGUUGCUGCCA5712 1194 800 AAGAAAGCAAGCUCAUCAU AUGAUGAGCUUGCUUUCUU 5713 2350 801UGAUCUUGGACUUGAUAUU AAUAUCAAGUCCAAGAUCA 5714 2948 802CUGAAUAAAGUGUAACAAU AUUGUUACACUUUAUUCAG 5715 2044 803ACUAAAUACCAUUCCAUUG CAAUGGAAUGGUAUUUAGU 5716 621 804 AUCCCACUAAUGUCCAGCGCGCUGGACAUUAGUGGGAU 5717 384 805 CCACUACCACAGCUCCUUC GAAGGAGCUGUGGUAGUGG5718 1898 806 CAUCAGGAUACCCAGCGCC GGCGCUGGGUAUCCUGAUG 5719 653 807UCACAGAUGCUGAAACAUG CAUGUUUCAGCAUCUGUGA 5720 1846 808UUUGCGUGAGCAGGGUGCC GGCACCCUGCUCACGCAAA 5721 2348 809GCUGAUCUUGGACUUGAUA UAUCAAGUCCAAGAUCAGC 5722 1150 810GGCUAUUACGACAGACUGC GCAGUCUGUCGUAAUAGCC 5723 298 811 GGACAUGGCCAUGGAACCAUGGUUCCAUGGCCAUGUCC 5724 1568 812 AACAAGAUGAUGGUCUGCCGGCAGACCAUCAUCUUGUU 5725 1058 813 UUACAUCAAGAAGGAGCUAUAGCUCCUUCUUGAUGUAA 5726 1835 814 AAUCAUGCACCUUUGCGUGCACGCAAAGGUGCAUGAUU 5727 1832 815 GCAAAUCAUGCACCUUUGCGCAAAGGUGCAUGAUUUGC 5728 406 816 GAGUGGUAAAGGCAAUCCU AGGAUUGCCUUUACCACUC5729 1723 817 UCGCCUUCACUAUGGACUA UAGUCCAUAGUGAAGGCGA 5730 371 818AUCCAUUCUGGUGCCACUA UAGUGGCACCAGAAUGGAU 5731 1899 819AUCAGGAUACCCAGCGCCG CGGCGCUGGGUAUCCUGAU 5732 522 820 AGUAUGCAAUGACUCGAGCGCUCGAGUCAUUGCAUACU 5733 2285 821 CGGCUUUCAGUUGAGCUGAUCAGCUCAACUGAAAGCCG 5734 779 822 GCUGCAGUUAUGGUCCAUC GAUGGACCAUAACUGCAGC5735 2896 823 AUUGAGUAAUGGUGUAGAA UUCUACACCAUUACUCAAU 5736 2943 824GUAAUCUGAAUAAAGUGUA UACACUUUAUUCAGAUUAC 5737 513 825 UUGAUGGACAGUAUGCAAUAUUGCAUACUGUCCAUCAA 5738 3084 826 GAUAUGUAUGGGUAGGGUAUACCCUACCCAUACAUAUC 5739 1567 827 GAACAAGAUGAUGGUCUGCGCAGACCAUCAUCUUGUUC 5740 2034 828 UUAUCAGAGGACUAAAUACGUAUUUAGUCCUCUGAUAA 5741 1003 829 UUCACCAGUGGAUUCUGUGCACAGAAUCCACUGGUGAA 5742 1980 830 AAGGUUGUACCGGAGCCCUAGGGCUCCGGUACAACCUU 5743 1340 831 GUAGAAGCUGGUGGAAUGCGCAUUCCACCAGCUUCUAC 5744 1437 832 AUGCUGCAACUAAACAGGAUCCUGUUUAGUUGCAGCAU 5745 2425 833 UCACUCUGGUGGAUAUGGCGCCAUAUCCACCAGAGUGA 5746 282 834 CUGAUUUGAUGGAGUUGGA UCCAACUCCAUCAAAUCAG5747 1206 835 UCAUCAUACUGGCUAGUGG CCACUAGCCAGUAUGAUGA 5748 1885 836GCUUGUUCGUGCACAUCAG CUGAUGUGCACGAACAAGC 5749 1314 837UCUGCUCUAGUAAUAAGCC GGCUUAUUACUAGAGCAGA 5750 1308 838UAUCUGUCUGCUCUAGUAA UUACUAGAGCAGACAGAUA 5751 1200 839GCAAGCUCAUCAUACUGGC GCCAGUAUGAUGAGCUUGC 5752 543 840 AGAGGGUACGAGCUGCUAUAUAGCAGCUCGUACCCUCU 5753 1609 841 UGUGCGUACUGUCCUUCGGCCGAAGGACAGUACGCACA 5754 1453 842 GGAAGGGAUGGAAGGUCUCGAGACCUUCCAUCCCUUCC 5755 833 843 AUGCGUUCUCCUCAGAUGG CCAUCUGAGGAGAACGCAU5756 2188 844 GACAGAGUUACUUCACUCU AGAGUGAAGUAACUCUGUC 5757 1148 845UUGGCUAUUACGACAGACU AGUCUGUCGUAAUAGCCAA 5758 1736 846GGACUACCAGUUGUGGUUA UAACCACAACUGGUAGUCC 5759 1401 847UUCAGAACUGUCUUUGGAC GUCCAAAGACAGUUCUGAA 5760 1677 848AUCUGACCAGCCGACACCA UGGUGUCGGCUGGUCAGAU 5761 1934 849ACACAGCAGCAAUUUGUGG CCACAAAUUGCUGCUGUGU 5762 388 850 UACCACAGCUCCUUCUCUGCAGAGAAGGAGCUGUGGUA 5763 1920 851 CGUCCAUGGGUGGGACACAUGUGUCCCACCCAUGGACG 5764 1747 852 UGUGGUUAAGCUCUUACACGUGUAAGAGCUUAACCACA 5765 861 853 UUGUACGUACCAUGCAGAA UUCUGCAUGGUACGUACAA5766 1904 854 GAUACCCAGCGCCGUACGU ACGUACGGCGCUGGGUAUC 5767 831 855UCAUGCGUUCUCCUCAGAU AUCUGAGGAGAACGCAUGA 5768 1895 856GCACAUCAGGAUACCCAGC GCUGGGUAUCCUGAUGUGC 5769 2273 857GAUUACAAGAAACGGCUUU AAAGCCGUUUCUUGUAAUC 5770 1738 858ACUACCAGUUGUGGUUAAG CUUAACCACAACUGGUAGU 5771 1395 859GUCUUGUUCAGAACUGUCU AGACAGUUCUGAACAAGAC 5772 1675 860UCAUCUGACCAGCCGACAC GUGUCGGCUGGUCAGAUGA 5773 1845 861CUUUGCGUGAGCAGGGUGC GCACCCUGCUCACGCAAAG 5774 1408 862CUGUCUUUGGACUCUCAGG CCUGAGAGUCCAAAGACAG 5775 1059 863UACAUCAAGAAGGAGCUAA UUAGCUCCUUCUUGAUGUA 5776 1381 864AGAUCCAAGUCAACGUCUU AAGACGUUGACUUGGAUCU 5777 1386 865CAAGUCAACGUCUUGUUCA UGAACAAGACGUUGACUUG 5778 1470 866UCCUUGGGACUCUUGUUCA UGAACAAGAGUCCCAAGGA 5779 1349 867GGUGGAAUGCAAGCUUUAG CUAAAGCUUGCAUUCCACC 5780 1440 868CUGCAACUAAACAGGAAGG CCUUCCUGUUUAGUUGCAG 5781 1364 869UUAGGACUUCACCUGACAG CUGUCAGGUGAAGUCCUAA 5782 502 870 AGUAGCUGAUAUUGAUGGAUCCAUCAAUAUCAGCUACU 5783 1246 871 UAUAAUGAGGACCUAUACUAGUAUAGGUCCUCAUUAUA 5784 3178 872 CCUGCUGUGAUACGAUGCUAGCAUCGUAUCACAGCAGG 5785 2483 873 AUGGGUGGCCACCACCCUGCAGGGUGGUGGCCACCCAU 5786 1417 874 GACUCUCAGGAAUCUUUCAUGAAAGAUUCCUGAGAGUC 5787 1893 875 GUGCACAUCAGGAUACCCAUGGGUAUCCUGAUGUGCAC 5788 817 876 UUCCAGACACGCUAUCAUG CAUGAUAGCGUGUCUGGAA5789 711 877 UUGCCACACGUGCAAUCCC GGGAUUGCACGUGUGGCAA 5790 1433 878UCAGAUGCUGCAACUAAAC GUUUAGUUGCAGCAUCUGA 5791 1362 879CUUUAGGACUUCACCUGAC GUCAGGUGAAGUCCUAAAG 5792 1838 880CAUGCACCUUUGCGUGAGC GCUCACGCAAAGGUGCAUG 5793 1037 881ACAACUCUCCACAACCUUU AAAGGUUGUGGAGAGUUGU 5794 1474 882UGGGACUCUUGUUCAGCUU AAGCUGAACAAGAGUCCCA 5795 997 883 GCUUGGUUCACCAGUGGAUAUCCACUGGUGAACCAAGC 5796 931 884 UUCCCAUCAUCGUGAGGGC GCCCUCACGAUGAUGGGAA5797 1313 885 GUCUGCUCUAGUAAUAAGC GCUUAUUACUAGAGCAGAC 5798 1487 886CAGCUUCUGGGUUCAGAUG CAUCUGAACCCAGAAGCUG 5799 1673 887CGUCAUCUGACCAGCCGAC GUCGGCUGGUCAGAUGACG 5800 561 888 UGUUCCCUGAGACAUUAGAUCUAAUGUCUCAGGGAACA 5801 1188 889 GCAACCAAGAAAGCAAGCUAGCUUGCUUUCUUGGUUGC 5802 292 890 GGAGUUGGACAUGGCCAUG CAUGGCCAUGUCCAACUCC5803 1958 891 GUCCGCAUGGAAGAAAUAG CUAUUUCUUCCAUGCGGAC 5804 2349 892CUGAUCUUGGACUUGAUAU AUAUCAAGUCCAAGAUCAG 5805 1460 893AUGGAAGGUCUCCUUGGGA UCCCAAGGAGACCUUCCAU 5806 1576 894GAUGGUCUGCCAAGUGGGU ACCCACUUGGCAGACCAUC 5807 690 895 ACUAUCAAGAUGAUGCAGAUCUGCAUCAUCUUGAUAGU 5808 655 896 ACAGAUGCUGAAACAUGCA UGCAUGUUUCAGCAUCUGU5809 2290 897 UUCAGUUGAGCUGACCAGC GCUGGUCAGCUCAACUGAA 5810 1600 898AGAGGCUCUUGUGCGUACU AGUACGCACAAGAGCCUCU 5811 2432 899GGUGGAUAUGGCCAGGAUG CAUCCUGGCCAUAUCCACC 5812 710 900 CUUGCCACACGUGCAAUCCGGAUUGCACGUGUGGCAAG 5813 1714 901 GAAUGCAGUUCGCCUUCACGUGAAGGCGAACUGCAUUC 5814 2005 902 CCUAGCUCGGGAUGUUCACGUGAACAUCCCGAGCUAGG 5815 1728 903 UUCACUAUGGACUACCAGUACUGGUAGUCCAUAGUGAA 5816 2482 904 GAUGGGUGGCCACCACCCUAGGGUGGUGGCCACCCAUC 5817 768 905 UGGUUAAUAAGGCUGCAGU ACUGCAGCCUUAUUAACCA5818 693 906 AUCAAGAUGAUGCAGAACU AGUUCUGCAUCAUCUUGAU 5819 3179 907CUGCUGUGAUACGAUGCUU AAGCAUCGUAUCACAGCAG 5820 2448 908AUGCCUUGGGUAUGGACCC GGGUCCAUACCCAAGGCAU 5821 3183 909UGUGAUACGAUGCUUCAAG CUUGAAGCAUCGUAUCACA 5822 1293 910GAGUGCUGAAGGUGCUAUC GAUAGCACCUUCAGCACUC 5823 544 911 GAGGGUACGAGCUGCUAUGCAUAGCAGCUCGUACCCUC 5824 2937 912 UUAAUUGUAAUCUGAAUAAUUAUUCAGAUUACAAUUAA 5825 1691 913 CACCAAGAAGCAGAGAUGGCCAUCUCUGCUUCUUGGUG 5826 1353 914 GAAUGCAAGCUUUAGGACUAGUCCUAAAGCUUGCAUUC 5827 1843 915 ACCUUUGCGUGAGCAGGGUACCCUGCUCACGCAAAGGU 5828 1302 916 AGGUGCUAUCUGUCUGCUCGAGCAGACAGAUAGCACCU 5829 2130 917 UUGCUCAGGACAAGGAAGCGCUUCCUUGUCCUGAGCAA 5830 2165 918 GCUGAGGGAGCCACAGCUCGAGCUGUGGCUCCCUCAGC 5831 387 919 CUACCACAGCUCCUUCUCU AGAGAAGGAGCUGUGGUAG5832 2472 920 UGGAACAUGAGAUGGGUGG CCACCCAUCUCAUGUUCCA 5833 857 921GCUAUUGUACGUACCAUGC GCAUGGUACGUACAAUAGC 5834 1816 922UCUUGCCCUUUGUCCCGCA UGCGGGACAAAGGGCAAGA 5835 1561 923UUAUAAGAACAAGAUGAUG CAUCAUCUUGUUCUUAUAA 5836 811 924 GGAAGCUUCCAGACACGCUAGCGUGUCUGGAAGCUUCC 5837 1327 925 UAAGCCGGCUAUUGUAGAAUUCUACAAUAGCCGGCUUA 5838 757 926 GGACCAGGUGGUGGUUAAU AUUAACCACCACCUGGUCC5839 507 927 CUGAUAUUGAUGGACAGUA UACUGUCCAUCAAUAUCAG 5840 3092 928UGGGUAGGGUAAAUCAGUA UACUGAUUUACCCUACCCA 5841 2359 929ACUUGAUAUUGGUGCCCAG CUGGGCACCAAUAUCAAGU 5842 1753 930UAAGCUCUUACACCCACCA UGGUGGGUGUAAGAGCUUA 5843 273 931 CUACUCAAGCUGAUUUGAUAUCAAAUCAGCUUGAGUAG 5844 1859 932 GGUGCCAUUCCACGACUAGCUAGUCGUGGAAUGGCACC 5845 296 933 UUGGACAUGGCCAUGGAAC GUUCCAUGGCCAUGUCCAA5846 615 934 CUGCUCAUCCCACUAAUGU ACAUUAGUGGGAUGAGCAG 5847 301 935CAUGGCCAUGGAACCAGAC GUCUGGUUCCAUGGCCAUG 5848 1184 936UAUGGCAACCAAGAAAGCA UGCUUUCUUGGUUGCCAUA 5849 1006 937ACCAGUGGAUUCUGUGUUG CAACACAGAAUCCACUGGU 5850 2189 938ACAGAGUUACUUCACUCUA UAGAGUGAAGUAACUCUGU 5851 1365 939UAGGACUUCACCUGACAGA UCUGUCAGGUGAAGUCCUA 5852 2442 940GCCAGGAUGCCUUGGGUAU AUACCCAAGGCAUCCUGGC 5853 1249 941AAUGAGGACCUAUACUUAC GUAAGUAUAGGUCCUCAUU 5854 1144 942AUUCUUGGCUAUUACGACA UGUCGUAAUAGCCAAGAAU 5855 2075 943CUUUAUUCUCCCAUUGAAA UUUCAAUGGGAGAAUAAAG 5856 504 944 UAGCUGAUAUUGAUGGACAUGUCCAUCAAUAUCAGCUA 5857 1405 945 GAACUGUCUUUGGACUCUCGAGAGUCCAAAGACAGUUC 5858 333 946 UUAGUCACUGGCAGCAACA UGUUGCUGCCAGUGACUAA5859 1032 947 CCAUUACAACUCUCCACAA UUGUGGAGAGUUGUAAUGG 5860 1748 948GUGGUUAAGCUCUUACACC GGUGUAAGAGCUUAACCAC 5861 283 949 UGAUUUGAUGGAGUUGGACGUCCAACUCCAUCAAAUCA 5862 1700 950 GCAGAGAUGGCCCAGAAUGCAUUCUGGGCCAUCUCUGC 5863 1445 951 ACUAAACAGGAAGGGAUGGCCAUCCCUUCCUGUUUAGU 5864 1133 952 ACAAAUGUUAAAUUCUUGGCCAAGAAUUUAACAUUUGU 5865 527 953 GCAAUGACUCGAGCUCAGA UCUGAGCUCGAGUCAUUGC5866 2010 954 CUCGGGAUGUUCACAACCG CGGUUGUGAACAUCCCGAG 5867 851 955GUGUCUGCUAUUGUACGUA UACGUACAAUAGCAGACAC 5868 436 956 UGUGGAUACCUCCCAAGUCGACUUGGGAGGUAUCCACA 5869 2446 957 GGAUGCCUUGGGUAUGGACGUCCAUACCCAAGGCAUCC 5870 1142 958 AAAUUCUUGGCUAUUACGAUCGUAAUAGCCAAGAAUUU 5871 549 959 UACGAGCUGCUAUGUUCCC GGGAACAUAGCAGCUCGUA5872 1083 960 CAGUGCGUUUAGCUGGUGG CCACCAGCUAAACGCACUG 5873 695 961CAAGAUGAUGCAGAACUUG CAAGUUCUGCAUCAUCUUG 5874 885 962 AUGAUGUAGAAACAGCUCGCGAGCUGUUUCUACAUCAU 5875 2067 963 UGCAGCUGCUUUAUUCUCCGGAGAAUAAAGCAGCUGCA 5876 390 964 CCACAGCUCCUUCUCUGAG CUCAGAGAAGGAGCUGUGG5877 1719 965 CAGUUCGCCUUCACUAUGG CCAUAGUGAAGGCGAACUG 5878 813 966AAGCUUCCAGACACGCUAU AUAGCGUGUCUGGAAGCUU 5879 2289 967UUUCAGUUGAGCUGACCAG CUGGUCAGCUCAACUGAAA 5880 377 968 UCUGGUGCCACUACCACAGCUGUGGUAGUGGCACCAGA 5881 826 969 CGCUAUCAUGCGUUCUCCU AGGAGAACGCAUGAUAGCG5882 1634 970 GACAGGGAAGACAUCACUG CAGUGAUGUCUUCCCUGUC 5883 1208 971AUCAUACUGGCUAGUGGUG CACCACUAGCCAGUAUGAU 5884 1628 972GCUGGUGACAGGGAAGACA UGUCUUCCCUGUCACCAGC 5885 2003 973AUCCUAGCUCGGGAUGUUC GAACAUCCCGAGCUAGGAU 5886 452 974 GUCCUGUAUGAGUGGGAACGUUCCCACUCAUACAGGAC 5887 3081 975 UGGGAUAUGUAUGGGUAGGCCUACCCAUACAUAUCCCA 5888 2354 976 CUUGGACUUGAUAUUGGUGCACCAAUAUCAAGUCCAAG 5889 1822 977 CCUUUGUCCCGCAAAUCAUAUGAUUUGCGGGACAAAGG 5890 1299 978 UGAAGGUGCUAUCUGUCUGCAGACAGAUAGCACCUUCA 5891 486 979 CCUUCACUCAAGAACAAGU ACUUGUUCUUGAGUGAAGG5892 1463 980 GAAGGUCUCCUUGGGACUC GAGUCCCAAGGAGACCUUC 5893 2280 981AGAAACGGCUUUCAGUUGA UCAACUGAAAGCCGUUUCU 5894 1907 982ACCCAGCGCCGUACGUCCA UGGACGUACGGCGCUGGGU 5895 923 983 CAUAACCUUUCCCAUCAUCGAUGAUGGGAAAGGUUAUG 5896 1979 984 GAAGGUUGUACCGGAGCCCGGGCUCCGGUACAACCUUC 5897 1827 985 GUCCCGCAAAUCAUGCACCGGUGCAUGAUUUGCGGGAC 5898 1201 986 CAAGCUCAUCAUACUGGCUAGCCAGUAUGAUGAGCUUG 5899 1913 987 CGCCGUACGUCCAUGGGUGCACCCAUGGACGUACGGCG 5900 2191 988 AGAGUUACUUCACUCUAGGCCUAGAGUGAAGUAACUCU 5901 295 989 GUUGGACAUGGCCAUGGAA UUCCAUGGCCAUGUCCAAC5902 1149 990 UGGCUAUUACGACAGACUG CAGUCUGUCGUAAUAGCCA 5903 533 991ACUCGAGCUCAGAGGGUAC GUACCCUCUGAGCUCGAGU 5904 604 992 ACAGUUUGAUGCUGCUCAUAUGAGCAGCAUCAAACUGU 5905 766 993 GGUGGUUAAUAAGGCUGCA UGCAGCCUUAUUAACCACC5906 1823 994 CUUUGUCCCGCAAAUCAUG CAUGAUUUGCGGGACAAAG 5907 2048 995AAUACCAUUCCAUUGUUUG CAAACAAUGGAAUGGUAUU 5908 714 996 CCACACGUGCAAUCCCUGAUCAGGGAUUGCACGUGUGG 5909 2439 997 AUGGCCAGGAUGCCUUGGGCCCAAGGCAUCCUGGCCAU 5910 1903 998 GGAUACCCAGCGCCGUACGCGUACGGCGCUGGGUAUCC 5911 2395 999 UCGCCAGGAUGAUCCUAGCGCUAGGAUCAUCCUGGCGA 5912 789 1000 UGGUCCAUCAGCUUUCUAAUUAGAAAGCUGAUGGACCA 5913 3085 1001 AUAUGUAUGGGUAGGGUAAUUACCCUACCCAUACAUAU 5914 1710 1002 CCCAGAAUGCAGUUCGCCUAGGCGAACUGCAUUCUGGG 5915 1336 1003 UAUUGUAGAAGCUGGUGGAUCCACCAGCUUCUACAAUA 5916 3089 1004 GUAUGGGUAGGGUAAAUCAUGAUUUACCCUACCCAUAC 5917 2351 1005 GAUCUUGGACUUGAUAUUGCAAUAUCAAGUCCAAGAUC 5918 716 1006 ACACGUGCAAUCCCUGAACGUUCAGGGAUUGCACGUGU 5919 1911 1007 AGCGCCGUACGUCCAUGGGCCCAUGGACGUACGGCGCU 5920 1985 1008 UGUACCGGAGCCCUUCACAUGUGAAGGGCUCCGGUACA 5921 2516 1009 GUUGAUGGGCUGCCAGAUCGAUCUGGCAGCCCAUCAAC 5922 1762 1010 ACACCCACCAUCCCACUGGCCAGUGGGAUGGUGGGUGU 5923 1156 1011 UACGACAGACUGCCUUCAAUUGAAGGCAGUCUGUCGUA 5924 1887 1012 UUGUUCGUGCACAUCAGGAUCCUGAUGUGCACGAACAA 5925 1833 1013 CAAAUCAUGCACCUUUGCGCGCAAAGGUGCAUGAUUUG 5926 967 1014 GUCUGGAGGCAUUCCUGCCGGCAGGAAUGCCUCCAGAC 5927 1730 1015 CACUAUGGACUACCAGUUGCAACUGGUAGUCCAUAGUG 5928 829 1016 UAUCAUGCGUUCUCCUCAGCUGAGGAGAACGCAUGAUA 5929 890 1017 GUAGAAACAGCUCGUUGUAUACAACGAGCUGUUUCUAC 5930 2181 1018 CUCCUCUGACAGAGUUACUAGUAACUCUGUCAGAGGAG 5931 2131 1019 UGCUCAGGACAAGGAAGCUAGCUUCCUUGUCCUGAGCA 5932 1586 1020 CAAGUGGGUGGUAUAGAGGCCUCUAUACCACCCACUUG 5933 765 1021 UGGUGGUUAAUAAGGCUGCGCAGCCUUAUUAACCACCA 5934 1369 1022 ACUUCACCUGACAGAUCCAUGGAUCUGUCAGGUGAAGU 5935 1724 1023 CGCCUUCACUAUGGACUACGUAGUCCAUAGUGAAGGCG 5936 834 1024 UGCGUUCUCCUCAGAUGGUACCAUCUGAGGAGAACGCA 5937 1983 1025 GUUGUACCGGAGCCCUUCAUGAAGGGCUCCGGUACAAC 5938 1688 1026 CGACACCAAGAAGCAGAGAUCUCUGCUUCUUGGUGUCG 5939 1004 1027 UCACCAGUGGAUUCUGUGUACACAGAAUCCACUGGUGA 5940 1631 1028 GGUGACAGGGAAGACAUCAUGAUGUCUUCCCUGUCACC 5941 1319 1029 UCUAGUAAUAAGCCGGCUAUAGCCGGCUUAUUACUAGA 5942 767 1030 GUGGUUAAUAAGGCUGCAGCUGCAGCCUUAUUAACCAC 5943 841 1031 UCCUCAGAUGGUGUCUGCUAGCAGACACCAUCUGAGGA 5944 516 1032 AUGGACAGUAUGCAAUGACGUCAUUGCAUACUGUCCAU 5945 1848 1033 UGCGUGAGCAGGGUGCCAUAUGGCACCCUGCUCACGCA 5946 2202 1034 ACUCUAGGAAUGAAGGUGUACACCUUCAUUCCUAGAGU 5947 571 1035 GACAUUAGAUGAGGGCAUGCAUGCCCUCAUCUAAUGUC 5948 1629 1036 CUGGUGACAGGGAAGACAUAUGUCUUCCCUGUCACCAG 5949 1806 1037 UGAUUCGAAAUCUUGCCCUAGGGCAAGAUUUCGAAUCA 5950 1756 1038 GCUCUUACACCCACCAUCCGGAUGGUGGGUGUAAGAGC 5951 1619 1039 GUCCUUCGGGCUGGUGACAUGUCACCAGCCCGAAGGAC 5952 1610 1040 GUGCGUACUGUCCUUCGGGCCCGAAGGACAGUACGCAC 5953 2500 1041 UGGUGCUGACUAUCCAGUUAACUGGAUAGUCAGCACCA 5954 2156 1042 GCUAUUGAAGCUGAGGGAGCUCCCUCAGCUUCAAUAGC 5955 1189 1043 CAACCAAGAAAGCAAGCUCGAGCUUGCUUUCUUGGUUG 5956 2066 1044 GUGCAGCUGCUUUAUUCUCGAGAAUAAAGCAGCUGCAC 5957 1307 1045 CUAUCUGUCUGCUCUAGUAUACUAGAGCAGACAGAUAG 5958 1448 1046 AAACAGGAAGGGAUGGAAGCUUCCAUCCCUUCCUGUUU 5959 1213 1047 ACUGGCUAGUGGUGGACCCGGGUCCACCACUAGCCAGU 5960 2119 1048 CCUCUGUGAACUUGCUCAGCUGAGCAAGUUCACAGAGG 5961 889 1049 UGUAGAAACAGCUCGUUGUACAACGAGCUGUUUCUACA 5962 1376 1050 CUGACAGAUCCAAGUCAACGUUGACUUGGAUCUGUCAG 5963 427 1051 GGAAGAGGAUGUGGAUACCGGUAUCCACAUCCUCUUCC 5964 649 1052 ACCAUCACAGAUGCUGAAAUUUCAGCAUCUGUGAUGGU 5965 1915 1053 CCGUACGUCCAUGGGUGGGCCCACCCAUGGACGUACGG 5966 2053 1054 CAUUCCAUUGUUUGUGCAGCUGCACAAACAAUGGAAUG 5967 2568 1055 CUCCAGGUGACAGCAAUCAUGAUUGCUGUCACCUGGAG 5968 1739 1056 CUACCAGUUGUGGUUAAGCGCUUAACCACAACUGGUAG 5969 1746 1057 UUGUGGUUAAGCUCUUACAUGUAAGAGCUUAACCACAA 5970 1321 1058 UAGUAAUAAGCCGGCUAUUAAUAGCCGGCUUAUUACUA 5971 482 1059 CAGUCCUUCACUCAAGAACGUUCUUGAGUGAAGGACUG 5972 280 1060 AGCUGAUUUGAUGGAGUUGCAACUCCAUCAAAUCAGCU 5973 1465 1061 AGGUCUCCUUGGGACUCUUAAGAGUCCCAAGGAGACCU 5974 1731 1062 ACUAUGGACUACCAGUUGUACAACUGGUAGUCCAUAGU 5975 1937 1063 CAGCAGCAAUUUGUGGAGGCCUCCACAAAUUGCUGCUG 5976 1892 1064 CGUGCACAUCAGGAUACCCGGGUAUCCUGAUGUGCACG 5977 836 1065 CGUUCUCCUCAGAUGGUGUACACCAUCUGAGGAGAACG 5978 521 1066 CAGUAUGCAAUGACUCGAGCUCGAGUCAUUGCAUACUG 5979 1595 1067 GGUAUAGAGGCUCUUGUGCGCACAAGAGCCUCUAUACC 5980 2511 1068 AUCCAGUUGAUGGGCUGCCGGCAGCCCAUCAACUGGAU 5981 1583 1069 UGCCAAGUGGGUGGUAUAGCUAUACCACCCACUUGGCA 5982 1897 1070 ACAUCAGGAUACCCAGCGCGCGCUGGGUAUCCUGAUGU 5983 956 1071 GCCAUCUUUAAGUCUGGAGCUCCAGACUUAAAGAUGGC 5984 926 1072 AACCUUUCCCAUCAUCGUGCACGAUGAUGGGAAAGGUU 5985 1874 1073 CUAGUUCAGUUGCUUGUUCGAACAAGCAACUGAACUAG 5986 488 1074 UUCACUCAAGAACAAGUAGCUACUUGUUCUUGAGUGAA 5987 1695 1075 AAGAAGCAGAGAUGGCCCAUGGGCCAUCUCUGCUUCUU 5988 2182 1076 UCCUCUGACAGAGUUACUUAAGUAACUCUGUCAGAGGA 5989 2029 1077 AAUUGUUAUCAGAGGACUAUAGUCCUCUGAUAACAAUU 5990 479 1078 UCUCAGUCCUUCACUCAAGCUUGAGUGAAGGACUGAGA 5991 818 1079 UCCAGACACGCUAUCAUGCGCAUGAUAGCGUGUCUGGA 5992 625 1080 CACUAAUGUCCAGCGUUUGCAAACGCUGGACAUUAGUG 5993 3172 1081 UUGUAACCUGCUGUGAUACGUAUCACAGCAGGUUACAA 5994 1490 1082 CUUCUGGGUUCAGAUGAUAUAUCAUCUGAACCCAGAAG 5995 1914 1083 GCCGUACGUCCAUGGGUGGCCACCCAUGGACGUACGGC 5996 1974 1084 UAGUUGAAGGUUGUACCGGCCGGUACAACCUUCAACUA 5997 2258 1085 GAGGACAAGCCACAAGAUUAAUCUUGUGGCUUGUCCUC 5998 2170 1086 GGGAGCCACAGCUCCUCUGCAGAGGAGCUGUGGCUCCC 5999 1370 1087 CUUCACCUGACAGAUCCAAUUGGAUCUGUCAGGUGAAG 6000 1429 1088 UCUUUCAGAUGCUGCAACUAGUUGCAGCAUCUGAAAGA 6001 3173 1089 UGUAACCUGCUGUGAUACGCGUAUCACAGCAGGUUACA 6002 444 1090 CCUCCCAAGUCCUGUAUGAUCAUACAGGACUUGGGAGG 6003 1081 1091 GGCAGUGCGUUUAGCUGGUACCAGCUAAACGCACUGCC 6004 1318 1092 CUCUAGUAAUAAGCCGGCUAGCCGGCUUAUUACUAGAG 6005 329 1093 GCUGUUAGUCACUGGCAGCGCUGCCAGUGACUAACAGC 6006 1389 1094 GUCAACGUCUUGUUCAGAAUUCUGAACAAGACGUUGAC 6007 428 1095 GAAGAGGAUGUGGAUACCUAGGUAUCCACAUCCUCUUC 6008 3175 1096 UAACCUGCUGUGAUACGAUAUCGUAUCACAGCAGGUUA 6009 3117 1097 GUUAUUUGGAACCUUGUUUAAACAAGGUUCCAAAUAAC 6010 2020 1098 UCACAACCGAAUUGUUAUCGAUAACAAUUCGGUUGUGA 6011 1625 1099 CGGGCUGGUGACAGGGAAGCUUCCCUGUCACCAGCCCG 6012 2022 1100 ACAACCGAAUUGUUAUCAGCUGAUAACAAUUCGGUUGU 6013 624 1101 CCACUAAUGUCCAGCGUUUAAACGCUGGACAUUAGUGG 6014 1648 1102 CACUGAGCCUGCCAUCUGUACAGAUGGCAGGCUCAGUG 6015 790 1103 GGUCCAUCAGCUUUCUAAAUUUAGAAAGCUGAUGGACC 6016 3160 1104 AUCCCAAAGUUGUUGUAACGUUACAACAACUUUGGGAU 6017 1251 1105 UGAGGACCUAUACUUACGAUCGUAAGUAUAGGUCCUCA 6018 2253 1106 UGUCUGAGGACAAGCCACAUGUGGCUUGUCCUCAGACA 6019 2515 1107 AGUUGAUGGGCUGCCAGAUAUCUGGCAGCCCAUCAACU 6020 1680 1108 UGACCAGCCGACACCAAGAUCUUGGUGUCGGCUGGUCA 6021 2169 1109 AGGGAGCCACAGCUCCUCUAGAGGAGCUGUGGCUCCCU 6022 3165 1110 AAAGUUGUUGUAACCUGCUAGCAGGUUACAACAACUUU 6023 780 1111 CUGCAGUUAUGGUCCAUCAUGAUGGACCAUAACUGCAG 6024 1978 1112 UGAAGGUUGUACCGGAGCCGGCUCCGGUACAACCUUCA 6025 563 1113 UUCCCUGAGACAUUAGAUGCAUCUAAUGUCUCAGGGAA 6026 1622 1114 CUUCGGGCUGGUGACAGGGCCCUGUCACCAGCCCGAAG 6027 2295 1115 UUGAGCUGACCAGCUCUCUAGAGAGCUGGUCAGCUCAA 6028 2126 1116 GAACUUGCUCAGGACAAGGCCUUGUCCUGAGCAAGUUC 6029 1683 1117 CCAGCCGACACCAAGAAGCGCUUCUUGGUGUCGGCUGG 6030 1857 1118 AGGGUGCCAUUCCACGACUAGUCGUGGAAUGGCACCCU 6031 2064 1119 UUGUGCAGCUGCUUUAUUCGAAUAAAGCAGCUGCACAA 6032 489 1120 UCACUCAAGAACAAGUAGCGCUACUUGUUCUUGAGUGA 6033 1346 1121 GCUGGUGGAAUGCAAGCUUAAGCUUGCAUUCCACCAGC 6034 1442 1122 GCAACUAAACAGGAAGGGAUCCCUUCCUGUUUAGUUGC 6035 1981 1123 AGGUUGUACCGGAGCCCUUAAGGGCUCCGGUACAACCU 6036 777 1124 AGGCUGCAGUUAUGGUCCAUGGACCAUAACUGCAGCCU 6037 589 1125 GCAGAUCCCAUCUACACAGCUGUGUAGAUGGGAUCUGC 6038 2205 1126 CUAGGAAUGAAGGUGUGGCGCCACACCUUCAUUCCUAG 6039 394 1127 AGCUCCUUCUCUGAGUGGUACCACUCAGAGAAGGAGCU 6040 1035 1128 UUACAACUCUCCACAACCUAGGUUGUGGAGAGUUGUAA 6041 410 1129 GGUAAAGGCAAUCCUGAGGCCUCAGGAUUGCCUUUACC 6042 1721 1130 GUUCGCCUUCACUAUGGACGUCCAUAGUGAAGGCGAAC 6043 1134 1131 CAAAUGUUAAAUUCUUGGCGCCAAGAAUUUAACAUUUG 6044 3182 1132 CUGUGAUACGAUGCUUCAAUUGAAGCAUCGUAUCACAG 6045 881 1133 ACAAAUGAUGUAGAAACAGCUGUUUCUACAUCAUUUGU 6046 547 1134 GGUACGAGCUGCUAUGUUCGAACAUAGCAGCUCGUACC 6047 2028 1135 GAAUUGUUAUCAGAGGACUAGUCCUCUGAUAACAAUUC 6048 2023 1136 CAACCGAAUUGUUAUCAGAUCUGAUAACAAUUCGGUUG 6049 3184 1137 GUGAUACGAUGCUUCAAGAUCUUGAAGCAUCGUAUCAC 6050 413 1138 AAAGGCAAUCCUGAGGAAGCUUCCUCAGGAUUGCCUUU 6051 2178 1139 CAGCUCCUCUGACAGAGUUAACUCUGUCAGAGGAGCUG 6052 1577 1140 AUGGUCUGCCAAGUGGGUGCACCCACUUGGCAGACCAU 6053 1793 1141 GCUACUGUUGGAUUGAUUCGAAUCAAUCCAACAGUAGC 6054 526 1142 UGCAAUGACUCGAGCUCAGCUGAGCUCGAGUCAUUGCA 6055 2358 1143 GACUUGAUAUUGGUGCCCAUGGGCACCAAUAUCAAGUC 6056 1403 1144 CAGAACUGUCUUUGGACUCGAGUCCAAAGACAGUUCUG 6057 1875 1145 UAGUUCAGUUGCUUGUUCGCGAACAAGCAACUGAACUA 6058 1160 1146 ACAGACUGCCUUCAAAUUUAAAUUUGAAGGCAGUCUGU 6059 1591 1147 GGGUGGUAUAGAGGCUCUUAAGAGCCUCUAUACCACCC 6060 1734 1148 AUGGACUACCAGUUGUGGUACCACAACUGGUAGUCCAU 6061 2030 1149 AUUGUUAUCAGAGGACUAAUUAGUCCUCUGAUAACAAU 6062 775 1150 UAAGGCUGCAGUUAUGGUCGACCAUAACUGCAGCCUUA 6063 1813 1151 AAAUCUUGCCCUUUGUCCCGGGACAAAGGGCAAGAUUU 6064 1938 1152 AGCAGCAAUUUGUGGAGGGCCCUCCACAAAUUGCUGCU 6065 2039 1153 AGAGGACUAAAUACCAUUCGAAUGGUAUUUAGUCCUCU 6066 1297 1154 GCUGAAGGUGCUAUCUGUCGACAGAUAGCACCUUCAGC 6067 456 1155 UGUAUGAGUGGGAACAGGGCCCUGUUCCCACUCAUACA 6068 590 1156 CAGAUCCCAUCUACACAGUACUGUGUAGAUGGGAUCUG 6069 1933 1157 GACACAGCAGCAAUUUGUGCACAAAUUGCUGCUGUGUC 6070 583 1158 GGGCAUGCAGAUCCCAUCUAGAUGGGAUCUGCAUGCCC 6071 2540 1159 CAUGCCCAGGACCUCAUGGCCAUGAGGUCCUGGGCAUG 6072 2162 1160 GAAGCUGAGGGAGCCACAGCUGUGGCUCCCUCAGCUUC 6073 330 1161 CUGUUAGUCACUGGCAGCAUGCUGCCAGUGACUAACAG 6074 1481 1162 CUUGUUCAGCUUCUGGGUUAACCCAGAAGCUGAACAAG 6075 1344 1163 AAGCUGGUGGAAUGCAAGCGCUUGCAUUCCACCAGCUU 6076 431 1164 GAGGAUGUGGAUACCUCCCGGGAGGUAUCCACAUCCUC 6077 1508 1165 AUAAAUGUGGUCACCUGUGCACAGGUGACCACAUUUAU 6078 1918 1166 UACGUCCAUGGGUGGGACAUGUCCCACCCAUGGACGUA 6079 289 1167 GAUGGAGUUGGACAUGGCCGGCCAUGUCCAACUCCAUC 6080 631 1168 UGUCCAGCGUUUGGCUGAAUUCAGCCAAACGCUGGACA 6081 1853 1169 GAGCAGGGUGCCAUUCCACGUGGAAUGGCACCCUGCUC 6082 1243 1170 AAAUAUAAUGAGGACCUAUAUAGGUCCUCAUUAUAUUU 6083 1212 1171 UACUGGCUAGUGGUGGACCGGUCCACCACUAGCCAGUA 6084 996 1172 UGCUUGGUUCACCAGUGGAUCCACUGGUGAACCAAGCA 6085 2256 1173 CUGAGGACAAGCCACAAGAUCUUGUGGCUUGUCCUCAG 6086 1607 1174 CUUGUGCGUACUGUCCUUCGAAGGACAGUACGCACAAG 6087 3116 1175 UGUUAUUUGGAACCUUGUUAACAAGGUUCCAAAUAACA 6088 1179 1176 UAGCUUAUGGCAACCAAGAUCUUGGUUGCCAUAAGCUA 6089 3185 1177 UGAUACGAUGCUUCAAGAGCUCUUGAAGCAUCGUAUCA 6090 1594 1178 UGGUAUAGAGGCUCUUGUGCACAAGAGCCUCUAUACCA 6091 887 1179 GAUGUAGAAACAGCUCGUUAACGAGCUGUUUCUACAUC 6092 928 1180 CCUUUCCCAUCAUCGUGAGCUCACGAUGAUGGGAAAGG 6093 835 1181 GCGUUCUCCUCAGAUGGUGCACCAUCUGAGGAGAACGC 6094 1900 1182 UCAGGAUACCCAGCGCCGUACGGCGCUGGGUAUCCUGA 6095 2284 1183 ACGGCUUUCAGUUGAGCUGCAGCUCAACUGAAAGCCGU 6096 1976 1184 GUUGAAGGUUGUACCGGAGCUCCGGUACAACCUUCAAC 6097 2393 1185 UAUCGCCAGGAUGAUCCUAUAGGAUCAUCCUGGCGAUA 6098 1295 1186 GUGCUGAAGGUGCUAUCUGCAGAUAGCACCUUCAGCAC 6099 1410 1187 GUCUUUGGACUCUCAGGAAUUCCUGAGAGUCCAAAGAC 6100 1457 1188 GGGAUGGAAGGUCUCCUUGCAAGGAGACCUUCCAUCCC 6101 2296 1189 UGAGCUGACCAGCUCUCUCGAGAGAGCUGGUCAGCUCA 6102 929 1190 CUUUCCCAUCAUCGUGAGGCCUCACGAUGAUGGGAAAG 6103 1359 1191 AAGCUUUAGGACUUCACCUAGGUGAAGUCCUAAAGCUU 6104 1351 1192 UGGAAUGCAAGCUUUAGGAUCCUAAAGCUUGCAUUCCA 6105 969 1193 CUGGAGGCAUUCCUGCCCUAGGGCAGGAAUGCCUCCAG 6106 1876 1194 AGUUCAGUUGCUUGUUCGUACGAACAAGCAACUGAACU 6107 552 1195 GAGCUGCUAUGUUCCCUGAUCAGGGAACAUAGCAGCUC 6108 2441 1196 GGCCAGGAUGCCUUGGGUAUACCCAAGGCAUCCUGGCC 6109 2402 1197 GAUGAUCCUAGCUAUCGUUAACGAUAGCUAGGAUCAUC 6110 1803 1198 GAUUGAUUCGAAAUCUUGCGCAAGAUUUCGAAUCAAUC 6111 1701 1199 CAGAGAUGGCCCAGAAUGCGCAUUCUGGGCCAUCUCUG 6112 1910 1200 CAGCGCCGUACGUCCAUGGCCAUGGACGUACGGCGCUG 6113 888 1201 AUGUAGAAACAGCUCGUUGCAACGAGCUGUUUCUACAU 6114 1294 1202 AGUGCUGAAGGUGCUAUCUAGAUAGCACCUUCAGCACU 6115 1737 1203 GACUACCAGUUGUGGUUAAUUAACCACAACUGGUAGUC 6116 1450 1204 ACAGGAAGGGAUGGAAGGUACCUUCCAUCCCUUCCUGU 6117 761 1205 CAGGUGGUGGUUAAUAAGGCCUUAUUAACCACCACCUG 6118 776 1206 AAGGCUGCAGUUAUGGUCCGGACCAUAACUGCAGCCUU 6119 1509 1207 UAAAUGUGGUCACCUGUGCGCACAGGUGACCACAUUUA 6120 1788 1208 UAAAGGCUACUGUUGGAUUAAUCCAACAGUAGCCUUUA 6121 515 1209 GAUGGACAGUAUGCAAUGAUCAUUGCAUACUGUCCAUC 6122 1491 1210 UUCUGGGUUCAGAUGAUAUAUAUCAUCUGAACCCAGAA 6123 1614 1211 GUACUGUCCUUCGGGCUGGCCAGCCCGAAGGACAGUAC 6124 998 1212 CUUGGUUCACCAGUGGAUUAAUCCACUGGUGAACCAAG 6125 2158 1213 UAUUGAAGCUGAGGGAGCCGGCUCCCUCAGCUUCAAUA 6126 3168 1214 GUUGUUGUAACCUGCUGUGCACAGCAGGUUACAACAAC 6127 1854 1215 AGCAGGGUGCCAUUCCACGCGUGGAAUGGCACCCUGCU 6128 2117 1216 GUCCUCUGUGAACUUGCUCGAGCAAGUUCACAGAGGAC 6129 1678 1217 UCUGACCAGCCGACACCAAUUGGUGUCGGCUGGUCAGA 6130 305 1218 GCCAUGGAACCAGACAGAAUUCUGUCUGGUUCCAUGGC 6131 2154 1219 AAGCUAUUGAAGCUGAGGGCCCUCAGCUUCAAUAGCUU 6132 1807 1220 GAUUCGAAAUCUUGCCCUUAAGGGCAAGAUUUCGAAUC 6133 1881 1221 AGUUGCUUGUUCGUGCACAUGUGCACGAACAAGCAACU 6134 1565 1222 AAGAACAAGAUGAUGGUCUAGACCAUCAUCUUGUUCUU 6135 407 1223 AGUGGUAAAGGCAAUCCUGCAGGAUUGCCUUUACCACU 6136 1434 1224 CAGAUGCUGCAACUAAACAUGUUUAGUUGCAGCAUCUG 6137 566 1225 CCUGAGACAUUAGAUGAGGCCUCAUCUAAUGUCUCAGG 6138 3161 1226 UCCCAAAGUUGUUGUAACCGGUUACAACAACUUUGGGA 6139 1679 1227 CUGACCAGCCGACACCAAGCUUGGUGUCGGCUGGUCAG 6140 2096 1228 AUCCAAAGAGUAGCUGCAGCUGCAGCUACUCUUUGGAU 6141 630 1229 AUGUCCAGCGUUUGGCUGAUCAGCCAAACGCUGGACAU 6142 1606 1230 UCUUGUGCGUACUGUCCUUAAGGACAGUACGCACAAGA 6143 432 1231 AGGAUGUGGAUACCUCCCAUGGGAGGUAUCCACAUCCU 6144 778 1232 GGCUGCAGUUAUGGUCCAUAUGGACCAUAACUGCAGCC 6145 1999 1233 UCACAUCCUAGCUCGGGAUAUCCCGAGCUAGGAUGUGA 6146 1692 1234 ACCAAGAAGCAGAGAUGGCGCCAUCUCUGCUUCUUGGU 6147 2490 1235 GCCACCACCCUGGUGCUGAUCAGCACCAGGGUGGUGGC 6148 623 1236 CCCACUAAUGUCCAGCGUUAACGCUGGACAUUAGUGGG 6149 339 1237 ACUGGCAGCAACAGUCUUAUAAGACUGUUGCUGCCAGU 6150 2946 1238 AUCUGAAUAAAGUGUAACAUGUUACACUUUAUUCAGAU 6151 1654 1239 GCCUGCCAUCUGUGCUCUUAAGAGCACAGAUGGCAGGC 6152 1033 1240 CAUUACAACUCUCCACAACGUUGUGGAGAGUUGUAAUG 6153 840 1241 CUCCUCAGAUGGUGUCUGCGCAGACACCAUCUGAGGAG 6154 1880 1242 CAGUUGCUUGUUCGUGCACGUGCACGAACAAGCAACUG 6155 420 1243 AUCCUGAGGAAGAGGAUGUACAUCCUCUUCCUCAGGAU 6156 1005 1244 CACCAGUGGAUUCUGUGUUAACACAGAAUCCACUGGUG 6157 1193 1245 CAAGAAAGCAAGCUCAUCAUGAUGAGCUUGCUUUCUUG 6158 919 1246 CUUGCAUAACCUUUCCCAUAUGGGAAAGGUUAUGCAAG 6159 1727 1247 CUUCACUAUGGACUACCAGCUGGUAGUCCAUAGUGAAG 6160 1883 1248 UUGCUUGUUCGUGCACAUCGAUGUGCACGAACAAGCAA 6161 859 1249 UAUUGUACGUACCAUGCAGCUGCAUGGUACGUACAAUA 6162 1812 1250 GAAAUCUUGCCCUUUGUCCGGACAAAGGGCAAGAUUUC 6163 1605 1251 CUCUUGUGCGUACUGUCCUAGGACAGUACGCACAAGAG 6164 2021 1252 CACAACCGAAUUGUUAUCAUGAUAACAAUUCGGUUGUG 6165 2180 1253 GCUCCUCUGACAGAGUUACGUAACUCUGUCAGAGGAGC 6166 636 1254 AGCGUUUGGCUGAACCAUCGAUGGUUCAGCCAAACGCU 6167 2282 1255 AAACGGCUUUCAGUUGAGCGCUCAACUGAAAGCCGUUU 6168 1824 1256 UUUGUCCCGCAAAUCAUGCGCAUGAUUUGCGGGACAAA 6169 2204 1257 UCUAGGAAUGAAGGUGUGGCCACACCUUCAUUCCUAGA 6170 450 1258 AAGUCCUGUAUGAGUGGGAUCCCACUCAUACAGGACUU 6171 1001 1259 GGUUCACCAGUGGAUUCUGCAGAAUCCACUGGUGAACC 6172 1579 1260 GGUCUGCCAAGUGGGUGGUACCACCCACUUGGCAGACC 6173 2179 1261 AGCUCCUCUGACAGAGUUAUAACUCUGUCAGAGGAGCU 6174 376 1262 UUCUGGUGCCACUACCACAUGUGGUAGUGGCACCAGAA 6175 556 1263 UGCUAUGUUCCCUGAGACAUGUCUCAGGGAACAUAGCA 6176 1804 1264 AUUGAUUCGAAAUCUUGCCGGCAAGAUUUCGAAUCAAU 6177 2552 1265 CUCAUGGAUGGGCUGCCUCGAGGCAGCCCAUCCAUGAG 6178 2071 1266 GCUGCUUUAUUCUCCCAUUAAUGGGAGAAUAAAGCAGC 6179 1836 1267 AUCAUGCACCUUUGCGUGAUCACGCAAAGGUGCAUGAU 6180 336 1268 GUCACUGGCAGCAACAGUCGACUGUUGCUGCCAGUGAC 6181 460 1269 UGAGUGGGAACAGGGAUUUAAAUCCCUGUUCCCACUCA 6182 1559 1270 AAUUAUAAGAACAAGAUGAUCAUCUUGUUCUUAUAAUU 6183 3136 1271 UGGACAGUUUACCAGUUGCGCAACUGGUAAACUGUCCA 6184 1250 1272 AUGAGGACCUAUACUUACGCGUAAGUAUAGGUCCUCAU 6185 1462 1273 GGAAGGUCUCCUUGGGACUAGUCCCAAGGAGACCUUCC 6186 1965 1274 UGGAAGAAAUAGUUGAAGGCCUUCAACUAUUUCUUCCA 6187 3114 1275 GGUGUUAUUUGGAACCUUGCAAGGUUCCAAAUAACACC 6188 1665 1276 GUGCUCUUCGUCAUCUGACGUCAGAUGACGAAGAGCAC 6189 304 1277 GGCCAUGGAACCAGACAGAUCUGUCUGGUUCCAUGGCC 6190 327 1278 CGGCUGUUAGUCACUGGCAUGCCAGUGACUAACAGCCG 6191 1866 1279 UUCCACGACUAGUUCAGUUAACUGAACUAGUCGUGGAA 6192 1699 1280 AGCAGAGAUGGCCCAGAAUAUUCUGGGCCAUCUCUGCU 6193 2397 1281 GCCAGGAUGAUCCUAGCUAUAGCUAGGAUCAUCCUGGC 6194 1658 1282 GCCAUCUGUGCUCUUCGUCGACGAAGAGCACAGAUGGC 6195 891 1283 UAGAAACAGCUCGUUGUACGUACAACGAGCUGUUUCUA 6196 1572 1284 AGAUGAUGGUCUGCCAAGUACUUGGCAGACCAUCAUCU 6197 927 1285 ACCUUUCCCAUCAUCGUGAUCACGAUGAUGGGAAAGGU 6198 290 1286 AUGGAGUUGGACAUGGCCAUGGCCAUGUCCAACUCCAU 6199 1663 1287 CUGUGCUCUUCGUCAUCUGCAGAUGACGAAGAGCACAG 6200 1562 1288 UAUAAGAACAAGAUGAUGGCCAUCAUCUUGUUCUUAUA 6201 2947 1289 UCUGAAUAAAGUGUAACAAUUGUUACACUUUAUUCAGA 6202 1711 1290 CCAGAAUGCAGUUCGCCUUAAGGCGAACUGCAUUCUGG 6203 1566 1291 AGAACAAGAUGAUGGUCUGCAGACCAUCAUCUUGUUCU 6204 1815 1292 AUCUUGCCCUUUGUCCCGCGCGGGACAAAGGGCAAGAU 6205 1087 1293 GCGUUUAGCUGGUGGGCUGCAGCCCACCAGCUAAACGC 6206 1495 1294 GGGUUCAGAUGAUAUAAAUAUUUAUAUCAUCUGAACCC 6207 1363 1295 UUUAGGACUUCACCUGACAUGUCAGGUGAAGUCCUAAA 6208 391 1296 CACAGCUCCUUCUCUGAGUACUCAGAGAAGGAGCUGUG 6209 1392 1297 AACGUCUUGUUCAGAACUGCAGUUCUGAACAAGACGUU 6210 1935 1298 CACAGCAGCAAUUUGUGGAUCCACAAAUUGCUGCUGUG 6211 1872 1299 GACUAGUUCAGUUGCUUGUACAAGCAACUGAACUAGUC 6212 1159 1300 GACAGACUGCCUUCAAAUUAAUUUGAAGGCAGUCUGUC 6213 2308 1301 CUCUCUCUUCAGAACAGAGCUCUGUUCUGAAGAGAGAG 6214 632 1302 GUCCAGCGUUUGGCUGAACGUUCAGCCAAACGCUGGAC 6215 1564 1303 UAAGAACAAGAUGAUGGUCGACCAUCAUCUUGUUCUUA 6216 1384 1304 UCCAAGUCAACGUCUUGUUAACAAGACGUUGACUUGGA 6217 1690 1305 ACACCAAGAAGCAGAGAUGCAUCUCUGCUUCUUGGUGU 6218 1421 1306 CUCAGGAAUCUUUCAGAUGCAUCUGAAAGAUUCCUGAG 6219 1141 1307 UAAAUUCUUGGCUAUUACGCGUAAUAGCCAAGAAUUUA 6220 1732 1308 CUAUGGACUACCAGUUGUGCACAACUGGUAGUCCAUAG 6221 634 1309 CCAGCGUUUGGCUGAACCAUGGUUCAGCCAAACGCUGG 6222 932 1310 UCCCAUCAUCGUGAGGGCUAGCCCUCACGAUGAUGGGA 6223 1366 1311 AGGACUUCACCUGACAGAUAUCUGUCAGGUGAAGUCCU 6224 1608 1312 UUGUGCGUACUGUCCUUCGCGAAGGACAGUACGCACAA 6225 1923 1313 CCAUGGGUGGGACACAGCAUGCUGUGUCCCACCCAUGG 6226 1458 1314 GGAUGGAAGGUCUCCUUGGCCAAGGAGACCUUCCAUCC 6227 1908 1315 CCCAGCGCCGUACGUCCAUAUGGACGUACGGCGCUGGG 6228 539 1316 GCUCAGAGGGUACGAGCUGCAGCUCGUACCCUCUGAGC 6229 2016 1317 AUGUUCACAACCGAAUUGUACAAUUCGGUUGUGAACAU 6230 1884 1318 UGCUUGUUCGUGCACAUCAUGAUGUGCACGAACAAGCA 6231 560 1319 AUGUUCCCUGAGACAUUAGCUAAUGUCUCAGGGAACAU 6232 411 1320 GUAAAGGCAAUCCUGAGGAUCCUCAGGAUUGCCUUUAC 6233 338 1321 CACUGGCAGCAACAGUCUUAAGACUGUUGCUGCCAGUG 6234 830 1322 AUCAUGCGUUCUCCUCAGAUCUGAGGAGAACGCAUGAU 6235 3086 1323 UAUGUAUGGGUAGGGUAAAUUUACCCUACCCAUACAUA 6236 3115 1324 GUGUUAUUUGGAACCUUGUACAAGGUUCCAAAUAACAC 6237 2177 1325 ACAGCUCCUCUGACAGAGUACUCUGUCAGAGGAGCUGU 6238 1733 1326 UAUGGACUACCAGUUGUGGCCACAACUGGUAGUCCAUA 6239 375 1327 AUUCUGGUGCCACUACCACGUGGUAGUGGCACCAGAAU 6240 2565 1328 UGCCUCCAGGUGACAGCAAUUGCUGUCACCUGGAGGCA 6241 442 1329 UACCUCCCAAGUCCUGUAUAUACAGGACUUGGGAGGUA 6242 819 1330 CCAGACACGCUAUCAUGCGCGCAUGAUAGCGUGUCUGG 6243 700 1331 UGAUGCAGAACUUGCCACAUGUGGCAAGUUCUGCAUCA 6244 1089 1332 GUUUAGCUGGUGGGCUGCAUGCAGCCCACCAGCUAAAC 6245 1580 1333 GUCUGCCAAGUGGGUGGUAUACCACCCACUUGGCAGAC 6246 1982 1334 GGUUGUACCGGAGCCCUUCGAAGGGCUCCGGUACAACC 6247 1986 1335 GUACCGGAGCCCUUCACAUAUGUGAAGGGCUCCGGUAC 6248 418 1336 CAAUCCUGAGGAAGAGGAUAUCCUCUUCCUCAGGAUUG 6249 1306 1337 GCUAUCUGUCUGCUCUAGUACUAGAGCAGACAGAUAGC 6250 1377 1338 UGACAGAUCCAAGUCAACGCGUUGACUUGGAUCUGUCA 6251 2467 1339 CAUGAUGGAACAUGAGAUGCAUCUCAUGUUCCAUCAUG 6252 1414 1340 UUGGACUCUCAGGAAUCUUAAGAUUCCUGAGAGUCCAA 6253 1668 1341 CUCUUCGUCAUCUGACCAGCUGGUCAGAUGACGAAGAG 6254 1818 1342 UUGCCCUUUGUCCCGCAAAUUUGCGGGACAAAGGGCAA 6255 1697 1343 GAAGCAGAGAUGGCCCAGAUCUGGGCCAUCUCUGCUUC 6256 918 1344 CCUUGCAUAACCUUUCCCAUGGGAAAGGUUAUGCAAGG 6257 605 1345 CAGUUUGAUGCUGCUCAUCGAUGAGCAGCAUCAAACUG 6258 1374 1346 ACCUGACAGAUCCAAGUCAUGACUUGGAUCUGUCAGGU 6259 1430 1347 CUUUCAGAUGCUGCAACUAUAGUUGCAGCAUCUGAAAG 6260 3186 1348 GAUACGAUGCUUCAAGAGAUCUCUUGAAGCAUCGUAUC 6261 1355 1349 AUGCAAGCUUUAGGACUUCGAAGUCCUAAAGCUUGCAU 6262 433 1350 GGAUGUGGAUACCUCCCAAUUGGGAGGUAUCCACAUCC 6263 1713 1351 AGAAUGCAGUUCGCCUUCAUGAAGGCGAACUGCAUUCU 6264 1811 1352 CGAAAUCUUGCCCUUUGUCGACAAAGGGCAAGAUUUCG 6265 491 1353 ACUCAAGAACAAGUAGCUGCAGCUACUUGUUCUUGAGU 6266 2209 1354 GAAUGAAGGUGUGGCGACAUGUCGCCACACCUUCAUUC 6267 1840 1355 UGCACCUUUGCGUGAGCAGCUGCUCACGCAAAGGUGCA 6268 550 1356 ACGAGCUGCUAUGUUCCCUAGGGAACAUAGCAGCUCGU 6269 429 1357 AAGAGGAUGUGGAUACCUCGAGGUAUCCACAUCCUCUU 6270 2436 1358 GAUAUGGCCAGGAUGCCUUAAGGCAUCCUGGCCAUAUC 6271 1597 1359 UAUAGAGGCUCUUGUGCGUACGCACAAGAGCCUCUAUA 6272 1496 1360 GGUUCAGAUGAUAUAAAUGCAUUUAUAUCAUCUGAACC 6273 1456 1361 AGGGAUGGAAGGUCUCCUUAAGGAGACCUUCCAUCCCU 6274 3159 1362 UAUCCCAAAGUUGUUGUAAUUACAACAACUUUGGGAUA 6275 2309 1363 UCUCUCUUCAGAACAGAGCGCUCUGUUCUGAAGAGAGA 6276 2300 1364 CUGACCAGCUCUCUCUUCAUGAAGAGAGAGCUGGUCAG 6277 3177 1365 ACCUGCUGUGAUACGAUGCGCAUCGUAUCACAGCAGGU 6278 1079 1366 AUGGCAGUGCGUUUAGCUGCAGCUAAACGCACUGCCAU 6279 1383 1367 AUCCAAGUCAACGUCUUGUACAAGACGUUGACUUGGAU 6280 2563 1368 GCUGCCUCCAGGUGACAGCGCUGUCACCUGGAGGCAGC 6281 1084 1369 AGUGCGUUUAGCUGGUGGGCCCACCAGCUAAACGCACU 6282 1329 1370 AGCCGGCUAUUGUAGAAGCGCUUCUACAAUAGCCGGCU 6283 573 1371 CAUUAGAUGAGGGCAUGCAUGCAUGCCCUCAUCUAAUG 6284 2213 1372 GAAGGUGUGGCGACAUAUGCAUAUGUCGCCACACCUUC 6285 1587 1373 AAGUGGGUGGUAUAGAGGCGCCUCUAUACCACCCACUU 6286 2166 1374 CUGAGGGAGCCACAGCUCCGGAGCUGUGGCUCCCUCAG 6287 637 1375 GCGUUUGGCUGAACCAUCAUGAUGGUUCAGCCAAACGC 6288 397 1376 UCCUUCUCUGAGUGGUAAAUUUACCACUCAGAGAAGGA 6289 1718 1377 GCAGUUCGCCUUCACUAUGCAUAGUGAAGGCGAACUGC 6290 2357 1378 GGACUUGAUAUUGGUGCCCGGGCACCAAUAUCAAGUCC 6291 639 1379 GUUUGGCUGAACCAUCACAUGUGAUGGUUCAGCCAAAC 6292 585 1380 GCAUGCAGAUCCCAUCUACGUAGAUGGGAUCUGCAUGC 6293 2519 1381 GAUGGGCUGCCAGAUCUGGCCAGAUCUGGCAGCCCAUC 6294 1367 1382 GGACUUCACCUGACAGAUCGAUCUGUCAGGUGAAGUCC 6295 1391 1383 CAACGUCUUGUUCAGAACUAGUUCUGAACAAGACGUUG 6296 509 1384 GAUAUUGAUGGACAGUAUGCAUACUGUCCAUCAAUAUC 6297 303 1385 UGGCCAUGGAACCAGACAGCUGUCUGGUUCCAUGGCCA 6298 494 1386 CAAGAACAAGUAGCUGAUAUAUCAGCUACUUGUUCUUG 6299 328 1387 GGCUGUUAGUCACUGGCAGCUGCCAGUGACUAACAGCC 6300 2058 1388 CAUUGUUUGUGCAGCUGCUAGCAGCUGCACAAACAAUG 6301 1447 1389 UAAACAGGAAGGGAUGGAAUUCCAUCCCUUCCUGUUUA 6302 1563 1390 AUAAGAACAAGAUGAUGGUACCAUCAUCUUGUUCUUAU 6303 1350 1391 GUGGAAUGCAAGCUUUAGGCCUAAAGCUUGCAUUCCAC 6304 2208 1392 GGAAUGAAGGUGUGGCGACGUCGCCACACCUUCAUUCC 6305 1689 1393 GACACCAAGAAGCAGAGAUAUCUCUGCUUCUUGGUGUC 6306 1407 1394 ACUGUCUUUGGACUCUCAGCUGAGAGUCCAAAGACAGU 6307 2137 1395 GGACAAGGAAGCUGCAGAAUUCUGCAGCUUCCUUGUCC 6308 854 1396 UCUGCUAUUGUACGUACCAUGGUACGUACAAUAGCAGA 6309 2070 1397 AGCUGCUUUAUUCUCCCAUAUGGGAGAAUAAAGCAGCU 6310 545 1398 AGGGUACGAGCUGCUAUGUACAUAGCAGCUCGUACCCU 6311 1640 1399 GAAGACAUCACUGAGCCUGCAGGCUCAGUGAUGUCUUC 6312 2012 1400 CGGGAUGUUCACAACCGAAUUCGGUUGUGAACAUCCCG 6313 1684 1401 CAGCCGACACCAAGAAGCAUGCUUCUUGGUGUCGGCUG 6314 2017 1402 UGUUCACAACCGAAUUGUUAACAAUUCGGUUGUGAACA 6315 2307 1403 GCUCUCUCUUCAGAACAGAUCUGUUCUGAAGAGAGAGC 6316 844 1404 UCAGAUGGUGUCUGCUAUUAAUAGCAGACACCAUCUGA 6317 405 1405 UGAGUGGUAAAGGCAAUCCGGAUUGCCUUUACCACUCA 6318 379 1406 UGGUGCCACUACCACAGCUAGCUGUGGUAGUGGCACCA 6319 1825 1407 UUGUCCCGCAAAUCAUGCAUGCAUGAUUUGCGGGACAA 6320 2495 1408 CACCCUGGUGCUGACUAUCGAUAGUCAGCACCAGGGUG 6321 629 1409 AAUGUCCAGCGUUUGGCUGCAGCCAAACGCUGGACAUU 6322 2561 1410 GGGCUGCCUCCAGGUGACAUGUCACCUGGAGGCAGCCC 6323 2192 1411 GAGUUACUUCACUCUAGGAUCCUAGAGUGAAGUAACUC 6324 1809 1412 UUCGAAAUCUUGCCCUUUGCAAAGGGCAAGAUUUCGAA 6325 1596 1413 GUAUAGAGGCUCUUGUGCGCGCACAAGAGCCUCUAUAC 6326 2298 1414 AGCUGACCAGCUCUCUCUUAAGAGAGAGCUGGUCAGCU 6327 858 1415 CUAUUGUACGUACCAUGCAUGCAUGGUACGUACAAUAG 6328 524 1416 UAUGCAAUGACUCGAGCUCGAGCUCGAGUCAUUGCAUA 6329 2542 1417 UGCCCAGGACCUCAUGGAUAUCCAUGAGGUCCUGGGCA 6330 498 1418 AACAAGUAGCUGAUAUUGAUCAAUAUCAGCUACUUGUU 6331 414 1419 AAGGCAAUCCUGAGGAAGAUCUUCCUCAGGAUUGCCUU 6332 1570 1420 CAAGAUGAUGGUCUGCCAAUUGGCAGACCAUCAUCUUG 6333 1030 1421 UGCCAUUACAACUCUCCACGUGGAGAGUUGUAAUGGCA 6334 3087 1422 AUGUAUGGGUAGGGUAAAUAUUUACCCUACCCAUACAU 6335 1664 1423 UGUGCUCUUCGUCAUCUGAUCAGAUGACGAAGAGCACA 6336 1790 1424 AAGGCUACUGUUGGAUUGAUCAAUCCAACAGUAGCCUU 6337 1615 1425 UACUGUCCUUCGGGCUGGUACCAGCCCGAAGGACAGUA 6338 774 1426 AUAAGGCUGCAGUUAUGGUACCAUAACUGCAGCCUUAU 6339 1672 1427 UCGUCAUCUGACCAGCCGAUCGGCUGGUCAGAUGACGA 6340 3171 1428 GUUGUAACCUGCUGUGAUAUAUCACAGCAGGUUACAAC 6341 2271 1429 AAGAUUACAAGAAACGGCUAGCCGUUUCUUGUAAUCUU 6342 1183 1430 UUAUGGCAACCAAGAAAGCGCUUUCUUGGUUGCCAUAA 6343 2512 1431 UCCAGUUGAUGGGCUGCCAUGGCAGCCCAUCAACUGGA 6344 1931 1432 GGGACACAGCAGCAAUUUGCAAAUUGCUGCUGUGUCCC 6345 2468 1433 AUGAUGGAACAUGAGAUGGCCAUCUCAUGUUCCAUCAU 6346 3077 1434 UAUUUGGGAUAUGUAUGGGCCCAUACAUAUCCCAAAUA 6347 2069 1435 CAGCUGCUUUAUUCUCCCAUGGGAGAAUAAAGCAGCUG 6348 272 1436 GCUACUCAAGCUGAUUUGAUCAAAUCAGCUUGAGUAGC 6349 564 1437 UCCCUGAGACAUUAGAUGAUCAUCUAAUGUCUCAGGGA 6350 437 1438 GUGGAUACCUCCCAAGUCCGGACUUGGGAGGUAUCCAC 6351 2206 1439 UAGGAAUGAAGGUGUGGCGCGCCACACCUUCAUUCCUA 6352 2187 1440 UGACAGAGUUACUUCACUCGAGUGAAGUAACUCUGUCA 6353 325 1441 AGCGGCUGUUAGUCACUGGCCAGUGACUAACAGCCGCU 6354 3222 1442 AUGGUUCAGAAUUAAACUUAAGUUUAAUUCUGAACCAU 6355 2024 1443 AACCGAAUUGUUAUCAGAGCUCUGAUAACAAUUCGGUU 6356 1858 1444 GGGUGCCAUUCCACGACUAUAGUCGUGGAAUGGCACCC 6357 1574 1445 AUGAUGGUCUGCCAAGUGGCCACUUGGCAGACCAUCAU 6358 1896 1446 CACAUCAGGAUACCCAGCGCGCUGGGUAUCCUGAUGUG 6359 2207 1447 AGGAAUGAAGGUGUGGCGAUCGCCACACCUUCAUUCCU 6360 1300 1448 GAAGGUGCUAUCUGUCUGCGCAGACAGAUAGCACCUUC 6361 1192 1449 CCAAGAAAGCAAGCUCAUCGAUGAGCUUGCUUUCUUGG 6362 551 1450 CGAGCUGCUAUGUUCCCUGCAGGGAACAUAGCAGCUCG 6363 2498 1451 CCUGGUGCUGACUAUCCAGCUGGAUAGUCAGCACCAGG 6364 1305 1452 UGCUAUCUGUCUGCUCUAGCUAGAGCAGACAGAUAGCA 6365 1337 1453 AUUGUAGAAGCUGGUGGAAUUCCACCAGCUUCUACAAU 6366

For each oligonucleotide of a target sequence, the two individual,complementary strands of the siNA were synthesized separately usingsolid phase synthesis, then purified separately by reversed phase solidphase extraction (SPE). The complementary strands were annealed to formthe double strand (duplex) and delivered in the desired concentrationand buffer of choice.

Briefly, the single strand oligonucleotides were synthesized usingphosphoramidite chemistry on an automated solid-phase synthesizer, usingprocedures as are generally known in the art (see for example U.S.application Ser. No. 12/064,014). A synthesis column was packed withsolid support derivatized with the first nucleoside residue (natural orchemically modified). Synthesis was initiated by detritylation of theacid labile 5′-O-dimethoxytrityl group to release the 5′-hydroxyl. Asuitably protected phosphoramidite and a suitable activator inacetonitrile were delivered simultaneously to the synthesis columnresulting in coupling of the amidite to the 5′-hydroxyl. The column wasthen washed with a solvent, such as acetonitrile. An oxidizing solution,such as an iodine solution was pumped through the column to oxidize thephosphite triester linkage P(III) to its phosphotriester P(V) analog.Unreacted 5′-hydroxyl groups were capped using reagents such as aceticanhydride in the presence of 2,6-lutidine and N-methylimidazole. Theelongation cycle was resumed with the detritylation step for the nextphosphoramidite incorporation. This process was repeated until thedesired sequence was synthesized. The synthesis concluded with the final5′-terminus protecting group (trityl or 5′-O-dimethoxytrityl).

Upon completion of the synthesis, the solid-support and associatedoligonucleotide were dried under argon pressure or vacuum. Aqueous basewas added and the mixture was heated to effect cleavage of the succinyllinkage, removal of the cyanoethyl phosphate protecting group, anddeprotection of the exocyclic amine protection.

The following process was performed on single strands that do notcontain ribonucleotides. After treating the solid support with theaqueous base, the mixture was filtered to separate the solid supportfrom the deprotected crude synthesis material. The solid support wasthen rinsed with water, which is combined with the filtrate. Theresultant basic solution allows for retention of the5′-O-dimethoxytrityl group to remain on the 5′ terminal position(trityl-on).

For single strands that contain ribonucleotides, the following processwas performed. After treating the solid support with the aqueous base,the mixture was filtered to separate the solid support from thedeprotected crude synthesis material. The solid support was then rinsedwith dimethylsulfoxide (DMSO), which was combined with the filtrate.Fluoride reagent, such as triethylamine trihydrofluoride, was added tothe mixture, and the solution was heated. The reaction was quenched withsuitable buffer to provide a solution of crude single strand with the5′-O-dimethoxytrityl group on the final 5′ terminal position.

The trityl-on solution of each crude single strand was purified usingchromatographic purification, such as SPE RPC purification. Thehydrophobic nature of the trityl group permits stronger retention of thedesired full-length oligo than the non-tritylated truncated failuresequences. The failure sequences were selectively washed from the resinwith a suitable solvent, such as low percent acetonitrile. Retainedoligonucleotides were then detritylated on-column with trifluoroaceticacid to remove the acid-labile trityl group. Residual acid was washedfrom the column, a salt exchange was performed, and a final desalting ofthe material commenced. The full-length oligo was recovered in apurified form with an aqueous-organic solvent. The final product wasthen analyzed for purity (HPLC), identity (Maldi-TOF MS), and yield (UVA₂₆₀). The oligos were dried via lyophilization or vacuum condensation.

Annealing:

Based on the analysis of the product, the dried oligos were dissolved inappropriate buffers followed by mixing equal molar amounts (calculatedusing the theoretical extinction coefficient) of the sense and antisenseoligonucleotide strands. The solution was then analyzed for purity ofduplex by chromatographic methods and desired final concentration. Ifthe analysis indicated an excess of either strand, then the additionalnon-excess strand was titrated until duplexing was complete. Whenanalysis indicated that the target product purity has been achieved thematerial was delivered and ready for use.

Below is a table showing various modified siNAs synthesized using thisprotocol or that can be synthesized using this protocol or using methodsknown in the art.

TABLE 1c CTNNB1 siNA Strands Synthesized (Antisense sequences arereadily identified as being complementary to the target sequence shown).Target SEQ SEQ Site ID ID R Number (human) NO: 1 Target SequenceModified Sequence NO: 2 R-008247452-000C 535 1 UCGAGCUCAGAGGGUACGA BucGAGcucAGAGGGuAcGATT B 1454 R-008247452-000C 535 1 UCGAGCUCAGAGGGUACGAUCGuAcccucuGAGcucGAUU 1455 R-008247449-000W 1601 2 GAGGCUCUUGUGCGUACUG BGAGGcucuuGuGcGuAcuGTT B 1456 R-008247449-000W 1601 2 GAGGCUCUUGUGCGUACUGCAGuAcGcAcAAGAGccucUU 1457 R-008247575-000Y 1709 3 GCCCAGAAUGCAGUUCGCC BGcccAGAAuGcAGuucGccTT B 1458 R-008247575-000Y 1709 3 GCCCAGAAUGCAGUUCGCCGGCGAAcuGcAuucuGGGcUU 1459 R-008247572-000X 536 4 CGAGCUCAGAGGGUACGAG BcGAGcucAGAGGGuAcGAGTT B 1460 R-008247572-000X 536 4 CGAGCUCAGAGGGUACGAGCUCGuAcccucuGAGcucGUU 1461 R-008247569-000R 1797 5 CUGUUGGAUUGAUUCGAAAUUUcGAAucAAuccAAcAGUU 1463 R-008247569-000R 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAATT B 1462 R-008247446-000V 853 6 GUCUGCUAUUGUACGUACCB GucuGcuAuuGuAcGuAccTT B 1464 R-008247446-000V 853 6GUCUGCUAUUGUACGUACC GGUAcGuAcAAuAGcAGAcUU 1465 R-008247566-000P 1143 7AAUUCUUGGCUAUUACGAC GUCGuAAuAGccAAGAAuuUU 1467 R-008247566-000P 1143 7AAUUCUUGGCUAUUACGAC B AAuucuuGGcuAuuAcGAcTT B 1466 R-008247563-000N 20148 GGAUGUUCACAACCGAAUU B GGAuGuucAcAAccGAAuuTT B 1468 R-008247563-000N2014 8 GGAUGUUCACAACCGAAUU AAUucGGuuGuGAAcAuccUU 1469 R-008247560-000M520 9 ACAGUAUGCAAUGACUCGA B AcAGuAuGcAAuGAcucGATT B 1470R-008247560-000M 520 9 ACAGUAUGCAAUGACUCGA UCGAGucAuuGcAuAcuGuUU 1471R-008247443-000U 814 10 AGCUUCCAGACACGCUAUC B AGcuuccAGAcAcGcuAucTT B1472 R-008247443-000U 814 10 AGCUUCCAGACACGCUAUC GAUAGcGuGucuGGAAGcuUU1473 R-008247440-000T 852 11 UGUCUGCUAUUGUACGUAC GUAcGuAcAAuAGcAGAcAUU1475 R-008247440-000T 852 11 UGUCUGCUAUUGUACGUAC B uGucuGcuAuuGuAcGuAcTTB 1474 R-008247557-000F 1796 12 ACUGUUGGAUUGAUUCGAAUUCGAAucAAuccAAcAGuUU 1477 R-008247557-000F 1796 12 ACUGUUGGAUUGAUUCGAAB AcuGuuGGAuuGAuucGAATT B 1476 R-008247437-000L 1901 13CAGGAUACCCAGCGCCGUA UACGGcGcuGGGuAuccuGUU 1479 R-008247437-000L 1901 13CAGGAUACCCAGCGCCGUA B cAGGAuAcccAGcGccGuATT B 1478 R-008247554-000E 82214 GACACGCUAUCAUGCGUUC B GAcAcGcuAucAuGcGuucTT B 1480 R-008247554-000E822 14 GACACGCUAUCAUGCGUUC GAAcGcAuGAuAGcGuGucUU 1481 R-008247551-000D1795 15 UACUGUUGGAUUGAUUCGA UCGAAucAAuccAAcAGuAUU 1483 R-008247551-000D1795 15 UACUGUUGGAUUGAUUCGA B uAcuGuuGGAuuGAuucGATT B 1482R-008247548-000X 1145 16 UUCUUGGCUAUUACGACAG B uucuuGGcuAuuAcGAcAGTT B1484 R-008247548-000X 1145 16 UUCUUGGCUAUUACGACAG CUGucGuAAuAGccAAGAAUU1485 R-008247545-000W 823 17 ACACGCUAUCAUGCGUUCU B AcAcGcuAucAuGcGuucuTTB 1486 R-008247545-000W 823 17 ACACGCUAUCAUGCGUUCU AGAAcGcAuGAuAGcGuGuUU1487 R-008247434-000K 820 18 CAGACACGCUAUCAUGCGU B cAGAcAcGcuAucAuGcGuTTB 1488 R-008247434-000K 820 18 CAGACACGCUAUCAUGCGU ACGcAuGAuAGcGuGucuGUU1489 R-008247431-000J 1798 19 UGUUGGAUUGAUUCGAAAU BuGuuGGAuuGAuucGAAAuTT B 1490 R-008247431-000J 1798 19UGUUGGAUUGAUUCGAAAU AUUucGAAucAAuccAAcAUU 1491 R-008247428-000C 1380 20CAGAUCCAAGUCAACGUCU B cAGAuccAAGucAAcGucuTT B 1492 R-008247428-000C 138020 CAGAUCCAAGUCAACGUCU AGAcGuuGAcuuGGAucuGUU 1493 R-008247542-000V 160221 AGGCUCUUGUGCGUACUGU B AGGcucuuGuGcGuAcuGuTT B 1494 R-008247542-000V1602 21 AGGCUCUUGUGCGUACUGU ACAGuAcGcAcAAGAGccuUU 1495 R-008247539-000N1612 22 GCGUACUGUCCUUCGGGCU B GcGuAcuGuccuucGGGcuTT B 1496R-008247539-000N 1612 22 GCGUACUGUCCUUCGGGCU AGCccGAAGGAcAGuAcGcUU 1497R-008247425-000B 626 23 ACUAAUGUCCAGCGUUUGG B AcuAAuGuccAGcGuuuGGTT B1498 R-008247425-000B 626 23 ACUAAUGUCCAGCGUUUGG CCAAAcGcuGGAcAuuAGuUU1499 R-008247536-000M 2000 24 CACAUCCUAGCUCGGGAUG BcAcAuccuAGcucGGGAuGTT B 1500 R-008247536-000M 2000 24CACAUCCUAGCUCGGGAUG CAUcccGAGcuAGGAuGuGUU 1501 R-008247422-000A 2665 25GUUGCUGAGAGGGCUCGAG B GuuGcuGAGAGGGcucGAGTT B 1502 R-008247422-000A 266525 GUUGCUGAGAGGGCUCGAG CUCGAGcccucucAGcAAcUU 1503 R-008247533-000L 167626 CAUCUGACCAGCCGACACC GGUGucGGcuGGucAGAuGUU 1505 R-008247533-000L 167626 CAUCUGACCAGCCGACACC B cAucuGAccAGccGAcAccTT B 1504 R-008247530-000K1611 27 UGCGUACUGUCCUUCGGGC B uGcGuAcuGuccuucGGGcTT B 1506R-008247530-000K 1611 27 UGCGUACUGUCCUUCGGGC GCCcGAAGGAcAGuAcGcAUU 1507R-008247419-000U 2269 28 ACAAGAUUACAAGAAACGG B AcAAGAuuAcAAGAAAcGGTT B1508 R-008247419-000U 2269 28 ACAAGAUUACAAGAAACGG CCGuuucuuGuAAucuuGuUU1509 R-008247527-000D 674 29 GUUGUAAACUUGAUUAACU B GuuGuAAAcuuGAuuAAcuTTB 1510 R-008247527-000D 674 29 GUUGUAAACUUGAUUAACU AGUuAAucAAGuuuAcAAcUU1511 R-008247602-000K 678 30 UAAACUUGAUUAACUAUCA B uAAAcuuGAuuAAcuAucATTB 1512 R-008247602-000K 678 30 UAAACUUGAUUAACUAUCA UGAuAGuuAAucAAGuuuAUU1513 R-008247599-000T 1245 31 AUAUAAUGAGGACCUAUAC BAuAuAAuGAGGAccuAuAcTT B 1514 R-008247599-000T 1245 31AUAUAAUGAGGACCUAUAC GUAuAGGuccucAuuAuAuUU 1515 R-008247596-000S 679 32AAACUUGAUUAACUAUCAA B AAAcuuGAuuAAcuAucAATT B 1516 R-008247596-000S 67932 AAACUUGAUUAACUAUCAA UUGAuAGuuAAucAAGuuuUU 1517 R-008247593-000R 197033 GAAAUAGUUGAAGGUUGUA B GAAAuAGuuGAAGGuuGuATT B 1518 R-008247593-000R1970 33 GAAAUAGUUGAAGGUUGUA UACAAccuucAAcuAuuucUU 1519 R-008247590-000P1247 34 AUAAUGAGGACCUAUACUU AAGuAuAGGuccucAuuAuUU 1521 R-008247590-000P1247 34 AUAAUGAGGACCUAUACUU B AuAAuGAGGAccuAuAcuuTT B 1520R-008247464-000M 1140 35 UUAAAUUCUUGGCUAUUAC B uuAAAuucuuGGcuAuuAcTT B1522 R-008247464-000M 1140 35 UUAAAUUCUUGGCUAUUAC GUAAuAGccAAGAAuuuAAUU1523 R-008247587-000H 676 36 UGUAAACUUGAUUAACUAU B uGuAAAcuuGAuuAAcuAuTTB 1524 R-008247587-000H 676 36 UGUAAACUUGAUUAACUAU AUAGuuAAucAAGuuuAcAUU1525 R-008247461-000L 677 37 GUAAACUUGAUUAACUAUC GAUAGuuAAucAAGuuuAcUU1527 R-008247461-000L 677 37 GUAAACUUGAUUAACUAUC B GuAAAcuuGAuuAAcuAucTTB 1526 R-008247458-000E 675 38 UUGUAAACUUGAUUAACUA BuuGuAAAcuuGAuuAAcuATT B 1528 R-008247458-000E 675 38 UUGUAAACUUGAUUAACUAUAGuuAAucAAGuuuAcAAUU 1529 R-008247584-000G 1235 39 GCUUUAGUAAAUAUAAUGAB GcuuuAGuAAAuAuAAuGATT B 1530 R-008247584-000G 1235 39GCUUUAGUAAAUAUAAUGA UCAuuAuAuuuAcuAAAGcUU 1531 R-008247581-000F 2488 40UGGCCACCACCCUGGUGCU B uGGccAccAcccuGGuGcuTT B 1532 R-008247581-000F 248840 UGGCCACCACCCUGGUGCU AGCAccAGGGuGGuGGccAUU 1533 R-008247578-000Z 123641 CUUUAGUAAAUAUAAUGAG B cuuuAGuAAAuAuAAuGAGTT B 1534 R-008247578-000Z1236 41 CUUUAGUAAAUAUAAUGAG CUCAuuAuAuuuAcuAAAGUU 1535 R-008247455-000D1237 42 UUUAGUAAAUAUAAUGAGG CCUcAuuAuAuuuAcuAAAUU 1537 R-008247455-000D1237 42 UUUAGUAAAUAUAAUGAGG B uuuAGuAAAuAuAAuGAGGTT B 1536R-008042883-001A 2555 43 GUAAAUCGUCCUUUAGGUA B GuAAAucGuccuuuAGGuATT B1538 R-008042883-001A 2555 43 GUAAAUCGUCCUUUAGGUA UACcuAAAGGAcGAuuuAcUU1539 R-008308583-000P 1545 44 ACCUCACUUGCAAUAAUUA BAccucAcuuGcAAuAAuuATT B 1540 R-008308583-000P 1545 44ACCUCACUUGCAAUAAUUA UAAuuAuuGcAAGuGAGGuUU 1541 R-008308520-000J 2050 45UACCAUUCCAUUGUUUGUG B uAccAuuccAuuGuuuGuGTT B 1542 R-008308520-000J 205045 UACCAUUCCAUUGUUUGUG CACAAAcAAuGGAAuGGuAUU 1543 R-008308622-000L 209746 UCCAAAGAGUAGCUGCAGG CCUGcAGcuAcucuuuGGAUU 1545 R-008308622-000L 209746 UCCAAAGAGUAGCUGCAGG B uccAAAGAGuAGcuGcAGGTT B 1544 R-008308652-000N2510 47 UAUCCAGUUGAUGGGCUGC B uAuccAGuuGAuGGGcuGcTT B 1546R-008308652-000N 2510 47 UAUCCAGUUGAUGGGCUGC GCAGcccAucAAcuGGAuAUU 1547R-008308718-000F 871 48 CAUGCAGAAUACAAAUGAU AUCAuuuGuAuucuGcAuGUU 1549R-008308718-000F 871 48 CAUGCAGAAUACAAAUGAU B cAuGcAGAAuAcAAAuGAuTT B1548 R-008308694-000A 2098 49 CCAAAGAGUAGCUGCAGGG CCCuGcAGcuAcucuuuGGUU1551 R-008308694-000A 2098 49 CCAAAGAGUAGCUGCAGGG BccAAAGAGuAGcuGcAGGGTT B 1550 R-008308517-000C 1767 50CACCAUCCCACUGGCCUCU B cAccAucccAcuGGccucuTT B 1552 R-008308517-000C 176750 CACCAUCCCACUGGCCUCU AGAGGccAGuGGGAuGGuGUU 1553 R-008308619-000E 86951 ACCAUGCAGAAUACAAAUG B AccAuGcAGAAuAcAAAuGTT B 1554 R-008308619-000E869 51 ACCAUGCAGAAUACAAAUG CAUuuGuAuucuGcAuGGuUU 1555 R-008308514-000B1641 52 AAGACAUCACUGAGCCUGC B AAGAcAucAcuGAGccuGcTT B 1556R-008308514-000B 1641 52 AAGACAUCACUGAGCCUGC GCAGGcucAGuGAuGucuuUU 1557R-008308616-000D 2582 53 AAUCAGCUGGCCUGGUUUG B AAucAGcuGGccuGGuuuGTT B1558 R-008308616-000D 2582 53 AAUCAGCUGGCCUGGUUUG CAAAccAGGccAGcuGAuuUU1559 R-008308580-000N 1544 54 AACCUCACUUGCAAUAAUU AAUuAuuGcAAGuGAGGuuUU1561 R-008308580-000N 1544 54 AACCUCACUUGCAAUAAUU BAAccucAcuuGcAAuAAuuTT B 1560 R-008308736-000Y 2550 55ACCUCAUGGAUGGGCUGCC B AccucAuGGAuGGGcuGccTT B 1562 R-008308736-000Y 255055 ACCUCAUGGAUGGGCUGCC GGCAGcccAuccAuGAGGuUU 1563 R-008308613-000C 205156 ACCAUUCCAUUGUUUGUGC GCAcAAAcAAuGGAAuGGuUU 1565 R-008308613-000C 205156 ACCAUUCCAUUGUUUGUGC B AccAuuccAuuGuuuGuGcTT B 1564 R-008308577-000G870 57 CCAUGCAGAAUACAAAUGA UCAuuuGuAuucuGcAuGGUU 1567 R-008308577-000G870 57 CCAUGCAGAAUACAAAUGA B ccAuGcAGAAuAcAAAuGATT B 1566R-008308691-000Z 1670 58 CUUCGUCAUCUGACCAGCC B cuucGucAucuGAccAGccTT B1568 R-008308691-000Z 1670 58 CUUCGUCAUCUGACCAGCC GGCuGGucAGAuGAcGAAGUU1569 R-008308649-000G 2122 59 CUGUGAACUUGCUCAGGAC BcuGuGAAcuuGcucAGGAcTT B 1570 R-008308649-000G 2122 59CUGUGAACUUGCUCAGGAC GUCcuGAGcAAGuucAcAGUU 1571 R-008308553-000M 1642 60AGACAUCACUGAGCCUGCC B AGAcAucAcuGAGccuGccTT B 1572 R-008308553-000M 164260 AGACAUCACUGAGCCUGCC GGCAGGcucAGuGAuGucuUU 1573 R-008308574-000F 232461 GAGCCAAUGGCUUGGAAUG B GAGccAAuGGcuuGGAAuGTT B 1574 R-008308574-000F2324 61 GAGCCAAUGGCUUGGAAUG CAUuccAAGccAuuGGcucUU 1575 R-008308688-000T1649 62 ACUGAGCCUGCCAUCUGUG B AcuGAGccuGccAucuGuGTT B 1576R-008308688-000T 1649 62 ACUGAGCCUGCCAUCUGUG CACAGAuGGcAGGcucAGuUU 1577R-008308550-000L 2159 63 AUUGAAGCUGAGGGAGCCA B AuuGAAGcuGAGGGAGccATT B1578 R-008308550-000L 2159 63 AUUGAAGCUGAGGGAGCCA UGGcucccucAGcuucAAuUU1579 R-008308511-000A 785 64 GUUAUGGUCCAUCAGCUUU B GuuAuGGuccAucAGcuuuTTB 1580 R-008308511-000A 785 64 GUUAUGGUCCAUCAGCUUU AAAGcuGAuGGAccAuAAcUU1581 R-008308685-000S 1511 65 AAUGUGGUCACCUGUGCAG BAAuGuGGucAccuGuGcAGTT B 1582 R-008308685-000S 1511 65AAUGUGGUCACCUGUGCAG CUGcAcAGGuGAccAcAuuUU 1583 R-008308610-000B 2586 66AGCUGGCCUGGUUUGAUAC B AGcuGGccuGGuuuGAuAcTT B 1584 R-008308610-000B 258666 AGCUGGCCUGGUUUGAUAC GUAucAAAccAGGccAGcuUU 1585 R-008308571-000E 64267 UGGCUGAACCAUCACAGAU B uGGcuGAAccAucAcAGAuTT B 1586 R-008308571-000E642 67 UGGCUGAACCAUCACAGAU AUCuGuGAuGGuucAGccAUU 1587 R-008308715-000E1763 68 CACCCACCAUCCCACUGGC B cAcccAccAucccAcuGGcTT B 1588R-008308715-000E 1763 68 CACCCACCAUCCCACUGGC GCCAGuGGGAuGGuGGGuGUU 1589R-008308682-000R 2328 69 CAAUGGCUUGGAAUGAGAC GUCucAuuccAAGccAuuGUU 1591R-008308682-000R 2328 69 CAAUGGCUUGGAAUGAGAC B cAAuGGcuuGGAAuGAGAcTT B1590 R-008308646-000F 1280 70 UGGACCACAAGCAGAGUGC GCAcucuGcuuGuGGuccAUU1593 R-008308646-000F 1280 70 UGGACCACAAGCAGAGUGC BuGGAccAcAAGcAGAGuGcTT B 1592 R-008308508-000U 2052 71CCAUUCCAUUGUUUGUGCA B ccAuuccAuuGuuuGuGcATT B 1594 R-008308508-000U 205271 CCAUUCCAUUGUUUGUGCA UGCAcAAAcAAuGGAAuGGUU 1595 R-008308547-000E 254672 CAGGACCUCAUGGAUGGGC GCCcAuccAuGAGGuccuGUU 1597 R-008308547-000E 254672 CAGGACCUCAUGGAUGGGC B cAGGAccucAuGGAuGGGcTT B 1596 R-008308505-000T2124 73 GUGAACUUGCUCAGGACAA UUGuccuGAGcAAGuucAcUU 1599 R-008308505-000T2124 73 GUGAACUUGCUCAGGACAA B GuGAAcuuGcucAGGAcAATT B 1598R-008308733-000X 2545 74 CCAGGACCUCAUGGAUGGG CCCAuccAuGAGGuccuGGUU 1601R-008308733-000X 2545 74 CCAGGACCUCAUGGAUGGG B ccAGGAccucAuGGAuGGGTT B1600 R-008308544-000D 643 75 GGCUGAACCAUCACAGAUG B GGcuGAAccAucAcAGAuGTTB 1602 R-008308544-000D 643 75 GGCUGAACCAUCACAGAUG CAUcuGuGAuGGuucAGccUU1603 R-008308643-000E 2501 76 GGUGCUGACUAUCCAGUUG BGGuGcuGAcuAuccAGuuGTT B 1604 R-008308643-000E 2501 76GGUGCUGACUAUCCAGUUG CAAcuGGAuAGucAGcAccUU 1605 R-008308712-000D 2330 77AUGGCUUGGAAUGAGACUG B AuGGcuuGGAAuGAGAcuGTT B 1606 R-008308712-000D 233077 AUGGCUUGGAAUGAGACUG CAGucucAuuccAAGccAuUU 1607 R-008308568-000Y 163878 GGGAAGACAUCACUGAGCC GGCucAGuGAuGucuucccUU 1609 R-008308568-000Y 163878 GGGAAGACAUCACUGAGCC B GGGAAGAcAucAcuGAGccTT B 1608 R-008308640-000D1630 79 UGGUGACAGGGAAGACAUC B uGGuGAcAGGGAAGAcAucTT B 1610R-008308640-000D 1630 79 UGGUGACAGGGAAGACAUC GAUGucuucccuGucAccAUU 1611R-008308541-000C 616 80 UGCUCAUCCCACUAAUGUC GACAuuAGuGGGAuGAGcAUU 1613R-008308541-000C 616 80 UGCUCAUCCCACUAAUGUC B uGcucAucccAcuAAuGucTT B1612 R-008308679-000J 2509 81 CUAUCCAGUUGAUGGGCUG BcuAuccAGuuGAuGGGcuGTT B 1614 R-008308679-000J 2509 81CUAUCCAGUUGAUGGGCUG CAGcccAucAAcuGGAuAGUU 1615 R-008308565-000X 2548 82GGACCUCAUGGAUGGGCUG B GGAccucAuGGAuGGGcuGTT B 1616 R-008308565-000X 254882 GGACCUCAUGGAUGGGCUG CAGcccAuccAuGAGGuccUU 1617 R-008308538-000W 177383 CCCACUGGCCUCUGAUAAA UUUAucAGAGGccAGuGGGUU 1619 R-008308538-000W 177383 CCCACUGGCCUCUGAUAAA B cccAcuGGccucuGAuAAATT B 1618 R-008308535-000V2247 84 UCCGAAUGUCUGAGGACAA UUGuccucAGAcAuucGGAUU 1621 R-008308535-000V2247 84 UCCGAAUGUCUGAGGACAA B uccGAAuGucuGAGGAcAATT B 1620R-008308637-000X 2331 85 UGGCUUGGAAUGAGACUGC B uGGcuuGGAAuGAGAcuGcTT B1622 R-008308637-000X 2331 85 UGGCUUGGAAUGAGACUGC GCAGucucAuuccAAGccAUU1623 R-008309111-000F 1498 86 UUCAGAUGAUAUAAAUGUG CACAuuuAuAucAucuGAAUU1625 R-008309111-000F 1498 86 UUCAGAUGAUAUAAAUGUG BuucAGAuGAuAuAAAuGuGTT B 1624 R-008309108-000Z 2267 87CCACAAGAUUACAAGAAAC B ccAcAAGAuuAcAAGAAAcTT B 1626 R-008309108-000Z 226787 CCACAAGAUUACAAGAAAC GUUucuuGuAAucuuGuGGUU 1627 R-008308994-000E 154788 CUCACUUGCAAUAAUUAUA UAUAAuuAuuGcAAGuGAGUU 1629 R-008308994-000E 154788 CUCACUUGCAAUAAUUAUA B cucAcuuGcAAuAAuuAuATT B 1628 R-008309075-000K1549 89 CACUUGCAAUAAUUAUAAG CUUAuAAuuAuuGcAAGuGUU 1631 R-008309075-000K1549 89 CACUUGCAAUAAUUAUAAG B cAcuuGcAAuAAuuAuAAGTT B 1630R-008309045-000H 867 90 GUACCAUGCAGAAUACAAA UUUGuAuucuGcAuGGuAcUU 1633R-008309045-000H 867 90 GUACCAUGCAGAAUACAAA B GuAccAuGcAGAAuAcAAATT B1632 R-008309072-000J 1390 91 UCAACGUCUUGUUCAGAAC BucAAcGucuuGuucAGAAcTT B 1634 R-008309072-000J 1390 91UCAACGUCUUGUUCAGAAC GUUcuGAAcAAGAcGuuGAUU 1635 R-008309027-000R 593 92AUCCCAUCUACACAGUUUG CAAAcuGuGuAGAuGGGAuUU 1637 R-008309027-000R 593 92AUCCCAUCUACACAGUUUG B AucccAucuAcAcAGuuuGTT B 1636 R-008309009-000Y 27493 UACUCAAGCUGAUUUGAUG CAUcAAAucAGcuuGAGuAUU 1639 R-008309009-000Y 27493 UACUCAAGCUGAUUUGAUG B uAcucAAGcuGAuuuGAuGTT B 1638 R-008309024-000P759 94 ACCAGGUGGUGGUUAAUAA B AccAGGuGGuGGuuAAuAATT B 1640R-008309024-000P 759 94 ACCAGGUGGUGGUUAAUAA UUAuuAAccAccAccuGGuUU 1641R-008309093-000C 1439 95 GCUGCAACUAAACAGGAAG B GcuGcAAcuAAAcAGGAAGTT B1642 R-008309093-000C 1439 95 GCUGCAACUAAACAGGAAG CUUccuGuuuAGuuGcAGcUU1643 R-008309069-000C 1801 96 UGGAUUGAUUCGAAAUCUU BuGGAuuGAuucGAAAucuuTT B 1644 R-008309069-000C 1801 96UGGAUUGAUUCGAAAUCUU AAGAuuucGAAucAAuccAUU 1645 R-008309021-000N 1500 97CAGAUGAUAUAAAUGUGGU B cAGAuGAuAuAAAuGuGGuTT B 1646 R-008309021-000N 150097 CAGAUGAUAUAAAUGUGGU ACCAcAuuuAuAucAucuGUU 1647 R-008309066-000B 84898 AUGGUGUCUGCUAUUGUAC B AuGGuGucuGcuAuuGuAcTT B 1648 R-008309066-000B848 98 AUGGUGUCUGCUAUUGUAC GUAcAAuAGcAGAcAccAuUU 1649 R-008309105-000Y2268 99 CACAAGAUUACAAGAAACG CGUuucuuGuAAucuuGuGUU 1651 R-008309105-000Y2268 99 CACAAGAUUACAAGAAACG B cAcAAGAuuAcAAGAAAcGTT B 1650R-008309042-000G 882 100 CAAAUGAUGUAGAAACAGC GCUGuuucuAcAucAuuuGUU 1653R-008309042-000G 882 100 CAAAUGAUGUAGAAACAGC B cAAAuGAuGuAGAAAcAGcTT B1652 R-008309063-000A 2266 101 GCCACAAGAUUACAAGAAA UUUcuuGuAAucuuGuGGcUU1655 R-008309063-000A 2266 101 GCCACAAGAUUACAAGAAA BGccAcAAGAuuAcAAGAAATT B 1654 R-008309018-000G 880 102UACAAAUGAUGUAGAAACA B uAcAAAuGAuGuAGAAAcATT B 1656 R-008309018-000G 880102 UACAAAUGAUGUAGAAACA UGUuucuAcAucAuuuGuAUU 1657 R-008309039-000A 1810103 UCGAAAUCUUGCCCUUUGU ACAAAGGGcAAGAuuucGAUU 1659 R-008309039-000A 1810103 UCGAAAUCUUGCCCUUUGU B ucGAAAucuuGcccuuuGuTT B 1658 R-008309015-000F685 104 GAUUAACUAUCAAGAUGAU B GAuuAAcuAucAAGAuGAuTT B 1660R-008309015-000F 685 104 GAUUAACUAUCAAGAUGAU AUCAucuuGAuAGuuAAucUU 1661R-008309060-000Z 1007 105 CCAGUGGAUUCUGUGUUGU ACAAcAcAGAAuccAcuGGUU 1663R-008309060-000Z 1007 105 CCAGUGGAUUCUGUGUUGU B ccAGuGGAuucuGuGuuGuTT B1662 R-008309057-000T 1789 106 AAAGGCUACUGUUGGAUUG BAAAGGcuAcuGuuGGAuuGTT B 1664 R-008309057-000T 1789 106AAAGGCUACUGUUGGAUUG CAAuccAAcAGuAGccuuuUU 1665 R-008309054-000S 499 107ACAAGUAGCUGAUAUUGAU AUCAAuAucAGcuAcuuGuUU 1667 R-008309054-000S 499 107ACAAGUAGCUGAUAUUGAU B AcAAGuAGcuGAuAuuGAuTT B 1666 R-008309090-000B 2470108 GAUGGAACAUGAGAUGGGU B GAuGGAAcAuGAGAuGGGuTT B 1668 R-008309090-000B2470 108 GAUGGAACAUGAGAUGGGU ACCcAucucAuGuuccAucUU 1669 R-008309051-000R694 109 UCAAGAUGAUGCAGAACUU B ucAAGAuGAuGcAGAAcuuTT B 1670R-008309051-000R 694 109 UCAAGAUGAUGCAGAACUU AAGuucuGcAucAucuuGAUU 1671R-008309036-000Z 278 110 CAAGCUGAUUUGAUGGAGU ACUccAucAAAucAGcuuGUU 1673R-008309036-000Z 278 110 CAAGCUGAUUUGAUGGAGU B cAAGcuGAuuuGAuGGAGuTT B1672 R-008309102-000X 1415 111 UGGACUCUCAGGAAUCUUU BuGGAcucucAGGAAucuuuTT B 1674 R-008309102-000X 1415 111UGGACUCUCAGGAAUCUUU AAAGAuuccuGAGAGuccAUU 1675 R-008308991-000D 2046 112UAAAUACCAUUCCAUUGUU AACAAuGGAAuGGuAuuuAUU 1677 R-008308991-000D 2046 112UAAAUACCAUUCCAUUGUU B uAAAuAccAuuccAuuGuuTT B 1676 R-008309006-000X 1057113 AUUACAUCAAGAAGGAGCU AGCuccuucuuGAuGuAAuUU 1679 R-008309006-000X 1057113 AUUACAUCAAGAAGGAGCU B AuuAcAucAAGAAGGAGcuTT B 1678 R-008309087-000V1422 114 UCAGGAAUCUUUCAGAUGC B ucAGGAAucuuucAGAuGcTT B 1680R-008309087-000V 1422 114 UCAGGAAUCUUUCAGAUGC GCAucuGAAAGAuuccuGAUU 1681R-008309084-000U 684 115 UGAUUAACUAUCAAGAUGA UCAucuuGAuAGuuAAucAUU 1683R-008309084-000U 684 115 UGAUUAACUAUCAAGAUGA B uGAuuAAcuAucAAGAuGATT B1682 R-008309099-000E 2197 116 ACUUCACUCUAGGAAUGAA BAcuucAcucuAGGAAuGAATT B 1684 R-008309099-000E 2197 116ACUUCACUCUAGGAAUGAA UUCAuuccuAGAGuGAAGuUU 1685 R-008309003-000W 666 117AACAUGCAGUUGUAAACUU B AAcAuGcAGuuGuAAAcuuTT B 1686 R-008309003-000W 666117 AACAUGCAGUUGUAAACUU AAGuuuAcAAcuGcAuGuuUU 1687 R-008309012-000E 279118 AAGCUGAUUUGAUGGAGUU AACuccAucAAAucAGcuuUU 1689 R-008309012-000E 279118 AAGCUGAUUUGAUGGAGUU B AAGcuGAuuuGAuGGAGuuTT B 1688 R-008309033-000Y1492 119 UCUGGGUUCAGAUGAUAUA B ucuGGGuucAGAuGAuAuATT B 1690R-008309033-000Y 1492 119 UCUGGGUUCAGAUGAUAUA UAUAucAucuGAAcccAGAUU 1691R-008309081-000T 2195 120 UUACUUCACUCUAGGAAUG CAUuccuAGAGuGAAGuAAUU 1693R-008309081-000T 2195 120 UUACUUCACUCUAGGAAUG B uuAcuucAcucuAGGAAuGTT B1692 R-008309048-000J 1424 121 AGGAAUCUUUCAGAUGCUG BAGGAAucuuucAGAuGcuGTT B 1694 R-008309048-000J 1424 121AGGAAUCUUUCAGAUGCUG CAGcAucuGAAAGAuuccuUU 1695 R-008309000-000V 661 122GCUGAAACAUGCAGUUGUA UACAAcuGcAuGuuucAGcUU 1697 R-008309000-000V 661 122GCUGAAACAUGCAGUUGUA B GcuGAAAcAuGcAGuuGuATT B 1696 R-008309078-000L 1882123 GUUGCUUGUUCGUGCACAU B GuuGcuuGuucGuGcAcAuTT B 1698 R-008309078-000L1882 123 GUUGCUUGUUCGUGCACAU AUGuGcAcGAAcAAGcAAcUU 1699 R-008309096-000D1966 124 GGAAGAAAUAGUUGAAGGU B GGAAGAAAuAGuuGAAGGuTT B 1700R-008309096-000D 1966 124 GGAAGAAAUAGUUGAAGGU ACCuucAAcuAuuucuuccUU 1701R-008308997-000F 2259 125 AGGACAAGCCACAAGAUUA B AGGAcAAGccAcAAGAuuATT B1702 R-008308997-000F 2259 125 AGGACAAGCCACAAGAUUA UAAucuuGuGGcuuGuccuUU1703 R-008309030-000X 832 126 CAUGCGUUCUCCUCAGAUG BcAuGcGuucuccucAGAuGTT B 1704 R-008309030-000X 832 126CAUGCGUUCUCCUCAGAUG CAUcuGAGGAGAAcGcAuGUU 1705 R-008042849-001H 2346 127GAUGAUCCCAGCUACCGUU AACGGuAGcuGGGAucAucUU 1707 R-008042849-001H 2346 127GAUGAUCCCAGCUACCGUU B GAuGAucccAGcuAccGuuTT B 1706 R-008308601-000T 1653128 AGCCUGCCAUCUGUGCUCU B AGccuGccAucuGuGcucuTT B 1708 R-008308601-000T1653 128 AGCCUGCCAUCUGUGCUCU AGAGcAcAGAuGGcAGGcuUU 1709 R-008308562-000W2389 129 UGGAUAUCGCCAGGAUGAU B uGGAuAucGccAGGAuGAuTT B 1710R-008308562-000W 2389 129 UGGAUAUCGCCAGGAUGAU AUCAuccuGGcGAuAuccAUU 1711R-008308709-000X 1669 130 UCUUCGUCAUCUGACCAGC B ucuucGucAucuGAccAGcTT B1712 R-008308709-000X 1669 130 UCUUCGUCAUCUGACCAGC GCUGGucAGAuGAcGAAGAUU1713 R-008308634-000W 2123 131 UGUGAACUUGCUCAGGACA BuGuGAAcuuGcucAGGAcATT B 1714 R-008308634-000W 2123 131UGUGAACUUGCUCAGGACA UGUccuGAGcAAGuucAcAUU 1715 R-008308667-000Z 1521 132CCUGUGCAGCUGGAAUUCU B ccuGuGcAGcuGGAAuucuTT B 1716 R-008308667-000Z 1521132 CCUGUGCAGCUGGAAUUCU AGAAuuccAGcuGcAcAGGUU 1717 R-008308706-000W 2125133 UGAACUUGCUCAGGACAAG CUUGuccuGAGcAAGuucAUU 1719 R-008308706-000W 2125133 UGAACUUGCUCAGGACAAG B uGAAcuuGcucAGGAcAAGTT B 1718 R-008308724-000N2503 134 UGCUGACUAUCCAGUUGAU B uGcuGAcuAuccAGuuGAuTT B 1720R-008308724-000N 2503 134 UGCUGACUAUCCAGUUGAU AUCAAcuGGAuAGucAGcAUU 1721R-008308703-000V 1502 135 GAUGAUAUAAAUGUGGUCA UGAccAcAuuuAuAucAucUU 1723R-008308703-000V 1502 135 GAUGAUAUAAAUGUGGUCA B GAuGAuAuAAAuGuGGucATT B1722 R-008308496-000Y 2502 136 GUGCUGACUAUCCAGUUGA UCAAcuGGAuAGucAGcAcUU1725 R-008308496-000Y 2502 136 GUGCUGACUAUCCAGUUGA BGuGcuGAcuAuccAGuuGATT B 1724 R-008308625-000M 2506 137UGACUAUCCAGUUGAUGGG CCCAucAAcuGGAuAGucAUU 1727 R-008308625-000M 2506 137UGACUAUCCAGUUGAUGGG B uGAcuAuccAGuuGAuGGGTT B 1726 R-008308589-000S 2127138 AACUUGCUCAGGACAAGGA B AAcuuGcucAGGAcAAGGATT B 1728 R-008308589-000S2127 138 AACUUGCUCAGGACAAGGA UCCuuGuccuGAGcAAGuuUU 1729 R-008308586-000R2505 139 CUGACUAUCCAGUUGAUGG B cuGAcuAuccAGuuGAuGGTT B 1730R-008308586-000R 2505 139 CUGACUAUCCAGUUGAUGG CCAucAAcuGGAuAGucAGUU 1731R-008308493-000X 617 140 GCUCAUCCCACUAAUGUCC B GcucAucccAcuAAuGuccTT B1732 R-008308493-000X 617 140 GCUCAUCCCACUAAUGUCC GGAcAuuAGuGGGAuGAGcUU1733 R-008308697-000B 2504 141 GCUGACUAUCCAGUUGAUG BGcuGAcuAuccAGuuGAuGTT B 1734 R-008308697-000B 2504 141GCUGACUAUCCAGUUGAUG CAUcAAcuGGAuAGucAGcUU 1735 R-008308661-000X 1503 142AUGAUAUAAAUGUGGUCAC GUGAccAcAuuuAuAucAuUU 1737 R-008308661-000X 1503 142AUGAUAUAAAUGUGGUCAC B AuGAuAuAAAuGuGGucAcTT B 1736 R-008308526-000L 618143 CUCAUCCCACUAAUGUCCA UGGAcAuuAGuGGGAuGAGUU 1739 R-008308526-000L 618143 CUCAUCCCACUAAUGUCCA B cucAucccAcuAAuGuccATT B 1738 R-008308556-000N2074 144 GCUUUAUUCUCCCAUUGAA B GcuuuAuucucccAuuGAATT B 1740R-008308556-000N 2074 144 GCUUUAUUCUCCCAUUGAA UUCAAuGGGAGAAuAAAGcUU 1741R-008308523-000K 2499 145 CUGGUGCUGACUAUCCAGU B cuGGuGcuGAcuAuccAGuTT B1742 R-008308523-000K 2499 145 CUGGUGCUGACUAUCCAGU ACUGGAuAGucAGcAccAGUU1743 R-008362860-000A 1406 146 AACUGUCUUUGGACUCUCA BAAcuGucuuuGGAcucucATT B 1744 R-008362860-000A 1406 146AACUGUCUUUGGACUCUCA UGAGAGuccAAAGAcAGuuUU 1745 R-008362809-000Z 582 147AGGGCAUGCAGAUCCCAUC GAUGGGAucuGcAuGcccuUU 1747 R-008362809-000Z 582 147AGGGCAUGCAGAUCCCAUC B AGGGcAuGcAGAucccAucTT B 1746 R-008362908-000A 1505148 GAUAUAAAUGUGGUCACCU B GAuAuAAAuGuGGucAccuTT B 1748 R-008362908-000A1505 148 GAUAUAAAUGUGGUCACCU AGGuGAccAcAuuuAuAucUU 1749 R-008362713-000E1432 149 UUCAGAUGCUGCAACUAAA UUUAGuuGcAGcAucuGAAUU 1751 R-008362713-000E1432 149 UUCAGAUGCUGCAACUAAA B uucAGAuGcuGcAAcuAAATT B 1750R-008363073-000K 1968 150 AAGAAAUAGUUGAAGGUUG B AAGAAAuAGuuGAAGGuuGTT B1752 R-008363073-000K 1968 150 AAGAAAUAGUUGAAGGUUG CAAccuucAAcuAuuucuuUU1753 R-008362947-000L 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuTT B 1754 R-008362947-000L 2398 151CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUU 1755 R-008363070-000J 954 152UGGCCAUCUUUAAGUCUGG CCAGAcuuAAAGAuGGccAUU 1757 R-008363070-000J 954 152UGGCCAUCUUUAAGUCUGG B uGGccAucuuuAAGucuGGTT B 1756 R-008362857-000U 505153 AGCUGAUAUUGAUGGACAG B AGcuGAuAuuGAuGGAcAGTT B 1758 R-008362857-000U505 153 AGCUGAUAUUGAUGGACAG CUGuccAucAAuAucAGcuUU 1759 R-008363067-000C2011 154 UCGGGAUGUUCACAACCGA B ucGGGAuGuucAcAAccGATT B 1760R-008363067-000C 2011 154 UCGGGAUGUUCACAACCGA UCGGuuGuGAAcAucccGAUU 1761R-008362944-000K 1339 155 UGUAGAAGCUGGUGGAAUG B uGuAGAAGcuGGuGGAAuGTT B1762 R-008362944-000K 1339 155 UGUAGAAGCUGGUGGAAUG CAUuccAccAGcuucuAcAUU1763 R-008362761-000Z 1242 156 UAAAUAUAAUGAGGACCUA BuAAAuAuAAuGAGGAccuATT B 1764 R-008362761-000Z 1242 156UAAAUAUAAUGAGGACCUA UAGGuccucAuuAuAuuuAUU 1765 R-008362758-000T 567 157CUGAGACAUUAGAUGAGGG B cuGAGAcAuuAGAuGAGGGTT B 1766 R-008362758-000T 567157 CUGAGACAUUAGAUGAGGG CCCucAucuAAuGucucAGUU 1767 R-008363007-000Y 1240158 AGUAAAUAUAAUGAGGACC B AGuAAAuAuAAuGAGGAccTT B 1768 R-008363007-000Y1240 158 AGUAAAUAUAAUGAGGACC GGUccucAuuAuAuuuAcuUU 1769 R-008362854-000T438 159 UGGAUACCUCCCAAGUCCU B uGGAuAccucccAAGuccuTT B 1770R-008362854-000T 438 159 UGGAUACCUCCCAAGUCCU AGGAcuuGGGAGGuAuccAUU 1771R-008362755-000S 2445 160 AGGAUGCCUUGGGUAUGGA UCCAuAcccAAGGcAuccuUU 1773R-008362755-000S 2445 160 AGGAUGCCUUGGGUAUGGA B AGGAuGccuuGGGuAuGGATT B1772 R-008363064-000B 860 161 AUUGUACGUACCAUGCAGA BAuuGuAcGuAccAuGcAGATT B 1774 R-008363064-000B 860 161AUUGUACGUACCAUGCAGA UCUGcAuGGuAcGuAcAAuUU 1775 R-008362752-000R 1413 162UUUGGACUCUCAGGAAUCU B uuuGGAcucucAGGAAucuTT B 1776 R-008362752-000R 1413162 UUUGGACUCUCAGGAAUCU AGAuuccuGAGAGuccAAAUU 1777 R-008363061-000A 1800163 UUGGAUUGAUUCGAAAUCU AGAuuucGAAucAAuccAAUU 1779 R-008363061-000A 1800163 UUGGAUUGAUUCGAAAUCU B uuGGAuuGAuucGAAAucuTT B 1778 R-008363004-000X2037 164 UCAGAGGACUAAAUACCAU AUGGuAuuuAGuccucuGAUU 1781 R-008363004-000X2037 164 UCAGAGGACUAAAUACCAU B ucAGAGGAcuAAAuAccAuTT B 1780R-008362851-000S 2443 165 CCAGGAUGCCUUGGGUAUG B ccAGGAuGccuuGGGuAuGTT B1782 R-008362851-000S 2443 165 CCAGGAUGCCUUGGGUAUG CAUAcccAAGGcAuccuGGUU1783 R-008363001-000W 2471 166 AUGGAACAUGAGAUGGGUG BAuGGAAcAuGAGAuGGGuGTT B 1784 R-008363001-000W 2471 166AUGGAACAUGAGAUGGGUG CACccAucucAuGuuccAuUU 1785 R-008362905-000Z 1792 167GGCUACUGUUGGAUUGAUU B GGcuAcuGuuGGAuuGAuuTT B 1786 R-008362905-000Z 1792167 GGCUACUGUUGGAUUGAUU AAUcAAuccAAcAGuAGccUU 1787 R-008362902-000Y 2547168 AGGACCUCAUGGAUGGGCU B AGGAccucAuGGAuGGGcuTT B 1788 R-008362902-000Y2547 168 AGGACCUCAUGGAUGGGCU AGCccAuccAuGAGGuccuUU 1789 R-008362998-000G1662 169 UCUGUGCUCUUCGUCAUCU AGAuGAcGAAGAGcAcAGAUU 1791 R-008362998-000G1662 169 UCUGUGCUCUUCGUCAUCU B ucuGuGcucuucGucAucuTT B 1790R-008362848-000K 288 170 UGAUGGAGUUGGACAUGGC GCCAuGuccAAcuccAucAUU 1793R-008362848-000K 288 170 UGAUGGAGUUGGACAUGGC B uGAuGGAGuuGGAcAuGGcTT B1792 R-008362710-000D 579 171 AUGAGGGCAUGCAGAUCCC GGGAucuGcAuGcccucAuUU1795 R-008362710-000D 579 171 AUGAGGGCAUGCAGAUCCC BAuGAGGGcAuGcAGAucccTT B 1794 R-008362707-000X 2508 172ACUAUCCAGUUGAUGGGCU AGCccAucAAcuGGAuAGuUU 1797 R-008362707-000X 2508 172ACUAUCCAGUUGAUGGGCU B AcuAuccAGuuGAuGGGcuTT B 1796 R-008362806-000Y 580173 UGAGGGCAUGCAGAUCCCA B uGAGGGcAuGcAGAucccATT B 1798 R-008362806-000Y580 173 UGAGGGCAUGCAGAUCCCA UGGGAucuGcAuGcccucAUU 1799 R-008362803-000X2388 174 UUGGAUAUCGCCAGGAUGA B uuGGAuAucGccAGGAuGATT B 1800R-008362803-000X 2388 174 UUGGAUAUCGCCAGGAUGA UCAuccuGGcGAuAuccAAUU 1801R-008362899-000F 2543 175 GCCCAGGACCUCAUGGAUG B GcccAGGAccucAuGGAuGTT B1802 R-008362899-000F 2543 175 GCCCAGGACCUCAUGGAUG CAUccAuGAGGuccuGGGcUU1803 R-008362749-000J 708 176 AACUUGCCACACGUGCAAU BAAcuuGccAcAcGuGcAAuTT B 1804 R-008362749-000J 708 176AACUUGCCACACGUGCAAU AUUGcAcGuGuGGcAAGuuUU 1805 R-008362845-000J 447 177CCCAAGUCCUGUAUGAGUG B cccAAGuccuGuAuGAGuGTT B 1806 R-008362845-000J 447177 CCCAAGUCCUGUAUGAGUG CACucAuAcAGGAcuuGGGUU 1807 R-008362842-000H 654178 CACAGAUGCUGAAACAUGC GCAuGuuucAGcAucuGuGUU 1809 R-008362842-000H 654178 CACAGAUGCUGAAACAUGC B cAcAGAuGcuGAAAcAuGcTT B 1808 R-008362896-000E912 179 CUGGGACCUUGCAUAACCU B cuGGGAccuuGcAuAAccuTT B 1810R-008362896-000E 912 179 CUGGGACCUUGCAUAACCU AGGuuAuGcAAGGucccAGUU 1811R-008363058-000U 1009 180 AGUGGAUUCUGUGUUGUUU AAAcAAcAcAGAAuccAcuUU 1813R-008363058-000U 1009 180 AGUGGAUUCUGUGUUGUUU B AGuGGAuucuGuGuuGuuuTT B1812 R-008362941-000J 1354 181 AAUGCAAGCUUUAGGACUU BAAuGcAAGcuuuAGGAcuuTT B 1814 R-008362941-000J 1354 181AAUGCAAGCUUUAGGACUU AAGuccuAAAGcuuGcAuuUU 1815 R-008362839-000B 1969 182AGAAAUAGUUGAAGGUUGU B AGAAAuAGuuGAAGGuuGuTT B 1816 R-008362839-000B 1969182 AGAAAUAGUUGAAGGUUGU ACAAccuucAAcuAuuucuUU 1817 R-008363055-000T 1959183 UCCGCAUGGAAGAAAUAGU ACUAuuucuuccAuGcGGAUU 1819 R-008363055-000T 1959183 UCCGCAUGGAAGAAAUAGU B uccGcAuGGAAGAAAuAGuTT B 1818 R-008362836-000A557 184 GCUAUGUUCCCUGAGACAU B GcuAuGuucccuGAGAcAuTT B 1820R-008362836-000A 557 184 GCUAUGUUCCCUGAGACAU AUGucucAGGGAAcAuAGcUU 1821R-008363052-000S 403 185 UCUGAGUGGUAAAGGCAAU AUUGccuuuAccAcucAGAUU 1823R-008363052-000S 403 185 UCUGAGUGGUAAAGGCAAU B ucuGAGuGGuAAAGGcAAuTT B1822 R-008363049-000K 1356 186 UGCAAGCUUUAGGACUUCA BuGcAAGcuuuAGGAcuucATT B 1824 R-008363049-000K 1356 186UGCAAGCUUUAGGACUUCA UGAAGuccuAAAGcuuGcAUU 1825 R-008362893-000D 517 187UGGACAGUAUGCAAUGACU B uGGAcAGuAuGcAAuGAcuTT B 1826 R-008362893-000D 517187 UGGACAGUAUGCAAUGACU AGUcAuuGcAuAcuGuccAUU 1827 R-008362890-000C 1238188 UUAGUAAAUAUAAUGAGGA UCCucAuuAuAuuuAcuAAUU 1829 R-008362890-000C 1238188 UUAGUAAAUAUAAUGAGGA B uuAGuAAAuAuAAuGAGGATT B 1828 R-008362995-000F843 189 CUCAGAUGGUGUCUGCUAU B cucAGAuGGuGucuGcuAuTT B 1830R-008362995-000F 843 189 CUCAGAUGGUGUCUGCUAU AUAGcAGAcAccAucuGAGUU 1831R-008362992-000E 496 190 AGAACAAGUAGCUGAUAUU B AGAAcAAGuAGcuGAuAuuTT B1832 R-008362992-000E 496 190 AGAACAAGUAGCUGAUAUU AAUAucAGcuAcuuGuucuUU1833 R-008363046-000J 2387 191 CUUGGAUAUCGCCAGGAUG BcuuGGAuAucGccAGGAuGTT B 1834 R-008363046-000J 2387 191CUUGGAUAUCGCCAGGAUG CAUccuGGcGAuAuccAAGUU 1835 R-008362704-000W 1660 192CAUCUGUGCUCUUCGUCAU AUGAcGAAGAGcAcAGAuGUU 1837 R-008362704-000W 1660 192CAUCUGUGCUCUUCGUCAU B cAucuGuGcucuucGucAuTT B 1836 R-008362938-000C 2497193 CCCUGGUGCUGACUAUCCA B cccuGGuGcuGAcuAuccATT B 1838 R-008362938-000C2497 193 CCCUGGUGCUGACUAUCCA UGGAuAGucAGcAccAGGGUU 1839 R-008363043-000H1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 1840R-008363043-000H 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUU 1841R-008362746-000H 2353 195 UCUUGGACUUGAUAUUGGU B ucuuGGAcuuGAuAuuGGuTT B1842 R-008362746-000H 2353 195 UCUUGGACUUGAUAUUGGU ACCAAuAucAAGuccAAGAUU1843 R-008362743-000G 2401 196 GGAUGAUCCUAGCUAUCGU BGGAuGAuccuAGcuAucGuTT B 1844 R-008362743-000G 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUU 1845 R-008362887-000W 1238 188UUAGUAAAUAUAAUGAGGA B UUAGUAAAUAUAAUGAGGATT B 1846 R-008362887-000W 1238188 UUAGUAAAUAUAAUGAGGA UCCUCAUUAUAUUUACUAAUU 1847 R-008363040-000G 2125133 UGAACUUGCUCAGGACAAG B UGAACUUGCUCAGGACAAGTT B 1848 R-008363040-000G2125 133 UGAACUUGCUCAGGACAAG CUUGUCCUGAGCAAGUUCAUU 1849 R-008362935-000B843 189 CUCAGAUGGUGUCUGCUAU AUAGCAGACACCAUCUGAGUU 1851 R-008362935-000B843 189 CUCAGAUGGUGUCUGCUAU B CUCAGAUGGUGUCUGCUAUTT B 1850R-008362740-000F 496 190 AGAACAAGUAGCUGAUAUU AAUAUCAGCUACUUGUUCUUU 1853R-008362740-000F 496 190 AGAACAAGUAGCUGAUAUU B AGAACAAGUAGCUGAUAUUTT B1852 R-008362884-000V 2074 144 GCUUUAUUCUCCCAUUGAA UUCAAUGGGAGAAUAAAGCUU1855 R-008362884-000V 2074 144 GCUUUAUUCUCCCAUUGAA BGCUUUAUUCUCCCAUUGAATT B 1854 R-008362701-000V 2503 134UGCUGACUAUCCAGUUGAU B UGCUGACUAUCCAGUUGAUTT B 1856 R-008362701-000V 2503134 UGCUGACUAUCCAGUUGAU AUCAACUGGAUAGUCAGCAUU 1857 R-008362698-000C 2387191 CUUGGAUAUCGCCAGGAUG B CUUGGAUAUCGCCAGGAUGTT B 1858 R-008362698-000C2387 191 CUUGGAUAUCGCCAGGAUG CAUCCUGGCGAUAUCCAAGUU 1859 R-008362800-000W1660 192 CAUCUGUGCUCUUCGUCAU AUGACGAAGAGCACAGAUGUU 1861 R-008362800-000W1660 192 CAUCUGUGCUCUUCGUCAU B CAUCUGUGCUCUUCGUCAUTT B 1860R-008362737-000Z 2497 193 CCCUGGUGCUGACUAUCCA B CCCUGGUGCUGACUAUCCATT B1862 R-008362737-000Z 2497 193 CCCUGGUGCUGACUAUCCA UGGAUAGUCAGCACCAGGGUU1863 R-008363037-000A 1503 142 AUGAUAUAAAUGUGGUCAC BAUGAUAUAAAUGUGGUCACTT B 1864 R-008363037-000A 1503 142AUGAUAUAAAUGUGGUCAC GUGACCACAUUUAUAUCAUUU 1865 R-008362734-000Y 2506 137UGACUAUCCAGUUGAUGGG CCCAUCAACUGGAUAGUCAUU 1867 R-008362734-000Y 2506 137UGACUAUCCAGUUGAUGGG B UGACUAUCCAGUUGAUGGGTT B 1866 R-008362797-000D 205271 CCAUUCCAUUGUUUGUGCA UGCACAAACAAUGGAAUGGUU 1869 R-008362797-000D 205271 CCAUUCCAUUGUUUGUGCA B CCAUUCCAUUGUUUGUGCATT B 1868 R-008362731-000X2389 129 UGGAUAUCGCCAGGAUGAU B UGGAUAUCGCCAGGAUGAUTT B 1870R-008362731-000X 2389 129 UGGAUAUCGCCAGGAUGAU AUCAUCCUGGCGAUAUCCAUU 1871R-008362794-000C 1406 146 AACUGUCUUUGGACUCUCA B AACUGUCUUUGGACUCUCATT B1872 R-008362794-000C 1406 146 AACUGUCUUUGGACUCUCA UGAGAGUCCAAAGACAGUUUU1873 R-008362833-000Z 1796 12 ACUGUUGGAUUGAUUCGAA BACUGUUGGAUUGAUUCGAATT B 1874 R-008362833-000Z 1796 12ACUGUUGGAUUGAUUCGAA UUCGAAUCAAUCCAACAGUUU 1875 R-008362989-000Y 2505 139CUGACUAUCCAGUUGAUGG B CUGACUAUCCAGUUGAUGGTT B 1876 R-008362989-000Y 2505139 CUGACUAUCCAGUUGAUGG CCAUCAACUGGAUAGUCAGUU 1877 R-008362791-000B 17975 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAATT B 1878 R-008362791-000B1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUU 1879 R-008362881-000U643 75 GGCUGAACCAUCACAGAUG B GGCUGAACCAUCACAGAUGTT B 1880R-008362881-000U 643 75 GGCUGAACCAUCACAGAUG CAUCUGUGAUGGUUCAGCCUU 1881R-008363034-000Z 582 147 AGGGCAUGCAGAUCCCAUC GAUGGGAUCUGCAUGCCCUUU 1883R-008363034-000Z 582 147 AGGGCAUGCAGAUCCCAUC B AGGGCAUGCAGAUCCCAUCTT B1882 R-008362830-000Y 2502 136 GUGCUGACUAUCCAGUUGA BGUGCUGACUAUCCAGUUGATT B 1884 R-008362830-000Y 2502 136GUGCUGACUAUCCAGUUGA UCAACUGGAUAGUCAGCACUU 1885 R-008362827-000S 1505 148GAUAUAAAUGUGGUCACCU AGGUGACCACAUUUAUAUCUU 1887 R-008362827-000S 1505 148GAUAUAAAUGUGGUCACCU B GAUAUAAAUGUGGUCACCUTT B 1886 R-008362728-000R 1432149 UUCAGAUGCUGCAACUAAA B UUCAGAUGCUGCAACUAAATT B 1888 R-008362728-000R1432 149 UUCAGAUGCUGCAACUAAA UUUAGUUGCAGCAUCUGAAUU 1889 R-008362986-000X1968 150 AAGAAAUAGUUGAAGGUUG CAACCUUCAACUAUUUCUUUU 1891 R-008362986-000X1968 150 AAGAAAUAGUUGAAGGUUG B AAGAAAUAGUUGAAGGUUGTT B 1890R-008362878-000M 694 109 UCAAGAUGAUGCAGAACUU B UCAAGAUGAUGCAGAACUUTT B1892 R-008362878-000M 694 109 UCAAGAUGAUGCAGAACUU AAGUUCUGCAUCAUCUUGAUU1893 R-008362824-000R 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUU1895 R-008362824-000R 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGGAUGAUCCUAGCUAUTT B 1894 R-008362932-000A 2259 125AGGACAAGCCACAAGAUUA UAAUCUUGUGGCUUGUCCUUU 1897 R-008362932-000A 2259 125AGGACAAGCCACAAGAUUA B AGGACAAGCCACAAGAUUATT B 1896 R-008362788-000V 954152 UGGCCAUCUUUAAGUCUGG B UGGCCAUCUUUAAGUCUGGTT B 1898 R-008362788-000V954 152 UGGCCAUCUUUAAGUCUGG CCAGACUUAAAGAUGGCCAUU 1899 R-008362983-000W2197 116 ACUUCACUCUAGGAAUGAA B ACUUCACUCUAGGAAUGAATT B 1900R-008362983-000W 2197 116 ACUUCACUCUAGGAAUGAA UUCAUUCCUAGAGUGAAGUUU 1901R-008362929-000U 505 153 AGCUGAUAUUGAUGGACAG B AGCUGAUAUUGAUGGACAGTT B1902 R-008362929-000U 505 153 AGCUGAUAUUGAUGGACAG CUGUCCAUCAAUAUCAGCUUU1903 R-008362926-000T 2011 154 UCGGGAUGUUCACAACCGA BUCGGGAUGUUCACAACCGATT B 1904 R-008362926-000T 2011 154UCGGGAUGUUCACAACCGA UCGGUUGUGAACAUCCCGAUU 1905 R-008362923-000S 1339 155UGUAGAAGCUGGUGGAAUG B UGUAGAAGCUGGUGGAAUGTT B 1906 R-008362923-000S 1339155 UGUAGAAGCUGGUGGAAUG CAUUCCACCAGCUUCUACAUU 1907 R-008362695-000B 1242156 UAAAUAUAAUGAGGACCUA B UAAAUAUAAUGAGGACCUATT B 1908 R-008362695-000B1242 156 UAAAUAUAAUGAGGACCUA UAGGUCCUCAUUAUAUUUAUU 1909 R-008362692-000A499 107 ACAAGUAGCUGAUAUUGAU B ACAAGUAGCUGAUAUUGAUTT B 1910R-008362692-000A 499 107 ACAAGUAGCUGAUAUUGAU AUCAAUAUCAGCUACUUGUUU 1911R-008362689-000U 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUU 1913R-008362689-000U 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUTT B1912 R-008362785-000U 2353 195 UCUUGGACUUGAUAUUGGU BUCUUGGACUUGAUAUUGGUTT B 1914 R-008362785-000U 2353 195UCUUGGACUUGAUAUUGGU ACCAAUAUCAAGUCCAAGAUU 1915 R-008363031-000Y 2401 196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUU 1917 R-008363031-000Y 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUTT B 1916 R-008362920-000R 878197 AAUACAAAUGAUGUAGAAA UUUCUACAUCAUUUGUAUUUU 1919 R-008362920-000R 878197 AAUACAAAUGAUGUAGAAA B AAUACAAAUGAUGUAGAAATT B 1918 R-008362917-000J2046 112 UAAAUACCAUUCCAUUGUU AACAAUGGAAUGGUAUUUAUU 1921 R-008362917-000J2046 112 UAAAUACCAUUCCAUUGUU B UAAAUACCAUUCCAUUGUUTT B 1920R-008362980-000V 647 198 GAACCAUCACAGAUGCUGA UCAGCAUCUGUGAUGGUUCUU 1923R-008362980-000V 647 198 GAACCAUCACAGAUGCUGA B GAACCAUCACAGAUGCUGATT B1922 R-008362725-000P 1998 199 UUCACAUCCUAGCUCGGGA BUUCACAUCCUAGCUCGGGATT B 1924 R-008362725-000P 1998 199UUCACAUCCUAGCUCGGGA UCCCGAGCUAGGAUGUGAAUU 1925 R-008363028-000S 588 200UGCAGAUCCCAUCUACACA UGUGUAGAUGGGAUCUGCAUU 1927 R-008363028-000S 588 200UGCAGAUCCCAUCUACACA B UGCAGAUCCCAUCUACACATT B 1926 R-008362782-000T 2042201 GGACUAAAUACCAUUCCAU AUGGAAUGGUAUUUAGUCCUU 1929 R-008362782-000T 2042201 GGACUAAAUACCAUUCCAU B GGACUAAAUACCAUUCCAUTT B 1928 R-008362977-000N855 202 CUGCUAUUGUACGUACCAU B CUGCUAUUGUACGUACCAUTT B 1930R-008362977-000N 855 202 CUGCUAUUGUACGUACCAU AUGGUACGUACAAUAGCAGUU 1931R-008362686-000T 2038 203 CAGAGGACUAAAUACCAUU AAUGGUAUUUAGUCCUCUGUU 1933R-008362686-000T 2038 203 CAGAGGACUAAAUACCAUU B CAGAGGACUAAAUACCAUUTT B1932 R-008362875-000L 1786 204 GAUAAAGGCUACUGUUGGA UCCAACAGUAGCCUUUAUCUU1935 R-008362875-000L 1786 204 GAUAAAGGCUACUGUUGGA BGAUAAAGGCUACUGUUGGATT B 1934 R-008363025-000R 1501 205AGAUGAUAUAAAUGUGGUC B AGAUGAUAUAAAUGUGGUCTT B 1936 R-008363025-000R 1501205 AGAUGAUAUAAAUGUGGUC GACCACAUUUAUAUCAUCUUU 1937 R-008362914-000H 1834206 AAAUCAUGCACCUUUGCGU ACGCAAAGGUGCAUGAUUUUU 1939 R-008362914-000H 1834206 AAAUCAUGCACCUUUGCGU B AAAUCAUGCACCUUUGCGUTT B 1938 R-008362872-000K1157 207 ACGACAGACUGCCUUCAAA B ACGACAGACUGCCUUCAAATT B 1940R-008362872-000K 1157 207 ACGACAGACUGCCUUCAAA UUUGAAGGCAGUCUGUCGUUU 1941R-008362974-000M 1239 208 UAGUAAAUAUAAUGAGGAC B UAGUAAAUAUAAUGAGGACTT B1942 R-008362974-000M 1239 208 UAGUAAAUAUAAUGAGGAC GUCCUCAUUAUAUUUACUAUU1943 R-008362821-000P 1248 209 UAAUGAGGACCUAUACUUA BUAAUGAGGACCUAUACUUATT B 1944 R-008362821-000P 1248 209UAAUGAGGACCUAUACUUA UAAGUAUAGGUCCUCAUUAUU 1945 R-008362683-000S 660 210UGCUGAAACAUGCAGUUGU B UGCUGAAACAUGCAGUUGUTT B 1946 R-008362683-000S 660210 UGCUGAAACAUGCAGUUGU ACAACUGCAUGUUUCAGCAUU 1947 R-008363022-000P 285211 AUUUGAUGGAGUUGGACAU B AUUUGAUGGAGUUGGACAUTT B 1948 R-008363022-000P285 211 AUUUGAUGGAGUUGGACAU AUGUCCAACUCCAUCAAAUUU 1949 R-008362779-000L1582 212 CUGCCAAGUGGGUGGUAUA B CUGCCAAGUGGGUGGUAUATT B 1950R-008362779-000L 1582 212 CUGCCAAGUGGGUGGUAUA UAUACCACCCACUUGGCAGUU 1951R-008363019-000H 1735 213 UGGACUACCAGUUGUGGUU AACCACAACUGGUAGUCCAUU 1953R-008363019-000H 1735 213 UGGACUACCAGUUGUGGUU B UGGACUACCAGUUGUGGUUTT B1952 R-008362776-000K 771 214 UUAAUAAGGCUGCAGUUAU AUAACUGCAGCCUUAUUAAUU1955 R-008362776-000K 771 214 UUAAUAAGGCUGCAGUUAU BUUAAUAAGGCUGCAGUUAUTT B 1954 R-008363016-000G 1060 215ACAUCAAGAAGGAGCUAAA B ACAUCAAGAAGGAGCUAAATT B 1956 R-008363016-000G 1060215 ACAUCAAGAAGGAGCUAAA UUUAGCUCCUUCUUGAUGUUU 1957 R-008362773-000J 2390216 GGAUAUCGCCAGGAUGAUC GAUCAUCCUGGCGAUAUCCUU 1959 R-008362773-000J 2390216 GGAUAUCGCCAGGAUGAUC B GGAUAUCGCCAGGAUGAUCTT B 1958 R-008362971-000L2509 81 CUAUCCAGUUGAUGGGCUG CAGCCCAUCAACUGGAUAGUU 1961 R-008362971-000L2509 81 CUAUCCAGUUGAUGGGCUG B CUAUCCAGUUGAUGGGCUGTT B 1960R-008362722-000N 2186 217 CUGACAGAGUUACUUCACU B CUGACAGAGUUACUUCACUTT B1962 R-008362722-000N 2186 217 CUGACAGAGUUACUUCACU AGUGAAGUAACUCUGUCAGUU1963 R-008363013-000F 1632 218 GUGACAGGGAAGACAUCAC BGUGACAGGGAAGACAUCACTT B 1964 R-008363013-000F 1632 218GUGACAGGGAAGACAUCAC GUGAUGUCUUCCCUGUCACUU 1965 R-008362818-000H 619 219UCAUCCCACUAAUGUCCAG CUGGACAUUAGUGGGAUGAUU 1967 R-008362818-000H 619 219UCAUCCCACUAAUGUCCAG B UCAUCCCACUAAUGUCCAGTT B 1966 R-008362968-000E 1656220 CUGCCAUCUGUGCUCUUCG B CUGCCAUCUGUGCUCUUCGTT B 1968 R-008362968-000E1656 220 CUGCCAUCUGUGCUCUUCG CGAAGAGCACAGAUGGCAGUU 1969 R-008362815-000G1506 221 AUAUAAAUGUGGUCACCUG B AUAUAAAUGUGGUCACCUGTT B 1970R-008362815-000G 1506 221 AUAUAAAUGUGGUCACCUG CAGGUGACCACAUUUAUAUUU 1971R-008362869-000D 2501 76 GGUGCUGACUAUCCAGUUG B GGUGCUGACUAUCCAGUUGTT B1972 R-008362869-000D 2501 76 GGUGCUGACUAUCCAGUUG CAACUGGAUAGUCAGCACCUU1973 R-008362719-000G 2494 222 CCACCCUGGUGCUGACUAU AUAGUCAGCACCAGGGUGGUU1975 R-008362719-000G 2494 222 CCACCCUGGUGCUGACUAU BCCACCCUGGUGCUGACUAUTT B 1974 R-008362770-000H 1666 223UGCUCUUCGUCAUCUGACC GGUCAGAUGACGAAGAGCAUU 1977 R-008362770-000H 1666 223UGCUCUUCGUCAUCUGACC B UGCUCUUCGUCAUCUGACCTT B 1976 R-008362680-000R 1635224 ACAGGGAAGACAUCACUGA B ACAGGGAAGACAUCACUGATT B 1978 R-008362680-000R1635 224 ACAGGGAAGACAUCACUGA UCAGUGAUGUCUUCCCUGUUU 1979 R-008362866-000C294 225 AGUUGGACAUGGCCAUGGA UCCAUGGCCAUGUCCAACUUU 1981 R-008362866-000C294 225 AGUUGGACAUGGCCAUGGA B AGUUGGACAUGGCCAUGGATT B 1980R-008362863-000B 641 226 UUGGCUGAACCAUCACAGA B UUGGCUGAACCAUCACAGATT B1982 R-008362863-000B 641 226 UUGGCUGAACCAUCACAGA UCUGUGAUGGUUCAGCCAAUU1983 R-008362965-000D 576 227 UAGAUGAGGGCAUGCAGAU AUCUGCAUGCCCUCAUCUAUU1985 R-008362965-000D 576 227 UAGAUGAGGGCAUGCAGAU BUAGAUGAGGGCAUGCAGAUTT B 1984 R-008362911-000G 577 228AGAUGAGGGCAUGCAGAUC B AGAUGAGGGCAUGCAGAUCTT B 1986 R-008362911-000G 577228 AGAUGAGGGCAUGCAGAUC GAUCUGCAUGCCCUCAUCUUU 1987 R-008362767-000B 1661229 AUCUGUGCUCUUCGUCAUC GAUGACGAAGAGCACAGAUUU 1989 R-008362767-000B 1661229 AUCUGUGCUCUUCGUCAUC B AUCUGUGCUCUUCGUCAUCTT B 1988 R-008362962-000C707 230 GAACUUGCCACACGUGCAA B GAACUUGCCACACGUGCAATT B 1990R-008362962-000C 707 230 GAACUUGCCACACGUGCAA UUGCACGUGUGGCAAGUUCUU 1991R-008362677-000J 1659 231 CCAUCUGUGCUCUUCGUCA B CCAUCUGUGCUCUUCGUCATT B1992 R-008362677-000J 1659 231 CCAUCUGUGCUCUUCGUCA UGACGAAGAGCACAGAUGGUU1993 R-008362674-000H 1547 88 CUCACUUGCAAUAAUUAUA UAUAAUUAUUGCAAGUGAGUU1995 R-008362674-000H 1547 88 CUCACUUGCAAUAAUUAUA BCUCACUUGCAAUAAUUAUATT B 1994 R-008362959-000W 867 90 GUACCAUGCAGAAUACAAAUUUGUAUUCUGCAUGGUACUU 1997 R-008362959-000W 867 90 GUACCAUGCAGAAUACAAA BGUACCAUGCAGAAUACAAATT B 1996 R-008362956-000V 1185 232AUGGCAACCAAGAAAGCAA UUGCUUUCUUGGUUGCCAUUU 1999 R-008362956-000V 1185 232AUGGCAACCAAGAAAGCAA B AUGGCAACCAAGAAAGCAATT B 1998 R-008362764-000A 664233 GAAACAUGCAGUUGUAAAC GUUUACAACUGCAUGUUUCUU 2001 R-008362764-000A 664233 GAAACAUGCAGUUGUAAAC B GAAACAUGCAGUUGUAAACTT B 2000 R-008362716-000F820 18 CAGACACGCUAUCAUGCGU B CAGACACGCUAUCAUGCGUTT B 2002R-008362716-000F 820 18 CAGACACGCUAUCAUGCGU ACGCAUGAUAGCGUGUCUGUU 2003R-008362812-000F 2266 101 GCCACAAGAUUACAAGAAA UUUCUUGUAAUCUUGUGGCUU 2005R-008362812-000F 2266 101 GCCACAAGAUUACAAGAAA B GCCACAAGAUUACAAGAAATT B2004 R-008362671-000G 1749 234 UGGUUAAGCUCUUACACCC GGGUGUAAGAGCUUAACCAUU2007 R-008362671-000G 1749 234 UGGUUAAGCUCUUACACCC BUGGUUAAGCUCUUACACCCTT B 2006 R-008362953-000U 1234 235AGCUUUAGUAAAUAUAAUG B AGCUUUAGUAAAUAUAAUGTT B 2008 R-008362953-000U 1234235 AGCUUUAGUAAAUAUAAUG CAUUAUAUUUACUAAAGCUUU 2009 R-008362950-000T 691236 CUAUCAAGAUGAUGCAGAA B CUAUCAAGAUGAUGCAGAATT B 2010 R-008362950-000T691 236 CUAUCAAGAUGAUGCAGAA UUCUGCAUCAUCUUGAUAGUU 2011 R-008363010-000E1387 237 AAGUCAACGUCUUGUUCAG B AAGUCAACGUCUUGUUCAGTT B 2012R-008363010-000E 1387 237 AAGUCAACGUCUUGUUCAG CUGAACAAGACGUUGACUUUU 2013R-008381224-000R 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2015R-008381224-000R 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2014 R-008381211-000X 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAAUsU B 2017 R-008381211-000X 1797 5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381038-000Y 1797 5CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019 R-008381038-000Y 1797 5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA UsU B 2018 R-008381052-000F1797 5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381052-000F1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008381158-000T 1797 5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016R-008381158-000T 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2021 R-008381341-000J 1797 5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU2016 R-008381341-000J 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAAUsU B 2022 R-008381109-000P 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381109-000P1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023 R-008380818-000X1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008380818-000X 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023R-008381199-000W 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023R-008381199-000W 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B2022 R-008381296-000E 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2024 R-008381296-000E 1797 5 CUGUUGGAUUGAUUCGAAA BCUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381042-000N 1797 5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024 R-008381042-000N 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008380923-000F1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008380923-000F 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024R-008381104-000W 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025R-008381104-000W 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2020 R-008381098-000C 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU2025 R-008381098-000C 1797 5 CUGUUGGAUUGAUUCGAAA BCUGUUGGAUUGAUUCGAAAUsU B 2021 R-008380916-000P 1797 5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008380916-000P1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025 R-008380906-000X1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008380906-000X 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019R-008381291-000L 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019R-008381291-000L 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2021 R-008381334-000T 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU2019 R-008381334-000T 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAAUsU B 2022 R-008381330-000H 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381330-000H1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381036-000F1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381036-000F1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381287-000W 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B2022 R-008381287-000W 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU2026 R-008381027-000X 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGGAUGAUCCUAGCUAUUsU B 2027 R-008381027-000X 2398 151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2028 R-008380896-000U 2398151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2029 R-008380896-000U2398 151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030R-008381153-000Z 2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU2032 R-008381153-000Z 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuUsU B 2031 R-008381323-000S 2398 151CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381323-000S 2398151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381315-000S2398 151 CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030R-008381315-000S 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2034 R-008380888-000U 2398 151 CCAGGAUGAUCCUAGCUAUAuAGcuAGGAucAuccuGGUsU 2030 R-008380888-000U 2398 151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381013-000V2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381013-000V 2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2036 R-008381007-000M 2398 151 CCAGGAUGAUCCUAGCUAUAUAgCUaggaUCaUCCUggUsU 2036 R-008381007-000M 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008380995-000V2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035R-008380995-000V 2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2036 R-008380878-000B 2398 151 CCAGGAUGAUCCUAGCUAUAUAGCUAGGAUCAUCCUGGUsU 2037 R-008380878-000B 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381143-000G2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037R-008381143-000G 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2034 R-008381282-000C 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuUsU B 2035 R-008381282-000C 2398 151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2037 R-008380985-000C 2398151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008380985-000C2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381278-000M 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2038 R-008381278-000M 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381139-000S 2398 151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008381139-000S 2398151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008380871-000R2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032R-008380871-000R 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2033 R-008381272-000K 2398 151 CCAGGAUGAUCCUAGCUAUAUAGcuAGGAucAuccuGGUsU 2032 R-008381272-000K 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381268-000V2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032R-008381268-000V 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B2035 R-008381133-000P 2398 151 CCAGGAUGAUCCUAGCUAUAUAgCUaggaUCaUCCUggUsU 2039 R-008381133-000P 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381261-000J2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2039R-008381261-000J 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2034 R-008381091-000S 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuUsU B 2035 R-008381091-000S 2398 151CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2039 R-008380861-000Y 1870194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2041 R-008380861-000Y1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2040R-008380853-000Y 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2043 R-008380853-000Y 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuUsU B 2042 R-008380811-000L 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2044 R-008380811-000L1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045R-008380974-000B 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2043 R-008380974-000B 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2046 R-008380966-000B 1870 194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043 R-008380966-000B 1870194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381310-000Y1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043R-008381310-000Y 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B2048 R-008381194-000C 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2046 R-008381194-000C 1870 194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2049 R-008380833-000N 1870194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008380833-000N1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2049R-008381115-000X 1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2049 R-008381115-000X 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuUsU B 2048 R-008381242-000H 1870 194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2050 R-008381242-000H 1870194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381235-000S1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008381235-000S 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2050 R-008381231-000G 1870 194 ACGACUAGUUCAGUUGCUUAAGCAACUGAACUAGUCGUUsU 2050 R-008381231-000G 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381304-000R1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051R-008381304-000R 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B2046 R-008380828-000P 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2047 R-008380828-000P 1870 194ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008380926-000G 1870194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2051 R-008380926-000G1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048R-008381350-000T 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008381350-000T 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2046 R-008381162-000H 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381162-000H1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045R-008380823-000W 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008380823-000W 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuUsU B 2048 R-008381068-000A 1870 194ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052 R-008381068-000A 1870194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381190-000T1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052R-008381190-000T 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B2047 R-008380959-000K 1870 194 ACGACUAGUUCAGUUGCUUAAGCaaCUgaaCUagUCgUUsU 2052 R-008380959-000K 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381084-000A2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2054R-008381084-000A 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2053 R-008380848-000Z 2401 196 GGAUGAUCCUAGCUAUCGU BGGAuGAuccuAGcuAucGuUsU B 2055 R-008380848-000Z 2401 196GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056 R-008380807-000W 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2057 R-008380807-000W2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058R-008380843-000F 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2059 R-008380843-000F 2401 196 GGAUGAUCCUAGCUAUCGUAcGAuAGcuAGGAucAuccUsU 2056 R-008381185-000U 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381185-000U2401 196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056R-008380951-000R 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B2061 R-008380951-000R 2401 196 GGAUGAUCCUAGCUAUCGUAcGAuAGcuAGGAucAuccUsU 2056 R-008380804-000V 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380804-000V2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2062R-008381179-000L 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2060 R-008381179-000L 2401 196 GGAUGAUCCUAGCUAUCGUACGaUagCUaggaUCaUCCUsU 2062 R-008381127-000G 2401 196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2062 R-008381127-000G 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008380945-000H2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008380945-000H 2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2063 R-008381071-000G 2401 196 GGAUGAUCCUAGCUAUCGU BGGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381071-000G 2401 196GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063 R-008381173-000J 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008381173-000J2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063R-008381122-000N 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2059 R-008381122-000N 2401 196 GGAUGAUCCUAGCUAUCGUACGAUAGCUAGGAUCAUCCUsU 2064 R-008380801-000U 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008380801-000U2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2064R-008380839-000R 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B2061 R-008380839-000R 2401 196 GGAUGAUCCUAGCUAUCGUACGAUAGCUAGGAUCAUCCUsU 2064 R-008380835-000F 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008380835-000F 2401196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381258-000C2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058R-008381258-000C 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2060 R-008381169-000U 2401 196 GGAUGAUCCUAGCUAUCGUACGAuAGcuAGGAucAuccUsU 2058 R-008381169-000U 2401 196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008380937-000H2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008380937-000H 2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU2065 R-008381251-000S 2401 196 GGAUGAUCCUAGCUAUCGU BGGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381251-000S 2401 196GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2065 R-008380933-000Y 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008380933-000Y2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2065R-008381748-000J 1797 5 CUGUUGGAUUGAUUCGAAA B CUgUuG GAUU GAUUCGaAAUsU B 2066 R-008381748-000J 1797 5 CUGUUGGAUUGAUUCGAAAUUUCGaAUCAauccaACAGUsU 2067 R-008381708-000P 1797 5 CUGUUGGAUUGAUUCGAAAB CUGUuG GaUUGaUUCGAAaUsU B 2069 R-008381708-000P 1797 5CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUsU 2068 R-008381704-000E 1797 5CUGUUGGAUUGAUUCGAAA uUUcgAaUCaAuCCAACAGUsU 2070 R-008381704-000E 1797 5CUGUUGGAUUGAUUCGAAA B CUGUuGgaUUG AUuCGaA A UsU B 2071 R-008381746-000S1797 5 CUGUUGGAUUGAUUCGAAA UUUCGaaUCAAUCcAacaGUsU 2073 R-008381746-000S1797 5 CUGUUGGAUUGAUUCGAAA B C UgUUGgaUUGaUUCgA A A UsU B 2072R-008381728-000Z 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU UGG A UUG AUuCgAAAUsU B 2074 R-008381728-000Z 1797 5 CUGUUGGAUUGAUUCGAAAUUucGaAUCAAUCcAAcagUsU 2075 R-008381686-000B 1797 5 CUGUUGGAUUGAUUCGAAAuuUCGAAUcaaUCCAAcAgUsU 2076 R-008381686-000B 1797 5 CUGUUGGAUUGAUUCGAAAB CuG U UGgaUUgAuUCG AaaUsU B 2077 R-008381726-000G 1797 5CUGUUGGAUUGAUUCGAAA uuUcGAAUCaaUcCAACaGUsU 2078 R-008381726-000G 1797 5CUGUUGGAUUGAUUCGAAA B C UgUUgGaUU G AU UCGaaA UsU B 2079R-008381629-000Y 1797 5 CUGUUGGAUUGAUUCGAAA UUucGAAuCaaUCCAacAGUsU 2081R-008381629-000Y 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGG AU U GaUU CGAaAUsU B 2080 R-008381724-000P 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU U GgAUugAUUCgAAaUsU B 2083 R-008381724-000P 1797 5 CUGUUGGAUUGAUUCGAAAuuuCgaAUCAAUCcAACagUsU 2082 R-008381670-000G 1797 5 CUGUUGGAUUGAUUCGAAAB CugUUGG A UUGaUUcgaaaUsU B 2084 R-008381670-000G 1797 5CUGUUGGAUUGAUUCGAAA UuuCgAAUCAAUCcaACAGUsU 2085 R-008381666-000S 1797 5CUGUUGGAUUGAUUCGAAA UuuCGaauCAaUccaACAGUsU 2087 R-008381666-000S 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUgGaUugAUuCGaAAUsU B 2086 R-008381722-000X1797 5 CUGUUGGAUUGAUUCGAAA B CUG U UgGA U UG A UUCgA A AUsU B 2088R-008381722-000X 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgAauCAAUCcAAcagUsU 2089R-008381700-000V 1797 5 CUGUUGGAUUGAUUCGAAA uUuCGAAUCAaUCcaaCAGUsU 2090R-008381700-000V 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU UggAUUgaUUCGaAA UsU B2091 R-008381650-000X 1797 5 CUGUUGGAUUGAUUCGAAA UuUCGAAUcaauCCaACaGUsU2093 R-008381650-000X 1797 5 CUGUUGGAUUGAUUCGAAA B CU GUUG GaUUGaUUCgAAA UsU B 2092 R-008381647-000R 1797 5 CUGUUGGAUUGAUUCGAAA B CUGU UGGaU UgaU UCgAaaUsU B 2094 R-008381647-000R 1797 5 CUGUUGGAUUGAUUCGAAAUUUCgAAuCAauCcaaCAgUsU 2095 R-008381624-000E 1797 5 CUGUUGGAUUGAUUCGAAAUUUcGaAUCAauCCAaCAGUsU 2097 R-008381624-000E 1797 5 CUGUUGGAUUGAUUCGAAAB CuGuUgGAUUgaU UCGAaAUsU B 2096 R-008381682-000S 1797 5CUGUUGGAUUGAUUCGAAA B C UGUUGgAUUGA U UCGaaaUsU B 2098 R-008381682-000S1797 5 CUGUUGGAUUGAUUCGAAA UUUcgaAUcAAUcCAACagUsU 2099 R-008381622-000M1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAaUcaAUCcaACAgUsU 2101 R-008381622-000M1797 5 CUGUUGGAUUGAUUCGAAA B CUgUUggaUUgaUUCgaaaUsU B 2100R-008381680-000Z 2398 151 CCAGGAUGAUCCUAGCUAU AuaGCUAggAUCAuCCuGGUsU2103 R-008381680-000Z 2398 151 CCAGGAUGAUCCUAGCUAU B C C A GGAUgaUcCUaGCUAU UsU B 2102 R-008381606-000M 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGgaU GaUCCU AgCUA UUsU B 2104 R-008381606-000M 2398 151CCAGGAUGAUCCUAGCUAU AUAgcuaGgaUCAuCcUGgUsU 2105 R-008381714-000X 2398151 CCAGGAUGAUCCUAGCUAU aUagCUAGGaUCauccUGgUsU 2106 R-008381714-000X2398 151 CCAGGAUGAUCCUAGCUAU B CCagG AUgA U CC U AGCUaUUsU B 2107R-008381642-000X 2398 151 CCAGGAUGAUCCUAGCUAU B CCAG GAUG AU CCUA G CUaUUsU B 2109 R-008381642-000X 2398 151 CCAGGAUGAUCCUAGCUAUaUagCuagGAUCAucCugGUsU 2108 R-008381662-000G 2398 151CCAGGAUGAUCCUAGCUAU AUAGcUAgGAuCauCCUggUsU 2111 R-008381662-000G 2398151 CCAGGAUGAUCCUAGCUAU B cC AGgAUGaUCCUagCUA UUsU B 2110R-008381618-000X 2398 151 CCAGGAUGAUCCUAGCUAU auAgCUaGGAuCauCCUGGUsU2112 R-008381618-000X 2398 151 CCAGGAUGAUCCUAGCUAU B CCA GGAUGAUC C U AGCU AUUsU B 2113 R-008381698-000L 2398 151 CCAGGAUGAUCCUAGCUAUaUaGCuaggAUcaUcCUGGUsU 2114 R-008381698-000L 2398 151CCAGGAUGAUCCUAGCUAU B CCAGG A UGAUC C UagC UaUUsU B 2115R-008381742-000G 2398 151 CCAGGAUGAUCCUAGCUAU B CC AgGAUgaU C CUaGCU A UUsU B 2117 R-008381742-000G 2398 151 CCAGGAUGAUCCUAGCUAUaUagCUAggAuCAuCCuGgUsU 2116 R-008381738-000S 2398 151CCAGGAUGAUCCUAGCUAU B CCaggaUgaUCCUagCUaU UsU B 2118 R-008381738-000S2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUaGGAUcauCCUgGUsU 2119R-008381660-000P 2398 151 CCAGGAUGAUCCUAGCUAU B C CAgGAUG AU CCUAGcUAUUsU B 2121 R-008381660-000P 2398 151 CCAGGAUGAUCCUAGCUAUaUagcUAGGAUcaUCCugGUsU 2120 R-008381696-000U 2398 151CCAGGAUGAUCCUAGCUAU B CCaGGaUG A U CCUA G C U AU UsU B 2123R-008381696-000U 2398 151 CCAGGAUGAUCCUAGCUAU auAGcUaggauCAUCCuGGUsU2122 R-008381636-000P 2398 151 CCAGGAUGAUCCUAGCUAUAUAGCUAGgaUCauCcuGGUsU 2125 R-008381636-000P 2398 151CCAGGAUGAUCCUAGCUAU B CC AGGaUGaUC CuAgCUA UUsU B 2124 R-008381634-000X2398 151 CCAGGAUGAUCCUAGCUAU AUaGCUagGAucAuCCUgGUsU 2127R-008381634-000X 2398 151 CCAGGAUGAUCCUAGCUAU B cCAGGaU G AuCCUaGCUaUUsU B 2126 R-008381632-000E 2398 151 CCAGGAUGAUCCUAGCUAU B CCaGgAUgAuCCUAGcU AUUsU B 2129 R-008381632-000E 2398 151 CCAGGAUGAUCCUAGCUAUaUAGCuAGGAUCAUCcUggUsU 2128 R-008381736-000Z 2398 151CCAGGAUGAUCCUAGCUAU AUaGCuAGGaUcAUcCUggUsU 2131 R-008381736-000Z 2398151 CCAGGAUGAUCCUAGCUAU B CcaggAugaUCCU AG CUaU UsU B 2130R-008381600-000K 2398 151 CCAGGAUGAUCCUAGCUAU aUaGcUaggAUCAucCUGGUsU2132 R-008381600-000K 2398 151 CCAGGAUGAUCCUAGCUAU B CCAgGaU GAUcCUaGCUA U UsU B 2133 R-008381732-000P 2398 151 CCAGGAUGAUCCUAGCUAUaUagCuAGGaUCAuCcUgGUsU 2134 R-008381732-000P 2398 151CCAGGAUGAUCCUAGCUAU B CCAggaUGAUC C U AgCU AuUsU B 2135 R-008381656-000Z2398 151 CCAGGAUGAUCCUAGCUAU B CC AGgAUgAU CCUAGcuaUUsU B 2136R-008381656-000Z 2398 151 CCAGGAUGAUCCUAGCUAU AuagCUAgGauCAUcCUGGUsU2137 R-008381750-000G 1870 194 ACGACUAGUUCAGUUGCUUaagCAaCUGaAcuAGUCgUUsU 2138 R-008381750-000G 1870 194ACGACUAGUUCAGUUGCUU B ACgACuAgUUcAGU U GCUU UsU B 2139 R-008381690-000S1870 194 ACGACUAGUUCAGUUGCUU aAGcAACUgAaCUaGUCguUsU 2140R-008381690-000S 1870 194 ACGACUAGUUCAGUUGCUU B aC G ACUAGuUCAgUugcUUUsU B 2141 R-008381616-000E 1870 194 ACGACUAGUUCAGUUGCUUAAGcaACuGaaCUaGuCGUUsU 2143 R-008381616-000E 1870 194ACGACUAGUUCAGUUGCUU B aCGACUagUU CaG UUgCUU UsU B 2142 R-008381688-000U1870 194 ACGACUAGUUCAGUUGCUU aAgCaAcUGAACUAgUcGUUsU 2144R-008381688-000U 1870 194 ACGACUAGUUCAGUUGCUU B aCgaCuAGUuC AgUUgcUUUsU B 2145 R-008381614-000M 1870 194 ACGACUAGUUCAGUUGCUU B aCgaCUAguUCAGUUGC U U UsU B 2147 R-008381614-000M 1870 194ACGACUAGUUCAGUUGCUU aaGCAAcUgAaCuagUcGUUsU 2146 R-008381706-000X 1870194 ACGACUAGUUCAGUUGCUU B ACGaCUA GUU C A GUU GCuU UsU B 2148R-008381706-000X 1870 194 ACGACUAGUUCAGUUGCUU AAgCAAcUGaACUaGUcgUUsU2149 R-008381672-000Z 1870 194 ACGACUAGUUCAGUUGCUUAAgCAacugAAcUagUCGUUsU 2151 R-008381672-000Z 1870 194ACGACUAGUUCAGUUGCUU B ACgAC U A GUUCaG U UGcU UUsU B 2150R-008381730-000X 1870 194 ACGACUAGUUCAGUUGCUU AagcAaCUgaaCUAGucgUUsU2153 R-008381730-000X 1870 194 ACGACUAGUUCAGUUGCUU B acG ACUagUUCagUuGCuU UsU B 2152 R-008381612-000V 1870 194 ACGACUAGUUCAGUUGCUUB aCGAcU A GUU CA GUUgCUUUsU B 2154 R-008381612-000V 1870 194ACGACUAGUUCAGUUGCUU AaGCaAcUGAacUaGUcGUUsU 2155 R-008381702-000M 1870194 ACGACUAGUUCAGUUGCUU AAgcaaCUGAACuaGUCGUUsU 2157 R-008381702-000M1870 194 ACGACUAGUUCAGUUGCUU B A C GA C UaGUUCaGUUgCUU UsU B 2156R-008381744-000Z 1870 194 ACGACUAGUUCAGUUGCUU B ACGaCUaGU U CA G U UGcUU UsU B 2158 R-008381744-000Z 1870 194 ACGACUAGUUCAGUUGCUUAaGCAACUgaACUAGuCGUUsU 2159 R-008381610-000C 1870 194ACGACUAGUUCAGUUGCUU aAgCAACUGAacUaGuCgUUsU 2160 R-008381610-000C 1870194 ACGACUAGUUCAGUUGCUU B ACgAC U AgUUCAgUUgCUUUsU B 2161R-008381608-000E 1870 194 ACGACUAGUUCAGUUGCUU B ACGaCUaGuUCagUUGCUUUsU B 2162 R-008381608-000E 1870 194 ACGACUAGUUCAGUUGCUUAAgCAACUGaACUaGUCguUsU 2163 R-008381654-000G 1870 194ACGACUAGUUCAGUUGCUU aAgCAaCuGaAcuaGUCgUUsU 2164 R-008381654-000G 1870194 ACGACUAGUUCAGUUGCUU B A C GaCUaG UUCaguUgCUuUsU B 2165R-008381668-000J 1870 194 ACGACUAGUUCAGUUGCUU B A CGAC U AG UUCAGUU GCUU UsU B 2167 R-008381668-000J 1870 194 ACGACUAGUUCAGUUGCUUaAgCAACugAACuaguCgUUsU 2166 R-008381627-000F 1870 194ACGACUAGUUCAGUUGCUU B aCgaCUAG UUCaGUUGC UUUsU B 2169 R-008381627-000F1870 194 ACGACUAGUUCAGUUGCUU aAGCAacUgaACUaGUcGUUsU 2168R-008381719-000R 1870 194 ACGACUAGUUCAGUUGCUU B ACgAcU AgUuC AgUUGCUUUsU B 2170 R-008381719-000R 1870 194 ACGACUAGUUCAGUUGCUUAAGCAAcUGAaCUaGUCGuUsU 2171 R-008381717-000Y 1870 194ACGACUAGUUCAGUUGCUU B aCgaCUagUUCagUUgCUU UsU B 2173 R-008381717-000Y1870 194 ACGACUAGUUCAGUUGCUU aaGCAACuGaACUagUcGuUsU 2172R-008381652-000P 2401 196 GGAUGAUCCUAGCUAUCGU ACgaUAGcuAGgauCAUCcUsU2175 R-008381652-000P 2401 196 GGAUGAUCCUAGCUAUCGU B gGaugaUcCUaGCuAUCgU UsU B 2174 R-008381684-000J 2401 196 GGAUGAUCCUAGCUAUCGU BGgAUGaUCCuagcU AUCgUUsU B 2177 R-008381684-000J 2401 196GGAUGAUCCUAGCUAUCGU aCgAUagcuaGGAUcAUCCUsU 2176 R-008381664-000Z 2401196 GGAUGAUCCUAGCUAUCGU B gGA UgAUCCU A GCuaUC GUUsU B 2179R-008381664-000Z 2401 196 GGAUGAUCCUAGCUAUCGU aCGauAGCuAgGaUcauCCUsU2178 R-008381645-000Y 2401 196 GGAUGAUCCUAGCUAUCGUacgAUAGCUaGgAUCAuCCUsU 2180 R-008381645-000Y 2401 196GGAUGAUCCUAGCUAUCGU B gG A U GAUCCUAgC UauCGUUsU B 2181 R-008381678-000B2401 196 GGAUGAUCCUAGCUAUCGU ACgaUAgCUaGGAuCAUCcUsU 2183R-008381678-000B 2401 196 GGAUGAUCCUAGCUAUCGU B ggaUgaUCCUagCUaUCgUUsU B 2182 R-008381620-000V 2401 196 GGAUGAUCCUAGCUAUCGUaCgauAgCUAggAucaUcCUsU 2184 R-008381620-000V 2401 196GGAUGAUCCUAGCUAUCGU B G GaUGAUCCUAG CUaU CgU UsU B 2185 R-008381712-000E2401 196 GGAUGAUCCUAGCUAUCGU aCGAuaGCuAGGAuCaUCCUsU 2186R-008381712-000E 2401 196 GGAUGAUCCUAGCUAUCGU B GGaU G A U C CUaGCUAUCgUUsU B 2187 R-008381710-000M 2401 196 GGAUGAUCCUAGCUAUCGU BgGaUgAU CC UaGCUAUCG UUsU B 2188 R-008381710-000M 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAgcUaGGAUCauCCUsU 2189 R-008381676-000J 2401196 GGAUGAUCCUAGCUAUCGU aCGAuaGCUAGgAUCaUccUsU 2190 R-008381676-000J2401 196 GGAUGAUCCUAGCUAUCGU B GgAUGauC CUAGCUAU CguUsU B 2191R-008381604-000V 2401 196 GGAUGAUCCUAGCUAUCGU B GgaUgAUCcUagCUaUCGuUsU B2192 R-008381604-000V 2401 196 GGAUGAUCCUAGCUAUCGUACGAuAgCUagGAuCAUCcUsU 2193 R-008381640-000E 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGaU C CUaGCUaUcgU UsU B 2194 R-008381640-000E2401 196 GGAUGAUCCUAGCUAUCGU AcGAUAGCUAGgaucaUCCUsU 2195R-008381740-000P 2401 196 GGAUGAUCCUAGCUAUCGU acgAuaGCUagGauCAUcCUsU2196 R-008381740-000P 2401 196 GGAUGAUCCUAGCUAUCGU B GgAUGA UCCUagCU AUC G U UsU B 2197 R-008381674-000S 2401 196 GGAUGAUCCUAGCUAUCGU B G GAUGAuC CUaG CUAU C GU UsU B 2199 R-008381674-000S 2401 196GGAUGAUCCUAGCUAUCGU aCgAUagcUAGGAuCAuCCUsU 2198 R-008381694-000B 2401196 GGAUGAUCCUAGCUAUCGU B GgaU GaUCC UAgCUAUCGUUsU B 2201R-008381694-000B 2401 196 GGAUGAUCCUAGCUAUCGU aCGAUaGCuAGGauCauCCUsU2200 R-008381638-000G 2401 196 GGAUGAUCCUAGCUAUCGU B G GA UgA UCC UAgcUAU CgUUsU B 2203 R-008381638-000G 2401 196 GGAUGAUCCUAGCUAUCGUaCGaUagcUAgGAUcAuCcUsU 2202 R-008381602-000C 2401 196GGAUGAUCCUAGCUAUCGU B GGaUgaU CCuAG CuA UCGU UsU B 2204 R-008381602-000C2401 196 GGAUGAUCCUAGCUAUCGU AcGAUaGCUaGGauCAUccUsU 2205R-008381692-000J 2401 196 GGAUGAUCCUAGCUAUCGU AcgaUagCUAGGAUcAucCUsU2207 R-008381692-000J 2401 196 GGAUGAUCCUAGCUAUCGU B GG AUGAUCCUagCUAuCGU UsU B 2206 R-008381658-000S 2401 196 GGAUGAUCCUAGCUAUCGU BgGAUgaUCCUAGC UaU C GU UsU B 2208 R-008381658-000S 2401 196GGAUGAUCCUAGCUAUCGU ACGaUAGcuaggAuCAUcCUsU 2209 R-008381178-000C 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381178-000C1797 5 CUGUUGGAUUGAUUCGAAA UUUCGaAUCAauccaACAGUsU 2067 R-008380929-000H1797 5 CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUsU 2068 R-008380929-000H1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381019-000X 1797 5 CUGUUGGAUUGAUUCGAAA uUUcgAaUCaAuCCAACAGUsU 2070R-008381019-000X 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B2022 R-008381256-000K 1797 5 CUGUUGGAUUGAUUCGAAA BCUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381256-000K 1797 5CUGUUGGAUUGAUUCGAAA UUUCGaaUCAAUCcAacaGUsU 2073 R-008381552-000E 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381552-000E1797 5 CUGUUGGAUUGAUUCGAAA UUucGaAUCAAUCcAAcagUsU 2075 R-008381002-000U1797 5 CUGUUGGAUUGAUUCGAAA uuUCGAAUcaaUCCAAcAgUsU 2076 R-008381002-000U1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008381394-000X 1797 5 CUGUUGGAUUGAUUCGAAA uuUcGAAUCaaUcCAACaGUsU 2078R-008381394-000X 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2020 R-008381383-000W 1797 5 CUGUUGGAUUGAUUCGAAA UUucGAAuCaaUCCAacAGUsU2081 R-008381383-000W 1797 5 CUGUUGGAUUGAUUCGAAA BCUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381093-000J 1797 5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022 R-008381093-000J1797 5 CUGUUGGAUUGAUUCGAAA uuuCgaAUCAAUCcAACagUsU 2082 R-008381375-000W1797 5 CUGUUGGAUUGAUUCGAAA UuuCgAAUCAAUCcaACAGUsU 2085 R-008381375-000W1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020R-008381543-000W 1797 5 CUGUUGGAUUGAUUCGAAA UuuCGaauCAaUccaACAGUsU 2087R-008381543-000W 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B2021 R-008381535-000W 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgAauCAAUCcAAcagUsU2089 R-008381535-000W 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAAUsU B 2022 R-008381528-000E 1797 5CUGUUGGAUUGAUUCGAAA uUuCGAAUCAaUCcaaCAGUsU 2090 R-008381528-000E 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2020 R-008381365-000D1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021R-008381365-000D 1797 5 CUGUUGGAUUGAUUCGAAA UuUCGAAUcaauCCaACaGUsU 2093R-008381520-000K 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgAAuCAauCcaaCAgUsU 2095R-008381520-000K 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B2022 R-008380915-000F 1797 5 CUGUUGGAUUGAUUCGAAA BCUGUUGGAUUGAUUCGAAAUsU B 2020 R-008380915-000F 1797 5CUGUUGGAUUGAUUCGAAA UUUcGaAUCAauCCAaCAGUsU 2097 R-008381359-000W 1797 5CUGUUGGAUUGAUUCGAAA UUUcgaAUcAAUcCAACagUsU 2099 R-008381359-000W 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUsU B 2021 R-008381249-000U1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAAUsU B 2022R-008381249-000U 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAaUcaAUCcaACAgUsU 2101R-008381082-000H 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2033 R-008381082-000H 2398 151 CCAGGAUGAUCCUAGCUAUAuaGCUAggAUCAuCCuGGUsU 2103 R-008381240-000R 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381240-000R2398 151 CCAGGAUGAUCCUAGCUAU AUAgcuaGgaUCAuCcUGgUsU 2105R-008380907-000F 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B2035 R-008380907-000F 2398 151 CCAGGAUGAUCCUAGCUAUaUagCUAGGaUCauccUGgUsU 2106 R-008381164-000A 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381164-000A2398 151 CCAGGAUGAUCCUAGCUAU aUagCuagGAUCAucCugGUsU 2108R-008381072-000R 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2034 R-008381072-000R 2398 151 CCAGGAUGAUCCUAGCUAUAUAGcUAgGAuCauCCUggUsU 2111 R-008381450-000C 2398 151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381450-000C2398 151 CCAGGAUGAUCCUAGCUAU auAgCUaGGAuCauCCUGGUsU 2112R-008381059-000S 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B2033 R-008381059-000S 2398 151 CCAGGAUGAUCCUAGCUAUaUaGCuaggAUcaUcCUGGUsU 2114 R-008381154-000H 2398 151CCAGGAUGAUCCUAGCUAU aUagCUAggAuCAuCCuGgUsU 2116 R-008381154-000H 2398151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381443-000L2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUaGGAUcauCCUgGUsU 2119R-008381443-000L 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B2035 R-008381049-000Z 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381049-000Z 2398 151CCAGGAUGAUCCUAGCUAU aUagcUAGGAUcaUCCugGUsU 2120 R-008381292-000V 2398151 CCAGGAUGAUCCUAGCUAU auAGcUaggauCAUCCuGGUsU 2122 R-008381292-000V2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034R-008381010-000U 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGgaUCauCcuGGUsU2125 R-008381010-000U 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuUsU B 2035 R-008381284-000V 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033 R-008381284-000V2398 151 CCAGGAUGAUCCUAGCUAU AUaGCUagGAucAuCCUgGUsU 2127R-008381417-000U 2398 151 CCAGGAUGAUCCUAGCUAU aUAGCuAGGAUCAUCcUggUsU2128 R-008381417-000U 2398 151 CCAGGAUGAUCCUAGCUAU BCCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381265-000U 2398 151CCAGGAUGAUCCUAGCUAU AUaGCuAGGaUcAUcCUggUsU 2131 R-008381265-000U 2398151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035 R-008381464-000E2398 151 CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2033R-008381464-000E 2398 151 CCAGGAUGAUCCUAGCUAU aUaGcUaggAUCAucCUGGUsU2132 R-008381170-000H 2398 151 CCAGGAUGAUCCUAGCUAUaUagCuAGGaUCAuCcUgGUsU 2134 R-008381170-000H 2398 151CCAGGAUGAUCCUAGCUAU B CCAGGAUGAUCCUAGCUAUUsU B 2034 R-008381408-000K2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuUsU B 2035R-008381408-000K 2398 151 CCAGGAUGAUCCUAGCUAU AuagCUAgGauCAUcCUGGUsU2137 R-008381110-000D 1870 194 ACGACUAGUUCAGUUGCUUaagCAaCUGaAcuAGUCgUUsU 2138 R-008381110-000D 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381558-000G1870 194 ACGACUAGUUCAGUUGCUU aAGcAACUgAaCUaGUCguUsU 2140R-008381558-000G 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B2047 R-008381456-000E 1870 194 ACGACUAGUUCAGUUGCUUAAGcaACuGaaCUaGuCGUUsU 2143 R-008381456-000E 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381401-000Z1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046R-008381401-000Z 1870 194 ACGACUAGUUCAGUUGCUU aAgCaAcUGAACUAgUcGUUsU2144 R-008380922-000X 1870 194 ACGACUAGUUCAGUUGCUUaaGCAAcUgAaCuagUcGUUsU 2146 R-008380922-000X 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381101-000V1870 194 ACGACUAGUUCAGUUGCUU AAgCAAcUGaACUaGUcgUUsU 2149R-008381101-000V 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B2048 R-008381556-000P 1870 194 ACGACUAGUUCAGUUGCUUAAgCAacugAAcUagUCGUUsU 2151 R-008381556-000P 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008381426-000C1870 194 ACGACUAGUUCAGUUGCUU AagcAaCUgaaCUAGucgUUsU 2153R-008381426-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B2047 R-008380979-000V 1870 194 ACGACUAGUUCAGUUGCUUAaGCaAcUGAacUaGUcGUUsU 2155 R-008380979-000V 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008380882-000S1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046R-008380882-000S 1870 194 ACGACUAGUUCAGUUGCUU AAgcaaCUGAACuaGUCGUUsU2157 R-008381204-000F 1870 194 ACGACUAGUUCAGUUGCUUAaGCAACUgaACUAGuCGUUsU 2159 R-008381204-000F 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047 R-008381471-000W1870 194 ACGACUAGUUCAGUUGCUU aAgCAACUGAacUaGuCgUUsU 2160R-008381471-000W 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B2048 R-008381197-000D 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2046 R-008381197-000D 1870 194ACGACUAGUUCAGUUGCUU AAgCAACUGaACUaGUCguUsU 2163 R-008380970-000S 1870194 ACGACUAGUUCAGUUGCUU aAgCAaCuGaAcuaGUCgUUsU 2164 R-008380970-000S1870 194 ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2047R-008381511-000B 1870 194 ACGACUAGUUCAGUUGCUU aAgCAACugAACuaguCgUUsU2166 R-008381511-000B 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuUsU B 2048 R-008380992-000U 1870 194ACGACUAGUUCAGUUGCUU B ACGACUAGUUCAGUUGCUUUsU B 2046 R-008380992-000U1870 194 ACGACUAGUUCAGUUGCUU aAGCAacUgaACUaGUcGUUsU 2168R-008381233-000Z 1870 194 ACGACUAGUUCAGUUGCUU AAGCAAcUGAaCUaGUCGuUsU2171 R-008381233-000Z 1870 194 ACGACUAGUUCAGUUGCUU BACGACUAGUUCAGUUGCUUUsU B 2047 R-008381352-000K 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuUsU B 2048 R-008381352-000K1870 194 ACGACUAGUUCAGUUGCUU aaGCAACuGaACUagUcGuUsU 2172R-008380987-000V 2401 196 GGAUGAUCCUAGCUAUCGU ACgaUAGcuAGgauCAUCcUsU2175 R-008380987-000V 2401 196 GGAUGAUCCUAGCUAUCGU BGGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381345-000U 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381345-000U2401 196 GGAUGAUCCUAGCUAUCGU aCgAUagcuaGGAUcAUCCUsU 2176R-008381146-000H 2401 196 GGAUGAUCCUAGCUAUCGU aCGauAGCuAgGaUcauCCUsU2178 R-008381146-000H 2401 196 GGAUGAUCCUAGCUAUCGU BGGAuGAuccuAGcuAucGuUsU B 2061 R-008381503-000B 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381503-000B2401 196 GGAUGAUCCUAGCUAUCGU acgAUAGCUaGgAUCAuCCUsU 2180R-008381137-000Z 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2060 R-008381137-000Z 2401 196 GGAUGAUCCUAGCUAUCGUACgaUAgCUaGGAuCAUCcUsU 2183 R-008381337-000U 2401 196GGAUGAUCCUAGCUAUCGU aCgauAgCUAggAucaUcCUsU 2184 R-008381337-000U 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008380900-000V2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008380900-000V 2401 196 GGAUGAUCCUAGCUAUCGU aCGAuaGCuAGGAuCaUCCUsU2186 R-008381328-000K 2401 196 GGAUGAUCCUAGCUAUCGU BGGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381328-000K 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAgcUaGGAUCauCCUsU 2189 R-008381222-000Y 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008381222-000Y2401 196 GGAUGAUCCUAGCUAUCGU aCGAuaGCUAGgAUCaUccUsU 2190R-008381494-000G 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAgCUagGAuCAUCcUsU2193 R-008381494-000G 2401 196 GGAUGAUCCUAGCUAUCGU BGGAUGAUCCUAGCUAUCGUUsU B 2059 R-008381212-000F 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008381212-000F2401 196 GGAUGAUCCUAGCUAUCGU AcGAUAGCUAGgaucaUCCUsU 2195R-008381434-000C 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B2061 R-008381434-000C 2401 196 GGAUGAUCCUAGCUAUCGUacgAuaGCUagGauCAUcCUsU 2196 R-008380895-000K 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059 R-008380895-000K2401 196 GGAUGAUCCUAGCUAUCGU aCgAUagcUAGGAuCAuCCUsU 2198R-008381488-000Z 2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B2060 R-008381488-000Z 2401 196 GGAUGAUCCUAGCUAUCGUaCGAUaGCuAGGauCauCCUsU 2200 R-008381126-000Y 2401 196GGAUGAUCCUAGCUAUCGU aCGaUagcUAgGAUcAuCcUsU 2202 R-008381126-000Y 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061 R-008381479-000R2401 196 GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2059R-008381479-000R 2401 196 GGAUGAUCCUAGCUAUCGU AcGAUaGCUaGGauCAUccUsU2205 R-008381319-000B 2401 196 GGAUGAUCCUAGCUAUCGUAcgaUagCUAGGAUcAucCUsU 2207 R-008381319-000B 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGAUCCUAGCUAUCGUUsU B 2060 R-008380889-000C2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuUsU B 2061R-008380889-000C 2401 196 GGAUGAUCCUAGCUAUCGU ACGaUAGcuaggAuCAUcCUsU2209 R-008381831-000R 1797 5 CUGUUGGAUUGAUUCGAAA B CUgUuG GAUU GAUUCGaAAUsU B 2066 R-008381831-000R 1797 5 CUGUUGGAUUGAUUCGAAAuuucGAAucAAuccAAcAGUsU 2016 R-008381842-000S 1797 5 CUGUUGGAUUGAUUCGAAAB CUGUuG GaUUGaUUCGAAaUsU B 2069 R-008381842-000S 1797 5CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381850-000S 1797 5CUGUUGGAUUGAUUCGAAA B CUGUuGgaUUG AUuCGaA A UsU B 2071 R-008381850-000S1797 5 CUGUUGGAUUGAUUCGAAA uuucGAAucAAuccAAcAGUsU 2016 R-008381815-000R1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023 R-008381815-000R1797 5 CUGUUGGAUUGAUUCGAAA B C UgUUGgaUUGaUUCgA A A UsU B 2072R-008381783-000K 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU UGG A UUG AUuCgAAAUsU B 2074 R-008381783-000K 1797 5 CUGUUGGAUUGAUUCGAAAUUUCgaaUCaaUCCaaCagUsU 2023 R-008381799-000E 1797 5 CUGUUGGAUUGAUUCGAAAB CuG U UGgaUUgAuUCG AaaUsU B 2077 R-008381799-000E 1797 5CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2023 R-008381814-000G 1797 5CUGUUGGAUUGAUUCGAAA B C UgUUgGaUU G AU UCGaaA UsU B 2079R-008381814-000G 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024R-008381780-000J 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2024R-008381780-000J 1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGG AU U GaUU CGAaAUsU B 2080 R-008381841-000H 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU U GgAUugAUUCgAAaUsU B 2083 R-008381841-000H 1797 5 CUGUUGGAUUGAUUCGAAAUUUCGAAUCAAUCCAACAGUsU 2024 R-008381791-000K 1797 5 CUGUUGGAUUGAUUCGAAAB CugUUGG A UUGaUUcgaaaUsU B 2084 R-008381791-000K 1797 5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025 R-008381839-000K 1797 5CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025 R-008381839-000K 1797 5CUGUUGGAUUGAUUCGAAA B CUGUUgGaUugAUuCGaAAUsU B 2086 R-008381796-000D1797 5 CUGUUGGAUUGAUUCGAAA B CUG U UgGA U UG A UUCgA A AUsU B 2088R-008381796-000D 1797 5 CUGUUGGAUUGAUUCGAAA UUUCGAAUCAAUCCAACAGUsU 2025R-008381838-000B 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019R-008381838-000B 1797 5 CUGUUGGAUUGAUUCGAAA B CUgU UggAUUgaUUCGaAA UsU B2091 R-008381790-000B 1797 5 CUGUUGGAUUGAUUCGAAA B CU GUUG GaUUGaUUCgAAA UsU B 2092 R-008381790-000B 1797 5 CUGUUGGAUUGAUUCGAAAUUUcGAAucAAuccAAcAGUsU 2019 R-008381825-000H 1797 5 CUGUUGGAUUGAUUCGAAAB CUGU U GGaU UgaU UCgAaaUsU B 2094 R-008381825-000H 1797 5CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUsU 2019 R-008381789-000M 1797 5CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381789-000M 1797 5CUGUUGGAUUGAUUCGAAA B CuGuUgGAUUgaU UCGAaAUsU B 2096 R-008381805-000Y1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026 R-008381805-000Y1797 5 CUGUUGGAUUGAUUCGAAA B C UGUUGgAUUGA U UCGaaaUsU B 2098R-008381788-000D 1797 5 CUGUUGGAUUGAUUCGAAA UUUCgaaUCaaUCCaaCagUsU 2026R-008381788-000D 1797 5 CUGUUGGAUUGAUUCGAAA B CUgUUggaUUgaUUCgaaaUsU B2100 R-008381847-000K 2398 151 CCAGGAUGAUCCUAGCUAU B C C A GGAUgaUcCUaGCUAU UsU B 2102 R-008381847-000K 2398 151 CCAGGAUGAUCCUAGCUAUAuAGcuAGGAucAuccuGGUsU 2030 R-008381837-000T 2398 151CCAGGAUGAUCCUAGCUAU AuAGcuAGGAucAuccuGGUsU 2030 R-008381837-000T 2398151 CCAGGAUGAUCCUAGCUAU B CCAGgaU GaUCCU AgCUA UUsU B 2104R-008381824-000Z 2398 151 CCAGGAUGAUCCUAGCUAU B CCagG AUgA U CC UAGCUaUUsU B 2107 R-008381824-000Z 2398 151 CCAGGAUGAUCCUAGCUAUAuAGcuAGGAucAuccuGGUsU 2030 R-008381810-000X 2398 151CCAGGAUGAUCCUAGCUAU B CCAG GAUG AU CCUA G C UaUUsU B 2109R-008381810-000X 2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2036 R-008381802-000X 2398 151 CCAGGAUGAUCCUAGCUAU B cC AGgAUGaUCCUagCUAUUsU B 2110 R-008381802-000X 2398 151 CCAGGAUGAUCCUAGCUAUAUAgCUaggaUCaUCCUggUsU 2036 R-008381820-000P 2398 151CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU 2036 R-008381820-000P 2398151 CCAGGAUGAUCCUAGCUAU B CCA GGAUGAUC C U A GCU AUUsU B 2113R-008381819-000A 2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU2037 R-008381819-000A 2398 151 CCAGGAUGAUCCUAGCUAU B CCAGG A UGAUC CUagC UaUUsU B 2115 R-008381787-000V 2398 151 CCAGGAUGAUCCUAGCUAUAUAGCUAGGAUCAUCCUGGUsU 2037 R-008381787-000V 2398 151CCAGGAUGAUCCUAGCUAU B CC AgGAUgaU C CUaGCU A U UsU B 2117R-008381835-000A 2398 151 CCAGGAUGAUCCUAGCUAU B CCaggaUgaUCCUagCUaUUsU B 2118 R-008381835-000A 2398 151 CCAGGAUGAUCCUAGCUAUAUAGCUAGGAUCAUCCUGGUsU 2037 R-008381844-000J 2398 151CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038 R-008381844-000J 2398151 CCAGGAUGAUCCUAGCUAU B C C AgGAUG AU CCUAGcUA UUsU B 2121R-008381853-000T 2398 151 CCAGGAUGAUCCUAGCUAU B CCaGGaUG A U CCUA G C UAU UsU B 2123 R-008381853-000T 2398 151 CCAGGAUGAUCCUAGCUAUAUAGCUAGGAUCAUCCUGGUsU 2038 R-008381833-000H 2398 151CCAGGAUGAUCCUAGCUAU B CC AGGaUGaUC CuAgCUA UUsU B 2124 R-008381833-000H2398 151 CCAGGAUGAUCCUAGCUAU AUAGCUAGGAUCAUCCUGGUsU 2038R-008381817-000H 2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU2032 R-008381817-000H 2398 151 CCAGGAUGAUCCUAGCUAU B cCAGGaU GAuCCUaGCUaU UsU B 2126 R-008381786-000L 2398 151 CCAGGAUGAUCCUAGCUAUAUAGcuAGGAucAuccuGGUsU 2032 R-008381786-000L 2398 151CCAGGAUGAUCCUAGCUAU B CCaGgAUgAuCCU AGcU AUUsU B 2129 R-008381851-000A2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUsU 2032R-008381851-000A 2398 151 CCAGGAUGAUCCUAGCUAU B CcaggAugaUCCU AG CUaUUsU B 2130 R-008381809-000H 2398 151 CCAGGAUGAUCCUAGCUAUAUAgCUaggaUCaUCCUggUsU 2039 R-008381809-000H 2398 151CCAGGAUGAUCCUAGCUAU B CCAgGaU GAUcCUaGC UA U UsU B 2133 R-008381808-000Z2398 151 CCAGGAUGAUCCUAGCUAU B CCAggaUGAUC C U AgCU AuUsU B 2135R-008381808-000Z 2398 151 CCAGGAUGAUCCUAGCUAU AUAgCUaggaUCaUCCUggUsU2039 R-008381784-000U 2398 151 CCAGGAUGAUCCUAGCUAUAUAgCUaggaUCaUCCUggUsU 2039 R-008381784-000U 2398 151CCAGGAUGAUCCUAGCUAU B C CAGgAUgAU CCUAGcuaUUsU B 2136 R-008381793-000C1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043R-008381793-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACgACuAgUUcAGU U GCUUUsU B 2139 R-008381807-000R 1870 194 ACGACUAGUUCAGUUGCUUAAGcAAcuGAAcuAGucGuUsU 2043 R-008381807-000R 1870 194ACGACUAGUUCAGUUGCUU B aC G A CUAGuUCAgUugcUUUsU B 2141 R-008381816-000Z1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2043R-008381816-000Z 1870 194 ACGACUAGUUCAGUUGCUU B aCGACUagUU CaG UUgCUUUsU B 2142 R-008381830-000G 1870 194 ACGACUAGUUCAGUUGCUUAAGCaaCUgaaCUagUCgUUsU 2049 R-008381830-000G 1870 194ACGACUAGUUCAGUUGCUU B aCgaCuAGUuC AgU UgcUUUsU B 2145 R-008381782-000B1870 194 ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU UUsU B 2147R-008381782-000B 1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU2049 R-008381849-000C 1870 194 ACGACUAGUUCAGUUGCUU B ACGaCUA GUU C A GUUGCuU UsU B 2148 R-008381849-000C 1870 194 ACGACUAGUUCAGUUGCUUAAGCaaCUgaaCUagUCgUUsU 2049 R-008381781-000T 1870 194ACGACUAGUUCAGUUGCUU B ACgAC U A GUUCaG U UGcU UUsU B 2150R-008381781-000T 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2050 R-008381829-000T 1870 194 ACGACUAGUUCAGUUGCUU B acG ACUagUUCagUuGCuU UsU B 2152 R-008381829-000T 1870 194 ACGACUAGUUCAGUUGCUUAAGCAACUGAACUAGUCGUUsU 2050 R-008381792-000U 1870 194ACGACUAGUUCAGUUGCUU B aCGAcU A GUU CA GUUgCUUUsU B 2154 R-008381792-000U1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU 2050R-008381798-000W 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2051 R-008381798-000W 1870 194 ACGACUAGUUCAGUUGCUU B A C GA CUaGUUCaGUUgCUU UsU B 2156 R-008381828-000J 1870 194 ACGACUAGUUCAGUUGCUUAAGCAACUGAACUAGUCGUUsU 2051 R-008381828-000J 1870 194ACGACUAGUUCAGUUGCUU B A CGaCUaGU U CA G U U GcUU UsU B 2158R-008381840-000Z 1870 194 ACGACUAGUUCAGUUGCUU AAGCAACUGAACUAGUCGUUsU2051 R-008381840-000Z 1870 194 ACGACUAGUUCAGUUGCUU B ACgAC UAgUUCAgUUgCUUUsU B 2161 R-008381797-000M 1870 194 ACGACUAGUUCAGUUGCUU BACGaCUaGuUCagUUG CUUUsU B 2162 R-008381797-000M 1870 194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU 2045 R-008381813-000Y 1870194 ACGACUAGUUCAGUUGCUU B A C GaCUaG UUCaguUgCUuUsU B 2165R-008381813-000Y 1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUsU2045 R-008381827-000A 1870 194 ACGACUAGUUCAGUUGCUU B A CGAC U AG UUCAGUUG CUU UsU B 2167 R-008381827-000A 1870 194 ACGACUAGUUCAGUUGCUUAAGcAAcuGAAcuAGucGuUsU 2045 R-008381812-000P 1870 194ACGACUAGUUCAGUUGCUU B aCgaCUAG UUCaGUUG C UUUsU B 2169 R-008381812-000P1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052R-008381848-000U 1870 194 ACGACUAGUUCAGUUGCUU B ACgAcU AgUuC AgUUGCUUUsU B 2170 R-008381848-000U 1870 194 ACGACUAGUUCAGUUGCUUAAGCaaCUgaaCUagUCgUUsU 2052 R-008381779-000V 1870 194ACGACUAGUUCAGUUGCUU B aCgaCUagUUCagUUgCUU UsU B 2173 R-008381779-000V1870 194 ACGACUAGUUCAGUUGCUU AAGCaaCUgaaCUagUCgUUsU 2052R-008381846-000B 2401 196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU2056 R-008381846-000B 2401 196 GGAUGAUCCUAGCUAUCGU B gGaugaUcCUaGCuAUCgUUsU B 2174 R-008381811-000F 2401 196 GGAUGAUCCUAGCUAUCGU BGgAUGaUCCuagcU AUCgUUsU B 2177 R-008381811-000F 2401 196GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU 2056 R-008381845-000T 2401196 GGAUGAUCCUAGCUAUCGU B gGA UgAUC CU A GCuaUC GUUsU B 2179R-008381845-000T 2401 196 GGAUGAUCCUAGCUAUCGU AcGAuAGcuAGGAucAuccUsU2056 R-008381795-000V 2401 196 GGAUGAUCCUAGCUAUCGUACGaUagCUaggaUCaUCCUsU 2062 R-008381795-000V 2401 196GGAUGAUCCUAGCUAUCGU B gG A U GAUCCUAgC UauCGUUsU B 2181 R-008381823-000R2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2062R-008381823-000R 2401 196 GGAUGAUCCUAGCUAUCGU B ggaUgaUCCUagCUaUCgUUsU B 2182 R-008381803-000F 2401 196 GGAUGAUCCUAGCUAUCGUACGaUagCUaggaUCaUCCUsU 2062 R-008381803-000F 2401 196GGAUGAUCCUAGCUAUCGU B G GaUGAUCCUAG CUaU CgU UsU B 2185 R-008381822-000G2401 196 GGAUGAUCCUAGCUAUCGU B GGaU G A U C C UaGCUAUCgUUsU B 2187R-008381822-000G 2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU2063 R-008381836-000J 2401 196 GGAUGAUCCUAGCUAUCGU B gGaUgAU CCUaGCUAUCG UUsU B 2188 R-008381836-000J 2401 196 GGAUGAUCCUAGCUAUCGUACGAUAGCUAGGAUCAUCCUsU 2063 R-008381854-000B 2401 196GGAUGAUCCUAGCUAUCGU B GgAUGauC CUAGCUAU CguUsU B 2191 R-008381854-000B2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2063R-008381801-000N 2401 196 GGAUGAUCCUAGCUAUCGU B GgaUgAUCcUagCUaUCGuUsU B2192 R-008381801-000N 2401 196 GGAUGAUCCUAGCUAUCGUACGAUAGCUAGGAUCAUCCUsU 2064 R-008381800-000E 2401 196GGAUGAUCCUAGCUAUCGU B GGAUGaU C CUaGCUaUcgU UsU B 2194 R-008381800-000E2401 196 GGAUGAUCCUAGCUAUCGU ACGAUAGCUAGGAUCAUCCUsU 2064R-008381834-000S 2401 196 GGAUGAUCCUAGCUAUCGU B GgAUGA UCCUagCU A UC G UUsU B 2197 R-008381834-000S 2401 196 GGAUGAUCCUAGCUAUCGUACGAUAGCUAGGAUCAUCCUsU 2064 R-008381852-000J 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU 2058 R-008381852-000J 2401196 GGAUGAUCCUAGCUAUCGU B G GAUG AuC CUaG CUAU C GU UsU B 2199R-008381843-000A 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUsU2058 R-008381843-000A 2401 196 GGAUGAUCCUAGCUAUCGU B GgaU GaUCCUAgCUAUCGUUsU B 2201 R-008381832-000Z 2401 196 GGAUGAUCCUAGCUAUCGUACGAuAGcuAGGAucAuccUsU 2058 R-008381832-000Z 2401 196GGAUGAUCCUAGCUAUCGU B G GA UgA UCC U AgcUAU CgUUsU B 2203R-008381818-000S 2401 196 GGAUGAUCCUAGCUAUCGU B GGaUgaU CCuAG CuA UCGUUsU B 2204 R-008381818-000S 2401 196 GGAUGAUCCUAGCUAUCGUACGaUagCUaggaUCaUCCUsU 2065 R-008381785-000C 2401 196GGAUGAUCCUAGCUAUCGU B GG AUGAUCCUagCUAuC GU UsU B 2206 R-008381785-000C2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU 2065R-008381794-000L 2401 196 GGAUGAUCCUAGCUAUCGU ACGaUagCUaggaUCaUCCUsU2065 R-008381794-000L 2401 196 GGAUGAUCCUAGCUAUCGU B gGAUgaUCCUAGC UaU CGU UsU B 2208 R-008395187-000D 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAA TT B 2210 R-008395187-000D 1797 5CUGUUGGAUUGAUUCGAAA UUUcGAAucAAuccAAcAGUU 1463 R-008395244-000T 1797 5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B 2210 R-008395244-000T1797 5 CUGUUGGAUUGAUUCGAAA IUUcGAAucAAuccAAcAGUU 2211 R-008395198-000E1797 5 CUGUUGGAUUGAUUCGAAA UIUcGAAucAAuccAAcAGUU 2212 R-008395198-000E1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B 2210R-008395222-000R 1797 5 CUGUUGGAUUGAUUCGAAA UUIcGAAucAAuccAAcAGUU 2213R-008395222-000R 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B2210 R-008395155-000J 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAATT B 2210 R-008395155-000J 1797 5 CUGUUGGAUUGAUUCGAAAUUUIGAAucAAuccAAcAGUU 2214 R-008395242-000A 1797 5 CUGUUGGAUUGAUUCGAAA BcuGuuGGAuuGAuucGAAA TT B 2210 R-008395242-000A 1797 5CUGUUGGAUUGAUUCGAAA UUUcIAAucAAuccAAcAGUU 2215 R-008395267-000D 1797 5CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B 2210 R-008395267-000D1797 5 CUGUUGGAUUGAUUCGAAA UUUcGIAucAAuccAAcAGUU 2216 R-008395153-000S1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B 2210R-008395153-000S 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAIucAAuccAAcAGUU 2217R-008395286-000E 1797 5 CUGUUGGAUUGAUUCGAAA B cuGuuGGAuuGAuucGAAA TT B2210 R-008395286-000E 1797 5 CUGUUGGAUUGAUUCGAAA UUUcGAAIcAAuccAAcAGUU2218 R-008395196-000M 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuTT B 2219 R-008395196-000M 1870 194ACGACUAGUUCAGUUGCUU AAGcAAcuGAAcuAGucGuUU 1841 R-008395168-000C 1870 194ACGACUAGUUCAGUUGCUU IAGcAAcuGAAcuAGucGuUU 2220 R-008395168-000C 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395265-000L 1870194 ACGACUAGUUCAGUUGCUU AIGcAAcuGAAcuAGucGuUU 2221 R-008395265-000L 1870194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395150-000R1870 194 ACGACUAGUUCAGUUGCUU AAIcAAcuGAAcuAGucGuUU 2222 R-008395150-000R1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219R-008395263-000U 1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B2219 R-008395263-000U 1870 194 ACGACUAGUUCAGUUGCUU AAGIAAcuGAAcuAGucGuUU2223 R-008395172-000T 1870 194 ACGACUAGUUCAGUUGCUU AAGcIAcuGAAcuAGucGuUU2224 R-008395172-000T 1870 194 ACGACUAGUUCAGUUGCUU BAcGAcuAGuucAGuuGcuuTT B 2219 R-008395170-000A 1870 194ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395170-000A 1870194 ACGACUAGUUCAGUUGCUU AAGcAIcuGAAcuAGucGuUU 2225 R-008395226-000A 1870194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219 R-008395226-000A1870 194 ACGACUAGUUCAGUUGCUU AAGcAAIuGAAcuAGucGuUU 2226 R-008395207-000Z1870 194 ACGACUAGUUCAGUUGCUU AAGcAAcIGAAcuAGucGuUU 2227 R-008395207-000Z1870 194 ACGACUAGUUCAGUUGCUU B AcGAcuAGuucAGuuGcuuTT B 2219R-008395205-000G 2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAGGAucAuccuGGUU 1755R-008395205-000G 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B2228 R-008395250-000A 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuTT B 2228 R-008395250-000A 2398 151CCAGGAUGAUCCUAGCUAU IUAGcuAGGAucAuccuGGUU 2229 R-008395248-000C 2398 151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395248-000C 2398151 CCAGGAUGAUCCUAGCUAU AIAGcuAGGAucAuccuGGUU 2230 R-008395275-000D 2398151 CCAGGAUGAUCCUAGCUAU AUIGcuAGGAucAuccuGGUU 2231 R-008395275-000D 2398151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395163-000J2398 151 CCAGGAUGAUCCUAGCUAU AUAIcuAGGAucAuccuGGUU 2232 R-008395163-000J2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228R-008395224-000H 2398 151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B2228 R-008395224-000H 2398 151 CCAGGAUGAUCCUAGCUAU AUAGIuAGGAucAuccuGGUU2233 R-008395161-000S 2398 151 CCAGGAUGAUCCUAGCUAU AUAGcIAGGAucAuccuGGUU2234 R-008395161-000S 2398 151 CCAGGAUGAUCCUAGCUAU BccAGGAuGAuccuAGcuAuTT B 2228 R-008395290-000V 2398 151CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395290-000V 2398151 CCAGGAUGAUCCUAGCUAU AUAGcuIGGAucAuccuGGUU 2235 R-008395273-000L 2398151 CCAGGAUGAUCCUAGCUAU B ccAGGAuGAuccuAGcuAuTT B 2228 R-008395273-000L2398 151 CCAGGAUGAUCCUAGCUAU AUAGcuAIGAucAuccuGGUU 2236 R-008395188-000M2401 196 GGAUGAUCCUAGCUAUCGU ACGAuAGcuAGGAucAuccUU 1845 R-008395188-000M2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237R-008395204-000Y 2401 196 GGAUGAUCCUAGCUAUCGU ICGAuAGcuAGGAucAuccUU 2238R-008395204-000Y 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B2237 R-008395202-000F 2401 196 GGAUGAUCCUAGCUAUCGU AIGAuAGcuAGGAucAuccUU2239 R-008395202-000F 2401 196 GGAUGAUCCUAGCUAUCGU BGGAuGAuccuAGcuAucGuTT B 2237 R-008395158-000K 2401 196GGAUGAUCCUAGCUAUCGU ACIAuAGcuAGGAucAuccUU 2240 R-008395158-000K 2401 196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395246-000K 2401196 GGAUGAUCCUAGCUAUCGU ACGIuAGcuAGGAucAuccUU 2241 R-008395246-000K 2401196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008395271-000U2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237R-008395271-000U 2401 196 GGAUGAUCCUAGCUAUCGU ACGAIAGcuAGGAucAuccUU 2242R-008395200-000N 2401 196 GGAUGAUCCUAGCUAUCGU ACGAuIGcuAGGAucAuccUU 2243R-008395200-000N 2401 196 GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B2237 R-008395288-000X 2401 196 GGAUGAUCCUAGCUAUCGU BGGAuGAuccuAGcuAucGuTT B 2237 R-008395288-000X 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAIcuAGGAucAuccUU 2244 R-008395269-000W 2401 196GGAUGAUCCUAGCUAUCGU ACGAuAGIuAGGAucAuccUU 2245 R-008395269-000W 2401 196GGAUGAUCCUAGCUAUCGU B GGAuGAuccuAGcuAucGuTT B 2237 R-008397891-000B 1382238 GAUCCAAGUCAACGUCUUG B GAUCCAAGUCAACGUCUUGTT B 2246 R-008397891-000B1382 238 GAUCCAAGUCAACGUCUUG CAAGACGUUGACUUGGAUCUU 2247 R-008397894-000C828 239 CUAUCAUGCGUUCUCCUCA B CUAUCAUGCGUUCUCCUCATT B 2248R-008397894-000C 828 239 CUAUCAUGCGUUCUCCUCA UGAGGAGAACGCAUGAUAGUU 2249R-008396925-000E 1244 240 AAUAUAAUGAGGACCUAUA B AAUAUAAUGAGGACCUAUATT B2250 R-008396925-000E 1244 240 AAUAUAAUGAGGACCUAUA UAUAGGUCCUCAUUAUAUUUU2251 R-008395941-000K 1304 241 GUGCUAUCUGUCUGCUCUA BGUGCUAUCUGUCUGCUCUATT B 2252 R-008395941-000K 1304 241GUGCUAUCUGUCUGCUCUA UAGAGCAGACAGAUAGCACUU 2253 R-008395944-000L 812 242GAAGCUUCCAGACACGCUA B GAAGCUUCCAGACACGCUATT B 2254 R-008395944-000L 812242 GAAGCUUCCAGACACGCUA UAGCGUGUCUGGAAGCUUCUU 2255 R-008397498-000Y 1558243 UAAUUAUAAGAACAAGAUG B UAAUUAUAAGAACAAGAUGTT B 2256 R-008397498-000Y1558 243 UAAUUAUAAGAACAAGAUG CAUCUUGUUCUUAUAAUUAUU 2257 R-008397501-000R879 244 AUACAAAUGAUGUAGAAAC B AUACAAAUGAUGUAGAAACTT B 2258R-008397501-000R 879 244 AUACAAAUGAUGUAGAAAC GUUUCUACAUCAUUUGUAUUU 2259R-008396451-000Y 1311 245 CUGUCUGCUCUAGUAAUAA UUAUUACUAGAGCAGACAGUU 2261R-008396451-000Y 1311 245 CUGUCUGCUCUAGUAAUAA B CUGUCUGCUCUAGUAAUAATT B2260 R-008397504-000S 856 246 UGCUAUUGUACGUACCAUG BUGCUAUUGUACGUACCAUGTT B 2262 R-008397504-000S 856 246UGCUAUUGUACGUACCAUG CAUGGUACGUACAAUAGCAUU 2263 R-008396961-000P 1296 247UGCUGAAGGUGCUAUCUGU B UGCUGAAGGUGCUAUCUGUTT B 2264 R-008396961-000P 1296247 UGCUGAAGGUGCUAUCUGU ACAGAUAGCACCUUCAGCAUU 2265 R-008396967-000S 123539 GCUUUAGUAAAUAUAAUGA B GCUUUAGUAAAUAUAAUGATT B 2266 R-008396967-000S1235 39 GCUUUAGUAAAUAUAAUGA UCAUUAUAUUUACUAAAGCUU 2267 R-008396463-000H960 248 UCUUUAAGUCUGGAGGCAU AUGCCUCCAGACUUAAAGAUU 2269 R-008396463-000H960 248 UCUUUAAGUCUGGAGGCAU B UCUUUAAGUCUGGAGGCAUTT B 2268R-008398998-000S 2049 249 AUACCAUUCCAUUGUUUGU B AUACCAUUCCAUUGUUUGUTT B2270 R-008398998-000S 2049 249 AUACCAUUCCAUUGUUUGU ACAAACAAUGGAAUGGUAUUU2271 R-008398515-000M 1791 250 AGGCUACUGUUGGAUUGAU AUCAAUCCAACAGUAGCCUUU2273 R-008398515-000M 1791 250 AGGCUACUGUUGGAUUGAU BAGGCUACUGUUGGAUUGAUTT B 2272 R-008395947-000M 783 251CAGUUAUGGUCCAUCAGCU B CAGUUAUGGUCCAUCAGCUTT B 2274 R-008395947-000M 783251 CAGUUAUGGUCCAUCAGCU AGCUGAUGGACCAUAACUGUU 2275 R-008396466-000J 1569252 ACAAGAUGAUGGUCUGCCA B ACAAGAUGAUGGUCUGCCATT B 2276 R-008396466-000J1569 252 ACAAGAUGAUGGUCUGCCA UGGCAGACCAUCAUCUUGUUU 2277 R-008396970-000Y2224 253 GACAUAUGCAGCUGCUGUU AACAGCAGCUGCAUAUGUCUU 2279 R-008396970-000Y2224 253 GACAUAUGCAGCUGCUGUU B GACAUAUGCAGCUGCUGUUTT B 2278R-008395989-000Z 1882 123 GUUGCUUGUUCGUGCACAU B GUUGCUUGUUCGUGCACAUTT B2280 R-008395989-000Z 1882 123 GUUGCUUGUUCGUGCACAU AUGUGCACGAACAAGCAACUU2281 R-008398626-000Y 934 254 CCAUCAUCGUGAGGGCUUA BCCAUCAUCGUGAGGGCUUATT B 2282 R-008398626-000Y 934 254CCAUCAUCGUGAGGGCUUA UAAGCCCUCACGAUGAUGGUU 2283 R-008396121-000S 1378 255GACAGAUCCAAGUCAACGU B GACAGAUCCAAGUCAACGUTT B 2284 R-008396121-000S 1378255 GACAGAUCCAAGUCAACGU ACGUUGACUUGGAUCUGUCUU 2285 R-008396001-000X 569256 GAGACAUUAGAUGAGGGCA UGCCCUCAUCUAAUGUCUCUU 2287 R-008396001-000X 569256 GAGACAUUAGAUGAGGGCA B GAGACAUUAGAUGAGGGCATT B 2286 R-008396007-000Z1722 257 UUCGCCUUCACUAUGGACU B UUCGCCUUCACUAUGGACUTT B 2288R-008396007-000Z 1722 257 UUCGCCUUCACUAUGGACU AGUCCAUAGUGAAGGCGAAUU 2289R-008396547-000T 1483 258 UGUUCAGCUUCUGGGUUCA B UGUUCAGCUUCUGGGUUCATT B2290 R-008396547-000T 1483 258 UGUUCAGCUUCUGGGUUCA UGAACCCAGAAGCUGAACAUU2291 R-008399088-000F 2352 259 AUCUUGGACUUGAUAUUGG CCAAUAUCAAGUCCAAGAUUU2293 R-008399088-000F 2352 259 AUCUUGGACUUGAUAUUGG BAUCUUGGACUUGAUAUUGGTT B 2292 R-008398596-000K 719 260CGUGCAAUCCCUGAACUGA B CGUGCAAUCCCUGAACUGATT B 2294 R-008398596-000K 719260 CGUGCAAUCCCUGAACUGA UCAGUUCAGGGAUUGCACGUU 2295 R-008399094-000N 762261 AGGUGGUGGUUAAUAAGGC B AGGUGGUGGUUAAUAAGGCTT B 2296 R-008399094-000N762 261 AGGUGGUGGUUAAUAAGGC GCCUUAUUAACCACCACCUUU 2297 R-008397585-000P599 262 UCUACACAGUUUGAUGCUG B UCUACACAGUUUGAUGCUGTT B 2298R-008397585-000P 599 262 UCUACACAGUUUGAUGCUG CAGCAUCAAACUGUGUAGAUU 2299R-008396073-000L 1704 263 AGAUGGCCCAGAAUGCAGU B AGAUGGCCCAGAAUGCAGUTT B2300 R-008396073-000L 1704 263 AGAUGGCCCAGAAUGCAGU ACUGCAUUCUGGGCCAUCUUU2301 R-008398599-000L 2270 264 CAAGAUUACAAGAAACGGC GCCGUUUCUUGUAAUCUUGUU2303 R-008398599-000L 2270 264 CAAGAUUACAAGAAACGGC BCAAGAUUACAAGAAACGGCTT B 2302 R-008399532-000R 1810 103UCGAAAUCUUGCCCUUUGU ACAAAGGGCAAGAUUUCGAUU 2305 R-008399532-000R 1810 103UCGAAAUCUUGCCCUUUGU B UCGAAAUCUUGCCCUUUGUTT B 2304 R-008398602-000D 662265 CUGAAACAUGCAGUUGUAA B CUGAAACAUGCAGUUGUAATT B 2306 R-008398602-000D662 265 CUGAAACAUGCAGUUGUAA UUACAACUGCAUGUUUCAGUU 2307 R-008399106-000J396 266 CUCCUUCUCUGAGUGGUAA UUACCACUCAGAGAAGGAGUU 2309 R-008399106-000J396 266 CUCCUUCUCUGAGUGGUAA B CUCCUUCUCUGAGUGGUAATT B 2308R-008398053-000R 1199 267 AGCAAGCUCAUCAUACUGG CCAGUAUGAUGAGCUUGCUUU 2311R-008398053-000R 1199 267 AGCAAGCUCAUCAUACUGG B AGCAAGCUCAUCAUACUGGTT B2310 R-008396583-000C 1560 268 AUUAUAAGAACAAGAUGAU BAUUAUAAGAACAAGAUGAUTT B 2312 R-008396583-000C 1560 268AUUAUAAGAACAAGAUGAU AUCAUCUUGUUCUUAUAAUUU 2313 R-008399028-000B 593 92AUCCCAUCUACACAGUUUG CAAACUGUGUAGAUGGGAUUU 2315 R-008399028-000B 593 92AUCCCAUCUACACAGUUUG B AUCCCAUCUACACAGUUUGTT B 2314 R-008398104-000X 1310269 UCUGUCUGCUCUAGUAAUA B UCUGUCUGCUCUAGUAAUATT B 2316 R-008398104-000X1310 269 UCUGUCUGCUCUAGUAAUA UAUUACUAGAGCAGACAGAUU 2317 R-008398113-000F1233 270 AAGCUUUAGUAAAUAUAAU B AAGCUUUAGUAAAUAUAAUTT B 2318R-008398113-000F 1233 270 AAGCUUUAGUAAAUAUAAU AUUAUAUUUACUAAAGCUUUU 2319R-008399622-000H 1330 271 GCCGGCUAUUGUAGAAGCU B GCCGGCUAUUGUAGAAGCUTT B2320 R-008399622-000H 1330 271 GCCGGCUAUUGUAGAAGCU AGCUUCUACAAUAGCCGGCUU2321 R-008399151-000C 1312 272 UGUCUGCUCUAGUAAUAAG BUGUCUGCUCUAGUAAUAAGTT B 2322 R-008399151-000C 1312 272UGUCUGCUCUAGUAAUAAG CUUAUUACUAGAGCAGACAUU 2323 R-008396127-000U 1556 273AAUAAUUAUAAGAACAAGA UCUUGUUCUUAUAAUUAUUUU 2325 R-008396127-000U 1556 273AAUAAUUAUAAGAACAAGA B AAUAAUUAUAAGAACAAGATT B 2324 R-008395707-000Y 2438274 UAUGGCCAGGAUGCCUUGG B UAUGGCCAGGAUGCCUUGGTT B 2326 R-008395707-000Y2438 274 UAUGGCCAGGAUGCCUUGG CCAAGGCAUCCUGGCCAUAUU 2327 R-008395710-000E1826 275 UGUCCCGCAAAUCAUGCAC GUGCAUGAUUUGCGGGACAUU 2329 R-008395710-000E1826 275 UGUCCCGCAAAUCAUGCAC B UGUCCCGCAAAUCAUGCACTT B 2328R-008395713-000F 1397 276 CUUGUUCAGAACUGUCUUU B CUUGUUCAGAACUGUCUUUTT B2330 R-008395713-000F 1397 276 CUUGUUCAGAACUGUCUUU AAAGACAGUUCUGAACAAGUU2331 R-008395716-000G 3181 277 GCUGUGAUACGAUGCUUCA UGAAGCAUCGUAUCACAGCUU2333 R-008395716-000G 3181 277 GCUGUGAUACGAUGCUUCA BGCUGUGAUACGAUGCUUCATT B 2332 R-008395719-000H 1912 278GCGCCGUACGUCCAUGGGU B GCGCCGUACGUCCAUGGGUTT B 2334 R-008395719-000H 1912278 GCGCCGUACGUCCAUGGGU ACCCAUGGACGUACGGCGCUU 2335 R-008395722-000P 846279 AGAUGGUGUCUGCUAUUGU B AGAUGGUGUCUGCUAUUGUTT B 2336 R-008395722-000P846 279 AGAUGGUGUCUGCUAUUGU ACAAUAGCAGACACCAUCUUU 2337 R-008395725-000R1404 280 AGAACUGUCUUUGGACUCU B AGAACUGUCUUUGGACUCUTT B 2338R-008395725-000R 1404 280 AGAACUGUCUUUGGACUCU AGAGUCCAAAGACAGUUCUUU 2339R-008395728-000S 586 281 CAUGCAGAUCCCAUCUACA UGUAGAUGGGAUCUGCAUGUU 2341R-008395728-000S 586 281 CAUGCAGAUCCCAUCUACA B CAUGCAGAUCCCAUCUACATT B2340 R-008395731-000Y 1469 282 CUCCUUGGGACUCUUGUUC GAACAAGAGUCCCAAGGAGUU2343 R-008395731-000Y 1469 282 CUCCUUGGGACUCUUGUUC BCUCCUUGGGACUCUUGUUCTT B 2342 R-008395734-000Z 380 283GGUGCCACUACCACAGCUC B GGUGCCACUACCACAGCUCTT B 2344 R-008395734-000Z 380283 GGUGCCACUACCACAGCUC GAGCUGUGGUAGUGGCACCUU 2345 R-008395737-000A 1345284 AGCUGGUGGAAUGCAAGCU B AGCUGGUGGAAUGCAAGCUTT B 2346 R-008395737-000A1345 284 AGCUGGUGGAAUGCAAGCU AGCUUGCAUUCCACCAGCUUU 2347 R-008395740-000G1863 285 CCAUUCCACGACUAGUUCA B CCAUUCCACGACUAGUUCATT B 2348R-008395740-000G 1863 285 CCAUUCCACGACUAGUUCA UGAACUAGUCGUGGAAUGGUU 2349R-008395743-000H 635 286 CAGCGUUUGGCUGAACCAU AUGGUUCAGCCAAACGCUGUU 2351R-008395743-000H 635 286 CAGCGUUUGGCUGAACCAU B CAGCGUUUGGCUGAACCAUTT B2350 R-008395746-000J 959 287 AUCUUUAAGUCUGGAGGCA UGCCUCCAGACUUAAAGAUUU2353 R-008395746-000J 959 287 AUCUUUAAGUCUGGAGGCA BAUCUUUAAGUCUGGAGGCATT B 2352 R-008395749-000K 2440 288UGGCCAGGAUGCCUUGGGU B UGGCCAGGAUGCCUUGGGUTT B 2354 R-008395749-000K 2440288 UGGCCAGGAUGCCUUGGGU ACCCAAGGCAUCCUGGCCAUU 2355 R-008395752-000S 877289 GAAUACAAAUGAUGUAGAA UUCUACAUCAUUUGUAUUCUU 2357 R-008395752-000S 877289 GAAUACAAAUGAUGUAGAA B GAAUACAAAUGAUGUAGAATT B 2356 R-008395755-000T2556 290 UGGAUGGGCUGCCUCCAGG CCUGGAGGCAGCCCAUCCAUU 2359 R-008395755-000T2556 290 UGGAUGGGCUGCCUCCAGG B UGGAUGGGCUGCCUCCAGGTT B 2358R-008395758-000U 1916 291 CGUACGUCCAUGGGUGGGA B CGUACGUCCAUGGGUGGGATT B2360 R-008395758-000U 1916 291 CGUACGUCCAUGGGUGGGA UCCCACCCAUGGACGUACGUU2361 R-008395761-000A 850 292 GGUGUCUGCUAUUGUACGU BGGUGUCUGCUAUUGUACGUTT B 2362 R-008395761-000A 850 292GGUGUCUGCUAUUGUACGU ACGUACAAUAGCAGACACCUU 2363 R-008395764-000B 1303 293GGUGCUAUCUGUCUGCUCU B GGUGCUAUCUGUCUGCUCUTT B 2364 R-008395764-000B 1303293 GGUGCUAUCUGUCUGCUCU AGAGCAGACAGAUAGCACCUU 2365 R-008395767-000C 1726294 CCUUCACUAUGGACUACCA UGGUAGUCCAUAGUGAAGGUU 2367 R-008395767-000C 1726294 CCUUCACUAUGGACUACCA B CCUUCACUAUGGACUACCATT B 2366 R-008395770-000J1477 295 GACUCUUGUUCAGCUUCUG CAGAAGCUGAACAAGAGUCUU 2369 R-008395770-000J1477 295 GACUCUUGUUCAGCUUCUG B GACUCUUGUUCAGCUUCUGTT B 2368R-008395773-000K 598 296 AUCUACACAGUUUGAUGCU B AUCUACACAGUUUGAUGCUTT B2370 R-008395773-000K 598 296 AUCUACACAGUUUGAUGCU AGCAUCAAACUGUGUAGAUUU2371 R-008395776-000L 2062 297 GUUUGUGCAGCUGCUUUAU BGUUUGUGCAGCUGCUUUAUTT B 2372 R-008395776-000L 2062 297GUUUGUGCAGCUGCUUUAU AUAAAGCAGCUGCACAAACUU 2373 R-008395779-000M 2278 298CAAGAAACGGCUUUCAGUU B CAAGAAACGGCUUUCAGUUTT B 2374 R-008395779-000M 2278298 CAAGAAACGGCUUUCAGUU AACUGAAAGCCGUUUCUUGUU 2375 R-008395782-000U 1877299 GUUCAGUUGCUUGUUCGUG CACGAACAAGCAACUGAACUU 2377 R-008395782-000U 1877299 GUUCAGUUGCUUGUUCGUG B GUUCAGUUGCUUGUUCGUGTT B 2376 R-008395785-000V1499 300 UCAGAUGAUAUAAAUGUGG B UCAGAUGAUAUAAAUGUGGTT B 2378R-008395785-000V 1499 300 UCAGAUGAUAUAAAUGUGG CCACAUUUAUAUCAUCUGAUU 2379R-008395788-000W 1136 301 AAUGUUAAAUUCUUGGCUA B AAUGUUAAAUUCUUGGCUATT B2380 R-008395788-000W 1136 301 AAUGUUAAAUUCUUGGCUA UAGCCAAGAAUUUAACAUUUU2381 R-008395791-000C 1494 302 UGGGUUCAGAUGAUAUAAA UUUAUAUCAUCUGAACCCAUU2383 R-008395791-000C 1494 302 UGGGUUCAGAUGAUAUAAA BUGGGUUCAGAUGAUAUAAATT B 2382 R-008395794-000D 1972 303AAUAGUUGAAGGUUGUACC B AAUAGUUGAAGGUUGUACCTT B 2384 R-008395794-000D 1972303 AAUAGUUGAAGGUUGUACC GGUACAACCUUCAACUAUUUU 2385 R-008395797-000E 668304 CAUGCAGUUGUAAACUUGA UCAAGUUUACAACUGCAUGUU 2387 R-008395797-000E 668304 CAUGCAGUUGUAAACUUGA B CAUGCAGUUGUAAACUUGATT B 2386 R-008395800-000X2945 305 AAUCUGAAUAAAGUGUAAC GUUACACUUUAUUCAGAUUUU 2389 R-008395800-000X2945 305 AAUCUGAAUAAAGUGUAAC B AAUCUGAAUAAAGUGUAACTT B 2388R-008395803-000Y 2492 306 CACCACCCUGGUGCUGACU B CACCACCCUGGUGCUGACUTT B2390 R-008395803-000Y 2492 306 CACCACCCUGGUGCUGACU AGUCAGCACCAGGGUGGUGUU2391 R-008395806-000Z 293 307 GAGUUGGACAUGGCCAUGG BGAGUUGGACAUGGCCAUGGTT B 2392 R-008395806-000Z 293 307GAGUUGGACAUGGCCAUGG CCAUGGCCAUGUCCAACUCUU 2393 R-008395809-000A 1905 308AUACCCAGCGCCGUACGUC B AUACCCAGCGCCGUACGUCTT B 2394 R-008395809-000A 1905308 AUACCCAGCGCCGUACGUC GACGUACGGCGCUGGGUAUUU 2395 R-008395812-000G 944309 GAGGGCUUACUGGCCAUCU AGAUGGCCAGUAAGCCCUCUU 2397 R-008395812-000G 944309 GAGGGCUUACUGGCCAUCU B GAGGGCUUACUGGCCAUCUTT B 2396 R-008395815-000H581 310 GAGGGCAUGCAGAUCCCAU B GAGGGCAUGCAGAUCCCAUTT B 2398R-008395815-000H 581 310 GAGGGCAUGCAGAUCCCAU AUGGGAUCUGCAUGCCCUCUU 2399R-008395818-000J 1454 311 GAAGGGAUGGAAGGUCUCC B GAAGGGAUGGAAGGUCUCCTT B2400 R-008395818-000J 1454 311 GAAGGGAUGGAAGGUCUCC GGAGACCUUCCAUCCCUUCUU2401 R-008395821-000R 2254 312 GUCUGAGGACAAGCCACAA BGUCUGAGGACAAGCCACAATT B 2402 R-008395821-000R 2254 312GUCUGAGGACAAGCCACAA UUGUGGCUUGUCCUCAGACUU 2403 R-008395824-000S 1837 313UCAUGCACCUUUGCGUGAG CUCACGCAAAGGUGCAUGAUU 2405 R-008395824-000S 1837 313UCAUGCACCUUUGCGUGAG B UCAUGCACCUUUGCGUGAGTT B 2404 R-008395827-000T 1425314 GGAAUCUUUCAGAUGCUGC B GGAAUCUUUCAGAUGCUGCTT B 2406 R-008395827-000T1425 314 GGAAUCUUUCAGAUGCUGC GCAGCAUCUGAAAGAUUCCUU 2407 R-008395830-000Z1372 315 UCACCUGACAGAUCCAAGU ACUUGGAUCUGUCAGGUGAUU 2409 R-008395830-000Z1372 315 UCACCUGACAGAUCCAAGU B UCACCUGACAGAUCCAAGUTT B 2408R-008395833-000A 1298 316 CUGAAGGUGCUAUCUGUCU B CUGAAGGUGCUAUCUGUCUTT B2410 R-008395833-000A 1298 316 CUGAAGGUGCUAUCUGUCU AGACAGAUAGCACCUUCAGUU2411 R-008395836-000B 1674 317 GUCAUCUGACCAGCCGACA BGUCAUCUGACCAGCCGACATT B 2412 R-008395836-000B 1674 317GUCAUCUGACCAGCCGACA UGUCGGCUGGUCAGAUGACUU 2413 R-008395839-000C 1864 318CAUUCCACGACUAGUUCAG CUGAACUAGUCGUGGAAUGUU 2415 R-008395839-000C 1864 318CAUUCCACGACUAGUUCAG B CAUUCCACGACUAGUUCAGTT B 2414 R-008395842-000J 2404319 UGAUCCUAGCUAUCGUUCU AGAACGAUAGCUAGGAUCAUU 2417 R-008395842-000J 2404319 UGAUCCUAGCUAUCGUUCU B UGAUCCUAGCUAUCGUUCUTT B 2416 R-008395845-000K1992 320 GAGCCCUUCACAUCCUAGC GCUAGGAUGUGAAGGGCUCUU 2419 R-008395845-000K1992 320 GAGCCCUUCACAUCCUAGC B GAGCCCUUCACAUCCUAGCTT B 2418R-008395848-000L 2124 73 GUGAACUUGCUCAGGACAA UUGUCCUGAGCAAGUUCACUU 2421R-008395848-000L 2124 73 GUGAACUUGCUCAGGACAA B GUGAACUUGCUCAGGACAATT B2420 R-008395851-000T 578 321 GAUGAGGGCAUGCAGAUCC GGAUCUGCAUGCCCUCAUCUU2423 R-008395851-000T 578 321 GAUGAGGGCAUGCAGAUCC BGAUGAGGGCAUGCAGAUCCTT B 2422 R-008395854-000U 3091 322AUGGGUAGGGUAAAUCAGU B AUGGGUAGGGUAAAUCAGUTT B 2424 R-008395854-000U 3091322 AUGGGUAGGGUAAAUCAGU ACUGAUUUACCCUACCCAUUU 2425 R-008395857-000V 720323 GUGCAAUCCCUGAACUGAC B GUGCAAUCCCUGAACUGACTT B 2426 R-008395857-000V720 323 GUGCAAUCCCUGAACUGAC GUCAGUUCAGGGAUUGCACUU 2427 R-008395860-000B2054 324 AUUCCAUUGUUUGUGCAGC B AUUCCAUUGUUUGUGCAGCTT B 2428R-008395860-000B 2054 324 AUUCCAUUGUUUGUGCAGC GCUGCACAAACAAUGGAAUUU 2429R-008395863-000C 1237 42 UUUAGUAAAUAUAAUGAGG CCUCAUUAUAUUUACUAAAUU 2431R-008395863-000C 1237 42 UUUAGUAAAUAUAAUGAGG B UUUAGUAAAUAUAAUGAGGTT B2430 R-008395866-000D 374 325 CAUUCUGGUGCCACUACCA UGGUAGUGGCACCAGAAUGUU2433 R-008395866-000D 374 325 CAUUCUGGUGCCACUACCA BCAUUCUGGUGCCACUACCATT B 2432 R-008395869-000E 868 326UACCAUGCAGAAUACAAAU AUUUGUAUUCUGCAUGGUAUU 2435 R-008395869-000E 868 326UACCAUGCAGAAUACAAAU B UACCAUGCAGAAUACAAAUTT B 2434 R-008395872-000L 62623 ACUAAUGUCCAGCGUUUGG CCAAACGCUGGACAUUAGUUU 2437 R-008395872-000L 62623 ACUAAUGUCCAGCGUUUGG B ACUAAUGUCCAGCGUUUGGTT B 2436 R-008395875-000M1716 327 AUGCAGUUCGCCUUCACUA B AUGCAGUUCGCCUUCACUATT B 2438R-008395875-000M 1716 327 AUGCAGUUCGCCUUCACUA UAGUGAAGGCGAACUGCAUUU 2439R-008395878-000N 950 328 UUACUGGCCAUCUUUAAGU B UUACUGGCCAUCUUUAAGUTT B2440 R-008395878-000N 950 328 UUACUGGCCAUCUUUAAGU ACUUAAAGAUGGCCAGUAAUU2441 R-008395881-000V 1489 329 GCUUCUGGGUUCAGAUGAU BGCUUCUGGGUUCAGAUGAUTT B 2442 R-008395881-000V 1489 329GCUUCUGGGUUCAGAUGAU AUCAUCUGAACCCAGAAGCUU 2443 R-008395884-000W 1451 330CAGGAAGGGAUGGAAGGUC B CAGGAAGGGAUGGAAGGUCTT B 2444 R-008395884-000W 1451330 CAGGAAGGGAUGGAAGGUC GACCUUCCAUCCCUUCCUGUU 2445 R-008395887-000X 438159 UGGAUACCUCCCAAGUCCU AGGACUUGGGAGGUAUCCAUU 2447 R-008395887-000X 438159 UGGAUACCUCCCAAGUCCU B UGGAUACCUCCCAAGUCCUTT B 2446 R-008395890-000D1181 331 GCUUAUGGCAACCAAGAAA UUUCUUGGUUGCCAUAAGCUU 2449 R-008395890-000D1181 331 GCUUAUGGCAACCAAGAAA B GCUUAUGGCAACCAAGAAATT B 2448R-008395893-000E 1633 332 UGACAGGGAAGACAUCACU AGUGAUGUCUUCCCUGUCAUU 2451R-008395893-000E 1633 332 UGACAGGGAAGACAUCACU B UGACAGGGAAGACAUCACUTT B2450 R-008395896-000F 2394 333 AUCGCCAGGAUGAUCCUAG CUAGGAUCAUCCUGGCGAUUU2453 R-008395896-000F 2394 333 AUCGCCAGGAUGAUCCUAG BAUCGCCAGGAUGAUCCUAGTT B 2452 R-008395899-000G 1322 334AGUAAUAAGCCGGCUAUUG B AGUAAUAAGCCGGCUAUUGTT B 2454 R-008395899-000G 1322334 AGUAAUAAGCCGGCUAUUG CAAUAGCCGGCUUAUUACUUU 2455 R-008395902-000Z 884335 AAUGAUGUAGAAACAGCUC GAGCUGUUUCUACAUCAUUUU 2457 R-008395902-000Z 884335 AAUGAUGUAGAAACAGCUC B AAUGAUGUAGAAACAGCUCTT B 2456 R-008395905-000A2255 336 UCUGAGGACAAGCCACAAG B UCUGAGGACAAGCCACAAGTT B 2458R-008395905-000A 2255 336 UCUGAGGACAAGCCACAAG CUUGUGGCUUGUCCUCAGAUU 2459R-008395908-000B 1466 337 GGUCUCCUUGGGACUCUUG CAAGAGUCCCAAGGAGACCUU 2461R-008395908-000B 1466 337 GGUCUCCUUGGGACUCUUG B GGUCUCCUUGGGACUCUUGTT B2460 R-008395911-000H 1399 338 UGUUCAGAACUGUCUUUGG CCAAAGACAGUUCUGAACAUU2463 R-008395911-000H 1399 338 UGUUCAGAACUGUCUUUGG BUGUUCAGAACUGUCUUUGGTT B 2462 R-008395914-000J 378 339CUGGUGCCACUACCACAGC B CUGGUGCCACUACCACAGCTT B 2464 R-008395914-000J 378339 CUGGUGCCACUACCACAGC GCUGUGGUAGUGGCACCAGUU 2465 R-008395917-000K 1921340 GUCCAUGGGUGGGACACAG CUGUGUCCCACCCAUGGACUU 2467 R-008395917-000K 1921340 GUCCAUGGGUGGGACACAG B GUCCAUGGGUGGGACACAGTT B 2466 R-008395920-000S1085 341 GUGCGUUUAGCUGGUGGGC B GUGCGUUUAGCUGGUGGGCTT B 2468R-008395920-000S 1085 341 GUGCGUUUAGCUGGUGGGC GCCCACCAGCUAAACGCACUU 2469R-008395923-000T 865 342 ACGUACCAUGCAGAAUACA B ACGUACCAUGCAGAAUACATT B2470 R-008395923-000T 865 342 ACGUACCAUGCAGAAUACA UGUAUUCUGCAUGGUACGUUU2471 R-008395926-000U 2015 343 GAUGUUCACAACCGAAUUG BGAUGUUCACAACCGAAUUGTT B 2472 R-008395926-000U 2015 343GAUGUUCACAACCGAAUUG CAAUUCGGUUGUGAACAUCUU 2473 R-008395929-000V 1195 344AGAAAGCAAGCUCAUCAUA B AGAAAGCAAGCUCAUCAUATT B 2474 R-008395929-000V 1195344 AGAAAGCAAGCUCAUCAUA UAUGAUGAGCUUGCUUUCUUU 2475 R-008395932-000B 1484345 GUUCAGCUUCUGGGUUCAG CUGAACCCAGAAGCUGAACUU 2477 R-008395932-000B 1484345 GUUCAGCUUCUGGGUUCAG B GUUCAGCUUCUGGGUUCAGTT B 2476 R-008395935-000C1855 346 GCAGGGUGCCAUUCCACGA B GCAGGGUGCCAUUCCACGATT B 2478R-008395935-000C 1855 346 GCAGGGUGCCAUUCCACGA UCGUGGAAUGGCACCCUGCUU 2479R-008395938-000D 1341 347 UAGAAGCUGGUGGAAUGCA B UAGAAGCUGGUGGAAUGCATT B2480 R-008395938-000D 1341 347 UAGAAGCUGGUGGAAUGCA UGCAUUCCACCAGCUUCUAUU2481 R-008395950-000U 1963 348 CAUGGAAGAAAUAGUUGAA UUCAACUAUUUCUUCCAUGUU2483 R-008395950-000U 1963 348 CAUGGAAGAAAUAGUUGAA BCAUGGAAGAAAUAGUUGAATT B 2482 R-008395953-000V 2362 349UGAUAUUGGUGCCCAGGGA B UGAUAUUGGUGCCCAGGGATT B 2484 R-008395953-000V 2362349 UGAUAUUGGUGCCCAGGGA UCCCUGGGCACCAAUAUCAUU 2485 R-008395956-000W 584350 GGCAUGCAGAUCCCAUCUA B GGCAUGCAGAUCCCAUCUATT B 2486 R-008395956-000W584 350 GGCAUGCAGAUCCCAUCUA UAGAUGGGAUCUGCAUGCCUU 2487 R-008395959-000X1613 351 CGUACUGUCCUUCGGGCUG B CGUACUGUCCUUCGGGCUGTT B 2488R-008395959-000X 1613 351 CGUACUGUCCUUCGGGCUG CAGCCCGAAGGACAGUACGUU 2489R-008395962-000D 1155 352 UUACGACAGACUGCCUUCA UGAAGGCAGUCUGUCGUAAUU 2491R-008395962-000D 1155 352 UUACGACAGACUGCCUUCA B UUACGACAGACUGCCUUCATT B2490 R-008395965-000E 334 353 UAGUCACUGGCAGCAACAG BUAGUCACUGGCAGCAACAGTT B 2492 R-008395965-000E 334 353UAGUCACUGGCAGCAACAG CUGUUGCUGCCAGUGACUAUU 2493 R-008395968-000F 1031 354GCCAUUACAACUCUCCACA B GCCAUUACAACUCUCCACATT B 2494 R-008395968-000F 1031354 GCCAUUACAACUCUCCACA UGUGGAGAGUUGUAAUGGCUU 2495 R-008395971-000M 1725355 GCCUUCACUAUGGACUACC B GCCUUCACUAUGGACUACCTT B 2496 R-008395971-000M1725 355 GCCUUCACUAUGGACUACC GGUAGUCCAUAGUGAAGGCUU 2497 R-008395974-000N2018 356 GUUCACAACCGAAUUGUUA B GUUCACAACCGAAUUGUUATT B 2498R-008395974-000N 2018 356 GUUCACAACCGAAUUGUUA UAACAAUUCGGUUGUGAACUU 2499R-008395977-000P 914 357 GGGACCUUGCAUAACCUUU AAAGGUUAUGCAAGGUCCCUU 2501R-008395977-000P 914 357 GGGACCUUGCAUAACCUUU B GGGACCUUGCAUAACCUUUTT B2500 R-008395980-000W 2264 358 AAGCCACAAGAUUACAAGA BAAGCCACAAGAUUACAAGATT B 2502 R-008395980-000W 2264 358AAGCCACAAGAUUACAAGA UCUUGUAAUCUUGUGGCUUUU 2503 R-008395983-000X 343 359GCAGCAACAGUCUUACCUG CAGGUAAGACUGUUGCUGCUU 2505 R-008395983-000X 343 359GCAGCAACAGUCUUACCUG B GCAGCAACAGUCUUACCUGTT B 2504 R-008395986-000Y 1056360 UAUUACAUCAAGAAGGAGC B UAUUACAUCAAGAAGGAGCTT B 2506 R-008395986-000Y1056 360 UAUUACAUCAAGAAGGAGC GCUCCUUCUUGAUGUAAUAUU 2507 R-008395992-000F772 361 UAAUAAGGCUGCAGUUAUG B UAAUAAGGCUGCAGUUAUGTT B 2508R-008395992-000F 772 361 UAAUAAGGCUGCAGUUAUG CAUAACUGCAGCCUUAUUAUU 2509R-008395995-000G 1390 91 UCAACGUCUUGUUCAGAAC GUUCUGAACAAGACGUUGAUU 2511R-008395995-000G 1390 91 UCAACGUCUUGUUCAGAAC B UCAACGUCUUGUUCAGAACTT B2510 R-008395998-000H 1959 183 UCCGCAUGGAAGAAAUAGU ACUAUUUCUUCCAUGCGGAUU2513 R-008395998-000H 1959 183 UCCGCAUGGAAGAAAUAGU BUCCGCAUGGAAGAAAUAGUTT B 2512 R-008396004-000Y 763 362GGUGGUGGUUAAUAAGGCU B GGUGGUGGUUAAUAAGGCUTT B 2514 R-008396004-000Y 763362 GGUGGUGGUUAAUAAGGCU AGCCUUAUUAACCACCACCUU 2515 R-008396010-000F 628363 UAAUGUCCAGCGUUUGGCU B UAAUGUCCAGCGUUUGGCUTT B 2516 R-008396010-000F628 363 UAAUGUCCAGCGUUUGGCU AGCCAAACGCUGGACAUUAUU 2517 R-008396013-000G399 364 CUUCUCUGAGUGGUAAAGG B CUUCUCUGAGUGGUAAAGGTT B 2518R-008396013-000G 399 364 CUUCUCUGAGUGGUAAAGG CCUUUACCACUCAGAGAAGUU 2519R-008396016-000H 1682 365 ACCAGCCGACACCAAGAAG CUUCUUGGUGUCGGCUGGUUU 2521R-008396016-000H 1682 365 ACCAGCCGACACCAAGAAG B ACCAGCCGACACCAAGAAGTT B2520 R-008396019-000J 441 366 AUACCUCCCAAGUCCUGUA BAUACCUCCCAAGUCCUGUATT B 2522 R-008396019-000J 441 366AUACCUCCCAAGUCCUGUA UACAGGACUUGGGAGGUAUUU 2523 R-008396022-000R 1729 367UCACUAUGGACUACCAGUU B UCACUAUGGACUACCAGUUTT B 2524 R-008396022-000R 1729367 UCACUAUGGACUACCAGUU AACUGGUAGUCCAUAGUGAUU 2525 R-008396025-000S 1902368 AGGAUACCCAGCGCCGUAC GUACGGCGCUGGGUAUCCUUU 2527 R-008396025-000S 1902368 AGGAUACCCAGCGCCGUAC B AGGAUACCCAGCGCCGUACTT B 2526 R-008396028-000T1637 369 AGGGAAGACAUCACUGAGC B AGGGAAGACAUCACUGAGCTT B 2528R-008396028-000T 1637 369 AGGGAAGACAUCACUGAGC GCUCAGUGAUGUCUUCCCUUU 2529R-008396031-000Z 2391 370 GAUAUCGCCAGGAUGAUCC B GAUAUCGCCAGGAUGAUCCTT B2530 R-008396031-000Z 2391 370 GAUAUCGCCAGGAUGAUCC GGAUCAUCCUGGCGAUAUCUU2531 R-008396034-000A 501 371 AAGUAGCUGAUAUUGAUGG BAAGUAGCUGAUAUUGAUGGTT B 2532 R-008396034-000A 501 371AAGUAGCUGAUAUUGAUGG CCAUCAAUAUCAGCUACUUUU 2533 R-008396037-000B 1358 372CAAGCUUUAGGACUUCACC B CAAGCUUUAGGACUUCACCTT B 2534 R-008396037-000B 1358372 CAAGCUUUAGGACUUCACC GGUGAAGUCCUAAAGCUUGUU 2535 R-008396040-000H 1821373 CCCUUUGUCCCGCAAAUCA B CCCUUUGUCCCGCAAAUCATT B 2536 R-008396040-000H1821 373 CCCUUUGUCCCGCAAAUCA UGAUUUGCGGGACAAAGGGUU 2537 R-008396043-000J575 374 UUAGAUGAGGGCAUGCAGA B UUAGAUGAGGGCAUGCAGATT B 2538R-008396043-000J 575 374 UUAGAUGAGGGCAUGCAGA UCUGCAUGCCCUCAUCUAAUU 2539R-008396046-000K 528 375 CAAUGACUCGAGCUCAGAG B CAAUGACUCGAGCUCAGAGTT B2540 R-008396046-000K 528 375 CAAUGACUCGAGCUCAGAG CUCUGAGCUCGAGUCAUUGUU2541 R-008396049-000L 2433 376 GUGGAUAUGGCCAGGAUGC BGUGGAUAUGGCCAGGAUGCTT B 2542 R-008396049-000L 2433 376GUGGAUAUGGCCAGGAUGC GCAUCCUGGCCAUAUCCACUU 2543 R-008396052-000T 1497 377GUUCAGAUGAUAUAAAUGU ACAUUUAUAUCAUCUGAACUU 2545 R-008396052-000T 1497 377GUUCAGAUGAUAUAAAUGU B GUUCAGAUGAUAUAAAUGUTT B 2544 R-008396055-000U 2134378 UCAGGACAAGGAAGCUGCA B UCAGGACAAGGAAGCUGCATT B 2546 R-008396055-000U2134 378 UCAGGACAAGGAAGCUGCA UGCAGCUUCCUUGUCCUGAUU 2547 R-008396058-000V2160 379 UUGAAGCUGAGGGAGCCAC GUGGCUCCCUCAGCUUCAAUU 2549 R-008396058-000V2160 379 UUGAAGCUGAGGGAGCCAC B UUGAAGCUGAGGGAGCCACTT B 2548R-008396061-000B 291 380 UGGAGUUGGACAUGGCCAU AUGGCCAUGUCCAACUCCAUU 2551R-008396061-000B 291 380 UGGAGUUGGACAUGGCCAU B UGGAGUUGGACAUGGCCAUTT B2550 R-008396064-000C 657 381 AGAUGCUGAAACAUGCAGU BAGAUGCUGAAACAUGCAGUTT B 2552 R-008396064-000C 657 381AGAUGCUGAAACAUGCAGU ACUGCAUGUUUCAGCAUCUUU 2553 R-008396067-000D 1575 382UGAUGGUCUGCCAAGUGGG B UGAUGGUCUGCCAAGUGGGTT B 2554 R-008396067-000D 1575382 UGAUGGUCUGCCAAGUGGG CCCACUUGGCAGACCAUCAUU 2555 R-008396070-000K 667383 ACAUGCAGUUGUAAACUUG CAAGUUUACAACUGCAUGUUU 2557 R-008396070-000K 667383 ACAUGCAGUUGUAAACUUG B ACAUGCAGUUGUAAACUUGTT B 2556 R-008396076-000M2190 384 CAGAGUUACUUCACUCUAG B CAGAGUUACUUCACUCUAGTT B 2558R-008396076-000M 2190 384 CAGAGUUACUUCACUCUAG CUAGAGUGAAGUAACUCUGUU 2559R-008396079-000N 532 385 GACUCGAGCUCAGAGGGUA UACCCUCUGAGCUCGAGUCUU 2561R-008396079-000N 532 385 GACUCGAGCUCAGAGGGUA B GACUCGAGCUCAGAGGGUATT B2560 R-008396082-000V 953 386 CUGGCCAUCUUUAAGUCUG CAGACUUAAAGAUGGCCAGUU2563 R-008396082-000V 953 386 CUGGCCAUCUUUAAGUCUG BCUGGCCAUCUUUAAGUCUGTT B 2562 R-008396085-000W 3188 387UACGAUGCUUCAAGAGAAA UUUCUCUUGAAGCAUCGUAUU 2565 R-008396085-000W 3188 387UACGAUGCUUCAAGAGAAA B UACGAUGCUUCAAGAGAAATT B 2564 R-008396088-000X 2301388 UGACCAGCUCUCUCUUCAG B UGACCAGCUCUCUCUUCAGTT B 2566 R-008396088-000X2301 388 UGACCAGCUCUCUCUUCAG CUGAAGAGAGAGCUGGUCAUU 2567 R-008396091-000D2310 389 CUCUCUUCAGAACAGAGCC B CUCUCUUCAGAACAGAGCCTT B 2568R-008396091-000D 2310 389 CUCUCUUCAGAACAGAGCC GGCUCUGUUCUGAAGAGAGUU 2569R-008396094-000E 2287 390 GCUUUCAGUUGAGCUGACC B GCUUUCAGUUGAGCUGACCTT B2570 R-008396094-000E 2287 390 GCUUUCAGUUGAGCUGACC GGUCAGCUCAACUGAAAGCUU2571 R-008396097-000F 1927 391 GGGUGGGACACAGCAGCAA UUGCUGCUGUGUCCCACCCUU2573 R-008396097-000F 1927 391 GGGUGGGACACAGCAGCAA BGGGUGGGACACAGCAGCAATT B 2572 R-008396100-000Y 712 392UGCCACACGUGCAAUCCCU AGGGAUUGCACGUGUGGCAUU 2575 R-008396100-000Y 712 392UGCCACACGUGCAAUCCCU B UGCCACACGUGCAAUCCCUTT B 2574 R-008396103-000Z 2121393 UCUGUGAACUUGCUCAGGA B UCUGUGAACUUGCUCAGGATT B 2576 R-008396103-000Z2121 393 UCUGUGAACUUGCUCAGGA UCCUGAGCAAGUUCACAGAUU 2577 R-008396106-000A2898 394 UGAGUAAUGGUGUAGAACA B UGAGUAAUGGUGUAGAACATT B 2578R-008396106-000A 2898 394 UGAGUAAUGGUGUAGAACA UGUUCUACACCAUUACUCAUU 2579R-008396109-000B 1799 395 GUUGGAUUGAUUCGAAAUC B GUUGGAUUGAUUCGAAAUCTT B2580 R-008396109-000B 1799 395 GUUGGAUUGAUUCGAAAUC GAUUUCGAAUCAAUCCAACUU2581 R-008396112-000H 1036 396 UACAACUCUCCACAACCUU AAGGUUGUGGAGAGUUGUAUU2583 R-008396112-000H 1036 396 UACAACUCUCCACAACCUU BUACAACUCUCCACAACCUUTT B 2582 R-008396115-000J 449 397CAAGUCCUGUAUGAGUGGG CCCACUCAUACAGGACUUGUU 2585 R-008396115-000J 449 397CAAGUCCUGUAUGAGUGGG B CAAGUCCUGUAUGAGUGGGTT B 2584 R-008396118-000K 1452398 AGGAAGGGAUGGAAGGUCU B AGGAAGGGAUGGAAGGUCUTT B 2586 R-008396118-000K1452 398 AGGAAGGGAUGGAAGGUCU AGACCUUCCAUCCCUUCCUUU 2587 R-008396124-000T1203 399 AGCUCAUCAUACUGGCUAG B AGCUCAUCAUACUGGCUAGTT B 2588R-008396124-000T 1203 399 AGCUCAUCAUACUGGCUAG CUAGCCAGUAUGAUGAGCUUU 2589R-008396130-000A 1357 400 GCAAGCUUUAGGACUUCAC GUGAAGUCCUAAAGCUUGCUU 2591R-008396130-000A 1357 400 GCAAGCUUUAGGACUUCAC B GCAAGCUUUAGGACUUCACTT B2590 R-008396133-000B 1512 401 AUGUGGUCACCUGUGCAGC GCUGCACAGGUGACCACAUUU2593 R-008396133-000B 1512 401 AUGUGGUCACCUGUGCAGC BAUGUGGUCACCUGUGCAGCTT B 2592 R-008396136-000C 275 402ACUCAAGCUGAUUUGAUGG B ACUCAAGCUGAUUUGAUGGTT B 2594 R-008396136-000C 275402 ACUCAAGCUGAUUUGAUGG CCAUCAAAUCAGCUUGAGUUU 2595 R-008396139-000D 299403 GACAUGGCCAUGGAACCAG CUGGUUCCAUGGCCAUGUCUU 2597 R-008396139-000D 299403 GACAUGGCCAUGGAACCAG B GACAUGGCCAUGGAACCAGTT B 2596 R-008396142-000K1241 404 GUAAAUAUAAUGAGGACCU B GUAAAUAUAAUGAGGACCUTT B 2598R-008396142-000K 1241 404 GUAAAUAUAAUGAGGACCU AGGUCCUCAUUAUAUUUACUU 2599R-008396145-000L 1961 405 CGCAUGGAAGAAAUAGUUG CAACUAUUUCUUCCAUGCGUU 2601R-008396145-000L 1961 405 CGCAUGGAAGAAAUAGUUG B CGCAUGGAAGAAAUAGUUGTT B2600 R-008396148-000M 1436 406 GAUGCUGCAACUAAACAGG BGAUGCUGCAACUAAACAGGTT B 2602 R-008396148-000M 1436 406GAUGCUGCAACUAAACAGG CCUGUUUAGUUGCAGCAUCUU 2603 R-008396151-000U 2469 407UGAUGGAACAUGAGAUGGG B UGAUGGAACAUGAGAUGGGTT B 2604 R-008396151-000U 2469407 UGAUGGAACAUGAGAUGGG CCCAUCUCAUGUUCCAUCAUU 2605 R-008396154-000V 760408 CCAGGUGGUGGUUAAUAAG B CCAGGUGGUGGUUAAUAAGTT B 2606 R-008396154-000V760 408 CCAGGUGGUGGUUAAUAAG CUUAUUAACCACCACCUGGUU 2607 R-008396157-000W2504 141 GCUGACUAUCCAGUUGAUG CAUCAACUGGAUAGUCAGCUU 2609 R-008396157-000W2504 141 GCUGACUAUCCAGUUGAUG B GCUGACUAUCCAGUUGAUGTT B 2608R-008396160-000C 2257 409 UGAGGACAAGCCACAAGAU AUCUUGUGGCUUGUCCUCAUU 2611R-008396160-000C 2257 409 UGAGGACAAGCCACAAGAU B UGAGGACAAGCCACAAGAUTT B2610 R-008396163-000D 952 410 ACUGGCCAUCUUUAAGUCU AGACUUAAAGAUGGCCAGUUU2613 R-008396163-000D 952 410 ACUGGCCAUCUUUAAGUCU BACUGGCCAUCUUUAAGUCUTT B 2612 R-008396166-000E 2283 411AACGGCUUUCAGUUGAGCU B AACGGCUUUCAGUUGAGCUTT B 2614 R-008396166-000E 2283411 AACGGCUUUCAGUUGAGCU AGCUCAACUGAAAGCCGUUUU 2615 R-008396169-000F 164962 ACUGAGCCUGCCAUCUGUG B ACUGAGCCUGCCAUCUGUGTT B 2616 R-008396169-000F1649 62 ACUGAGCCUGCCAUCUGUG CACAGAUGGCAGGCUCAGUUU 2617 R-008396172-000M2014 8 GGAUGUUCACAACCGAAUU AAUUCGGUUGUGAACAUCCUU 2619 R-008396172-000M2014 8 GGAUGUUCACAACCGAAUU B GGAUGUUCACAACCGAAUUTT B 2618R-008396175-000N 1794 412 CUACUGUUGGAUUGAUUCG CGAAUCAAUCCAACAGUAGUU 2621R-008396175-000N 1794 412 CUACUGUUGGAUUGAUUCG B CUACUGUUGGAUUGAUUCGTT B2620 R-008396178-000P 1745 413 GUUGUGGUUAAGCUCUUAC BGUUGUGGUUAAGCUCUUACTT B 2622 R-008396178-000P 1745 413GUUGUGGUUAAGCUCUUAC GUAAGAGCUUAACCACAACUU 2623 R-008396181-000W 1211 414AUACUGGCUAGUGGUGGAC GUCCACCACUAGCCAGUAUUU 2625 R-008396181-000W 1211 414AUACUGGCUAGUGGUGGAC B AUACUGGCUAGUGGUGGACTT B 2624 R-008396184-000X 2549415 GACCUCAUGGAUGGGCUGC B GACCUCAUGGAUGGGCUGCTT B 2626 R-008396184-000X2549 415 GACCUCAUGGAUGGGCUGC GCAGCCCAUCCAUGAGGUCUU 2627 R-008396187-000Y2007 416 UAGCUCGGGAUGUUCACAA UUGUGAACAUCCCGAGCUAUU 2629 R-008396187-000Y2007 416 UAGCUCGGGAUGUUCACAA B UAGCUCGGGAUGUUCACAATT B 2628R-008396190-000E 2474 417 GAACAUGAGAUGGGUGGCC B GAACAUGAGAUGGGUGGCCTT B2630 R-008396190-000E 2474 417 GAACAUGAGAUGGGUGGCC GGCCACCCAUCUCAUGUUCUU2631 R-008396193-000F 1712 418 CAGAAUGCAGUUCGCCUUC GAAGGCGAACUGCAUUCUGUU2633 R-008396193-000F 1712 418 CAGAAUGCAGUUCGCCUUC BCAGAAUGCAGUUCGCCUUCTT B 2632 R-008396196-000G 1919 419ACGUCCAUGGGUGGGACAC B ACGUCCAUGGGUGGGACACTT B 2634 R-008396196-000G 1919419 ACGUCCAUGGGUGGGACAC GUGUCCCACCCAUGGACGUUU 2635 R-008396199-000H 1000420 UGGUUCACCAGUGGAUUCU AGAAUCCACUGGUGAACCAUU 2637 R-008396199-000H 1000420 UGGUUCACCAGUGGAUUCU B UGGUUCACCAGUGGAUUCUTT B 2636 R-008396202-000A2392 421 AUAUCGCCAGGAUGAUCCU AGGAUCAUCCUGGCGAUAUUU 2639 R-008396202-000A2392 421 AUAUCGCCAGGAUGAUCCU B AUAUCGCCAGGAUGAUCCUTT B 2638R-008396205-000B 1449 422 AACAGGAAGGGAUGGAAGG B AACAGGAAGGGAUGGAAGGTT B2640 R-008396205-000B 1449 422 AACAGGAAGGGAUGGAAGG CCUUCCAUCCCUUCCUGUUUU2641 R-008396208-000C 2294 423 GUUGAGCUGACCAGCUCUC GAGAGCUGGUCAGCUCAACUU2643 R-008396208-000C 2294 423 GUUGAGCUGACCAGCUCUC BGUUGAGCUGACCAGCUCUCTT B 2642 R-008396211-000J 1135 424AAAUGUUAAAUUCUUGGCU B AAAUGUUAAAUUCUUGGCUTT B 2644 R-008396211-000J 1135424 AAAUGUUAAAUUCUUGGCU AGCCAAGAAUUUAACAUUUUU 2645 R-008396214-000K 82214 GACACGCUAUCAUGCGUUC B GACACGCUAUCAUGCGUUCTT B 2646 R-008396214-000K822 14 GACACGCUAUCAUGCGUUC GAACGCAUGAUAGCGUGUCUU 2647 R-008396217-000L1333 425 GGCUAUUGUAGAAGCUGGU ACCAGCUUCUACAAUAGCCUU 2649 R-008396217-000L1333 425 GGCUAUUGUAGAAGCUGGU B GGCUAUUGUAGAAGCUGGUTT B 2648R-008396220-000T 1743 426 CAGUUGUGGUUAAGCUCUU AAGAGCUUAACCACAACUGUU 2651R-008396220-000T 1743 426 CAGUUGUGGUUAAGCUCUU B CAGUUGUGGUUAAGCUCUUTT B2650 R-008396223-000U 600 427 CUACACAGUUUGAUGCUGC GCAGCAUCAAACUGUGUAGUU2653 R-008396223-000U 600 427 CUACACAGUUUGAUGCUGC BCUACACAGUUUGAUGCUGCTT B 2652 R-008396226-000V 970 428UGGAGGCAUUCCUGCCCUG CAGGGCAGGAAUGCCUCCAUU 2655 R-008396226-000V 970 428UGGAGGCAUUCCUGCCCUG B UGGAGGCAUUCCUGCCCUGTT B 2654 R-008396229-000W 3137429 GGACAGUUUACCAGUUGCC B GGACAGUUUACCAGUUGCCTT B 2656 R-008396229-000W3137 429 GGACAGUUUACCAGUUGCC GGCAACUGGUAAACUGUCCUU 2657 R-008396232-000C372 430 UCCAUUCUGGUGCCACUAC GUAGUGGCACCAGAAUGGAUU 2659 R-008396232-000C372 430 UCCAUUCUGGUGCCACUAC B UCCAUUCUGGUGCCACUACTT B 2658R-008396235-000D 1761 431 UACACCCACCAUCCCACUG B UACACCCACCAUCCCACUGTT B2660 R-008396235-000D 1761 431 UACACCCACCAUCCCACUG CAGUGGGAUGGUGGGUGUAUU2661 R-008396238-000E 1650 432 CUGAGCCUGCCAUCUGUGC GCACAGAUGGCAGGCUCAGUU2663 R-008396238-000E 1650 432 CUGAGCCUGCCAUCUGUGC BCUGAGCCUGCCAUCUGUGCTT B 2662 R-008396241-000L 972 433GAGGCAUUCCUGCCCUGGU B GAGGCAUUCCUGCCCUGGUTT B 2664 R-008396241-000L 972433 GAGGCAUUCCUGCCCUGGU ACCAGGGCAGGAAUGCCUCUU 2665 R-008396244-000M 1147434 CUUGGCUAUUACGACAGAC GUCUGUCGUAAUAGCCAAGUU 2667 R-008396244-000M 1147434 CUUGGCUAUUACGACAGAC B CUUGGCUAUUACGACAGACTT B 2666 R-008396247-000N565 435 CCCUGAGACAUUAGAUGAG B CCCUGAGACAUUAGAUGAGTT B 2668R-008396247-000N 565 435 CCCUGAGACAUUAGAUGAG CUCAUCUAAUGUCUCAGGGUU 2669R-008396250-000V 525 436 AUGCAAUGACUCGAGCUCA B AUGCAAUGACUCGAGCUCATT B2670 R-008396250-000V 525 436 AUGCAAUGACUCGAGCUCA UGAGCUCGAGUCAUUGCAUUU2671 R-008396253-000W 1599 437 UAGAGGCUCUUGUGCGUAC BUAGAGGCUCUUGUGCGUACTT B 2672 R-008396253-000W 1599 437UAGAGGCUCUUGUGCGUAC GUACGCACAAGAGCCUCUAUU 2673 R-008396256-000X 2199 438UUCACUCUAGGAAUGAAGG B UUCACUCUAGGAAUGAAGGTT B 2674 R-008396256-000X 2199438 UUCACUCUAGGAAUGAAGG CCUUCAUUCCUAGAGUGAAUU 2675 R-008396259-000Y 2261439 GACAAGCCACAAGAUUACA B GACAAGCCACAAGAUUACATT B 2676 R-008396259-000Y2261 439 GACAAGCCACAAGAUUACA UGUAAUCUUGUGGCUUGUCUU 2677 R-008396262-000E705 440 CAGAACUUGCCACACGUGC B CAGAACUUGCCACACGUGCTT B 2678R-008396262-000E 705 440 CAGAACUUGCCACACGUGC GCACGUGUGGCAAGUUCUGUU 2679R-008396265-000F 916 441 GACCUUGCAUAACCUUUCC B GACCUUGCAUAACCUUUCCTT B2680 R-008396265-000F 916 441 GACCUUGCAUAACCUUUCC GGAAAGGUUAUGCAAGGUCUU2681 R-008396268-000G 385 442 CACUACCACAGCUCCUUCU AGAAGGAGCUGUGGUAGUGUU2683 R-008396268-000G 385 442 CACUACCACAGCUCCUUCU BCACUACCACAGCUCCUUCUTT B 2682 R-008396271-000N 3076 443CUAUUUGGGAUAUGUAUGG B CUAUUUGGGAUAUGUAUGGTT B 2684 R-008396271-000N 3076443 CUAUUUGGGAUAUGUAUGG CCAUACAUAUCCCAAAUAGUU 2685 R-008396274-000P 1396444 UCUUGUUCAGAACUGUCUU B UCUUGUUCAGAACUGUCUUTT B 2686 R-008396274-000P1396 444 UCUUGUUCAGAACUGUCUU AAGACAGUUCUGAACAAGAUU 2687 R-008396277-000R2447 445 GAUGCCUUGGGUAUGGACC GGUCCAUACCCAAGGCAUCUU 2689 R-008396277-000R2447 445 GAUGCCUUGGGUAUGGACC B GAUGCCUUGGGUAUGGACCTT B 2688R-008396280-000X 1338 446 UUGUAGAAGCUGGUGGAAU B UUGUAGAAGCUGGUGGAAUTT B2690 R-008396280-000X 1338 446 UUGUAGAAGCUGGUGGAAU AUUCCACCAGCUUCUACAAUU2691 R-008396283-000Y 2215 447 AGGUGUGGCGACAUAUGCA UGCAUAUGUCGCCACACCUUU2693 R-008396283-000Y 2215 447 AGGUGUGGCGACAUAUGCA BAGGUGUGGCGACAUAUGCATT B 2692 R-008396286-000Z 722 448GCAAUCCCUGAACUGACAA B GCAAUCCCUGAACUGACAATT B 2694 R-008396286-000Z 722448 GCAAUCCCUGAACUGACAA UUGUCAGUUCAGGGAUUGCUU 2695 R-008396289-000A 1316449 UGCUCUAGUAAUAAGCCGG CCGGCUUAUUACUAGAGCAUU 2697 R-008396289-000A 1316449 UGCUCUAGUAAUAAGCCGG B UGCUCUAGUAAUAAGCCGGTT B 2696 R-008396292-000G1687 450 CCGACACCAAGAAGCAGAG B CCGACACCAAGAAGCAGAGTT B 2698R-008396292-000G 1687 450 CCGACACCAAGAAGCAGAG CUCUGCUUCUUGGUGUCGGUU 2699R-008396295-000H 697 451 AGAUGAUGCAGAACUUGCC B AGAUGAUGCAGAACUUGCCTT B2700 R-008396295-000H 697 451 AGAUGAUGCAGAACUUGCC GGCAAGUUCUGCAUCAUCUUU2701 R-008396298-000J 2517 452 UUGAUGGGCUGCCAGAUCU BUUGAUGGGCUGCCAGAUCUTT B 2702 R-008396298-000J 2517 452UUGAUGGGCUGCCAGAUCU AGAUCUGGCAGCCCAUCAAUU 2703 R-008396301-000B 1685 453AGCCGACACCAAGAAGCAG B AGCCGACACCAAGAAGCAGTT B 2704 R-008396301-000B 1685453 AGCCGACACCAAGAAGCAG CUGCUUCUUGGUGUCGGCUUU 2705 R-008396304-000C 3090454 UAUGGGUAGGGUAAAUCAG CUGAUUUACCCUACCCAUAUU 2707 R-008396304-000C 3090454 UAUGGGUAGGGUAAAUCAG B UAUGGGUAGGGUAAAUCAGTT B 2706 R-008396307-000D1205 455 CUCAUCAUACUGGCUAGUG B CUCAUCAUACUGGCUAGUGTT B 2708R-008396307-000D 1205 455 CUCAUCAUACUGGCUAGUG CACUAGCCAGUAUGAUGAGUU 2709R-008396310-000K 1153 456 UAUUACGACAGACUGCCUU B UAUUACGACAGACUGCCUUTT B2710 R-008396310-000K 1153 456 UAUUACGACAGACUGCCUU AAGGCAGUCUGUCGUAAUAUU2711 R-008396313-000L 723 457 CAAUCCCUGAACUGACAAA BCAAUCCCUGAACUGACAAATT B 2712 R-008396313-000L 723 457CAAUCCCUGAACUGACAAA UUUGUCAGUUCAGGGAUUGUU 2713 R-008396316-000M 1468 458UCUCCUUGGGACUCUUGUU AACAAGAGUCCCAAGGAGAUU 2715 R-008396316-000M 1468 458UCUCCUUGGGACUCUUGUU B UCUCCUUGGGACUCUUGUUTT B 2714 R-008396319-000N 2480459 GAGAUGGGUGGCCACCACC B GAGAUGGGUGGCCACCACCTT B 2716 R-008396319-000N2480 459 GAGAUGGGUGGCCACCACC GGUGGUGGCCACCCAUCUCUU 2717 R-008396322-000V1856 460 CAGGGUGCCAUUCCACGAC B CAGGGUGCCAUUCCACGACTT B 2718R-008396322-000V 1856 460 CAGGGUGCCAUUCCACGAC GUCGUGGAAUGGCACCCUGUU 2719R-008396325-000W 2193 461 AGUUACUUCACUCUAGGAA B AGUUACUUCACUCUAGGAATT B2720 R-008396325-000W 2193 461 AGUUACUUCACUCUAGGAA UUCCUAGAGUGAAGUAACUUU2721 R-008396328-000X 2355 462 UUGGACUUGAUAUUGGUGC BUUGGACUUGAUAUUGGUGCTT B 2722 R-008396328-000X 2355 462UUGGACUUGAUAUUGGUGC GCACCAAUAUCAAGUCCAAUU 2723 R-008396331-000D 1995 463CCCUUCACAUCCUAGCUCG CGAGCUAGGAUGUGAAGGGUU 2725 R-008396331-000D 1995 463CCCUUCACAUCCUAGCUCG B CCCUUCACAUCCUAGCUCGTT B 2724 R-008396334-000E 821464 AGACACGCUAUCAUGCGUU B AGACACGCUAUCAUGCGUUTT B 2726 R-008396334-000E821 464 AGACACGCUAUCAUGCGUU AACGCAUGAUAGCGUGUCUUU 2727 R-008396337-000F1715 465 AAUGCAGUUCGCCUUCACU B AAUGCAGUUCGCCUUCACUTT B 2728R-008396337-000F 1715 465 AAUGCAGUUCGCCUUCACU AGUGAAGGCGAACUGCAUUUU 2729R-008396340-000M 1182 466 CUUAUGGCAACCAAGAAAG CUUUCUUGGUUGCCAUAAGUU 2731R-008396340-000M 1182 466 CUUAUGGCAACCAAGAAAG B CUUAUGGCAACCAAGAAAGTT B2730 R-008396343-000N 445 467 CUCCCAAGUCCUGUAUGAG BCUCCCAAGUCCUGUAUGAGTT B 2732 R-008396343-000N 445 467CUCCCAAGUCCUGUAUGAG CUCAUACAGGACUUGGGAGUU 2733 R-008396346-000P 1759 468CUUACACCCACCAUCCCAC GUGGGAUGGUGGGUGUAAGUU 2735 R-008396346-000P 1759 468CUUACACCCACCAUCCCAC B CUUACACCCACCAUCCCACTT B 2734 R-008396349-000R 1461469 UGGAAGGUCUCCUUGGGAC B UGGAAGGUCUCCUUGGGACTT B 2736 R-008396349-000R1461 469 UGGAAGGUCUCCUUGGGAC GUCCCAAGGAGACCUUCCAUU 2737 R-008396352-000X1993 470 AGCCCUUCACAUCCUAGCU AGCUAGGAUGUGAAGGGCUUU 2739 R-008396352-000X1993 470 AGCCCUUCACAUCCUAGCU B AGCCCUUCACAUCCUAGCUTT B 2738R-008396355-000Y 2558 471 GAUGGGCUGCCUCCAGGUG B GAUGGGCUGCCUCCAGGUGTT B2740 R-008396355-000Y 2558 471 GAUGGGCUGCCUCCAGGUG CACCUGGAGGCAGCCCAUCUU2741 R-008396358-000Z 1488 472 AGCUUCUGGGUUCAGAUGA BAGCUUCUGGGUUCAGAUGATT B 2742 R-008396358-000Z 1488 472AGCUUCUGGGUUCAGAUGA UCAUCUGAACCCAGAAGCUUU 2743 R-008396361-000F 1652 473GAGCCUGCCAUCUGUGCUC B GAGCCUGCCAUCUGUGCUCTT B 2744 R-008396361-000F 1652473 GAGCCUGCCAUCUGUGCUC GAGCACAGAUGGCAGGCUCUU 2745 R-008396364-000G 963474 UUAAGUCUGGAGGCAUUCC B UUAAGUCUGGAGGCAUUCCTT B 2746 R-008396364-000G963 474 UUAAGUCUGGAGGCAUUCC GGAAUGCCUCCAGACUUAAUU 2747 R-008396367-000H1520 475 ACCUGUGCAGCUGGAAUUC B ACCUGUGCAGCUGGAAUUCTT B 2748R-008396367-000H 1520 475 ACCUGUGCAGCUGGAAUUC GAAUUCCAGCUGCACAGGUUU 2749R-008396370-000P 1828 476 UCCCGCAAAUCAUGCACCU AGGUGCAUGAUUUGCGGGAUU 2751R-008396370-000P 1828 476 UCCCGCAAAUCAUGCACCU B UCCCGCAAAUCAUGCACCUTT B2750 R-008396373-000R 2214 477 AAGGUGUGGCGACAUAUGC BAAGGUGUGGCGACAUAUGCTT B 2752 R-008396373-000R 2214 477AAGGUGUGGCGACAUAUGC GCAUAUGUCGCCACACCUUUU 2753 R-008396376-000S 2155 478AGCUAUUGAAGCUGAGGGA UCCCUCAGCUUCAAUAGCUUU 2755 R-008396376-000S 2155 478AGCUAUUGAAGCUGAGGGA B AGCUAUUGAAGCUGAGGGATT B 2754 R-008396379-000T 332479 GUUAGUCACUGGCAGCAAC GUUGCUGCCAGUGACUAACUU 2757 R-008396379-000T 332479 GUUAGUCACUGGCAGCAAC B GUUAGUCACUGGCAGCAACTT B 2756 R-008396382-000Z2545 74 CCAGGACCUCAUGGAUGGG CCCAUCCAUGAGGUCCUGGUU 2759 R-008396382-000Z2545 74 CCAGGACCUCAUGGAUGGG B CCAGGACCUCAUGGAUGGGTT B 2758R-008396385-000A 1878 480 UUCAGUUGCUUGUUCGUGC B UUCAGUUGCUUGUUCGUGCTT B2760 R-008396385-000A 1878 480 UUCAGUUGCUUGUUCGUGC GCACGAACAAGCAACUGAAUU2761 R-008396388-000B 1789 106 AAAGGCUACUGUUGGAUUG CAAUCCAACAGUAGCCUUUUU2763 R-008396388-000B 1789 106 AAAGGCUACUGUUGGAUUG BAAAGGCUACUGUUGGAUUGTT B 2762 R-008396391-000H 2547 168AGGACCUCAUGGAUGGGCU B AGGACCUCAUGGAUGGGCUTT B 2764 R-008396391-000H 2547168 AGGACCUCAUGGAUGGGCU AGCCCAUCCAUGAGGUCCUUU 2765 R-008396394-000J 1573481 GAUGAUGGUCUGCCAAGUG B GAUGAUGGUCUGCCAAGUGTT B 2766 R-008396394-000J1573 481 GAUGAUGGUCUGCCAAGUG CACUUGGCAGACCAUCAUCUU 2767 R-008396397-000K1446 482 CUAAACAGGAAGGGAUGGA B CUAAACAGGAAGGGAUGGATT B 2768R-008396397-000K 1446 482 CUAAACAGGAAGGGAUGGA UCCAUCCCUUCCUGUUUAGUU 2769R-008396400-000C 1868 483 CCACGACUAGUUCAGUUGC GCAACUGAACUAGUCGUGGUU 2771R-008396400-000C 1868 483 CCACGACUAGUUCAGUUGC B CCACGACUAGUUCAGUUGCTT B2770 R-008396403-000D 1873 484 ACUAGUUCAGUUGCUUGUU AACAAGCAACUGAACUAGUUU2773 R-008396403-000D 1873 484 ACUAGUUCAGUUGCUUGUU BACUAGUUCAGUUGCUUGUUTT B 2772 R-008396406-000E 1002 485GUUCACCAGUGGAUUCUGU B GUUCACCAGUGGAUUCUGUTT B 2774 R-008396406-000E 1002485 GUUCACCAGUGGAUUCUGU ACAGAAUCCACUGGUGAACUU 2775 R-008396409-000F 408486 GUGGUAAAGGCAAUCCUGA B GUGGUAAAGGCAAUCCUGATT B 2776 R-008396409-000F408 486 GUGGUAAAGGCAAUCCUGA UCAGGAUUGCCUUUACCACUU 2777 R-008396412-000M287 487 UUGAUGGAGUUGGACAUGG CCAUGUCCAACUCCAUCAAUU 2779 R-008396412-000M287 487 UUGAUGGAGUUGGACAUGG B UUGAUGGAGUUGGACAUGGTT B 2778R-008396415-000N 1492 119 UCUGGGUUCAGAUGAUAUA UAUAUCAUCUGAACCCAGAUU 2781R-008396415-000N 1492 119 UCUGGGUUCAGAUGAUAUA B UCUGGGUUCAGAUGAUAUATT B2780 R-008396418-000P 517 187 UGGACAGUAUGCAAUGACU BUGGACAGUAUGCAAUGACUTT B 2782 R-008396418-000P 517 187UGGACAGUAUGCAAUGACU AGUCAUUGCAUACUGUCCAUU 2783 R-008396421-000W 447 177CCCAAGUCCUGUAUGAGUG B CCCAAGUCCUGUAUGAGUGTT B 2784 R-008396421-000W 447177 CCCAAGUCCUGUAUGAGUG CACUCAUACAGGACUUGGGUU 2785 R-008396424-000X 2128488 ACUUGCUCAGGACAAGGAA UUCCUUGUCCUGAGCAAGUUU 2787 R-008396424-000X 2128488 ACUUGCUCAGGACAAGGAA B ACUUGCUCAGGACAAGGAATT B 2786 R-008396427-000Y2513 489 CCAGUUGAUGGGCUGCCAG B CCAGUUGAUGGGCUGCCAGTT B 2788R-008396427-000Y 2513 489 CCAGUUGAUGGGCUGCCAG CUGGCAGCCCAUCAACUGGUU 2789R-008396430-000E 1196 490 GAAAGCAAGCUCAUCAUAC GUAUGAUGAGCUUGCUUUCUU 2791R-008396430-000E 1196 490 GAAAGCAAGCUCAUCAUAC B GAAAGCAAGCUCAUCAUACTT B2790 R-008396433-000F 572 491 ACAUUAGAUGAGGGCAUGC BACAUUAGAUGAGGGCAUGCTT B 2792 R-008396433-000F 572 491ACAUUAGAUGAGGGCAUGC GCAUGCCCUCAUCUAAUGUUU 2793 R-008396436-000G 622 492UCCCACUAAUGUCCAGCGU B UCCCACUAAUGUCCAGCGUTT B 2794 R-008396436-000G 622492 UCCCACUAAUGUCCAGCGU ACGCUGGACAUUAGUGGGAUU 2795 R-008396439-000H 1187493 GGCAACCAAGAAAGCAAGC GCUUGCUUUCUUGGUUGCCUU 2797 R-008396439-000H 1187493 GGCAACCAAGAAAGCAAGC B GGCAACCAAGAAAGCAAGCTT B 2796 R-008396442-000P2098 49 CCAAAGAGUAGCUGCAGGG B CCAAAGAGUAGCUGCAGGGTT B 2798R-008396442-000P 2098 49 CCAAAGAGUAGCUGCAGGG CCCUGCAGCUACUCUUUGGUU 2799R-008396445-000R 1971 494 AAAUAGUUGAAGGUUGUAC B AAAUAGUUGAAGGUUGUACTT B2800 R-008396445-000R 1971 494 AAAUAGUUGAAGGUUGUAC GUACAACCUUCAACUAUUUUU2801 R-008396448-000S 3083 495 GGAUAUGUAUGGGUAGGGU ACCCUACCCAUACAUAUCCUU2803 R-008396448-000S 3083 495 GGAUAUGUAUGGGUAGGGU BGGAUAUGUAUGGGUAGGGUTT B 2802 R-008396454-000Z 2944 496UAAUCUGAAUAAAGUGUAA UUACACUUUAUUCAGAUUAUU 2805 R-008396454-000Z 2944 496UAAUCUGAAUAAAGUGUAA B UAAUCUGAAUAAAGUGUAATT B 2804 R-008396457-000A 1894497 UGCACAUCAGGAUACCCAG B UGCACAUCAGGAUACCCAGTT B 2806 R-008396457-000A1894 497 UGCACAUCAGGAUACCCAG CUGGGUAUCCUGAUGUGCAUU 2807 R-008396460-000G1323 498 GUAAUAAGCCGGCUAUUGU B GUAAUAAGCCGGCUAUUGUTT B 2808R-008396460-000G 1323 498 GUAAUAAGCCGGCUAUUGU ACAAUAGCCGGCUUAUUACUU 2809R-008396469-000K 1202 499 AAGCUCAUCAUACUGGCUA B AAGCUCAUCAUACUGGCUATT B2810 R-008396469-000K 1202 499 AAGCUCAUCAUACUGGCUA UAGCCAGUAUGAUGAGCUUUU2811 R-008396472-000S 718 500 ACGUGCAAUCCCUGAACUG CAGUUCAGGGAUUGCACGUUU2813 R-008396472-000S 718 500 ACGUGCAAUCCCUGAACUG BACGUGCAAUCCCUGAACUGTT B 2812 R-008396475-000T 2097 46UCCAAAGAGUAGCUGCAGG CCUGCAGCUACUCUUUGGAUU 2815 R-008396475-000T 2097 46UCCAAAGAGUAGCUGCAGG B UCCAAAGAGUAGCUGCAGGTT B 2814 R-008396478-000U 1744501 AGUUGUGGUUAAGCUCUUA B AGUUGUGGUUAAGCUCUUATT B 2816 R-008396478-000U1744 501 AGUUGUGGUUAAGCUCUUA UAAGAGCUUAACCACAACUUU 2817 R-008396481-000A756 502 AGGACCAGGUGGUGGUUAA UUAACCACCACCUGGUCCUUU 2819 R-008396481-000A756 502 AGGACCAGGUGGUGGUUAA B AGGACCAGGUGGUGGUUAATT B 2818R-008396484-000B 1317 503 GCUCUAGUAAUAAGCCGGC GCCGGCUUAUUACUAGAGCUU 2821R-008396484-000B 1317 503 GCUCUAGUAAUAAGCCGGC B GCUCUAGUAAUAAGCCGGCTT B2820 R-008396487-000C 284 504 GAUUUGAUGGAGUUGGACA BGAUUUGAUGGAGUUGGACATT B 2822 R-008396487-000C 284 504GAUUUGAUGGAGUUGGACA UGUCCAACUCCAUCAAAUCUU 2823 R-008396490-000J 886 505UGAUGUAGAAACAGCUCGU B UGAUGUAGAAACAGCUCGUTT B 2824 R-008396490-000J 886505 UGAUGUAGAAACAGCUCGU ACGAGCUGUUUCUACAUCAUU 2825 R-008396493-000K 2430506 CUGGUGGAUAUGGCCAGGA B CUGGUGGAUAUGGCCAGGATT B 2826 R-008396493-000K2430 506 CUGGUGGAUAUGGCCAGGA UCCUGGCCAUAUCCACCAGUU 2827 R-008396496-000L1207 507 CAUCAUACUGGCUAGUGGU B CAUCAUACUGGCUAGUGGUTT B 2828R-008396496-000L 1207 507 CAUCAUACUGGCUAGUGGU ACCACUAGCCAGUAUGAUGUU 2829R-008396499-000M 592 508 GAUCCCAUCUACACAGUUU AAACUGUGUAGAUGGGAUCUU 2831R-008396499-000M 592 508 GAUCCCAUCUACACAGUUU B GAUCCCAUCUACACAGUUUTT B2830 R-008396502-000E 824 509 CACGCUAUCAUGCGUUCUC GAGAACGCAUGAUAGCGUGUU2833 R-008396502-000E 824 509 CACGCUAUCAUGCGUUCUC BCACGCUAUCAUGCGUUCUCTT B 2832 R-008396505-000F 519 510GACAGUAUGCAAUGACUCG B GACAGUAUGCAAUGACUCGTT B 2834 R-008396505-000F 519510 GACAGUAUGCAAUGACUCG CGAGUCAUUGCAUACUGUCUU 2835 R-008396508-000G 3166511 AAGUUGUUGUAACCUGCUG CAGCAGGUUACAACAACUUUU 2837 R-008396508-000G 3166511 AAGUUGUUGUAACCUGCUG B AAGUUGUUGUAACCUGCUGTT B 2836 R-008396511-000N1151 512 GCUAUUACGACAGACUGCC B GCUAUUACGACAGACUGCCTT B 2838R-008396511-000N 1151 512 GCUAUUACGACAGACUGCC GGCAGUCUGUCGUAAUAGCUU 2839R-008396514-000P 2566 513 GCCUCCAGGUGACAGCAAU B GCCUCCAGGUGACAGCAAUTT B2840 R-008396514-000P 2566 513 GCCUCCAGGUGACAGCAAU AUUGCUGUCACCUGGAGGCUU2841 R-008396517-000R 453 514 UCCUGUAUGAGUGGGAACA UGUUCCCACUCAUACAGGAUU2843 R-008396517-000R 453 514 UCCUGUAUGAGUGGGAACA BUCCUGUAUGAGUGGGAACATT B 2842 R-008396520-000X 587 515AUGCAGAUCCCAUCUACAC GUGUAGAUGGGAUCUGCAUUU 2845 R-008396520-000X 587 515AUGCAGAUCCCAUCUACAC B AUGCAGAUCCCAUCUACACTT B 2844 R-008396523-000Y 930516 UUUCCCAUCAUCGUGAGGG B UUUCCCAUCAUCGUGAGGGTT B 2846 R-008396523-000Y930 516 UUUCCCAUCAUCGUGAGGG CCCUCACGAUGAUGGGAAAUU 2847 R-008396526-000Z1585 517 CCAAGUGGGUGGUAUAGAG B CCAAGUGGGUGGUAUAGAGTT B 2848R-008396526-000Z 1585 517 CCAAGUGGGUGGUAUAGAG CUCUAUACCACCCACUUGGUU 2849R-008396529-000A 915 518 GGACCUUGCAUAACCUUUC B GGACCUUGCAUAACCUUUCTT B2850 R-008396529-000A 915 518 GGACCUUGCAUAACCUUUC GAAAGGUUAUGCAAGGUCCUU2851 R-008396532-000G 446 519 UCCCAAGUCCUGUAUGAGU ACUCAUACAGGACUUGGGAUU2853 R-008396532-000G 446 519 UCCCAAGUCCUGUAUGAGU BUCCCAAGUCCUGUAUGAGUTT B 2852 R-008396535-000H 1869 520CACGACUAGUUCAGUUGCU AGCAACUGAACUAGUCGUGUU 2855 R-008396535-000H 1869 520CACGACUAGUUCAGUUGCU B CACGACUAGUUCAGUUGCUTT B 2854 R-008396538-000J 1960521 CCGCAUGGAAGAAAUAGUU AACUAUUUCUUCCAUGCGGUU 2857 R-008396538-000J 1960521 CCGCAUGGAAGAAAUAGUU B CCGCAUGGAAGAAAUAGUUTT B 2856 R-008396541-000R1708 522 GGCCCAGAAUGCAGUUCGC B GGCCCAGAAUGCAGUUCGCTT B 2858R-008396541-000R 1708 522 GGCCCAGAAUGCAGUUCGC GCGAACUGCAUUCUGGGCCUU 2859R-008396544-000S 306 523 CCAUGGAACCAGACAGAAA UUUCUGUCUGGUUCCAUGGUU 2861R-008396544-000S 306 523 CCAUGGAACCAGACAGAAA B CCAUGGAACCAGACAGAAATT B2860 R-008396550-000Z 2281 524 GAAACGGCUUUCAGUUGAG BGAAACGGCUUUCAGUUGAGTT B 2862 R-008396550-000Z 2281 524GAAACGGCUUUCAGUUGAG CUCAACUGAAAGCCGUUUCUU 2863 R-008396553-000A 3082 525GGGAUAUGUAUGGGUAGGG B GGGAUAUGUAUGGGUAGGGTT B 2864 R-008396553-000A 3082525 GGGAUAUGUAUGGGUAGGG CCCUACCCAUACAUAUCCCUU 2865 R-008396556-000B 1473526 UUGGGACUCUUGUUCAGCU AGCUGAACAAGAGUCCCAAUU 2867 R-008396556-000B 1473526 UUGGGACUCUUGUUCAGCU B UUGGGACUCUUGUUCAGCUTT B 2866 R-008396559-000C559 527 UAUGUUCCCUGAGACAUUA UAAUGUCUCAGGGAACAUAUU 2869 R-008396559-000C559 527 UAUGUUCCCUGAGACAUUA B UAUGUUCCCUGAGACAUUATT B 2868R-008396562-000J 1416 528 GGACUCUCAGGAAUCUUUC B GGACUCUCAGGAAUCUUUCTT B2870 R-008396562-000J 1416 528 GGACUCUCAGGAAUCUUUC GAAAGAUUCCUGAGAGUCCUU2871 R-008396565-000K 2145 529 AAGCUGCAGAAGCUAUUGA BAAGCUGCAGAAGCUAUUGATT B 2872 R-008396565-000K 2145 529AAGCUGCAGAAGCUAUUGA UCAAUAGCUUCUGCAGCUUUU 2873 R-008396568-000L 1994 530GCCCUUCACAUCCUAGCUC B GCCCUUCACAUCCUAGCUCTT B 2874 R-008396568-000L 1994530 GCCCUUCACAUCCUAGCUC GAGCUAGGAUGUGAAGGGCUU 2875 R-008396571-000T 161127 UGCGUACUGUCCUUCGGGC B UGCGUACUGUCCUUCGGGCTT B 2876 R-008396571-000T1611 27 UGCGUACUGUCCUUCGGGC GCCCGAAGGACAGUACGCAUU 2877 R-008396574-000U1702 531 AGAGAUGGCCCAGAAUGCA B AGAGAUGGCCCAGAAUGCATT B 2878R-008396574-000U 1702 531 AGAGAUGGCCCAGAAUGCA UGCAUUCUGGGCCAUCUCUUU 2879R-008396577-000V 417 532 GCAAUCCUGAGGAAGAGGA B GCAAUCCUGAGGAAGAGGATT B2880 R-008396577-000V 417 532 GCAAUCCUGAGGAAGAGGA UCCUCUUCCUCAGGAUUGCUU2881 R-008396580-000B 2444 533 CAGGAUGCCUUGGGUAUGG BCAGGAUGCCUUGGGUAUGGTT B 2882 R-008396580-000B 2444 533CAGGAUGCCUUGGGUAUGG CCAUACCCAAGGCAUCCUGUU 2883 R-008396586-000D 555 534CUGCUAUGUUCCCUGAGAC B CUGCUAUGUUCCCUGAGACTT B 2884 R-008396586-000D 555534 CUGCUAUGUUCCCUGAGAC GUCUCAGGGAACAUAGCAGUU 2885 R-008396589-000E 2019535 UUCACAACCGAAUUGUUAU B UUCACAACCGAAUUGUUAUTT B 2886 R-008396589-000E2019 535 UUCACAACCGAAUUGUUAU AUAACAAUUCGGUUGUGAAUU 2887 R-008396592-000L1197 536 AAAGCAAGCUCAUCAUACU B AAAGCAAGCUCAUCAUACUTT B 2888R-008396592-000L 1197 536 AAAGCAAGCUCAUCAUACU AGUAUGAUGAGCUUGCUUUUU 2889R-008396595-000M 415 537 AGGCAAUCCUGAGGAAGAG CUCUUCCUCAGGAUUGCCUUU 2891R-008396595-000M 415 537 AGGCAAUCCUGAGGAAGAG B AGGCAAUCCUGAGGAAGAGTT B2890 R-008396598-000N 2061 538 UGUUUGUGCAGCUGCUUUA BUGUUUGUGCAGCUGCUUUATT B 2892 R-008396598-000N 2061 538UGUUUGUGCAGCUGCUUUA UAAAGCAGCUGCACAAACAUU 2893 R-008396601-000F 1352 539GGAAUGCAAGCUUUAGGAC B GGAAUGCAAGCUUUAGGACTT B 2894 R-008396601-000F 1352539 GGAAUGCAAGCUUUAGGAC GUCCUAAAGCUUGCAUUCCUU 2895 R-008396604-000G 1502135 GAUGAUAUAAAUGUGGUCA UGACCACAUUUAUAUCAUCUU 2897 R-008396604-000G 1502135 GAUGAUAUAAAUGUGGUCA B GAUGAUAUAAAUGUGGUCATT B 2896 R-008396607-000H1331 540 CCGGCUAUUGUAGAAGCUG B CCGGCUAUUGUAGAAGCUGTT B 2898R-008396607-000H 1331 540 CCGGCUAUUGUAGAAGCUG CAGCUUCUACAAUAGCCGGUU 2899R-008396610-000P 1325 541 AAUAAGCCGGCUAUUGUAG B AAUAAGCCGGCUAUUGUAGTT B2900 R-008396610-000P 1325 541 AAUAAGCCGGCUAUUGUAG CUACAAUAGCCGGCUUAUUUU2901 R-008396613-000R 1486 542 UCAGCUUCUGGGUUCAGAU BUCAGCUUCUGGGUUCAGAUTT B 2902 R-008396613-000R 1486 542UCAGCUUCUGGGUUCAGAU AUCUGAACCCAGAAGCUGAUU 2903 R-008396616-000S 454 543CCUGUAUGAGUGGGAACAG B CCUGUAUGAGUGGGAACAGTT B 2904 R-008396616-000S 454543 CCUGUAUGAGUGGGAACAG CUGUUCCCACUCAUACAGGUU 2905 R-008396619-000T 490544 CACUCAAGAACAAGUAGCU B CACUCAAGAACAAGUAGCUTT B 2906 R-008396619-000T490 544 CACUCAAGAACAAGUAGCU AGCUACUUGUUCUUGAGUGUU 2907 R-008396622-000Z1996 545 CCUUCACAUCCUAGCUCGG B CCUUCACAUCCUAGCUCGGTT B 2908R-008396622-000Z 1996 545 CCUUCACAUCCUAGCUCGG CCGAGCUAGGAUGUGAAGGUU 2909R-008396625-000A 1839 546 AUGCACCUUUGCGUGAGCA B AUGCACCUUUGCGUGAGCATT B2910 R-008396625-000A 1839 546 AUGCACCUUUGCGUGAGCA UGCUCACGCAAAGGUGCAUUU2911 R-008396628-000B 1888 547 UGUUCGUGCACAUCAGGAU AUCCUGAUGUGCACGAACAUU2913 R-008396628-000B 1888 547 UGUUCGUGCACAUCAGGAU BUGUUCGUGCACAUCAGGAUTT B 2912 R-008396631-000H 1879 548UCAGUUGCUUGUUCGUGCA B UCAGUUGCUUGUUCGUGCATT B 2914 R-008396631-000H 1879548 UCAGUUGCUUGUUCGUGCA UGCACGAACAAGCAACUGAUU 2915 R-008396634-000J 2508172 ACUAUCCAGUUGAUGGGCU B ACUAUCCAGUUGAUGGGCUTT B 2916 R-008396634-000J2508 172 ACUAUCCAGUUGAUGGGCU AGCCCAUCAACUGGAUAGUUU 2917 R-008396637-000K1829 549 CCCGCAAAUCAUGCACCUU AAGGUGCAUGAUUUGCGGGUU 2919 R-008396637-000K1829 549 CCCGCAAAUCAUGCACCUU B CCCGCAAAUCAUGCACCUUTT B 2918R-008396640-000S 281 550 GCUGAUUUGAUGGAGUUGG B GCUGAUUUGAUGGAGUUGGTT B2920 R-008396640-000S 281 550 GCUGAUUUGAUGGAGUUGG CCAACUCCAUCAAAUCAGCUU2921 R-008396643-000T 1598 551 AUAGAGGCUCUUGUGCGUA UACGCACAAGAGCCUCUAUUU2923 R-008396643-000T 1598 551 AUAGAGGCUCUUGUGCGUA BAUAGAGGCUCUUGUGCGUATT B 2922 R-008396646-000U 2135 552CAGGACAAGGAAGCUGCAG B CAGGACAAGGAAGCUGCAGTT B 2924 R-008396646-000U 2135552 CAGGACAAGGAAGCUGCAG CUGCAGCUUCCUUGUCCUGUU 2925 R-008396649-000V 64267 UGGCUGAACCAUCACAGAU AUCUGUGAUGGUUCAGCCAUU 2927 R-008396649-000V 64267 UGGCUGAACCAUCACAGAU B UGGCUGAACCAUCACAGAUTT B 2926 R-008396652-000B1755 553 AGCUCUUACACCCACCAUC B AGCUCUUACACCCACCAUCTT B 2928R-008396652-000B 1755 553 AGCUCUUACACCCACCAUC GAUGGUGGGUGUAAGAGCUUU 2929R-008396655-000C 651 554 CAUCACAGAUGCUGAAACA B CAUCACAGAUGCUGAAACATT B2930 R-008396655-000C 651 554 CAUCACAGAUGCUGAAACA UGUUUCAGCAUCUGUGAUGUU2931 R-008396658-000D 1335 555 CUAUUGUAGAAGCUGGUGG CCACCAGCUUCUACAAUAGUU2933 R-008396658-000D 1335 555 CUAUUGUAGAAGCUGGUGG BCUAUUGUAGAAGCUGGUGGTT B 2932 R-008396661-000K 2541 556AUGCCCAGGACCUCAUGGA UCCAUGAGGUCCUGGGCAUUU 2935 R-008396661-000K 2541 556AUGCCCAGGACCUCAUGGA B AUGCCCAGGACCUCAUGGATT B 2934 R-008396664-000L 531557 UGACUCGAGCUCAGAGGGU B UGACUCGAGCUCAGAGGGUTT B 2936 R-008396664-000L531 557 UGACUCGAGCUCAGAGGGU ACCCUCUGAGCUCGAGUCAUU 2937 R-008396667-000M606 558 AGUUUGAUGCUGCUCAUCC B AGUUUGAUGCUGCUCAUCCTT B 2938R-008396667-000M 606 558 AGUUUGAUGCUGCUCAUCC GGAUGAGCAGCAUCAAACUUU 2939R-008396670-000U 1620 559 UCCUUCGGGCUGGUGACAG B UCCUUCGGGCUGGUGACAGTT B2940 R-008396670-000U 1620 559 UCCUUCGGGCUGGUGACAG CUGUCACCAGCCCGAAGGAUU2941 R-008396673-000V 2211 560 AUGAAGGUGUGGCGACAUA BAUGAAGGUGUGGCGACAUATT B 2942 R-008396673-000V 2211 560AUGAAGGUGUGGCGACAUA UAUGUCGCCACACCUUCAUUU 2943 R-008396676-000W 2293 561AGUUGAGCUGACCAGCUCU B AGUUGAGCUGACCAGCUCUTT B 2944 R-008396676-000W 2293561 AGUUGAGCUGACCAGCUCU AGAGCUGGUCAGCUCAACUUU 2945 R-008396679-000X 151165 AAUGUGGUCACCUGUGCAG B AAUGUGGUCACCUGUGCAGTT B 2946 R-008396679-000X1511 65 AAUGUGGUCACCUGUGCAG CUGCACAGGUGACCACAUUUU 2947 R-008396682-000D455 562 CUGUAUGAGUGGGAACAGG B CUGUAUGAGUGGGAACAGGTT B 2948R-008396682-000D 455 562 CUGUAUGAGUGGGAACAGG CCUGUUCCCACUCAUACAGUU 2949R-008396685-000E 540 563 CUCAGAGGGUACGAGCUGC B CUCAGAGGGUACGAGCUGCTT B2950 R-008396685-000E 540 563 CUCAGAGGGUACGAGCUGC GCAGCUCGUACCCUCUGAGUU2951 R-008396688-000F 416 564 GGCAAUCCUGAGGAAGAGG CCUCUUCCUCAGGAUUGCCUU2953 R-008396688-000F 416 564 GGCAAUCCUGAGGAAGAGG BGGCAAUCCUGAGGAAGAGGTT B 2952 R-008396691-000M 1669 130UCUUCGUCAUCUGACCAGC GCUGGUCAGAUGACGAAGAUU 2955 R-008396691-000M 1669 130UCUUCGUCAUCUGACCAGC B UCUUCGUCAUCUGACCAGCTT B 2954 R-008396694-000N 1210565 CAUACUGGCUAGUGGUGGA B CAUACUGGCUAGUGGUGGATT B 2956 R-008396694-000N1210 565 CAUACUGGCUAGUGGUGGA UCCACCACUAGCCAGUAUGUU 2957 R-008396697-000P2262 566 ACAAGCCACAAGAUUACAA UUGUAAUCUUGUGGCUUGUUU 2959 R-008396697-000P2262 566 ACAAGCCACAAGAUUACAA B ACAAGCCACAAGAUUACAATT B 2958R-008396700-000G 1604 567 GCUCUUGUGCGUACUGUCC GGACAGUACGCACAAGAGCUU 2961R-008396700-000G 1604 567 GCUCUUGUGCGUACUGUCC B GCUCUUGUGCGUACUGUCCTT B2960 R-008396703-000H 435 568 AUGUGGAUACCUCCCAAGU BAUGUGGAUACCUCCCAAGUTT B 2962 R-008396703-000H 435 568AUGUGGAUACCUCCCAAGU ACUUGGGAGGUAUCCACAUUU 2963 R-008396706-000J 2060 569UUGUUUGUGCAGCUGCUUU B UUGUUUGUGCAGCUGCUUUTT B 2964 R-008396706-000J 2060569 UUGUUUGUGCAGCUGCUUU AAAGCAGCUGCACAAACAAUU 2965 R-008396709-000K 2225570 ACAUAUGCAGCUGCUGUUU B ACAUAUGCAGCUGCUGUUUTT B 2966 R-008396709-000K2225 570 ACAUAUGCAGCUGCUGUUU AAACAGCAGCUGCAUAUGUUU 2967 R-008396712-000S2510 47 UAUCCAGUUGAUGGGCUGC B UAUCCAGUUGAUGGGCUGCTT B 2968R-008396712-000S 2510 47 UAUCCAGUUGAUGGGCUGC GCAGCCCAUCAACUGGAUAUU 2969R-008396715-000T 481 571 UCAGUCCUUCACUCAAGAA UUCUUGAGUGAAGGACUGAUU 2971R-008396715-000T 481 571 UCAGUCCUUCACUCAAGAA B UCAGUCCUUCACUCAAGAATT B2970 R-008396718-000U 917 572 ACCUUGCAUAACCUUUCCC BACCUUGCAUAACCUUUCCCTT B 2972 R-008396718-000U 917 572ACCUUGCAUAACCUUUCCC GGGAAAGGUUAUGCAAGGUUU 2973 R-008396721-000A 2221 573GGCGACAUAUGCAGCUGCU B GGCGACAUAUGCAGCUGCUTT B 2974 R-008396721-000A 2221573 GGCGACAUAUGCAGCUGCU AGCAGCUGCAUAUGUCGCCUU 2975 R-008396724-000B 849574 UGGUGUCUGCUAUUGUACG CGUACAAUAGCAGACACCAUU 2977 R-008396724-000B 849574 UGGUGUCUGCUAUUGUACG B UGGUGUCUGCUAUUGUACGTT B 2976 R-008396727-000C562 575 GUUCCCUGAGACAUUAGAU B GUUCCCUGAGACAUUAGAUTT B 2978R-008396727-000C 562 575 GUUCCCUGAGACAUUAGAU AUCUAAUGUCUCAGGGAACUU 2979R-008396730-000J 617 140 GCUCAUCCCACUAAUGUCC GGACAUUAGUGGGAUGAGCUU 2981R-008396730-000J 617 140 GCUCAUCCCACUAAUGUCC B GCUCAUCCCACUAAUGUCCTT B2980 R-008396733-000K 1787 576 AUAAAGGCUACUGUUGGAU BAUAAAGGCUACUGUUGGAUTT B 2982 R-008396733-000K 1787 576AUAAAGGCUACUGUUGGAU AUCCAACAGUAGCCUUUAUUU 2983 R-008396736-000L 1860 577GUGCCAUUCCACGACUAGU ACUAGUCGUGGAAUGGCACUU 2985 R-008396736-000L 1860 577GUGCCAUUCCACGACUAGU B GUGCCAUUCCACGACUAGUTT B 2984 R-008396739-000M 1590578 UGGGUGGUAUAGAGGCUCU B UGGGUGGUAUAGAGGCUCUTT B 2986 R-008396739-000M1590 578 UGGGUGGUAUAGAGGCUCU AGAGCCUCUAUACCACCCAUU 2987 R-008396742-000U955 579 GGCCAUCUUUAAGUCUGGA UCCAGACUUAAAGAUGGCCUU 2989 R-008396742-000U955 579 GGCCAUCUUUAAGUCUGGA B GGCCAUCUUUAAGUCUGGATT B 2988R-008396745-000V 2365 580 UAUUGGUGCCCAGGGAGAA B UAUUGGUGCCCAGGGAGAATT B2990 R-008396745-000V 2365 580 UAUUGGUGCCCAGGGAGAA UUCUCCCUGGGCACCAAUAUU2991 R-008396748-000W 534 581 CUCGAGCUCAGAGGGUACG BCUCGAGCUCAGAGGGUACGTT B 2992 R-008396748-000W 534 581CUCGAGCUCAGAGGGUACG CGUACCCUCUGAGCUCGAGUU 2993 R-008396751-000C 706 582AGAACUUGCCACACGUGCA UGCACGUGUGGCAAGUUCUUU 2995 R-008396751-000C 706 582AGAACUUGCCACACGUGCA B AGAACUUGCCACACGUGCATT B 2994 R-008396754-000D 1740583 UACCAGUUGUGGUUAAGCU B UACCAGUUGUGGUUAAGCUTT B 2996 R-008396754-000D1740 583 UACCAGUUGUGGUUAAGCU AGCUUAACCACAACUGGUAUU 2997 R-008396757-000E638 584 CGUUUGGCUGAACCAUCAC B CGUUUGGCUGAACCAUCACTT B 2998R-008396757-000E 638 584 CGUUUGGCUGAACCAUCAC GUGAUGGUUCAGCCAAACGUU 2999R-008396760-000L 1334 585 GCUAUUGUAGAAGCUGGUG CACCAGCUUCUACAAUAGCUU 3001R-008396760-000L 1334 585 GCUAUUGUAGAAGCUGGUG B GCUAUUGUAGAAGCUGGUGTT B3000 R-008396763-000M 971 586 GGAGGCAUUCCUGCCCUGG BGGAGGCAUUCCUGCCCUGGTT B 3002 R-008396763-000M 971 586GGAGGCAUUCCUGCCCUGG CCAGGGCAGGAAUGCCUCCUU 3003 R-008396766-000N 2493 587ACCACCCUGGUGCUGACUA UAGUCAGCACCAGGGUGGUUU 3005 R-008396766-000N 2493 587ACCACCCUGGUGCUGACUA B ACCACCCUGGUGCUGACUATT B 3004 R-008396769-000P 1814588 AAUCUUGCCCUUUGUCCCG B AAUCUUGCCCUUUGUCCCGTT B 3006 R-008396769-000P1814 588 AAUCUUGCCCUUUGUCCCG CGGGACAAAGGGCAAGAUUUU 3007 R-008396772-000W1088 589 CGUUUAGCUGGUGGGCUGC GCAGCCCACCAGCUAAACGUU 3009 R-008396772-000W1088 589 CGUUUAGCUGGUGGGCUGC B CGUUUAGCUGGUGGGCUGCTT B 3008R-008396775-000X 2292 590 CAGUUGAGCUGACCAGCUC GAGCUGGUCAGCUCAACUGUU 3011R-008396775-000X 2292 590 CAGUUGAGCUGACCAGCUC B CAGUUGAGCUGACCAGCUCTT B3010 R-008396778-000Y 1504 591 UGAUAUAAAUGUGGUCACC GGUGACCACAUUUAUAUCAUU3013 R-008396778-000Y 1504 591 UGAUAUAAAUGUGGUCACC BUGAUAUAAAUGUGGUCACCTT B 3012 R-008396781-000E 404 592CUGAGUGGUAAAGGCAAUC GAUUGCCUUUACCACUCAGUU 3015 R-008396781-000E 404 592CUGAGUGGUAAAGGCAAUC B CUGAGUGGUAAAGGCAAUCTT B 3014 R-008396784-000F 1301593 AAGGUGCUAUCUGUCUGCU AGCAGACAGAUAGCACCUUUU 3017 R-008396784-000F 1301593 AAGGUGCUAUCUGUCUGCU B AAGGUGCUAUCUGUCUGCUTT B 3016 R-008396787-000G2004 594 UCCUAGCUCGGGAUGUUCA UGAACAUCCCGAGCUAGGAUU 3019 R-008396787-000G2004 594 UCCUAGCUCGGGAUGUUCA B UCCUAGCUCGGGAUGUUCATT B 3018R-008396790-000N 853 6 GUCUGCUAUUGUACGUACC GGUACGUACAAUAGCAGACUU 3021R-008396790-000N 853 6 GUCUGCUAUUGUACGUACC B GUCUGCUAUUGUACGUACCTT B3020 R-008396793-000P 277 595 UCAAGCUGAUUUGAUGGAG BUCAAGCUGAUUUGAUGGAGTT B 3022 R-008396793-000P 277 595UCAAGCUGAUUUGAUGGAG CUCCAUCAAAUCAGCUUGAUU 3023 R-008396796-000R 2304 596CCAGCUCUCUCUUCAGAAC GUUCUGAAGAGAGAGCUGGUU 3025 R-008396796-000R 2304 596CCAGCUCUCUCUUCAGAAC B CCAGCUCUCUCUUCAGAACTT B 3024 R-008396799-000S 300597 ACAUGGCCAUGGAACCAGA B ACAUGGCCAUGGAACCAGATT B 3026 R-008396799-000S300 597 ACAUGGCCAUGGAACCAGA UCUGGUUCCAUGGCCAUGUUU 3027 R-008396802-000J1906 598 UACCCAGCGCCGUACGUCC B UACCCAGCGCCGUACGUCCTT B 3028R-008396802-000J 1906 598 UACCCAGCGCCGUACGUCC GGACGUACGGCGCUGGGUAUU 3029R-008396805-000K 1973 599 AUAGUUGAAGGUUGUACCG CGGUACAACCUUCAACUAUUU 3031R-008396805-000K 1973 599 AUAGUUGAAGGUUGUACCG B AUAGUUGAAGGUUGUACCGTT B3030 R-008396808-000L 1360 600 AGCUUUAGGACUUCACCUG BAGCUUUAGGACUUCACCUGTT B 3032 R-008396808-000L 1360 600AGCUUUAGGACUUCACCUG CAGGUGAAGUCCUAAAGCUUU 3033 R-008396811-000T 2094 601ACAUCCAAAGAGUAGCUGC GCAGCUACUCUUUGGAUGUUU 3035 R-008396811-000T 2094 601ACAUCCAAAGAGUAGCUGC B ACAUCCAAAGAGUAGCUGCTT B 3034 R-008396814-000U 920602 UUGCAUAACCUUUCCCAUC B UUGCAUAACCUUUCCCAUCTT B 3036 R-008396814-000U920 602 UUGCAUAACCUUUCCCAUC GAUGGGAAAGGUUAUGCAAUU 3037 R-008396817-000V1707 603 UGGCCCAGAAUGCAGUUCG CGAACUGCAUUCUGGGCCAUU 3039 R-008396817-000V1707 603 UGGCCCAGAAUGCAGUUCG B UGGCCCAGAAUGCAGUUCGTT B 3038R-008396820-000B 1808 604 AUUCGAAAUCUUGCCCUUU B AUUCGAAAUCUUGCCCUUUTT B3040 R-008396820-000B 1808 604 AUUCGAAAUCUUGCCCUUU AAAGGGCAAGAUUUCGAAUUU3041 R-008396823-000C 1326 605 AUAAGCCGGCUAUUGUAGA UCUACAAUAGCCGGCUUAUUU3043 R-008396823-000C 1326 605 AUAAGCCGGCUAUUGUAGA BAUAAGCCGGCUAUUGUAGATT B 3042 R-008396826-000D 1158 606CGACAGACUGCCUUCAAAU B CGACAGACUGCCUUCAAAUTT B 3044 R-008396826-000D 1158606 CGACAGACUGCCUUCAAAU AUUUGAAGGCAGUCUGUCGUU 3045 R-008396829-000E 781607 UGCAGUUAUGGUCCAUCAG B UGCAGUUAUGGUCCAUCAGTT B 3046 R-008396829-000E781 607 UGCAGUUAUGGUCCAUCAG CUGAUGGACCAUAACUGCAUU 3047 R-008396832-000L607 608 GUUUGAUGCUGCUCAUCCC B GUUUGAUGCUGCUCAUCCCTT B 3048R-008396832-000L 607 608 GUUUGAUGCUGCUCAUCCC GGGAUGAGCAGCAUCAAACUU 3049R-008396835-000M 627 609 CUAAUGUCCAGCGUUUGGC GCCAAACGCUGGACAUUAGUU 3051R-008396835-000M 627 609 CUAAUGUCCAGCGUUUGGC B CUAAUGUCCAGCGUUUGGCTT B3050 R-008396838-000N 500 610 CAAGUAGCUGAUAUUGAUG BCAAGUAGCUGAUAUUGAUGTT B 3052 R-008396838-000N 500 610CAAGUAGCUGAUAUUGAUG CAUCAAUAUCAGCUACUUGUU 3053 R-008396841-000V 2185 611UCUGACAGAGUUACUUCAC B UCUGACAGAGUUACUUCACTT B 3054 R-008396841-000V 2185611 UCUGACAGAGUUACUUCAC GUGAAGUAACUCUGUCAGAUU 3055 R-008396844-000W 1592612 GGUGGUAUAGAGGCUCUUG B GGUGGUAUAGAGGCUCUUGTT B 3056 R-008396844-000W1592 612 GGUGGUAUAGAGGCUCUUG CAAGAGCCUCUAUACCACCUU 3057 R-008396847-000X758 613 GACCAGGUGGUGGUUAAUA B GACCAGGUGGUGGUUAAUATT B 3058R-008396847-000X 758 613 GACCAGGUGGUGGUUAAUA UAUUAACCACCACCUGGUCUU 3059R-008396850-000D 2551 614 CCUCAUGGAUGGGCUGCCU B CCUCAUGGAUGGGCUGCCUTT B3060 R-008396850-000D 2551 614 CCUCAUGGAUGGGCUGCCU AGGCAGCCCAUCCAUGAGGUU3061 R-008396853-000E 1409 615 UGUCUUUGGACUCUCAGGA BUGUCUUUGGACUCUCAGGATT B 3062 R-008396853-000E 1409 615UGUCUUUGGACUCUCAGGA UCCUGAGAGUCCAAAGACAUU 3063 R-008396856-000F 497 616GAACAAGUAGCUGAUAUUG B GAACAAGUAGCUGAUAUUGTT B 3064 R-008396856-000F 497616 GAACAAGUAGCUGAUAUUG CAAUAUCAGCUACUUGUUCUU 3065 R-008396859-000G 381617 GUGCCACUACCACAGCUCC B GUGCCACUACCACAGCUCCTT B 3066 R-008396859-000G381 617 GUGCCACUACCACAGCUCC GGAGCUGUGGUAGUGGCACUU 3067 R-008396862-000N1841 618 GCACCUUUGCGUGAGCAGG CCUGCUCACGCAAAGGUGCUU 3069 R-008396862-000N1841 618 GCACCUUUGCGUGAGCAGG B GCACCUUUGCGUGAGCAGGTT B 3068R-008396865-000P 1368 619 GACUUCACCUGACAGAUCC B GACUUCACCUGACAGAUCCTT B3070 R-008396865-000P 1368 619 GACUUCACCUGACAGAUCC GGAUCUGUCAGGUGAAGUCUU3071 R-008396868-000R 2047 620 AAAUACCAUUCCAUUGUUU AAACAAUGGAAUGGUAUUUUU3073 R-008396868-000R 2047 620 AAAUACCAUUCCAUUGUUU BAAAUACCAUUCCAUUGUUUTT B 3072 R-008396871-000X 492 621CUCAAGAACAAGUAGCUGA B CUCAAGAACAAGUAGCUGATT B 3074 R-008396871-000X 492621 CUCAAGAACAAGUAGCUGA UCAGCUACUUGUUCUUGAGUU 3075 R-008396874-000Y 832126 CAUGCGUUCUCCUCAGAUG B CAUGCGUUCUCCUCAGAUGTT B 3076 R-008396874-000Y832 126 CAUGCGUUCUCCUCAGAUG CAUCUGAGGAGAACGCAUGUU 3077 R-008396877-000Z2118 622 UCCUCUGUGAACUUGCUCA B UCCUCUGUGAACUUGCUCATT B 3078R-008396877-000Z 2118 622 UCCUCUGUGAACUUGCUCA UGAGCAAGUUCACAGAGGAUU 3079R-008396880-000F 968 623 UCUGGAGGCAUUCCUGCCC GGGCAGGAAUGCCUCCAGAUU 3081R-008396880-000F 968 623 UCUGGAGGCAUUCCUGCCC B UCUGGAGGCAUUCCUGCCCTT B3080 R-008396883-000G 965 624 AAGUCUGGAGGCAUUCCUG CAGGAAUGCCUCCAGACUUUU3083 R-008396883-000G 965 624 AAGUCUGGAGGCAUUCCUG BAAGUCUGGAGGCAUUCCUGTT B 3082 R-008396886-000H 1977 625UUGAAGGUUGUACCGGAGC GCUCCGGUACAACCUUCAAUU 3085 R-008396886-000H 1977 625UUGAAGGUUGUACCGGAGC B UUGAAGGUUGUACCGGAGCTT B 3084 R-008396889-000J 2001626 ACAUCCUAGCUCGGGAUGU B ACAUCCUAGCUCGGGAUGUTT B 3086 R-008396889-000J2001 626 ACAUCCUAGCUCGGGAUGU ACAUCCCGAGCUAGGAUGUUU 3087 R-008396892-000R1191 627 ACCAAGAAAGCAAGCUCAU B ACCAAGAAAGCAAGCUCAUTT B 3088R-008396892-000R 1191 627 ACCAAGAAAGCAAGCUCAU AUGAGCUUGCUUUCUUGGUUU 3089R-008396895-000S 640 628 UUUGGCUGAACCAUCACAG B UUUGGCUGAACCAUCACAGTT B3090 R-008396895-000S 640 628 UUUGGCUGAACCAUCACAG CUGUGAUGGUUCAGCCAAAUU3091 R-008396898-000T 715 629 CACACGUGCAAUCCCUGAA BCACACGUGCAAUCCCUGAATT B 3092 R-008396898-000T 715 629CACACGUGCAAUCCCUGAA UUCAGGGAUUGCACGUGUGUU 3093 R-008396901-000K 1204 630GCUCAUCAUACUGGCUAGU ACUAGCCAGUAUGAUGAGCUU 3095 R-008396901-000K 1204 630GCUCAUCAUACUGGCUAGU B GCUCAUCAUACUGGCUAGUTT B 3094 R-008396904-000L 3093631 GGGUAGGGUAAAUCAGUAA B GGGUAGGGUAAAUCAGUAATT B 3096 R-008396904-000L3093 631 GGGUAGGGUAAAUCAGUAA UUACUGAUUUACCCUACCCUU 3097 R-008396907-000M1371 632 UUCACCUGACAGAUCCAAG CUUGGAUCUGUCAGGUGAAUU 3099 R-008396907-000M1371 632 UUCACCUGACAGAUCCAAG B UUCACCUGACAGAUCCAAGTT B 3098R-008396910-000U 1424 121 AGGAAUCUUUCAGAUGCUG B AGGAAUCUUUCAGAUGCUGTT B3100 R-008396910-000U 1424 121 AGGAAUCUUUCAGAUGCUG CAGCAUCUGAAAGAUUCCUUU3101 R-008396913-000V 860 161 AUUGUACGUACCAUGCAGA BAUUGUACGUACCAUGCAGATT B 3102 R-008396913-000V 860 161AUUGUACGUACCAUGCAGA UCUGCAUGGUACGUACAAUUU 3103 R-008396916-000W 409 633UGGUAAAGGCAAUCCUGAG B UGGUAAAGGCAAUCCUGAGTT B 3104 R-008396916-000W 409633 UGGUAAAGGCAAUCCUGAG CUCAGGAUUGCCUUUACCAUU 3105 R-008396919-000X 11437 AAUUCUUGGCUAUUACGAC GUCGUAAUAGCCAAGAAUUUU 3107 R-008396919-000X 1143 7AAUUCUUGGCUAUUACGAC B AAUUCUUGGCUAUUACGACTT B 3106 R-008396922-000D 2405634 GAUCCUAGCUAUCGUUCUU B GAUCCUAGCUAUCGUUCUUTT B 3108 R-008396922-000D2405 634 GAUCCUAGCUAUCGUUCUU AAGAACGAUAGCUAGGAUCUU 3109 R-008396928-000F1671 635 UUCGUCAUCUGACCAGCCG CGGCUGGUCAGAUGACGAAUU 3111 R-008396928-000F1671 635 UUCGUCAUCUGACCAGCCG B UUCGUCAUCUGACCAGCCGTT B 3110R-008396931-000M 1427 636 AAUCUUUCAGAUGCUGCAA B AAUCUUUCAGAUGCUGCAATT B3112 R-008396931-000M 1427 636 AAUCUUUCAGAUGCUGCAA UUGCAGCAUCUGAAAGAUUUU3113 R-008396934-000N 1717 637 UGCAGUUCGCCUUCACUAU AUAGUGAAGGCGAACUGCAUU3115 R-008396934-000N 1717 637 UGCAGUUCGCCUUCACUAU BUGCAGUUCGCCUUCACUAUTT B 3114 R-008396937-000P 2400 638AGGAUGAUCCUAGCUAUCG CGAUAGCUAGGAUCAUCCUUU 3117 R-008396937-000P 2400 638AGGAUGAUCCUAGCUAUCG B AGGAUGAUCCUAGCUAUCGTT B 3116 R-008396940-000W 2305639 CAGCUCUCUCUUCAGAACA B CAGCUCUCUCUUCAGAACATT B 3118 R-008396940-000W2305 639 CAGCUCUCUCUUCAGAACA UGUUCUGAAGAGAGAGCUGUU 3119 R-008396943-000X1928 640 GGUGGGACACAGCAGCAAU B GGUGGGACACAGCAGCAAUTT B 3120R-008396943-000X 1928 640 GGUGGGACACAGCAGCAAU AUUGCUGCUGUGUCCCACCUU 3121R-008396946-000Y 2399 641 CAGGAUGAUCCUAGCUAUC B CAGGAUGAUCCUAGCUAUCTT B3122 R-008396946-000Y 2399 641 CAGGAUGAUCCUAGCUAUC GAUAGCUAGGAUCAUCCUGUU3123 R-008396949-000Z 426 642 AGGAAGAGGAUGUGGAUAC BAGGAAGAGGAUGUGGAUACTT B 3124 R-008396949-000Z 426 642AGGAAGAGGAUGUGGAUAC GUAUCCACAUCCUCUUCCUUU 3125 R-008396952-000F 1309 643AUCUGUCUGCUCUAGUAAU AUUACUAGAGCAGACAGAUUU 3127 R-008396952-000F 1309 643AUCUGUCUGCUCUAGUAAU B AUCUGUCUGCUCUAGUAAUTT B 3126 R-008396955-000G 925644 UAACCUUUCCCAUCAUCGU B UAACCUUUCCCAUCAUCGUTT B 3128 R-008396955-000G925 644 UAACCUUUCCCAUCAUCGU ACGAUGAUGGGAAAGGUUAUU 3129 R-008396958-000H2072 645 CUGCUUUAUUCUCCCAUUG CAAUGGGAGAAUAAAGCAGUU 3131 R-008396958-000H2072 645 CUGCUUUAUUCUCCCAUUG B CUGCUUUAUUCUCCCAUUGTT B 3130R-008396964-000R 2939 646 AAUUGUAAUCUGAAUAAAG B AAUUGUAAUCUGAAUAAAGTT B3132 R-008396964-000R 2939 646 AAUUGUAAUCUGAAUAAAG CUUUAUUCAGAUUACAAUUUU3133 R-008396973-000Z 1480 647 UCUUGUUCAGCUUCUGGGU BUCUUGUUCAGCUUCUGGGUTT B 3134 R-008396973-000Z 1480 647UCUUGUUCAGCUUCUGGGU ACCCAGAAGCUGAACAAGAUU 3135 R-008396976-000A 1889 648GUUCGUGCACAUCAGGAUA B GUUCGUGCACAUCAGGAUATT B 3136 R-008396976-000A 1889648 GUUCGUGCACAUCAGGAUA UAUCCUGAUGUGCACGAACUU 3137 R-008396979-000B 699649 AUGAUGCAGAACUUGCCAC B AUGAUGCAGAACUUGCCACTT B 3138 R-008396979-000B699 649 AUGAUGCAGAACUUGCCAC GUGGCAAGUUCUGCAUCAUUU 3139 R-008396982-000H506 650 GCUGAUAUUGAUGGACAGU B GCUGAUAUUGAUGGACAGUTT B 3140R-008396982-000H 506 650 GCUGAUAUUGAUGGACAGU ACUGUCCAUCAAUAUCAGCUU 3141R-008396985-000J 1750 651 GGUUAAGCUCUUACACCCA UGGGUGUAAGAGCUUAACCUU 3143R-008396985-000J 1750 651 GGUUAAGCUCUUACACCCA B GGUUAAGCUCUUACACCCATT B3142 R-008396988-000K 1820 652 GCCCUUUGUCCCGCAAAUC BGCCCUUUGUCCCGCAAAUCTT B 3144 R-008396988-000K 1820 652GCCCUUUGUCCCGCAAAUC GAUUUGCGGGACAAAGGGCUU 3145 R-008396991-000S 541 653UCAGAGGGUACGAGCUGCU AGCAGCUCGUACCCUCUGAUU 3147 R-008396991-000S 541 653UCAGAGGGUACGAGCUGCU B UCAGAGGGUACGAGCUGCUTT B 3146 R-008396994-000T 880102 UACAAAUGAUGUAGAAACA B UACAAAUGAUGUAGAAACATT B 3148 R-008396994-000T880 102 UACAAAUGAUGUAGAAACA UGUUUCUACAUCAUUUGUAUU 3149 R-008396997-000U665 654 AAACAUGCAGUUGUAAACU B AAACAUGCAGUUGUAAACUTT B 3150R-008396997-000U 665 654 AAACAUGCAGUUGUAAACU AGUUUACAACUGCAUGUUUUU 3151R-008397000-000H 1817 655 CUUGCCCUUUGUCCCGCAA UUGCGGGACAAAGGGCAAGUU 3153R-008397000-000H 1817 655 CUUGCCCUUUGUCCCGCAA B CUUGCCCUUUGUCCCGCAATT B3152 R-008397003-000J 2275 656 UUACAAGAAACGGCUUUCA UGAAAGCCGUUUCUUGUAAUU3155 R-008397003-000J 2275 656 UUACAAGAAACGGCUUUCA BUUACAAGAAACGGCUUUCATT B 3154 R-008397006-000K 2426 657CACUCUGGUGGAUAUGGCC GGCCAUAUCCACCAGAGUGUU 3157 R-008397006-000K 2426 657CACUCUGGUGGAUAUGGCC B CACUCUGGUGGAUAUGGCCTT B 3156 R-008397009-000L 958658 CAUCUUUAAGUCUGGAGGC B CAUCUUUAAGUCUGGAGGCTT B 3158 R-008397009-000L958 658 CAUCUUUAAGUCUGGAGGC GCCUCCAGACUUAAAGAUGUU 3159 R-008397012-000T1657 659 UGCCAUCUGUGCUCUUCGU B UGCCAUCUGUGCUCUUCGUTT B 3160R-008397012-000T 1657 659 UGCCAUCUGUGCUCUUCGU ACGAAGAGCACAGAUGGCAUU 3161R-008397015-000U 1146 660 UCUUGGCUAUUACGACAGA UCUGUCGUAAUAGCCAAGAUU 3163R-008397015-000U 1146 660 UCUUGGCUAUUACGACAGA B UCUUGGCUAUUACGACAGATT B3162 R-008397018-000V 3078 661 AUUUGGGAUAUGUAUGGGU BAUUUGGGAUAUGUAUGGGUTT B 3164 R-008397018-000V 3078 661AUUUGGGAUAUGUAUGGGU ACCCAUACAUAUCCCAAAUUU 3165 R-008397021-000B 1008 662CAGUGGAUUCUGUGUUGUU AACAACACAGAAUCCACUGUU 3167 R-008397021-000B 1008 662CAGUGGAUUCUGUGUUGUU B CAGUGGAUUCUGUGUUGUUTT B 3166 R-008397024-000C 1621663 CCUUCGGGCUGGUGACAGG CCUGUCACCAGCCCGAAGGUU 3169 R-008397024-000C 1621663 CCUUCGGGCUGGUGACAGG B CCUUCGGGCUGGUGACAGGTT B 3168 R-008397027-000D1932 664 GGACACAGCAGCAAUUUGU B GGACACAGCAGCAAUUUGUTT B 3170R-008397027-000D 1932 664 GGACACAGCAGCAAUUUGU ACAAAUUGCUGCUGUGUCCUU 3171R-008397030-000K 1909 665 CCAGCGCCGUACGUCCAUG CAUGGACGUACGGCGCUGGUU 3173R-008397030-000K 1909 665 CCAGCGCCGUACGUCCAUG B CCAGCGCCGUACGUCCAUGTT B3172 R-008397033-000L 2279 666 AAGAAACGGCUUUCAGUUG CAACUGAAAGCCGUUUCUUUU3175 R-008397033-000L 2279 666 AAGAAACGGCUUUCAGUUG BAAGAAACGGCUUUCAGUUGTT B 3174 R-008397036-000M 574 667AUUAGAUGAGGGCAUGCAG B AUUAGAUGAGGGCAUGCAGTT B 3176 R-008397036-000M 574667 AUUAGAUGAGGGCAUGCAG CUGCAUGCCCUCAUCUAAUUU 3177 R-008397039-000N 2303668 ACCAGCUCUCUCUUCAGAA UUCUGAAGAGAGAGCUGGUUU 3179 R-008397039-000N 2303668 ACCAGCUCUCUCUUCAGAA B ACCAGCUCUCUCUUCAGAATT B 3178 R-008397042-000V784 669 AGUUAUGGUCCAUCAGCUU B AGUUAUGGUCCAUCAGCUUTT B 3180R-008397042-000V 784 669 AGUUAUGGUCCAUCAGCUU AAGCUGAUGGACCAUAACUUU 3181R-008397045-000W 2507 670 GACUAUCCAGUUGAUGGGC GCCCAUCAACUGGAUAGUCUU 3183R-008397045-000W 2507 670 GACUAUCCAGUUGAUGGGC B GACUAUCCAGUUGAUGGGCTT B3182 R-008397048-000X 995 671 AUGCUUGGUUCACCAGUGG BAUGCUUGGUUCACCAGUGGTT B 3184 R-008397048-000X 995 671AUGCUUGGUUCACCAGUGG CCACUGGUGAACCAAGCAUUU 3185 R-008397051-000D 2006 672CUAGCUCGGGAUGUUCACA UGUGAACAUCCCGAGCUAGUU 3187 R-008397051-000D 2006 672CUAGCUCGGGAUGUUCACA B CUAGCUCGGGAUGUUCACATT B 3186 R-008397054-000E 1757673 CUCUUACACCCACCAUCCC GGGAUGGUGGGUGUAAGAGUU 3189 R-008397054-000E 1757673 CUCUUACACCCACCAUCCC B CUCUUACACCCACCAUCCCTT B 3188 R-008397057-000F2129 674 CUUGCUCAGGACAAGGAAG B CUUGCUCAGGACAAGGAAGTT B 3190R-008397057-000F 2129 674 CUUGCUCAGGACAAGGAAG CUUCCUUGUCCUGAGCAAGUU 3191R-008397060-000M 2272 675 AGAUUACAAGAAACGGCUU B AGAUUACAAGAAACGGCUUTT B3192 R-008397060-000M 2272 675 AGAUUACAAGAAACGGCUU AAGCCGUUUCUUGUAAUCUUU3193 R-008397063-000N 389 676 ACCACAGCUCCUUCUCUGA BACCACAGCUCCUUCUCUGATT B 3194 R-008397063-000N 389 676ACCACAGCUCCUUCUCUGA UCAGAGAAGGAGCUGUGGUUU 3195 R-008397066-000P 708 176AACUUGCCACACGUGCAAU B AACUUGCCACACGUGCAAUTT B 3196 R-008397066-000P 708176 AACUUGCCACACGUGCAAU AUUGCACGUGUGGCAAGUUUU 3197 R-008397069-000R 1435677 AGAUGCUGCAACUAAACAG CUGUUUAGUUGCAGCAUCUUU 3199 R-008397069-000R 1435677 AGAUGCUGCAACUAAACAG B AGAUGCUGCAACUAAACAGTT B 3198 R-008397072-000X1247 34 AUAAUGAGGACCUAUACUU B AUAAUGAGGACCUAUACUUTT B 3200R-008397072-000X 1247 34 AUAAUGAGGACCUAUACUU AAGUAUAGGUCCUCAUUAUUU 3201R-008397075-000Y 1752 678 UUAAGCUCUUACACCCACC GGUGGGUGUAAGAGCUUAAUU 3203R-008397075-000Y 1752 678 UUAAGCUCUUACACCCACC B UUAAGCUCUUACACCCACCTT B3202 R-008397078-000Z 773 679 AAUAAGGCUGCAGUUAUGG CCAUAACUGCAGCCUUAUUUU3205 R-008397078-000Z 773 679 AAUAAGGCUGCAGUUAUGG BAAUAAGGCUGCAGUUAUGGTT B 3204 R-008397081-000F 3080 680UUGGGAUAUGUAUGGGUAG CUACCCAUACAUAUCCCAAUU 3207 R-008397081-000F 3080 680UUGGGAUAUGUAUGGGUAG B UUGGGAUAUGUAUGGGUAGTT B 3206 R-008397084-000G 3174681 GUAACCUGCUGUGAUACGA B GUAACCUGCUGUGAUACGATT B 3208 R-008397084-000G3174 681 GUAACCUGCUGUGAUACGA UCGUAUCACAGCAGGUUACUU 3209 R-008397087-000H1578 682 UGGUCUGCCAAGUGGGUGG B UGGUCUGCCAAGUGGGUGGTT B 3210R-008397087-000H 1578 682 UGGUCUGCCAAGUGGGUGG CCACCCACUUGGCAGACCAUU 3211R-008397090-000P 398 683 CCUUCUCUGAGUGGUAAAG B CCUUCUCUGAGUGGUAAAGTT B3212 R-008397090-000P 398 683 CCUUCUCUGAGUGGUAAAG CUUUACCACUCAGAGAAGGUU3213 R-008397093-000R 2153 684 GAAGCUAUUGAAGCUGAGG CCUCAGCUUCAAUAGCUUCUU3215 R-008397093-000R 2153 684 GAAGCUAUUGAAGCUGAGG BGAAGCUAUUGAAGCUGAGGTT B 3214 R-008397096-000S 702 685AUGCAGAACUUGCCACACG CGUGUGGCAAGUUCUGCAUUU 3217 R-008397096-000S 702 685AUGCAGAACUUGCCACACG B AUGCAGAACUUGCCACACGTT B 3216 R-008397099-000T 503686 GUAGCUGAUAUUGAUGGAC B GUAGCUGAUAUUGAUGGACTT B 3218 R-008397099-000T503 686 GUAGCUGAUAUUGAUGGAC GUCCAUCAAUAUCAGCUACUU 3219 R-008397102-000K276 687 CUCAAGCUGAUUUGAUGGA B CUCAAGCUGAUUUGAUGGATT B 3220R-008397102-000K 276 687 CUCAAGCUGAUUUGAUGGA UCCAUCAAAUCAGCUUGAGUU 3221R-008397105-000L 1962 688 GCAUGGAAGAAAUAGUUGA B GCAUGGAAGAAAUAGUUGATT B3222 R-008397105-000L 1962 688 GCAUGGAAGAAAUAGUUGA UCAACUAUUUCUUCCAUGCUU3223 R-008397108-000M 1347 689 CUGGUGGAAUGCAAGCUUU BCUGGUGGAAUGCAAGCUUUTT B 3224 R-008397108-000M 1347 689CUGGUGGAAUGCAAGCUUU AAAGCUUGCAUUCCACCAGUU 3225 R-008397111-000U 2544 690CCCAGGACCUCAUGGAUGG CCAUCCAUGAGGUCCUGGGUU 3227 R-008397111-000U 2544 690CCCAGGACCUCAUGGAUGG B CCCAGGACCUCAUGGAUGGTT B 3226 R-008397114-000V 3079691 UUUGGGAUAUGUAUGGGUA B UUUGGGAUAUGUAUGGGUATT B 3228 R-008397114-000V3079 691 UUUGGGAUAUGUAUGGGUA UACCCAUACAUAUCCCAAAUU 3229 R-008397117-000W3164 692 CAAAGUUGUUGUAACCUGC GCAGGUUACAACAACUUUGUU 3231 R-008397117-000W3164 692 CAAAGUUGUUGUAACCUGC B CAAAGUUGUUGUAACCUGCTT B 3230R-008397120-000C 2026 693 CCGAAUUGUUAUCAGAGGA B CCGAAUUGUUAUCAGAGGATT B3232 R-008397120-000C 2026 693 CCGAAUUGUUAUCAGAGGA UCCUCUGAUAACAAUUCGGUU3233 R-008397123-000D 2938 694 UAAUUGUAAUCUGAAUAAA BUAAUUGUAAUCUGAAUAAATT B 3234 R-008397123-000D 2938 694UAAUUGUAAUCUGAAUAAA UUUAUUCAGAUUACAAUUAUU 3235 R-008397126-000E 2940 695AUUGUAAUCUGAAUAAAGU ACUUUAUUCAGAUUACAAUUU 3237 R-008397126-000E 2940 695AUUGUAAUCUGAAUAAAGU B AUUGUAAUCUGAAUAAAGUTT B 3236 R-008397129-000F 2027696 CGAAUUGUUAUCAGAGGAC B CGAAUUGUUAUCAGAGGACTT B 3238 R-008397129-000F2027 696 CGAAUUGUUAUCAGAGGAC GUCCUCUGAUAACAAUUCGUU 3239 R-008397132-000M448 697 CCAAGUCCUGUAUGAGUGG CCACUCAUACAGGACUUGGUU 3241 R-008397132-000M448 697 CCAAGUCCUGUAUGAGUGG B CCAAGUCCUGUAUGAGUGGTT B 3240R-008397135-000N 1328 698 AAGCCGGCUAUUGUAGAAG B AAGCCGGCUAUUGUAGAAGTT B3242 R-008397135-000N 1328 698 AAGCCGGCUAUUGUAGAAG CUUCUACAAUAGCCGGCUUUU3243 R-008397138-000P 1970 33 GAAAUAGUUGAAGGUUGUA UACAACCUUCAACUAUUUCUU3245 R-008397138-000P 1970 33 GAAAUAGUUGAAGGUUGUA BGAAAUAGUUGAAGGUUGUATT B 3244 R-008397141-000W 2406 699AUCCUAGCUAUCGUUCUUU AAAGAACGAUAGCUAGGAUUU 3247 R-008397141-000W 2406 699AUCCUAGCUAUCGUUCUUU B AUCCUAGCUAUCGUUCUUUTT B 3246 R-008397144-000X 924700 AUAACCUUUCCCAUCAUCG B AUAACCUUUCCCAUCAUCGTT B 3248 R-008397144-000X924 700 AUAACCUUUCCCAUCAUCG CGAUGAUGGGAAAGGUUAUUU 3249 R-008397147-000Y1584 701 GCCAAGUGGGUGGUAUAGA UCUAUACCACCCACUUGGCUU 3251 R-008397147-000Y1584 701 GCCAAGUGGGUGGUAUAGA B GCCAAGUGGGUGGUAUAGATT B 3250R-008397150-000E 1871 702 CGACUAGUUCAGUUGCUUG B CGACUAGUUCAGUUGCUUGTT B3252 R-008397150-000E 1871 702 CGACUAGUUCAGUUGCUUG CAAGCAACUGAACUAGUCGUU3253 R-008397153-000F 999 703 UUGGUUCACCAGUGGAUUC BUUGGUUCACCAGUGGAUUCTT B 3254 R-008397153-000F 999 703UUGGUUCACCAGUGGAUUC GAAUCCACUGGUGAACCAAUU 3255 R-008397156-000G 1400 704GUUCAGAACUGUCUUUGGA UCCAAAGACAGUUCUGAACUU 3257 R-008397156-000G 1400 704GUUCAGAACUGUCUUUGGA B GUUCAGAACUGUCUUUGGATT B 3256 R-008397159-000H 3180705 UGCUGUGAUACGAUGCUUC GAAGCAUCGUAUCACAGCAUU 3259 R-008397159-000H 3180705 UGCUGUGAUACGAUGCUUC B UGCUGUGAUACGAUGCUUCTT B 3258 R-008397162-000P2569 706 UCCAGGUGACAGCAAUCAG CUGAUUGCUGUCACCUGGAUU 3261 R-008397162-000P2569 706 UCCAGGUGACAGCAAUCAG B UCCAGGUGACAGCAAUCAGTT B 3260R-008397165-000R 787 707 UAUGGUCCAUCAGCUUUCU AGAAAGCUGAUGGACCAUAUU 3263R-008397165-000R 787 707 UAUGGUCCAUCAGCUUUCU B UAUGGUCCAUCAGCUUUCUTT B3262 R-008397168-000S 1861 708 UGCCAUUCCACGACUAGUU BUGCCAUUCCACGACUAGUUTT B 3264 R-008397168-000S 1861 708UGCCAUUCCACGACUAGUU AACUAGUCGUGGAAUGGCAUU 3265 R-008397171-000Y 1190 709AACCAAGAAAGCAAGCUCA UGAGCUUGCUUUCUUGGUUUU 3267 R-008397171-000Y 1190 709AACCAAGAAAGCAAGCUCA B AACCAAGAAAGCAAGCUCATT B 3266 R-008397174-000Z 1557710 AUAAUUAUAAGAACAAGAU AUCUUGUUCUUAUAAUUAUUU 3269 R-008397174-000Z 1557710 AUAAUUAUAAGAACAAGAU B AUAAUUAUAAGAACAAGAUTT B 3268 R-008397177-000A1751 711 GUUAAGCUCUUACACCCAC B GUUAAGCUCUUACACCCACTT B 3270R-008397177-000A 1751 711 GUUAAGCUCUUACACCCAC GUGGGUGUAAGAGCUUAACUU 3271R-008397180-000G 2897 712 UUGAGUAAUGGUGUAGAAC B UUGAGUAAUGGUGUAGAACTT B3272 R-008397180-000G 2897 712 UUGAGUAAUGGUGUAGAAC GUUCUACACCAUUACUCAAUU3273 R-008397183-000H 2217 713 GUGUGGCGACAUAUGCAGC GCUGCAUAUGUCGCCACACUU3275 R-008397183-000H 2217 713 GUGUGGCGACAUAUGCAGC BGUGUGGCGACAUAUGCAGCTT B 3274 R-008397186-000J 2302 714GACCAGCUCUCUCUUCAGA UCUGAAGAGAGAGCUGGUCUU 3277 R-008397186-000J 2302 714GACCAGCUCUCUCUUCAGA B GACCAGCUCUCUCUUCAGATT B 3276 R-008397189-000K 1984715 UUGUACCGGAGCCCUUCAC GUGAAGGGCUCCGGUACAAUU 3279 R-008397189-000K 1984715 UUGUACCGGAGCCCUUCAC B UUGUACCGGAGCCCUUCACTT B 3278 R-008397192-000S302 716 AUGGCCAUGGAACCAGACA B AUGGCCAUGGAACCAGACATT B 3280R-008397192-000S 302 716 AUGGCCAUGGAACCAGACA UGUCUGGUUCCAUGGCCAUUU 3281R-008397195-000T 2431 717 UGGUGGAUAUGGCCAGGAU B UGGUGGAUAUGGCCAGGAUTT B3282 R-008397195-000T 2431 717 UGGUGGAUAUGGCCAGGAU AUCCUGGCCAUAUCCACCAUU3283 R-008397198-000U 2183 718 CCUCUGACAGAGUUACUUC GAAGUAACUCUGUCAGAGGUU3285 R-008397198-000U 2183 718 CCUCUGACAGAGUUACUUC BCCUCUGACAGAGUUACUUCTT B 3284 R-008397201-000L 2403 719AUGAUCCUAGCUAUCGUUC GAACGAUAGCUAGGAUCAUUU 3287 R-008397201-000L 2403 719AUGAUCCUAGCUAUCGUUC B AUGAUCCUAGCUAUCGUUCTT B 3286 R-008397204-000M 788720 AUGGUCCAUCAGCUUUCUA B AUGGUCCAUCAGCUUUCUATT B 3288 R-008397204-000M788 720 AUGGUCCAUCAGCUUUCUA UAGAAAGCUGAUGGACCAUUU 3289 R-008397207-000N1476 721 GGACUCUUGUUCAGCUUCU B GGACUCUUGUUCAGCUUCUTT B 3290R-008397207-000N 1476 721 GGACUCUUGUUCAGCUUCU AGAAGCUGAACAAGAGUCCUU 3291R-008397210-000V 827 722 GCUAUCAUGCGUUCUCCUC B GCUAUCAUGCGUUCUCCUCTT B3292 R-008397210-000V 827 722 GCUAUCAUGCGUUCUCCUC GAGGAGAACGCAUGAUAGCUU3293 R-008397213-000W 2299 723 GCUGACCAGCUCUCUCUUC BGCUGACCAGCUCUCUCUUCTT B 3294 R-008397213-000W 2299 723GCUGACCAGCUCUCUCUUC GAAGAGAGAGCUGGUCAGCUU 3295 R-008397216-000X 1891 724UCGUGCACAUCAGGAUACC B UCGUGCACAUCAGGAUACCTT B 3296 R-008397216-000X 1891724 UCGUGCACAUCAGGAUACC GGUAUCCUGAUGUGCACGAUU 3297 R-008397219-000Y 2196725 UACUUCACUCUAGGAAUGA UCAUUCCUAGAGUGAAGUAUU 3299 R-008397219-000Y 2196725 UACUUCACUCUAGGAAUGA B UACUUCACUCUAGGAAUGATT B 3298 R-008397222-000E663 726 UGAAACAUGCAGUUGUAAA UUUACAACUGCAUGUUUCAUU 3301 R-008397222-000E663 726 UGAAACAUGCAGUUGUAAA B UGAAACAUGCAGUUGUAAATT B 3300R-008397225-000F 1028 727 UAUGCCAUUACAACUCUCC GGAGAGUUGUAAUGGCAUAUU 3303R-008397225-000F 1028 727 UAUGCCAUUACAACUCUCC B UAUGCCAUUACAACUCUCCTT B3302 R-008397228-000G 2032 728 UGUUAUCAGAGGACUAAAU AUUUAGUCCUCUGAUAACAUU3305 R-008397228-000G 2032 728 UGUUAUCAGAGGACUAAAU BUGUUAUCAGAGGACUAAAUTT B 3304 R-008397231-000N 1459 729GAUGGAAGGUCUCCUUGGG B GAUGGAAGGUCUCCUUGGGTT B 3306 R-008397231-000N 1459729 GAUGGAAGGUCUCCUUGGG CCCAAGGAGACCUUCCAUCUU 3307 R-008397234-000P 2095730 CAUCCAAAGAGUAGCUGCA UGCAGCUACUCUUUGGAUGUU 3309 R-008397234-000P 2095730 CAUCCAAAGAGUAGCUGCA B CAUCCAAAGAGUAGCUGCATT B 3308 R-008397237-000R1686 731 GCCGACACCAAGAAGCAGA B GCCGACACCAAGAAGCAGATT B 3310R-008397237-000R 1686 731 GCCGACACCAAGAAGCAGA UCUGCUUCUUGGUGUCGGCUU 3311R-008397240-000X 1412 732 CUUUGGACUCUCAGGAAUC B CUUUGGACUCUCAGGAAUCTT B3312 R-008397240-000X 1412 732 CUUUGGACUCUCAGGAAUC GAUUCCUGAGAGUCCAAAGUU3313 R-008397243-000Y 2473 733 GGAACAUGAGAUGGGUGGC GCCACCCAUCUCAUGUUCCUU3315 R-008397243-000Y 2473 733 GGAACAUGAGAUGGGUGGC BGGAACAUGAGAUGGGUGGCTT B 3314 R-008397246-000Z 1080 734UGGCAGUGCGUUUAGCUGG CCAGCUAAACGCACUGCCAUU 3317 R-008397246-000Z 1080 734UGGCAGUGCGUUUAGCUGG B UGGCAGUGCGUUUAGCUGGTT B 3316 R-008397249-000A 2143735 GGAAGCUGCAGAAGCUAUU AAUAGCUUCUGCAGCUUCCUU 3319 R-008397249-000A 2143735 GGAAGCUGCAGAAGCUAUU B GGAAGCUGCAGAAGCUAUUTT B 3318 R-008397252-000G2203 736 CUCUAGGAAUGAAGGUGUG B CUCUAGGAAUGAAGGUGUGTT B 3320R-008397252-000G 2203 736 CUCUAGGAAUGAAGGUGUG CACACCUUCAUUCCUAGAGUU 3321R-008397255-000H 548 737 GUACGAGCUGCUAUGUUCC B GUACGAGCUGCUAUGUUCCTT B3322 R-008397255-000H 548 737 GUACGAGCUGCUAUGUUCC GGAACAUAGCAGCUCGUACUU3323 R-008397258-000J 2050 45 UACCAUUCCAUUGUUUGUG CACAAACAAUGGAAUGGUAUU3325 R-008397258-000J 2050 45 UACCAUUCCAUUGUUUGUG BUACCAUUCCAUUGUUUGUGTT B 3324 R-008397261-000R 1867 738UCCACGACUAGUUCAGUUG B UCCACGACUAGUUCAGUUGTT B 3326 R-008397261-000R 1867738 UCCACGACUAGUUCAGUUG CAACUGAACUAGUCGUGGAUU 3327 R-008397264-000S 842739 CCUCAGAUGGUGUCUGCUA B CCUCAGAUGGUGUCUGCUATT B 3328 R-008397264-000S842 739 CCUCAGAUGGUGUCUGCUA UAGCAGACACCAUCUGAGGUU 3329 R-008397267-000T2120 740 CUCUGUGAACUUGCUCAGG CCUGAGCAAGUUCACAGAGUU 3331 R-008397267-000T2120 740 CUCUGUGAACUUGCUCAGG B CUCUGUGAACUUGCUCAGGTT B 3330R-008397270-000Z 782 741 GCAGUUAUGGUCCAUCAGC B GCAGUUAUGGUCCAUCAGCTT B3332 R-008397270-000Z 782 741 GCAGUUAUGGUCCAUCAGC GCUGAUGGACCAUAACUGCUU3333 R-008397273-000A 1758 742 UCUUACACCCACCAUCCCA UGGGAUGGUGGGUGUAAGAUU3335 R-008397273-000A 1758 742 UCUUACACCCACCAUCCCA BUCUUACACCCACCAUCCCATT B 3334 R-008397276-000B 2396 743CGCCAGGAUGAUCCUAGCU B CGCCAGGAUGAUCCUAGCUTT B 3336 R-008397276-000B 2396743 CGCCAGGAUGAUCCUAGCU AGCUAGGAUCAUCCUGGCGUU 3337 R-008397279-000C 1373744 CACCUGACAGAUCCAAGUC GACUUGGAUCUGUCAGGUGUU 3339 R-008397279-000C 1373744 CACCUGACAGAUCCAAGUC B CACCUGACAGAUCCAAGUCTT B 3338 R-008397282-000J1518 745 UCACCUGUGCAGCUGGAAU B UCACCUGUGCAGCUGGAAUTT B 3340R-008397282-000J 1518 745 UCACCUGUGCAGCUGGAAU AUUCCAGCUGCACAGGUGAUU 3341R-008397285-000K 2557 746 GGAUGGGCUGCCUCCAGGU ACCUGGAGGCAGCCCAUCCUU 3343R-008397285-000K 2557 746 GGAUGGGCUGCCUCCAGGU B GGAUGGGCUGCCUCCAGGUTT B3342 R-008397288-000L 1987 747 UACCGGAGCCCUUCACAUC BUACCGGAGCCCUUCACAUCTT B 3344 R-008397288-000L 1987 747UACCGGAGCCCUUCACAUC GAUGUGAAGGGCUCCGGUAUU 3345 R-008397291-000T 568 748UGAGACAUUAGAUGAGGGC GCCCUCAUCUAAUGUCUCAUU 3347 R-008397291-000T 568 748UGAGACAUUAGAUGAGGGC B UGAGACAUUAGAUGAGGGCTT B 3346 R-008397294-000U 2201749 CACUCUAGGAAUGAAGGUG B CACUCUAGGAAUGAAGGUGTT B 3348 R-008397294-000U2201 749 CACUCUAGGAAUGAAGGUG CACCUUCAUUCCUAGAGUGUU 3349 R-008397297-000V609 750 UUGAUGCUGCUCAUCCCAC GUGGGAUGAGCAGCAUCAAUU 3351 R-008397297-000V609 750 UUGAUGCUGCUCAUCCCAC B UUGAUGCUGCUCAUCCCACTT B 3350R-008397300-000M 400 751 UUCUCUGAGUGGUAAAGGC GCCUUUACCACUCAGAGAAUU 3353R-008397300-000M 400 751 UUCUCUGAGUGGUAAAGGC B UUCUCUGAGUGGUAAAGGCTT B3352 R-008397303-000N 331 752 UGUUAGUCACUGGCAGCAA UUGCUGCCAGUGACUAACAUU3355 R-008397303-000N 331 752 UGUUAGUCACUGGCAGCAA BUGUUAGUCACUGGCAGCAATT B 3354 R-008397306-000P 1967 753GAAGAAAUAGUUGAAGGUU AACCUUCAACUAUUUCUUCUU 3357 R-008397306-000P 1967 753GAAGAAAUAGUUGAAGGUU B GAAGAAAUAGUUGAAGGUUTT B 3356 R-008397309-000R 2198754 CUUCACUCUAGGAAUGAAG CUUCAUUCCUAGAGUGAAGUU 3359 R-008397309-000R 2198754 CUUCACUCUAGGAAUGAAG B CUUCACUCUAGGAAUGAAGTT B 3358 R-008397312-000X1493 755 CUGGGUUCAGAUGAUAUAA UUAUAUCAUCUGAACCCAGUU 3361 R-008397312-000X1493 755 CUGGGUUCAGAUGAUAUAA B CUGGGUUCAGAUGAUAUAATT B 3360R-008397315-000Y 2260 756 GGACAAGCCACAAGAUUAC GUAAUCUUGUGGCUUGUCCUU 3363R-008397315-000Y 2260 756 GGACAAGCCACAAGAUUAC B GGACAAGCCACAAGAUUACTT B3362 R-008397318-000Z 2496 757 ACCCUGGUGCUGACUAUCC BACCCUGGUGCUGACUAUCCTT B 3364 R-008397318-000Z 2496 757ACCCUGGUGCUGACUAUCC GGAUAGUCAGCACCAGGGUUU 3365 R-008397321-000F 2361 758UUGAUAUUGGUGCCCAGGG B UUGAUAUUGGUGCCCAGGGTT B 3366 R-008397321-000F 2361758 UUGAUAUUGGUGCCCAGGG CCCUGGGCACCAAUAUCAAUU 3367 R-008397324-000G 443759 ACCUCCCAAGUCCUGUAUG CAUACAGGACUUGGGAGGUUU 3369 R-008397324-000G 443759 ACCUCCCAAGUCCUGUAUG B ACCUCCCAAGUCCUGUAUGTT B 3368 R-008397327-000H523 760 GUAUGCAAUGACUCGAGCU B GUAUGCAAUGACUCGAGCUTT B 3370R-008397327-000H 523 760 GUAUGCAAUGACUCGAGCU AGCUCGAGUCAUUGCAUACUU 3371R-008397330-000P 1742 761 CCAGUUGUGGUUAAGCUCU B CCAGUUGUGGUUAAGCUCUTT B3372 R-008397330-000P 1742 761 CCAGUUGUGGUUAAGCUCU AGAGCUUAACCACAACUGGUU3373 R-008397333-000R 530 762 AUGACUCGAGCUCAGAGGG BAUGACUCGAGCUCAGAGGGTT B 3374 R-008397333-000R 530 762AUGACUCGAGCUCAGAGGG CCCUCUGAGCUCGAGUCAUUU 3375 R-008397336-000S 3169 763UUGUUGUAACCUGCUGUGA B UUGUUGUAACCUGCUGUGATT B 3376 R-008397336-000S 3169763 UUGUUGUAACCUGCUGUGA UCACAGCAGGUUACAACAAUU 3377 R-008397339-000T 1385764 CCAAGUCAACGUCUUGUUC B CCAAGUCAACGUCUUGUUCTT B 3378 R-008397339-000T1385 764 CCAAGUCAACGUCUUGUUC GAACAAGACGUUGACUUGGUU 3379 R-008397342-000Z2123 131 UGUGAACUUGCUCAGGACA B UGUGAACUUGCUCAGGACATT B 3380R-008397342-000Z 2123 131 UGUGAACUUGCUCAGGACA UGUCCUGAGCAAGUUCACAUU 3381R-008397345-000A 2036 765 AUCAGAGGACUAAAUACCA B AUCAGAGGACUAAAUACCATT B3382 R-008397345-000A 2036 765 AUCAGAGGACUAAAUACCA UGGUAUUUAGUCCUCUGAUUU3383 R-008397348-000B 3088 766 UGUAUGGGUAGGGUAAAUC GAUUUACCCUACCCAUACAUU3385 R-008397348-000B 3088 766 UGUAUGGGUAGGGUAAAUC BUGUAUGGGUAGGGUAAAUCTT B 3384 R-008397351-000H 2051 56ACCAUUCCAUUGUUUGUGC GCACAAACAAUGGAAUGGUUU 3387 R-008397351-000H 2051 56ACCAUUCCAUUGUUUGUGC B ACCAUUCCAUUGUUUGUGCTT B 3386 R-008397354-000J 288170 UGAUGGAGUUGGACAUGGC GCCAUGUCCAACUCCAUCAUU 3389 R-008397354-000J 288170 UGAUGGAGUUGGACAUGGC B UGAUGGAGUUGGACAUGGCTT B 3388 R-008397357-000K1850 767 CGUGAGCAGGGUGCCAUUC B CGUGAGCAGGGUGCCAUUCTT B 3390R-008397357-000K 1850 767 CGUGAGCAGGGUGCCAUUC GAAUGGCACCCUGCUCACGUU 3391R-008397360-000S 2548 82 GGACCUCAUGGAUGGGCUG B GGACCUCAUGGAUGGGCUGTT B3392 R-008397360-000S 2548 82 GGACCUCAUGGAUGGGCUG CAGCCCAUCCAUGAGGUCCUU3393 R-008397363-000T 2518 768 UGAUGGGCUGCCAGAUCUG BUGAUGGGCUGCCAGAUCUGTT B 3394 R-008397363-000T 2518 768UGAUGGGCUGCCAGAUCUG CAGAUCUGGCAGCCCAUCAUU 3395 R-008397366-000U 1886 769CUUGUUCGUGCACAUCAGG B CUUGUUCGUGCACAUCAGGTT B 3396 R-008397366-000U 1886769 CUUGUUCGUGCACAUCAGG CCUGAUGUGCACGAACAAGUU 3397 R-008397369-000V 650770 CCAUCACAGAUGCUGAAAC GUUUCAGCAUCUGUGAUGGUU 3399 R-008397369-000V 650770 CCAUCACAGAUGCUGAAAC B CCAUCACAGAUGCUGAAACTT B 3398 R-008397372-000B3139 771 ACAGUUUACCAGUUGCCUU AAGGCAACUGGUAAACUGUUU 3401 R-008397372-000B3139 771 ACAGUUUACCAGUUGCCUU B ACAGUUUACCAGUUGCCUUTT B 3400R-008397375-000C 2025 772 ACCGAAUUGUUAUCAGAGG CCUCUGAUAACAAUUCGGUUU 3403R-008397375-000C 2025 772 ACCGAAUUGUUAUCAGAGG B ACCGAAUUGUUAUCAGAGGTT B3402 R-008397378-000D 1082 773 GCAGUGCGUUUAGCUGGUG CACCAGCUAAACGCACUGCUU3405 R-008397378-000D 1082 773 GCAGUGCGUUUAGCUGGUG BGCAGUGCGUUUAGCUGGUGTT B 3404 R-008397381-000K 2475 774AACAUGAGAUGGGUGGCCA UGGCCACCCAUCUCAUGUUUU 3407 R-008397381-000K 2475 774AACAUGAGAUGGGUGGCCA B AACAUGAGAUGGGUGGCCATT B 3406 R-008397384-000L 1375775 CCUGACAGAUCCAAGUCAA UUGACUUGGAUCUGUCAGGUU 3409 R-008397384-000L 1375775 CCUGACAGAUCCAAGUCAA B CCUGACAGAUCCAAGUCAATT B 3408 R-008397387-000M2013 776 GGGAUGUUCACAACCGAAU B GGGAUGUUCACAACCGAAUTT B 3410R-008397387-000M 2013 776 GGGAUGUUCACAACCGAAU AUUCGGUUGUGAACAUCCCUU 3411R-008397390-000U 1236 41 CUUUAGUAAAUAUAAUGAG CUCAUUAUAUUUACUAAAGUU 3413R-008397390-000U 1236 41 CUUUAGUAAAUAUAAUGAG B CUUUAGUAAAUAUAAUGAGTT B3412 R-008397393-000V 1653 128 AGCCUGCCAUCUGUGCUCU BAGCCUGCCAUCUGUGCUCUTT B 3414 R-008397393-000V 1653 128AGCCUGCCAUCUGUGCUCU AGAGCACAGAUGGCAGGCUUU 3415 R-008397396-000W 1802 777GGAUUGAUUCGAAAUCUUG B GGAUUGAUUCGAAAUCUUGTT B 3416 R-008397396-000W 1802777 GGAUUGAUUCGAAAUCUUG CAAGAUUUCGAAUCAAUCCUU 3417 R-008397399-000X 2144778 GAAGCUGCAGAAGCUAUUG CAAUAGCUUCUGCAGCUUCUU 3419 R-008397399-000X 2144778 GAAGCUGCAGAAGCUAUUG B GAAGCUGCAGAAGCUAUUGTT B 3418 R-008397402-000P529 779 AAUGACUCGAGCUCAGAGG B AAUGACUCGAGCUCAGAGGTT B 3420R-008397402-000P 529 779 AAUGACUCGAGCUCAGAGG CCUCUGAGCUCGAGUCAUUUU 3421R-008397405-000R 1482 780 UUGUUCAGCUUCUGGGUUC GAACCCAGAAGCUGAACAAUU 3423R-008397405-000R 1482 780 UUGUUCAGCUUCUGGGUUC B UUGUUCAGCUUCUGGGUUCTT B3422 R-008397408-000S 1546 781 CCUCACUUGCAAUAAUUAU BCCUCACUUGCAAUAAUUAUTT B 3424 R-008397408-000S 1546 781CCUCACUUGCAAUAAUUAU AUAAUUAUUGCAAGUGAGGUU 3425 R-008397411-000Y 845 782CAGAUGGUGUCUGCUAUUG CAAUAGCAGACACCAUCUGUU 3427 R-008397411-000Y 845 782CAGAUGGUGUCUGCUAUUG B CAGAUGGUGUCUGCUAUUGTT B 3426 R-008397414-000Z 487783 CUUCACUCAAGAACAAGUA B CUUCACUCAAGAACAAGUATT B 3428 R-008397414-000Z487 783 CUUCACUCAAGAACAAGUA UACUUGUUCUUGAGUGAAGUU 3429 R-008397417-000A652 784 AUCACAGAUGCUGAAACAU AUGUUUCAGCAUCUGUGAUUU 3431 R-008397417-000A652 784 AUCACAGAUGCUGAAACAU B AUCACAGAUGCUGAAACAUTT B 3430R-008397420-000G 1720 785 AGUUCGCCUUCACUAUGGA UCCAUAGUGAAGGCGAACUUU 3433R-008397420-000G 1720 785 AGUUCGCCUUCACUAUGGA B AGUUCGCCUUCACUAUGGATT B3432 R-008397423-000H 951 786 UACUGGCCAUCUUUAAGUC GACUUAAAGAUGGCCAGUAUU3435 R-008397423-000H 951 786 UACUGGCCAUCUUUAAGUC BUACUGGCCAUCUUUAAGUCTT B 3434 R-008397426-000J 1232 787CAAGCUUUAGUAAAUAUAA UUAUAUUUACUAAAGCUUGUU 3437 R-008397426-000J 1232 787CAAGCUUUAGUAAAUAUAA B CAAGCUUUAGUAAAUAUAATT B 3436 R-008397429-000K 226928 ACAAGAUUACAAGAAACGG B ACAAGAUUACAAGAAACGGTT B 3438 R-008397429-000K2269 28 ACAAGAUUACAAGAAACGG CCGUUUCUUGUAAUCUUGUUU 3439 R-008397432-000S2265 788 AGCCACAAGAUUACAAGAA B AGCCACAAGAUUACAAGAATT B 3440R-008397432-000S 2265 788 AGCCACAAGAUUACAAGAA UUCUUGUAAUCUUGUGGCUUU 3441R-008397435-000T 1698 789 AAGCAGAGAUGGCCCAGAA B AAGCAGAGAUGGCCCAGAATT B3442 R-008397435-000T 1698 789 AAGCAGAGAUGGCCCAGAA UUCUGGGCCAUCUCUGCUUUU3443 R-008397438-000U 701 790 GAUGCAGAACUUGCCACAC GUGUGGCAAGUUCUGCAUCUU3445 R-008397438-000U 701 790 GAUGCAGAACUUGCCACAC BGAUGCAGAACUUGCCACACTT B 3444 R-008397441-000A 1428 791AUCUUUCAGAUGCUGCAAC GUUGCAGCAUCUGAAAGAUUU 3447 R-008397441-000A 1428 791AUCUUUCAGAUGCUGCAAC B AUCUUUCAGAUGCUGCAACTT B 3446 R-008397444-000B 1930792 UGGGACACAGCAGCAAUUU B UGGGACACAGCAGCAAUUUTT B 3448 R-008397444-000B1930 792 UGGGACACAGCAGCAAUUU AAAUUGCUGCUGUGUCCCAUU 3449 R-008397447-000C1379 793 ACAGAUCCAAGUCAACGUC GACGUUGACUUGGAUCUGUUU 3451 R-008397447-000C1379 793 ACAGAUCCAAGUCAACGUC B ACAGAUCCAAGUCAACGUCTT B 3450R-008397450-000J 1936 794 ACAGCAGCAAUUUGUGGAG B ACAGCAGCAAUUUGUGGAGTT B3452 R-008397450-000J 1936 794 ACAGCAGCAAUUUGUGGAG CUCCACAAAUUGCUGCUGUUU3453 R-008397453-000K 1441 795 UGCAACUAAACAGGAAGGG CCCUUCCUGUUUAGUUGCAUU3455 R-008397453-000K 1441 795 UGCAACUAAACAGGAAGGG BUGCAACUAAACAGGAAGGGTT B 3454 R-008397456-000L 2132 796GCUCAGGACAAGGAAGCUG CAGCUUCCUUGUCCUGAGCUU 3457 R-008397456-000L 2132 796GCUCAGGACAAGGAAGCUG B GCUCAGGACAAGGAAGCUGTT B 3456 R-008397459-000M 2443165 CCAGGAUGCCUUGGGUAUG B CCAGGAUGCCUUGGGUAUGTT B 3458 R-008397459-000M2443 165 CCAGGAUGCCUUGGGUAUG CAUACCCAAGGCAUCCUGGUU 3459 R-008397462-000U1800 163 UUGGAUUGAUUCGAAAUCU AGAUUUCGAAUCAAUCCAAUU 3461 R-008397462-000U1800 163 UUGGAUUGAUUCGAAAUCU B UUGGAUUGAUUCGAAAUCUTT B 3460R-008397465-000V 403 185 UCUGAGUGGUAAAGGCAAU AUUGCCUUUACCACUCAGAUU 3463R-008397465-000V 403 185 UCUGAGUGGUAAAGGCAAU B UCUGAGUGGUAAAGGCAAUTT B3462 R-008397468-000W 1007 105 CCAGUGGAUUCUGUGUUGU ACAACACAGAAUCCACUGGUU3465 R-008397468-000W 1007 105 CCAGUGGAUUCUGUGUUGU BCCAGUGGAUUCUGUGUUGUTT B 3464 R-008397471-000C 1057 113AUUACAUCAAGAAGGAGCU AGCUCCUUCUUGAUGUAAUUU 3467 R-008397471-000C 1057 113AUUACAUCAAGAAGGAGCU B AUUACAUCAAGAAGGAGCUTT B 3466 R-008397474-000D 226787 CCACAAGAUUACAAGAAAC B CCACAAGAUUACAAGAAACTT B 3468 R-008397474-000D2267 87 CCACAAGAUUACAAGAAAC GUUUCUUGUAAUCUUGUGGUU 3469 R-008397477-000E1240 158 AGUAAAUAUAAUGAGGACC B AGUAAAUAUAAUGAGGACCTT B 3470R-008397477-000E 1240 158 AGUAAAUAUAAUGAGGACC GGUCCUCAUUAUAUUUACUUU 3471R-008397480-000L 2043 797 GACUAAAUACCAUUCCAUU AAUGGAAUGGUAUUUAGUCUU 3473R-008397480-000L 2043 797 GACUAAAUACCAUUCCAUU B GACUAAAUACCAUUCCAUUTT B3472 R-008397483-000M 608 798 UUUGAUGCUGCUCAUCCCA UGGGAUGAGCAGCAUCAAAUU3475 R-008397483-000M 608 798 UUUGAUGCUGCUCAUCCCA BUUUGAUGCUGCUCAUCCCATT B 3474 R-008397486-000N 341 799UGGCAGCAACAGUCUUACC B UGGCAGCAACAGUCUUACCTT B 3476 R-008397486-000N 341799 UGGCAGCAACAGUCUUACC GGUAAGACUGUUGCUGCCAUU 3477 R-008397489-000P 1194800 AAGAAAGCAAGCUCAUCAU B AAGAAAGCAAGCUCAUCAUTT B 3478 R-008397489-000P1194 800 AAGAAAGCAAGCUCAUCAU AUGAUGAGCUUGCUUUCUUUU 3479 R-008397492-000W2350 801 UGAUCUUGGACUUGAUAUU B UGAUCUUGGACUUGAUAUUTT B 3480R-008397492-000W 2350 801 UGAUCUUGGACUUGAUAUU AAUAUCAAGUCCAAGAUCAUU 3481R-008397495-000X 2948 802 CUGAAUAAAGUGUAACAAU B CUGAAUAAAGUGUAACAAUTT B3482 R-008397495-000X 2948 802 CUGAAUAAAGUGUAACAAU AUUGUUACACUUUAUUCAGUU3483 R-008397507-000T 2044 803 ACUAAAUACCAUUCCAUUG BACUAAAUACCAUUCCAUUGTT B 3484 R-008397507-000T 2044 803ACUAAAUACCAUUCCAUUG CAAUGGAAUGGUAUUUAGUUU 3485 R-008397510-000Z 621 804AUCCCACUAAUGUCCAGCG CGCUGGACAUUAGUGGGAUUU 3487 R-008397510-000Z 621 804AUCCCACUAAUGUCCAGCG B AUCCCACUAAUGUCCAGCGTT B 3486 R-008397513-000A 384805 CCACUACCACAGCUCCUUC B CCACUACCACAGCUCCUUCTT B 3488 R-008397513-000A384 805 CCACUACCACAGCUCCUUC GAAGGAGCUGUGGUAGUGGUU 3489 R-008397516-000B1898 806 CAUCAGGAUACCCAGCGCC B CAUCAGGAUACCCAGCGCCTT B 3490R-008397516-000B 1898 806 CAUCAGGAUACCCAGCGCC GGCGCUGGGUAUCCUGAUGUU 3491R-008397519-000C 1795 15 UACUGUUGGAUUGAUUCGA UCGAAUCAAUCCAACAGUAUU 3493R-008397519-000C 1795 15 UACUGUUGGAUUGAUUCGA B UACUGUUGGAUUGAUUCGATT B3492 R-008397522-000J 653 807 UCACAGAUGCUGAAACAUG CAUGUUUCAGCAUCUGUGAUU3495 R-008397522-000J 653 807 UCACAGAUGCUGAAACAUG BUCACAGAUGCUGAAACAUGTT B 3494 R-008397525-000K 1846 808UUUGCGUGAGCAGGGUGCC GGCACCCUGCUCACGCAAAUU 3497 R-008397525-000K 1846 808UUUGCGUGAGCAGGGUGCC B UUUGCGUGAGCAGGGUGCCTT B 3496 R-008397528-000L 2348809 GCUGAUCUUGGACUUGAUA UAUCAAGUCCAAGAUCAGCUU 3499 R-008397528-000L 2348809 GCUGAUCUUGGACUUGAUA B GCUGAUCUUGGACUUGAUATT B 3498 R-008397531-000T1798 19 UGUUGGAUUGAUUCGAAAU AUUUCGAAUCAAUCCAACAUU 3501 R-008397531-000T1798 19 UGUUGGAUUGAUUCGAAAU B UGUUGGAUUGAUUCGAAAUTT B 3500R-008397534-000U 1150 810 GGCUAUUACGACAGACUGC B GGCUAUUACGACAGACUGCTT B3502 R-008397534-000U 1150 810 GGCUAUUACGACAGACUGC GCAGUCUGUCGUAAUAGCCUU3503 R-008397537-000V 1009 180 AGUGGAUUCUGUGUUGUUU AAACAACACAGAAUCCACUUU3505 R-008397537-000V 1009 180 AGUGGAUUCUGUGUUGUUU BAGUGGAUUCUGUGUUGUUUTT B 3504 R-008397540-000B 654 178CACAGAUGCUGAAACAUGC B CACAGAUGCUGAAACAUGCTT B 3506 R-008397540-000B 654178 CACAGAUGCUGAAACAUGC GCAUGUUUCAGCAUCUGUGUU 3507 R-008397543-000C 298811 GGACAUGGCCAUGGAACCA B GGACAUGGCCAUGGAACCATT B 3508 R-008397543-000C298 811 GGACAUGGCCAUGGAACCA UGGUUCCAUGGCCAUGUCCUU 3509 R-008397546-000D1568 812 AACAAGAUGAUGGUCUGCC B AACAAGAUGAUGGUCUGCCTT B 3510R-008397546-000D 1568 812 AACAAGAUGAUGGUCUGCC GGCAGACCAUCAUCUUGUUUU 3511R-008397549-000E 1058 813 UUACAUCAAGAAGGAGCUA B UUACAUCAAGAAGGAGCUATT B3512 R-008397549-000E 1058 813 UUACAUCAAGAAGGAGCUA UAGCUCCUUCUUGAUGUAAUU3513 R-008397552-000L 1835 814 AAUCAUGCACCUUUGCGUG BAAUCAUGCACCUUUGCGUGTT B 3514 R-008397552-000L 1835 814AAUCAUGCACCUUUGCGUG CACGCAAAGGUGCAUGAUUUU 3515 R-008397555-000M 1832 815GCAAAUCAUGCACCUUUGC B GCAAAUCAUGCACCUUUGCTT B 3516 R-008397555-000M 1832815 GCAAAUCAUGCACCUUUGC GCAAAGGUGCAUGAUUUGCUU 3517 R-008397558-000N 255055 ACCUCAUGGAUGGGCUGCC GGCAGCCCAUCCAUGAGGUUU 3519 R-008397558-000N 255055 ACCUCAUGGAUGGGCUGCC B ACCUCAUGGAUGGGCUGCCTT B 3518 R-008397561-000V406 816 GAGUGGUAAAGGCAAUCCU AGGAUUGCCUUUACCACUCUU 3521 R-008397561-000V406 816 GAGUGGUAAAGGCAAUCCU B GAGUGGUAAAGGCAAUCCUTT B 3520R-008397564-000W 1723 817 UCGCCUUCACUAUGGACUA B UCGCCUUCACUAUGGACUATT B3522 R-008397564-000W 1723 817 UCGCCUUCACUAUGGACUA UAGUCCAUAGUGAAGGCGAUU3523 R-008397567-000X 371 818 AUCCAUUCUGGUGCCACUA UAGUGGCACCAGAAUGGAUUU3525 R-008397567-000X 371 818 AUCCAUUCUGGUGCCACUA BAUCCAUUCUGGUGCCACUATT B 3524 R-008397570-000D 1899 819AUCAGGAUACCCAGCGCCG CGGCGCUGGGUAUCCUGAUUU 3527 R-008397570-000D 1899 819AUCAGGAUACCCAGCGCCG B AUCAGGAUACCCAGCGCCGTT B 3526 R-008397573-000E 522820 AGUAUGCAAUGACUCGAGC B AGUAUGCAAUGACUCGAGCTT B 3528 R-008397573-000E522 820 AGUAUGCAAUGACUCGAGC GCUCGAGUCAUUGCAUACUUU 3529 R-008397576-000F2285 821 CGGCUUUCAGUUGAGCUGA B CGGCUUUCAGUUGAGCUGATT B 3530R-008397576-000F 2285 821 CGGCUUUCAGUUGAGCUGA UCAGCUCAACUGAAAGCCGUU 3531R-008397579-000G 779 822 GCUGCAGUUAUGGUCCAUC GAUGGACCAUAACUGCAGCUU 3533R-008397579-000G 779 822 GCUGCAGUUAUGGUCCAUC B GCUGCAGUUAUGGUCCAUCTT B3532 R-008397582-000N 2896 823 AUUGAGUAAUGGUGUAGAA BAUUGAGUAAUGGUGUAGAATT B 3534 R-008397582-000N 2896 823AUUGAGUAAUGGUGUAGAA UUCUACACCAUUACUCAAUUU 3535 R-008397588-000R 2943 824GUAAUCUGAAUAAAGUGUA UACACUUUAUUCAGAUUACUU 3537 R-008397588-000R 2943 824GUAAUCUGAAUAAAGUGUA B GUAAUCUGAAUAAAGUGUATT B 3536 R-008397591-000X 513825 UUGAUGGACAGUAUGCAAU B UUGAUGGACAGUAUGCAAUTT B 3538 R-008397591-000X513 825 UUGAUGGACAGUAUGCAAU AUUGCAUACUGUCCAUCAAUU 3539 R-008397594-000Y3084 826 GAUAUGUAUGGGUAGGGUA B GAUAUGUAUGGGUAGGGUATT B 3540R-008397594-000Y 3084 826 GAUAUGUAUGGGUAGGGUA UACCCUACCCAUACAUAUCUU 3541R-008397597-000Z 1567 827 GAACAAGAUGAUGGUCUGC B GAACAAGAUGAUGGUCUGCTT B3542 R-008397597-000Z 1567 827 GAACAAGAUGAUGGUCUGC GCAGACCAUCAUCUUGUUCUU3543 R-008397600-000S 2034 828 UUAUCAGAGGACUAAAUAC BUUAUCAGAGGACUAAAUACTT B 3544 R-008397600-000S 2034 828UUAUCAGAGGACUAAAUAC GUAUUUAGUCCUCUGAUAAUU 3545 R-008397603-000T 1003 829UUCACCAGUGGAUUCUGUG B UUCACCAGUGGAUUCUGUGTT B 3546 R-008397603-000T 1003829 UUCACCAGUGGAUUCUGUG CACAGAAUCCACUGGUGAAUU 3547 R-008397606-000U 1980830 AAGGUUGUACCGGAGCCCU AGGGCUCCGGUACAACCUUUU 3549 R-008397606-000U 1980830 AAGGUUGUACCGGAGCCCU B AAGGUUGUACCGGAGCCCUTT B 3548 R-008397609-000V1340 831 GUAGAAGCUGGUGGAAUGC GCAUUCCACCAGCUUCUACUU 3551 R-008397609-000V1340 831 GUAGAAGCUGGUGGAAUGC B GUAGAAGCUGGUGGAAUGCTT B 3550R-008397612-000B 1437 832 AUGCUGCAACUAAACAGGA B AUGCUGCAACUAAACAGGATT B3552 R-008397612-000B 1437 832 AUGCUGCAACUAAACAGGA UCCUGUUUAGUUGCAGCAUUU3553 R-008397615-000C 2499 145 CUGGUGCUGACUAUCCAGU BCUGGUGCUGACUAUCCAGUTT B 3554 R-008397615-000C 2499 145CUGGUGCUGACUAUCCAGU ACUGGAUAGUCAGCACCAGUU 3555 R-008397618-000D 785 64GUUAUGGUCCAUCAGCUUU AAAGCUGAUGGACCAUAACUU 3557 R-008397618-000D 785 64GUUAUGGUCCAUCAGCUUU B GUUAUGGUCCAUCAGCUUUTT B 3556 R-008397621-000K 2425833 UCACUCUGGUGGAUAUGGC B UCACUCUGGUGGAUAUGGCTT B 3558 R-008397621-000K2425 833 UCACUCUGGUGGAUAUGGC GCCAUAUCCACCAGAGUGAUU 3559 R-008397624-000L282 834 CUGAUUUGAUGGAGUUGGA UCCAACUCCAUCAAAUCAGUU 3561 R-008397624-000L282 834 CUGAUUUGAUGGAGUUGGA B CUGAUUUGAUGGAGUUGGATT B 3560R-008397627-000M 1206 835 UCAUCAUACUGGCUAGUGG B UCAUCAUACUGGCUAGUGGTT B3562 R-008397627-000M 1206 835 UCAUCAUACUGGCUAGUGG CCACUAGCCAGUAUGAUGAUU3563 R-008397630-000U 1885 836 GCUUGUUCGUGCACAUCAG CUGAUGUGCACGAACAAGCUU3565 R-008397630-000U 1885 836 GCUUGUUCGUGCACAUCAG BGCUUGUUCGUGCACAUCAGTT B 3564 R-008397633-000V 1314 837UCUGCUCUAGUAAUAAGCC B UCUGCUCUAGUAAUAAGCCTT B 3566 R-008397633-000V 1314837 UCUGCUCUAGUAAUAAGCC GGCUUAUUACUAGAGCAGAUU 3567 R-008397636-000W 2388174 UUGGAUAUCGCCAGGAUGA B UUGGAUAUCGCCAGGAUGATT B 3568 R-008397636-000W2388 174 UUGGAUAUCGCCAGGAUGA UCAUCCUGGCGAUAUCCAAUU 3569 R-008397639-000X1308 838 UAUCUGUCUGCUCUAGUAA B UAUCUGUCUGCUCUAGUAATT B 3570R-008397639-000X 1308 838 UAUCUGUCUGCUCUAGUAA UUACUAGAGCAGACAGAUAUU 3571R-008397642-000D 1200 839 GCAAGCUCAUCAUACUGGC GCCAGUAUGAUGAGCUUGCUU 3573R-008397642-000D 1200 839 GCAAGCUCAUCAUACUGGC B GCAAGCUCAUCAUACUGGCTT B3572 R-008397645-000E 543 840 AGAGGGUACGAGCUGCUAU BAGAGGGUACGAGCUGCUAUTT B 3574 R-008397645-000E 543 840AGAGGGUACGAGCUGCUAU AUAGCAGCUCGUACCCUCUUU 3575 R-008397648-000F 1609 841UGUGCGUACUGUCCUUCGG B UGUGCGUACUGUCCUUCGGTT B 3576 R-008397648-000F 1609841 UGUGCGUACUGUCCUUCGG CCGAAGGACAGUACGCACAUU 3577 R-008397651-000M 1453842 GGAAGGGAUGGAAGGUCUC B GGAAGGGAUGGAAGGUCUCTT B 3578 R-008397651-000M1453 842 GGAAGGGAUGGAAGGUCUC GAGACCUUCCAUCCCUUCCUU 3579 R-008397654-000N2127 138 AACUUGCUCAGGACAAGGA B AACUUGCUCAGGACAAGGATT B 3580R-008397654-000N 2127 138 AACUUGCUCAGGACAAGGA UCCUUGUCCUGAGCAAGUUUU 3581R-008397657-000P 833 843 AUGCGUUCUCCUCAGAUGG B AUGCGUUCUCCUCAGAUGGTT B3582 R-008397657-000P 833 843 AUGCGUUCUCCUCAGAUGG CCAUCUGAGGAGAACGCAUUU3583 R-008397660-000W 2188 844 GACAGAGUUACUUCACUCU BGACAGAGUUACUUCACUCUTT B 3584 R-008397660-000W 2188 844GACAGAGUUACUUCACUCU AGAGUGAAGUAACUCUGUCUU 3585 R-008397663-000X 1148 845UUGGCUAUUACGACAGACU B UUGGCUAUUACGACAGACUTT B 3586 R-008397663-000X 1148845 UUGGCUAUUACGACAGACU AGUCUGUCGUAAUAGCCAAUU 3587 R-008397666-000Y 1736846 GGACUACCAGUUGUGGUUA B GGACUACCAGUUGUGGUUATT B 3588 R-008397666-000Y1736 846 GGACUACCAGUUGUGGUUA UAACCACAACUGGUAGUCCUU 3589 R-008397669-000Z1401 847 UUCAGAACUGUCUUUGGAC GUCCAAAGACAGUUCUGAAUU 3591 R-008397669-000Z1401 847 UUCAGAACUGUCUUUGGAC B UUCAGAACUGUCUUUGGACTT B 3590R-008397672-000F 1677 848 AUCUGACCAGCCGACACCA UGGUGUCGGCUGGUCAGAUUU 3593R-008397672-000F 1677 848 AUCUGACCAGCCGACACCA B AUCUGACCAGCCGACACCATT B3592 R-008397675-000G 1934 849 ACACAGCAGCAAUUUGUGG BACACAGCAGCAAUUUGUGGTT B 3594 R-008397675-000G 1934 849ACACAGCAGCAAUUUGUGG CCACAAAUUGCUGCUGUGUUU 3595 R-008397678-000H 388 850UACCACAGCUCCUUCUCUG CAGAGAAGGAGCUGUGGUAUU 3597 R-008397678-000H 388 850UACCACAGCUCCUUCUCUG B UACCACAGCUCCUUCUCUGTT B 3596 R-008397681-000P 1920851 CGUCCAUGGGUGGGACACA B CGUCCAUGGGUGGGACACATT B 3598 R-008397681-000P1920 851 CGUCCAUGGGUGGGACACA UGUGUCCCACCCAUGGACGUU 3599 R-008397684-000R1747 852 UGUGGUUAAGCUCUUACAC GUGUAAGAGCUUAACCACAUU 3601 R-008397684-000R1747 852 UGUGGUUAAGCUCUUACAC B UGUGGUUAAGCUCUUACACTT B 3600R-008397687-000S 861 853 UUGUACGUACCAUGCAGAA B UUGUACGUACCAUGCAGAATT B3602 R-008397687-000S 861 853 UUGUACGUACCAUGCAGAA UUCUGCAUGGUACGUACAAUU3603 R-008397690-000Y 1904 854 GAUACCCAGCGCCGUACGU BGAUACCCAGCGCCGUACGUTT B 3604 R-008397690-000Y 1904 854GAUACCCAGCGCCGUACGU ACGUACGGCGCUGGGUAUCUU 3605 R-008397693-000Z 831 855UCAUGCGUUCUCCUCAGAU B UCAUGCGUUCUCCUCAGAUTT B 3606 R-008397693-000Z 831855 UCAUGCGUUCUCCUCAGAU AUCUGAGGAGAACGCAUGAUU 3607 R-008397696-000A 1895856 GCACAUCAGGAUACCCAGC GCUGGGUAUCCUGAUGUGCUU 3609 R-008397696-000A 1895856 GCACAUCAGGAUACCCAGC B GCACAUCAGGAUACCCAGCTT B 3608 R-008397699-000B2273 857 GAUUACAAGAAACGGCUUU AAAGCCGUUUCUUGUAAUCUU 3611 R-008397699-000B2273 857 GAUUACAAGAAACGGCUUU B GAUUACAAGAAACGGCUUUTT B 3610R-008397702-000U 1738 858 ACUACCAGUUGUGGUUAAG B ACUACCAGUUGUGGUUAAGTT B3612 R-008397702-000U 1738 858 ACUACCAGUUGUGGUUAAG CUUAACCACAACUGGUAGUUU3613 R-008397705-000V 1395 859 GUCUUGUUCAGAACUGUCU BGUCUUGUUCAGAACUGUCUTT B 3614 R-008397705-000V 1395 859GUCUUGUUCAGAACUGUCU AGACAGUUCUGAACAAGACUU 3615 R-008397708-000W 1675 860UCAUCUGACCAGCCGACAC B UCAUCUGACCAGCCGACACTT B 3616 R-008397708-000W 1675860 UCAUCUGACCAGCCGACAC GUGUCGGCUGGUCAGAUGAUU 3617 R-008397711-000C 1845861 CUUUGCGUGAGCAGGGUGC B CUUUGCGUGAGCAGGGUGCTT B 3618 R-008397711-000C1845 861 CUUUGCGUGAGCAGGGUGC GCACCCUGCUCACGCAAAGUU 3619 R-008397714-000D1408 862 CUGUCUUUGGACUCUCAGG CCUGAGAGUCCAAAGACAGUU 3621 R-008397714-000D1408 862 CUGUCUUUGGACUCUCAGG B CUGUCUUUGGACUCUCAGGTT B 3620R-008397717-000E 1059 863 UACAUCAAGAAGGAGCUAA B UACAUCAAGAAGGAGCUAATT B3622 R-008397717-000E 1059 863 UACAUCAAGAAGGAGCUAA UUAGCUCCUUCUUGAUGUAUU3623 R-008397720-000L 1381 864 AGAUCCAAGUCAACGUCUU AAGACGUUGACUUGGAUCUUU3625 R-008397720-000L 1381 864 AGAUCCAAGUCAACGUCUU BAGAUCCAAGUCAACGUCUUTT B 3624 R-008397723-000M 1386 865CAAGUCAACGUCUUGUUCA B CAAGUCAACGUCUUGUUCATT B 3626 R-008397723-000M 1386865 CAAGUCAACGUCUUGUUCA UGAACAAGACGUUGACUUGUU 3627 R-008397726-000N 1470866 UCCUUGGGACUCUUGUUCA UGAACAAGAGUCCCAAGGAUU 3629 R-008397726-000N 1470866 UCCUUGGGACUCUUGUUCA B UCCUUGGGACUCUUGUUCATT B 3628 R-008397729-000P1349 867 GGUGGAAUGCAAGCUUUAG CUAAAGCUUGCAUUCCACCUU 3631 R-008397729-000P1349 867 GGUGGAAUGCAAGCUUUAG B GGUGGAAUGCAAGCUUUAGTT B 3630R-008397732-000W 1440 868 CUGCAACUAAACAGGAAGG CCUUCCUGUUUAGUUGCAGUU 3633R-008397732-000W 1440 868 CUGCAACUAAACAGGAAGG B CUGCAACUAAACAGGAAGGTT B3632 R-008397735-000X 1364 869 UUAGGACUUCACCUGACAG CUGUCAGGUGAAGUCCUAAUU3635 R-008397735-000X 1364 869 UUAGGACUUCACCUGACAG BUUAGGACUUCACCUGACAGTT B 3634 R-008397738-000Y 502 870AGUAGCUGAUAUUGAUGGA B AGUAGCUGAUAUUGAUGGATT B 3636 R-008397738-000Y 502870 AGUAGCUGAUAUUGAUGGA UCCAUCAAUAUCAGCUACUUU 3637 R-008397741-000E 1246871 UAUAAUGAGGACCUAUACU AGUAUAGGUCCUCAUUAUAUU 3639 R-008397741-000E 1246871 UAUAAUGAGGACCUAUACU B UAUAAUGAGGACCUAUACUTT B 3638 R-008397744-000F3178 872 CCUGCUGUGAUACGAUGCU AGCAUCGUAUCACAGCAGGUU 3641 R-008397744-000F3178 872 CCUGCUGUGAUACGAUGCU B CCUGCUGUGAUACGAUGCUTT B 3640R-008397747-000G 2483 873 AUGGGUGGCCACCACCCUG B AUGGGUGGCCACCACCCUGTT B3642 R-008397747-000G 2483 873 AUGGGUGGCCACCACCCUG CAGGGUGGUGGCCACCCAUUU3643 R-008397750-000N 1417 874 GACUCUCAGGAAUCUUUCA BGACUCUCAGGAAUCUUUCATT B 3644 R-008397750-000N 1417 874GACUCUCAGGAAUCUUUCA UGAAAGAUUCCUGAGAGUCUU 3645 R-008397753-000P 1893 875GUGCACAUCAGGAUACCCA B GUGCACAUCAGGAUACCCATT B 3646 R-008397753-000P 1893875 GUGCACAUCAGGAUACCCA UGGGUAUCCUGAUGUGCACUU 3647 R-008397756-000R 817876 UUCCAGACACGCUAUCAUG CAUGAUAGCGUGUCUGGAAUU 3649 R-008397756-000R 817876 UUCCAGACACGCUAUCAUG B UUCCAGACACGCUAUCAUGTT B 3648 R-008397759-000S711 877 UUGCCACACGUGCAAUCCC GGGAUUGCACGUGUGGCAAUU 3651 R-008397759-000S711 877 UUGCCACACGUGCAAUCCC B UUGCCACACGUGCAAUCCCTT B 3650R-008397762-000Y 1433 878 UCAGAUGCUGCAACUAAAC GUUUAGUUGCAGCAUCUGAUU 3653R-008397762-000Y 1433 878 UCAGAUGCUGCAACUAAAC B UCAGAUGCUGCAACUAAACTT B3652 R-008397765-000Z 1362 879 CUUUAGGACUUCACCUGAC GUCAGGUGAAGUCCUAAAGUU3655 R-008397765-000Z 1362 879 CUUUAGGACUUCACCUGAC BCUUUAGGACUUCACCUGACTT B 3654 R-008397768-000A 1838 880CAUGCACCUUUGCGUGAGC B CAUGCACCUUUGCGUGAGCTT B 3656 R-008397768-000A 1838880 CAUGCACCUUUGCGUGAGC GCUCACGCAAAGGUGCAUGUU 3657 R-008397771-000G 1037881 ACAACUCUCCACAACCUUU AAAGGUUGUGGAGAGUUGUUU 3659 R-008397771-000G 1037881 ACAACUCUCCACAACCUUU B ACAACUCUCCACAACCUUUTT B 3658 R-008397774-000H1474 882 UGGGACUCUUGUUCAGCUU B UGGGACUCUUGUUCAGCUUTT B 3660R-008397774-000H 1474 882 UGGGACUCUUGUUCAGCUU AAGCUGAACAAGAGUCCCAUU 3661R-008397777-000J 997 883 GCUUGGUUCACCAGUGGAU B GCUUGGUUCACCAGUGGAUTT B3662 R-008397777-000J 997 883 GCUUGGUUCACCAGUGGAU AUCCACUGGUGAACCAAGCUU3663 R-008397780-000R 931 884 UUCCCAUCAUCGUGAGGGC BUUCCCAUCAUCGUGAGGGCTT B 3664 R-008397780-000R 931 884UUCCCAUCAUCGUGAGGGC GCCCUCACGAUGAUGGGAAUU 3665 R-008397783-000S 1313 885GUCUGCUCUAGUAAUAAGC GCUUAUUACUAGAGCAGACUU 3667 R-008397783-000S 1313 885GUCUGCUCUAGUAAUAAGC B GUCUGCUCUAGUAAUAAGCTT B 3666 R-008397786-000T 1487886 CAGCUUCUGGGUUCAGAUG B CAGCUUCUGGGUUCAGAUGTT B 3668 R-008397786-000T1487 886 CAGCUUCUGGGUUCAGAUG CAUCUGAACCCAGAAGCUGUU 3669 R-008397789-000U1673 887 CGUCAUCUGACCAGCCGAC B CGUCAUCUGACCAGCCGACTT B 3670R-008397789-000U 1673 887 CGUCAUCUGACCAGCCGAC GUCGGCUGGUCAGAUGACGUU 3671R-008397792-000A 561 888 UGUUCCCUGAGACAUUAGA UCUAAUGUCUCAGGGAACAUU 3673R-008397792-000A 561 888 UGUUCCCUGAGACAUUAGA B UGUUCCCUGAGACAUUAGATT B3672 R-008397795-000B 1188 889 GCAACCAAGAAAGCAAGCU BGCAACCAAGAAAGCAAGCUTT B 3674 R-008397795-000B 1188 889GCAACCAAGAAAGCAAGCU AGCUUGCUUUCUUGGUUGCUU 3675 R-008397798-000C 292 890GGAGUUGGACAUGGCCAUG B GGAGUUGGACAUGGCCAUGTT B 3676 R-008397798-000C 292890 GGAGUUGGACAUGGCCAUG CAUGGCCAUGUCCAACUCCUU 3677 R-008397801-000V 1958891 GUCCGCAUGGAAGAAAUAG B GUCCGCAUGGAAGAAAUAGTT B 3678 R-008397801-000V1958 891 GUCCGCAUGGAAGAAAUAG CUAUUUCUUCCAUGCGGACUU 3679 R-008397804-000W2349 892 CUGAUCUUGGACUUGAUAU B CUGAUCUUGGACUUGAUAUTT B 3680R-008397804-000W 2349 892 CUGAUCUUGGACUUGAUAU AUAUCAAGUCCAAGAUCAGUU 3681R-008397807-000X 1460 893 AUGGAAGGUCUCCUUGGGA UCCCAAGGAGACCUUCCAUUU 3683R-008397807-000X 1460 893 AUGGAAGGUCUCCUUGGGA B AUGGAAGGUCUCCUUGGGATT B3682 R-008397810-000D 1576 894 GAUGGUCUGCCAAGUGGGU BGAUGGUCUGCCAAGUGGGUTT B 3684 R-008397810-000D 1576 894GAUGGUCUGCCAAGUGGGU ACCCACUUGGCAGACCAUCUU 3685 R-008397813-000E 536 4CGAGCUCAGAGGGUACGAG B CGAGCUCAGAGGGUACGAGTT B 3686 R-008397813-000E 5364 CGAGCUCAGAGGGUACGAG CUCGUACCCUCUGAGCUCGUU 3687 R-008397816-000F 690895 ACUAUCAAGAUGAUGCAGA UCUGCAUCAUCUUGAUAGUUU 3689 R-008397816-000F 690895 ACUAUCAAGAUGAUGCAGA B ACUAUCAAGAUGAUGCAGATT B 3688 R-008397819-000G655 896 ACAGAUGCUGAAACAUGCA B ACAGAUGCUGAAACAUGCATT B 3690R-008397819-000G 655 896 ACAGAUGCUGAAACAUGCA UGCAUGUUUCAGCAUCUGUUU 3691R-008397822-000N 2290 897 UUCAGUUGAGCUGACCAGC GCUGGUCAGCUCAACUGAAUU 3693R-008397822-000N 2290 897 UUCAGUUGAGCUGACCAGC B UUCAGUUGAGCUGACCAGCTT B3692 R-008397825-000P 1600 898 AGAGGCUCUUGUGCGUACU BAGAGGCUCUUGUGCGUACUTT B 3694 R-008397825-000P 1600 898AGAGGCUCUUGUGCGUACU AGUACGCACAAGAGCCUCUUU 3695 R-008397828-000R 2432 899GGUGGAUAUGGCCAGGAUG CAUCCUGGCCAUAUCCACCUU 3697 R-008397828-000R 2432 899GGUGGAUAUGGCCAGGAUG B GGUGGAUAUGGCCAGGAUGTT B 3696 R-008397831-000X 710900 CUUGCCACACGUGCAAUCC B CUUGCCACACGUGCAAUCCTT B 3698 R-008397831-000X710 900 CUUGCCACACGUGCAAUCC GGAUUGCACGUGUGGCAAGUU 3699 R-008397834-000Y1714 901 GAAUGCAGUUCGCCUUCAC B GAAUGCAGUUCGCCUUCACTT B 3700R-008397834-000Y 1714 901 GAAUGCAGUUCGCCUUCAC GUGAAGGCGAACUGCAUUCUU 3701R-008397837-000Z 2005 902 CCUAGCUCGGGAUGUUCAC B CCUAGCUCGGGAUGUUCACTT B3702 R-008397837-000Z 2005 902 CCUAGCUCGGGAUGUUCAC GUGAACAUCCCGAGCUAGGUU3703 R-008397840-000F 1728 903 UUCACUAUGGACUACCAGU BUUCACUAUGGACUACCAGUTT B 3704 R-008397840-000F 1728 903UUCACUAUGGACUACCAGU ACUGGUAGUCCAUAGUGAAUU 3705 R-008397843-000G 2482 904GAUGGGUGGCCACCACCCU AGGGUGGUGGCCACCCAUCUU 3707 R-008397843-000G 2482 904GAUGGGUGGCCACCACCCU B GAUGGGUGGCCACCACCCUTT B 3706 R-008397846-000H 768905 UGGUUAAUAAGGCUGCAGU B UGGUUAAUAAGGCUGCAGUTT B 3708 R-008397846-000H768 905 UGGUUAAUAAGGCUGCAGU ACUGCAGCCUUAUUAACCAUU 3709 R-008397849-000J693 906 AUCAAGAUGAUGCAGAACU B AUCAAGAUGAUGCAGAACUTT B 3710R-008397849-000J 693 906 AUCAAGAUGAUGCAGAACU AGUUCUGCAUCAUCUUGAUUU 3711R-008397852-000R 3179 907 CUGCUGUGAUACGAUGCUU B CUGCUGUGAUACGAUGCUUTT B3712 R-008397852-000R 3179 907 CUGCUGUGAUACGAUGCUU AAGCAUCGUAUCACAGCAGUU3713 R-008397855-000S 1549 89 CACUUGCAAUAAUUAUAAG CUUAUAAUUAUUGCAAGUGUU3715 R-008397855-000S 1549 89 CACUUGCAAUAAUUAUAAG BCACUUGCAAUAAUUAUAAGTT B 3714 R-008397858-000T 1792 167GGCUACUGUUGGAUUGAUU AAUCAAUCCAACAGUAGCCUU 3717 R-008397858-000T 1792 167GGCUACUGUUGGAUUGAUU B GGCUACUGUUGGAUUGAUUTT B 3716 R-008397861-000Z 2448908 AUGCCUUGGGUAUGGACCC GGGUCCAUACCCAAGGCAUUU 3719 R-008397861-000Z 2448908 AUGCCUUGGGUAUGGACCC B AUGCCUUGGGUAUGGACCCTT B 3718 R-008397864-000A3183 909 UGUGAUACGAUGCUUCAAG B UGUGAUACGAUGCUUCAAGTT B 3720R-008397864-000A 3183 909 UGUGAUACGAUGCUUCAAG CUUGAAGCAUCGUAUCACAUU 3721R-008397867-000B 1293 910 GAGUGCUGAAGGUGCUAUC GAUAGCACCUUCAGCACUCUU 3723R-008397867-000B 1293 910 GAGUGCUGAAGGUGCUAUC B GAGUGCUGAAGGUGCUAUCTT B3722 R-008397870-000H 544 911 GAGGGUACGAGCUGCUAUG CAUAGCAGCUCGUACCCUCUU3725 R-008397870-000H 544 911 GAGGGUACGAGCUGCUAUG BGAGGGUACGAGCUGCUAUGTT B 3724 R-008397873-000J 1676 26CAUCUGACCAGCCGACACC GGUGUCGGCUGGUCAGAUGUU 3727 R-008397873-000J 1676 26CAUCUGACCAGCCGACACC B CAUCUGACCAGCCGACACCTT B 3726 R-008397876-000K 2937912 UUAAUUGUAAUCUGAAUAA B UUAAUUGUAAUCUGAAUAATT B 3728 R-008397876-000K2937 912 UUAAUUGUAAUCUGAAUAA UUAUUCAGAUUACAAUUAAUU 3729 R-008397879-000L1691 913 CACCAAGAAGCAGAGAUGG CCAUCUCUGCUUCUUGGUGUU 3731 R-008397879-000L1691 913 CACCAAGAAGCAGAGAUGG B CACCAAGAAGCAGAGAUGGTT B 3730R-008397882-000T 2195 120 UUACUUCACUCUAGGAAUG B UUACUUCACUCUAGGAAUGTT B3732 R-008397882-000T 2195 120 UUACUUCACUCUAGGAAUG CAUUCCUAGAGUGAAGUAAUU3733 R-008397885-000U 1356 186 UGCAAGCUUUAGGACUUCA BUGCAAGCUUUAGGACUUCATT B 3734 R-008397885-000U 1356 186UGCAAGCUUUAGGACUUCA UGAAGUCCUAAAGCUUGCAUU 3735 R-008397888-000V 557 184GCUAUGUUCCCUGAGACAU AUGUCUCAGGGAACAUAGCUU 3737 R-008397888-000V 557 184GCUAUGUUCCCUGAGACAU B GCUAUGUUCCCUGAGACAUTT B 3736 R-008397897-000D 1353914 GAAUGCAAGCUUUAGGACU AGUCCUAAAGCUUGCAUUCUU 3739 R-008397897-000D 1353914 GAAUGCAAGCUUUAGGACU B GAAUGCAAGCUUUAGGACUTT B 3738 R-008397900-000W1843 915 ACCUUUGCGUGAGCAGGGU B ACCUUUGCGUGAGCAGGGUTT B 3740R-008397900-000W 1843 915 ACCUUUGCGUGAGCAGGGU ACCCUGCUCACGCAAAGGUUU 3741R-008397903-000X 1302 916 AGGUGCUAUCUGUCUGCUC B AGGUGCUAUCUGUCUGCUCTT B3742 R-008397903-000X 1302 916 AGGUGCUAUCUGUCUGCUC GAGCAGACAGAUAGCACCUUU3743 R-008397906-000Y 2130 917 UUGCUCAGGACAAGGAAGC BUUGCUCAGGACAAGGAAGCTT B 3744 R-008397906-000Y 2130 917UUGCUCAGGACAAGGAAGC GCUUCCUUGUCCUGAGCAAUU 3745 R-008397909-000Z 2165 918GCUGAGGGAGCCACAGCUC B GCUGAGGGAGCCACAGCUCTT B 3746 R-008397909-000Z 2165918 GCUGAGGGAGCCACAGCUC GAGCUGUGGCUCCCUCAGCUU 3747 R-008397912-000F 387919 CUACCACAGCUCCUUCUCU B CUACCACAGCUCCUUCUCUTT B 3748 R-008397912-000F387 919 CUACCACAGCUCCUUCUCU AGAGAAGGAGCUGUGGUAGUU 3749 R-008397915-000G2472 920 UGGAACAUGAGAUGGGUGG CCACCCAUCUCAUGUUCCAUU 3751 R-008397915-000G2472 920 UGGAACAUGAGAUGGGUGG B UGGAACAUGAGAUGGGUGGTT B 3750R-008397918-000H 857 921 GCUAUUGUACGUACCAUGC B GCUAUUGUACGUACCAUGCTT B3752 R-008397918-000H 857 921 GCUAUUGUACGUACCAUGC GCAUGGUACGUACAAUAGCUU3753 R-008397921-000P 1816 922 UCUUGCCCUUUGUCCCGCA UGCGGGACAAAGGGCAAGAUU3755 R-008397921-000P 1816 922 UCUUGCCCUUUGUCCCGCA BUCUUGCCCUUUGUCCCGCATT B 3754 R-008397924-000R 1561 923UUAUAAGAACAAGAUGAUG CAUCAUCUUGUUCUUAUAAUU 3757 R-008397924-000R 1561 923UUAUAAGAACAAGAUGAUG B UUAUAAGAACAAGAUGAUGTT B 3756 R-008397927-000S 811924 GGAAGCUUCCAGACACGCU B GGAAGCUUCCAGACACGCUTT B 3758 R-008397927-000S811 924 GGAAGCUUCCAGACACGCU AGCGUGUCUGGAAGCUUCCUU 3759 R-008397930-000Y1327 925 UAAGCCGGCUAUUGUAGAA B UAAGCCGGCUAUUGUAGAATT B 3760R-008397930-000Y 1327 925 UAAGCCGGCUAUUGUAGAA UUCUACAAUAGCCGGCUUAUU 3761R-008397933-000Z 757 926 GGACCAGGUGGUGGUUAAU B GGACCAGGUGGUGGUUAAUTT B3762 R-008397933-000Z 757 926 GGACCAGGUGGUGGUUAAU AUUAACCACCACCUGGUCCUU3763 R-008397936-000A 507 927 CUGAUAUUGAUGGACAGUA BCUGAUAUUGAUGGACAGUATT B 3764 R-008397936-000A 507 927CUGAUAUUGAUGGACAGUA UACUGUCCAUCAAUAUCAGUU 3765 R-008397939-000B 3092 928UGGGUAGGGUAAAUCAGUA B UGGGUAGGGUAAAUCAGUATT B 3766 R-008397939-000B 3092928 UGGGUAGGGUAAAUCAGUA UACUGAUUUACCCUACCCAUU 3767 R-008397942-000H 2359929 ACUUGAUAUUGGUGCCCAG B ACUUGAUAUUGGUGCCCAGTT B 3768 R-008397942-000H2359 929 ACUUGAUAUUGGUGCCCAG CUGGGCACCAAUAUCAAGUUU 3769 R-008397945-000J1753 930 UAAGCUCUUACACCCACCA B UAAGCUCUUACACCCACCATT B 3770R-008397945-000J 1753 930 UAAGCUCUUACACCCACCA UGGUGGGUGUAAGAGCUUAUU 3771R-008397948-000K 273 931 CUACUCAAGCUGAUUUGAU AUCAAAUCAGCUUGAGUAGUU 3773R-008397948-000K 273 931 CUACUCAAGCUGAUUUGAU B CUACUCAAGCUGAUUUGAUTT B3772 R-008397951-000S 1859 932 GGUGCCAUUCCACGACUAG CUAGUCGUGGAAUGGCACCUU3775 R-008397951-000S 1859 932 GGUGCCAUUCCACGACUAG BGGUGCCAUUCCACGACUAGTT B 3774 R-008397954-000T 296 933UUGGACAUGGCCAUGGAAC B UUGGACAUGGCCAUGGAACTT B 3776 R-008397954-000T 296933 UUGGACAUGGCCAUGGAAC GUUCCAUGGCCAUGUCCAAUU 3777 R-008397957-000U 615934 CUGCUCAUCCCACUAAUGU ACAUUAGUGGGAUGAGCAGUU 3779 R-008397957-000U 615934 CUGCUCAUCCCACUAAUGU B CUGCUCAUCCCACUAAUGUTT B 3778 R-008397960-000A301 935 CAUGGCCAUGGAACCAGAC GUCUGGUUCCAUGGCCAUGUU 3781 R-008397960-000A301 935 CAUGGCCAUGGAACCAGAC B CAUGGCCAUGGAACCAGACTT B 3780R-008397963-000B 1184 936 UAUGGCAACCAAGAAAGCA B UAUGGCAACCAAGAAAGCATT B3782 R-008397963-000B 1184 936 UAUGGCAACCAAGAAAGCA UGCUUUCUUGGUUGCCAUAUU3783 R-008397966-000C 1006 937 ACCAGUGGAUUCUGUGUUG BACCAGUGGAUUCUGUGUUGTT B 3784 R-008397966-000C 1006 937ACCAGUGGAUUCUGUGUUG CAACACAGAAUCCACUGGUUU 3785 R-008397969-000D 2189 938ACAGAGUUACUUCACUCUA B ACAGAGUUACUUCACUCUATT B 3786 R-008397969-000D 2189938 ACAGAGUUACUUCACUCUA UAGAGUGAAGUAACUCUGUUU 3787 R-008397972-000K 1365939 UAGGACUUCACCUGACAGA UCUGUCAGGUGAAGUCCUAUU 3789 R-008397972-000K 1365939 UAGGACUUCACCUGACAGA B UAGGACUUCACCUGACAGATT B 3788 R-008397975-000L2442 940 GCCAGGAUGCCUUGGGUAU B GCCAGGAUGCCUUGGGUAUTT B 3790R-008397975-000L 2442 940 GCCAGGAUGCCUUGGGUAU AUACCCAAGGCAUCCUGGCUU 3791R-008397978-000M 1249 941 AAUGAGGACCUAUACUUAC B AAUGAGGACCUAUACUUACTT B3792 R-008397978-000M 1249 941 AAUGAGGACCUAUACUUAC GUAAGUAUAGGUCCUCAUUUU3793 R-008397981-000U 1144 942 AUUCUUGGCUAUUACGACA BAUUCUUGGCUAUUACGACATT B 3794 R-008397981-000U 1144 942AUUCUUGGCUAUUACGACA UGUCGUAAUAGCCAAGAAUUU 3795 R-008397984-000V 2075 943CUUUAUUCUCCCAUUGAAA B CUUUAUUCUCCCAUUGAAATT B 3796 R-008397984-000V 2075943 CUUUAUUCUCCCAUUGAAA UUUCAAUGGGAGAAUAAAGUU 3797 R-008397987-000W 75994 ACCAGGUGGUGGUUAAUAA B ACCAGGUGGUGGUUAAUAATT B 3798 R-008397987-000W759 94 ACCAGGUGGUGGUUAAUAA UUAUUAACCACCACCUGGUUU 3799 R-008397990-000C1545 44 ACCUCACUUGCAAUAAUUA B ACCUCACUUGCAAUAAUUATT B 3800R-008397990-000C 1545 44 ACCUCACUUGCAAUAAUUA UAAUUAUUGCAAGUGAGGUUU 3801R-008397993-000D 504 944 UAGCUGAUAUUGAUGGACA UGUCCAUCAAUAUCAGCUAUU 3803R-008397993-000D 504 944 UAGCUGAUAUUGAUGGACA B UAGCUGAUAUUGAUGGACATT B3802 R-008397996-000E 1405 945 GAACUGUCUUUGGACUCUC BGAACUGUCUUUGGACUCUCTT B 3804 R-008397996-000E 1405 945GAACUGUCUUUGGACUCUC GAGAGUCCAAAGACAGUUCUU 3805 R-008397999-000F 333 946UUAGUCACUGGCAGCAACA UGUUGCUGCCAGUGACUAAUU 3807 R-008397999-000F 333 946UUAGUCACUGGCAGCAACA B UUAGUCACUGGCAGCAACATT B 3806 R-008398002-000V 1032947 CCAUUACAACUCUCCACAA B CCAUUACAACUCUCCACAATT B 3808 R-008398002-000V1032 947 CCAUUACAACUCUCCACAA UUGUGGAGAGUUGUAAUGGUU 3809 R-008398005-000W1748 948 GUGGUUAAGCUCUUACACC B GUGGUUAAGCUCUUACACCTT B 3810R-008398005-000W 1748 948 GUGGUUAAGCUCUUACACC GGUGUAAGAGCUUAACCACUU 3811R-008398008-000X 283 949 UGAUUUGAUGGAGUUGGAC GUCCAACUCCAUCAAAUCAUU 3813R-008398008-000X 283 949 UGAUUUGAUGGAGUUGGAC B UGAUUUGAUGGAGUUGGACTT B3812 R-008398011-000D 1700 950 GCAGAGAUGGCCCAGAAUG BGCAGAGAUGGCCCAGAAUGTT B 3814 R-008398011-000D 1700 950GCAGAGAUGGCCCAGAAUG CAUUCUGGGCCAUCUCUGCUU 3815 R-008398014-000E 1445 951ACUAAACAGGAAGGGAUGG B ACUAAACAGGAAGGGAUGGTT B 3816 R-008398014-000E 1445951 ACUAAACAGGAAGGGAUGG CCAUCCCUUCCUGUUUAGUUU 3817 R-008398017-000F 1133952 ACAAAUGUUAAAUUCUUGG CCAAGAAUUUAACAUUUGUUU 3819 R-008398017-000F 1133952 ACAAAUGUUAAAUUCUUGG B ACAAAUGUUAAAUUCUUGGTT B 3818 R-008398020-000M527 953 GCAAUGACUCGAGCUCAGA UCUGAGCUCGAGUCAUUGCUU 3821 R-008398020-000M527 953 GCAAUGACUCGAGCUCAGA B GCAAUGACUCGAGCUCAGATT B 3820R-008398023-000N 2010 954 CUCGGGAUGUUCACAACCG CGGUUGUGAACAUCCCGAGUU 3823R-008398023-000N 2010 954 CUCGGGAUGUUCACAACCG B CUCGGGAUGUUCACAACCGTT B3822 R-008398026-000P 851 955 GUGUCUGCUAUUGUACGUA UACGUACAAUAGCAGACACUU3825 R-008398026-000P 851 955 GUGUCUGCUAUUGUACGUA BGUGUCUGCUAUUGUACGUATT B 3824 R-008398029-000R 436 956UGUGGAUACCUCCCAAGUC B UGUGGAUACCUCCCAAGUCTT B 3826 R-008398029-000R 436956 UGUGGAUACCUCCCAAGUC GACUUGGGAGGUAUCCACAUU 3827 R-008398032-000X 16012 GAGGCUCUUGUGCGUACUG B GAGGCUCUUGUGCGUACUGTT B 3828 R-008398032-000X1601 2 GAGGCUCUUGUGCGUACUG CAGUACGCACAAGAGCCUCUU 3829 R-008398035-000Y2446 957 GGAUGCCUUGGGUAUGGAC B GGAUGCCUUGGGUAUGGACTT B 3830R-008398035-000Y 2446 957 GGAUGCCUUGGGUAUGGAC GUCCAUACCCAAGGCAUCCUU 3831R-008398038-000Z 1142 958 AAAUUCUUGGCUAUUACGA B AAAUUCUUGGCUAUUACGATT B3832 R-008398038-000Z 1142 958 AAAUUCUUGGCUAUUACGA UCGUAAUAGCCAAGAAUUUUU3833 R-008398041-000F 549 959 UACGAGCUGCUAUGUUCCC BUACGAGCUGCUAUGUUCCCTT B 3834 R-008398041-000F 549 959UACGAGCUGCUAUGUUCCC GGGAACAUAGCAGCUCGUAUU 3835 R-008398044-000G 1083 960CAGUGCGUUUAGCUGGUGG CCACCAGCUAAACGCACUGUU 3837 R-008398044-000G 1083 960CAGUGCGUUUAGCUGGUGG B CAGUGCGUUUAGCUGGUGGTT B 3836 R-008398047-000H 695961 CAAGAUGAUGCAGAACUUG CAAGUUCUGCAUCAUCUUGUU 3839 R-008398047-000H 695961 CAAGAUGAUGCAGAACUUG B CAAGAUGAUGCAGAACUUGTT B 3838 R-008398050-000P885 962 AUGAUGUAGAAACAGCUCG B AUGAUGUAGAAACAGCUCGTT B 3840R-008398050-000P 885 962 AUGAUGUAGAAACAGCUCG CGAGCUGUUUCUACAUCAUUU 3841R-008398056-000S 2067 963 UGCAGCUGCUUUAUUCUCC B UGCAGCUGCUUUAUUCUCCTT B3842 R-008398056-000S 2067 963 UGCAGCUGCUUUAUUCUCC GGAGAAUAAAGCAGCUGCAUU3843 R-008398059-000T 390 964 CCACAGCUCCUUCUCUGAG CUCAGAGAAGGAGCUGUGGUU3845 R-008398059-000T 390 964 CCACAGCUCCUUCUCUGAG BCCACAGCUCCUUCUCUGAGTT B 3844 R-008398062-000Z 1719 965CAGUUCGCCUUCACUAUGG B CAGUUCGCCUUCACUAUGGTT B 3846 R-008398062-000Z 1719965 CAGUUCGCCUUCACUAUGG CCAUAGUGAAGGCGAACUGUU 3847 R-008398065-000A 813966 AAGCUUCCAGACACGCUAU AUAGCGUGUCUGGAAGCUUUU 3849 R-008398065-000A 813966 AAGCUUCCAGACACGCUAU B AAGCUUCCAGACACGCUAUTT B 3848 R-008398068-000B2289 967 UUUCAGUUGAGCUGACCAG B UUUCAGUUGAGCUGACCAGTT B 3850R-008398068-000B 2289 967 UUUCAGUUGAGCUGACCAG CUGGUCAGCUCAACUGAAAUU 3851R-008398071-000H 377 968 UCUGGUGCCACUACCACAG B UCUGGUGCCACUACCACAGTT B3852 R-008398071-000H 377 968 UCUGGUGCCACUACCACAG CUGUGGUAGUGGCACCAGAUU3853 R-008398074-000J 826 969 CGCUAUCAUGCGUUCUCCU AGGAGAACGCAUGAUAGCGUU3855 R-008398074-000J 826 969 CGCUAUCAUGCGUUCUCCU BCGCUAUCAUGCGUUCUCCUTT B 3854 R-008398077-000K 1634 970GACAGGGAAGACAUCACUG CAGUGAUGUCUUCCCUGUCUU 3857 R-008398077-000K 1634 970GACAGGGAAGACAUCACUG B GACAGGGAAGACAUCACUGTT B 3856 R-008398080-000S 1208971 AUCAUACUGGCUAGUGGUG B AUCAUACUGGCUAGUGGUGTT B 3858 R-008398080-000S1208 971 AUCAUACUGGCUAGUGGUG CACCACUAGCCAGUAUGAUUU 3859 R-008398083-000T1628 972 GCUGGUGACAGGGAAGACA UGUCUUCCCUGUCACCAGCUU 3861 R-008398083-000T1628 972 GCUGGUGACAGGGAAGACA B GCUGGUGACAGGGAAGACATT B 3860R-008398086-000U 2003 973 AUCCUAGCUCGGGAUGUUC GAACAUCCCGAGCUAGGAUUU 3863R-008398086-000U 2003 973 AUCCUAGCUCGGGAUGUUC B AUCCUAGCUCGGGAUGUUCTT B3862 R-008398089-000V 452 974 GUCCUGUAUGAGUGGGAAC BGUCCUGUAUGAGUGGGAACTT B 3864 R-008398089-000V 452 974GUCCUGUAUGAGUGGGAAC GUUCCCACUCAUACAGGACUU 3865 R-008398092-000B 2543 175GCCCAGGACCUCAUGGAUG CAUCCAUGAGGUCCUGGGCUU 3867 R-008398092-000B 2543 175GCCCAGGACCUCAUGGAUG B GCCCAGGACCUCAUGGAUGTT B 3866 R-008398095-000C 3081975 UGGGAUAUGUAUGGGUAGG CCUACCCAUACAUAUCCCAUU 3869 R-008398095-000C 3081975 UGGGAUAUGUAUGGGUAGG B UGGGAUAUGUAUGGGUAGGTT B 3868 R-008398098-000D2354 976 CUUGGACUUGAUAUUGGUG B CUUGGACUUGAUAUUGGUGTT B 3870R-008398098-000D 2354 976 CUUGGACUUGAUAUUGGUG CACCAAUAUCAAGUCCAAGUU 3871R-008398101-000W 1822 977 CCUUUGUCCCGCAAAUCAU B CCUUUGUCCCGCAAAUCAUTT B3872 R-008398101-000W 1822 977 CCUUUGUCCCGCAAAUCAU AUGAUUUGCGGGACAAAGGUU3873 R-008398107-000Y 1299 978 UGAAGGUGCUAUCUGUCUG CAGACAGAUAGCACCUUCAUU3875 R-008398107-000Y 1299 978 UGAAGGUGCUAUCUGUCUG BUGAAGGUGCUAUCUGUCUGTT B 3874 R-008398110-000E 486 979CCUUCACUCAAGAACAAGU B CCUUCACUCAAGAACAAGUTT B 3876 R-008398110-000E 486979 CCUUCACUCAAGAACAAGU ACUUGUUCUUGAGUGAAGGUU 3877 R-008398116-000G 1463980 GAAGGUCUCCUUGGGACUC B GAAGGUCUCCUUGGGACUCTT B 3878 R-008398116-000G1463 980 GAAGGUCUCCUUGGGACUC GAGUCCCAAGGAGACCUUCUU 3879 R-008398119-000H2280 981 AGAAACGGCUUUCAGUUGA B AGAAACGGCUUUCAGUUGATT B 3880R-008398119-000H 2280 981 AGAAACGGCUUUCAGUUGA UCAACUGAAAGCCGUUUCUUU 3881R-008398122-000P 1907 982 ACCCAGCGCCGUACGUCCA B ACCCAGCGCCGUACGUCCATT B3882 R-008398122-000P 1907 982 ACCCAGCGCCGUACGUCCA UGGACGUACGGCGCUGGGUUU3883 R-008398125-000R 923 983 CAUAACCUUUCCCAUCAUC BCAUAACCUUUCCCAUCAUCTT B 3884 R-008398125-000R 923 983CAUAACCUUUCCCAUCAUC GAUGAUGGGAAAGGUUAUGUU 3885 R-008398128-000S 1979 984GAAGGUUGUACCGGAGCCC B GAAGGUUGUACCGGAGCCCTT B 3886 R-008398128-000S 1979984 GAAGGUUGUACCGGAGCCC GGGCUCCGGUACAACCUUCUU 3887 R-008398131-000Y 1827985 GUCCCGCAAAUCAUGCACC B GUCCCGCAAAUCAUGCACCTT B 3888 R-008398131-000Y1827 985 GUCCCGCAAAUCAUGCACC GGUGCAUGAUUUGCGGGACUU 3889 R-008398134-000Z1201 986 CAAGCUCAUCAUACUGGCU AGCCAGUAUGAUGAGCUUGUU 3891 R-008398134-000Z1201 986 CAAGCUCAUCAUACUGGCU B CAAGCUCAUCAUACUGGCUTT B 3890R-008398137-000A 1913 987 CGCCGUACGUCCAUGGGUG B CGCCGUACGUCCAUGGGUGTT B3892 R-008398137-000A 1913 987 CGCCGUACGUCCAUGGGUG CACCCAUGGACGUACGGCGUU3893 R-008398140-000G 2191 988 AGAGUUACUUCACUCUAGG CCUAGAGUGAAGUAACUCUUU3895 R-008398140-000G 2191 988 AGAGUUACUUCACUCUAGG BAGAGUUACUUCACUCUAGGTT B 3894 R-008398143-000H 295 989GUUGGACAUGGCCAUGGAA UUCCAUGGCCAUGUCCAACUU 3897 R-008398143-000H 295 989GUUGGACAUGGCCAUGGAA B GUUGGACAUGGCCAUGGAATT B 3896 R-008398146-000J 1149990 UGGCUAUUACGACAGACUG B UGGCUAUUACGACAGACUGTT B 3898 R-008398146-000J1149 990 UGGCUAUUACGACAGACUG CAGUCUGUCGUAAUAGCCAUU 3899 R-008398149-000K533 991 ACUCGAGCUCAGAGGGUAC B ACUCGAGCUCAGAGGGUACTT B 3900R-008398149-000K 533 991 ACUCGAGCUCAGAGGGUAC GUACCCUCUGAGCUCGAGUUU 3901R-008398152-000S 604 992 ACAGUUUGAUGCUGCUCAU B ACAGUUUGAUGCUGCUCAUTT B3902 R-008398152-000S 604 992 ACAGUUUGAUGCUGCUCAU AUGAGCAGCAUCAAACUGUUU3903 R-008398155-000T 766 993 GGUGGUUAAUAAGGCUGCA BGGUGGUUAAUAAGGCUGCATT B 3904 R-008398155-000T 766 993GGUGGUUAAUAAGGCUGCA UGCAGCCUUAUUAACCACCUU 3905 R-008398158-000U 1823 994CUUUGUCCCGCAAAUCAUG B CUUUGUCCCGCAAAUCAUGTT B 3906 R-008398158-000U 1823994 CUUUGUCCCGCAAAUCAUG CAUGAUUUGCGGGACAAAGUU 3907 R-008398161-000A 2048995 AAUACCAUUCCAUUGUUUG CAAACAAUGGAAUGGUAUUUU 3909 R-008398161-000A 2048995 AAUACCAUUCCAUUGUUUG B AAUACCAUUCCAUUGUUUGTT B 3908 R-008398164-000B714 996 CCACACGUGCAAUCCCUGA B CCACACGUGCAAUCCCUGATT B 3910R-008398164-000B 714 996 CCACACGUGCAAUCCCUGA UCAGGGAUUGCACGUGUGGUU 3911R-008398167-000C 2439 997 AUGGCCAGGAUGCCUUGGG CCCAAGGCAUCCUGGCCAUUU 3913R-008398167-000C 2439 997 AUGGCCAGGAUGCCUUGGG B AUGGCCAGGAUGCCUUGGGTT B3912 R-008398170-000J 1903 998 GGAUACCCAGCGCCGUACG BGGAUACCCAGCGCCGUACGTT B 3914 R-008398170-000J 1903 998GGAUACCCAGCGCCGUACG CGUACGGCGCUGGGUAUCCUU 3915 R-008398173-000K 2395 999UCGCCAGGAUGAUCCUAGC GCUAGGAUCAUCCUGGCGAUU 3917 R-008398173-000K 2395 999UCGCCAGGAUGAUCCUAGC B UCGCCAGGAUGAUCCUAGCTT B 3916 R-008398176-000L 7891000 UGGUCCAUCAGCUUUCUAA UUAGAAAGCUGAUGGACCAUU 3919 R-008398176-000L 7891000 UGGUCCAUCAGCUUUCUAA B UGGUCCAUCAGCUUUCUAATT B 3918 R-008398179-000M3085 1001 AUAUGUAUGGGUAGGGUAA UUACCCUACCCAUACAUAUUU 3921R-008398179-000M 3085 1001 AUAUGUAUGGGUAGGGUAA B AUAUGUAUGGGUAGGGUAATT B3920 R-008398182-000U 1710 1002 CCCAGAAUGCAGUUCGCCU BCCCAGAAUGCAGUUCGCCUTT B 3922 R-008398182-000U 1710 1002CCCAGAAUGCAGUUCGCCU AGGCGAACUGCAUUCUGGGUU 3923 R-008398185-000V 13361003 UAUUGUAGAAGCUGGUGGA B UAUUGUAGAAGCUGGUGGATT B 3924 R-008398185-000V1336 1003 UAUUGUAGAAGCUGGUGGA UCCACCAGCUUCUACAAUAUU 3925R-008398188-000W 3089 1004 GUAUGGGUAGGGUAAAUCA UGAUUUACCCUACCCAUACUU3927 R-008398188-000W 3089 1004 GUAUGGGUAGGGUAAAUCA BGUAUGGGUAGGGUAAAUCATT B 3926 R-008398191-000C 2351 1005GAUCUUGGACUUGAUAUUG B GAUCUUGGACUUGAUAUUGTT B 3928 R-008398191-000C 23511005 GAUCUUGGACUUGAUAUUG CAAUAUCAAGUCCAAGAUCUU 3929 R-008398194-000D 7161006 ACACGUGCAAUCCCUGAAC B ACACGUGCAAUCCCUGAACTT B 3930 R-008398194-000D716 1006 ACACGUGCAAUCCCUGAAC GUUCAGGGAUUGCACGUGUUU 3931 R-008398197-000E1911 1007 AGCGCCGUACGUCCAUGGG B AGCGCCGUACGUCCAUGGGTT B 3932R-008398197-000E 1911 1007 AGCGCCGUACGUCCAUGGG CCCAUGGACGUACGGCGCUUU3933 R-008398200-000X 1985 1008 UGUACCGGAGCCCUUCACAUGUGAAGGGCUCCGGUACAUU 3935 R-008398200-000X 1985 1008UGUACCGGAGCCCUUCACA B UGUACCGGAGCCCUUCACATT B 3934 R-008398203-000Y 25161009 GUUGAUGGGCUGCCAGAUC B GUUGAUGGGCUGCCAGAUCTT B 3936 R-008398203-000Y2516 1009 GUUGAUGGGCUGCCAGAUC GAUCUGGCAGCCCAUCAACUU 3937R-008398206-000Z 1762 1010 ACACCCACCAUCCCACUGG CCAGUGGGAUGGUGGGUGUUU3939 R-008398206-000Z 1762 1010 ACACCCACCAUCCCACUGG BACACCCACCAUCCCACUGGTT B 3938 R-008398209-000A 1156 1011UACGACAGACUGCCUUCAA B UACGACAGACUGCCUUCAATT B 3940 R-008398209-000A 11561011 UACGACAGACUGCCUUCAA UUGAAGGCAGUCUGUCGUAUU 3941 R-008398212-000G1887 1012 UUGUUCGUGCACAUCAGGA B UUGUUCGUGCACAUCAGGATT B 3942R-008398212-000G 1887 1012 UUGUUCGUGCACAUCAGGA UCCUGAUGUGCACGAACAAUU3943 R-008398215-000H 1833 1013 CAAAUCAUGCACCUUUGCGCGCAAAGGUGCAUGAUUUGUU 3945 R-008398215-000H 1833 1013CAAAUCAUGCACCUUUGCG B CAAAUCAUGCACCUUUGCGTT B 3944 R-008398218-000J 9671014 GUCUGGAGGCAUUCCUGCC GGCAGGAAUGCCUCCAGACUU 3947 R-008398218-000J 9671014 GUCUGGAGGCAUUCCUGCC B GUCUGGAGGCAUUCCUGCCTT B 3946 R-008398221-000R1730 1015 CACUAUGGACUACCAGUUG CAACUGGUAGUCCAUAGUGUU 3949R-008398221-000R 1730 1015 CACUAUGGACUACCAGUUG B CACUAUGGACUACCAGUUGTT B3948 R-008398224-000S 829 1016 UAUCAUGCGUUCUCCUCAG CUGAGGAGAACGCAUGAUAUU3951 R-008398224-000S 829 1016 UAUCAUGCGUUCUCCUCAG BUAUCAUGCGUUCUCCUCAGTT B 3950 R-008398227-000T 890 1017GUAGAAACAGCUCGUUGUA B GUAGAAACAGCUCGUUGUATT B 3952 R-008398227-000T 8901017 GUAGAAACAGCUCGUUGUA UACAACGAGCUGUUUCUACUU 3953 R-008398230-000Z2181 1018 CUCCUCUGACAGAGUUACU AGUAACUCUGUCAGAGGAGUU 3955R-008398230-000Z 2181 1018 CUCCUCUGACAGAGUUACU B CUCCUCUGACAGAGUUACUTT B3954 R-008398233-000A 2131 1019 UGCUCAGGACAAGGAAGCU BUGCUCAGGACAAGGAAGCUTT B 3956 R-008398233-000A 2131 1019UGCUCAGGACAAGGAAGCU AGCUUCCUUGUCCUGAGCAUU 3957 R-008398236-000B 15861020 CAAGUGGGUGGUAUAGAGG B CAAGUGGGUGGUAUAGAGGTT B 3958 R-008398236-000B1586 1020 CAAGUGGGUGGUAUAGAGG CCUCUAUACCACCCACUUGUU 3959R-008398239-000C 765 1021 UGGUGGUUAAUAAGGCUGC B UGGUGGUUAAUAAGGCUGCTT B3960 R-008398239-000C 765 1021 UGGUGGUUAAUAAGGCUGC GCAGCCUUAUUAACCACCAUU3961 R-008398242-000J 1369 1022 ACUUCACCUGACAGAUCCA BACUUCACCUGACAGAUCCATT B 3962 R-008398242-000J 1369 1022ACUUCACCUGACAGAUCCA UGGAUCUGUCAGGUGAAGUUU 3963 R-008398245-000K 17241023 CGCCUUCACUAUGGACUAC GUAGUCCAUAGUGAAGGCGUU 3965 R-008398245-000K1724 1023 CGCCUUCACUAUGGACUAC B CGCCUUCACUAUGGACUACTT B 3964R-008398248-000L 834 1024 UGCGUUCUCCUCAGAUGGU ACCAUCUGAGGAGAACGCAUU 3967R-008398248-000L 834 1024 UGCGUUCUCCUCAGAUGGU B UGCGUUCUCCUCAGAUGGUTT B3966 R-008398251-000T 1983 1025 GUUGUACCGGAGCCCUUCA BGUUGUACCGGAGCCCUUCATT B 3968 R-008398251-000T 1983 1025GUUGUACCGGAGCCCUUCA UGAAGGGCUCCGGUACAACUU 3969 R-008398254-000U 16881026 CGACACCAAGAAGCAGAGA B CGACACCAAGAAGCAGAGATT B 3970 R-008398254-000U1688 1026 CGACACCAAGAAGCAGAGA UCUCUGCUUCUUGGUGUCGUU 3971R-008398257-000V 1004 1027 UCACCAGUGGAUUCUGUGU B UCACCAGUGGAUUCUGUGUTT B3972 R-008398257-000V 1004 1027 UCACCAGUGGAUUCUGUGUACACAGAAUCCACUGGUGAUU 3973 R-008398260-000B 1631 1028GGUGACAGGGAAGACAUCA UGAUGUCUUCCCUGUCACCUU 3975 R-008398260-000B 16311028 GGUGACAGGGAAGACAUCA B GGUGACAGGGAAGACAUCATT B 3974 R-008398263-000C1319 1029 UCUAGUAAUAAGCCGGCUA UAGCCGGCUUAUUACUAGAUU 3977R-008398263-000C 1319 1029 UCUAGUAAUAAGCCGGCUA B UCUAGUAAUAAGCCGGCUATT B3976 R-008398266-000D 767 1030 GUGGUUAAUAAGGCUGCAG BGUGGUUAAUAAGGCUGCAGTT B 3978 R-008398266-000D 767 1030GUGGUUAAUAAGGCUGCAG CUGCAGCCUUAUUAACCACUU 3979 R-008398269-000E 841 1031UCCUCAGAUGGUGUCUGCU AGCAGACACCAUCUGAGGAUU 3981 R-008398269-000E 841 1031UCCUCAGAUGGUGUCUGCU B UCCUCAGAUGGUGUCUGCUTT B 3980 R-008398272-000L 5161032 AUGGACAGUAUGCAAUGAC B AUGGACAGUAUGCAAUGACTT B 3982 R-008398272-000L516 1032 AUGGACAGUAUGCAAUGAC GUCAUUGCAUACUGUCCAUUU 3983 R-008398275-000M1848 1033 UGCGUGAGCAGGGUGCCAU AUGGCACCCUGCUCACGCAUU 3985R-008398275-000M 1848 1033 UGCGUGAGCAGGGUGCCAU B UGCGUGAGCAGGGUGCCAUTT B3984 R-008398278-000N 2202 1034 ACUCUAGGAAUGAAGGUGU BACUCUAGGAAUGAAGGUGUTT B 3986 R-008398278-000N 2202 1034ACUCUAGGAAUGAAGGUGU ACACCUUCAUUCCUAGAGUUU 3987 R-008398281-000V 571 1035GACAUUAGAUGAGGGCAUG B GACAUUAGAUGAGGGCAUGTT B 3988 R-008398281-000V 5711035 GACAUUAGAUGAGGGCAUG CAUGCCCUCAUCUAAUGUCUU 3989 R-008398284-000W1629 1036 CUGGUGACAGGGAAGACAU B CUGGUGACAGGGAAGACAUTT B 3990R-008398284-000W 1629 1036 CUGGUGACAGGGAAGACAU AUGUCUUCCCUGUCACCAGUU3991 R-008398287-000X 1806 1037 UGAUUCGAAAUCUUGCCCU BUGAUUCGAAAUCUUGCCCUTT B 3992 R-008398287-000X 1806 1037UGAUUCGAAAUCUUGCCCU AGGGCAAGAUUUCGAAUCAUU 3993 R-008398290-000D 17561038 GCUCUUACACCCACCAUCC B GCUCUUACACCCACCAUCCTT B 3994 R-008398290-000D1756 1038 GCUCUUACACCCACCAUCC GGAUGGUGGGUGUAAGAGCUU 3995R-008398293-000E 1619 1039 GUCCUUCGGGCUGGUGACA UGUCACCAGCCCGAAGGACUU3997 R-008398293-000E 1619 1039 GUCCUUCGGGCUGGUGACA BGUCCUUCGGGCUGGUGACATT B 3996 R-008398296-000F 1610 1040GUGCGUACUGUCCUUCGGG B GUGCGUACUGUCCUUCGGGTT B 3998 R-008398296-000F 16101040 GUGCGUACUGUCCUUCGGG CCCGAAGGACAGUACGCACUU 3999 R-008398299-000G2500 1041 UGGUGCUGACUAUCCAGUU B UGGUGCUGACUAUCCAGUUTT B 4000R-008398299-000G 2500 1041 UGGUGCUGACUAUCCAGUU AACUGGAUAGUCAGCACCAUU4001 R-008398302-000Z 2156 1042 GCUAUUGAAGCUGAGGGAG BGCUAUUGAAGCUGAGGGAGTT B 4002 R-008398302-000Z 2156 1042GCUAUUGAAGCUGAGGGAG CUCCCUCAGCUUCAAUAGCUU 4003 R-008398305-000A 11891043 CAACCAAGAAAGCAAGCUC GAGCUUGCUUUCUUGGUUGUU 4005 R-008398305-000A1189 1043 CAACCAAGAAAGCAAGCUC B CAACCAAGAAAGCAAGCUCTT B 4004R-008398308-000B 2066 1044 GUGCAGCUGCUUUAUUCUC GAGAAUAAAGCAGCUGCACUU4007 R-008398308-000B 2066 1044 GUGCAGCUGCUUUAUUCUC BGUGCAGCUGCUUUAUUCUCTT B 4006 R-008398311-000H 1307 1045CUAUCUGUCUGCUCUAGUA UACUAGAGCAGACAGAUAGUU 4009 R-008398311-000H 13071045 CUAUCUGUCUGCUCUAGUA B CUAUCUGUCUGCUCUAGUATT B 4008 R-008398314-000J1448 1046 AAACAGGAAGGGAUGGAAG CUUCCAUCCCUUCCUGUUUUU 4011R-008398314-000J 1448 1046 AAACAGGAAGGGAUGGAAG B AAACAGGAAGGGAUGGAAGTT B4010 R-008398317-000K 1213 1047 ACUGGCUAGUGGUGGACCC BACUGGCUAGUGGUGGACCCTT B 4012 R-008398317-000K 1213 1047ACUGGCUAGUGGUGGACCC GGGUCCACCACUAGCCAGUUU 4013 R-008398320-000S 21191048 CCUCUGUGAACUUGCUCAG B CCUCUGUGAACUUGCUCAGTT B 4014 R-008398320-000S2119 1048 CCUCUGUGAACUUGCUCAG CUGAGCAAGUUCACAGAGGUU 4015R-008398323-000T 2546 72 CAGGACCUCAUGGAUGGGC B CAGGACCUCAUGGAUGGGCTT B4016 R-008398323-000T 2546 72 CAGGACCUCAUGGAUGGGC GCCCAUCCAUGAGGUCCUGUU4017 R-008398326-000U 889 1049 UGUAGAAACAGCUCGUUGU BUGUAGAAACAGCUCGUUGUTT B 4018 R-008398326-000U 889 1049UGUAGAAACAGCUCGUUGU ACAACGAGCUGUUUCUACAUU 4019 R-008398329-000V 13761050 CUGACAGAUCCAAGUCAAC B CUGACAGAUCCAAGUCAACTT B 4020 R-008398329-000V1376 1050 CUGACAGAUCCAAGUCAAC GUUGACUUGGAUCUGUCAGUU 4021R-008398332-000B 427 1051 GGAAGAGGAUGUGGAUACC GGUAUCCACAUCCUCUUCCUU 4023R-008398332-000B 427 1051 GGAAGAGGAUGUGGAUACC B GGAAGAGGAUGUGGAUACCTT B4022 R-008398335-000C 649 1052 ACCAUCACAGAUGCUGAAA BACCAUCACAGAUGCUGAAATT B 4024 R-008398335-000C 649 1052ACCAUCACAGAUGCUGAAA UUUCAGCAUCUGUGAUGGUUU 4025 R-008398338-000D 19151053 CCGUACGUCCAUGGGUGGG B CCGUACGUCCAUGGGUGGGTT B 4026 R-008398338-000D1915 1053 CCGUACGUCCAUGGGUGGG CCCACCCAUGGACGUACGGUU 4027R-008398341-000K 2053 1054 CAUUCCAUUGUUUGUGCAG B CAUUCCAUUGUUUGUGCAGTT B4028 R-008398341-000K 2053 1054 CAUUCCAUUGUUUGUGCAGCUGCACAAACAAUGGAAUGUU 4029 R-008398344-000L 2000 24 CACAUCCUAGCUCGGGAUGCAUCCCGAGCUAGGAUGUGUU 4031 R-008398344-000L 2000 24 CACAUCCUAGCUCGGGAUGB CACAUCCUAGCUCGGGAUGTT B 4030 R-008398347-000M 2568 1055CUCCAGGUGACAGCAAUCA B CUCCAGGUGACAGCAAUCATT B 4032 R-008398347-000M 25681055 CUCCAGGUGACAGCAAUCA UGAUUGCUGUCACCUGGAGUU 4033 R-008398350-000U1739 1056 CUACCAGUUGUGGUUAAGC GCUUAACCACAACUGGUAGUU 4035R-008398350-000U 1739 1056 CUACCAGUUGUGGUUAAGC B CUACCAGUUGUGGUUAAGCTT B4034 R-008398353-000V 1746 1057 UUGUGGUUAAGCUCUUACA BUUGUGGUUAAGCUCUUACATT B 4036 R-008398353-000V 1746 1057UUGUGGUUAAGCUCUUACA UGUAAGAGCUUAACCACAAUU 4037 R-008398356-000W 13211058 UAGUAAUAAGCCGGCUAUU AAUAGCCGGCUUAUUACUAUU 4039 R-008398356-000W1321 1058 UAGUAAUAAGCCGGCUAUU B UAGUAAUAAGCCGGCUAUUTT B 4038R-008398359-000X 482 1059 CAGUCCUUCACUCAAGAAC GUUCUUGAGUGAAGGACUGUU 4041R-008398359-000X 482 1059 CAGUCCUUCACUCAAGAAC B CAGUCCUUCACUCAAGAACTT B4040 R-008398362-000D 280 1060 AGCUGAUUUGAUGGAGUUG CAACUCCAUCAAAUCAGCUUU4043 R-008398362-000D 280 1060 AGCUGAUUUGAUGGAGUUG BAGCUGAUUUGAUGGAGUUGTT B 4042 R-008398365-000E 1465 1061AGGUCUCCUUGGGACUCUU B AGGUCUCCUUGGGACUCUUTT B 4044 R-008398365-000E 14651061 AGGUCUCCUUGGGACUCUU AAGAGUCCCAAGGAGACCUUU 4045 R-008398368-000F1731 1062 ACUAUGGACUACCAGUUGU ACAACUGGUAGUCCAUAGUUU 4047R-008398368-000F 1731 1062 ACUAUGGACUACCAGUUGU B ACUAUGGACUACCAGUUGUTT B4046 R-008398371-000M 1937 1063 CAGCAGCAAUUUGUGGAGG BCAGCAGCAAUUUGUGGAGGTT B 4048 R-008398371-000M 1937 1063CAGCAGCAAUUUGUGGAGG CCUCCACAAAUUGCUGCUGUU 4049 R-008398374-000N 18921064 CGUGCACAUCAGGAUACCC B CGUGCACAUCAGGAUACCCTT B 4050 R-008398374-000N1892 1064 CGUGCACAUCAGGAUACCC GGGUAUCCUGAUGUGCACGUU 4051R-008398377-000P 836 1065 CGUUCUCCUCAGAUGGUGU B CGUUCUCCUCAGAUGGUGUTT B4052 R-008398377-000P 836 1065 CGUUCUCCUCAGAUGGUGU ACACCAUCUGAGGAGAACGUU4053 R-008398380-000W 521 1066 CAGUAUGCAAUGACUCGAG CUCGAGUCAUUGCAUACUGUU4055 R-008398380-000W 521 1066 CAGUAUGCAAUGACUCGAG BCAGUAUGCAAUGACUCGAGTT B 4054 R-008398383-000X 1595 1067GGUAUAGAGGCUCUUGUGC GCACAAGAGCCUCUAUACCUU 4057 R-008398383-000X 15951067 GGUAUAGAGGCUCUUGUGC B GGUAUAGAGGCUCUUGUGCTT B 4056 R-008398386-000Y2511 1068 AUCCAGUUGAUGGGCUGCC GGCAGCCCAUCAACUGGAUUU 4059R-008398386-000Y 2511 1068 AUCCAGUUGAUGGGCUGCC B AUCCAGUUGAUGGGCUGCCTT B4058 R-008398389-000Z 1583 1069 UGCCAAGUGGGUGGUAUAG BUGCCAAGUGGGUGGUAUAGTT B 4060 R-008398389-000Z 1583 1069UGCCAAGUGGGUGGUAUAG CUAUACCACCCACUUGGCAUU 4061 R-008398392-000F 18971070 ACAUCAGGAUACCCAGCGC GCGCUGGGUAUCCUGAUGUUU 4063 R-008398392-000F1897 1070 ACAUCAGGAUACCCAGCGC B ACAUCAGGAUACCCAGCGCTT B 4062R-008398395-000G 956 1071 GCCAUCUUUAAGUCUGGAG CUCCAGACUUAAAGAUGGCUU 4065R-008398395-000G 956 1071 GCCAUCUUUAAGUCUGGAG B GCCAUCUUUAAGUCUGGAGTT B4064 R-008398398-000H 926 1072 AACCUUUCCCAUCAUCGUG BAACCUUUCCCAUCAUCGUGTT B 4066 R-008398398-000H 926 1072AACCUUUCCCAUCAUCGUG CACGAUGAUGGGAAAGGUUUU 4067 R-008398401-000A 18741073 CUAGUUCAGUUGCUUGUUC GAACAAGCAACUGAACUAGUU 4069 R-008398401-000A1874 1073 CUAGUUCAGUUGCUUGUUC B CUAGUUCAGUUGCUUGUUCTT B 4068R-008398404-000B 488 1074 UUCACUCAAGAACAAGUAG B UUCACUCAAGAACAAGUAGTT B4070 R-008398404-000B 488 1074 UUCACUCAAGAACAAGUAG CUACUUGUUCUUGAGUGAAUU4071 R-008398407-000C 1602 21 AGGCUCUUGUGCGUACUGU BAGGCUCUUGUGCGUACUGUTT B 4072 R-008398407-000C 1602 21AGGCUCUUGUGCGUACUGU ACAGUACGCACAAGAGCCUUU 4073 R-008398410-000J 16951075 AAGAAGCAGAGAUGGCCCA UGGGCCAUCUCUGCUUCUUUU 4075 R-008398410-000J1695 1075 AAGAAGCAGAGAUGGCCCA B AAGAAGCAGAGAUGGCCCATT B 4074R-008398413-000K 2182 1076 UCCUCUGACAGAGUUACUU B UCCUCUGACAGAGUUACUUTT B4076 R-008398413-000K 2182 1076 UCCUCUGACAGAGUUACUUAAGUAACUCUGUCAGAGGAUU 4077 R-008398416-000L 2029 1077AAUUGUUAUCAGAGGACUA UAGUCCUCUGAUAACAAUUUU 4079 R-008398416-000L 20291077 AAUUGUUAUCAGAGGACUA B AAUUGUUAUCAGAGGACUATT B 4078 R-008398419-000M479 1078 UCUCAGUCCUUCACUCAAG B UCUCAGUCCUUCACUCAAGTT B 4080R-008398419-000M 479 1078 UCUCAGUCCUUCACUCAAG CUUGAGUGAAGGACUGAGAUU 4081R-008398422-000U 818 1079 UCCAGACACGCUAUCAUGC GCAUGAUAGCGUGUCUGGAUU 4083R-008398422-000U 818 1079 UCCAGACACGCUAUCAUGC B UCCAGACACGCUAUCAUGCTT B4082 R-008398425-000V 625 1080 CACUAAUGUCCAGCGUUUG BCACUAAUGUCCAGCGUUUGTT B 4084 R-008398425-000V 625 1080CACUAAUGUCCAGCGUUUG CAAACGCUGGACAUUAGUGUU 4085 R-008398428-000W 31721081 UUGUAACCUGCUGUGAUAC B UUGUAACCUGCUGUGAUACTT B 4086 R-008398428-000W3172 1081 UUGUAACCUGCUGUGAUAC GUAUCACAGCAGGUUACAAUU 4087R-008398431-000C 1490 1082 CUUCUGGGUUCAGAUGAUA B CUUCUGGGUUCAGAUGAUATT B4088 R-008398431-000C 1490 1082 CUUCUGGGUUCAGAUGAUAUAUCAUCUGAACCCAGAAGUU 4089 R-008398434-000D 1914 1083GCCGUACGUCCAUGGGUGG B GCCGUACGUCCAUGGGUGGTT B 4090 R-008398434-000D 19141083 GCCGUACGUCCAUGGGUGG CCACCCAUGGACGUACGGCUU 4091 R-008398437-000E 882100 CAAAUGAUGUAGAAACAGC GCUGUUUCUACAUCAUUUGUU 4093 R-008398437-000E 882100 CAAAUGAUGUAGAAACAGC B CAAAUGAUGUAGAAACAGCTT B 4092 R-008398440-000L1974 1084 UAGUUGAAGGUUGUACCGG CCGGUACAACCUUCAACUAUU 4095R-008398440-000L 1974 1084 UAGUUGAAGGUUGUACCGG B UAGUUGAAGGUUGUACCGGTT B4094 R-008398443-000M 2258 1085 GAGGACAAGCCACAAGAUU BGAGGACAAGCCACAAGAUUTT B 4096 R-008398443-000M 2258 1085GAGGACAAGCCACAAGAUU AAUCUUGUGGCUUGUCCUCUU 4097 R-008398446-000N 21701086 GGGAGCCACAGCUCCUCUG CAGAGGAGCUGUGGCUCCCUU 4099 R-008398446-000N2170 1086 GGGAGCCACAGCUCCUCUG B GGGAGCCACAGCUCCUCUGTT B 4098R-008398449-000P 1370 1087 CUUCACCUGACAGAUCCAA B CUUCACCUGACAGAUCCAATT B4100 R-008398449-000P 1370 1087 CUUCACCUGACAGAUCCAAUUGGAUCUGUCAGGUGAAGUU 4101 R-008398452-000W 1429 1088UCUUUCAGAUGCUGCAACU B UCUUUCAGAUGCUGCAACUTT B 4102 R-008398452-000W 14291088 UCUUUCAGAUGCUGCAACU AGUUGCAGCAUCUGAAAGAUU 4103 R-008398455-000X3173 1089 UGUAACCUGCUGUGAUACG B UGUAACCUGCUGUGAUACGTT B 4104R-008398455-000X 3173 1089 UGUAACCUGCUGUGAUACG CGUAUCACAGCAGGUUACAUU4105 R-008398458-000Y 444 1090 CCUCCCAAGUCCUGUAUGA BCCUCCCAAGUCCUGUAUGATT B 4106 R-008398458-000Y 444 1090CCUCCCAAGUCCUGUAUGA UCAUACAGGACUUGGGAGGUU 4107 R-008398461-000E 10811091 GGCAGUGCGUUUAGCUGGU B GGCAGUGCGUUUAGCUGGUTT B 4108 R-008398461-000E1081 1091 GGCAGUGCGUUUAGCUGGU ACCAGCUAAACGCACUGCCUU 4109R-008398464-000F 1318 1092 CUCUAGUAAUAAGCCGGCU AGCCGGCUUAUUACUAGAGUU4111 R-008398464-000F 1318 1092 CUCUAGUAAUAAGCCGGCU BCUCUAGUAAUAAGCCGGCUTT B 4110 R-008398467-000G 329 1093GCUGUUAGUCACUGGCAGC B GCUGUUAGUCACUGGCAGCTT B 4112 R-008398467-000G 3291093 GCUGUUAGUCACUGGCAGC GCUGCCAGUGACUAACAGCUU 4113 R-008398470-000N1389 1094 GUCAACGUCUUGUUCAGAA UUCUGAACAAGACGUUGACUU 4115R-008398470-000N 1389 1094 GUCAACGUCUUGUUCAGAA B GUCAACGUCUUGUUCAGAATT B4114 R-008398473-000P 428 1095 GAAGAGGAUGUGGAUACCU AGGUAUCCACAUCCUCUUCUU4117 R-008398473-000P 428 1095 GAAGAGGAUGUGGAUACCU BGAAGAGGAUGUGGAUACCUTT B 4116 R-008398476-000R 3175 1096UAACCUGCUGUGAUACGAU AUCGUAUCACAGCAGGUUAUU 4119 R-008398476-000R 31751096 UAACCUGCUGUGAUACGAU B UAACCUGCUGUGAUACGAUTT B 4118 R-008398479-000S1422 114 UCAGGAAUCUUUCAGAUGC B UCAGGAAUCUUUCAGAUGCTT B 4120R-008398479-000S 1422 114 UCAGGAAUCUUUCAGAUGC GCAUCUGAAAGAUUCCUGAUU 4121R-008398482-000Y 1500 97 CAGAUGAUAUAAAUGUGGU ACCACAUUUAUAUCAUCUGUU 4123R-008398482-000Y 1500 97 CAGAUGAUAUAAAUGUGGU B CAGAUGAUAUAAAUGUGGUTT B4122 R-008398485-000Z 3117 1097 GUUAUUUGGAACCUUGUUU BGUUAUUUGGAACCUUGUUUTT B 4124 R-008398485-000Z 3117 1097GUUAUUUGGAACCUUGUUU AAACAAGGUUCCAAAUAACUU 4125 R-008398488-000A 20201098 UCACAACCGAAUUGUUAUC B UCACAACCGAAUUGUUAUCTT B 4126 R-008398488-000A2020 1098 UCACAACCGAAUUGUUAUC GAUAACAAUUCGGUUGUGAUU 4127R-008398491-000G 1625 1099 CGGGCUGGUGACAGGGAAG B CGGGCUGGUGACAGGGAAGTT B4128 R-008398491-000G 1625 1099 CGGGCUGGUGACAGGGAAGCUUCCCUGUCACCAGCCCGUU 4129 R-008398494-000H 2022 1100ACAACCGAAUUGUUAUCAG B ACAACCGAAUUGUUAUCAGTT B 4130 R-008398494-000H 20221100 ACAACCGAAUUGUUAUCAG CUGAUAACAAUUCGGUUGUUU 4131 R-008398497-000J 6241101 CCACUAAUGUCCAGCGUUU B CCACUAAUGUCCAGCGUUUTT B 4132 R-008398497-000J624 1101 CCACUAAUGUCCAGCGUUU AAACGCUGGACAUUAGUGGUU 4133 R-008398500-000B1648 1102 CACUGAGCCUGCCAUCUGU ACAGAUGGCAGGCUCAGUGUU 4135R-008398500-000B 1648 1102 CACUGAGCCUGCCAUCUGU B CACUGAGCCUGCCAUCUGUTT B4134 R-008398503-000C 790 1103 GGUCCAUCAGCUUUCUAAA BGGUCCAUCAGCUUUCUAAATT B 4136 R-008398503-000C 790 1103GGUCCAUCAGCUUUCUAAA UUUAGAAAGCUGAUGGACCUU 4137 R-008398506-000D 2122 59CUGUGAACUUGCUCAGGAC B CUGUGAACUUGCUCAGGACTT B 4138 R-008398506-000D 212259 CUGUGAACUUGCUCAGGAC GUCCUGAGCAAGUUCACAGUU 4139 R-008398509-000E 31601104 AUCCCAAAGUUGUUGUAAC B AUCCCAAAGUUGUUGUAACTT B 4140 R-008398509-000E3160 1104 AUCCCAAAGUUGUUGUAAC GUUACAACAACUUUGGGAUUU 4141R-008398512-000L 1251 1105 UGAGGACCUAUACUUACGA B UGAGGACCUAUACUUACGATT B4142 R-008398512-000L 1251 1105 UGAGGACCUAUACUUACGAUCGUAAGUAUAGGUCCUCAUU 4143 R-008398518-000N 2253 1106UGUCUGAGGACAAGCCACA UGUGGCUUGUCCUCAGACAUU 4145 R-008398518-000N 22531106 UGUCUGAGGACAAGCCACA B UGUCUGAGGACAAGCCACATT B 4144 R-008398521-000V2515 1107 AGUUGAUGGGCUGCCAGAU B AGUUGAUGGGCUGCCAGAUTT B 4146R-008398521-000V 2515 1107 AGUUGAUGGGCUGCCAGAU AUCUGGCAGCCCAUCAACUUU4147 R-008398524-000W 1680 1108 UGACCAGCCGACACCAAGA BUGACCAGCCGACACCAAGATT B 4148 R-008398524-000W 1680 1108UGACCAGCCGACACCAAGA UCUUGGUGUCGGCUGGUCAUU 4149 R-008398527-000X 21691109 AGGGAGCCACAGCUCCUCU B AGGGAGCCACAGCUCCUCUTT B 4150 R-008398527-000X2169 1109 AGGGAGCCACAGCUCCUCU AGAGGAGCUGUGGCUCCCUUU 4151R-008398530-000D 3165 1110 AAAGUUGUUGUAACCUGCU AGCAGGUUACAACAACUUUUU4153 R-008398530-000D 3165 1110 AAAGUUGUUGUAACCUGCU BAAAGUUGUUGUAACCUGCUTT B 4152 R-008398533-000E 780 1111CUGCAGUUAUGGUCCAUCA UGAUGGACCAUAACUGCAGUU 4155 R-008398533-000E 780 1111CUGCAGUUAUGGUCCAUCA B CUGCAGUUAUGGUCCAUCATT B 4154 R-008398536-000F 19781112 UGAAGGUUGUACCGGAGCC B UGAAGGUUGUACCGGAGCCTT B 4156 R-008398536-000F1978 1112 UGAAGGUUGUACCGGAGCC GGCUCCGGUACAACCUUCAUU 4157R-008398539-000G 661 122 GCUGAAACAUGCAGUUGUA B GCUGAAACAUGCAGUUGUATT B4158 R-008398539-000G 661 122 GCUGAAACAUGCAGUUGUA UACAACUGCAUGUUUCAGCUU4159 R-008398542-000N 1354 181 AAUGCAAGCUUUAGGACUU BAAUGCAAGCUUUAGGACUUTT B 4160 R-008398542-000N 1354 181AAUGCAAGCUUUAGGACUU AAGUCCUAAAGCUUGCAUUUU 4161 R-008398545-000P 563 1113UUCCCUGAGACAUUAGAUG B UUCCCUGAGACAUUAGAUGTT B 4162 R-008398545-000P 5631113 UUCCCUGAGACAUUAGAUG CAUCUAAUGUCUCAGGGAAUU 4163 R-008398548-000R1622 1114 CUUCGGGCUGGUGACAGGG B CUUCGGGCUGGUGACAGGGTT B 4164R-008398548-000R 1622 1114 CUUCGGGCUGGUGACAGGG CCCUGUCACCAGCCCGAAGUU4165 R-008398551-000X 2295 1115 UUGAGCUGACCAGCUCUCUAGAGAGCUGGUCAGCUCAAUU 4167 R-008398551-000X 2295 1115UUGAGCUGACCAGCUCUCU B UUGAGCUGACCAGCUCUCUTT B 4166 R-008398554-000Y 21261116 GAACUUGCUCAGGACAAGG CCUUGUCCUGAGCAAGUUCUU 4169 R-008398554-000Y2126 1116 GAACUUGCUCAGGACAAGG B GAACUUGCUCAGGACAAGGTT B 4168R-008398557-000Z 1683 1117 CCAGCCGACACCAAGAAGC GCUUCUUGGUGUCGGCUGGUU4171 R-008398557-000Z 1683 1117 CCAGCCGACACCAAGAAGC BCCAGCCGACACCAAGAAGCTT B 4170 R-008398560-000F 1857 1118AGGGUGCCAUUCCACGACU AGUCGUGGAAUGGCACCCUUU 4173 R-008398560-000F 18571118 AGGGUGCCAUUCCACGACU B AGGGUGCCAUUCCACGACUTT B 4172 R-008398563-000G2064 1119 UUGUGCAGCUGCUUUAUUC GAAUAAAGCAGCUGCACAAUU 4175R-008398563-000G 2064 1119 UUGUGCAGCUGCUUUAUUC B UUGUGCAGCUGCUUUAUUCTT B4174 R-008398566-000H 1245 31 AUAUAAUGAGGACCUAUAC GUAUAGGUCCUCAUUAUAUUU4177 R-008398566-000H 1245 31 AUAUAAUGAGGACCUAUAC BAUAUAAUGAGGACCUAUACTT B 4176 R-008398569-000J 489 1120UCACUCAAGAACAAGUAGC B UCACUCAAGAACAAGUAGCTT B 4178 R-008398569-000J 4891120 UCACUCAAGAACAAGUAGC GCUACUUGUUCUUGAGUGAUU 4179 R-008398572-000R1346 1121 GCUGGUGGAAUGCAAGCUU B GCUGGUGGAAUGCAAGCUUTT B 4180R-008398572-000R 1346 1121 GCUGGUGGAAUGCAAGCUU AAGCUUGCAUUCCACCAGCUU4181 R-008398575-000S 1442 1122 GCAACUAAACAGGAAGGGAUCCCUUCCUGUUUAGUUGCUU 4183 R-008398575-000S 1442 1122GCAACUAAACAGGAAGGGA B GCAACUAAACAGGAAGGGATT B 4182 R-008398578-000T 19811123 AGGUUGUACCGGAGCCCUU B AGGUUGUACCGGAGCCCUUTT B 4184 R-008398578-000T1981 1123 AGGUUGUACCGGAGCCCUU AAGGGCUCCGGUACAACCUUU 4185R-008398581-000Z 777 1124 AGGCUGCAGUUAUGGUCCA UGGACCAUAACUGCAGCCUUU 4187R-008398581-000Z 777 1124 AGGCUGCAGUUAUGGUCCA B AGGCUGCAGUUAUGGUCCATT B4186 R-008398584-000A 589 1125 GCAGAUCCCAUCUACACAG CUGUGUAGAUGGGAUCUGCUU4189 R-008398584-000A 589 1125 GCAGAUCCCAUCUACACAG BGCAGAUCCCAUCUACACAGTT B 4188 R-008398587-000B 2205 1126CUAGGAAUGAAGGUGUGGC GCCACACCUUCAUUCCUAGUU 4191 R-008398587-000B 22051126 CUAGGAAUGAAGGUGUGGC B CUAGGAAUGAAGGUGUGGCTT B 4190 R-008398590-000H394 1127 AGCUCCUUCUCUGAGUGGU B AGCUCCUUCUCUGAGUGGUTT B 4192R-008398590-000H 394 1127 AGCUCCUUCUCUGAGUGGU ACCACUCAGAGAAGGAGCUUU 4193R-008398593-000J 1035 1128 UUACAACUCUCCACAACCU B UUACAACUCUCCACAACCUTT B4194 R-008398593-000J 1035 1128 UUACAACUCUCCACAACCUAGGUUGUGGAGAGUUGUAAUU 4195 R-008398605-000E 410 1129 GGUAAAGGCAAUCCUGAGGB GGUAAAGGCAAUCCUGAGGTT B 4196 R-008398605-000E 410 1129GGUAAAGGCAAUCCUGAGG CCUCAGGAUUGCCUUUACCUU 4197 R-008398608-000F 17211130 GUUCGCCUUCACUAUGGAC GUCCAUAGUGAAGGCGAACUU 4199 R-008398608-000F1721 1130 GUUCGCCUUCACUAUGGAC B GUUCGCCUUCACUAUGGACTT B 4198R-008398611-000M 1134 1131 CAAAUGUUAAAUUCUUGGC GCCAAGAAUUUAACAUUUGUU4201 R-008398611-000M 1134 1131 CAAAUGUUAAAUUCUUGGC BCAAAUGUUAAAUUCUUGGCTT B 4200 R-008398614-000N 3182 1132CUGUGAUACGAUGCUUCAA B CUGUGAUACGAUGCUUCAATT B 4202 R-008398614-000N 31821132 CUGUGAUACGAUGCUUCAA UUGAAGCAUCGUAUCACAGUU 4203 R-008398617-000P 8811133 ACAAAUGAUGUAGAAACAG B ACAAAUGAUGUAGAAACAGTT B 4204 R-008398617-000P881 1133 ACAAAUGAUGUAGAAACAG CUGUUUCUACAUCAUUUGUUU 4205 R-008398620-000W547 1134 GGUACGAGCUGCUAUGUUC GAACAUAGCAGCUCGUACCUU 4207 R-008398620-000W547 1134 GGUACGAGCUGCUAUGUUC B GGUACGAGCUGCUAUGUUCTT B 4206R-008398623-000X 2028 1135 GAAUUGUUAUCAGAGGACU AGUCCUCUGAUAACAAUUCUU4209 R-008398623-000X 2028 1135 GAAUUGUUAUCAGAGGACU BGAAUUGUUAUCAGAGGACUTT B 4208 R-008398629-000Z 2023 1136CAACCGAAUUGUUAUCAGA B CAACCGAAUUGUUAUCAGATT B 4210 R-008398629-000Z 20231136 CAACCGAAUUGUUAUCAGA UCUGAUAACAAUUCGGUUGUU 4211 R-008398632-000F3184 1137 GUGAUACGAUGCUUCAAGA B GUGAUACGAUGCUUCAAGATT B 4212R-008398632-000F 3184 1137 GUGAUACGAUGCUUCAAGA UCUUGAAGCAUCGUAUCACUU4213 R-008398635-000G 413 1138 AAAGGCAAUCCUGAGGAAG CUUCCUCAGGAUUGCCUUUUU4215 R-008398635-000G 413 1138 AAAGGCAAUCCUGAGGAAG BAAAGGCAAUCCUGAGGAAGTT B 4214 R-008398638-000H 2178 1139CAGCUCCUCUGACAGAGUU B CAGCUCCUCUGACAGAGUUTT B 4216 R-008398638-000H 21781139 CAGCUCCUCUGACAGAGUU AACUCUGUCAGAGGAGCUGUU 4217 R-008398641-000P 618143 CUCAUCCCACUAAUGUCCA B CUCAUCCCACUAAUGUCCATT B 4218 R-008398641-000P618 143 CUCAUCCCACUAAUGUCCA UGGACAUUAGUGGGAUGAGUU 4219 R-008398644-000R1577 1140 AUGGUCUGCCAAGUGGGUG B AUGGUCUGCCAAGUGGGUGTT B 4220R-008398644-000R 1577 1140 AUGGUCUGCCAAGUGGGUG CACCCACUUGGCAGACCAUUU4221 R-008398647-000S 1793 1141 GCUACUGUUGGAUUGAUUCGAAUCAAUCCAACAGUAGCUU 4223 R-008398647-000S 1793 1141GCUACUGUUGGAUUGAUUC B GCUACUGUUGGAUUGAUUCTT B 4222 R-008398650-000Y 5261142 UGCAAUGACUCGAGCUCAG B UGCAAUGACUCGAGCUCAGTT B 4224 R-008398650-000Y526 1142 UGCAAUGACUCGAGCUCAG CUGAGCUCGAGUCAUUGCAUU 4225 R-008398653-000Z2358 1143 GACUUGAUAUUGGUGCCCA UGGGCACCAAUAUCAAGUCUU 4227R-008398653-000Z 2358 1143 GACUUGAUAUUGGUGCCCA B GACUUGAUAUUGGUGCCCATT B4226 R-008398656-000A 852 11 UGUCUGCUAUUGUACGUAC B UGUCUGCUAUUGUACGUACTTB 4228 R-008398656-000A 852 11 UGUCUGCUAUUGUACGUAC GUACGUACAAUAGCAGACAUU4229 R-008398659-000B 1403 1144 CAGAACUGUCUUUGGACUCGAGUCCAAAGACAGUUCUGUU 4231 R-008398659-000B 1403 1144CAGAACUGUCUUUGGACUC B CAGAACUGUCUUUGGACUCTT B 4230 R-008398662-000H 18751145 UAGUUCAGUUGCUUGUUCG CGAACAAGCAACUGAACUAUU 4233 R-008398662-000H1875 1145 UAGUUCAGUUGCUUGUUCG B UAGUUCAGUUGCUUGUUCGTT B 4232R-008398665-000J 1160 1146 ACAGACUGCCUUCAAAUUU B ACAGACUGCCUUCAAAUUUTT B4234 R-008398665-000J 1160 1146 ACAGACUGCCUUCAAAUUUAAAUUUGAAGGCAGUCUGUUU 4235 R-008398668-000K 1591 1147GGGUGGUAUAGAGGCUCUU AAGAGCCUCUAUACCACCCUU 4237 R-008398668-000K 15911147 GGGUGGUAUAGAGGCUCUU B GGGUGGUAUAGAGGCUCUUTT B 4236 R-008398671-000S1734 1148 AUGGACUACCAGUUGUGGU B AUGGACUACCAGUUGUGGUTT B 4238R-008398671-000S 1734 1148 AUGGACUACCAGUUGUGGU ACCACAACUGGUAGUCCAUUU4239 R-008398674-000T 2030 1149 AUUGUUAUCAGAGGACUAAUUAGUCCUCUGAUAACAAUUU 4241 R-008398674-000T 2030 1149AUUGUUAUCAGAGGACUAA B AUUGUUAUCAGAGGACUAATT B 4240 R-008398677-000U 7751150 UAAGGCUGCAGUUAUGGUC GACCAUAACUGCAGCCUUAUU 4243 R-008398677-000U 7751150 UAAGGCUGCAGUUAUGGUC B UAAGGCUGCAGUUAUGGUCTT B 4242 R-008398680-000A1813 1151 AAAUCUUGCCCUUUGUCCC GGGACAAAGGGCAAGAUUUUU 4245R-008398680-000A 1813 1151 AAAUCUUGCCCUUUGUCCC B AAAUCUUGCCCUUUGUCCCTT B4244 R-008398683-000B 1938 1152 AGCAGCAAUUUGUGGAGGG BAGCAGCAAUUUGUGGAGGGTT B 4246 R-008398683-000B 1938 1152AGCAGCAAUUUGUGGAGGG CCCUCCACAAAUUGCUGCUUU 4247 R-008398686-000C 20391153 AGAGGACUAAAUACCAUUC B AGAGGACUAAAUACCAUUCTT B 4248 R-008398686-000C2039 1153 AGAGGACUAAAUACCAUUC GAAUGGUAUUUAGUCCUCUUU 4249R-008398689-000D 1297 1154 GCUGAAGGUGCUAUCUGUC B GCUGAAGGUGCUAUCUGUCTT B4250 R-008398689-000D 1297 1154 GCUGAAGGUGCUAUCUGUCGACAGAUAGCACCUUCAGCUU 4251 R-008398692-000K 456 1155 UGUAUGAGUGGGAACAGGGCCCUGUUCCCACUCAUACAUU 4253 R-008398692-000K 456 1155 UGUAUGAGUGGGAACAGGGB UGUAUGAGUGGGAACAGGGTT B 4252 R-008398695-000L 869 51ACCAUGCAGAAUACAAAUG B ACCAUGCAGAAUACAAAUGTT B 4254 R-008398695-000L 86951 ACCAUGCAGAAUACAAAUG CAUUUGUAUUCUGCAUGGUUU 4255 R-008398698-000M 5901156 CAGAUCCCAUCUACACAGU B CAGAUCCCAUCUACACAGUTT B 4256 R-008398698-000M590 1156 CAGAUCCCAUCUACACAGU ACUGUGUAGAUGGGAUCUGUU 4257 R-008398701-000E1933 1157 GACACAGCAGCAAUUUGUG B GACACAGCAGCAAUUUGUGTT B 4258R-008398701-000E 1933 1157 GACACAGCAGCAAUUUGUG CACAAAUUGCUGCUGUGUCUU4259 R-008398704-000F 583 1158 GGGCAUGCAGAUCCCAUCU AGAUGGGAUCUGCAUGCCCUU4261 R-008398704-000F 583 1158 GGGCAUGCAGAUCCCAUCU BGGGCAUGCAGAUCCCAUCUTT B 4260 R-008398707-000G 2540 1159CAUGCCCAGGACCUCAUGG B CAUGCCCAGGACCUCAUGGTT B 4262 R-008398707-000G 25401159 CAUGCCCAGGACCUCAUGG CCAUGAGGUCCUGGGCAUGUU 4263 R-008398710-000N2162 1160 GAAGCUGAGGGAGCCACAG B GAAGCUGAGGGAGCCACAGTT B 4264R-008398710-000N 2162 1160 GAAGCUGAGGGAGCCACAG CUGUGGCUCCCUCAGCUUCUU4265 R-008398713-000P 330 1161 CUGUUAGUCACUGGCAGCA BCUGUUAGUCACUGGCAGCATT B 4266 R-008398713-000P 330 1161CUGUUAGUCACUGGCAGCA UGCUGCCAGUGACUAACAGUU 4267 R-008398716-000R 14811162 CUUGUUCAGCUUCUGGGUU B CUUGUUCAGCUUCUGGGUUTT B 4268 R-008398716-000R1481 1162 CUUGUUCAGCUUCUGGGUU AACCCAGAAGCUGAACAAGUU 4269R-008398719-000S 1612 22 GCGUACUGUCCUUCGGGCU AGCCCGAAGGACAGUACGCUU 4271R-008398719-000S 1612 22 GCGUACUGUCCUUCGGGCU B GCGUACUGUCCUUCGGGCUTT B4270 R-008398722-000Y 1709 3 GCCCAGAAUGCAGUUCGCC GGCGAACUGCAUUCUGGGCUU4273 R-008398722-000Y 1709 3 GCCCAGAAUGCAGUUCGCC B GCCCAGAAUGCAGUUCGCCTTB 4272 R-008398725-000Z 1344 1163 AAGCUGGUGGAAUGCAAGCGCUUGCAUUCCACCAGCUUUU 4275 R-008398725-000Z 1344 1163AAGCUGGUGGAAUGCAAGC B AAGCUGGUGGAAUGCAAGCTT B 4274 R-008398728-000A 4311164 GAGGAUGUGGAUACCUCCC GGGAGGUAUCCACAUCCUCUU 4277 R-008398728-000A 4311164 GAGGAUGUGGAUACCUCCC B GAGGAUGUGGAUACCUCCCTT B 4276 R-008398731-000G1508 1165 AUAAAUGUGGUCACCUGUG CACAGGUGACCACAUUUAUUU 4279R-008398731-000G 1508 1165 AUAAAUGUGGUCACCUGUG B AUAAAUGUGGUCACCUGUGTT B4278 R-008398734-000H 1918 1166 UACGUCCAUGGGUGGGACA BUACGUCCAUGGGUGGGACATT B 4280 R-008398734-000H 1918 1166UACGUCCAUGGGUGGGACA UGUCCCACCCAUGGACGUAUU 4281 R-008398737-000J 289 1167GAUGGAGUUGGACAUGGCC GGCCAUGUCCAACUCCAUCUU 4283 R-008398737-000J 289 1167GAUGGAGUUGGACAUGGCC B GAUGGAGUUGGACAUGGCCTT B 4282 R-008398740-000R 6311168 UGUCCAGCGUUUGGCUGAA B UGUCCAGCGUUUGGCUGAATT B 4284 R-008398740-000R631 1168 UGUCCAGCGUUUGGCUGAA UUCAGCCAAACGCUGGACAUU 4285 R-008398743-000S1642 60 AGACAUCACUGAGCCUGCC B AGACAUCACUGAGCCUGCCTT B 4286R-008398743-000S 1642 60 AGACAUCACUGAGCCUGCC GGCAGGCUCAGUGAUGUCUUU 4287R-008398746-000T 1853 1169 GAGCAGGGUGCCAUUCCAC B GAGCAGGGUGCCAUUCCACTT B4288 R-008398746-000T 1853 1169 GAGCAGGGUGCCAUUCCACGUGGAAUGGCACCCUGCUCUU 4289 R-008398749-000U 1243 1170AAAUAUAAUGAGGACCUAU AUAGGUCCUCAUUAUAUUUUU 4291 R-008398749-000U 12431170 AAAUAUAAUGAGGACCUAU B AAAUAUAAUGAGGACCUAUTT B 4290 R-008398752-000A1212 1171 UACUGGCUAGUGGUGGACC GGUCCACCACUAGCCAGUAUU 4293R-008398752-000A 1212 1171 UACUGGCUAGUGGUGGACC B UACUGGCUAGUGGUGGACCTT B4292 R-008398755-000B 996 1172 UGCUUGGUUCACCAGUGGA UCCACUGGUGAACCAAGCAUU4295 R-008398755-000B 996 1172 UGCUUGGUUCACCAGUGGA BUGCUUGGUUCACCAGUGGATT B 4294 R-008398758-000C 2256 1173CUGAGGACAAGCCACAAGA B CUGAGGACAAGCCACAAGATT B 4296 R-008398758-000C 22561173 CUGAGGACAAGCCACAAGA UCUUGUGGCUUGUCCUCAGUU 4297 R-008398761-000J1607 1174 CUUGUGCGUACUGUCCUUC GAAGGACAGUACGCACAAGUU 4299R-008398761-000J 1607 1174 CUUGUGCGUACUGUCCUUC B CUUGUGCGUACUGUCCUUCTT B4298 R-008398764-000K 3116 1175 UGUUAUUUGGAACCUUGUU BUGUUAUUUGGAACCUUGUUTT B 4300 R-008398764-000K 3116 1175UGUUAUUUGGAACCUUGUU AACAAGGUUCCAAAUAACAUU 4301 R-008398767-000L 11791176 UAGCUUAUGGCAACCAAGA UCUUGGUUGCCAUAAGCUAUU 4303 R-008398767-000L1179 1176 UAGCUUAUGGCAACCAAGA B UAGCUUAUGGCAACCAAGATT B 4302R-008398770-000T 3185 1177 UGAUACGAUGCUUCAAGAG CUCUUGAAGCAUCGUAUCAUU4305 R-008398770-000T 3185 1177 UGAUACGAUGCUUCAAGAG BUGAUACGAUGCUUCAAGAGTT B 4304 R-008398773-000U 1594 1178UGGUAUAGAGGCUCUUGUG CACAAGAGCCUCUAUACCAUU 4307 R-008398773-000U 15941178 UGGUAUAGAGGCUCUUGUG B UGGUAUAGAGGCUCUUGUGTT B 4306 R-008398776-000V887 1179 GAUGUAGAAACAGCUCGUU B GAUGUAGAAACAGCUCGUUTT B 4308R-008398776-000V 887 1179 GAUGUAGAAACAGCUCGUU AACGAGCUGUUUCUACAUCUU 4309R-008398779-000W 928 1180 CCUUUCCCAUCAUCGUGAG B CCUUUCCCAUCAUCGUGAGTT B4310 R-008398779-000W 928 1180 CCUUUCCCAUCAUCGUGAG CUCACGAUGAUGGGAAAGGUU4311 R-008398782-000C 835 1181 GCGUUCUCCUCAGAUGGUG CACCAUCUGAGGAGAACGCUU4313 R-008398782-000C 835 1181 GCGUUCUCCUCAGAUGGUG BGCGUUCUCCUCAGAUGGUGTT B 4312 R-008398785-000D 1900 1182UCAGGAUACCCAGCGCCGU B UCAGGAUACCCAGCGCCGUTT B 4314 R-008398785-000D 19001182 UCAGGAUACCCAGCGCCGU ACGGCGCUGGGUAUCCUGAUU 4315 R-008398788-000E2284 1183 ACGGCUUUCAGUUGAGCUG B ACGGCUUUCAGUUGAGCUGTT B 4316R-008398788-000E 2284 1183 ACGGCUUUCAGUUGAGCUG CAGCUCAACUGAAAGCCGUUU4317 R-008398791-000L 1976 1184 GUUGAAGGUUGUACCGGAGCUCCGGUACAACCUUCAACUU 4319 R-008398791-000L 1976 1184GUUGAAGGUUGUACCGGAG B GUUGAAGGUUGUACCGGAGTT B 4318 R-008398794-000M 23931185 UAUCGCCAGGAUGAUCCUA B UAUCGCCAGGAUGAUCCUATT B 4320 R-008398794-000M2393 1185 UAUCGCCAGGAUGAUCCUA UAGGAUCAUCCUGGCGAUAUU 4321R-008398797-000N 1295 1186 GUGCUGAAGGUGCUAUCUG B GUGCUGAAGGUGCUAUCUGTT B4322 R-008398797-000N 1295 1186 GUGCUGAAGGUGCUAUCUGCAGAUAGCACCUUCAGCACUU 4323 R-008398800-000F 1410 1187GUCUUUGGACUCUCAGGAA UUCCUGAGAGUCCAAAGACUU 4325 R-008398800-000F 14101187 GUCUUUGGACUCUCAGGAA B GUCUUUGGACUCUCAGGAATT B 4324 R-008398803-000G1457 1188 GGGAUGGAAGGUCUCCUUG B GGGAUGGAAGGUCUCCUUGTT B 4326R-008398803-000G 1457 1188 GGGAUGGAAGGUCUCCUUG CAAGGAGACCUUCCAUCCCUU4327 R-008398806-000H 2296 1189 UGAGCUGACCAGCUCUCUC BUGAGCUGACCAGCUCUCUCTT B 4328 R-008398806-000H 2296 1189UGAGCUGACCAGCUCUCUC GAGAGAGCUGGUCAGCUCAUU 4329 R-008398809-000J 929 1190CUUUCCCAUCAUCGUGAGG CCUCACGAUGAUGGGAAAGUU 4331 R-008398809-000J 929 1190CUUUCCCAUCAUCGUGAGG B CUUUCCCAUCAUCGUGAGGTT B 4330 R-008398812-000R 13591191 AAGCUUUAGGACUUCACCU B AAGCUUUAGGACUUCACCUTT B 4332 R-008398812-000R1359 1191 AAGCUUUAGGACUUCACCU AGGUGAAGUCCUAAAGCUUUU 4333R-008398815-000S 1351 1192 UGGAAUGCAAGCUUUAGGA B UGGAAUGCAAGCUUUAGGATT B4334 R-008398815-000S 1351 1192 UGGAAUGCAAGCUUUAGGAUCCUAAAGCUUGCAUUCCAUU 4335 R-008398818-000T 969 1193 CUGGAGGCAUUCCUGCCCUB CUGGAGGCAUUCCUGCCCUTT B 4336 R-008398818-000T 969 1193CUGGAGGCAUUCCUGCCCU AGGGCAGGAAUGCCUCCAGUU 4337 R-008398821-000Z 18761194 AGUUCAGUUGCUUGUUCGU ACGAACAAGCAACUGAACUUU 4339 R-008398821-000Z1876 1194 AGUUCAGUUGCUUGUUCGU B AGUUCAGUUGCUUGUUCGUTT B 4338R-008398824-000A 552 1195 GAGCUGCUAUGUUCCCUGA B GAGCUGCUAUGUUCCCUGATT B4340 R-008398824-000A 552 1195 GAGCUGCUAUGUUCCCUGA UCAGGGAACAUAGCAGCUCUU4341 R-008398827-000B 2441 1196 GGCCAGGAUGCCUUGGGUA BGGCCAGGAUGCCUUGGGUATT B 4342 R-008398827-000B 2441 1196GGCCAGGAUGCCUUGGGUA UACCCAAGGCAUCCUGGCCUU 4343 R-008398830-000H 24021197 GAUGAUCCUAGCUAUCGUU B GAUGAUCCUAGCUAUCGUUTT B 4344 R-008398830-000H2402 1197 GAUGAUCCUAGCUAUCGUU AACGAUAGCUAGGAUCAUCUU 4345R-008398833-000J 1803 1198 GAUUGAUUCGAAAUCUUGC GCAAGAUUUCGAAUCAAUCUU4347 R-008398833-000J 1803 1198 GAUUGAUUCGAAAUCUUGC BGAUUGAUUCGAAAUCUUGCTT B 4346 R-008398836-000K 1701 1199CAGAGAUGGCCCAGAAUGC B CAGAGAUGGCCCAGAAUGCTT B 4348 R-008398836-000K 17011199 CAGAGAUGGCCCAGAAUGC GCAUUCUGGGCCAUCUCUGUU 4349 R-008398839-000L1910 1200 CAGCGCCGUACGUCCAUGG CCAUGGACGUACGGCGCUGUU 4351R-008398839-000L 1910 1200 CAGCGCCGUACGUCCAUGG B CAGCGCCGUACGUCCAUGGTT B4350 R-008398842-000T 888 1201 AUGUAGAAACAGCUCGUUG CAACGAGCUGUUUCUACAUUU4353 R-008398842-000T 888 1201 AUGUAGAAACAGCUCGUUG BAUGUAGAAACAGCUCGUUGTT B 4352 R-008398845-000U 1294 1202AGUGCUGAAGGUGCUAUCU AGAUAGCACCUUCAGCACUUU 4355 R-008398845-000U 12941202 AGUGCUGAAGGUGCUAUCU B AGUGCUGAAGGUGCUAUCUTT B 4354 R-008398848-000V1737 1203 GACUACCAGUUGUGGUUAA UUAACCACAACUGGUAGUCUU 4357R-008398848-000V 1737 1203 GACUACCAGUUGUGGUUAA B GACUACCAGUUGUGGUUAATT B4356 R-008398851-000B 1450 1204 ACAGGAAGGGAUGGAAGGU BACAGGAAGGGAUGGAAGGUTT B 4358 R-008398851-000B 1450 1204ACAGGAAGGGAUGGAAGGU ACCUUCCAUCCCUUCCUGUUU 4359 R-008398854-000C 761 1205CAGGUGGUGGUUAAUAAGG CCUUAUUAACCACCACCUGUU 4361 R-008398854-000C 761 1205CAGGUGGUGGUUAAUAAGG B CAGGUGGUGGUUAAUAAGGTT B 4360 R-008398857-000D 7761206 AAGGCUGCAGUUAUGGUCC B AAGGCUGCAGUUAUGGUCCTT B 4362 R-008398857-000D776 1206 AAGGCUGCAGUUAUGGUCC GGACCAUAACUGCAGCCUUUU 4363 R-008398860-000K1509 1207 UAAAUGUGGUCACCUGUGC GCACAGGUGACCACAUUUAUU 4365R-008398860-000K 1509 1207 UAAAUGUGGUCACCUGUGC B UAAAUGUGGUCACCUGUGCTT B4364 R-008398863-000L 1788 1208 UAAAGGCUACUGUUGGAUU BUAAAGGCUACUGUUGGAUUTT B 4366 R-008398863-000L 1788 1208UAAAGGCUACUGUUGGAUU AAUCCAACAGUAGCCUUUAUU 4367 R-008398866-000M 515 1209GAUGGACAGUAUGCAAUGA UCAUUGCAUACUGUCCAUCUU 4369 R-008398866-000M 515 1209GAUGGACAGUAUGCAAUGA B GAUGGACAGUAUGCAAUGATT B 4368 R-008398869-000N 14911210 UUCUGGGUUCAGAUGAUAU B UUCUGGGUUCAGAUGAUAUTT B 4370 R-008398869-000N1491 1210 UUCUGGGUUCAGAUGAUAU AUAUCAUCUGAACCCAGAAUU 4371R-008398872-000V 1614 1211 GUACUGUCCUUCGGGCUGG B GUACUGUCCUUCGGGCUGGTT B4372 R-008398872-000V 1614 1211 GUACUGUCCUUCGGGCUGGCCAGCCCGAAGGACAGUACUU 4373 R-008398875-000W 998 1212 CUUGGUUCACCAGUGGAUUB CUUGGUUCACCAGUGGAUUTT B 4374 R-008398875-000W 998 1212CUUGGUUCACCAGUGGAUU AAUCCACUGGUGAACCAAGUU 4375 R-008398878-000X 21581213 UAUUGAAGCUGAGGGAGCC B UAUUGAAGCUGAGGGAGCCTT B 4376 R-008398878-000X2158 1213 UAUUGAAGCUGAGGGAGCC GGCUCCCUCAGCUUCAAUAUU 4377R-008398881-000D 3168 1214 GUUGUUGUAACCUGCUGUG B GUUGUUGUAACCUGCUGUGTT B4378 R-008398881-000D 3168 1214 GUUGUUGUAACCUGCUGUGCACAGCAGGUUACAACAACUU 4379 R-008398884-000E 1854 1215AGCAGGGUGCCAUUCCACG B AGCAGGGUGCCAUUCCACGTT B 4380 R-008398884-000E 18541215 AGCAGGGUGCCAUUCCACG CGUGGAAUGGCACCCUGCUUU 4381 R-008398887-000F2117 1216 GUCCUCUGUGAACUUGCUC GAGCAAGUUCACAGAGGACUU 4383R-008398887-000F 2117 1216 GUCCUCUGUGAACUUGCUC B GUCCUCUGUGAACUUGCUCTT B4382 R-008398890-000M 1678 1217 UCUGACCAGCCGACACCAAUUGGUGUCGGCUGGUCAGAUU 4385 R-008398890-000M 1678 1217UCUGACCAGCCGACACCAA B UCUGACCAGCCGACACCAATT B 4384 R-008398893-000N 215963 AUUGAAGCUGAGGGAGCCA B AUUGAAGCUGAGGGAGCCATT B 4386 R-008398893-000N2159 63 AUUGAAGCUGAGGGAGCCA UGGCUCCCUCAGCUUCAAUUU 4387 R-008398896-000P305 1218 GCCAUGGAACCAGACAGAA UUCUGUCUGGUUCCAUGGCUU 4389 R-008398896-000P305 1218 GCCAUGGAACCAGACAGAA B GCCAUGGAACCAGACAGAATT B 4388R-008398899-000R 2154 1219 AAGCUAUUGAAGCUGAGGG B AAGCUAUUGAAGCUGAGGGTT B4390 R-008398899-000R 2154 1219 AAGCUAUUGAAGCUGAGGGCCCUCAGCUUCAAUAGCUUUU 4391 R-008398902-000H 1807 1220GAUUCGAAAUCUUGCCCUU B GAUUCGAAAUCUUGCCCUUTT B 4392 R-008398902-000H 18071220 GAUUCGAAAUCUUGCCCUU AAGGGCAAGAUUUCGAAUCUU 4393 R-008398905-000J1881 1221 AGUUGCUUGUUCGUGCACA B AGUUGCUUGUUCGUGCACATT B 4394R-008398905-000J 1881 1221 AGUUGCUUGUUCGUGCACA UGUGCACGAACAAGCAACUUU4395 R-008398908-000K 1565 1222 AAGAACAAGAUGAUGGUCU BAAGAACAAGAUGAUGGUCUTT B 4396 R-008398908-000K 1565 1222AAGAACAAGAUGAUGGUCU AGACCAUCAUCUUGUUCUUUU 4397 R-008398911-000S 407 1223AGUGGUAAAGGCAAUCCUG B AGUGGUAAAGGCAAUCCUGTT B 4398 R-008398911-000S 4071223 AGUGGUAAAGGCAAUCCUG CAGGAUUGCCUUUACCACUUU 4399 R-008398914-000T1434 1224 CAGAUGCUGCAACUAAACA UGUUUAGUUGCAGCAUCUGUU 4401R-008398914-000T 1434 1224 CAGAUGCUGCAACUAAACA B CAGAUGCUGCAACUAAACATT B4400 R-008398917-000U 566 1225 CCUGAGACAUUAGAUGAGG BCCUGAGACAUUAGAUGAGGTT B 4402 R-008398917-000U 566 1225CCUGAGACAUUAGAUGAGG CCUCAUCUAAUGUCUCAGGUU 4403 R-008398920-000A 31611226 UCCCAAAGUUGUUGUAACC GGUUACAACAACUUUGGGAUU 4405 R-008398920-000A3161 1226 UCCCAAAGUUGUUGUAACC B UCCCAAAGUUGUUGUAACCTT B 4404R-008398923-000B 666 117 AACAUGCAGUUGUAAACUU AAGUUUACAACUGCAUGUUUU 4407R-008398923-000B 666 117 AACAUGCAGUUGUAAACUU B AACAUGCAGUUGUAAACUUTT B4406 R-008398926-000C 848 98 AUGGUGUCUGCUAUUGUAC GUACAAUAGCAGACACCAUUU4409 R-008398926-000C 848 98 AUGGUGUCUGCUAUUGUAC B AUGGUGUCUGCUAUUGUACTTB 4408 R-008398929-000D 1679 1227 CUGACCAGCCGACACCAAG BCUGACCAGCCGACACCAAGTT B 4410 R-008398929-000D 1679 1227CUGACCAGCCGACACCAAG CUUGGUGUCGGCUGGUCAGUU 4411 R-008398932-000K 20961228 AUCCAAAGAGUAGCUGCAG B AUCCAAAGAGUAGCUGCAGTT B 4412 R-008398932-000K2096 1228 AUCCAAAGAGUAGCUGCAG CUGCAGCUACUCUUUGGAUUU 4413R-008398935-000L 630 1229 AUGUCCAGCGUUUGGCUGA B AUGUCCAGCGUUUGGCUGATT B4414 R-008398935-000L 630 1229 AUGUCCAGCGUUUGGCUGA UCAGCCAAACGCUGGACAUUU4415 R-008398938-000M 1606 1230 UCUUGUGCGUACUGUCCUUAAGGACAGUACGCACAAGAUU 4417 R-008398938-000M 1606 1230UCUUGUGCGUACUGUCCUU B UCUUGUGCGUACUGUCCUUTT B 4416 R-008398941-000U 4321231 AGGAUGUGGAUACCUCCCA UGGGAGGUAUCCACAUCCUUU 4419 R-008398941-000U 4321231 AGGAUGUGGAUACCUCCCA B AGGAUGUGGAUACCUCCCATT B 4418 R-008398944-000V778 1232 GGCUGCAGUUAUGGUCCAU B GGCUGCAGUUAUGGUCCAUTT B 4420R-008398944-000V 778 1232 GGCUGCAGUUAUGGUCCAU AUGGACCAUAACUGCAGCCUU 4421R-008398947-000W 1999 1233 UCACAUCCUAGCUCGGGAU B UCACAUCCUAGCUCGGGAUTT B4422 R-008398947-000W 1999 1233 UCACAUCCUAGCUCGGGAUAUCCCGAGCUAGGAUGUGAUU 4423 R-008398950-000C 1692 1234ACCAAGAAGCAGAGAUGGC GCCAUCUCUGCUUCUUGGUUU 4425 R-008398950-000C 16921234 ACCAAGAAGCAGAGAUGGC B ACCAAGAAGCAGAGAUGGCTT B 4424 R-008398953-000D2490 1235 GCCACCACCCUGGUGCUGA B GCCACCACCCUGGUGCUGATT B 4426R-008398953-000D 2490 1235 GCCACCACCCUGGUGCUGA UCAGCACCAGGGUGGUGGCUU4427 R-008398956-000E 623 1236 CCCACUAAUGUCCAGCGUU AACGCUGGACAUUAGUGGGUU4429 R-008398956-000E 623 1236 CCCACUAAUGUCCAGCGUU BCCCACUAAUGUCCAGCGUUTT B 4428 R-008398959-000F 339 1237ACUGGCAGCAACAGUCUUA B ACUGGCAGCAACAGUCUUATT B 4430 R-008398959-000F 3391237 ACUGGCAGCAACAGUCUUA UAAGACUGUUGCUGCCAGUUU 4431 R-008398962-000M2471 166 AUGGAACAUGAGAUGGGUG CACCCAUCUCAUGUUCCAUUU 4433 R-008398962-000M2471 166 AUGGAACAUGAGAUGGGUG B AUGGAACAUGAGAUGGGUGTT B 4432R-008398965-000N 2037 164 UCAGAGGACUAAAUACCAU AUGGUAUUUAGUCCUCUGAUU 4435R-008398965-000N 2037 164 UCAGAGGACUAAAUACCAU B UCAGAGGACUAAAUACCAUTT B4434 R-008398968-000P 912 179 CUGGGACCUUGCAUAACCU AGGUUAUGCAAGGUCCCAGUU4437 R-008398968-000P 912 179 CUGGGACCUUGCAUAACCU BCUGGGACCUUGCAUAACCUTT B 4436 R-008398971-000W 2946 1238AUCUGAAUAAAGUGUAACA B AUCUGAAUAAAGUGUAACATT B 4438 R-008398971-000W 29461238 AUCUGAAUAAAGUGUAACA UGUUACACUUUAUUCAGAUUU 4439 R-008398974-000X1654 1239 GCCUGCCAUCUGUGCUCUU AAGAGCACAGAUGGCAGGCUU 4441R-008398974-000X 1654 1239 GCCUGCCAUCUGUGCUCUU B GCCUGCCAUCUGUGCUCUUTT B4440 R-008398977-000Y 1033 1240 CAUUACAACUCUCCACAAC BCAUUACAACUCUCCACAACTT B 4442 R-008398977-000Y 1033 1240CAUUACAACUCUCCACAAC GUUGUGGAGAGUUGUAAUGUU 4443 R-008398980-000E 840 1241CUCCUCAGAUGGUGUCUGC GCAGACACCAUCUGAGGAGUU 4445 R-008398980-000E 840 1241CUCCUCAGAUGGUGUCUGC B CUCCUCAGAUGGUGUCUGCTT B 4444 R-008398983-000F 18801242 CAGUUGCUUGUUCGUGCAC GUGCACGAACAAGCAACUGUU 4447 R-008398983-000F1880 1242 CAGUUGCUUGUUCGUGCAC B CAGUUGCUUGUUCGUGCACTT B 4446R-008398986-000G 420 1243 AUCCUGAGGAAGAGGAUGU B AUCCUGAGGAAGAGGAUGUTT B4448 R-008398986-000G 420 1243 AUCCUGAGGAAGAGGAUGU ACAUCCUCUUCCUCAGGAUUU4449 R-008398989-000H 1005 1244 CACCAGUGGAUUCUGUGUU BCACCAGUGGAUUCUGUGUUTT B 4450 R-008398989-000H 1005 1244CACCAGUGGAUUCUGUGUU AACACAGAAUCCACUGGUGUU 4451 R-008398992-000P 11931245 CAAGAAAGCAAGCUCAUCA B CAAGAAAGCAAGCUCAUCATT B 4452 R-008398992-000P1193 1245 CAAGAAAGCAAGCUCAUCA UGAUGAGCUUGCUUUCUUGUU 4453R-008398995-000R 919 1246 CUUGCAUAACCUUUCCCAU AUGGGAAAGGUUAUGCAAGUU 4455R-008398995-000R 919 1246 CUUGCAUAACCUUUCCCAU B CUUGCAUAACCUUUCCCAUTT B4454 R-008399001-000F 1727 1247 CUUCACUAUGGACUACCAGCUGGUAGUCCAUAGUGAAGUU 4457 R-008399001-000F 1727 1247CUUCACUAUGGACUACCAG B CUUCACUAUGGACUACCAGTT B 4456 R-008399004-000G 18831248 UUGCUUGUUCGUGCACAUC B UUGCUUGUUCGUGCACAUCTT B 4458 R-008399004-000G1883 1248 UUGCUUGUUCGUGCACAUC GAUGUGCACGAACAAGCAAUU 4459R-008399007-000H 859 1249 UAUUGUACGUACCAUGCAG B UAUUGUACGUACCAUGCAGTT B4460 R-008399007-000H 859 1249 UAUUGUACGUACCAUGCAG CUGCAUGGUACGUACAAUAUU4461 R-008399010-000P 870 57 CCAUGCAGAAUACAAAUGA B CCAUGCAGAAUACAAAUGATTB 4462 R-008399010-000P 870 57 CCAUGCAGAAUACAAAUGA UCAUUUGUAUUCUGCAUGGUU4463 R-008399013-000R 1812 1250 GAAAUCUUGCCCUUUGUCCGGACAAAGGGCAAGAUUUCUU 4465 R-008399013-000R 1812 1250GAAAUCUUGCCCUUUGUCC B GAAAUCUUGCCCUUUGUCCTT B 4464 R-008399016-000S 16051251 CUCUUGUGCGUACUGUCCU AGGACAGUACGCACAAGAGUU 4467 R-008399016-000S1605 1251 CUCUUGUGCGUACUGUCCU B CUCUUGUGCGUACUGUCCUTT B 4466R-008399019-000T 2021 1252 CACAACCGAAUUGUUAUCA UGAUAACAAUUCGGUUGUGUU4469 R-008399019-000T 2021 1252 CACAACCGAAUUGUUAUCA BCACAACCGAAUUGUUAUCATT B 4468 R-008399022-000Z 2180 1253GCUCCUCUGACAGAGUUAC GUAACUCUGUCAGAGGAGCUU 4471 R-008399022-000Z 21801253 GCUCCUCUGACAGAGUUAC B GCUCCUCUGACAGAGUUACTT B 4470 R-008399025-000A636 1254 AGCGUUUGGCUGAACCAUC B AGCGUUUGGCUGAACCAUCTT B 4472R-008399025-000A 636 1254 AGCGUUUGGCUGAACCAUC GAUGGUUCAGCCAAACGCUUU 4473R-008399031-000H 871 48 CAUGCAGAAUACAAAUGAU B CAUGCAGAAUACAAAUGAUTT B4474 R-008399031-000H 871 48 CAUGCAGAAUACAAAUGAU AUCAUUUGUAUUCUGCAUGUU4475 R-008399034-000J 1801 96 UGGAUUGAUUCGAAAUCUU BUGGAUUGAUUCGAAAUCUUTT B 4476 R-008399034-000J 1801 96UGGAUUGAUUCGAAAUCUU AAGAUUUCGAAUCAAUCCAUU 4477 R-008399037-000K 22821255 AAACGGCUUUCAGUUGAGC GCUCAACUGAAAGCCGUUUUU 4479 R-008399037-000K2282 1255 AAACGGCUUUCAGUUGAGC B AAACGGCUUUCAGUUGAGCTT B 4478R-008399040-000S 1824 1256 UUUGUCCCGCAAAUCAUGC GCAUGAUUUGCGGGACAAAUU4481 R-008399040-000S 1824 1256 UUUGUCCCGCAAAUCAUGC BUUUGUCCCGCAAAUCAUGCTT B 4480 R-008399043-000T 2204 1257UCUAGGAAUGAAGGUGUGG CCACACCUUCAUUCCUAGAUU 4483 R-008399043-000T 22041257 UCUAGGAAUGAAGGUGUGG B UCUAGGAAUGAAGGUGUGGTT B 4482 R-008399046-000U450 1258 AAGUCCUGUAUGAGUGGGA B AAGUCCUGUAUGAGUGGGATT B 4484R-008399046-000U 450 1258 AAGUCCUGUAUGAGUGGGA UCCCACUCAUACAGGACUUUU 4485R-008399049-000V 1001 1259 GGUUCACCAGUGGAUUCUG B GGUUCACCAGUGGAUUCUGTT B4486 R-008399049-000V 1001 1259 GGUUCACCAGUGGAUUCUGCAGAAUCCACUGGUGAACCUU 4487 R-008399052-000B 1579 1260GGUCUGCCAAGUGGGUGGU ACCACCCACUUGGCAGACCUU 4489 R-008399052-000B 15791260 GGUCUGCCAAGUGGGUGGU B GGUCUGCCAAGUGGGUGGUTT B 4488 R-008399055-000C2179 1261 AGCUCCUCUGACAGAGUUA UAACUCUGUCAGAGGAGCUUU 4491R-008399055-000C 2179 1261 AGCUCCUCUGACAGAGUUA B AGCUCCUCUGACAGAGUUATT B4490 R-008399058-000D 376 1262 UUCUGGUGCCACUACCACA BUUCUGGUGCCACUACCACATT B 4492 R-008399058-000D 376 1262UUCUGGUGCCACUACCACA UGUGGUAGUGGCACCAGAAUU 4493 R-008399061-000K 556 1263UGCUAUGUUCCCUGAGACA B UGCUAUGUUCCCUGAGACATT B 4494 R-008399061-000K 5561263 UGCUAUGUUCCCUGAGACA UGUCUCAGGGAACAUAGCAUU 4495 R-008399064-000L1804 1264 AUUGAUUCGAAAUCUUGCC B AUUGAUUCGAAAUCUUGCCTT B 4496R-008399064-000L 1804 1264 AUUGAUUCGAAAUCUUGCC GGCAAGAUUUCGAAUCAAUUU4497 R-008399067-000M 2552 1265 CUCAUGGAUGGGCUGCCUC BCUCAUGGAUGGGCUGCCUCTT B 4498 R-008399067-000M 2552 1265CUCAUGGAUGGGCUGCCUC GAGGCAGCCCAUCCAUGAGUU 4499 R-008399070-000U 20711266 GCUGCUUUAUUCUCCCAUU B GCUGCUUUAUUCUCCCAUUTT B 4500 R-008399070-000U2071 1266 GCUGCUUUAUUCUCCCAUU AAUGGGAGAAUAAAGCAGCUU 4501R-008399073-000V 1145 16 UUCUUGGCUAUUACGACAG B UUCUUGGCUAUUACGACAGTT B4502 R-008399073-000V 1145 16 UUCUUGGCUAUUACGACAG CUGUCGUAAUAGCCAAGAAUU4503 R-008399076-000W 1836 1267 AUCAUGCACCUUUGCGUGAUCACGCAAAGGUGCAUGAUUU 4505 R-008399076-000W 1836 1267AUCAUGCACCUUUGCGUGA B AUCAUGCACCUUUGCGUGATT B 4504 R-008399079-000X 3361268 GUCACUGGCAGCAACAGUC B GUCACUGGCAGCAACAGUCTT B 4506 R-008399079-000X336 1268 GUCACUGGCAGCAACAGUC GACUGUUGCUGCCAGUGACUU 4507 R-008399082-000D460 1269 UGAGUGGGAACAGGGAUUU AAAUCCCUGUUCCCACUCAUU 4509 R-008399082-000D460 1269 UGAGUGGGAACAGGGAUUU B UGAGUGGGAACAGGGAUUUTT B 4508R-008399085-000E 1559 1270 AAUUAUAAGAACAAGAUGA B AAUUAUAAGAACAAGAUGATT B4510 R-008399085-000E 1559 1270 AAUUAUAAGAACAAGAUGAUCAUCUUGUUCUUAUAAUUUU 4511 R-008399091-000M 3136 1271UGGACAGUUUACCAGUUGC B UGGACAGUUUACCAGUUGCTT B 4512 R-008399091-000M 31361271 UGGACAGUUUACCAGUUGC GCAACUGGUAAACUGUCCAUU 4513 R-008399097-000P1250 1272 AUGAGGACCUAUACUUACG B AUGAGGACCUAUACUUACGTT B 4514R-008399097-000P 1250 1272 AUGAGGACCUAUACUUACG CGUAAGUAUAGGUCCUCAUUU4515 R-008399100-000G 1462 1273 GGAAGGUCUCCUUGGGACU BGGAAGGUCUCCUUGGGACUTT B 4516 R-008399100-000G 1462 1273GGAAGGUCUCCUUGGGACU AGUCCCAAGGAGACCUUCCUU 4517 R-008399103-000H 19651274 UGGAAGAAAUAGUUGAAGG B UGGAAGAAAUAGUUGAAGGTT B 4518 R-008399103-000H1965 1274 UGGAAGAAAUAGUUGAAGG CCUUCAACUAUUUCUUCCAUU 4519R-008399109-000K 3114 1275 GGUGUUAUUUGGAACCUUG CAAGGUUCCAAAUAACACCUU4521 R-008399109-000K 3114 1275 GGUGUUAUUUGGAACCUUG BGGUGUUAUUUGGAACCUUGTT B 4520 R-008399112-000S 1665 1276GUGCUCUUCGUCAUCUGAC B GUGCUCUUCGUCAUCUGACTT B 4522 R-008399112-000S 16651276 GUGCUCUUCGUCAUCUGAC GUCAGAUGACGAAGAGCACUU 4523 R-008399115-000T 3041277 GGCCAUGGAACCAGACAGA UCUGUCUGGUUCCAUGGCCUU 4525 R-008399115-000T 3041277 GGCCAUGGAACCAGACAGA B GGCCAUGGAACCAGACAGATT B 4524 R-008399118-000U327 1278 CGGCUGUUAGUCACUGGCA UGCCAGUGACUAACAGCCGUU 4527 R-008399118-000U327 1278 CGGCUGUUAGUCACUGGCA B CGGCUGUUAGUCACUGGCATT B 4526R-008399121-000A 1866 1279 UUCCACGACUAGUUCAGUU B UUCCACGACUAGUUCAGUUTT B4528 R-008399121-000A 1866 1279 UUCCACGACUAGUUCAGUUAACUGAACUAGUCGUGGAAUU 4529 R-008399124-000B 1699 1280AGCAGAGAUGGCCCAGAAU AUUCUGGGCCAUCUCUGCUUU 4531 R-008399124-000B 16991280 AGCAGAGAUGGCCCAGAAU B AGCAGAGAUGGCCCAGAAUTT B 4530 R-008399127-000C2397 1281 GCCAGGAUGAUCCUAGCUA UAGCUAGGAUCAUCCUGGCUU 4533R-008399127-000C 2397 1281 GCCAGGAUGAUCCUAGCUA B GCCAGGAUGAUCCUAGCUATT B4532 R-008399130-000J 1658 1282 GCCAUCUGUGCUCUUCGUC BGCCAUCUGUGCUCUUCGUCTT B 4534 R-008399130-000J 1658 1282GCCAUCUGUGCUCUUCGUC GACGAAGAGCACAGAUGGCUU 4535 R-008399133-000K 891 1283UAGAAACAGCUCGUUGUAC GUACAACGAGCUGUUUCUAUU 4537 R-008399133-000K 891 1283UAGAAACAGCUCGUUGUAC B UAGAAACAGCUCGUUGUACTT B 4536 R-008399136-000L 15721284 AGAUGAUGGUCUGCCAAGU B AGAUGAUGGUCUGCCAAGUTT B 4538 R-008399136-000L1572 1284 AGAUGAUGGUCUGCCAAGU ACUUGGCAGACCAUCAUCUUU 4539R-008399139-000M 927 1285 ACCUUUCCCAUCAUCGUGA B ACCUUUCCCAUCAUCGUGATT B4540 R-008399139-000M 927 1285 ACCUUUCCCAUCAUCGUGA UCACGAUGAUGGGAAAGGUUU4541 R-008399142-000U 290 1286 AUGGAGUUGGACAUGGCCA UGGCCAUGUCCAACUCCAUUU4543 R-008399142-000U 290 1286 AUGGAGUUGGACAUGGCCA BAUGGAGUUGGACAUGGCCATT B 4542 R-008399145-000V 1663 1287CUGUGCUCUUCGUCAUCUG CAGAUGACGAAGAGCACAGUU 4545 R-008399145-000V 16631287 CUGUGCUCUUCGUCAUCUG B CUGUGCUCUUCGUCAUCUGTT B 4544 R-008399148-000W1562 1288 UAUAAGAACAAGAUGAUGG B UAUAAGAACAAGAUGAUGGTT B 4546R-008399148-000W 1562 1288 UAUAAGAACAAGAUGAUGG CCAUCAUCUUGUUCUUAUAUU4547 R-008399154-000D 2947 1289 UCUGAAUAAAGUGUAACAAUUGUUACACUUUAUUCAGAUU 4549 R-008399154-000D 2947 1289UCUGAAUAAAGUGUAACAA B UCUGAAUAAAGUGUAACAATT B 4548 R-008399157-000E 17111290 CCAGAAUGCAGUUCGCCUU AAGGCGAACUGCAUUCUGGUU 4551 R-008399157-000E1711 1290 CCAGAAUGCAGUUCGCCUU B CCAGAAUGCAGUUCGCCUUTT B 4550R-008399160-000L 1566 1291 AGAACAAGAUGAUGGUCUG B AGAACAAGAUGAUGGUCUGTT B4552 R-008399160-000L 1566 1291 AGAACAAGAUGAUGGUCUGCAGACCAUCAUCUUGUUCUUU 4553 R-008399163-000M 1815 1292AUCUUGCCCUUUGUCCCGC GCGGGACAAAGGGCAAGAUUU 4555 R-008399163-000M 18151292 AUCUUGCCCUUUGUCCCGC B AUCUUGCCCUUUGUCCCGCTT B 4554 R-008399166-000N1087 1293 GCGUUUAGCUGGUGGGCUG CAGCCCACCAGCUAAACGCUU 4557R-008399166-000N 1087 1293 GCGUUUAGCUGGUGGGCUG B GCGUUUAGCUGGUGGGCUGTT B4556 R-008399169-000P 1495 1294 GGGUUCAGAUGAUAUAAAU BGGGUUCAGAUGAUAUAAAUTT B 4558 R-008399169-000P 1495 1294GGGUUCAGAUGAUAUAAAU AUUUAUAUCAUCUGAACCCUU 4559 R-008399172-000W 13631295 UUUAGGACUUCACCUGACA B UUUAGGACUUCACCUGACATT B 4560 R-008399172-000W1363 1295 UUUAGGACUUCACCUGACA UGUCAGGUGAAGUCCUAAAUU 4561R-008399175-000X 391 1296 CACAGCUCCUUCUCUGAGU ACUCAGAGAAGGAGCUGUGUU 4563R-008399175-000X 391 1296 CACAGCUCCUUCUCUGAGU B CACAGCUCCUUCUCUGAGUTT B4562 R-008399178-000Y 1392 1297 AACGUCUUGUUCAGAACUGCAGUUCUGAACAAGACGUUUU 4565 R-008399178-000Y 1392 1297AACGUCUUGUUCAGAACUG B AACGUCUUGUUCAGAACUGTT B 4564 R-008399181-000E 19351298 CACAGCAGCAAUUUGUGGA B CACAGCAGCAAUUUGUGGATT B 4566 R-008399181-000E1935 1298 CACAGCAGCAAUUUGUGGA UCCACAAAUUGCUGCUGUGUU 4567R-008399184-000F 1872 1299 GACUAGUUCAGUUGCUUGU B GACUAGUUCAGUUGCUUGUTT B4568 R-008399184-000F 1872 1299 GACUAGUUCAGUUGCUUGUACAAGCAACUGAACUAGUCUU 4569 R-008399187-000G 1159 1300GACAGACUGCCUUCAAAUU AAUUUGAAGGCAGUCUGUCUU 4571 R-008399187-000G 11591300 GACAGACUGCCUUCAAAUU B GACAGACUGCCUUCAAAUUTT B 4570 R-008399190-000N2308 1301 CUCUCUCUUCAGAACAGAG CUCUGUUCUGAAGAGAGAGUU 4573R-008399190-000N 2308 1301 CUCUCUCUUCAGAACAGAG B CUCUCUCUUCAGAACAGAGTT B4572 R-008399193-000P 632 1302 GUCCAGCGUUUGGCUGAAC GUUCAGCCAAACGCUGGACUU4575 R-008399193-000P 632 1302 GUCCAGCGUUUGGCUGAAC BGUCCAGCGUUUGGCUGAACTT B 4574 R-008399196-000R 580 173UGAGGGCAUGCAGAUCCCA B UGAGGGCAUGCAGAUCCCATT B 4576 R-008399196-000R 580173 UGAGGGCAUGCAGAUCCCA UGGGAUCUGCAUGCCCUCAUU 4577 R-008399199-000S 15641303 UAAGAACAAGAUGAUGGUC B UAAGAACAAGAUGAUGGUCTT B 4578 R-008399199-000S1564 1303 UAAGAACAAGAUGAUGGUC GACCAUCAUCUUGUUCUUAUU 4579R-008399202-000J 1384 1304 UCCAAGUCAACGUCUUGUU B UCCAAGUCAACGUCUUGUUTT B4580 R-008399202-000J 1384 1304 UCCAAGUCAACGUCUUGUUAACAAGACGUUGACUUGGAUU 4581 R-008399205-000K 1690 1305ACACCAAGAAGCAGAGAUG B ACACCAAGAAGCAGAGAUGTT B 4582 R-008399205-000K 16901305 ACACCAAGAAGCAGAGAUG CAUCUCUGCUUCUUGGUGUUU 4583 R-008399208-000L1421 1306 CUCAGGAAUCUUUCAGAUG B CUCAGGAAUCUUUCAGAUGTT B 4584R-008399208-000L 1421 1306 CUCAGGAAUCUUUCAGAUG CAUCUGAAAGAUUCCUGAGUU4585 R-008399211-000T 1141 1307 UAAAUUCUUGGCUAUUACG BUAAAUUCUUGGCUAUUACGTT B 4586 R-008399211-000T 1141 1307UAAAUUCUUGGCUAUUACG CGUAAUAGCCAAGAAUUUAUU 4587 R-008399214-000U 17321308 CUAUGGACUACCAGUUGUG B CUAUGGACUACCAGUUGUGTT B 4588 R-008399214-000U1732 1308 CUAUGGACUACCAGUUGUG CACAACUGGUAGUCCAUAGUU 4589R-008399217-000V 634 1309 CCAGCGUUUGGCUGAACCA B CCAGCGUUUGGCUGAACCATT B4590 R-008399217-000V 634 1309 CCAGCGUUUGGCUGAACCA UGGUUCAGCCAAACGCUGGUU4591 R-008399220-000B 932 1310 UCCCAUCAUCGUGAGGGCU BUCCCAUCAUCGUGAGGGCUTT B 4592 R-008399220-000B 932 1310UCCCAUCAUCGUGAGGGCU AGCCCUCACGAUGAUGGGAUU 4593 R-008399223-000C 579 171AUGAGGGCAUGCAGAUCCC GGGAUCUGCAUGCCCUCAUUU 4595 R-008399223-000C 579 171AUGAGGGCAUGCAGAUCCC B AUGAGGGCAUGCAGAUCCCTT B 4594 R-008399226-000D 13661311 AGGACUUCACCUGACAGAU AUCUGUCAGGUGAAGUCCUUU 4597 R-008399226-000D1366 1311 AGGACUUCACCUGACAGAU B AGGACUUCACCUGACAGAUTT B 4596R-008399229-000E 1608 1312 UUGUGCGUACUGUCCUUCG B UUGUGCGUACUGUCCUUCGTT B4598 R-008399229-000E 1608 1312 UUGUGCGUACUGUCCUUCGCGAAGGACAGUACGCACAAUU 4599 R-008399232-000L 814 10 AGCUUCCAGACACGCUAUCGAUAGCGUGUCUGGAAGCUUU 4601 R-008399232-000L 814 10 AGCUUCCAGACACGCUAUC BAGCUUCCAGACACGCUAUCTT B 4600 R-008399235-000M 1923 1313CCAUGGGUGGGACACAGCA B CCAUGGGUGGGACACAGCATT B 4602 R-008399235-000M 19231313 CCAUGGGUGGGACACAGCA UGCUGUGUCCCACCCAUGGUU 4603 R-008399238-000N1458 1314 GGAUGGAAGGUCUCCUUGG CCAAGGAGACCUUCCAUCCUU 4605R-008399238-000N 1458 1314 GGAUGGAAGGUCUCCUUGG B GGAUGGAAGGUCUCCUUGGTT B4604 R-008399241-000V 1908 1315 CCCAGCGCCGUACGUCCAU BCCCAGCGCCGUACGUCCAUTT B 4606 R-008399241-000V 1908 1315CCCAGCGCCGUACGUCCAU AUGGACGUACGGCGCUGGGUU 4607 R-008399244-000W 539 1316GCUCAGAGGGUACGAGCUG CAGCUCGUACCCUCUGAGCUU 4609 R-008399244-000W 539 1316GCUCAGAGGGUACGAGCUG B GCUCAGAGGGUACGAGCUGTT B 4608 R-008399247-000X 20161317 AUGUUCACAACCGAAUUGU ACAAUUCGGUUGUGAACAUUU 4611 R-008399247-000X2016 1317 AUGUUCACAACCGAAUUGU B AUGUUCACAACCGAAUUGUTT B 4610R-008399250-000D 1884 1318 UGCUUGUUCGUGCACAUCA B UGCUUGUUCGUGCACAUCATT B4612 R-008399250-000D 1884 1318 UGCUUGUUCGUGCACAUCAUGAUGUGCACGAACAAGCAUU 4613 R-008399253-000E 560 1319 AUGUUCCCUGAGACAUUAGB AUGUUCCCUGAGACAUUAGTT B 4614 R-008399253-000E 560 1319AUGUUCCCUGAGACAUUAG CUAAUGUCUCAGGGAACAUUU 4615 R-008399256-000F 411 1320GUAAAGGCAAUCCUGAGGA UCCUCAGGAUUGCCUUUACUU 4617 R-008399256-000F 411 1320GUAAAGGCAAUCCUGAGGA B GUAAAGGCAAUCCUGAGGATT B 4616 R-008399259-000G 3381321 CACUGGCAGCAACAGUCUU AAGACUGUUGCUGCCAGUGUU 4619 R-008399259-000G 3381321 CACUGGCAGCAACAGUCUU B CACUGGCAGCAACAGUCUUTT B 4618 R-008399262-000N830 1322 AUCAUGCGUUCUCCUCAGA UCUGAGGAGAACGCAUGAUUU 4621 R-008399262-000N830 1322 AUCAUGCGUUCUCCUCAGA B AUCAUGCGUUCUCCUCAGATT B 4620R-008399265-000P 3086 1323 UAUGUAUGGGUAGGGUAAA B UAUGUAUGGGUAGGGUAAATT B4622 R-008399265-000P 3086 1323 UAUGUAUGGGUAGGGUAAAUUUACCCUACCCAUACAUAUU 4623 R-008399268-000R 3115 1324GUGUUAUUUGGAACCUUGU ACAAGGUUCCAAAUAACACUU 4625 R-008399268-000R 31151324 GUGUUAUUUGGAACCUUGU B GUGUUAUUUGGAACCUUGUTT B 4624 R-008399271-000X2177 1325 ACAGCUCCUCUGACAGAGU B ACAGCUCCUCUGACAGAGUTT B 4626R-008399271-000X 2177 1325 ACAGCUCCUCUGACAGAGU ACUCUGUCAGAGGAGCUGUUU4627 R-008399274-000Y 1733 1326 UAUGGACUACCAGUUGUGG BUAUGGACUACCAGUUGUGGTT B 4628 R-008399274-000Y 1733 1326UAUGGACUACCAGUUGUGG CCACAACUGGUAGUCCAUAUU 4629 R-008399277-000Z 375 1327AUUCUGGUGCCACUACCAC GUGGUAGUGGCACCAGAAUUU 4631 R-008399277-000Z 375 1327AUUCUGGUGCCACUACCAC B AUUCUGGUGCCACUACCACTT B 4630 R-008399280-000F 25651328 UGCCUCCAGGUGACAGCAA B UGCCUCCAGGUGACAGCAATT B 4632 R-008399280-000F2565 1328 UGCCUCCAGGUGACAGCAA UUGCUGUCACCUGGAGGCAUU 4633R-008399283-000G 442 1329 UACCUCCCAAGUCCUGUAU AUACAGGACUUGGGAGGUAUU 4635R-008399283-000G 442 1329 UACCUCCCAAGUCCUGUAU B UACCUCCCAAGUCCUGUAUTT B4634 R-008399286-000H 819 1330 CCAGACACGCUAUCAUGCG CGCAUGAUAGCGUGUCUGGUU4637 R-008399286-000H 819 1330 CCAGACACGCUAUCAUGCG BCCAGACACGCUAUCAUGCGTT B 4636 R-008399289-000J 700 1331UGAUGCAGAACUUGCCACA B UGAUGCAGAACUUGCCACATT B 4638 R-008399289-000J 7001331 UGAUGCAGAACUUGCCACA UGUGGCAAGUUCUGCAUCAUU 4639 R-008399292-000R1089 1332 GUUUAGCUGGUGGGCUGCA B GUUUAGCUGGUGGGCUGCATT B 4640R-008399292-000R 1089 1332 GUUUAGCUGGUGGGCUGCA UGCAGCCCACCAGCUAAACUU4641 R-008399295-000S 1580 1333 GUCUGCCAAGUGGGUGGUAUACCACCCACUUGGCAGACUU 4643 R-008399295-000S 1580 1333GUCUGCCAAGUGGGUGGUA B GUCUGCCAAGUGGGUGGUATT B 4642 R-008399298-000T 19821334 GGUUGUACCGGAGCCCUUC GAAGGGCUCCGGUACAACCUU 4645 R-008399298-000T1982 1334 GGUUGUACCGGAGCCCUUC B GGUUGUACCGGAGCCCUUCTT B 4644R-008399301-000K 1986 1335 GUACCGGAGCCCUUCACAU B GUACCGGAGCCCUUCACAUTT B4646 R-008399301-000K 1986 1335 GUACCGGAGCCCUUCACAUAUGUGAAGGGCUCCGGUACUU 4647 R-008399304-000L 418 1336 CAAUCCUGAGGAAGAGGAUAUCCUCUUCCUCAGGAUUGUU 4649 R-008399304-000L 418 1336 CAAUCCUGAGGAAGAGGAUB CAAUCCUGAGGAAGAGGAUTT B 4648 R-008399307-000M 1306 1337GCUAUCUGUCUGCUCUAGU ACUAGAGCAGACAGAUAGCUU 4651 R-008399307-000M 13061337 GCUAUCUGUCUGCUCUAGU B GCUAUCUGUCUGCUCUAGUTT B 4650 R-008399310-000U1377 1338 UGACAGAUCCAAGUCAACG CGUUGACUUGGAUCUGUCAUU 4653R-008399310-000U 1377 1338 UGACAGAUCCAAGUCAACG B UGACAGAUCCAAGUCAACGTT B4652 R-008399313-000V 2467 1339 CAUGAUGGAACAUGAGAUGCAUCUCAUGUUCCAUCAUGUU 4655 R-008399313-000V 2467 1339CAUGAUGGAACAUGAGAUG B CAUGAUGGAACAUGAGAUGTT B 4654 R-008399316-000W 14141340 UUGGACUCUCAGGAAUCUU B UUGGACUCUCAGGAAUCUUTT B 4656 R-008399316-000W1414 1340 UUGGACUCUCAGGAAUCUU AAGAUUCCUGAGAGUCCAAUU 4657R-008399319-000X 1668 1341 CUCUUCGUCAUCUGACCAG B CUCUUCGUCAUCUGACCAGTT B4658 R-008399319-000X 1668 1341 CUCUUCGUCAUCUGACCAGCUGGUCAGAUGACGAAGAGUU 4659 R-008399322-000D 1818 1342UUGCCCUUUGUCCCGCAAA B UUGCCCUUUGUCCCGCAAATT B 4660 R-008399322-000D 18181342 UUGCCCUUUGUCCCGCAAA UUUGCGGGACAAAGGGCAAUU 4661 R-008399325-000E1697 1343 GAAGCAGAGAUGGCCCAGA B GAAGCAGAGAUGGCCCAGATT B 4662R-008399325-000E 1697 1343 GAAGCAGAGAUGGCCCAGA UCUGGGCCAUCUCUGCUUCUU4663 R-008399328-000F 918 1344 CCUUGCAUAACCUUUCCCA BCCUUGCAUAACCUUUCCCATT B 4664 R-008399328-000F 918 1344CCUUGCAUAACCUUUCCCA UGGGAAAGGUUAUGCAAGGUU 4665 R-008399331-000M 605 1345CAGUUUGAUGCUGCUCAUC GAUGAGCAGCAUCAAACUGUU 4667 R-008399331-000M 605 1345CAGUUUGAUGCUGCUCAUC B CAGUUUGAUGCUGCUCAUCTT B 4666 R-008399334-000N 13741346 ACCUGACAGAUCCAAGUCA B ACCUGACAGAUCCAAGUCATT B 4668 R-008399334-000N1374 1346 ACCUGACAGAUCCAAGUCA UGACUUGGAUCUGUCAGGUUU 4669R-008399337-000P 1430 1347 CUUUCAGAUGCUGCAACUA UAGUUGCAGCAUCUGAAAGUU4671 R-008399337-000P 1430 1347 CUUUCAGAUGCUGCAACUA BCUUUCAGAUGCUGCAACUATT B 4670 R-008399340-000W 3186 1348GAUACGAUGCUUCAAGAGA UCUCUUGAAGCAUCGUAUCUU 4673 R-008399340-000W 31861348 GAUACGAUGCUUCAAGAGA B GAUACGAUGCUUCAAGAGATT B 4672 R-008399343-000X1355 1349 AUGCAAGCUUUAGGACUUC B AUGCAAGCUUUAGGACUUCTT B 4674R-008399343-000X 1355 1349 AUGCAAGCUUUAGGACUUC GAAGUCCUAAAGCUUGCAUUU4675 R-008399346-000Y 433 1350 GGAUGUGGAUACCUCCCAA UUGGGAGGUAUCCACAUCCUU4677 R-008399346-000Y 433 1350 GGAUGUGGAUACCUCCCAA BGGAUGUGGAUACCUCCCAATT B 4676 R-008399349-000Z 1901 13CAGGAUACCCAGCGCCGUA B CAGGAUACCCAGCGCCGUATT B 4678 R-008399349-000Z 190113 CAGGAUACCCAGCGCCGUA UACGGCGCUGGGUAUCCUGUU 4679 R-008399352-000F 17131351 AGAAUGCAGUUCGCCUUCA UGAAGGCGAACUGCAUUCUUU 4681 R-008399352-000F1713 1351 AGAAUGCAGUUCGCCUUCA B AGAAUGCAGUUCGCCUUCATT B 4680R-008399355-000G 823 17 ACACGCUAUCAUGCGUUCU AGAACGCAUGAUAGCGUGUUU 4683R-008399355-000G 823 17 ACACGCUAUCAUGCGUUCU B ACACGCUAUCAUGCGUUCUTT B4682 R-008399358-000H 1811 1352 CGAAAUCUUGCCCUUUGUC BCGAAAUCUUGCCCUUUGUCTT B 4684 R-008399358-000H 1811 1352CGAAAUCUUGCCCUUUGUC GACAAAGGGCAAGAUUUCGUU 4685 R-008399361-000P 491 1353ACUCAAGAACAAGUAGCUG B ACUCAAGAACAAGUAGCUGTT B 4686 R-008399361-000P 4911353 ACUCAAGAACAAGUAGCUG CAGCUACUUGUUCUUGAGUUU 4687 R-008399364-000R2209 1354 GAAUGAAGGUGUGGCGACA UGUCGCCACACCUUCAUUCUU 4689R-008399364-000R 2209 1354 GAAUGAAGGUGUGGCGACA B GAAUGAAGGUGUGGCGACATT B4688 R-008399367-000S 1840 1355 UGCACCUUUGCGUGAGCAG BUGCACCUUUGCGUGAGCAGTT B 4690 R-008399367-000S 1840 1355UGCACCUUUGCGUGAGCAG CUGCUCACGCAAAGGUGCAUU 4691 R-008399370-000Y 550 1356ACGAGCUGCUAUGUUCCCU AGGGAACAUAGCAGCUCGUUU 4693 R-008399370-000Y 550 1356ACGAGCUGCUAUGUUCCCU B ACGAGCUGCUAUGUUCCCUTT B 4692 R-008399373-000Z 4291357 AAGAGGAUGUGGAUACCUC GAGGUAUCCACAUCCUCUUUU 4695 R-008399373-000Z 4291357 AAGAGGAUGUGGAUACCUC B AAGAGGAUGUGGAUACCUCTT B 4694 R-008399376-000A2436 1358 GAUAUGGCCAGGAUGCCUU AAGGCAUCCUGGCCAUAUCUU 4697R-008399376-000A 2436 1358 GAUAUGGCCAGGAUGCCUU B GAUAUGGCCAGGAUGCCUUTT B4696 R-008399379-000B 1597 1359 UAUAGAGGCUCUUGUGCGU BUAUAGAGGCUCUUGUGCGUTT B 4698 R-008399379-000B 1597 1359UAUAGAGGCUCUUGUGCGU ACGCACAAGAGCCUCUAUAUU 4699 R-008399382-000H 14961360 GGUUCAGAUGAUAUAAAUG B GGUUCAGAUGAUAUAAAUGTT B 4700 R-008399382-000H1496 1360 GGUUCAGAUGAUAUAAAUG CAUUUAUAUCAUCUGAACCUU 4701R-008399385-000J 1456 1361 AGGGAUGGAAGGUCUCCUU AAGGAGACCUUCCAUCCCUUU4703 R-008399385-000J 1456 1361 AGGGAUGGAAGGUCUCCUU BAGGGAUGGAAGGUCUCCUUTT B 4702 R-008399388-000K 3159 1362UAUCCCAAAGUUGUUGUAA UUACAACAACUUUGGGAUAUU 4705 R-008399388-000K 31591362 UAUCCCAAAGUUGUUGUAA B UAUCCCAAAGUUGUUGUAATT B 4704 R-008399391-000S2309 1363 UCUCUCUUCAGAACAGAGC B UCUCUCUUCAGAACAGAGCTT B 4706R-008399391-000S 2309 1363 UCUCUCUUCAGAACAGAGC GCUCUGUUCUGAAGAGAGAUU4707 R-008399394-000T 2300 1364 CUGACCAGCUCUCUCUUCA BCUGACCAGCUCUCUCUUCATT B 4708 R-008399394-000T 2300 1364CUGACCAGCUCUCUCUUCA UGAAGAGAGAGCUGGUCAGUU 4709 R-008399397-000U 31771365 ACCUGCUGUGAUACGAUGC B ACCUGCUGUGAUACGAUGCTT B 4710 R-008399397-000U3177 1365 ACCUGCUGUGAUACGAUGC GCAUCGUAUCACAGCAGGUUU 4711R-008399400-000L 1079 1366 AUGGCAGUGCGUUUAGCUG B AUGGCAGUGCGUUUAGCUGTT B4712 R-008399400-000L 1079 1366 AUGGCAGUGCGUUUAGCUGCAGCUAAACGCACUGCCAUUU 4713 R-008399403-000M 1383 1367AUCCAAGUCAACGUCUUGU ACAAGACGUUGACUUGGAUUU 4715 R-008399403-000M 13831367 AUCCAAGUCAACGUCUUGU B AUCCAAGUCAACGUCUUGUTT B 4714 R-008399406-000N2563 1368 GCUGCCUCCAGGUGACAGC GCUGUCACCUGGAGGCAGCUU 4717R-008399406-000N 2563 1368 GCUGCCUCCAGGUGACAGC B GCUGCCUCCAGGUGACAGCTT B4716 R-008399409-000P 1084 1369 AGUGCGUUUAGCUGGUGGG BAGUGCGUUUAGCUGGUGGGTT B 4718 R-008399409-000P 1084 1369AGUGCGUUUAGCUGGUGGG CCCACCAGCUAAACGCACUUU 4719 R-008399412-000W 13291370 AGCCGGCUAUUGUAGAAGC B AGCCGGCUAUUGUAGAAGCTT B 4720 R-008399412-000W1329 1370 AGCCGGCUAUUGUAGAAGC GCUUCUACAAUAGCCGGCUUU 4721R-008399415-000X 1662 169 UCUGUGCUCUUCGUCAUCU AGAUGACGAAGAGCACAGAUU 4723R-008399415-000X 1662 169 UCUGUGCUCUUCGUCAUCU B UCUGUGCUCUUCGUCAUCUTT B4722 R-008399418-000Y 2268 99 CACAAGAUUACAAGAAACG CGUUUCUUGUAAUCUUGUGUU4725 R-008399418-000Y 2268 99 CACAAGAUUACAAGAAACG BCACAAGAUUACAAGAAACGTT B 4724 R-008399421-000E 2470 108GAUGGAACAUGAGAUGGGU B GAUGGAACAUGAGAUGGGUTT B 4726 R-008399421-000E 2470108 GAUGGAACAUGAGAUGGGU ACCCAUCUCAUGUUCCAUCUU 4727 R-008399424-000F 5731371 CAUUAGAUGAGGGCAUGCA B CAUUAGAUGAGGGCAUGCATT B 4728 R-008399424-000F573 1371 CAUUAGAUGAGGGCAUGCA UGCAUGCCCUCAUCUAAUGUU 4729 R-008399427-000G2213 1372 GAAGGUGUGGCGACAUAUG B GAAGGUGUGGCGACAUAUGTT B 4730R-008399427-000G 2213 1372 GAAGGUGUGGCGACAUAUG CAUAUGUCGCCACACCUUCUU4731 R-008399430-000N 1587 1373 AAGUGGGUGGUAUAGAGGC BAAGUGGGUGGUAUAGAGGCTT B 4732 R-008399430-000N 1587 1373AAGUGGGUGGUAUAGAGGC GCCUCUAUACCACCCACUUUU 4733 R-008399433-000P 21661374 CUGAGGGAGCCACAGCUCC B CUGAGGGAGCCACAGCUCCTT B 4734 R-008399433-000P2166 1374 CUGAGGGAGCCACAGCUCC GGAGCUGUGGCUCCCUCAGUU 4735R-008399436-000R 637 1375 GCGUUUGGCUGAACCAUCA UGAUGGUUCAGCCAAACGCUU 4737R-008399436-000R 637 1375 GCGUUUGGCUGAACCAUCA B GCGUUUGGCUGAACCAUCATT B4736 R-008399439-000S 397 1376 UCCUUCUCUGAGUGGUAAA BUCCUUCUCUGAGUGGUAAATT B 4738 R-008399439-000S 397 1376UCCUUCUCUGAGUGGUAAA UUUACCACUCAGAGAAGGAUU 4739 R-008399442-000Y 17181377 GCAGUUCGCCUUCACUAUG B GCAGUUCGCCUUCACUAUGTT B 4740 R-008399442-000Y1718 1377 GCAGUUCGCCUUCACUAUG CAUAGUGAAGGCGAACUGCUU 4741R-008399445-000Z 1415 111 UGGACUCUCAGGAAUCUUU B UGGACUCUCAGGAAUCUUUTT B4742 R-008399445-000Z 1415 111 UGGACUCUCAGGAAUCUUU AAAGAUUCCUGAGAGUCCAUU4743 R-008399448-000A 1413 162 UUUGGACUCUCAGGAAUCU BUUUGGACUCUCAGGAAUCUTT B 4744 R-008399448-000A 1413 162UUUGGACUCUCAGGAAUCU AGAUUCCUGAGAGUCCAAAUU 4745 R-008399451-000G 2445 160AGGAUGCCUUGGGUAUGGA B AGGAUGCCUUGGGUAUGGATT B 4746 R-008399451-000G 2445160 AGGAUGCCUUGGGUAUGGA UCCAUACCCAAGGCAUCCUUU 4747 R-008399454-000H 567157 CUGAGACAUUAGAUGAGGG B CUGAGACAUUAGAUGAGGGTT B 4748 R-008399454-000H567 157 CUGAGACAUUAGAUGAGGG CCCUCAUCUAAUGUCUCAGUU 4749 R-008399457-000J1498 86 UUCAGAUGAUAUAAAUGUG CACAUUUAUAUCAUCUGAAUU 4751 R-008399457-000J1498 86 UUCAGAUGAUAUAAAUGUG B UUCAGAUGAUAUAAAUGUGTT B 4750R-008399460-000R 2357 1378 GGACUUGAUAUUGGUGCCC B GGACUUGAUAUUGGUGCCCTT B4752 R-008399460-000R 2357 1378 GGACUUGAUAUUGGUGCCCGGGCACCAAUAUCAAGUCCUU 4753 R-008399463-000S 639 1379 GUUUGGCUGAACCAUCACAUGUGAUGGUUCAGCCAAACUU 4755 R-008399463-000S 639 1379 GUUUGGCUGAACCAUCACAB GUUUGGCUGAACCAUCACATT B 4754 R-008399466-000T 585 1380GCAUGCAGAUCCCAUCUAC GUAGAUGGGAUCUGCAUGCUU 4757 R-008399466-000T 585 1380GCAUGCAGAUCCCAUCUAC B GCAUGCAGAUCCCAUCUACTT B 4756 R-008399469-000U 25191381 GAUGGGCUGCCAGAUCUGG B GAUGGGCUGCCAGAUCUGGTT B 4758 R-008399469-000U2519 1381 GAUGGGCUGCCAGAUCUGG CCAGAUCUGGCAGCCCAUCUU 4759R-008399472-000A 1367 1382 GGACUUCACCUGACAGAUC B GGACUUCACCUGACAGAUCTT B4760 R-008399472-000A 1367 1382 GGACUUCACCUGACAGAUCGAUCUGUCAGGUGAAGUCCUU 4761 R-008399475-000B 1391 1383CAACGUCUUGUUCAGAACU B CAACGUCUUGUUCAGAACUTT B 4762 R-008399475-000B 13911383 CAACGUCUUGUUCAGAACU AGUUCUGAACAAGACGUUGUU 4763 R-008399478-000C 5091384 GAUAUUGAUGGACAGUAUG B GAUAUUGAUGGACAGUAUGTT B 4764 R-008399478-000C509 1384 GAUAUUGAUGGACAGUAUG CAUACUGUCCAUCAAUAUCUU 4765 R-008399481-000J303 1385 UGGCCAUGGAACCAGACAG B UGGCCAUGGAACCAGACAGTT B 4766R-008399481-000J 303 1385 UGGCCAUGGAACCAGACAG CUGUCUGGUUCCAUGGCCAUU 4767R-008399484-000K 494 1386 CAAGAACAAGUAGCUGAUA UAUCAGCUACUUGUUCUUGUU 4769R-008399484-000K 494 1386 CAAGAACAAGUAGCUGAUA B CAAGAACAAGUAGCUGAUATT B4768 R-008399487-000L 328 1387 GGCUGUUAGUCACUGGCAG CUGCCAGUGACUAACAGCCUU4771 R-008399487-000L 328 1387 GGCUGUUAGUCACUGGCAG BGGCUGUUAGUCACUGGCAGTT B 4770 R-008399490-000T 2058 1388CAUUGUUUGUGCAGCUGCU AGCAGCUGCACAAACAAUGUU 4773 R-008399490-000T 20581388 CAUUGUUUGUGCAGCUGCU B CAUUGUUUGUGCAGCUGCUTT B 4772 R-008399493-000U1447 1389 UAAACAGGAAGGGAUGGAA B UAAACAGGAAGGGAUGGAATT B 4774R-008399493-000U 1447 1389 UAAACAGGAAGGGAUGGAA UUCCAUCCCUUCCUGUUUAUU4775 R-008399496-000V 1563 1390 AUAAGAACAAGAUGAUGGUACCAUCAUCUUGUUCUUAUUU 4777 R-008399496-000V 1563 1390AUAAGAACAAGAUGAUGGU B AUAAGAACAAGAUGAUGGUTT B 4776 R-008399499-000W 13501391 GUGGAAUGCAAGCUUUAGG CCUAAAGCUUGCAUUCCACUU 4779 R-008399499-000W1350 1391 GUGGAAUGCAAGCUUUAGG B GUGGAAUGCAAGCUUUAGGTT B 4778R-008399502-000N 2208 1392 GGAAUGAAGGUGUGGCGAC GUCGCCACACCUUCAUUCCUU4781 R-008399502-000N 2208 1392 GGAAUGAAGGUGUGGCGAC BGGAAUGAAGGUGUGGCGACTT B 4780 R-008399505-000P 1689 1393GACACCAAGAAGCAGAGAU AUCUCUGCUUCUUGGUGUCUU 4783 R-008399505-000P 16891393 GACACCAAGAAGCAGAGAU B GACACCAAGAAGCAGAGAUTT B 4782 R-008399508-000R1407 1394 ACUGUCUUUGGACUCUCAG B ACUGUCUUUGGACUCUCAGTT B 4784R-008399508-000R 1407 1394 ACUGUCUUUGGACUCUCAG CUGAGAGUCCAAAGACAGUUU4785 R-008399511-000X 2137 1395 GGACAAGGAAGCUGCAGAA BGGACAAGGAAGCUGCAGAATT B 4786 R-008399511-000X 2137 1395GGACAAGGAAGCUGCAGAA UUCUGCAGCUUCCUUGUCCUU 4787 R-008399514-000Y 854 1396UCUGCUAUUGUACGUACCA B UCUGCUAUUGUACGUACCATT B 4788 R-008399514-000Y 8541396 UCUGCUAUUGUACGUACCA UGGUACGUACAAUAGCAGAUU 4789 R-008399517-000Z2070 1397 AGCUGCUUUAUUCUCCCAU AUGGGAGAAUAAAGCAGCUUU 4791R-008399517-000Z 2070 1397 AGCUGCUUUAUUCUCCCAU B AGCUGCUUUAUUCUCCCAUTT B4790 R-008399520-000F 545 1398 AGGGUACGAGCUGCUAUGU ACAUAGCAGCUCGUACCCUUU4793 R-008399520-000F 545 1398 AGGGUACGAGCUGCUAUGU BAGGGUACGAGCUGCUAUGUTT B 4792 R-008399523-000G 1640 1399GAAGACAUCACUGAGCCUG B GAAGACAUCACUGAGCCUGTT B 4794 R-008399523-000G 16401399 GAAGACAUCACUGAGCCUG CAGGCUCAGUGAUGUCUUCUU 4795 R-008399526-000H2012 1400 CGGGAUGUUCACAACCGAA UUCGGUUGUGAACAUCCCGUU 4797R-008399526-000H 2012 1400 CGGGAUGUUCACAACCGAA B CGGGAUGUUCACAACCGAATT B4796 R-008399529-000J 1684 1401 CAGCCGACACCAAGAAGCA BCAGCCGACACCAAGAAGCATT B 4798 R-008399529-000J 1684 1401CAGCCGACACCAAGAAGCA UGCUUCUUGGUGUCGGCUGUU 4799 R-008399535-000S 520 9ACAGUAUGCAAUGACUCGA UCGAGUCAUUGCAUACUGUUU 4801 R-008399535-000S 520 9ACAGUAUGCAAUGACUCGA B ACAGUAUGCAAUGACUCGATT B 4800 R-008399538-000T 1969182 AGAAAUAGUUGAAGGUUGU B AGAAAUAGUUGAAGGUUGUTT B 4802 R-008399538-000T1969 182 AGAAAUAGUUGAAGGUUGU ACAACCUUCAACUAUUUCUUU 4803 R-008399541-000Z2017 1402 UGUUCACAACCGAAUUGUU B UGUUCACAACCGAAUUGUUTT B 4804R-008399541-000Z 2017 1402 UGUUCACAACCGAAUUGUU AACAAUUCGGUUGUGAACAUU4805 R-008399544-000A 2307 1403 GCUCUCUCUUCAGAACAGA BGCUCUCUCUUCAGAACAGATT B 4806 R-008399544-000A 2307 1403GCUCUCUCUUCAGAACAGA UCUGUUCUGAAGAGAGAGCUU 4807 R-008399547-000B 844 1404UCAGAUGGUGUCUGCUAUU B UCAGAUGGUGUCUGCUAUUTT B 4808 R-008399547-000B 8441404 UCAGAUGGUGUCUGCUAUU AAUAGCAGACACCAUCUGAUU 4809 R-008399550-000H 4051405 UGAGUGGUAAAGGCAAUCC GGAUUGCCUUUACCACUCAUU 4811 R-008399550-000H 4051405 UGAGUGGUAAAGGCAAUCC B UGAGUGGUAAAGGCAAUCCTT B 4810 R-008399553-000J379 1406 UGGUGCCACUACCACAGCU B UGGUGCCACUACCACAGCUTT B 4812R-008399553-000J 379 1406 UGGUGCCACUACCACAGCU AGCUGUGGUAGUGGCACCAUU 4813R-008399556-000K 1825 1407 UUGUCCCGCAAAUCAUGCA B UUGUCCCGCAAAUCAUGCATT B4814 R-008399556-000K 1825 1407 UUGUCCCGCAAAUCAUGCAUGCAUGAUUUGCGGGACAAUU 4815 R-008399559-000L 2495 1408CACCCUGGUGCUGACUAUC GAUAGUCAGCACCAGGGUGUU 4817 R-008399559-000L 24951408 CACCCUGGUGCUGACUAUC B CACCCUGGUGCUGACUAUCTT B 4816 R-008399562-000T629 1409 AAUGUCCAGCGUUUGGCUG B AAUGUCCAGCGUUUGGCUGTT B 4818R-008399562-000T 629 1409 AAUGUCCAGCGUUUGGCUG CAGCCAAACGCUGGACAUUUU 4819R-008399565-000U 2561 1410 GGGCUGCCUCCAGGUGACA UGUCACCUGGAGGCAGCCCUU4821 R-008399565-000U 2561 1410 GGGCUGCCUCCAGGUGACA BGGGCUGCCUCCAGGUGACATT B 4820 R-008399568-000V 2192 1411GAGUUACUUCACUCUAGGA B GAGUUACUUCACUCUAGGATT B 4822 R-008399568-000V 21921411 GAGUUACUUCACUCUAGGA UCCUAGAGUGAAGUAACUCUU 4823 R-008399571-000B1809 1412 UUCGAAAUCUUGCCCUUUG B UUCGAAAUCUUGCCCUUUGTT B 4824R-008399571-000B 1809 1412 UUCGAAAUCUUGCCCUUUG CAAAGGGCAAGAUUUCGAAUU4825 R-008399574-000C 1596 1413 GUAUAGAGGCUCUUGUGCG BGUAUAGAGGCUCUUGUGCGTT B 4826 R-008399574-000C 1596 1413GUAUAGAGGCUCUUGUGCG CGCACAAGAGCCUCUAUACUU 4827 R-008399577-000D 22981414 AGCUGACCAGCUCUCUCUU AAGAGAGAGCUGGUCAGCUUU 4829 R-008399577-000D2298 1414 AGCUGACCAGCUCUCUCUU B AGCUGACCAGCUCUCUCUUTT B 4828R-008399580-000K 858 1415 CUAUUGUACGUACCAUGCA UGCAUGGUACGUACAAUAGUU 4831R-008399580-000K 858 1415 CUAUUGUACGUACCAUGCA B CUAUUGUACGUACCAUGCATT B4830 R-008399583-000L 524 1416 UAUGCAAUGACUCGAGCUC BUAUGCAAUGACUCGAGCUCTT B 4832 R-008399583-000L 524 1416UAUGCAAUGACUCGAGCUC GAGCUCGAGUCAUUGCAUAUU 4833 R-008399586-000M 25421417 UGCCCAGGACCUCAUGGAU B UGCCCAGGACCUCAUGGAUTT B 4834 R-008399586-000M2542 1417 UGCCCAGGACCUCAUGGAU AUCCAUGAGGUCCUGGGCAUU 4835R-008399589-000N 498 1418 AACAAGUAGCUGAUAUUGA B AACAAGUAGCUGAUAUUGATT B4836 R-008399589-000N 498 1418 AACAAGUAGCUGAUAUUGA UCAAUAUCAGCUACUUGUUUU4837 R-008399592-000V 414 1419 AAGGCAAUCCUGAGGAAGA UCUUCCUCAGGAUUGCCUUUU4839 R-008399592-000V 414 1419 AAGGCAAUCCUGAGGAAGA BAAGGCAAUCCUGAGGAAGATT B 4838 R-008399595-000W 1570 1420CAAGAUGAUGGUCUGCCAA B CAAGAUGAUGGUCUGCCAATT B 4840 R-008399595-000W 15701420 CAAGAUGAUGGUCUGCCAA UUGGCAGACCAUCAUCUUGUU 4841 R-008399598-000X1030 1421 UGCCAUUACAACUCUCCAC GUGGAGAGUUGUAAUGGCAUU 4843R-008399598-000X 1030 1421 UGCCAUUACAACUCUCCAC B UGCCAUUACAACUCUCCACTT B4842 R-008399601-000P 1380 20 CAGAUCCAAGUCAACGUCU AGACGUUGACUUGGAUCUGUU4845 R-008399601-000P 1380 20 CAGAUCCAAGUCAACGUCU BCAGAUCCAAGUCAACGUCUTT B 4844 R-008399604-000R 3087 1422AUGUAUGGGUAGGGUAAAU B AUGUAUGGGUAGGGUAAAUTT B 4846 R-008399604-000R 30871422 AUGUAUGGGUAGGGUAAAU AUUUACCCUACCCAUACAUUU 4847 R-008399607-000S1664 1423 UGUGCUCUUCGUCAUCUGA B UGUGCUCUUCGUCAUCUGATT B 4848R-008399607-000S 1664 1423 UGUGCUCUUCGUCAUCUGA UCAGAUGACGAAGAGCACAUU4849 R-008399610-000Y 1790 1424 AAGGCUACUGUUGGAUUGA BAAGGCUACUGUUGGAUUGATT B 4850 R-008399610-000Y 1790 1424AAGGCUACUGUUGGAUUGA UCAAUCCAACAGUAGCCUUUU 4851 R-008399613-000Z 16151425 UACUGUCCUUCGGGCUGGU ACCAGCCCGAAGGACAGUAUU 4853 R-008399613-000Z1615 1425 UACUGUCCUUCGGGCUGGU B UACUGUCCUUCGGGCUGGUTT B 4852R-008399616-000A 774 1426 AUAAGGCUGCAGUUAUGGU ACCAUAACUGCAGCCUUAUUU 4855R-008399616-000A 774 1426 AUAAGGCUGCAGUUAUGGU B AUAAGGCUGCAGUUAUGGUTT B4854 R-008399619-000B 1672 1427 UCGUCAUCUGACCAGCCGAUCGGCUGGUCAGAUGACGAUU 4857 R-008399619-000B 1672 1427UCGUCAUCUGACCAGCCGA B UCGUCAUCUGACCAGCCGATT B 4856 R-008399625-000J 31711428 GUUGUAACCUGCUGUGAUA UAUCACAGCAGGUUACAACUU 4859 R-008399625-000J3171 1428 GUUGUAACCUGCUGUGAUA B GUUGUAACCUGCUGUGAUATT B 4858R-008399628-000K 2271 1429 AAGAUUACAAGAAACGGCU B AAGAUUACAAGAAACGGCUTT B4860 R-008399628-000K 2271 1429 AAGAUUACAAGAAACGGCUAGCCGUUUCUUGUAAUCUUUU 4861 R-008399631-000S 1183 1430UUAUGGCAACCAAGAAAGC B UUAUGGCAACCAAGAAAGCTT B 4862 R-008399631-000S 11831430 UUAUGGCAACCAAGAAAGC GCUUUCUUGGUUGCCAUAAUU 4863 R-008399634-000T2512 1431 UCCAGUUGAUGGGCUGCCA B UCCAGUUGAUGGGCUGCCATT B 4864R-008399634-000T 2512 1431 UCCAGUUGAUGGGCUGCCA UGGCAGCCCAUCAACUGGAUU4865 R-008399637-000U 1521 132 CCUGUGCAGCUGGAAUUCU AGAAUUCCAGCUGCACAGGUU4867 R-008399637-000U 1521 132 CCUGUGCAGCUGGAAUUCU BCCUGUGCAGCUGGAAUUCUTT B 4866 R-008399640-000A 1931 1432GGGACACAGCAGCAAUUUG CAAAUUGCUGCUGUGUCCCUU 4869 R-008399640-000A 19311432 GGGACACAGCAGCAAUUUG B GGGACACAGCAGCAAUUUGTT B 4868 R-008399643-000B2468 1433 AUGAUGGAACAUGAGAUGG B AUGAUGGAACAUGAGAUGGTT B 4870R-008399643-000B 2468 1433 AUGAUGGAACAUGAGAUGG CCAUCUCAUGUUCCAUCAUUU4871 R-008399646-000C 3077 1434 UAUUUGGGAUAUGUAUGGG BUAUUUGGGAUAUGUAUGGGTT B 4872 R-008399646-000C 3077 1434UAUUUGGGAUAUGUAUGGG CCCAUACAUAUCCCAAAUAUU 4873 R-008399649-000D 20691435 CAGCUGCUUUAUUCUCCCA UGGGAGAAUAAAGCAGCUGUU 4875 R-008399649-000D2069 1435 CAGCUGCUUUAUUCUCCCA B CAGCUGCUUUAUUCUCCCATT B 4874R-008399652-000K 272 1436 GCUACUCAAGCUGAUUUGA B GCUACUCAAGCUGAUUUGATT B4876 R-008399652-000K 272 1436 GCUACUCAAGCUGAUUUGA UCAAAUCAGCUUGAGUAGCUU4877 R-008399655-000L 564 1437 UCCCUGAGACAUUAGAUGA UCAUCUAAUGUCUCAGGGAUU4879 R-008399655-000L 564 1437 UCCCUGAGACAUUAGAUGA BUCCCUGAGACAUUAGAUGATT B 4878 R-008399658-000M 437 1438GUGGAUACCUCCCAAGUCC GGACUUGGGAGGUAUCCACUU 4881 R-008399658-000M 437 1438GUGGAUACCUCCCAAGUCC B GUGGAUACCUCCCAAGUCCTT B 4880 R-008399661-000U 22061439 UAGGAAUGAAGGUGUGGCG B UAGGAAUGAAGGUGUGGCGTT B 4882 R-008399661-000U2206 1439 UAGGAAUGAAGGUGUGGCG CGCCACACCUUCAUUCCUAUU 4883R-008399664-000V 2187 1440 UGACAGAGUUACUUCACUC GAGUGAAGUAACUCUGUCAUU4885 R-008399664-000V 2187 1440 UGACAGAGUUACUUCACUC BUGACAGAGUUACUUCACUCTT B 4884 R-008399667-000W 325 1441AGCGGCUGUUAGUCACUGG CCAGUGACUAACAGCCGCUUU 4887 R-008399667-000W 325 1441AGCGGCUGUUAGUCACUGG B AGCGGCUGUUAGUCACUGGTT B 4886 R-008399670-000C 32221442 AUGGUUCAGAAUUAAACUU B AUGGUUCAGAAUUAAACUUTT B 4888 R-008399670-000C3222 1442 AUGGUUCAGAAUUAAACUU AAGUUUAAUUCUGAACCAUUU 4889R-008399673-000D 2024 1443 AACCGAAUUGUUAUCAGAG B AACCGAAUUGUUAUCAGAGTT B4890 R-008399673-000D 2024 1443 AACCGAAUUGUUAUCAGAGCUCUGAUAACAAUUCGGUUUU 4891 R-008399676-000E 1858 1444GGGUGCCAUUCCACGACUA B GGGUGCCAUUCCACGACUATT B 4892 R-008399676-000E 18581444 GGGUGCCAUUCCACGACUA UAGUCGUGGAAUGGCACCCUU 4893 R-008399679-000F1574 1445 AUGAUGGUCUGCCAAGUGG B AUGAUGGUCUGCCAAGUGGTT B 4894R-008399679-000F 1574 1445 AUGAUGGUCUGCCAAGUGG CCACUUGGCAGACCAUCAUUU4895 R-008399682-000M 1638 78 GGGAAGACAUCACUGAGCC BGGGAAGACAUCACUGAGCCTT B 4896 R-008399682-000M 1638 78GGGAAGACAUCACUGAGCC GGCUCAGUGAUGUCUUCCCUU 4897 R-008399685-000N 18961446 CACAUCAGGAUACCCAGCG B CACAUCAGGAUACCCAGCGTT B 4898 R-008399685-000N1896 1446 CACAUCAGGAUACCCAGCG CGCUGGGUAUCCUGAUGUGUU 4899R-008399688-000P 2207 1447 AGGAAUGAAGGUGUGGCGA B AGGAAUGAAGGUGUGGCGATT B4900 R-008399688-000P 2207 1447 AGGAAUGAAGGUGUGGCGAUCGCCACACCUUCAUUCCUUU 4901 R-008399691-000W 1300 1448GAAGGUGCUAUCUGUCUGC B GAAGGUGCUAUCUGUCUGCTT B 4902 R-008399691-000W 13001448 GAAGGUGCUAUCUGUCUGC GCAGACAGAUAGCACCUUCUU 4903 R-008399694-000X1192 1449 CCAAGAAAGCAAGCUCAUC GAUGAGCUUGCUUUCUUGGUU 4905R-008399694-000X 1192 1449 CCAAGAAAGCAAGCUCAUC B CCAAGAAAGCAAGCUCAUCTT B4904 R-008399697-000Y 551 1450 CGAGCUGCUAUGUUCCCUG BCGAGCUGCUAUGUUCCCUGTT B 4906 R-008399697-000Y 551 1450CGAGCUGCUAUGUUCCCUG CAGGGAACAUAGCAGCUCGUU 4907 R-008399700-000R 24981451 CCUGGUGCUGACUAUCCAG B CCUGGUGCUGACUAUCCAGTT B 4908 R-008399700-000R2498 1451 CCUGGUGCUGACUAUCCAG CUGGAUAGUCAGCACCAGGUU 4909R-008399703-000S 1305 1452 UGCUAUCUGUCUGCUCUAG B UGCUAUCUGUCUGCUCUAGTT B4910 R-008399703-000S 1305 1452 UGCUAUCUGUCUGCUCUAGCUAGAGCAGACAGAUAGCAUU 4911 R-008399706-000T 1337 1453AUUGUAGAAGCUGGUGGAA B AUUGUAGAAGCUGGUGGAATT B 4912 R-008399706-000T 13371453 AUUGUAGAAGCUGGUGGAA UUCCACCAGCUUCUACAAUUU 4913 R-008472717-000G1870 194 ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UsU B 2147R-008472717-000G 1870 194 ACGACUAGUUCAGUUGCUU aaGCAAcUgAAcuagUCGUUsU6367 R-008472765-000B 1870 194 ACGACUAGUUCAGUUGCUUaaGCaAcUGAAcuaGUCGUUsU 6368 R-008472765-000B 1870 194ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UsU B 2147 R-008488882-000B1797 5 CUGUUGGAUUGAUUCGAAA B CUGUUGGAUUGAUUCGAAAUU B 6370R-008488882-000B 1797 5 CUGUUGGAUUGAUUCGAAA uuucGAauCaAUCcAaCaGUU 6369R-008488887-000V 1870 194 ACGACUAGUUCAGUUGCUU aaGCAAcUgAaCuagUcGUUU 6371R-008488887-000V 1870 194 ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU UUU B 6372 R-008488885-000C 1870 194 ACGACUAGUUCAGUUGCUUaaGCAAcUgAAcuagUCGUUU 6373 R-008488885-000C 1870 194 ACGACUAGUUCAGUUGCUUB aCgaC UAguUCAGUUGCU U UU B 6372 R-008488889-000M 1870 194ACGACUAGUUCAGUUGCUU B aCgaC UAguUCAGUUGCU U UU B 6372 R-008488889-000M1870 194 ACGACUAGUUCAGUUGCUU aaGCaAcUGAAcuaGUCGUUU 6374wherein:A, C, G, and U=ribose A, C, G or Ua, g, c and u=2′-deoxy-2′-fluoro A, G, C or U

A, U, C and G=2′-O-methyl (2′-OMe) A, U, C, or G

A, U, C, and G=deoxy A, U, C, or GB=inverted abasicT=thymidineI=inosines=phosphorothioate linkage

Further Synthesis Steps for Commercial Preparation

Once analysis indicates that the target product purity has been achievedafter the annealing step, the material is transferred to the tangentialflow filtration (TFF) system for concentration and desalting, as opposedto doing this prior to the annealing step.

Ultrafiltration: The annealed product solution is concentrated using aTFF system containing an appropriate molecular weight cut-off membrane.Following concentration, the product solution is desalted viadiafiltration using Milli-Q water until the conductivity of the filtrateis that of water.

Lyophilization: The concentrated solution is transferred to a bottle,flash frozen and attached to a lyophilizer. The product is thenfreeze-dried to a powder. The bottle is removed from the lyophilizer andis now ready for use.

Initial Screening Protocol (96-Well Plate Transfections)

Cell Culture Preparation:

Human hepatoma cell line, HepG2, rhesus kidney epithelial cell line,LLC-MK2 Derivative, and the Huh7 cell line, were grown in modifiedEagle's medium. All the culture media were supplemented with 10% fetalbovine serum, 100 μg/mL streptomycin, 100 U/mL penicillin, and 1% sodiumbicarbonate.

Transfection and Screening

Cells were plated in all wells of tissue-culture treated, 96-well platesat a final count of 3500 (HepG2 and LLC-MK2 Derivative and Huh7)cells/well in 100 μL of the appropriate culture media. The cells werecultured for overnight after plating at 37° C. in the presence of 5%CO₂.

On the next day, complexes containing siNA and RNAiMax (Invitrogen) werecreated as follows. A solution of RNAiMax diluted 33-fold in OPTI-MEMwas prepared. In parallel, solutions of the siNAs for testing wereprepared to a final concentration of 120 nM in OPTI-MEM. Afterincubation of RNAiMax/OPTI-MEM solution at room temperature for 5 min,an equal volume of the siNA solution and the RNAiMax solution were addedtogether for each of the siNAs.

Mixing resulted in a solution of siNA/RNAiMax where the concentration ofsiNA was 60 nM. This solution was incubated at room temperature for 20minutes. After incubation, 20 μL of the solution was added to each ofthe relevant wells. The final concentration of siNA in each well was 10nM and the final volume of RNAiMax in each well was 0.3 ul.

For low concentration screens, siNAs were transfected at 200, 150, 100or 75 μM per well. For 12-point dose response curve studies, the siNAseries are 6-fold serial dilution starting at 30 nM or 4-fold serialdilution starting at 40 nM. All transfections were set up as multiplebiological replicates.

The time of incubation with the RNAiMax-siNA complexes was 24 hours andthere was no change in media between transfection and harvesting forscreening and dose response curve studies. For duration assays, the timeof incubation with the RNAiMax-siNA complexes was 24, 72, and 120 hours.There was no change in media between transfection and harvesting for 24-and 72-hour time points. Media was replaced with fresh media 72 hoursafter transfection for 120-hour time point.

Cells-to-Ct and Reverse Transcription Reactions

The culture medium was aspirated and discarded from the wells of theculture plates at the desired time points. The transfected cells werewashed once with 50 uL DPBS solution per well. Fifty microliters perwell of the Lysis Solution from the TaqMan® Gene Expression Cells-to-CT™Kit (Applied Biosystems, Cat#4399002) supplemented with DNase I wasadded directly to the plates to lyse the cells. Five microliters perwell of Stop Solution from the same kit was added to the plates toinactivate DNase I 5 minutes later. The lysis plates were incubated forat least 2 minutes at room temperature. The plates can be stored for 2hours at 4° C., or −80° C. for two months.

Each well of the reverse transcription plate required 10 uL of 2×reverse transcriptase buffer, 1 uL of 20× reverse transcription enzymeand 2 uL of nuclease-free water. The reverse transcription master mixwas prepared by mixing 2× reverse transcription buffer, 20× reversetranscription enzyme mix, and nuclease-free water. 13 uL of the reversetranscription master mix was dispensed into each well of the reversetranscription plate (semi-skirted). A separate reverse transcriptionplate was prepared for each cell plate. A separate reverse transcriptionplate was prepared for each cell plate. Seven microliters per lysatefrom the cell lysis procedure described above was added into each wellof the reverse transcription plate. The plate was sealed and spun on acentrifuge (1000 rpm for 30 seconds) to settle the contents to thebottom of the reverse transcription plate. The plate was placed in athermocycler at 37° C. for 60 min, 95° C. for 5 min, and 4° C. until theplate is removed from the thermocycler. Upon removal, if not usedimmediately, the plate was frozen at −20° C.

For duration assays, a similar protocol was followed, however, the cellswere lysed 1, 3, or 5 days after transfection. cDNA was generated usingCells-to-Ct™ Kit (Applied Biosystems).

Quantitative RT-PCR (Taqman)

A series of probes and primers were used to detect the various mRNAtranscripts of the genes of CTNNB1 and GAPDH. All Taqman probes andprimers for the experiments here-in described were supplied aspre-validated sets by Applied Biosystems, Inc. (see Table 2).

TABLE 2 Probes and primers used to carry out Real-Time RT/PCR (Taqman)reactions for CTNNB1 mRNA analysis. Species Gene ABI Cat. # Human CTNNB1Hs00355045_m1 Human GAPDH 4310884E Rhesus GAPDH Rh02621745_g1 MouseCTNNB1 Mm00483033_m1 Mouse GAPDH 4352339E

The assays were performed on an ABI 7900 instrument, according to themanufacturer's instructions. A TaqMan Gene Expression Master Mix(provided in the Cells-to-CT™ Kit, Applied Biosystems, Cat #4399002) wasused. The PCR reactions were carried out at 50° C. for 2 min, 95° C. for10 min followed by 40 cycles at 95° C. for 15 secs and 60° C. for 1minute.

Within each experiment, the baseline was set in the exponential phase ofthe amplification curve, and based on the intersection point of thebaselines with the amplification curve, a Ct value was assigned by theinstrument.

Calculations

The expression level of the gene of interest and % inhibition of geneexpression (% KD) was calculated using Comparative Ct method:

ΔCt=Ct _(Target) −Ct _(GAPDH)

ΔΔCt(log 2(fold change))=ΔCt _((Target siNA)) −ΔCt _((NTC))

Relative expression level=2^(−ΔΔCt)

% KD=100×(1−2^(−ΔΔCt))

The non-targeting control siNA was, unless otherwise indicated, chosenas the value against which to calculate the percent inhibition(knockdown) of gene expression, because it is the most relevant control.

Additionally, only normalized data, which reflects the general health ofthe cell and quality of the RNA extraction, was examined. This was doneby looking at the level of two different mRNAs in the treated cells, thefirst being the target mRNA and the second being the normalizer mRNA.This allowed for elimination of siNAs that might be potentially toxic tocells rather than solely knocking down the gene of interest. This wasdone by comparing the Ct for GAPDH in each well relative to the GAPDH Ctfor the entire plate.

All calculations of IC₅₀s were performed using R.2.9.2 software. Thedata were analyzed using the sigmoidal dose-response (variable slope)equation for simple ligand binding. In all of the calculations of thepercent inhibition (knock-down), the calculation was made relative tothe normalized level of expression of the gene of interest in thesamples treated with the non-targeting control (Ctrl siNA) unlessotherwise indicated.

The level of protein was quantified using the Bio-Rad VersaDoc Imageraccording to the protocols of that piece of equipment. A pixel count wasperformed in each lane using an area of identical size. Each sample wasthen compared to the appropriate control treated sample and converted toa percent of protein remaining compared to control.

The effects of lead siNAs on CTNNB1 protein level were compared to theeffects of the universal control using a two tail Student's T-test toobtain a P value. P<0.05 was considered significant.

Results:

The CTNNB1 siNAs were designed and synthesized as described previously.Various siNAs were screened in HepG2, MK2D and Huh7 cells. The log2(fold change) in CTNNB1 gene expression data upon treatment withvarious modified CTNNB1 siNAs in human cells is shown in Table 3a. Eachscreen was performed at 24 hrs. Quantitative RT-PCR was used to assessthe level of CTNNB1 mRNA and the data were normalized to the expressionlevel of GAPDH (an ubiquitously expressed ‘house-keeping’ gene). Eachtreatment was then normalized against the non-CTNNB1 targeting control.

TABLE 3a Primary screening data in HepG2 Cells, MK2D Cells and Huh7Cells (n = 2), recorded as log 2(fold change) in CTNNB1 gene expression.HEPG2 HEPG2 MK2D MK2D Huh7 Huh7 Mean SD Mean SD Mean SD siNA Duplex IDΔΔCt ΔΔCt ΔΔCt ΔΔCt ΔΔCt ΔΔCt R-008362875-000L 5.06 0.28 5.05 0.05 4.100.12 R-008362785-000U 4.92 0.24 4.98 0.05 4.05 0.14 R-008362959-000W4.76 0.11 4.90 0.14 3.99 0.05 R-008363073-000K 4.54 0.16 5.15 0.14 3.980.60 R-008308997-000F 4.27 0.32 4.86 0.17 3.97 0.16 R-008362932-000A4.57 0.50 5.13 0.13 3.97 0.11 R-008362713-000E 4.52 0.02 4.56 0.00 3.960.20 R-008362791-000B 5.14 0.21 5.96 0.04 3.94 0.06 R-008362689-000U5.16 0.20 5.24 0.04 3.94 0.08 R-008362692-000A 0.84 0.06 4.30 0.09 3.940.00 R-008363055-000T 4.87 0.16 5.19 0.11 3.86 0.13 R-008309033-000Y4.39 0.08 5.35 0.15 3.83 0.04 R-008363058-000U 4.20 0.23 4.68 0.22 3.830.43 R-008362755-000S 4.18 0.21 4.37 0.08 3.83 0.10 R-008362821-000P4.29 0.53 4.95 0.11 3.83 0.09 R-008362722-000N 5.37 0.36 5.27 0.19 3.820.25 R-008362824-000R 4.36 0.23 4.92 0.06 3.80 0.05 R-008363070-000J4.51 0.03 4.54 0.01 3.79 0.14 R-008362686-000T 4.84 0.26 5.03 0.08 3.790.34 R-008362947-000L 4.45 0.25 4.74 0.04 3.79 0.44 R-008362728-000R4.66 0.15 4.47 0.12 3.77 0.15 R-008363019-000H 4.75 0.08 5.06 0.05 3.770.21 R-008362833-000Z 4.26 0.11 4.61 0.15 3.75 0.09 R-008362812-000F4.79 0.14 4.93 0.17 3.75 0.37 R-008363064-000B 4.54 0.11 4.87 0.16 3.750.49 R-008362980-000V 1.07 0.02 4.48 0.13 3.73 0.09 R-008362992-000E0.35 0.09 4.24 0.04 3.72 0.00 R-008362872-000K 4.28 0.26 4.77 0.11 3.700.02 R-008362677-000J 4.37 0.06 4.60 0.01 3.68 0.08 R-008362878-000M3.85 0.09 4.54 0.06 3.67 0.01 R-008363031-000Y 4.82 0.26 5.19 0.14 3.650.00 R-008363043-000H 4.89 0.27 5.61 0.03 3.65 0.04 R-008362797-000D4.77 0.03 4.31 0.09 3.63 0.09 R-008362842-000H 3.92 0.00 4.71 0.09 3.630.26 R-008362704-000W 4.11 0.16 4.38 0.12 3.60 0.17 R-008362740-000F0.66 0.11 4.74 0.10 3.60 0.00 R-008362839-000B 4.10 0.22 4.43 0.16 3.570.40 R-008362950-000T 4.73 0.08 4.80 0.21 3.55 0.03 R-008363010-000E4.28 0.12 4.44 0.09 3.51 0.40 R-008362752-000R 3.42 0.03 2.93 0.04 3.500.33 R-008362854-000T 0.72 0.26 3.93 0.09 3.49 0.00 R-008362830-000Y4.59 0.12 4.90 0.04 3.48 0.03 R-008363016-000G 4.14 0.09 4.35 0.02 3.450.05 R-008362998-000G 4.29 0.18 4.05 0.12 3.45 0.01 R-008362674-000H4.55 0.14 4.55 0.01 3.45 0.32 R-008362938-000C 4.27 0.10 5.01 0.22 3.440.27 R-008362788-000V 4.11 0.21 4.48 0.09 3.44 0.11 R-008362884-000V4.11 0.08 4.90 0.13 3.44 0.11 R-008362896-000E 3.91 0.18 3.86 0.06 3.440.29 R-008363061-000A 3.84 0.17 4.34 0.01 3.43 0.14 R-008362782-000T3.73 0.60 5.27 0.13 3.43 0.43 R-008362776-000K 4.08 0.15 4.33 0.15 3.430.12 R-008362764-000A 1.00 0.02 4.82 0.14 3.40 0.31 R-008362683-000S0.85 0.00 4.80 0.12 3.39 0.32 R-008362869-000D 4.65 0.02 4.57 0.06 3.360.24 R-008309054-000S 0.88 0.01 4.27 0.08 3.36 0.12 R-008362746-000H4.22 0.08 4.85 0.07 3.35 0.47 R-008362935-000B 4.51 0.01 5.00 0.14 3.330.15 R-008362995-000F 3.52 0.02 4.80 0.02 3.31 0.25 R-008362923-000S4.16 0.16 4.15 0.08 3.31 0.09 R-008309099-000E 3.72 0.38 4.49 0.03 3.300.23 R-008362794-000C 3.97 0.05 3.81 0.05 3.30 0.12 R-008308556-000N4.54 0.04 4.69 0.19 3.29 0.13 R-008309087-000V 4.04 0.06 4.19 0.14 3.280.01 R-008362893-000D 0.66 0.15 4.31 0.05 3.27 0.20 R-008362725-000P4.20 0.22 4.54 0.23 3.26 0.05 R-008362863-000B 1.04 0.13 4.27 0.09 3.260.20 R-008362941-000J 3.93 0.42 4.38 0.16 3.24 0.34 R-008362929-000U1.45 0.05 3.98 0.08 3.23 0.04 R-008363052-000S 0.43 0.13 4.30 0.07 3.230.03 R-008362857-000U 1.73 0.12 3.70 0.08 3.23 0.37 R-008362758-000T0.70 0.16 4.19 0.10 3.22 0.41 R-008309048-000J 4.21 0.15 4.23 0.09 3.210.14 R-008363004-000X 3.76 0.12 4.55 0.07 3.20 0.43 R-008362719-000G3.88 0.16 4.61 0.31 3.20 0.09 R-008362671-000G 4.56 0.19 4.71 0.19 3.200.06 R-008363049-000K 3.40 0.08 3.01 0.01 3.19 0.22 R-008362902-000Y3.79 0.29 3.92 0.12 3.19 0.07 R-008363022-000P 4.32 0.21 4.06 0.12 3.140.43 R-008362848-000K 3.83 0.04 4.04 0.18 3.09 0.08 R-008362743-000G4.46 0.16 5.28 0.10 3.09 0.69 R-008362737-000Z 4.41 0.09 4.88 0.24 3.090.19 R-008362881-000U 0.77 0.02 4.08 0.10 3.09 0.05 R-008308601-000T4.21 0.54 4.56 0.02 3.08 0.17 R-008362983-000W 4.09 0.03 4.38 0.00 3.040.12 R-008362800-000W 4.42 0.15 4.69 0.06 3.02 0.38 R-008362971-000L4.10 0.14 4.48 0.05 3.02 0.01 R-008308661-000X 3.68 0.27 4.68 0.21 3.000.09 R-008362956-000V 3.89 0.10 3.97 0.19 3.00 0.05 R-008363001-000W3.97 0.05 4.25 0.06 2.99 0.02 R-008362680-000R 4.22 0.16 4.33 0.12 2.990.31 R-008309081-000T 3.97 0.11 4.21 0.01 2.99 0.35 R-008362860-000A3.39 0.49 3.39 0.01 2.98 0.19 R-008362716-000F 3.87 0.10 4.27 0.19 2.960.20 R-008362809-000Z 0.82 0.00 3.79 0.06 2.95 0.18 R-008308562-000W3.85 0.14 4.09 0.09 2.94 0.01 R-008362989-000Y 4.11 0.07 4.27 0.01 2.940.01 R-008309102-000X 3.95 0.05 3.89 0.20 2.90 0.11 R-008362773-000J3.92 0.23 3.99 0.02 2.89 0.06 R-008362779-000L 4.30 0.20 4.46 0.02 2.850.86 R-008362962-000C 3.67 0.08 3.59 0.09 2.82 0.00 R-008362905-000Z3.33 0.22 3.81 0.08 2.78 0.14 R-008362707-000X 3.53 0.49 4.13 0.15 2.780.03 R-008362977-000N 3.29 0.34 4.18 0.01 2.76 0.27 R-008362944-000K3.56 0.19 3.31 0.13 2.75 0.19 R-008309018-000G 3.53 0.13 4.22 0.07 2.720.16 R-008362770-000H 3.92 0.15 3.97 0.01 2.72 0.12 R-008362749-000J3.29 0.13 3.60 0.02 2.68 0.09 R-008308496-000Y 3.83 0.21 4.49 0.11 2.670.41 R-008362836-000A 0.49 0.02 3.94 0.05 2.67 0.81 R-008308667-000Z4.42 0.01 4.60 0.03 2.65 0.45 R-008362926-000T 4.22 0.08 5.81 0.12 2.600.18 R-008362851-000S 4.01 0.80 4.57 0.01 2.53 0.95 R-008363007-000Y3.23 0.05 2.93 0.15 2.51 0.19 R-008362701-000V 3.94 0.09 4.32 0.13 2.510.48 R-008362698-000C 4.10 0.03 4.15 0.13 2.50 0.24 R-008308625-000M3.77 0.09 3.42 0.24 2.46 0.03 R-008362815-000G 4.27 0.20 4.14 0.09 2.460.51 R-008363067-000C 4.14 0.27 5.42 0.16 2.46 0.06 R-008362914-000H3.78 0.03 3.66 0.06 2.41 0.25 R-008363028-000S 0.86 0.01 4.10 0.07 2.390.09 R-008362866-000C 3.42 0.03 3.68 0.01 2.38 0.07 R-008362695-000B3.06 0.18 2.78 0.06 2.37 0.27 R-008363013-000F 3.56 0.24 3.93 0.11 2.370.16 R-008362908-000A 3.20 0.11 2.63 0.01 2.35 0.09 R-008362917-000J3.01 0.04 3.23 0.05 2.34 0.15 R-008308508-000U 4.18 0.04 4.17 0.02 2.290.58 R-008308526-000L 0.59 0.04 3.87 0.09 2.27 0.15 R-008363034-000Z0.78 0.17 3.95 0.02 2.27 0.30 R-008362827-000S 3.74 0.00 3.12 0.05 2.250.09 R-008362968-000E 4.00 0.02 3.46 0.12 2.24 0.62 R-008309006-000X2.95 0.26 2.59 0.04 2.24 0.07 R-008362734-000Y 4.06 0.02 4.33 0.15 2.210.41 R-008362767-000B 4.22 0.05 4.19 0.13 2.13 0.41 R-008362806-000Y0.73 0.04 2.89 0.02 2.08 0.56 R-008308724-000N 3.34 0.05 3.55 0.01 2.060.04 R-008362818-000H 1.49 0.14 3.44 0.05 2.05 0.18 R-008309051-000R2.38 0.12 2.71 0.06 2.04 0.30 R-008362920-000R 2.82 0.31 3.00 0.13 1.980.03 R-008362965-000D 1.24 0.07 2.76 0.00 1.98 0.05 R-008308544-000D0.53 0.03 3.67 0.07 1.97 0.04 R-008308523-000K 3.15 0.01 3.69 0.12 1.940.17 R-008362986-000X 3.24 0.08 3.50 0.13 1.92 0.01 R-008362731-000X3.62 0.04 2.96 0.09 1.77 1.24 R-008363046-000J 2.67 0.02 3.94 0.05 1.750.07 R-008308733-000X 3.32 0.16 2.63 0.08 1.74 0.15 R-008362911-000G0.75 0.04 2.74 0.10 1.73 0.26 R-008308706-000W 3.31 0.01 4.09 0.17 1.610.09 R-008308709-000X 3.29 0.13 3.95 0.00 1.54 0.30 R-008362890-000C0.90 0.03 1.03 0.22 1.35 0.34 R-008363025-000R 2.95 0.06 3.05 0.08 1.320.81 R-008362953-000U 2.33 0.03 2.67 0.10 1.24 0.10 R-008362899-000F1.50 0.17 2.77 0.03 1.24 0.13 R-008308697-000B 2.18 0.11 2.19 0.04 1.170.02 R-008308589-000S 2.17 0.22 3.42 0.03 1.12 0.08 R-008308634-000W2.41 0.11 2.66 0.01 1.09 0.11 R-008362710-000D 0.71 0.10 2.17 0.11 1.060.18 R-008308493-000X 0.55 0.03 2.12 0.24 1.00 0.05 R-008308703-000V0.87 0.02 1.69 0.02 0.95 0.13 R-008308568-000Y 2.84 0.14 2.85 0.23 0.630.41 R-008362887-000W 0.83 0.14 0.93 0.09 0.33 0.07 R-008362974-000M0.80 0.07 0.96 0.02 0.23 0.02 R-008363037-000A 0.69 0.09 0.85 0.05 0.120.03 R-008363040-000G −0.07 0.02 −0.22 0.05 −0.19 0.09 R-008362845-000J−4.37 0.21 −1.50 0.07 −1.25 0.33 R-008362761-000Z −2.03 0.11 −3.54 0.05−1.88 0.24 R-008308586-000R −1.64 0.18 −1.83 0.01 −2.27 0.31R-008362803-000X −4.04 0.51 −4.61 0.01 −4.03 0.44

A subset of siNAs from Table 3a having a large log 2(fold change) in theprimary screen were rescreened in Huh7 cells. The results are shown inTable 3b.

TABLE 3b Primary screening data in Huh7 Cells (n = 2), recorded as log2(fold change) in CTNNB1 gene expression. Huh7 Mean Huh7 SD siNA DuplexID ΔΔCt ΔΔCt R-008362791-000B 4.24 0.05 R-008362812-000F 4.17 0.02R-008362689-000U 4.17 0.01 R-008362722-000N 4.17 0.04 R-008362932-000A4.07 0.17 R-008363043-000H 4.05 0.02 R-008362875-000L 4.03 0.12R-008308997-000F 3.99 0.35 R-008362947-000L 3.99 0.18 R-008362821-000P3.95 0.11 R-008362686-000T 3.94 0.13 R-008363070-000J 3.91 0.08R-008362824-000R 3.91 0.16 R-008362785-000U 3.88 0.06 R-008363031-000Y3.88 0.10 R-008363073-000K 3.87 0.19 R-008362782-000T 3.86 0.04R-008309033-000Y 3.85 0.00 R-008363064-000B 3.84 0.08 R-008362950-000T3.84 0.05 R-008362959-000W 3.83 0.28 R-008363019-000H 3.82 0.02R-008362842-000H 3.82 0.14 R-008363058-000U 3.75 0.11 R-008362713-000E3.73 0.08 R-008362938-000C 3.72 0.05 R-008362755-000S 3.71 0.16R-008362746-000H 3.59 0.22 R-008362830-000Y 3.56 0.16 R-008362704-000W3.55 0.11 R-008362839-000B 3.48 0.23 R-008362992-000E 3.45 0.04R-008363055-000T 3.44 0.26 R-008363061-000A 3.38 0.07 R-008362995-000F3.35 0.01

The CTNNB1 siNAs were designed and synthesized as described previously.Various siNAs were screened in MK2D cells. The log 2(fold change) inCTNNB1 gene expression data upon treatment with various modified CTNNB1siNAs in human cells is shown in Table 3c. Each screen was performed at24 hrs. Quantitative RT-PCR was used to assess the level of CTNNB1 mRNAand the data were normalized to the expression level of GAPDH (aubiquitously expressed ‘house-keeping’ gene). Each treatment was thennormalized against the non-CTNNB1 targeting control.

TABLE 3c Primary screening data in MK2D Cells (n = 2), recorded as log2(fold change) in CTNNB1 gene expression. MK2D MEAN MK2D SD siNA DuplexID ΔΔCT ΔΔCT R-008395722-000P 4.06 0.06 R-008395725-000R 3.78 0.08R-008395749-000K 4.20 0.02 R-008395752-000S 5.53 0.06 R-008395758-000U2.41 0.01 R-008395761-000A 5.61 0.08 R-008395767-000C 3.00 0.00R-008395770-000J 5.53 0.18 R-008395779-000M 4.93 0.16 R-008395785-000V2.56 0.19 R-008395791-000C 6.76 0.23 R-008395800-000X 2.87 0.07R-008395827-000T 2.89 0.14 R-008395863-000C 1.65 0.22 R-008395881-000V3.94 0.05 R-008395887-000X 4.54 0.24 R-008395977-000P 5.63 0.47R-008395980-000W 4.31 0.27 R-008395995-000G 4.83 0.12 R-008396004-000Y3.16 0.01 R-008396022-000R 4.83 0.13 R-008396052-000T 4.08 0.08R-008396061-000B −0.99 0.08 R-008396067-000D 3.52 0.39 R-008396070-000K4.84 0.03 R-008396079-000N 4.32 0.04 R-008396103-000Z 3.67 0.07R-008396106-000A 5.34 0.03 R-008396109-000B −1.10 0.03 R-008396112-000H5.19 0.26 R-008396118-000K 3.23 0.01 R-008396136-000C −2.56R-008396142-000K −0.95 0.10 R-008396148-000M 3.84 0.24 R-008396151-000U4.60 0.08 R-008396154-000V 4.77 0.07 R-008396172-000M 6.28 0.06R-008396214-000K 2.82 0.29 R-008396220-000T 5.40 0.05 R-008396223-000U4.57 0.06 R-008396226-000V 2.27 0.12 R-008396247-000N 3.32 0.08R-008396250-000V 3.79 1.00 R-008396253-000W 6.42 0.03 R-008396259-000Y2.14 0.03 R-008396274-000P 5.39 0.18 R-008396292-000G 3.85 0.05R-008396295-000H 2.57 0.08 R-008396298-000J 3.00 0.22 R-008396301-000B2.10 0.24 R-008396304-000C 3.24 0.04 R-008396343-000N 2.49 0.07R-008396349-000R 4.00 0.08 R-008396379-000T 4.29 0.22 R-008396382-000Z−0.44 0.02 R-008396388-000B 3.90 0.18 R-008396391-000H 2.23 0.05R-008396409-000F 3.96 0.26 R-008396415-000N 4.72 0.00 R-008396418-000P4.48 0.20 R-008396421-000W 3.78 0.14 R-008396457-000A 3.89 0.01R-008396478-000U 4.62 0.03 R-008396481-000A 4.29 0.14 R-008396529-000A4.69 0.10 R-008396532-000G 4.46 0.05 R-008396538-000J 5.59 0.05R-008396544-000S 5.04 0.20 R-008396550-000Z 3.79 0.18 R-008396553-000A2.32 0.01 R-008396556-000B 2.85 0.07 R-008396559-000C 5.20 0.12R-008396613-000R 4.92 0.10 R-008396616-000S 2.90 0.01 R-008396619-000T4.67 0.37 R-008396622-000Z 4.09 0.08 R-008396631-000H 4.28 0.13R-008396685-000E 4.01 0.10 R-008396694-000N 4.73 0.12 R-008396697-000P1.56 0.16 R-008396730-000J 2.19 0.02 R-008396730-000J 3.24 0.03R-008396733-000K 1.43 0.10 R-008396736-000L 5.14 0.04 R-008396742-000U0.78 0.28 R-008396751-000C 3.62 0.13 R-008396754-000D 4.17 0.05R-008396793-000P 2.68 0.01 R-008396796-000R 4.94 0.03 R-008396820-000B4.70 0.08 R-008396826-000D 4.73 0.20 R-008396832-000L 3.63 0.10R-008396835-000M 2.84 0.85 R-008396838-000N 3.40 0.20 R-008396868-000R3.99 0.14 R-008396871-000X 4.62 0.12 R-008396874-000Y 4.01 0.02R-008396898-000T 3.11 0.32 R-008396904-000L 2.46 0.06 R-008396910-000U2.30 0.03 R-008396919-000X 4.06 0.23 R-008396934-000N 3.37 0.18R-008396943-000X 3.77 0.01 R-008396949-000Z 3.40 0.07 R-008396958-000H5.29 0.05 R-008396985-000J 5.25 0.09 R-008396994-000T 3.08 0.40R-008397015-000U 4.41 0.08 R-008397018-000V 1.73 0.03 R-008397021-000B5.50 0.05 R-008397024-000C 3.45 0.27 R-008397039-000N 4.21 0.04R-008397060-000M 1.76 0.08 R-008397069-000R 3.16 0.14 R-008397072-000X3.94 0.17 R-008397081-000F 3.02 0.02 R-008397108-000M 5.62 0.08R-008397111-000U 4.08 0.10 R-008397114-000V 3.50 0.03 R-008397132-000M3.97 0.16 R-008397138-000P 6.60 0.17 R-008397141-000W 4.58 0.02R-008397147-000Y 3.73 0.00 R-008397150-000E 6.44 0.11 R-008397153-000F2.43 0.03 R-008397156-000G 4.04 0.31 R-008397165-000R 3.44 0.01R-008397168-000S 3.29 0.15 R-008397180-000G 4.46 0.02 R-008397186-000J5.22 0.06 R-008397237-000R 2.77 0.04 R-008397243-000Y 3.31 0.23R-008397246-000Z 3.21 0.21 R-008397255-000H 3.77 0.05 R-008397258-000J1.91 0.02 R-008397306-000P 3.04 0.05 R-008397309-000R 3.16 0.05R-008397312-000X 5.97 0.13 R-008397315-000Y 4.19 0.33 R-008397342-000Z3.04 0.06 R-008397345-000A 4.87 0.03 R-008397348-000B 3.62 0.04R-008397351-000H 2.29 0.15 R-008397354-000J 4.81 0.09 R-008397372-000B4.40 0.10 R-008397381-000K 3.38 0.08 R-008397384-000L 3.95 0.14R-008397387-000M 6.11 0.04 R-008397390-000U 3.84 0.16 R-008397396-000W6.69 0.24 R-008397408-000S 5.61 0.05 R-008397417-000A 3.92 0.49R-008397420-000G 4.53 0.02 R-008397429-000K 2.91 0.05 R-008397450-000J2.53 0.05 R-008397459-000M 4.75 0.00 R-008397462-000U 5.28 0.17R-008397465-000V 4.45 0.18 R-008397468-000W 4.05 0.09 R-008397471-000C3.22 0.12 R-008397474-000D 4.06 0.21 R-008397519-000C 3.67 0.03R-008397531-000T 5.94 0.10 R-008397537-000V 4.20 0.07 R-008397540-000B5.04 0.12 R-008397564-000W 5.95 0.12 R-008397576-000F 3.39 0.05R-008397579-000G 2.94 0.02 R-008397582-000N 3.95 0.12 R-008397588-000R4.25 0.07 R-008397591-000X 5.25 0.06 R-008397594-000Y 3.81 0.00R-008397618-000D 4.58 0.03 R-008397630-000U 3.46 0.15 R-008397645-000E3.71 0.07 R-008397657-000P −1.50 0.14 R-008397660-000W 4.85 0.04R-008397663-000X 2.62 0.03 R-008397666-000Y 3.68 0.09 R-008397669-000Z2.80 0.78 R-008397702-000U 2.34 0.78 R-008397705-000V 5.13 0.20R-008397732-000W 3.27 0.01 R-008397735-000X 2.92 0.03 R-008397738-000Y3.97 0.06 R-008397768-000A 1.62 0.05 R-008397771-000G 4.45 0.17R-008397774-000H −1.15 0.02 R-008397777-000J −1.16 0.09 R-008397783-000S−1.16 0.03 R-008397807-000X 2.52 0.05 R-008397828-000R 4.36 0.27R-008397855-000S 1.94 0.01 R-008397858-000T 4.43 0.17 R-008397882-000T5.26 0.10 R-008397885-000U 2.53 0.01 R-008397888-000V 3.55 0.03R-008397933-000Z 4.19 0.22 R-008397966-000C 5.19 0.17 R-008397969-000D3.35 0.11 R-008397987-000W 4.95 0.16 R-008397990-000C 4.69 0.09R-008397993-000D 2.17 0.01 R-008397996-000E −1.14 0.02 R-008398002-000V3.74 0.10 R-008398020-000M 3.51 0.06 R-008398026-000P 5.64 0.06R-008398050-000P 3.57 0.10 R-008398056-000S 4.46 0.13 R-008398086-000U3.65 0.18 R-008398098-000D 3.93 0.04 R-008398119-000H 2.68 0.25R-008398137-000A 5.16 0.02 R-008398140-000G 3.87 0.14 R-008398140-000G4.86 0.03 R-008398143-000H 1.74 0.05 R-008398146-000J 3.95 0.12R-008398149-000K 4.45 0.03 R-008398155-000T 4.37 0.25 R-008398161-000A3.82 0.05 R-008398176-000L 3.83 0.14 R-008398182-000U 4.52 0.06R-008398227-000T 6.28 0.06 R-008398239-000C 2.48 0.02 R-008398242-000J3.81 0.03 R-008398245-000K 5.34 0.23 R-008398275-000M 1.53 0.08R-008398278-000N 2.71 0.07 R-008398281-000V 4.31 0.14 R-008398326-000U5.66 0.09 R-008398329-000V 3.83 0.26 R-008398332-000B 4.63 0.02R-008398362-000D 2.98 0.17 R-008398365-000E 5.06 0.06 R-008398368-000F4.37 0.03 R-008398374-000N 3.66 0.03 R-008398377-000P −1.12 0.02R-008398401-000A 4.57 0.18 R-008398413-000K 3.23 0.07 R-008398419-000M3.78 0.10 R-008398422-000U 2.63 0.05 R-008398425-000V 3.31 0.02R-008398428-000W 4.20 0.05 R-008398431-000C 4.82 0.02 R-008398434-000D2.54 0.06 R-008398437-000E 5.38 0.09 R-008398479-000S 5.16 0.41R-008398482-000Y 1.55 0.01 R-008398533-000E 3.60 0.01 R-008398539-000G4.85 0.07 R-008398542-000N 3.64 0.01 R-008398563-000G 5.22 0.27R-008398566-000H 2.69 0.13 R-008398575-000S 4.79 0.03 R-008398584-000A2.92 0.04 R-008398590-000H 4.97 0.13 R-008398593-000J 4.52 0.03R-008398617-000P 3.50 0.01 R-008398647-000S 4.34 0.23 R-008398650-000Y4.26 0.01 R-008398653-000Z 3.27 0.22 R-008398656-000A 5.36 0.15R-008398662-000H 5.03 0.42 R-008398665-000J 3.28 0.08 R-008398668-000K5.53 0.41 R-008398677-000U 4.94 0.03 R-008398686-000C 1.43 0.14R-008398701-000E 4.38 0.10 R-008398740-000R 3.54 0.04 R-008398749-000U2.72 0.18 R-008398782-000C 2.87 0.02 R-008398785-000D −1.10 0.05R-008398788-000E 5.61 0.09 R-008398815-000S 3.68 0.14 R-008398821-000Z5.75 0.00 R-008398830-000H 4.45 0.21 R-008398833-000J 4.61 0.05R-008398836-000K 3.83 0.01 R-008398863-000L −1.22 0.03 R-008398866-000M3.99 0.02 R-008398869-000N 4.06 0.32 R-008398872-000V 4.32 0.18R-008398875-000W 3.28 0.08 R-008398902-000H 5.58 0.03 R-008398917-000U2.05 0.13 R-008398923-000B 5.33 0.13 R-008398926-000C 2.22 0.07R-008398956-000E 3.78 0.15 R-008398962-000M 1.67 0.04 R-008398965-000N4.87 0.13 R-008398968-000P 3.76 0.21 R-008399031-000H 4.84 0.16R-008399034-000J 5.71 0.05 R-008399037-000K 2.86 0.08 R-008399049-000V3.77 0.01 R-008399058-000D 3.88 0.26 R-008399070-000U 5.31 0.00R-008399091-000M 4.67 0.01 R-008399103-000H 3.75 0.18 R-008399109-000K5.39 0.14 R-008399133-000K 3.73 0.05 R-008399145-000V 4.27 0.01R-008399172-000W 3.39 0.07 R-008399175-000X 3.44 0.11 R-008399181-000E3.37 0.06 R-008399184-000F 6.50 0.11 R-008399187-000G 4.29 0.10R-008399202-000J 4.09 0.44 R-008399205-000K 2.85 0.21 R-008399208-000L4.45 0.00 R-008399211-000T 4.08 0.08 R-008399214-000U 4.54 0.01R-008399226-000D 2.02 0.05 R-008399262-000N 4.13 0.06 R-008399265-000P3.87 0.03 R-008399268-000R 5.89 0.30 R-008399271-000X 4.44 0.18R-008399274-000Y 1.24 0.07 R-008399334-000N 2.96 0.22 R-008399343-000X3.86 0.02 R-008399370-000Y 1.45 0.92 R-008399373-000Z 3.64 0.17R-008399376-000A 4.79 0.22 R-008399382-000H 4.33 0.06 R-008399394-000T4.40 0.09 R-008399415-000X 3.21 0.15 R-008399418-000Y 3.33 0.13R-008399421-000E 3.57 0.21 R-008399436-000R −1.18 0.08 R-008399439-000S3.23 0.13 R-008399442-000Y 4.12 0.04 R-008399445-000Z −0.90 0.12R-008399451-000G 2.57 0.66 R-008399454-000H 1.55 0.01 R-008399457-000J2.95 0.00 R-008399481-000J 2.30 0.08 R-008399487-000L 2.81 0.26R-008399526-000H 5.38 0.35 R-008399535-000S 3.24 0.04 R-008399538-000T4.18 0.28 R-008399568-000V 3.85 0.13 R-008399571-000B 4.51 0.28R-008399589-000N 2.43 0.07 R-008399592-000V 5.11 0.02 R-008399604-000R−1.15 0.03 R-008399610-000Y 4.97 0.16 R-008399616-000A 2.18 0.03R-008399628-000K 4.04 0.00 R-008399634-000T 3.53 0.23 R-008399640-000A3.90 0.16 R-008399652-000K 4.94 0.03 R-008399655-000L 3.57 0.14R-008399658-000M 3.74 0.42 R-008399661-000U 3.01 0.06 R-008399664-000V3.84 0.16 R-008399670-000C 5.25 0.09 R-008399679-000F 3.51 0.29R-008399682-000M 1.20 0.08

Select high ranking siNAs from Tables 3a & 3b were further analyzed forefficacy and potency in Huh7 cells use dose response curves. The resultsfor these siNAs are shown in Table 4. The potency 50 is the calculatedsiNA transfection concentration that produces 50% target mRNA knockdown.The IC50 was determined after 24 hour exposure time.

TABLE 4 Dose response data for various siNAs in Huh 7 cells. Calculatedmaximum ΔΔCt is determined from the dose response curve. Mean SD POTENCY50 IC50 siNA Duplex ID ΔΔCt ΔΔCt (nM) (nM) R-008362824-000R 4.18 0.090.02 0.02 R-008362821-000P 4.16 0.01 0.02 0.02 R-008363031-000Y 4.100.24 0.01 0.01 R-008362785-000U 4.00 0.31 0.03 0.03 R-008362686-000T3.98 0.18 0.07 0.06 R-008362782-000T 3.95 0.55 0.05 0.04R-008362875-000L 3.61 0.36 0.02 0.02 R-008308997-000F 3.59 0.14 0.020.02 R-008362722-000N 3.58 0.23 0.03 0.02 R-008362791-000B 3.51 0.890.02 0.01 R-008362932-000A 3.48 0.46 0.02 0.02 R-008362689-000U 3.390.81 0.02 0.02 R-008363043-000H 3.29 0.01 0.02 0.02 R-008363073-000K3.21 0.45 0.10 0.08 R-008362812-000F 3.07 0.40 0.03 0.03R-008362947-000L 3.07 0.28 0.02 0.01 R-008363070-000J 2.91 0.10 0.010.01

Additional siNAs from Tables 3a & 3b were further analyzed for efficacyand potency in MK2D cells using dose response curves. The results forthese siNAs are shown in Table 5. The potency 50 is the calculated siNAtransfection concentration that produces 50% target mRNA knockdown. TheIC50 was determined after 24 hour exposure time.

TABLE 5 Dose response data for various siNAs in MK2D cells. Calculatedmaximum ΔΔCt is determined from the dose response curve. Mean SD IC50siNA Duplex ID ΔΔCt ΔΔCt (nM) R-008380929-000H002 6.8 0.03 0.004R-008488882-000B001 5.8 0.01 0.004 R-008488885-000C001 6.1 0.03 0.007R-008488887-000V001 6.6 0.02 0.004 R-008488889-000M001 6.4 0.23 0.005

Example 2 Determining In Vitro Serum Stability of siNAs

siNAs are reconstituted as 50 μM to 100 μM stock solution with H₂O andadded to human serum pre-warmed to 37° C. to a final concentration of 20μg/mL. The mixture is then incubated at 37° C. for 0, 1 and 2 hours. Atthe end of each time point, the reactions are stopped by mixing withequal volume of Phenomenex Lysis-Loading Buffer. Oligonucleotides arepurified in 96-well format by Phenomenex Solid Phase Extraction andlyophilized until dry with Labconco Triad Lyo-00417. The lyophilizedsamples are reconstituted in 150 μL of 1 mM EDTA prepared withRNase-free H₂O. The sample solutions re then diluted 5 fold with 1 mMEDTA for liquid chromatography/mass spectrometry (LC/MS) analysis onThermoFisher Orbitrap. Serum metabolites of the siNAs were determinedbased on the measured molecular weights.

Example 3 Testing of Cytokine Induction

To assess immunostimulative effects of various siNAs of the inventionloaded in lipid nanoparticles (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPC in a40/48/2/10 ratio), C57Bl/6 mice are dosed with a single 3 mpk dose ofLNP formulated siNAs through tail vein injection. Serum or plasmasamples are collected at 3 and 24 hours post-dose. The cytokine andchemokine levels in these samples is measured with the SearchLight IRCytokine Array from Aushon Biosciences according to the manufacturer'sinstruction. The cytokines and chemokines measured are IL-1α, IL-1β,IL-6, KC, IL-10, IFNγ, TNF, GMCSF, MIP-1β, MCP-1/JE, and RANTES.

Example 4 Efficacy Studies in Mouse

Mice are dosed IV via tail vein injections with LNP encapsulated siNAsor vehicle control using 2 different 3-week dosing schemes: one 1 mg/kgdose for 3 consecutive days or a single 6 mg/kg does per week. In someexperiments, the mice are co-dosed with sorafenib at a dose of 100 mg/kgBID every day for 3 weeks. Total tumor burden is measured by micro-CTscan imaging. The animals are sacrificed 5 days after the last siNA dose(Day 23), and normal liver and tumor tissues from each animal iscollected for RNA purification. Total RNA is purified using RNeasy 96kit (Qiagen, Cat#74182). cDNA is generated from total RNA using HighCapacity cDNA Reverse Transcription Kit (Cat#: 4368813). QuantitativePCR reactions are performed with TaqMan Universal PCR Master Mix (Cat#:4304437). Human CTNNB1 TaqMan Gene Expression Assay (Hs00355045_m1) andhuman GAPDH TaqMan Gene Expression Assay is used to monitor the mRNAlevel of both transcripts in tumor tissue. Mouse CTNNB1 TaqMan GeneExpression Assay (Mm00483033_m1) and mouse GAPDH TaqMan Gene ExpressionAssay is used to monitor the mRNA level of both transcripts in livertissue. The expression level of CTNNB1 is normalized against GAPDH tominimize technical variations.

Example 5 Pharmacodynamic Study in Non-Human Primates

Rhesus macaque monkeys are dosed with a single 2.5 mpk dose of siNAloaded lipid nanoparticles through intravenous infusion. To monitortarget mRNA knockdown, liver biopsies are performed at various timepoints pre- and post-dose with 16T gauge Menghini needles for about 20mg tissue per animal. Whole blood and serum/plasma is also collected atdifferent time points pre- and post-dose to monitor potential toxicityassociated with the treatments. All procedures adhere to the regulationsoutlined in the USDA Animal Welfare Act (9 CFR, Parts 1, 2 and 3) andthe conditions specified in The Guide for Care and Use of LaboratoryAnimals (ILAR publication, 1996, National Academy Press). Total RNA fromthe liver biopsy tissue was purified using RNeasy 96 kit (Qiagen,Cat#74182). cDNA was generated from total RNA using High Capacity cDNAReverse Transcription Kit (Cat#: 4368813). Quantitative PCR reactionswere performed with TaqMan Universal PCR Master Mix (Cat#: 4304437).Human CTNNB1 TaqMan Gene Expression Assay (Hs00355045_m1) and rhesusGAPDH TaqMan Gene Expression Assay (Rh02621745_m1) is used to monitorthe mRNA level of both transcripts in liver biopsy tissue. Theexpression level of CTNNB1 is normalized against GAPDH to minimizetechnical variations.

LNP formulations (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPC in a 40/48/2/10ratio) comprising the siNA are tested. Log 2(fold change) in CTNNB1 geneexpression is determined on days 3, 7, 14, and 28 days post-dosing.Pre-dose CTNNB1 expression levels for the monkey is measured 7 daysbefore the first dosing.

Example 6 Pharmacodynamic Studies in Mouse

Mice were dosed IV via tail vein injections with LNP encapsulated siNAsor vehicle control using a single 0.33 mg/kg. Five animals whichreceived each treatment were sacrificed 2, 7, 14 and 21 days after thesiNA dose, and liver tissues from each animal was collected for RNApurification. Total RNA was purified using RNeasy 96 kit (Qiagen,Cat#74182). cDNA was generated from total RNA using High Capacity cDNAReverse Transcription Kit (Cat#: 4368813). Quantitative PCR reactionswere performed with TaqMan Universal PCR Master Mix (Cat#: 4304437).Mouse CTNNB1 TaqMan Gene Expression Assay (Mm00483033_m1) and mouseGAPDH TaqMan Gene Expression Assay was used to monitor the mRNA level ofboth transcripts. The expression level of CTNNB1 was normalized againstGAPDH to minimize technical variations. Data is shown in Table 6.

TABLE 6 In vivo screening data in C57Bl/6 mice, recorded as log 2(foldchange) in CTNNB1 gene expression. Day 2 Day 7 Day 14 Day 21 Mouse MouseMouse Mouse Mouse Mouse Mouse Mouse Mean SD Mean SD Mean SD Mean SD ΔΔCTΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT ΔΔCT PBS 0.00 0.23 0.00 0.21 0.00 0.160.00 0.15 R-008380929-000H 2.95 0.27 2.76 0.14 2.33 0.09 1.95 0.33R-008381104-000W 2.90 0.21 2.43 0.26 1.77 0.30 1.32 0.23R-008488882-000B 3.21 0.37 2.86 0.33 2.34 0.14 1.93 0.18R-008488885-000C 2.44 0.13 1.35 0.22 0.59 0.17 0.58 0.31R-008488887-000V 2.11 0.31 1.76 0.14 0.94 0.42 1.05 0.32R-008488889-000M 2.31 0.22 1.87 0.35 1.30 0.10 0.86 0.17

Example 7 Pharmacodynamic Study in Non-Human Primates

Rhesus macaque monkeys were dosed with a single 3.34 mg/m² of bodysurface area dose of siNA loaded lipid nanoparticles through intravenousinfusion. To monitor target mRNA knockdown, liver biopsies wereperformed at various time points pre- and post-dose with 16T gaugeMenghini needles for about 20 mg tissue per animal. Whole blood andserum/plasma is also collected at different time points pre- andpost-dose to monitor potential toxicity associated with the treatments.All procedures adhered to the regulations outlined in the USDA AnimalWelfare Act (9 CFR, Parts 1, 2 and 3) and the conditions specified inThe Guide for Care and Use of Laboratory Animals (ILAR publication,1996, National Academy Press). Total RNA from the liver biopsy tissuewas purified using RNeasy 96 kit (Qiagen, Cat#74182). cDNA was generatedfrom total RNA using High Capacity cDNA Reverse Transcription Kit (Cat#:4368813). Quantitative PCR reactions were performed with TaqManUniversal PCR Master Mix (Cat#: 4304437). Human CTNNB1 TaqMan GeneExpression Assay (Hs00355045 ml) and rhesus GAPDH TaqMan Gene ExpressionAssay (Rh02621745_m1) was used to monitor the mRNA level of bothtranscripts in liver biopsy tissue. The expression level of CTNNB1 wasnormalized against GAPDH to minimize technical variations. Data is shownin Table 7. LNP formulations (DLinDMA/Cholesterol/S-PEG-C-DMA/DSPC in a40/48/2/10 ratio) comprising the siNA were tested. Log 2(fold change) inCTNNB1 gene expression was determined on days 2 and 7 days post-dosing.Pre-dose CTNNB1 expression levels for the monkey is measured 6 daysbefore the first dosing.

TABLE 7 In vivo screening data in rhesus, recorded as log 2(fold change)in CTNNB1 gene expression. Day −6 Day 2 Day 7 Rhesus Rhesus RhesusRhesus Rhesus Rhesus Mean SD Mean SD Mean SD LNP siNA duplex ΔΔCT ΔΔCTΔΔCT ΔΔCT ΔΔCT ΔΔCT PBS 0.00 0.37 0.00 0.24 0.00 0.25 LNP-2R-008488882-000B −0.11 0.20 1.41 0.35 0.73 0.56 LNP-4 R-008488885-000C−0.15 0.13 1.79 0.46 1.64 0.59 LNP-1 R-008488889-000M 0.02 0.29 1.590.43 1.44 0.60 LNP-3 R-008380929-000H −0.10 0.25 1.89 0.17 1.60 0.04

Example 8 Short Interfering Nucleic Acid Lipid Nanoparticle (LNP)Formulations A. General LNP Process Description for LNP Formulations:

The lipid nanoparticles were prepared by an impinging jet process. Theparticles were formed by mixing lipids dissolved in alcohol with siNAdissolved in a citrate buffer. The lipid solution contained a cationiclipid, a helper lipid (cholesterol), PEG (e.g. PEG-C-DMA, PEG-DMG)lipid, and DSPC at a concentration of 5-15 mg/mL with a target of 9-12mg/mL in an alcohol (for example ethanol). The ratio of the lipids had amole percent range of 25-98 for the cationic lipid with a target of35-65, the helper lipid had a mole percent range from 0-75 with a targetof 30-50, the PEG lipid has a mole percent range from 1-15 with a targetof 1-6, and the DSPC had a mole percent range of 0-15 with a target of0-12. The siNA solution contained one or more siNA sequences at aconcentration range from 0.3 to 0.6 mg/mL with a target of 0.3-0.9 mg/mLin a sodium citrate buffered salt solution with pH in the range of3.5-5. The two solutions were heated to a temperature in the range of15-40° C., targeting 30-40° C., and then mixed in an impinging jet mixerinstantly forming the LNP. The teeID had a range from 0.25 to 1.0 mm anda total flow rate from 10-600 mL/minute. The combination of flow rateand tubing ID had the effect of controlling the particle size of theLNPs between 30 and 200 nm. The LNP suspension was then mixed with abuffered solution at a higher pH with a mixing ratio in the range of 1:1to 1:3 vol:vol, but targeting 1:2 vol:vol. This buffered solution was ata temperature in the range of 15-40° C., targeting 30-40° C. This LNPsuspension was further mixed with a buffered solution at a higher pH andwith a mixing ratio in the range of 1:1 to 1:3 vol:vol, but targeting1:2 vol:vol. The buffered solution was at a temperature in the range of15-40° C., targeting 30-40° C. The mixed LNPs were held from 30 minutesto 2 hrs prior to an anion exchange filtration step. The temperatureduring incubating was in the range of 15-40° C., targeting 30-40° C.After incubating, the LNP suspension was filtered through a 0.8 umfilter containing an anion exchange separation step. This process usedtubing IDs ranging from 1 mm ID to 5 mm ID and a flow rate from 10 to2000 mL/minute The LNPs were concentrated and diafiltered via anultrafiltration process where the alcohol was removed and the citratebuffer was exchanged for the final buffer solution such as phosphatebuffered saline. The ultrafiltration process used a tangential flowfiltration format (TFF). This process used a membrane nominal molecularweight cutoff range from 30-500 KD. The membrane format was hollow fiberor flat sheet cassette. The TFF processes with the proper molecularweight cutoff retained the LNP in the retentate and the filtrate orpermeate contained the alcohol; citrate buffer; and final buffer wastes.The TFF process is a multiple step process with an initial concentrationto a siNA concentration of 1-3 mg/mL. Following concentration, the LNPsuspension was diafiltered against the final buffer for 10-20 volumes toremove the alcohol and perform buffer exchange. The material was thenconcentrated an additional 1-3 fold. The final steps of the LNP processwere to sterile filter the concentrated LNP solution and vial theproduct.

Analytical Procedure:

1) siNA Concentration

The siNA duplex concentrations were determined by Strong Anion-ExchangeHigh-Performance Liquid Chromatography (SAX-HPLC) using Waters 2695Alliance system (Water Corporation, Milford Mass.) with a 2996 PDAdetector. The LNPs, otherwise referred to as RNAi Delivery Vehicles(RDVs), were treated with 0.5% Triton X-100 to free total siNA andanalyzed by SAX separation using a Dionex BioLC DNAPac PA 200 (4×250 mm)column with UV detection at 254 nm. Mobile phase was composed of A: 25mM NaClO₄, 10 mM Tris, 20% EtOH, pH 7.0 and B: 250 mM NaClO₄, 10 mMTris, 20% EtOH, pH 7.0 with a liner gradient from 0-15 min and a flowrate of 1 ml/minute. The siNA amount was determined by comparing to thesiNA standard curve.

2) Encapsulation Rate

Fluorescence reagent SYBR Gold was employed for RNA quantitation tomonitor the encapsulation rate of RDVs. RDVs with or without TritonX-100 were used to determine the free siNA and total siNA amount. Theassay is performed using a SpectraMax M5e microplate spectrophotometerfrom Molecular Devices (Sunnyvale, Calif.). Samples were excited at 485nm and fluorescence emission was measured at 530 nm. The siNA amount isdetermined by comparing to an siNA standard curve.

Encapsulation rate=(1−free siNA/total siNA)×100%

3) Particle Size and Polydispersity

RDVs containing 1 μg siNA were diluted to a final volume of 3 ml with1×PBS. The particle size and polydispersity of the samples was measuredby a dynamic light scattering method using ZetaPALS instrument(Brookhaven Instruments Corporation, Holtsville, N.Y.). The scatteredintensity was measured with He—Ne laser at 25° C. with a scatteringangle of 90°.

4) Zeta Potential Analysis

RDVs containing 1 μg siNA were diluted to a final volume of 2 ml with 1mM Tris buffer (pH 7.4). Electrophoretic mobility of samples wasdetermined using ZetaPALS instrument (Brookhaven InstrumentsCorporation, Holtsville, N.Y.) with electrode and He—Ne laser as a lightsource. The Smoluchowski limit was assumed in the calculation of zetapotentials.

5) Lipid Analysis

Individual lipid concentrations were determined by Reverse PhaseHigh-Performance Liquid Chromatography (RP-HPLC) using Waters 2695Alliance system (Water Corporation, Milford Mass.) with a Corona chargedaerosol detector (CAD) (ESA Biosciences, Inc, Chelmsford, Mass.).Individual lipids in RDVs were analyzed using an Agilent Zorbax SB-C18(50×4.6 mm, 1.8 μm particle size) column with CAD at 60° C. The mobilephase was composed of A: 0.1% TFA in H₂O and B: 0.1% TFA in IPA. Thegradient changed from 60% mobile phase A and 40% mobile phase B fromtime 0 to 40% mobile phase A and 60% mobile phase B at 1.00 min; 40%mobile phase A and 60% mobile phase B from 1.00 to 5.00 min; 40% mobilephase A and 60% mobile phase B from 5.00 min to 25% mobile phase A and75% mobile phase B at 10.00 min; 25% mobile phase A and 75% mobile phaseB from 10.00 min to 5% mobile phase A and 95% mobile phase B at 15.00min; and 5% mobile phase A and 95% mobile phase B from 15.00 to 60%mobile phase A and 40% mobile phase B at 20.00 min with a flow rate of 1ml/minute. The individual lipid concentration was determined bycomparing to the standard curve with all the lipid components in theRDVs with a quadratic curve fit. The molar percentage of each lipid wascalculated based on its molecular weight.

B. General LNP Preparation For Various Formulations in Table 11

siNA nanoparticle suspensions in Table 11 were prepared by dissolvingsiNAs and/or carrier molecules in 20 mM sodium citrate buffer (pH 5.0)at a concentration of about 0.40 mg/mL. Lipid solutions were prepared bydissolving a mixture of cationic lipid (e.g.,(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, see structurein Table 12), DSPC, Cholesterol, and PEG-DMG (ratios shown in Table 11)in absolute ethanol at a concentration of about 8 mg/mL. The nitrogen tophosphate ratio was approximated to 6:1.

Nearly equal volumes of siNA/carrier and lipid solutions were deliveredwith two FPLC pumps at the same flow rates to a mixing T connector. Aback pressure valve was used to adjust to the desired particle size. Theresulting milky mixture was collected in a sterile glass bottle. Thismixture was then diluted with an equal volume of citrate buffer,followed by equal volume of PBS (pH 7.4), and filtered through anion-exchange membrane to remove any free siNA/carrier in the mixture.Ultra filtration against PBS (7.4)) was employed to remove ethanol andto exchange buffer. The final LNP was obtained by concentrating to thedesired volume and sterile filtered through a 0.2 μm filter. Theobtained LNPs were characterized in term of particle size, Zetapotential, alcohol content, total lipid content, nucleic acidencapsulated, and total nucleic acid concentration.

LNP Manufacture Process

In a non-limiting example, LNPs were prepared in bulk as follows. Theprocess consisted of (1) preparing a lipid solution; (2) preparing ansiNA/carrier solution; (3) mixing/particle formation; (4) incubation;(5) dilution; (6) ultrafiltration and concentration.

1. Preparation of Lipid Solution

2 L glass reagent bottles and measuring cylinders were depyrogenated.The lipids were warmed to room temperature. Into the glass reagentbottle was transferred 8.0 g of(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine with a pipetteand 1.2 g of DSPC, 3.5 g of Cholesterol, 0.9 g of PEG-DMG were added. Tothe mixture is added 1 L of ethanol. The reagent bottle was placed inheated water bath, at a temperature not exceeding 50° C. The lipidsuspension was stirred with a stir bar. A thermocouple probe was putinto the suspension through one neck of the round bottom flask with asealed adapter. The suspension was heated at 30-40° C. until it becameclear. The solution was allowed to cool to room temperature.

2. Preparation of siNA/Carrier Solution

Into a sterile container (Corning storage bottle) was weighed 0.4 gtimes the water correction factor (approximately 1.2) of siNA powder.The siNA was transferred to a depyrogenated 2 L glass reagent bottle.The weighing container was rinsed 3× with citrate buffer (20 mM, pH 5.0)and the rinses were placed into the 2 L glass bottle, QS with citratebuffer to 1 L. The concentration of the siNA solution was determinedwith a UV spectrometer using the following procedure. 20 μL was removedfrom the solution, diluted 50 times to 1000 μL, and the UV readingrecorded at A260 nm after blanking with citrate buffer. This wasrepeated. Note, if the readings for the two samples are consistent, anaverage can be taken and the concentration calculated based on theextinction coefficients of the siNAs. If the final concentration is outof the range of 0.40±0.01 mg/mL, the concentration can be adjusted byadding more siNA/carrier powder, or adding more citrate buffer. Thisprocess can be repeated for the second siNA, if applicable

When the siNA/carrier solution comprised a single siNA duplex instead ofa cocktail of two or more siNA duplexes and/or carriers, then thesiNA/carrier was dissolved in 20 mM citrate buffer (pH 5.0) to give afinal concentration of 0.4 mg/mL.

The lipid and ethanol solutions were then sterile filtered through aPall Acropak 20 0.8/0.2 μm sterile filter PN 12203 into a depyrogenatedglass vessel using a Master Flex Peristaltic Pump Model 7520-40 toprovide a sterile starting material for the encapsulation process. Thefiltration process was run at an 80 mL scale with a membrane area of 20cm². The flow rate was 280 mL/minute. This process can be scaled byincreasing the tubing diameter and the filtration area.

3. Particle Formation—Mixing Step

Using a two-barrel syringe driven pump (Harvard 33 Twin Syringe), thesterile lipid/ethanol solution and the sterile siNA/carrier orsiNA/carrier cocktail/citrate buffer (20 mM citrate buffer, pH 5.0)solutions were mixed in a 0.5 mm ID T-mixer (Mixing Stage I) at equal,or nearly equal, flow rates. The resulting outlet LNP suspensioncontained 40-50 vol % ethanol. To obtain a 45 vol % ethanol outletsuspension, the sterile lipid/ethanol and the sterile siNA/carrier orsiNA/carrier cocktail/citrate buffer solutions were mixed at flow ratesof 54 mL/min and 66 mL/min, respectively, such that the total flow rateof the mixing outlet is 120 mL/min.

4. Dilution

The outlet stream of Mixing Stage I was fed directly into a 4 mm IDT-mixer (Mixing Stage 11), where it was diluted with a buffered solutionat higher pH (20 mM sodium citrate, 300 mM sodium chloride, pH 6.0) at aratio of 1:1 vol:vol %. This buffered solution was at a temperature inthe range of 30-40° C., and was delivered to the 4 mm T-mixer via aperistaltic pump (Cole Parmer MasterFlex L/S 600 RPM) at a flow rate of120 mL/min.

The outlet stream of Mixing Stage 11 was fed directly into a 6 mm IDT-mixer (Mixing Stage III), where it was diluted with a bufferedsolution at higher pH (PBS, pH 7.4) at a ratio of 1:1 vol:vol %. Thisbuffered solution was at a temperature in the range of 15-25° C., andwas delivered to the 6 mm T-mixer via peristaltic pump (Cole ParmerMasterFlex L/S 600 RPM) at a flow rate of 240 mL/min.

5. Incubation and Free siNA Removal

The outlet stream of Mixing Stage III was held after mixing for 30minute incubation. The incubation was conducted at temperature of 35-40°C. and the in-process suspension was protected from light. Followingincubation, free (un-encapsulated) siNA was removed via anion exchangewith Mustang Q chromatography filters (capsules). Prior to use, thechromatography filters were pre-treated sequentially with flushes of 1NNaOH, 1M NaCl, and a final solution of 12.5 vol % ethanol in PBS. The pHof the final flush was checked to ensure pH<8. The incubated LNP streamwas then filtered via Mustang Q filters via peristaltic pump (ColeParmer MasterFlex L/S 600 RPM) at flow rate of approximately 100 mL/min.The filtered stream was received into a sterile glass container forultrafiltration and concentration as follows.

6. Ultrafiltration, Concentration and Sterile Filtration

The ultrafiltration process is a timed process and the flow rates mustbe monitored carefully. This is a two step process; the first is aconcentration step taking the diluted material and concentratingapproximately 8-fold, to a concentration of approximately 0.3-0.6 mg/mLsiNA.

In the first step, a ring-stand with a ultrafiltration membrane 100 kDaPES (Spectrum Labs) installed was attached to a peristaltic pump(Spectrum KrosFloII System). 9.2 L of sterile distilled water was addedto the reservoir; 3 L was drained to waste and the remainder was drainedthrough permeate to waste. 5.3 L of 0.25 N sodium hydroxide was added tothe reservoir with 1.5 L drained to waste and 3.1 L drained throughpermeate to waste. The remaining sodium hydroxide was held in the systemfor sanitization (at least 10 minutes), and then the pump was drained.9.2 L of 70 (v/v) % isopropyl alcohol was added to the reservoir with1.5 L drained to waste and the remainder drained through permeate towaste. 6 L of conditioning buffer (12.5% ethanol in phosphate bufferedsaline) was added with 1.5 L drained to waste and the remainder drainedthough the permeate until the waste was of neutral pH (7-8). A membraneflux value was recorded, and the pump was then drained.

The diluted LNP solution was placed into the reservoir to the 1.1 Lmark. The pump was turned on at 2.3 L/min. After 5 minutes ofrecirculation, the permeate pump was turned on at 62.5 mL/min and theliquid level was constant at approximately 950 mL in the reservoir. Thediluted LNP solution was concentrated from 9.8 L to 1.1 L in 140minutes, and the pump was paused when all the diluted LNP solution hasbeen transferred to the reservoir.

The second step was a diafiltration step exchanging the ethanol/aqueousbuffer to phosphate buffered saline. During this step, approximately10-20 diafiltration volumes of phosphate buffered saline were used.Following diafiltration, a second concentration was undertaken toconcentrate the LNP suspension 3-fold to approximately 1-1.5 mg/mLsiRNA. The concentrated suspension was collected into sterile, plasticPETG bottles. The final suspension was then filtered sequentially viaPall 0.45 um PES and Pall 0.2 um PES filters for terminal sterilizationprior to vial filling.

The obtained LNPs were characterized in terms of particle size, Zetapotential, alcohol content, total lipid content, nucleic acidencapsulated, and total nucleic acid concentration.

C. Synthesis of novel cationic lipids

Synthesis of the novel cationic lipids is a linear process starting fromlipid acid (i). Coupling to N,O-dimethyl hydroxylamine gives the Weinrebamide ii. Grignard addition generates ketone iii. Titanium mediatedreductive amination gives final products of type iv.

Synthesis of the single carbon homologated cationic lipids v is a linearprocess starting from lipid ketone (iii). Conversion of the ketone tothe nitrile (iv) is accomplished via treatment with TOSMIC and potassiumtert-butoxide. Reduction of the nitrile to the primary amine followed byreductive amination provides final cationic lipids v.

Synthesis of two carbon homologated cationic lipids viii is a linearprocess starting from lipid ketone (iii). Conversion of the ketone tothe α,β-unsaturated amide vi is accomplished under Peterson conditions.Conjugate reduction of the α,β-unsaturation is performed usingLS-Selectride to give amide vii. Reduction of the amide with lithiumaluminum hydride provides final cationic lipids viii.

Cyclopropyl containing lipids are prepared according to General Scheme4. Unsaturated Weinreb amides ii are subjected to Simmons-Smithcyclopropanation conditions to give cyclopropyl containing Weinrebamides ix. These are carried on to final products as outlined in GeneralSchemes 1-3.

Synthesis of allylic amine cationic lipids xv is a linear processstarting with aldehyde x. Addition of t-butyl aceate generates β-hydroxyester xi. Conversion of the hydroxyl functionality to a fluoro groupfollowed by acid treatment generates β-fluoro acid xii. Conversion ofthe acid to the Weinreb amide followed by Grignard addition gives theβ-fluoro ketone xiv. Reductive amination results in simultaneouselimination to generate the desired allylic amine xv.

20,23-nonacosadien-10-amine, N,N-dimethyl-,(20Z,23Z) (Compound 1)

11,14-Eicosadienoic acid, (11Z,14Z)- (50 g, 162 mmol),N,O-Dimethylhydroxylamine hydrochloride (31.6 g, 324 mmol), HOAt (44.1g, 324 mmol), Et₃N (45.2 mL, 324 mmol), and EDC (62.1 g, 324 mmol) weremixed in DCM (810 mL) and stirred overnight at ambient temperature.Reaction was then washed 5×700 mL water, then washed 1×600 mL 1 M NaOH,dried with sodium sulfate, filtered through celite and evaporated toobtain 53.06 g (93%) 11,14-eicosadienamide, N-methoxy-N-methyl-,(11Z,14Z) as a clear golden oil. ¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H),3.68 (s, 3H), 3.18 (s, 3H), 2.77 (m, 2H), 2.41 (t, J=7 Hz, 2H), 2.05 (m,4H), 1.63 (m, 2H), 1.40-1.26 (m, 18H), 0.89 (t, J=7 Hz, 3H).

11,14-eicosadienamide, N-methoxy-N-methyl-, (11Z,14Z)-1 (4 g, 11.38mmol) was dissolved in dry THF (50.0 ml) in a 250 mL flask then 1 Mnonylmagnesium bromide (22.76 ml, 22.76 mmol) was added under nitrogenat ambient temperature. After 10 min, the reaction was slowly quenchedwith excess sat. aq NH₄Cl. The reaction was washed into a separatoryfunnel with hexane and water, shaken, the lower aqueous layer discarded,the upper layer dried with sodium sulfate, filtered, and evaporated togive crude ketone as a golden oil. To the above crude ketone was addeddimethylamine (2 M in THF) (14.22 ml, 28.4 mmol) followed by Ti(O-i-Pr)₄(6.67 ml, 22.76 mmol) and let stir overnight. The next day, added EtOH(50 ml) followed by NaBH₄ (0.646 g, 17.07 mmol). After 5 min ofstirring, directly injected entire reaction onto a 40 g silica columnthat was in line with a 330 g silica column. Eluted 10 min 100% DCM,then 30 min 0-15% MeOH/DCM, collected 20,23-nonacosadien-10-amine,N,N-dimethyl-, (20Z,23Z) (1) (2.45 g, 5.47 mmol, 48.1% yield) as afaintly golden oil. ¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 2.78 (m,2H), 2.23 (m, 1H), 2.21 (s, 6H), 2.05 (m, 4H), 1.45-1.16 (m, 38H), 0.89(m, 6H). HRMS calcd for C31H61N 448.4877. found 448.4872.

Compounds 2-30 are novel cationic lipids and were prepared according tothe General Scheme 1 above.

Compound Structure HRMS  2

calcd C28H56N 406.4407, found 406.4405.  3

calcd C27H54N 392.4251, found 392.4250.  4

calcd C24H48N 350.3781, found 350.3770.  5

calcd C23H46N 336.3625, found 336.3613.  6

calcd C25H50N 364.3938, found 364.3941.  7

calcd C26H52N 378.4094, found 378.4081.  8

calcd C29H58N 420.4564, found 420.4562.  9

calcd C26H52N 378.4094, found 378.4089. 10

calcd C25H50N 364.3938, found 364.3931. 11

calcd C30H60N 434.4720, found 434.4717. 12

calcd C29H58N 420.4564, found 420.4561. 13

calcd C28H56N 406.4407, found 406.4404. 14

calcd C27H54N 392.4251, found 392.4245. 15

calcd C33H66N 476.5190, found 476.5196. 16

calcd C32H64N 462.5033, found 462.5045. 17

calcd C29H59N 422.4720, found 422.4726. 18

calcd C28H57N 408.4564, found 408.4570. 19

calcd C30H59N 434.4720, found 434.4729. 20

calcd C29H61N 424.4877, found 424.4875. 21

calcd C32H64N 462.5033, found 462.5023. 22

calcd C33H64N 474.5033, found 474.5033. 23

calcd C29H60N 422.4720, found 422.4716. 24

calcd C29H60N 422.4720, found 422.4718. 25

calcd C31H64N 450.5033, found 450.5031. 26

calcd C31H64N 450.5033, found 450.5034. 27

calcd C35H72N 506.5659, found 506.5635. 28

calcd C31H64N 450.5033, found 450.5037. 29

calcd C33H68N 478.5346, found 478.5358. 30

calcd C27H56N 394.4407, found 394.4407.

(12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine (Compound 31)

A solution of keton iii (4.0 g, 9.55 mmol), TOSMIC (2.4 g, 12.4 mmol) indimethoxyethane (45 mL) was cooled to 0° C. and treated with potassiumtert-butoxide

-   -   (19.1 mmol, 19.1 mL of a 1M solution in tBuOH). After 90        minutes, the reaction was partitioned between hexanes and water.        The organics were washed with water, dried over sodium sulfate,        filtered and evaporated in vacuo. This material was purified by        flash chromatography (0-5% EtOAc/hexanes) to give desired        product (containing ˜20% of s.m.). This mixture was carried into        next step as is. LC/MS (M+H)=430.6.

Lithium aluminum hydride (23.9 mmol, 23.9 mL of a 1M solution in THF)was added directly to nitrile iv (3.42 g, 8 mmol) at ambient temperatureand the reaction was stirred for 20 minutes. The reaction was dilutedwith 100 mL THF, cooled to 0° C. and carefully quenched with sodiumsulfate decahydrate solution. The solids were filtered off and washedwith THF. The filtrate was evaporated in vacuo and carried directly intonext reaction crude. LC/MS (M+H)=434.6.

A solution of primary amine (3.45 g, 6.2 mmol) in dichloroethane (100mL) was treated with formaldehyde (1.6 mL, 21.7 mmol) followed by sodiumtriacetoxyborohydride (6.6 g, 31 mmol). After 5 minutes, the reactionwas partitioned between dichloromethane and 1N NaOH. The organics weredried over sodium sulfate, filtered and evaporated in vacuo. The crudemixture was purified by reverse phase preparative chromatography (C8column) to provide(12Z,15Z)—N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine. HRMS calc'd462.5033. found 462.5026. ¹H NMR (400 MHz, CDCl₃) δ 5.35 (m, 4H), 2.78(2H, t, J=5.6 Hz), 2.18 (s, 6H), 2.05 (m, 6H), 1.3 (m, 39H), 0.89 (m,6H).

(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine (Compound 32)

The silyl amide Peterson reagent (3.1 g, 16.7 mmol) was dissolved in THF(35 mL) and cooled to −63° C. To this solution was added nBuLi (16.7mmol, 6.7 mL of a 2.5M solution). The reaction was warmed to ambienttemperature for 30 minutes. The ketone (5.0 g, 11.9 mmol) was dissolvedin THF (25 mL) in a second flask. The Peterson reagent was transferredto the ketone solution at −60° C. The reaction was warmed to −40° C. for1 hour, then warmed to 0° C. for 30 minutes. The reaction was quenchedwith sodium bicarbonate, diluted with additional water and partitionedbetween water/hexanes. The organics were washed with brine, dried oversodium sulfate, filtered and evaporated in vacuo. Purification by flashchromatography (0-40% MTBE/hexanes) gave α,β-unsatured amide vi. ¹H NMR(400 MHz, CDCl₃) δ 5.75 (s, 1H), 5.36 (m, 4H), 3.01 (s, 3H), 2.99 (s,3H), 2.78 (t, 2H), 2.28 (t, 2H), 2.05 (m, 6H), 1.35 (m, 34H), 0.89 (m,6H).

α,β-unsatured amide vi (1 g, 2.1 mmol) and LS-Selectride (4.1 mmol, 4.1mL of a 1M solution) were combined in a sealed tube and heated to 60° C.for 24 hours. The reaction was cooled to ambient temperature andpartitioned between ammonium chloride solution and heptane. The organicswere dried over sodium sulfate, filtered and evaporated in vacuo to giveamide vii. This intermediate was carried directly into next reactioncrude.

To a solution of amide vii (2.85 g, 5.8 mmol) was added lithium aluminumhydride (8.7 mmol, 8.7 mL of a 1M solution). The reaction was stirred atambient temperature for 10 minutes then quenched by slow addition ofsodium sulfate decahydrate solution. The solids were filtered and washedwith THF and the filtrate evaporated in vacuo. The crude mixture waspurified by reverse phase preparative chromatography (C8 column) toprovide (13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine(Compound 32) as an oil. HRMS (M+H) calc'd 476.5190. found 476.5189. ¹HNMR (400 MHz, CDCl₃) δ 5.37 (m, 4H), 2.78 (t, 2H), 2.42 (m, 8H), 2.05(q, 4H), 1.28 (m, 41H), 0.89 (m, 6H).

N,N-dimethyl-1-(2-octylcyclopropyl)heptadecan-8-amine (Compound 33)

To a solution of oleic acid (1 g, 3.5 mmol) in DCM (500 mL) cooled to 0°C. was added CDI (0.63 g, 3.9 mmol). The reaction was warmed to ambienttemperature for 30 minutes before cooling to 0° C. and treating firstwith triethylamine (0.39 g, 3.9 mmol) and then dimethyl hydroxylaminehydrochloride (0.38 g, 3.9 mmol). After 1 hour the reaction waspartitioned between water and heptane. The organics were dried overmagnesium sulfate, filtered and evaporate in vacuo to give crude Weinrebamide ii which was carried directly into next reaction.

A solution of diethylzinc (70.3 mmol, 70.3 mL of a 1M solution) indichloromethane (130 mL) was cooled to −1° C. and treated dropwise withTFA (8.0 g, 70.3 mmol). After 30 minutes, diiodomethane (18.8 g, 70.3mmol) was added and this was aged for 30 minutes in the ice bath. Tothis solution was added Weinreb amide ii (7.6 g, 23.4 mmol). Thereaction was warmed to ambient temperature and stirred for 1 hour. Thereaction was quenched with ammonium chloride solution (100 mL) andorganic layer partitioned off, washed with 10% sodium thiosulfate, driedover magnesium sulfate, filtered and evaporated in vacuo. Purificationwas flash chromatography (0-30% MTBE/heptane) gave desired product ix.¹H NMR (400 MHz, CDCl₃) δ 3.72 (s, 3H), 3.22 (s, 3H), 2.48 (t, 2H), 1.65(m, 2H), 1.39 (m, 22H), 1.18 (m, 2H), 0.91 (t, 3H), 0.68 (m, 2H), 0.59(m, 1H), −0.32 (m, 1H).

Conversion of Weinreb amide ix to Compound 33 was carried out in amanner analogous to that described for Compound 1 above (nonyl Grignardaddition followed by reductive amination). LC/MS (M+H)=436.6. ¹H NMR(400 MHz, CDCl₃) δ 2.25 (s, 6H), 1.30 (m, 45H), 0.91 (m, 6H), 0.68 (m,2H), 0.59 (m, 1H), −0.31 (m, 1H).

Compounds 34-43 are novel cationic lipids and were prepared according toGeneral Schemes 1-4 above.

Compound Structure HRMS 34

calcd C30H62N 436.4877, found 436.4872. 35

calcd C32H66N 464.5190, found 464.5186. 36

calcd C34H70N 492.5503, found 492.5496. 37

calcd C33H66N 476.5190, found 476.5174. 38

calcd C29H60N 422.4720, found 422.4701. 39

calcd C30H62N 436.4877, found 436.4880. 40

calcd C32H66N 464.5190, found 464.5199. 41

calcd C30H62N 436.4877, found 436.4877. 42

calcd C30H62N 436.4877, found 436.4875. 43

LC/MS (M + H) 408.6.

(11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,23-trien-10-amine (Compound 44)

To a solution of LDA (95 mmol, 47.5 mL of a 2M solution) in THF (127 mL)cooled to −78° C. was added t-butyl acetate. The reaction was stirredfor 15 minutes followed by addition of aldehyde x. The reaction wasimmediately quenched with ammonium chloride solution, warmed to ambienttemperature and partitioned between water/pentane. The organics weredried over sodium sulfate, filtered and evaporated in vacuo. LC/MS(M+H-tBu)=325.4.

Hydroxy ketone xi (7 g, 18.4 mmol) was dissolved in dichloromethane (150mL) and cooled to 0° C. and treated with deoxofluor (7.3 g, 33.1 mmol).The reaction was warmed to ambient temperature with stirring for 16hours followed by quenching with sodium bicarbonate solution. Thereaction was partitioned and the organics dried over sodium sulfate,filtered and evaporate in vacuo. Flash column chromotagraphy (0-5% ethylacetate/hexanes) gave the -fluoro ester.

Fluoro ester intermediate (6 g, 15.6 mmol) in dichloromethane wastreated with hydrogen chloride (157 mmol, 39.2 mL of a 4M solution indioxane) and the reaction was stirred at ambient temperature for 16hours. The reaction was evaporated in vacuo to give desired β-fluoroacid xii. LC/MS (M+H)=327.3.

Fluoro carboxylic acid xii (5.1 g, 15.7 mmol), EDC (6.0 g, 31.4 mmol),N,O-dimethylhydroxylamine hydrochloride (3.1 g, 31.4 mmol),trimethylamine (4.0 g, 39.2 mmol), and HOAt (4.3 g, 31.4 mmol) werecombined in DCM (78 mL) and stirred at ambient temperature for 16 hours.The reaction was partitioned between water/DCM and the organics werewashed with water (3×) and NaOH solution (1×), dried over sodiumsulfate, filtered and evaporated in vacuo. Crude material was purifiedby reverse phase preparative chromatography to give desired Weinrebamide xiii. LC/MS (M+H)=370.4.

A solution of Weinreb amide xiii (4.3 g, 11.7 mmol) in THF (50 mL) wastreated with nonylmagnesium bromide (23.4 mmol, 23.4 mL of a 1Msolution) at ambient temperature. The reaction was quenched withammonium chloride solution after 1 hour and partitioned between waterand pentane. The organics were dried over sodium sulfate, filtered andevaporated in vacuo. This material was carried into next step crude.

Ketone xiv (5.1 g, 11.7 mmol) was treated with dimethylamine (29.3 mmol,14.7 mL of a 2M solution in THF) and titanium(IV) isopropoxide (6.7 g,23.5 mmol) and the reaction was stirred at ambient temperature for 16hours. To the reaction mixture was added ethanol (50 mL) followed bysodium borohydride (0.67 g, 17.6 mmol). The reaction was loaded directlyonto a silica column and purified by flash chromatography (0-15%MeOH/DCM). The material required a second purification by preparativereverse phase chromatography to give(11E,20Z,23Z)—N,N-dimethylnonacosa-11,20,23-trien-10-amine. HRMS calc'd446.4720. found 446.4724. ¹H NMR (400 MHz, CDCl₃) δ 5.48 (m, 1H), 5.37(m, 4H), 5.23 (m, 1H), 2.78 (t, 2H), 2.58 (m, 1H), 2.22 (s, 6H), 2.04(m, 6H), 1.56 (m, 1H), 1.30 (m, 31H), 0.89 (m, 6H).

Compound 45 is DLinKC2DMA as described in Nature Biotechnology, 2010,28, 172-176, WO 2010/042877 A1, WO 2010/048536 A2, WO 2010/088537 A2,and WO 2009/127060 A1.

Compound 46 is MC3 as described in WO 2010/054401, and WO 2010/144740A1.

D. Lipid Nanoparticle Compositions

The following lipid nanoparticle compositions (LNPs) of the instantinvention are useful for the delivery of oligonucleotides, specificallysiNA molecules of the invention:

Cationic Lipid/Cholesterol/PEG-DMG 56.6/38/5.4; CationicLipid/Cholesterol/PEG-DMG 60/38/2; Cationic Lipid/Cholesterol/PEG-DMG67.3/29/3.7; Cationic Lipid/Cholesterol/PEG-DMG 49.3/47/3.7; CationicLipid/Cholesterol/PEG-DMG 50.3/44.3/5.4; CationicLipid/Cholesterol/PEG-C-DMA/DSPC 40/48/2/10; CationicLipid/Cholesterol/PEG-DMG/DSPC 40/48/2/10; and CationicLipid/Cholesterol/PEG-DMG/DSPC 58/30/2/10.

One skilled in the art would readily appreciate that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those inherent therein. The methodsand compositions described herein, as presently representative ofpreferred embodiments, are exemplary and are not intended as limitationson the scope of the invention. Changes therein and other uses will occurto those skilled in the art, which are encompassed within the spirit ofthe invention, are defined by the scope of the claims.

TABLE 8 CTNNB1 Accession Numbers NM_001098210 Homo sapiens catenin(cadherin-associated protein), beta 1, 88 kDa, (CTNNB1), transcriptvariant 3, mRNA. NM_001098210.1 GI:148227671 NM_007614 Mus musculuscatenin (cadherin associated protein), beta 1(Ctnnb1), transcriptvariant 1, mRNA NM_007614.2 GI:31560726 XM_001115474 Macaca mulattacatenin (cadherin-associated protein), beta 1, 88 kDa, transcriptvariant (CTNNB1), mRNA. XM_001115474.1 GI:109041278

TABLE 9 Non-limiting examples of Stabilization Chemistries forchemically modified siNA constructs Non-limiting examples ofStabilization Chemistries for chemically modified siNA constructsChemistry pyrimidine purine caps p = S Strand “Stab 00” Ribo Ribo TT at3′- S/AS ends “Stab 1” Ribo Ribo — 5 at 5′-end S/AS 1 at 3′-end “Stab 2”Ribo Ribo — All linkages Usually AS “Stab 3” 2′-fluoro Ribo — 4 at5′-end Usually S 4 at 3′-end “Stab 4” 2′-fluoro Ribo 5′ and 3′- —Usually S ends “Stab 5” 2′-fluoro Ribo — 1 at 3′-end Usually AS “Stab 6”2′-O- Ribo 5′ and 3′- — Usually S Methyl ends “Stab 7” 2′-fluoro2′-deoxy 5′ and 3′- — Usually S ends “Stab 8” 2′-fluoro 2′-O- — 1 at3′-end S/AS Methyl “Stab 9” Ribo Ribo 5′ and 3′- — Usually S ends “Stab10” Ribo Ribo — 1 at 3′-end Usually AS “Stab 11” 2′-fluoro 2′-deoxy — 1at 3′-end Usually AS “Stab 12” 2′-fluoro LNA 5′ and 3′- Usually S ends“Stab 13” 2′-fluoro LNA 1 at 3′-end Usually AS “Stab 14” 2′-fluoro2′-deoxy 2 at 5′-end Usually AS 1 at 3′-end “Stab 15” 2′-deoxy 2′-deoxy2 at 5′-end Usually AS 1 at 3′-end “Stab 16” Ribo 2′-O- 5′ and 3′-Usually S Methyl ends “Stab 17” 2′-O- 2′-O- 5′ and 3′- Usually S MethylMethyl ends “Stab 18” 2′-fluoro 2′-O- 5′ and 3′- Usually S Methyl ends“Stab 19” 2′-fluoro 2′-O- 3′-end S/AS Methyl “Stab 20” 2′-fluoro2′-deoxy 3′-end Usually AS “Stab 21” 2′-fluoro Ribo 3′-end Usually AS“Stab 22” Ribo Ribo 3′-end Usually AS “Stab 23” 2′-fluoro* 2′-deoxy* 5′and 3′- Usually S ends “Stab 24” 2′-fluoro* 2′-O- — 1 at 3′-end S/ASMethyl* “Stab 25” 2′-fluoro* 2′-O- — 1 at 3′-end S/AS Methyl* “Stab 26”2′-fluoro* 2′-O- — S/AS Methyl* “Stab 27” 2′-fluoro* 2′-O- 3′-end S/ASMethyl* “Stab 28” 2′-fluoro* 2′-O- 3′-end S/AS Methyl* “Stab 29”2′-fluoro* 2′-O- 1 at 3′-end S/AS Methyl* “Stab 30” 2′-fluoro* 2′-O-S/AS Methyl* “Stab 31” 2′-fluoro* 2′-O- 3′-end S/AS Methyl* “Stab 32”2′-fluoro 2′-O- S/AS Methyl “Stab 33” 2′-fluoro 2′-deoxy* 5′ and 3′- —Usually S ends “Stab 34” 2′-fluoro 2′-O- 5′ and 3′- Usually S Methyl*ends “Stab 35” 2′-fluoro*† 2′-O- Usually AS Methyl*† “Stab 36”2′-fluoro*† 2′-O- Usually AS Methyl*† “Stab04H” 2′-fluoro‡ Ribo‡ 5′ and3′- 1 at 3′-end Ususally S ends “Stab06C” 2′-O- Ribo‡ 5′ and 3′-Ususally S Methyl‡ ends “Stab07H” 2′-fluoro‡ 2′-deoxy‡ 5′ and 3′- 1 at3′-end Ususally S ends “Stab07mU” 2′-fluoro‡ 2′-deoxy‡ 5′ and 3′-Ususally S ends “Stab09H” Ribo‡ Ribo‡ 5′ and 3′- 1 at 3′-end Ususally Sends “Stab16C” Ribo‡ 2′-O- 5′ and 3′- Ususally S Methyl‡ ends “Stab16H”Ribo‡ 2′-O- 5′ and 3′- 1 at 3′-end Ususally S Methyl‡ ends “Stab18C”2′-fluoro‡ 2′-O- 5′ and 3′- Ususally S Methyl‡ ends “Stab18H” 2′-fluoro‡2′-O- 5′ and 3′- 1 at 3′-end Ususally S Methyl‡ ends “Stab52H” 2′-O-Ribo‡ 5′ and 3′- 1 at 3′-end Ususally S Methyl‡ ends “Stab05C”2′-fluoro‡ Ribo‡ Ususally AS “Stab05N” 2′-fluoro‡ Ribo‡ 1 at 3′-endUsusally AS “Stab10C′ Ribo‡ Ribo‡ Ususally AS “Stab10N” Ribo‡ Ribo‡ 1 at3′-end Ususally AS “Stab35G*” 2′-fluoro‡ 2′-O- Ususally AS Methyl‡“Stab35N*” 2′-fluoro‡ 2′-O- 1 at 3′-end Ususally AS Methyl‡ “Stab35rev*”2′-O- 2′-fluoro‡ Ususally AS Methyl‡ “Stab50*” Ribo‡ 2′-O- Ususally ASMethyl‡ “Stab53*” 2′-O- Ribo‡ Ususally AS Methyl‡ “Stab53N*” 2′-O- Ribo‡1 at 3′-end Ususally AS Methyl‡ Stab54 Ribo‡ 2′-fluoro‡ Ususally AS CAP= any terminal cap, see for example FIG. 6. All Stab chemistries can beused in combination with each other for duplexes of the invention (e.g.,as combinations of sense and antisense strand chemistries), oralternately can be used in isolation, e.g., for single stranded nucleicacid molecules of the invention. All Stab chemistries can comprise3′-overhang nucleotides having 2′-O-alkyl, 2′-deoxy-2′-fluoro, 2′-deoxy,LNA or other modified nucleotides or non-nucleotides. All Stabchemistries typically comprise about 19-21 nucleotides, but can vary asdescribed herein. All Stab chemistries can also include a singleribonucleotide in the sense or passenger strand at the 11^(th) basepaired position of the double-stranded nucleic acid duplex as determinedfrom the 5′-end of the antisense or guide strand. All Stab chemistriescan also have in place of the Stab designation above a2′-deoxy-2′-fluoro modification at position 14 from the 5′ end of theantisense strand regardless of whether it is a purine or pyrimidine atthat position. All Stab chemistries of the antisense strand presentedabove can have a thymidine in place of a 2′-deoxy uridine at position 1,2, and/or 3 from the 5′ end of the antisense strand. S = sense strand.AS = antisense strand *Stab 23 has a single ribonucleotide adjacent to3′-CAP. *Stab 24 and Stab 28 have a single ribonucleotide at5′-terminus. *Stab 25, Stab 26, Stab 27, Stab 35, Stab 35G*, Stab 35N*,Stab 35rev*, Stab 36, Stab 50*, Stab53*, Stab 53N*, and Stab 54 havethree ribonucleotides at 5′-terminus. *Stab 29, Stab 30, Stab 31, Stab33, and Stab 34 any purine at first three nucleotide positions from5′-terminus are ribonucleotides. p = phosphorothioate linkage. †Stab 35has 2′-O-methyl U at 3′-overhangs and three ribonucleotides at5′-terminus. †Stab 36 has 2′-O-methyl overhangs that are complementaryto the target sequence, (naturally occurring overhangs) and threeribonucleotides at 5′-terminus. ‡Stab 04H, Stab 06C, Stabl07H, Stab07mU,Stab09H, Stab16C, Stab 16H, Stab18C, Stab 18H, Stab 52H, Stab 05C,Stab05N, Stab10C, Stab10N, Stab35G*, Stab35N*, Stab35N*, Stab35rev*,Stab 50*, Stab 53*, Stab 53N*, Stab 54 have two 2′-O-methyl U3′-overhangs. Stab35G*, Stab 35N*, Stab35rev*, Stab50*, Stab53*, andStab53N* do not allow for a 2′-O-methyl modification at position 14 ofthe guide strand as determined from the 5′-end.

TABLE 10 Exemplary Solid Phase Oligonucleotide Synthsis Conditions WaitTime* Wait Time* 2′-O- Wait Time* Reagent Equivalents Amount DNA methylRNA A. 2.5 μmol Synthesis Cycle ABI 394 Instrument Phosphoramidites 6.5163 μL 45 sec 2.5 min 7.5 min S-Ethyl Tetrazole 23.8 238 μL 45 sec 2.5min 7.5 min Acetic Anhydride 100 233 μL 5 sec 5 sec 5 sec N-CTNNB1hyl186 233 μL 5 sec 5 sec 5 sec Imidazole TCA 176 2.3 mL 21 sec 21 sec 21sec Iodine 11.2 1.7 mL 45 sec 45 sec 45 sec Beaucage 12.9 645 μL 100 sec300 sec 300 sec Acetonitrile NA 6.67 mL NA NA NA B. 0.2 μmol SynthesisCycle ABI 394 Instrument Phosphoramidites 15 31 μL 45 sec 233 sec 465sec S-Ethyl Tetrazole 38.7 31 μL 45 sec 233 min 465 sec Acetic Anhydride655 124 μL 5 sec 5 sec 5 sec N-CTNNB1hyl 1245 124 μL 5 sec 5 sec 5 secImidazole TCA 700 732 μL 10 sec 10 sec 10 sec Iodine 20.6 244 μL 15 sec15 sec 15 sec Beaucage 7.7 232 μL 100 sec 300 sec 300 sec AcetonitrileNA 2.64 mL NA NA NA C. 0.2 μmol Synthesis Cycle 96 well InstrumentEquivalents: Amount: Wait Time* DNA/2′-O- DNA/2′-O- Wait Time* 2′-O-Wait Time* Reagent methyl/Ribo methyl/Ribo DNA methyl RiboPhosphoramidites 22/33/66 40/60/120 μL 60 sec 180 sec 360 sec S-EthylTetrazole 70/105/210 40/60/120 μL 60 sec 180 min 360 sec AceticAnhydride 265/265/265 50/50/50 μL 10 sec 10 sec 10 sec N-CTNNB1hyl502/502/502 50/50/50 μL 10 sec 10 sec 10 sec Imidazole TCA 238/475/475250/500/500 μL 15 sec 15 sec 15 sec Iodine 6.8/6.8/6.8 80/80/80 μL 30sec 30 sec 30 sec Beaucage 34/51/51 80/120/120 100 sec 200 sec 200 secAcetonitrile NA 1150/1150/1150 μL NA NA NA

-   -   Wait time does not include contact time during delivery.    -   Tandem synthesis utilizes double coupling of linker molecule

TABLE 11 Composition of Select Lipid Nanoparticle Formulations LNP Iden-siNA tifier Lipid Components and Molar Ratios Duplex N/P LNP-1 CompoundCholes- DSPC PEG- R- 6 32 terol (10%) DMG 008488889- (50%) (30%) (2%)000M LNP-2 Compound Choles- DSPC PEG- R- 6 32 terol (10%) DMG 008488882-(50%) (30%) (2%) 000B LNP-3 Compound Choles- DSPC PEG- R- 6 32 terol(10%) DMG 008380929- (50%) (30%) (2%) 000H LNP-4 Compound Choles- DSPCPEG- R- 6 32 terol (10%) DMG 008488885- (50%) (30%) (2%) 000C N/P ratio= Nitrogen:Phosphorous ratio between cationic lipid and nucleic acid

TABLE 12 Chemical Structures of Lipids in Formulations of Table 11 LipidChemical Structure Compound 32

Cholesterol

DSPC

PEG-DMG

What is claimed is: 1.-4. (canceled)
 5. A double-stranded shortinterfering nucleic acid (siNA) molecule that inhibits the expression ofCTNNB1, wherein the siNA comprises: 5′-ACGACUAGUUCAGUUGCUU-3′ (SEQ IDNO: 194) and 5′-AAGCAACUGAACUAGUCGU-3′ (SEQ ID NO: 5107).
 6. Thedouble-stranded short interfering nucleic acid (siNA) molecule accordingto claim 5, wherein at least one nucleotide is a chemically modifiednucleotide.
 7. The double-stranded short interfering nucleic acid (siNA)molecule according to claim 5 further comprising at least onenon-nucleotide.
 8. The double-stranded short interfering nucleic acid(siNA) molecule according to claim 5, wherein at least one nucleotidecomprises a universal base.
 9. The double-stranded short interferingnucleic acid (siNA) molecule according to claim 5, having at least onephosphorothioate internucleotide linkage.
 10. The double-stranded shortinterfering nucleic acid (siNA) molecule according to claim 5,comprising a cap on the 3′-end, 5′-end or both 3′ and 5′ ends of atleast one strand.
 11. The double-stranded short interfering nucleic acid(siNA) molecule according to claim 5, comprising one or more 3′-overhangnucleotides on one or both strands.
 12. The double-stranded shortinterfering nucleic acid (siNA) molecule according to claim 5, whereinthe 5′ end of the antisense strand is phosphorylated.
 13. Thedouble-stranded short interfering nucleic acid (siNA) molecule of claim11, wherein the 3′-overhang nucleotides on at least one strand are2′-O-methyl nucleotides.
 14. The double-stranded short interferingnucleic acid (siNA) molecule of claim 13, wherein the 2′-O-methylnucleotides are linked with a phosphorothioate internucleotide linkage.15. The double-stranded short interfering nucleic acid (siNA) moleculeof claim 6, wherein the chemically modified nucleotide is a2′-deoxy-2′-fluoro nucleotide.
 16. The double-stranded short interferingnucleic acid (siNA) molecule of claim 6, wherein the chemically modifiednucleotide is a 2′-deoxy nucleotide.
 17. The double-stranded shortinterfering nucleic acid (siNA) molecule of claim 6, wherein thechemically modified nucleotide is a 2′-O-alkyl nucleotide. 18.-23.(canceled)
 24. A double-stranded short interfering nucleic acid (siNA)molecule comprising any of SEQ ID NOS: 6372, 6374, 6370, 6369, 2021,2068, 6372, 6373, 2147, or
 6368. 25.-30. (canceled)
 31. A compositioncomprising: (a) a double-stranded short interfering nucleic acid (siNA)having any of SEQ ID NOS: 6372, 6374, 6370, 6369, 2021, 2068, 6372,6373, 2147, or 6368; (b)(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine; (c)cholesterol; (d) DSPC; and (e) PEG-DMG. 32.-35. (canceled)
 36. Thecomposition according to claim 31, wherein the(13Z,16Z)—N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, cholesterol,DSPC, and PEG-DMG have a molar ratio of 50:30:10:2 respectively.
 37. Thecomposition according to claim 31, further comprising sucrose,trehalose, or any combination thereof. 38.-39. (canceled)